<SEC-DOCUMENT>0001528287-23-000026.txt : 20230504
<SEC-HEADER>0001528287-23-000026.hdr.sgml : 20230504
<ACCEPTANCE-DATETIME>20230504170416
ACCESSION NUMBER:		0001528287-23-000026
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		63
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230504
DATE AS OF CHANGE:		20230504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeuroPace Inc
		CENTRAL INDEX KEY:			0001528287
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				223550230
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40337
		FILM NUMBER:		23889834

	BUSINESS ADDRESS:	
		STREET 1:		455 N. BERNARDO AVENUE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94043
		BUSINESS PHONE:		6502372700

	MAIL ADDRESS:	
		STREET 1:		455 N. BERNARDO AVENUE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94043
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>npce-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:1fd4e094-c2e9-4b44-9de8-fd1ff4c54731,g:0a3c8fdc-3cf9-40a0-97f2-986b9fb768aa,d:2a59f7ea1762416695eae3249a8f9ede--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:npce="http://neuropace.com/20230331" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>npce-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80L2ZyYWc6YzkzNGJmYTUzMTllNDA4N2E3MWJmMzUxYzU2OWNjY2MvdGFibGU6M2VhYzNhOGJlOWZjNGY3Y2E3ODcwZjcyNWNlYWM3NjIvdGFibGVyYW5nZTozZWFjM2E4YmU5ZmM0ZjdjYTc4NzBmNzI1Y2VhYzc2Ml8wLTEtMS0xLTY5NjUy_2f573a6b-4d5c-4bac-8299-5bb31afa122b">false</ix:nonNumeric><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80L2ZyYWc6YzkzNGJmYTUzMTllNDA4N2E3MWJmMzUxYzU2OWNjY2MvdGFibGU6M2VhYzNhOGJlOWZjNGY3Y2E3ODcwZjcyNWNlYWM3NjIvdGFibGVyYW5nZTozZWFjM2E4YmU5ZmM0ZjdjYTc4NzBmNzI1Y2VhYzc2Ml8xLTEtMS0xLTY5NjUy_5078182d-4890-4390-8b49-42a9f7769a31">0001528287</ix:nonNumeric><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80L2ZyYWc6YzkzNGJmYTUzMTllNDA4N2E3MWJmMzUxYzU2OWNjY2MvdGFibGU6M2VhYzNhOGJlOWZjNGY3Y2E3ODcwZjcyNWNlYWM3NjIvdGFibGVyYW5nZTozZWFjM2E4YmU5ZmM0ZjdjYTc4NzBmNzI1Y2VhYzc2Ml8yLTEtMS0xLTY5NjUy_8c833692-2772-4b52-84ca-924f5a6e1868">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80L2ZyYWc6YzkzNGJmYTUzMTllNDA4N2E3MWJmMzUxYzU2OWNjY2MvdGFibGU6M2VhYzNhOGJlOWZjNGY3Y2E3ODcwZjcyNWNlYWM3NjIvdGFibGVyYW5nZTozZWFjM2E4YmU5ZmM0ZjdjYTc4NzBmNzI1Y2VhYzc2Ml8zLTEtMS0xLTY5NjUy_c272ef31-5a3e-49e4-aaf5-dab17bbc334b">2023</ix:nonNumeric><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80L2ZyYWc6YzkzNGJmYTUzMTllNDA4N2E3MWJmMzUxYzU2OWNjY2MvdGFibGU6M2VhYzNhOGJlOWZjNGY3Y2E3ODcwZjcyNWNlYWM3NjIvdGFibGVyYW5nZTozZWFjM2E4YmU5ZmM0ZjdjYTc4NzBmNzI1Y2VhYzc2Ml80LTEtMS0xLTY5NjUy_55a0bf4f-1c29-4eb6-b5fd-3a44554d345f">Q1</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="npce-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i537cbbe5a2c74417929006a9f9320b26_I20230501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i8daa853d90324638b7732e94aa400e74_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i67198705cd5b4be6a83655c796893924_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61be63c82dfc4be78e2f9d68b4f11019_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98a7716fe4f8442ea99bfcffe232e221_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8d9bf075ca645be8dba336153887c29_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98bf413ba1ce4032a1cdf3cbddd33acd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7809dc429fd8495f9d069ad7b000facc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62099d19b5164e1a965faa8cb79f62df_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b89c6fbb19942c7ba5917a6174e4e08_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac806c35c4c94cfbabaf3bf0aac255e4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ad874e29bb74c679f513a76324f85d3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e12eed5884041b78d03f7d55c84255f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63642277a31a4e158aa8e35fc5614bf2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4f3a4d01eb64c3d99f32042d0306005_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2672791bd16a4560ac4e6349ada7df02_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb6c3879fe2843cb86d6b11e28b0ece0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i583edd3895a14ca5acca2fc71f20f802_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb3a188a2ef045108bee1a5e3cdc8bf7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17c2f30808f842e79b03a1b5e2dc3a74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie317d529e039488fa3e2b724a267f0af_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ebcbcb47ad845b58adc86041e6d3e95_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83cf5939e5774de68da51a47ab212e1f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cf5d7f0fdf14d358770256db90ddb08_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i073cd7dafa2f45088fbdd34201842f90_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50b17b8c21b8445ebb59d9b3575ecf6f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a126628dbb0405eb5c4b1f67cdd87ab_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1616f745a37b421a8451f51495269b96_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d497eb241564565aff73765a48fe320_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic31468e5e435455380b814e3c2061589_D20210426-20210426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-26</xbrli:startDate><xbrli:endDate>2021-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0b1b62330d2427a92e83025c46122d5_I20210426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f49f5b3c47d4ba1ac4f833941af6ad6_D20210426-20210426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-26</xbrli:startDate><xbrli:endDate>2021-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd6ab3a83420410da0927243af8d2e90_D20221101-20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">npce:AtTheMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="id1b89218f85e4970ba94327f3911df2b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">npce:AtTheMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34fc98c3b9124df39be5fbc449566961_D20230101-20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fb4e476763541a694ffb3eb2be6c4dd_I20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea9e5bc642294c36a2e9ce408258fa44_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie20e4646b6c64bd484f8b50c7fcb7a1e_D20210601-20210601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id750435b22204579ab914565baeecdcc_D20220730-20220730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-30</xbrli:startDate><xbrli:endDate>2022-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63da6b904e2e4e799b8f63827d7dd2ec_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8548ff80a4ad42a7bc8f521cc07045af_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7320c8ff5d5a4db38fdb65660cdbc124_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b3e368885a4412aa08f736e786122f7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5504ee5ca136427291328b9cdbfd9ac2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i089087e88c2f4e4594e265ef1eac9189_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i733ca2b6b6c1414dac92793e9704c260_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b0dc4d765154685b20215349253bb6d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50fbc717732e47c78990b648a1fb6851_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56aad41cb82348889b805e52158fbf37_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie13bfccbf66c4ecab838a9cd17475bc2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">npce:MachineryEquipmentFurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72b74226bce34ccd820c481519df8f32_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">npce:MachineryEquipmentFurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92e875b8476a417484c9e720466e1c5c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">npce:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15f6bae5515b42c08088c9d68db5f5d6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">npce:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d52095ad0ee44e7b2c4a5bc8d88dcfb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic24aec2bd2a146c0b2ceeb0af31c9a57_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9a80d56ebf04d499b58bf88ca435e06_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibea6fa1c91014c4b8d2577a5a84d2960_I20110831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:LeaseFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7e26e273c0b48a4b9d9a2e7d4b6b51f_I20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:LeaseFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i855f72fe57c7466cb0fdbebf83edc239_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:LeaseFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2356a93c7f0842d59386f834f8ca8c04_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifffa9c7125464d7486ce57d0838a6f42_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4dd4f305a334652a40e5d347bc7628f_I20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i663f6b7d3d6c49a2bc184e2117245877_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f4f2b14460d4ab894ce8ce881d1e8bf_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief8e6ea33f5f49ba8c1945d7760420af_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82f97d12cf584623a6e5b81bd652ab53_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43f850c157d141ef9213ce882f01add9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eeeb9a80b68476f81a32985be7b3bbb_I20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i936af4736e104ba1b78e04ecf51e9485_I20230301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52f87175f69a4d5ba7551816e3e6d9f9_I20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff8d276c367b44d9b804890918cc832b_I20230301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic717d133e94248aeb47643602e049d84_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">npce:PaymentInCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83b57f4259104d73b1aa83bc7764aa5d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieddb0b8aa4b949f1a6e2bed0558ca9c0_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">npce:PaymentInCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9067c2fe52724e22a615ea36acafda17_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icabe16bffe8b4ea7bfe4bf0585864a95_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfc06477076049948beb4962edceb579_D20230201-20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>npce:installment</xbrli:measure></xbrli:unit><xbrli:context id="i112820749e8349ea97d447caf4294059_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfb0677a4b944e56b972e31d646b50b7_D20230201-20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad9b6795da0a45d5acf70ba4d680edb2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">npce:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e5845b14c67448eafe578cbd6b9e3fd_I20200924"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">npce:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i814c00557d744141babf3f0e6dcf97a1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i750b0ffd1c3643dca215a71011485722_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03bae0452175488495225eda73e7fe90_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7933e407f09241dcbaee799735452b05_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">npce:OptionsAvailableForGrant2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82a147b9aa3a438bbe5962d4d431b65a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">npce:OptionsAvailableForGrant2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9928356578b14783835e61b49e13bde7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">npce:OutstandingOptions2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia780dfd625a04653a5d751d2bac0cd4e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">npce:OutstandingOptions2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i106f4f143f4e47e38267866a576503c3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">npce:OptionsRestrictedStockUnit2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59a77cc78b754f55b5ff3d8bc740ad1b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">npce:OptionsRestrictedStockUnit2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1be39c24946144f8b22080563d21467c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">npce:CommonStockAvailableForESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id847acf3ca4e4e02a9c3aaf18d3001eb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">npce:CommonStockAvailableForESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8968a5068c274de7a24aab2154e22af1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">npce:A2021EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4072dc09d11d4232803ca241e4c4fd61_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">npce:A2021EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i898957e56f4f40b1800743493ec2650f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">npce:A2021EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75e07d1256df491e837d1a678fa4841f_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i881477cd12da4a8f82229279bbec5907_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">npce:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida17c9ecae0547af93d99c9010967769_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">npce:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06a5ce3c01de408795052e7b2448ca32_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">npce:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i400dca35646848acb6a6f7c825c240c5_D20221207-20230606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">npce:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-07</xbrli:startDate><xbrli:endDate>2023-06-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a1293fb162241768174865fa0b18818_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf61601566c5496eaf799d95dd6d08ab_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f6410c7ed884b1dac8048f069c34d10_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c03c7d6befd470b9c00ea069d4dec85_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie403128de0ed45939a20b7ba400d2deb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i639bac8ba3dc42db9ca14dffe873b9aa_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ab734a7b4054702ad1f354a8ba71a1a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ed9f75a9df14b418c706ff213e1dc62_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id666fdb85ced40d196e685e2eb0efbb9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8c8e2b0811a4c2085f3292fca112c80_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">npce:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a901df324314e06b06d59f030123b5d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">npce:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22c77f84a8524a16aee5a4f8921601bc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i387f9c0ddfda42738fd2f8d07cefdc23_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a949f95a2434c7b8352d1c7ddbea5aa_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">npce:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i660649a2805c490faa7479b8f8eb80f9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dd75294bff941ef89454c5ed2eebd0a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad266dd548874ca7800f0d7408df01b3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">npce:ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51515b8cbea941149bc22fc10e0f86ab_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">npce:ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59a019c9f65548d59de82befb2acc22f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4683af3b7a34481848a875e395fa408_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9840aaee62a3402abc9cc764247cdcc3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide54bdde89344a929a15191e91ab4bca_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001528287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i2a59f7ea1762416695eae3249a8f9ede_1"></div><div style="min-height:49.5pt;width:100%"><div style="text-align:center;text-indent:20.25pt"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.965%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDUx_38d31432-516c-4a7b-8fe5-d1014e1e95b2">10-Q</ix:nonNumeric></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.965%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGFibGU6OTk1MTg2ODNmZWNhNDEwMmFjOWY0ZjRkMDU5Y2U1MzYvdGFibGVyYW5nZTo5OTUxODY4M2ZlY2E0MTAyYWM5ZjRmNGQwNTljZTUzNl8wLTAtMS0xLTY5NjUy_eca7b092-c4a2-4fa3-b6d7-1bee14f08448">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8xMzc_44fda687-1129-4137-b356-032d93846f0d">March 31, 2023</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGFibGU6MjcxZGU5MmQ3ZGQxNDhlZmFhN2I3NDA3YzU4MzcwYmIvdGFibGVyYW5nZToyNzFkZTkyZDdkZDE0OGVmYWE3Yjc0MDdjNTgzNzBiYl8wLTAtMS0xLTY5NjUy_41ff42e0-ed4f-4532-bbac-69075a5ef03d">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For transition period from&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;to</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission File Number</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDU1_3ed6cc3d-b00a-4732-97b2-83e636c685d9">001-40337</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.965%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDU2_64c62421-0ecb-45bb-bbf2-014896fb4a92">NEUROPACE, INC.</ix:nonNumeric> </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.965%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.461%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.462%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGFibGU6ZDdjYzQ3YTM3YzlmNGY1MTgyYWJiY2Y2Y2ViMWFkZTgvdGFibGVyYW5nZTpkN2NjNDdhMzdjOWY0ZjUxODJhYmJjZjZjZWIxYWRlOF8wLTAtMS0xLTY5NjUy_33a987fe-623e-4af6-97fe-86f90220f358">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGFibGU6ZDdjYzQ3YTM3YzlmNGY1MTgyYWJiY2Y2Y2ViMWFkZTgvdGFibGVyYW5nZTpkN2NjNDdhMzdjOWY0ZjUxODJhYmJjZjZjZWIxYWRlOF8wLTItMS0xLTY5NjUy_7c2c035b-4791-4ff4-9606-2a4f710ff08a">22-3550230</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identification Number)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDU0_d6df6ea0-f234-4564-a9cb-76f30718d421">455 N. Bernardo Avenue</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDUy_7a2d2664-36fe-4585-98da-d57a59c30e2e">Mountain View</ix:nonNumeric>, <ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDQ2_9da113df-f4df-48d8-a3cf-ff62dc7812de">CA</ix:nonNumeric> <ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDU3_b6880ba1-e069-429d-b692-70eb1ec2443c">94043</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDQ3_03a66675-9da6-4de0-9923-ae843af4d922">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDU4_a952b728-4ff0-4bb7-81a5-84807b5f5974">237-2700</ix:nonNumeric> </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.965%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.758%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGFibGU6YjlkNjY5MTRkMTkwNDY5YjhjYjE3ZTVkNjg0MmU2NGMvdGFibGVyYW5nZTpiOWQ2NjkxNGQxOTA0NjliOGNiMTdlNWQ2ODQyZTY0Y18xLTAtMS0xLTY5NjUy_fb663a60-3e00-4b3b-80b8-9c886c387b01">Common Stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGFibGU6YjlkNjY5MTRkMTkwNDY5YjhjYjE3ZTVkNjg0MmU2NGMvdGFibGVyYW5nZTpiOWQ2NjkxNGQxOTA0NjliOGNiMTdlNWQ2ODQyZTY0Y18xLTItMS0xLTY5NjUy_b73426b6-7d8d-41c9-90d3-9a21a4de2d81">NPCE</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGFibGU6YjlkNjY5MTRkMTkwNDY5YjhjYjE3ZTVkNjg0MmU2NGMvdGFibGVyYW5nZTpiOWQ2NjkxNGQxOTA0NjliOGNiMTdlNWQ2ODQyZTY0Y18xLTQtMS0xLTY5NjUy_952cb14c-37a3-4716-ad1d-3dfdbc8e3621">Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDUz_94ef3c27-9d19-42a1-a5b7-3e569f84b378">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). <ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDQ4_26f5e8b3-d365-4e72-86c8-9f7865ccfa6c">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGFibGU6MjQxYmNiODUwNjNlNGE2ZmFhNmUzYjgxYWI1ODFhYTAvdGFibGVyYW5nZToyNDFiY2I4NTA2M2U0YTZmYWE2ZTNiODFhYjU4MWFhMF8xLTAtMS0xLTY5NjUy_d5b557bd-74a6-40da-b80c-d8a585f3f75a">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGFibGU6MjQxYmNiODUwNjNlNGE2ZmFhNmUzYjgxYWI1ODFhYTAvdGFibGVyYW5nZToyNDFiY2I4NTA2M2U0YTZmYWE2ZTNiODFhYjU4MWFhMF8xLTMtMS0xLTY5NjUy_cb8b90ba-2f58-4920-9a98-29c8accd1447">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGFibGU6MjQxYmNiODUwNjNlNGE2ZmFhNmUzYjgxYWI1ODFhYTAvdGFibGVyYW5nZToyNDFiY2I4NTA2M2U0YTZmYWE2ZTNiODFhYjU4MWFhMF8yLTMtMS0xLTY5NjUy_18c8d097-be36-4ac3-9776-b34d6daac388">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act. <ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDQ5_195d05e0-8097-49cb-bcf2-141a3500f524">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes &#9744; No <ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDUw_ded6f431-cac9-4e44-add0-cd05d8a84175">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of May 1, 2023, there were approximately <ix:nonFraction unitRef="shares" contextRef="i537cbbe5a2c74417929006a9f9320b26_I20230501" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8xOTkw_d47c8177-325f-4889-a58f-7ee99fa308b7">25,405,362</ix:nonFraction> shares of the registrant's common stock outstanding.</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div></div><div id="i2a59f7ea1762416695eae3249a8f9ede_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center;text-indent:20.25pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.516%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_13">Part I. Financial Information</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_16">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_19">Condensed Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_22">Condensed Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_22">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_25">Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_25">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_28">Condensed Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_28">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_31">Notes to Unaudited Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_31">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_76">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_76">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_76">17</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_106">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_106">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_106">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_109">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_109">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_109">28</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_112">Part II. Other Information</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_115">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_115">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_115">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_118">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_118">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_118">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_121">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_121">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_121">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_124">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_124">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_124">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_127">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_127">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_127">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_130">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_130">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_130">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_133">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_133">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_133">88</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2a59f7ea1762416695eae3249a8f9ede_136">Signatures</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div></div><div id="i2a59f7ea1762416695eae3249a8f9ede_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center;text-indent:20.25pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements regarding results or events that may occur in the future contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial condition, as well as expectations of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; or &#8220;would,&#8221; or the negative of these words or other similar terms or expressions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties, factors and assumptions more thoroughly described in &#8220;Risk Factors.&#8221;  These risks are not exhaustive. Other sections of this Quarterly Report on Form 10-Q, as well as our other disclosures and filings, include additional factors that could harm our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in, or implied by, any forward-looking statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely on these forward-looking statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Quarterly Report on Form 10-Q or to conform these statements to actual results or to changes in our expectations, whether as a result of any new information, future events, changed circumstances or otherwise. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expected future growth; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth potential of the markets for our products, and our ability to serve those markets; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to accurately forecast demand for our products; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the impact of the COVID-19 pandemic and macroeconomic conditions on our sales, business, financial condition and results of operations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance of our products; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">coverage and reimbursement for procedures performed using our products, including pre-implant evaluations, implant procedures, and follow-up care; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the performance of third parties in connection with the manufacturing and development of our products, including single-source suppliers; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the United States and in any foreign countries in which we may seek to do business; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain regulatory approval for our products or obtain regulatory approval for updates to our products, or new products or indications in the United States and in any foreign countries in which we may seek to do business;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our research and development for existing products and new products; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reliance on third-party suppliers for product components, some of which are single source suppliers; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center;text-indent:20.25pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manufacture our products in conformity with FDA requirements and with regulatory requirements of any foreign countries in which we may seek to do business; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to predict product performance, including battery life of our RNS device;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the impact that our sales and marketing initiatives will have on our sales;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain or scale our organizational culture; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the development, regulatory approval, efficacy and commercialization of competing products; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract and retain members of our board of directors, senior management, or operational personnel; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act and as a smaller reporting company under the federal securities laws; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop and maintain our corporate infrastructure, including our ability to maintain an effective system of internal control; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance and capital requirements; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding our ability to obtain, maintain and enforce intellectual property protection for our products and technology, as well as our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of others. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Quarterly Report on Form 10-Q as well as the documents that we reference in, and have filed as exhibits to, this report with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Quarterly Report on Form 10-Q. While we believe that such information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on them.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div></div><div id="i2a59f7ea1762416695eae3249a8f9ede_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center;text-indent:20.25pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i2a59f7ea1762416695eae3249a8f9ede_16"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Unaudited Financial Statements</span></div><div id="i2a59f7ea1762416695eae3249a8f9ede_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NeuroPace, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Condensed Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except share and per share amounts)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfNC0xLTEtMS02OTY1Mg_1cbb5718-1a56-4152-b39f-1ede5dcb2c29">6,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfNC0zLTEtMS02OTY1Mg_66ef8fb2-6451-4766-950d-935d4317ff61">6,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfNS0xLTEtMS02OTY1Mg_30fa3071-0c7a-4dc4-b19f-c62d7665a269">60,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfNS0zLTEtMS02OTY1Mg_7d7ee053-72a4-4257-9eb5-bc8fbb2724a4">70,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfNi0xLTEtMS02OTY1Mg_2385e115-a575-4db3-9f9e-96a6b052f255">9,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfNi0zLTEtMS02OTY1Mg_eb384855-eb5a-43fb-a04d-745d3f5d0a48">7,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfNy0xLTEtMS02OTY1Mg_1c7c3da2-f070-4a74-8e1e-6710b481feb9">10,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfNy0zLTEtMS02OTY1Mg_3ea8d240-03b3-43d2-9eba-75b89c21dda6">9,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfOC0xLTEtMS02OTY1Mg_909433ab-5b61-4246-8a41-4a4e289caebe">2,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfOC0zLTEtMS02OTY1Mg_e658197c-1089-4fb0-9a5f-de99b64deb3a">3,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfOS0xLTEtMS02OTY1Mg_9818c9e4-3d64-46b1-881a-f2b7c38fa426">90,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfOS0zLTEtMS02OTY1Mg_63d397f8-2362-49b8-9e17-a83afca4daf8">97,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTAtMS0xLTEtNjk2NTI_e3081a2c-e5be-4d6d-a992-c0826e2589fd">1,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTAtMy0xLTEtNjk2NTI_08c65df7-b6e0-459a-9273-22f84d9e1614">1,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTEtMS0xLTEtNjk2NTI_af5dd0db-586a-4ffe-bd66-1a9c6a7160c2">14,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTEtMy0xLTEtNjk2NTI_54c0d955-5adf-40ca-9581-3b08f02a6c7b">14,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTItMS0xLTEtNjk2NTI_c5048dfb-c048-48f8-aaef-35c6dfededab">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTItMy0xLTEtNjk2NTI_fb285d2c-96b1-4164-bbe4-395eaad45700">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:DeferredCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTMtMS0xLTEtNjk3Njg_0c213807-2d02-444b-9e03-98e1318433c8">457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:DeferredCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTMtMy0xLTEtNjk3Njg_9238ac54-739c-4db8-ad44-7063c59ca798">347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTMtMS0xLTEtNjk2NTI_f079cf07-6953-4fd9-93b8-d767154d871b">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTMtMy0xLTEtNjk2NTI_8156a877-c446-4f97-9093-453707b06d10">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTQtMS0xLTEtNjk2NTI_e65180ab-2221-42ce-b137-bca2e5efb8e3">106,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTQtMy0xLTEtNjk2NTI_d665a8ff-a883-4001-9eb0-294f3daf4340">114,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTctMS0xLTEtNjk2NTI_5dceb4d4-5db5-4365-a7c0-d84ddd0d4ac1">1,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTctMy0xLTEtNjk2NTI_01b66908-51d8-4c82-9fdf-61c0842c1af4">2,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTgtMS0xLTEtNjk2NTI_b24f88d2-c74b-4aea-b041-68edd6893ed8">6,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTgtMy0xLTEtNjk2NTI_390487ce-ce38-4a07-843a-a1c447300997">7,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTktMS0xLTEtNjk2NTI_771d2cc8-1bdc-4fc7-bc97-61db1d5f0ade">1,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTktMy0xLTEtNjk2NTI_fca28e1e-d95a-473a-b8a8-2c4faac40dd9">1,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjAtMS0xLTEtNjk2NTI_ea550a65-eb59-41a7-b607-308c3ca201cc">9,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjAtMy0xLTEtNjk2NTI_17b1fcdb-56b3-4473-a327-687a2d1ae426">10,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjItMS0xLTEtNjk2NTI_44adc49b-f898-41c0-8c96-84e4bbd7c9b4">53,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjItMy0xLTEtNjk2NTI_e69e655c-d6a3-4235-8bf3-c08e8960ef51">52,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjMtMS0xLTEtNjk2NTI_12cb8be1-01ce-4059-98d2-ce834635a319">15,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjMtMy0xLTEtNjk2NTI_d9399477-2e02-4b65-92a4-c5d42526166c">15,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjQtMS0xLTEtNjk2NTI_4aa9ca07-0fb2-44d3-a83e-c4b63aca6995">78,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjQtMy0xLTEtNjk2NTI_4a0882cd-be08-4344-a940-f4625589c875">79,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjUtMS0xLTEtNjk2NTI_fe24f917-9c72-4933-af69-dc6ae35b35a1"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjUtMy0xLTEtNjk2NTI_7af3983c-75d9-4271-8093-46aa0e8a3a2c"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjctMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjo5ODI5MzY2NjJiNjQ0M2RlODQyMjJmNWNmOGI0OGE0NF8yMQ_23e4b545-0a93-4125-bf3e-c7462c404a04"><ix:nonFraction unitRef="usdPerShare" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjctMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjo5ODI5MzY2NjJiNjQ0M2RlODQyMjJmNWNmOGI0OGE0NF8yMQ_abedb2fb-0caf-49f9-bd5f-4ae7e323b36a">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjctMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjo5ODI5MzY2NjJiNjQ0M2RlODQyMjJmNWNmOGI0OGE0NF8zNQ_735fbd7b-da20-4663-baae-a409e3705bd8"><ix:nonFraction unitRef="shares" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjctMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjo5ODI5MzY2NjJiNjQ0M2RlODQyMjJmNWNmOGI0OGE0NF8zNQ_d2a24ed1-cfb7-428c-98e4-2e9ad07bc1ef">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjctMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjo5ODI5MzY2NjJiNjQ0M2RlODQyMjJmNWNmOGI0OGE0NF82MA_38de2480-4708-442b-a598-5f1f304e7f63"><ix:nonFraction unitRef="shares" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjctMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjo5ODI5MzY2NjJiNjQ0M2RlODQyMjJmNWNmOGI0OGE0NF82MA_87ea88d2-6131-4f91-8ee7-aa23b6deb233"><ix:nonFraction unitRef="shares" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjctMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjo5ODI5MzY2NjJiNjQ0M2RlODQyMjJmNWNmOGI0OGE0NF82MA_cb6cad34-b607-452a-a5dd-2a8137021f78"><ix:nonFraction unitRef="shares" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjctMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjo5ODI5MzY2NjJiNjQ0M2RlODQyMjJmNWNmOGI0OGE0NF82MA_d0bf7283-f08c-46cc-8c5d-32a384a44b5c">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjctMS0xLTEtNjk2NTI_efa55fc4-e7fa-4b76-83af-fb5d9909c837">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjctMy0xLTEtNjk2NTI_36bd9c3e-38c0-4fcd-a2de-cf199d9a1c2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjgtMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjoyZTQ2NmM0NGUwN2Y0ZDQzYjc5MDk2YTIwZjgyYzEyOF8xOA_41358eac-1505-4ba6-aff2-c02fffa48d9c"><ix:nonFraction unitRef="usdPerShare" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjgtMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjoyZTQ2NmM0NGUwN2Y0ZDQzYjc5MDk2YTIwZjgyYzEyOF8xOA_95e35bfa-c065-4802-9d1c-7c6454cfbbfd">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjgtMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjoyZTQ2NmM0NGUwN2Y0ZDQzYjc5MDk2YTIwZjgyYzEyOF8zMg_9151bfd8-e1b3-4d8f-81c4-9afdfa4fdb3a"><ix:nonFraction unitRef="shares" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjgtMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjoyZTQ2NmM0NGUwN2Y0ZDQzYjc5MDk2YTIwZjgyYzEyOF8zMg_e9b354a6-95d1-403c-8577-72b4e594bb2d">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of March&#160;31, 2023 and December&#160;31, 2022; <ix:nonFraction unitRef="shares" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjgtMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjoyZTQ2NmM0NGUwN2Y0ZDQzYjc5MDk2YTIwZjgyYzEyOF83MA_1b22bc4f-3ea0-4f8d-b12d-f2e31395e863"><ix:nonFraction unitRef="shares" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjgtMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjoyZTQ2NmM0NGUwN2Y0ZDQzYjc5MDk2YTIwZjgyYzEyOF83MA_a922b099-0ef1-46a1-a313-8d4d83036d62">25,352,204</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjgtMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjoyZTQ2NmM0NGUwN2Y0ZDQzYjc5MDk2YTIwZjgyYzEyOF83Nw_44e2ca63-0d35-4aa5-8e37-45408a739532"><ix:nonFraction unitRef="shares" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjgtMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjoyZTQ2NmM0NGUwN2Y0ZDQzYjc5MDk2YTIwZjgyYzEyOF83Nw_47a6b247-8392-4b91-a831-392a8f914cd2">25,045,751</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjgtMS0xLTEtNjk2NTI_1611562e-783c-402b-97f1-8bc03bc82ae8">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjgtMy0xLTEtNjk2NTI_dd0137bc-f162-4084-b4e4-3f4da05e923d">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjktMS0xLTEtNjk2NTI_4d33e54b-bda2-47e5-8dd1-020dfa676062">508,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjktMy0xLTEtNjk2NTI_921ab6ec-1b45-4560-91c4-760d3cffdfdc">506,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMzAtMS0xLTEtNjk2NTI_43e705a8-662f-45cb-bb1b-59e5b86bc3c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMzAtMy0xLTEtNjk2NTI_72ed50b0-8d32-4d3f-b6ab-11075b503945">1,108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMzEtMS0xLTEtNjk2NTI_fe963c06-5741-4b5f-8490-908fb0cc84d2">481,228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMzEtMy0xLTEtNjk2NTI_c2ad1ccd-e106-4322-93df-25c416eaaa06">470,853</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMzItMS0xLTEtNjk2NTI_d281aac1-d216-46dd-b84f-c2d2be24cc68">27,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMzItMy0xLTEtNjk2NTI_52ceaa2c-a87c-4989-89ea-5e870658f40b">34,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMzMtMS0xLTEtNjk2NTI_dd861c8e-b648-4d52-9812-a0c1fccddbe9">106,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMzMtMy0xLTEtNjk2NTI_e04fd38b-2f17-41d8-aea0-baafa4686e8f">114,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited interim condensed financial statements.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i2a59f7ea1762416695eae3249a8f9ede_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NeuroPace, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Condensed Statements of Operations and Comprehensive Loss</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except share and per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMi02LTEtMS02OTY1Mg_d6a053bc-3ea2-40b0-96f4-75c7fec90fc3">14,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMi04LTEtMS02OTY1Mg_a52d6fc2-5484-47d7-8c98-617d04f55be0">11,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMy02LTEtMS02OTY1Mg_dd361db9-7c64-4244-b436-fe29b23f44c2">4,100</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMy04LTEtMS02OTY1Mg_79e7c685-a31b-4c15-81b3-e6343455c5a0">3,115</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfNC02LTEtMS02OTY1Mg_1908baef-13d7-4e14-be3b-bfcf82413723">10,372</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfNC04LTEtMS02OTY1Mg_7b4a718c-c0c9-48a7-a725-ad987b11f463">8,259</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfNi02LTEtMS02OTY1Mg_95e02a78-69a2-40c6-b1fb-53de306e848b">5,263</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfNi04LTEtMS02OTY1Mg_e9cabc31-ebf8-4019-947a-e6af0ec31295">5,577</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfNy02LTEtMS02OTY1Mg_e646c0ac-7f47-4aed-8ad6-7c0db2579249">13,428</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfNy04LTEtMS02OTY1Mg_32fcd9b8-1db2-4d5b-84ac-304f8656c4f8">12,444</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfOC02LTEtMS02OTY1Mg_a7a4b6be-6d85-4cc7-8307-1c638aa8a9ff">18,691</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfOC04LTEtMS02OTY1Mg_7d3fe5de-c5e9-48c3-9689-cc0b3e2e0e98">18,021</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfOS02LTEtMS02OTY1Mg_451efff9-a5c9-42e2-b6c8-7e57ad87ac85">8,319</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfOS04LTEtMS02OTY1Mg_c492114c-3870-45cb-a6b5-a1d82c2cfb0c">9,762</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTAtNi0xLTEtNjk2NTI_2377e6fe-39ca-4567-9137-62e1effa0c27">726</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTAtOC0xLTEtNjk2NTI_57906853-5807-47ce-9d43-d27aa12b9de0">134</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTEtNi0xLTEtNjk2NTI_5fa13a6f-83cf-423d-bdd9-22c5d1aa40e5">1,965</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTEtOC0xLTEtNjk2NTI_f450905e-0152-4d14-88c7-25077f4da48f">1,830</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTItNi0xLTEtNjk2NTI_49ec50a8-512e-49cb-be56-22d80abc1fb5">817</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTItOC0xLTEtNjk2NTI_07910e84-6133-43a3-b788-a99a50d75000">3</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTMtNi0xLTEtNjk2NTI_17c5addb-c199-4638-a627-e977cda0bc50">10,375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTMtOC0xLTEtNjk2NTI_2ad5a319-b4cf-441a-ba59-aa26ed882481">11,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on available-for-sale debt securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTQtNi0xLTEtNjk2NTI_06cd4e44-2fed-4260-b2c5-72881f2f1ef3">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTQtOC0xLTEtNjk2NTI_d6e41c10-741f-450a-a3d5-38a8caffee8a">710</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTUtNi0xLTEtNjk2NTI_168773fd-6a56-4748-892a-bdf851380397">10,375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTUtOC0xLTEtNjk2NTI_77a88e08-b988-40a2-9b71-8bfb6159bd41">12,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTYtNi0xLTEtNjk2NTI_6302e956-d4ad-47e7-bfc2-592bf9bdfec7"><ix:nonFraction unitRef="usdPerShare" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="INF" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTYtNi0xLTEtNjk2NTI_f089392a-55da-4e44-afa3-54eca2bb58b9">0.41</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTYtOC0xLTEtNjk2NTI_42b963fd-2ce9-48c5-b06b-c738191daa9d"><ix:nonFraction unitRef="usdPerShare" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="INF" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTYtOC0xLTEtNjk2NTI_6e36456c-b860-43e8-99a0-f9ac82ec6484">0.47</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTctNi0xLTEtNjk2NTI_52fae933-8a5a-4cf7-9b9d-49bb0a2915a1"><ix:nonFraction unitRef="shares" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTctNi0xLTEtNjk2NTI_93185e30-5cee-4104-9a41-2468988e1226">25,097,262</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTctOC0xLTEtNjk2NTI_84e3ba43-8981-4e29-a431-4c9fd84e6ab2"><ix:nonFraction unitRef="shares" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTctOC0xLTEtNjk2NTI_dcb47b59-7079-4515-94d2-7a5ad42243f3">24,307,485</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited interim condensed financial statements.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i2a59f7ea1762416695eae3249a8f9ede_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NeuroPace, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Condensed Statements of Stockholders&#8217; Equity</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:41.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.071%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances as of January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61be63c82dfc4be78e2f9d68b4f11019_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfMi0xLTEtMS02OTk5MQ_69ae5fed-5b9c-43d3-9cdf-55c942bb87d4">25,045,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61be63c82dfc4be78e2f9d68b4f11019_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfMi0zLTEtMS02OTk5MQ_9333a54d-84c1-49dd-b69c-bfeaf1c7e446">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a7716fe4f8442ea99bfcffe232e221_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfMi01LTEtMS02OTk5MQ_2aa08d6b-8530-4d54-8ed4-2da71cd11b46">506,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8d9bf075ca645be8dba336153887c29_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfMi03LTEtMS02OTk5MQ_783bb4b0-4891-417b-a1bf-81ed3e26cb5c">1,108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98bf413ba1ce4032a1cdf3cbddd33acd_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfMi05LTEtMS02OTk5MQ_acf3491c-0808-4a6f-b84f-022aabf449f7">470,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfMi0xMS0xLTEtNzE2ODA_068bd5c1-7544-494c-9af2-ff977565e5c5">34,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7809dc429fd8495f9d069ad7b000facc_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfMy05LTEtMS02OTk5MQ_42a4b1b4-6863-4f38-93cc-e7a1f4b9fd2d">10,375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfMy0xMS0xLTEtNzE2ODI_c6855882-0999-42ad-bd8b-8713f7f064ba">10,375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss adjustment for short-term investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62099d19b5164e1a965faa8cb79f62df_D20230101-20230331" decimals="-3" name="npce:OCIUnrealizedLossAdjustmentForShortTermInvestment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfNC03LTEtMS03MDA2NA_670485ba-7461-4bfb-a949-c173e691182b">1,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="npce:OCIUnrealizedLossAdjustmentForShortTermInvestment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfNC0xMS0xLTEtNzE2ODQ_75f6221b-f8f7-4885-aee3-c55ef12a8a06">1,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock pursuant to stock option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b89c6fbb19942c7ba5917a6174e4e08_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfNC0xLTEtMS02OTk5MQ_5f6f247a-7146-4e0f-a9c8-c8edb8cec439">17,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac806c35c4c94cfbabaf3bf0aac255e4_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfNC01LTEtMS02OTk5MQ_3686fce4-84ed-48e5-9f4c-194867c89b3b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfNS0xMS0xLTEtNzE2ODY_334054a8-a86d-46ab-987c-a7bc8842c6bd">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b89c6fbb19942c7ba5917a6174e4e08_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfNi0xLTEtMS03MDA4Ng_1cec9d79-4335-40a9-80c0-df54546c4501">325,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares withheld for taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6b89c6fbb19942c7ba5917a6174e4e08_D20230101-20230331" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfNy0xLTEtMS03MDA4Ng_48afad77-0624-4c22-986f-9afd6321d53b">35,562</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac806c35c4c94cfbabaf3bf0aac255e4_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfNy01LTEtMS03MDA4Ng_86098738-04c1-4316-91d9-570679699fa6">146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfNy0xMS0xLTEtNzE3MDI_c09c83c7-1e0b-4af3-a2fc-bcf871141a2f">146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6b89c6fbb19942c7ba5917a6174e4e08_D20230101-20230331" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfOC0xLTEtMS03Mjg4NA_eb608bab-d8ce-400e-8615-660f14a3be16">1,340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac806c35c4c94cfbabaf3bf0aac255e4_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfNS01LTEtMS02OTk5MQ_13198603-f4b8-45ae-b81f-1062fdde1b56">2,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfOC0xMS0xLTEtNzE3MDQ_d54da244-a714-4838-a8e9-e471b73742c1">2,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances as of March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ad874e29bb74c679f513a76324f85d3_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfOS0xLTEtMS03MTY4OA_8abdd006-a745-4431-a6d3-1e4d8636ade1">25,352,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ad874e29bb74c679f513a76324f85d3_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfOS0zLTEtMS03MTY5MA_aa67b9bc-affe-423a-8136-8e08570e52ae">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e12eed5884041b78d03f7d55c84255f_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfOS01LTEtMS03MTY5Mg_cbb2781c-702e-49c2-a892-98b2c4978132">508,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63642277a31a4e158aa8e35fc5614bf2_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfOS03LTEtMS03MTY5NA_ab9f4e06-7294-4ebc-bb6d-88d8549d8cba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4f3a4d01eb64c3d99f32042d0306005_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfOS05LTEtMS03MTY5Ng_4649a67e-9ae3-44fe-b18a-89c0323b39cd">481,228</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfOS0xMS0xLTEtNzE2OTg_5a7a2cf9-7b51-4cba-814b-82d239ef00fa">27,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:41.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.071%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances as of January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2672791bd16a4560ac4e6349ada7df02_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfMi0xLTEtMS02OTY1Mg_5a4cd9b9-35bc-45e9-a3f0-2e0c3dc39b80">24,452,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2672791bd16a4560ac4e6349ada7df02_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfMi0zLTEtMS02OTY1Mg_37453252-3c7b-468c-8625-978d8081a964">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb6c3879fe2843cb86d6b11e28b0ece0_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfMi01LTEtMS02OTY1Mg_e7f94abc-f817-4ad1-afd5-44c31c3dc5eb">497,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i583edd3895a14ca5acca2fc71f20f802_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfMi03LTEtMS02OTY1Mg_3ab4f886-fd7f-48d1-95dc-86b12d297bad">272</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb3a188a2ef045108bee1a5e3cdc8bf7_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfMi05LTEtMS02OTY1Mg_53f2ae7e-1a78-4088-a0dd-3bf725916c1f">423,771</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c2f30808f842e79b03a1b5e2dc3a74_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfMi0xMS0xLTEtNjk2NTI_b4fe318a-ca24-433b-91a3-ac661f2836df">73,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie317d529e039488fa3e2b724a267f0af_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfMy05LTEtMS02OTY1Mg_75ecdd71-9e60-45bc-91d8-53e2e1bd79ca">11,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfMy0xMS0xLTEtNjk2NTI_1c42d22a-25cf-4afc-ba16-07c51fb04e7b">11,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on available-for-sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ebcbcb47ad845b58adc86041e6d3e95_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfNC03LTEtMS02OTY1Mg_b0d2d0e4-5f55-4822-a8be-d1b71b84a8a0">710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfNC0xMS0xLTEtNjk2NTI_804cbbf8-85c8-40a1-9dfc-4f023ca5fd68">710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock pursuant to stock option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83cf5939e5774de68da51a47ab212e1f_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfNS0xLTEtMS02OTY1Mg_dd748899-cc7f-4be3-8b5d-70bcb17bb835">38,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cf5d7f0fdf14d358770256db90ddb08_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfNS01LTEtMS02OTY1Mg_33c0abbd-bd1f-418b-aa1b-031eaba3ee92">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfNS0xMS0xLTEtNjk2NTI_9ba62b59-ae2a-4661-a804-ac4d49879652">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i83cf5939e5774de68da51a47ab212e1f_D20220101-20220331" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfNi0xLTEtMS02OTY1Mg_bc632ebb-f196-4d83-8be4-aa89767ca863">14,454</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in early exercise liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cf5d7f0fdf14d358770256db90ddb08_D20220101-20220331" decimals="-3" sign="-" name="npce:AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfNy01LTEtMS02OTY1Mg_d4c34534-11bd-483c-bd9a-eb09ffebbd99">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" sign="-" name="npce:AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfNy0xMS0xLTEtNjk2NTI_33993bc7-9f58-440e-a04c-07614ff7e037">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cf5d7f0fdf14d358770256db90ddb08_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfOC01LTEtMS02OTY1Mg_c1d6a3d0-feb6-4380-8029-79074e790b7b">1,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfOC0xMS0xLTEtNjk2NTI_ac220d39-df5b-46f0-9b03-268fc4d7f0e9">1,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances as of March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i073cd7dafa2f45088fbdd34201842f90_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfOS0xLTEtMS02OTY1Mg_4c540bb8-a28c-4792-8d9b-6cf857da4913">24,477,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i073cd7dafa2f45088fbdd34201842f90_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfOS0zLTEtMS02OTY1Mg_81854a12-5756-4808-8d9b-1178edb2a911">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50b17b8c21b8445ebb59d9b3575ecf6f_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfOS01LTEtMS02OTY1Mg_2e242411-baa6-4fa1-a6f5-51c393475dd7">499,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a126628dbb0405eb5c4b1f67cdd87ab_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfOS03LTEtMS02OTY1Mg_23296e07-3b6f-41f6-8bce-859b7d6245f7">982</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1616f745a37b421a8451f51495269b96_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfOS05LTEtMS02OTY1Mg_39002524-ae6f-4050-870d-16b63440731b">435,232</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d497eb241564565aff73765a48fe320_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfOS0xMS0xLTEtNjk2NTI_e3e7fe1b-4d41-4352-9a15-2c98267090f4">62,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited interim condensed financial statements.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i2a59f7ea1762416695eae3249a8f9ede_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NeuroPace, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Condensed Statements of Cash Flows</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMy0xLTEtMS02OTY1Mg_a4924d46-8bd4-4184-8f89-bd2eea3a8aae">10,375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMy0zLTEtMS02OTY1Mg_98dfb3c3-b1fa-4d7e-8028-64b99fd469c1">11,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNS0xLTEtMS02OTY1Mg_2e12822b-87ce-46ac-bc75-8198fe64cdfa">2,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNS0zLTEtMS02OTY1Mg_8fd85596-e874-4e86-b011-1248bb9e58e7">1,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNi0xLTEtMS02OTY1Mg_96854885-65a7-49f1-b221-b112a6c9214d">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNi0zLTEtMS02OTY1Mg_0ad25b42-e60c-44c9-82dc-916131af39a2">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNy0xLTEtMS02OTY1Mg_8b19a20c-988e-4754-98a2-63c1f1c0dcba">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNy0zLTEtMS02OTY1Mg_f6761497-5340-4268-a666-67f20c2e22be">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="npce:IncreaseDecreaseInNonCashInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfOC0xLTEtMS02OTY1Mg_5ee7030e-1eb9-480c-9c9a-0b4f75b1fc6c">234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="npce:IncreaseDecreaseInNonCashInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfOC0zLTEtMS02OTY1Mg_284b20db-4e42-4d52-a753-35d66ec06377">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PIK interest incurred but not paid on term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfOS0xLTEtMS02OTY1Mg_dc1fa72a-f204-483a-85ae-3d80637c8619">649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfOS0zLTEtMS02OTY1Mg_92272bf8-d5d9-4f5d-8db5-0296e6ac86d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTAtMS0xLTEtNjk2NTI_b564b676-28c6-4b05-affd-f540603836d1">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTAtMy0xLTEtNjk2NTI_e541c01e-351f-4c5e-ad22-44b6acbe509f">672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTEtMS0xLTEtNjk2NTI_d69993af-41bc-419f-a1eb-73c5f4f7889c">817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTEtMy0xLTEtNjk2NTI_2f2caf01-b17f-41a4-bdce-3da6faf7d1cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory write-downs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTItMS0xLTEtNjk2NTI_2bc82c2e-470f-4b90-ba2d-266362a68217">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTItMy0xLTEtNjk2NTI_4c190786-8f2c-44cd-8122-58a21eefc61a">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTUtMS0xLTEtNjk2NTI_23d9542c-dda6-4af0-9032-6021c4600f95">1,713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTUtMy0xLTEtNjk2NTI_44dc326e-5e9e-48b6-8f6b-f09be4bc0947">1,970</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTYtMS0xLTEtNjk2NTI_a61b34c3-988e-4986-b821-ac3cea25089f">1,072</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTYtMy0xLTEtNjk2NTI_551b5166-c006-400b-b209-15d7e179c5cb">362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTctMS0xLTEtNjk2NTI_f7a70944-640d-444d-a889-6e0276b76e2b">514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTctMy0xLTEtNjk2NTI_bb1975cd-9ea5-4521-b4ec-5b86fbf76ba5">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTgtMS0xLTEtNjk2NTI_f3c331af-ee5b-4652-9c80-ecf5ac340bb9">193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTgtMy0xLTEtNjk2NTI_52eb8615-5d65-4126-acc3-dc07217b2fbc">820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTktMS0xLTEtNjk2NTI_0c826607-d6ea-49a0-a75f-1c878bbf1b23">834</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTktMy0xLTEtNjk2NTI_763e96a7-1f1a-4aa5-9892-4a1f704bc4e1">472</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMjAtMS0xLTEtNjk2NTI_b3902141-a3eb-4ef8-bb28-a5865946e33b">343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMjAtMy0xLTEtNjk2NTI_3bf3512f-b938-4e67-b280-a91e12622bc3">777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMjItMS0xLTEtNjk2NTI_6ac1d466-9013-4802-b907-387da34992e5">9,698</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMjItMy0xLTEtNjk2NTI_ecface9f-03c7-439c-9e45-a67490395daf">11,393</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMjQtMS0xLTEtNjk2NTI_1250ccc3-3cd6-41ca-9c2d-d20540b79a42">132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMjQtMy0xLTEtNjk2NTI_e266d588-3156-4acb-9725-121dd108f8b9">306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMjUtMS0xLTEtNjk2NTI_d65edd19-6597-41a2-8edb-5984602f48b1">10,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMjUtMy0xLTEtNjk2NTI_36ba756e-6bfe-4509-af42-04115d1ba74a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMjctMS0xLTEtNjk2NTI_0744c968-1cd2-44af-910d-da615ac1213b">10,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMjctMy0xLTEtNjk2NTI_52be434a-02c9-453e-8ae7-744a486618ce">306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under employee plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMjktMS0xLTEtNjk2NTI_b677caaa-7a78-4be1-a853-59b3e605d5cc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMjktMy0xLTEtNjk2NTI_042a3f0b-8045-4b20-8a06-aec4b7580bc7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes withheld and paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMzAtMS0xLTEtNjk2NTI_ee567736-ac10-4c51-aa73-a308c3948208">146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMzAtMy0xLTEtNjk2NTI_c26ada38-50de-4ed3-81a8-3d1beea293eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of deferred offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMzItMS0xLTEtNjk2NTI_fa293d56-ba01-4b99-a63e-33b303a69908">110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMzItMy0xLTEtNjk2NTI_a154644c-d85c-47fd-8a8f-dbade56aed48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMzQtMS0xLTEtNjk2NTI_b7af4930-6da3-45e9-a969-abebb534ec02">255</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMzQtMy0xLTEtNjk2NTI_fedd080e-cfe1-42ea-ba8d-24562e6b23a6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMzUtMS0xLTEtNjk2NTI_3dd14ac6-214c-4ab4-bb46-ad596975dfb2">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMzUtMy0xLTEtNjk2NTI_5228a26a-cf21-4a58-834b-42dbf237a753">11,698</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMzctMS0xLTEtNjk2NTI_f1a53a80-fe57-4356-9de6-ace88dbcfeee">6,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c2f30808f842e79b03a1b5e2dc3a74_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMzctMy0xLTEtNjk2NTI_f2c36109-44b6-4889-b241-14bc662eeb7f">19,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of the period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMzgtMS0xLTEtNjk2NTI_0e448521-41f2-41ba-bec8-9d4bdd239794">6,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d497eb241564565aff73765a48fe320_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMzgtMy0xLTEtNjk2NTI_9dc37fa0-823c-40a2-b96a-15f39dd83a2b">7,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash to balance sheets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNDAtMS0xLTEtNjk2NTI_1cbb5718-1a56-4152-b39f-1ede5dcb2c29">6,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d497eb241564565aff73765a48fe320_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNDAtMy0xLTEtNjk2NTI_7cbcf31c-54ec-42ee-ac02-6eec0f82a345">7,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNDEtMS0xLTEtNjk2NTI_c5048dfb-c048-48f8-aaef-35c6dfededab">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d497eb241564565aff73765a48fe320_I20220331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNDEtMy0xLTEtNjk2NTI_b2a1dd18-9c3a-4981-ab95-1f3d57d51321">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash in balance sheets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNDItMS0xLTEtNjk2NTI_92f2503f-3c22-4723-80cd-588816a6ef32">6,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d497eb241564565aff73765a48fe320_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNDItMy0xLTEtNjk2NTI_35c8162e-bb65-412e-84e3-808afec5821b">7,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNDUtMS0xLTEtNjk2NTI_497a08b2-2725-4be9-9246-3cfc4ef036d7">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNDUtMy0xLTEtNjk2NTI_179f63d7-3ca6-42a8-baa0-039456d7042b">1,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosures of non-cash investing and financing information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in accrued liabilities from early exercise of options</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="npce:IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNDgtMS0xLTEtNjk2NTI_c4079a16-7f6f-49e8-a1b3-99863414520e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" sign="-" name="npce:IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNDgtMy0xLTEtNjk2NTI_bf8ba494-a422-4764-942b-cd57ab473881">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of property and equipment included in accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNDktMS0xLTEtNjk2NTI_f1402a39-1086-4b6c-82ce-eb1d55a632e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNDktMy0xLTEtNjk2NTI_8fa8e32c-cb36-4e3b-be01-2941baed61d3">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited interim condensed financial statements.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i2a59f7ea1762416695eae3249a8f9ede_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NeuroPace, Inc.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Condensed Financial Statements</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2a59f7ea1762416695eae3249a8f9ede_34"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfNTE0MA_f498c945-73cd-4bba-86ac-f51706b739e0" continuedAt="ic281b9a8166242df93a567e61e893612" escape="true">The Company</ix:nonNumeric></span></div><ix:continuation id="ic281b9a8166242df93a567e61e893612" continuedAt="i55b9736d4c4d4092adc58d89180f0a6e"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NeuroPace, Inc., or the Company, was incorporated in the state of Delaware on November 19, 1997. The Company is a commercial-stage medical device company that has developed the RNS System, the only commercially available brain-responsive neuromodulation system designed for treating medically refractory focal epilepsy by delivering personalized, real-time treatment at the seizure source. The Company began commercializing its products in the United States in 2014.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Initial Public Offering</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2021, the Company&#8217;s registration statement on Form S-1 (File No. 333-254663) relating to its initial public offering, or IPO, of common stock became effective. The IPO closed on April 26, 2021, at which time the Company issued <ix:nonFraction unitRef="shares" contextRef="ic31468e5e435455380b814e3c2061589_D20210426-20210426" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfNzQ4_d23ff48b-4164-4dc7-85e7-ce23ce4c7a70">6,900,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if0b1b62330d2427a92e83025c46122d5_I20210426" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfNzky_6de51c61-addd-482c-9764-f64db5dec0fe">17.00</ix:nonFraction> per share, which included the issuance of shares in connection with the exercise by the underwriters of their option to purchase up to <ix:nonFraction unitRef="shares" contextRef="i6f49f5b3c47d4ba1ac4f833941af6ad6_D20210426-20210426" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfOTMw_f65482b5-0c94-4945-a6b0-ba2483089ce0">900,000</ix:nonFraction> additional shares. The Company received an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ic31468e5e435455380b814e3c2061589_D20210426-20210426" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfOTg5_1b3fb74c-f4ff-4507-a3a1-b9e98e0ed327">117.3</ix:nonFraction> million in gross proceeds, before underwriting discounts and commissions and offering costs, and approximately $<ix:nonFraction unitRef="usd" contextRef="ic31468e5e435455380b814e3c2061589_D20210426-20210426" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfMTA5NQ_2c66ab3f-9433-404c-af15-941e7a84a1a9">105.5</ix:nonFraction> million in net proceeds after deducting $<ix:nonFraction unitRef="usd" contextRef="ic31468e5e435455380b814e3c2061589_D20210426-20210426" decimals="-5" name="npce:SaleOfStockUnderwritingDiscounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfMTEzMA_9d8f2545-c971-46ec-9af6-0f5f64b3869a">8.2</ix:nonFraction>&#160;million in underwriting discounts and commissions and $<ix:nonFraction unitRef="usd" contextRef="ic31468e5e435455380b814e3c2061589_D20210426-20210426" decimals="-5" name="npce:SaleOfStockOfferingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfMTE3OQ_389ffa0c-4628-421e-bd28-c3c49424df85">3.6</ix:nonFraction>&#160;million in offering costs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At-the-Market Equity Offering</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company filed a Registration Statement on Form S-3, or Shelf, with the Securities and Exchange Commission in relation to the registration of common stock, preferred stock, debt securities, warrants or any combination thereof for up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ibd6ab3a83420410da0927243af8d2e90_D20221101-20221130" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfNTQ5NzU1ODIwMzgz_e3c576c8-cf57-4c25-b476-601ae63ffe0a">150.0</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="ibd6ab3a83420410da0927243af8d2e90_D20221101-20221130" decimals="-5" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfNTQ5NzU1ODIwNDAy_140c3312-1a29-4d45-a474-5a3b48c72f0d">50.0</ix:nonFraction>&#160;million may be issued and sold pursuant to an at-the-market, or ATM, offering program for sales of the Company&#8217;s common stock under a sales agreement, or Sales Agreement, with SVB Securities LLC, or SVB. The Company agreed to pay SVB up to <ix:nonFraction unitRef="number" contextRef="ibd6ab3a83420410da0927243af8d2e90_D20221101-20221130" decimals="3" name="npce:PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfMjc0ODc3OTA3OTEzMA_d82585a2-9255-4ec5-a562-085859665028">3.0</ix:nonFraction>% of the gross proceeds of sales of common stock made through the Sales Agreement. The Company&#8217;s common stock would be sold at prevailing market prices at the time of the sale and, as a result, prices may vary. The Company has <ix:nonFraction unitRef="shares" contextRef="id1b89218f85e4970ba94327f3911df2b_D20230101-20230331" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfMjc0ODc3OTA3OTEzNQ_60526a88-96f0-408e-91ef-03b63cca4a6f">no</ix:nonFraction>t issued or sold any securities pursuant to the Shelf or ATM offering program.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred operating losses and negative cash flows from operations since its inception and has an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfMjExNw_723920d0-aff7-48c1-8b61-0100eff3710b">481.2</ix:nonFraction> million as of March&#160;31, 2023. For the three months ended March&#160;31, 2023 and 2022, the Company used $<ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfMjE4NA_2b18bef7-5d4d-49e8-8010-b39c8aed6643">9.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfMjE5MQ_9ba568d4-e00e-45e9-b5b5-12164193ae82">11.4</ix:nonFraction> million of cash, respectively, in its operating activities. As of March&#160;31, 2023, the Company had cash, cash equivalents and short-term investments of $<ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfMjMyNQ_cc975419-9f1c-461b-b6c4-ac3e1fcb34bf">67.6</ix:nonFraction> million. Historically, the Company has funded its operations principally through the sales of its products, issuance of redeemable convertible preferred stock and debt financing.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed financial statements have been prepared on the basis of the Company continuing as a going concern for the next 12 months. Management believes that the Company&#8217;s cash, cash equivalents and short-term investments will allow the Company to continue its planned operations for at least the next 12 months from the date of the issuance of these unaudited interim condensed financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Term Loan described in Note 6, the Company will need to be in compliance with a minimum annual net revenue covenant determined in accordance with generally accepted accounting principles of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i34fc98c3b9124df39be5fbc449566961_D20230101-20231231" decimals="-5" name="npce:DebtInstrumentCovenantMinimumAnnualNetRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfMzI5Mw_7c0c256d-df67-43da-85d8-10bbf2b440a2">45.0</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the year ended December 31, 2023, and maintain a minimum cash and cash equivalents balance of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i2fb4e476763541a694ffb3eb2be6c4dd_I20231231" decimals="-5" name="npce:DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfMzM5Mw_a89631da-c8be-4f1f-b2e9-554d663462cc">5.0</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If the Company cannot generate sufficient revenue in the future, the Company may not be in compliance with the annual net revenue covenant and the lender may call the debt resulting in the Company immediately needing additional capital, and resulting in a going concern. The Company&#8217;s ability to raise additional capital may be adversely impacted by global economic conditions and the recent disruptions to, and volatility in, the financial markets in the United States and worldwide. If the Company is unable to raise capital when needed, it will need to delay, limit, reduce or terminate planned commercialization or product development activities in order to reduce costs. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company was in compliance with all covenants of the Term Loan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global spread of the COVID-19 pandemic, including the different COVID-19 variants and measures introduced by local, state and federal governments to contain the pandemic and mitigate its public health effects, </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NeuroPace, Inc.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Condensed Financial Statements</span></div></div><div style="margin-bottom:9pt"><ix:continuation id="i55b9736d4c4d4092adc58d89180f0a6e"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have significantly impacted the global economy and negatively impacted our business. Beginning in March 2020, the Company&#8217;s net sales were negatively impacted by the COVID-19 pandemic as hospitals delayed or canceled elective procedures. The decrease in hospital admission rates and elective surgeries reduced both the number of patients being evaluated for treatment with and demand for elective procedures using the Company's RNS System. By the second half of 2022, the impact of the pandemic on the Company&#8217;s revenue had diminished. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, the future impact of the COVID-19 pandemic on the Company&#8217;s business, financial condition and results of operations is dependent on future developments, including the potential emergence of new COVID-19 variants and spikes in COVID-19 cases, which </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remain highly uncertain and cannot be predicted.</span></ix:continuation></div><div id="i2a59f7ea1762416695eae3249a8f9ede_37"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTcyMjM_d3b19c4a-4679-4d8f-8bdb-6094bcbf02ce" continuedAt="i80786b90a4ac4343a8f639aeb193f11c" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i80786b90a4ac4343a8f639aeb193f11c" continuedAt="i7346b49a1d164de589b79cc8bd19ce2f"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTcyMzA_04ffeffe-62a4-4387-a3b4-b63c3c9120fb" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed financial statements have been prepared in conformity with generally accepted accounting principles in the United States, or GAAP, as defined by the Financial Accounting Standards Board, or the FASB.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed balance sheet as of December 31, 2022 was derived from the Company&#8217;s audited financial statements, but does not include all disclosures required by GAAP. The accompanying unaudited condensed financial statements as of March 31, 2023 and for the three months ended March 31, 2023 and 2022, have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC, for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. Accordingly, these financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2022 and notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the SEC on March 2, 2023. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company&#8217;s condensed financial position as of March 31, 2023 and condensed results of operations and condensed cash flows for the three months ended March 31, 2023 and 2022 have been made. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2023.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTcyMjI_d55a7243-d4be-4296-9d0f-b2576173bdce" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited interim condensed financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. The Company uses significant judgment when making estimates related to the valuation of deferred tax assets and related valuation allowances and provision for excess and obsolete inventories. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTcyMzE_b3bc1aaa-4669-40cb-9320-043a840423d5" continuedAt="ie7497e4eec1b4b9e94d2873d28ce1e80" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amounts of certain of the Company&#8217;s financial instruments, including cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value because of the short-term nature of these instruments. The Company has a short-term investment in a fixed income mutual fund, which is classified as equity security and carried at fair value based on quoted market prices. Changes in the fair value of the short-term investment are recorded in income or loss. The Company believes that its borrowings bear interest at the prevailing market rates for instruments with similar characteristics; accordingly, the carrying value of this instrument approximates its fair value. The Company determines the fair value of financial and non-financial assets and </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NeuroPace, Inc.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Condensed Financial Statements</span></div></div><ix:continuation id="i7346b49a1d164de589b79cc8bd19ce2f" continuedAt="i6ddde2988cb949aab6f69b7e9bc45c1c"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie7497e4eec1b4b9e94d2873d28ce1e80" continuedAt="ie5b782a08c6e45f1873ee7cb11e5b895">liabilities using the fair value hierarchy which establishes three levels of inputs that may be used to measure fair value (see Note 3).</ix:continuation></span></div><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTcyMzI_57d452b5-2930-4298-94da-ca7e9df65103" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk, and Other Risks and Uncertainties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, short-term investments and accounts receivable to the extent of the amounts recorded on the balance sheets. The Company&#8217;s cash is invested in major financial institutions in the United States. Deposits in these financial institutions may exceed federally insured limits, and the Company is exposed to credit risk on deposits in the event of default of the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation. The Company&#8217;s cash equivalents are invested in money market funds.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable are due from a variety of health care organizations in the United States. For the three months ended March&#160;31, 2023 and 2022, there were no customers that represented 10% or more of revenue. As of March&#160;31, 2023 and December&#160;31, 2022, no customer represented 10% or more of the Company&#8217;s accounts receivable.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain risks, including that its devices may not be approved or cleared or continue to be approved or cleared for marketing by governmental authorities or be successfully marketed for expanded indications. There can be no assurance that the Company&#8217;s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and speed and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence on healthcare providers to prescribe initial implants and replacements, dependence upon third-party payors to provide adequate coverage and reimbursement, dependence on key personnel, single-source suppliers and vendors in connection with the manufacture of its products, concentration of CECs and epileptologists, obtaining, maintaining, protecting, enforcing, and defending intellectual property rights and proprietary technology, product liability claims, legal proceedings, and compliance with government regulations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s medical devices require approvals or clearances from the U.S. Food and Drug Administration, or the FDA, or international regulatory agencies. In addition, in order to continue the Company&#8217;s operations, compliance with various federal and state laws is required. If approvals or clearances were withdrawn by the FDA for the Company&#8217;s current products or if such approvals or clearances were denied or delayed for future products, product updates, or expanded indications for use, it would have a material adverse impact on the Company.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMjc0ODc3OTA5NzYxNw_48d99562-0202-4373-a572-dad8dba686ee" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company makes estimates on the collectability of customer accounts based primarily on analysis of historical trends and experience, the age of the receivable and changes in customers&#8217; financial condition. The Company uses its judgment, based on the best available facts and circumstances, and records an allowance against amounts due to reduce the receivable to the amount that is expected to be collected. The Company determined that no allowance was required as of March&#160;31, 2023 and December 31, 2022. To date, the Company has not experienced any credit-related losses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTcyMjc_2b77f7a8-1dad-4624-aa8e-259c545e90f4" continuedAt="ic91aa73b36bd4e5b8da75879a7047bcb" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Programs</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company was awarded a grant by the National Institutes of Health, or NIH, to support research of thalamocortical responsive neurostimulation for the treatment of Lennox-Gastaut Syndrome, a type of epilepsy. The award was issued for a <ix:nonNumeric contextRef="iea9e5bc642294c36a2e9ce408258fa44_D20210501-20210531" name="npce:ResearchAndDevelopmentArrangementWithFederalGovernmentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTcyMjQ_4cb5a518-aa10-4208-8cf0-29fe7128c6ce">five-year</ix:nonNumeric> period and has a total budget of over $<ix:nonFraction unitRef="usd" contextRef="iea9e5bc642294c36a2e9ce408258fa44_D20210501-20210531" decimals="-5" name="npce:ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfOTk1Mw_480dbf6c-bd51-4870-b169-66f76959c882">9.3</ix:nonFraction>&#160;million, which includes approximately $<ix:nonFraction unitRef="usd" contextRef="iea9e5bc642294c36a2e9ce408258fa44_D20210501-20210531" decimals="-5" name="npce:ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfOTk4Ng_34f3d941-438a-421a-b4e4-b1e74e4946f2">5.5</ix:nonFraction>&#160;million in funding for subawards to third party academic epilepsy centers that are collaborating on the study and are subinvestigators on the study funded by NIH. The subawardees are determined by NIH. The Company&#8217;s responsibility for the subawards is to submit the funding requests on behalf of the subawardees. The funding of subawards does not have any impact on the Company&#8217;s condensed financial statements. Initially funding was approved for the first year beginning June 1, 2021 and provides for reimbursement of qualified direct and indirect expenses in the amount of $<ix:nonFraction unitRef="usd" contextRef="ie20e4646b6c64bd484f8b50c7fcb7a1e_D20210601-20210601" decimals="-5" name="npce:ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTA1NTY_ecf0f39e-d0f4-4ce3-9e18-26eafcedb2e5">0.8</ix:nonFraction>&#160;million, including $<ix:nonFraction unitRef="usd" contextRef="ie20e4646b6c64bd484f8b50c7fcb7a1e_D20210601-20210601" decimals="-5" name="npce:ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTA1NzA_8256c804-3132-44e7-8604-e2e5abc6dbc8">0.4</ix:nonFraction>&#160;million for subawards. Approvals of funds for years </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NeuroPace, Inc.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Condensed Financial Statements</span></div></div><ix:continuation id="i6ddde2988cb949aab6f69b7e9bc45c1c"><ix:continuation id="ic91aa73b36bd4e5b8da75879a7047bcb"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">two through five are subject to the completion of certain milestones. On July 30, 2022, the Company received funding approval for year two in the amount of $<ix:nonFraction unitRef="usd" contextRef="id750435b22204579ab914565baeecdcc_D20220730-20220730" decimals="-5" name="npce:ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTA3NzM_2df62113-9288-4875-932b-28ad18df14e6">2.6</ix:nonFraction>&#160;million, which includes $<ix:nonFraction unitRef="usd" contextRef="id750435b22204579ab914565baeecdcc_D20220730-20220730" decimals="-5" name="npce:ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTA3OTI_ef136b26-a85d-4cf7-99db-b4cd8f1fa232">1.6</ix:nonFraction>&#160;million for subawards.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For funds received under the NIH funding agreement, the Company recognizes a reduction in research and development expenses in an amount equal to the qualifying expenses incurred in each period up to the amount awarded by the NIH. Qualifying expenses incurred by the Company in advance of funding by the NIH are recorded within prepaid expenses and other current assets on the balance sheets. Through March&#160;31, 2023, $<ix:nonFraction unitRef="usd" contextRef="i63da6b904e2e4e799b8f63827d7dd2ec_D20230101-20230331" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTEyMTU_23821f73-d8f9-40dc-beb7-ae84d54737f1">1.0</ix:nonFraction>&#160;million of qualifying expenses have been incurred and funded by the NIH related to the first and second year funding. As of March&#160;31, 2023, the Company recorded prepaid expenses and other current assets of $<ix:nonFraction unitRef="usd" contextRef="i8548ff80a4ad42a7bc8f521cc07045af_I20230331" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTE0MTQ_54b70142-4228-45f5-b2ad-4d96303772cc">0.1</ix:nonFraction>&#160;million related to the second year funding.</span></div></ix:continuation><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTcyMjg_a365b108-f7fd-44a4-b806-672612f536f3" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss per Share Attributable to Common Stockholders</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, stock options, common stock subject to repurchase related to early exercise of stock options, and restricted stock units are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities. The Company considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of the shares issued upon early exercise of stock options subject to repurchase do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTcyMjk_b1d5f148-de63-43a1-8850-7e936ca0f3f7" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends existing guidance on the impairment of financial assets and adds an impairment model that is based on expected losses rather than incurred losses and requires an entity to recognize as an allowance its estimate of expected credit losses for its financial assets. An entity will apply this guidance through a cumulative-effect adjustment to retained earnings upon adoption (a modified-retrospective approach) while a prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. For public business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, adoption is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. For SEC filers that are eligible to be smaller reporting companies and for all other entities, this ASU is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company adopted this ASU effective January 1, 2023. The adoption of this ASU did not have a material effect on the Company&#8217;s financial statements and related disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2a59f7ea1762416695eae3249a8f9ede_43"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RleHRyZWdpb246MGM2NTE4NDAyOGU1NGQzYmJmYmRkNTliNmQ0ZDJjNjVfMjk3Ng_a2c03ed4-b52c-4f0f-8ef6-d10fb13e63c4" continuedAt="i02846727e4824b998077824359d7ea80" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="ie5b782a08c6e45f1873ee7cb11e5b895" continuedAt="i14b55d4b593541568667986325ff0bc0"><ix:continuation id="i02846727e4824b998077824359d7ea80" continuedAt="i125f2b83b9bc4291a52c303c24f47f62"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.77pt">Quoted prices in active markets for identical assets or liabilities.</span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NeuroPace, Inc.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Condensed Financial Statements</span></div></div><ix:continuation id="i125f2b83b9bc4291a52c303c24f47f62"><ix:continuation id="i14b55d4b593541568667986325ff0bc0"><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.77pt">Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.77pt">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the market approach to measure fair value for its financial assets and liabilities. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.</span></div></ix:continuation><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RleHRyZWdpb246MGM2NTE4NDAyOGU1NGQzYmJmYmRkNTliNmQ0ZDJjNjVfMjk3Mw_24e22aa3-d825-4fb6-9da4-68757bb64590" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the&#160;Company&#8217;s financial assets (cash equivalents and marketable securities) at fair value as of March&#160;31, 2023 (in thousands):</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of March&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis for Fair Value Measurements</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjdjZGVkMjQyYzBjMzQ3MGY4MWE2MTg1YzNjMzc5MWNiL3RhYmxlcmFuZ2U6N2NkZWQyNDJjMGMzNDcwZjgxYTYxODVjM2MzNzkxY2JfMy0xLTEtMS02OTY1Mg_56f2ef12-f14e-4bd1-b3a7-04ae303552bd">6,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7320c8ff5d5a4db38fdb65660cdbc124_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjdjZGVkMjQyYzBjMzQ3MGY4MWE2MTg1YzNjMzc5MWNiL3RhYmxlcmFuZ2U6N2NkZWQyNDJjMGMzNDcwZjgxYTYxODVjM2MzNzkxY2JfMy0zLTEtMS02OTY1Mg_0cdd7444-49a2-4aa1-bbe9-e3c3db15caaf">6,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b3e368885a4412aa08f736e786122f7_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjdjZGVkMjQyYzBjMzQ3MGY4MWE2MTg1YzNjMzc5MWNiL3RhYmxlcmFuZ2U6N2NkZWQyNDJjMGMzNDcwZjgxYTYxODVjM2MzNzkxY2JfMy01LTEtMS02OTY1Mg_a9a5af3c-4017-4ff6-8285-5756aff5bf83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5504ee5ca136427291328b9cdbfd9ac2_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjdjZGVkMjQyYzBjMzQ3MGY4MWE2MTg1YzNjMzc5MWNiL3RhYmxlcmFuZ2U6N2NkZWQyNDJjMGMzNDcwZjgxYTYxODVjM2MzNzkxY2JfMy03LTEtMS02OTY1Mg_5091123d-88a8-42fd-84d9-8e3136f331bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income mutual fund, included in short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjdjZGVkMjQyYzBjMzQ3MGY4MWE2MTg1YzNjMzc5MWNiL3RhYmxlcmFuZ2U6N2NkZWQyNDJjMGMzNDcwZjgxYTYxODVjM2MzNzkxY2JfNC0xLTEtMS02OTY1Mg_cf59c0a7-b9b4-462b-8515-f71adf506de8">60,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7320c8ff5d5a4db38fdb65660cdbc124_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjdjZGVkMjQyYzBjMzQ3MGY4MWE2MTg1YzNjMzc5MWNiL3RhYmxlcmFuZ2U6N2NkZWQyNDJjMGMzNDcwZjgxYTYxODVjM2MzNzkxY2JfNC0zLTEtMS02OTY1Mg_eb08c8ed-32f5-4d0f-a6a4-e917ae27140c">60,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b3e368885a4412aa08f736e786122f7_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjdjZGVkMjQyYzBjMzQ3MGY4MWE2MTg1YzNjMzc5MWNiL3RhYmxlcmFuZ2U6N2NkZWQyNDJjMGMzNDcwZjgxYTYxODVjM2MzNzkxY2JfNC01LTEtMS02OTY1Mg_d7a134c6-ae80-45f4-b7ee-58d9d9212b70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5504ee5ca136427291328b9cdbfd9ac2_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjdjZGVkMjQyYzBjMzQ3MGY4MWE2MTg1YzNjMzc5MWNiL3RhYmxlcmFuZ2U6N2NkZWQyNDJjMGMzNDcwZjgxYTYxODVjM2MzNzkxY2JfNC03LTEtMS02OTY1Mg_79b10691-c5ca-4324-8b3c-2aad91529bdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjdjZGVkMjQyYzBjMzQ3MGY4MWE2MTg1YzNjMzc5MWNiL3RhYmxlcmFuZ2U6N2NkZWQyNDJjMGMzNDcwZjgxYTYxODVjM2MzNzkxY2JfNS0xLTEtMS02OTY1Mg_88508f43-2709-4b10-9b0b-afe5d24a71bf">67,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7320c8ff5d5a4db38fdb65660cdbc124_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjdjZGVkMjQyYzBjMzQ3MGY4MWE2MTg1YzNjMzc5MWNiL3RhYmxlcmFuZ2U6N2NkZWQyNDJjMGMzNDcwZjgxYTYxODVjM2MzNzkxY2JfNS0zLTEtMS02OTY1Mg_4fb860bc-23d2-4aab-b487-587af7c67a83">67,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b3e368885a4412aa08f736e786122f7_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjdjZGVkMjQyYzBjMzQ3MGY4MWE2MTg1YzNjMzc5MWNiL3RhYmxlcmFuZ2U6N2NkZWQyNDJjMGMzNDcwZjgxYTYxODVjM2MzNzkxY2JfNS01LTEtMS02OTY1Mg_4dd7292e-2f7e-4ee7-8c17-19f00a6feb93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5504ee5ca136427291328b9cdbfd9ac2_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjdjZGVkMjQyYzBjMzQ3MGY4MWE2MTg1YzNjMzc5MWNiL3RhYmxlcmFuZ2U6N2NkZWQyNDJjMGMzNDcwZjgxYTYxODVjM2MzNzkxY2JfNS03LTEtMS02OTY1Mg_2c16325c-d391-4349-8555-7129d561a8ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the&#160;Company&#8217;s financial assets (cash equivalents and marketable securities) at fair value as of December&#160;31, 2022 (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of December&#160;31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis for Fair Value Measurements</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjA2MDc5MWUzNWQ2MDRiOGNiNGVlYjg1NGVhMDZkODA1L3RhYmxlcmFuZ2U6MDYwNzkxZTM1ZDYwNGI4Y2I0ZWViODU0ZWEwNmQ4MDVfMy0xLTEtMS02OTY1Mg_9597ac2e-62fc-4c04-bb6f-3303ceae44c1">6,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i089087e88c2f4e4594e265ef1eac9189_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjA2MDc5MWUzNWQ2MDRiOGNiNGVlYjg1NGVhMDZkODA1L3RhYmxlcmFuZ2U6MDYwNzkxZTM1ZDYwNGI4Y2I0ZWViODU0ZWEwNmQ4MDVfMy0zLTEtMS02OTY1Mg_63d8358b-f0d0-4d43-9c60-4d18f18ce4f6">6,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733ca2b6b6c1414dac92793e9704c260_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjA2MDc5MWUzNWQ2MDRiOGNiNGVlYjg1NGVhMDZkODA1L3RhYmxlcmFuZ2U6MDYwNzkxZTM1ZDYwNGI4Y2I0ZWViODU0ZWEwNmQ4MDVfMy01LTEtMS02OTY1Mg_90a7005c-1945-48c7-b4ca-b4706f74af2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0dc4d765154685b20215349253bb6d_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjA2MDc5MWUzNWQ2MDRiOGNiNGVlYjg1NGVhMDZkODA1L3RhYmxlcmFuZ2U6MDYwNzkxZTM1ZDYwNGI4Y2I0ZWViODU0ZWEwNmQ4MDVfMy03LTEtMS02OTY1Mg_d751fd92-2b4d-4959-9077-89a42f80b5ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income mutual fund, included in short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjA2MDc5MWUzNWQ2MDRiOGNiNGVlYjg1NGVhMDZkODA1L3RhYmxlcmFuZ2U6MDYwNzkxZTM1ZDYwNGI4Y2I0ZWViODU0ZWEwNmQ4MDVfNC0xLTEtMS02OTY1Mg_52dc218c-2854-4ee2-aa90-32b6f65d4886">70,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i089087e88c2f4e4594e265ef1eac9189_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjA2MDc5MWUzNWQ2MDRiOGNiNGVlYjg1NGVhMDZkODA1L3RhYmxlcmFuZ2U6MDYwNzkxZTM1ZDYwNGI4Y2I0ZWViODU0ZWEwNmQ4MDVfNC0zLTEtMS02OTY1Mg_cfc848b2-aeaa-419f-9c63-56da2cbfa03b">70,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733ca2b6b6c1414dac92793e9704c260_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjA2MDc5MWUzNWQ2MDRiOGNiNGVlYjg1NGVhMDZkODA1L3RhYmxlcmFuZ2U6MDYwNzkxZTM1ZDYwNGI4Y2I0ZWViODU0ZWEwNmQ4MDVfNC01LTEtMS02OTY1Mg_6489949f-8b64-42fe-ab03-b73558d7e5ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0dc4d765154685b20215349253bb6d_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjA2MDc5MWUzNWQ2MDRiOGNiNGVlYjg1NGVhMDZkODA1L3RhYmxlcmFuZ2U6MDYwNzkxZTM1ZDYwNGI4Y2I0ZWViODU0ZWEwNmQ4MDVfNC03LTEtMS02OTY1Mg_d7d86762-b23a-4379-b2e8-5d8bc331c7ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjA2MDc5MWUzNWQ2MDRiOGNiNGVlYjg1NGVhMDZkODA1L3RhYmxlcmFuZ2U6MDYwNzkxZTM1ZDYwNGI4Y2I0ZWViODU0ZWEwNmQ4MDVfNS0xLTEtMS02OTY1Mg_58fe88d2-b357-4f74-bf36-7559fbfec488">76,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i089087e88c2f4e4594e265ef1eac9189_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjA2MDc5MWUzNWQ2MDRiOGNiNGVlYjg1NGVhMDZkODA1L3RhYmxlcmFuZ2U6MDYwNzkxZTM1ZDYwNGI4Y2I0ZWViODU0ZWEwNmQ4MDVfNS0zLTEtMS02OTY1Mg_ac6e7067-e23e-4644-87eb-5159aa38241a">76,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733ca2b6b6c1414dac92793e9704c260_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjA2MDc5MWUzNWQ2MDRiOGNiNGVlYjg1NGVhMDZkODA1L3RhYmxlcmFuZ2U6MDYwNzkxZTM1ZDYwNGI4Y2I0ZWViODU0ZWEwNmQ4MDVfNS01LTEtMS02OTY1Mg_0fe92432-9d8d-4582-b280-7c32286e3d75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0dc4d765154685b20215349253bb6d_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjA2MDc5MWUzNWQ2MDRiOGNiNGVlYjg1NGVhMDZkODA1L3RhYmxlcmFuZ2U6MDYwNzkxZTM1ZDYwNGI4Y2I0ZWViODU0ZWEwNmQ4MDVfNS03LTEtMS02OTY1Mg_2aa24e3f-66b5-4476-8e27-27ef58b7f891">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="INF" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RleHRyZWdpb246MGM2NTE4NDAyOGU1NGQzYmJmYmRkNTliNmQ0ZDJjNjVfMTc0NA_67d36670-7c9f-467c-8b69-164e19776995"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="INF" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RleHRyZWdpb246MGM2NTE4NDAyOGU1NGQzYmJmYmRkNTliNmQ0ZDJjNjVfMTc0NA_a020bb2d-d487-493f-a8fd-1c6801f8df4d">no</ix:nonFraction></ix:nonFraction> liabilities measured at fair value on a recurring and non-recurring basis as of March&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The money market funds are highly liquid and primarily invest in short-term fixed income securities issued by the U.S. government and U.S. government agencies. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s available-for-sale investment comprises a short-term investment in a fixed income mutual fund, which primarily invests in debt securities issued by the U.S. government and U.S. government agencies and corporate bonds and notes. Interest income from its short-term investment is recorded in interest income.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of December 31, 2022, the Company&#8217;s short-term investment had a fair value of $<ix:nonFraction unitRef="usd" contextRef="i50fbc717732e47c78990b648a1fb6851_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RleHRyZWdpb246MGM2NTE4NDAyOGU1NGQzYmJmYmRkNTliNmQ0ZDJjNjVfNjQzNg_a02daf5e-ff83-4127-942e-f6ae2dc94e61">70.8</ix:nonFraction>&#160;million, a cost basis of $<ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RleHRyZWdpb246MGM2NTE4NDAyOGU1NGQzYmJmYmRkNTliNmQ0ZDJjNjVfNjQ0MA_350adfb5-7479-48e5-b20c-57d532715eab">71.9</ix:nonFraction>&#160;million, and an unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="i50fbc717732e47c78990b648a1fb6851_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RleHRyZWdpb246MGM2NTE4NDAyOGU1NGQzYmJmYmRkNTliNmQ0ZDJjNjVfNjQ0NA_00d31fcb-f65c-458f-b444-b0c473b2b87f">1.1</ix:nonFraction>&#160;million, which was recorded in accumulated other comprehensive loss.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the three months ended March 31, 2023, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i56aad41cb82348889b805e52158fbf37_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RleHRyZWdpb246MGM2NTE4NDAyOGU1NGQzYmJmYmRkNTliNmQ0ZDJjNjVfMjE5OTAyMzI2MjE2MA_a44e1b91-d079-4a33-81cf-d4a52d7c0543">0.4</ix:nonFraction>&#160;million in unrealized gains from its short-term investment. As of March 31, 2023, the Company&#8217;s short-term investment had a cumulative unrealized net loss of $<ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RleHRyZWdpb246MGM2NTE4NDAyOGU1NGQzYmJmYmRkNTliNmQ0ZDJjNjVfOTM0NTg0ODg0MTY1MA_aa2aed75-411e-45c4-bb5f-5535e1f6b789">0.7</ix:nonFraction>&#160;million, which included an adjustment of $<ix:nonFraction unitRef="usd" contextRef="i56aad41cb82348889b805e52158fbf37_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RleHRyZWdpb246MGM2NTE4NDAyOGU1NGQzYmJmYmRkNTliNmQ0ZDJjNjVfOTM0NTg0ODg0MTY2NA_5902c99c-c23c-4b45-9315-3cac0d44a6a4">1.1</ix:nonFraction>&#160;million unrealized loss recorded </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in other income (expense), net in the three months ended March 31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adjustment was not material to any previously issued financial statements.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i2a59f7ea1762416695eae3249a8f9ede_46"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NeuroPace, Inc.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Condensed Financial Statements</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RleHRyZWdpb246ZWVlN2I1NDZjYWNiNDY1YWIwMzZiYjAxYTk3ZDIxZDBfMzg0ODI5MDY5ODA1OQ_4b056f61-5528-4cff-b069-2bb88536dd83" continuedAt="ied4064d580e64f6b889563fad0c51de6" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="ied4064d580e64f6b889563fad0c51de6"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></div><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RleHRyZWdpb246ZWVlN2I1NDZjYWNiNDY1YWIwMzZiYjAxYTk3ZDIxZDBfNDcy_21411611-2b19-491c-bead-c2d608dd2ccd" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjI5MmZkZjhlMTJkYjQ3Mzg5ZTI3YjIwNzk1NTNhZDRjL3RhYmxlcmFuZ2U6MjkyZmRmOGUxMmRiNDczODllMjdiMjA3OTU1M2FkNGNfMi0xLTEtMS02OTY1Mg_c242e786-82fa-4bb1-a6ce-6612f2332b6e">4,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjI5MmZkZjhlMTJkYjQ3Mzg5ZTI3YjIwNzk1NTNhZDRjL3RhYmxlcmFuZ2U6MjkyZmRmOGUxMmRiNDczODllMjdiMjA3OTU1M2FkNGNfMi0zLTEtMS02OTY1Mg_0e6ee3ce-9886-4442-af3e-b3a05f6aed30">2,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjI5MmZkZjhlMTJkYjQ3Mzg5ZTI3YjIwNzk1NTNhZDRjL3RhYmxlcmFuZ2U6MjkyZmRmOGUxMmRiNDczODllMjdiMjA3OTU1M2FkNGNfMy0xLTEtMS02OTY1Mg_5cdb7ac9-9997-4572-a27b-b4b1b025c013">592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjI5MmZkZjhlMTJkYjQ3Mzg5ZTI3YjIwNzk1NTNhZDRjL3RhYmxlcmFuZ2U6MjkyZmRmOGUxMmRiNDczODllMjdiMjA3OTU1M2FkNGNfMy0zLTEtMS02OTY1Mg_166fdbb7-69da-454a-b2b4-e01f0cb50a38">1,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjI5MmZkZjhlMTJkYjQ3Mzg5ZTI3YjIwNzk1NTNhZDRjL3RhYmxlcmFuZ2U6MjkyZmRmOGUxMmRiNDczODllMjdiMjA3OTU1M2FkNGNfNC0xLTEtMS02OTY1Mg_95365f49-1d53-4141-bd08-677030ad9699">5,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjI5MmZkZjhlMTJkYjQ3Mzg5ZTI3YjIwNzk1NTNhZDRjL3RhYmxlcmFuZ2U6MjkyZmRmOGUxMmRiNDczODllMjdiMjA3OTU1M2FkNGNfNC0zLTEtMS02OTY1Mg_3be11e0c-6915-4568-b0d9-c31ac697b3eb">5,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjI5MmZkZjhlMTJkYjQ3Mzg5ZTI3YjIwNzk1NTNhZDRjL3RhYmxlcmFuZ2U6MjkyZmRmOGUxMmRiNDczODllMjdiMjA3OTU1M2FkNGNfNS0xLTEtMS02OTY1Mg_3846cab3-52b6-4040-a95c-65d969d46b8d">10,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjI5MmZkZjhlMTJkYjQ3Mzg5ZTI3YjIwNzk1NTNhZDRjL3RhYmxlcmFuZ2U6MjkyZmRmOGUxMmRiNDczODllMjdiMjA3OTU1M2FkNGNfNS0zLTEtMS02OTY1Mg_8c58120d-e913-4bb0-9990-9985c13e4bb7">9,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-bottom:9pt;text-indent:18pt"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RleHRyZWdpb246ZWVlN2I1NDZjYWNiNDY1YWIwMzZiYjAxYTk3ZDIxZDBfNDcz_1d2b21d1-f8c4-4800-86e9-3561e17f1366" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery, equipment, furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie13bfccbf66c4ecab838a9cd17475bc2_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjcyZDRkMjJkNDEzYjQxYjU4OGM0Yjk5MmJiMGE4Yjk1L3RhYmxlcmFuZ2U6NzJkNGQyMmQ0MTNiNDFiNTg4YzRiOTkyYmIwYThiOTVfMi0xLTEtMS02OTY1Mg_a064b471-e7b1-4401-8496-dc56f6e89c5f">4,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72b74226bce34ccd820c481519df8f32_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjcyZDRkMjJkNDEzYjQxYjU4OGM0Yjk5MmJiMGE4Yjk1L3RhYmxlcmFuZ2U6NzJkNGQyMmQ0MTNiNDFiNTg4YzRiOTkyYmIwYThiOTVfMi0zLTEtMS02OTY1Mg_82227c79-783e-439e-90c4-849dcf46bc98">4,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92e875b8476a417484c9e720466e1c5c_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjcyZDRkMjJkNDEzYjQxYjU4OGM0Yjk5MmJiMGE4Yjk1L3RhYmxlcmFuZ2U6NzJkNGQyMmQ0MTNiNDFiNTg4YzRiOTkyYmIwYThiOTVfMy0xLTEtMS02OTY1Mg_5dcdc41f-b7b7-4698-a029-b5e02001310b">2,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15f6bae5515b42c08088c9d68db5f5d6_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjcyZDRkMjJkNDEzYjQxYjU4OGM0Yjk5MmJiMGE4Yjk1L3RhYmxlcmFuZ2U6NzJkNGQyMmQ0MTNiNDFiNTg4YzRiOTkyYmIwYThiOTVfMy0zLTEtMS02OTY1Mg_4b556bad-88dd-4dbb-aea5-508ddaf38ac4">2,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d52095ad0ee44e7b2c4a5bc8d88dcfb_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjcyZDRkMjJkNDEzYjQxYjU4OGM0Yjk5MmJiMGE4Yjk1L3RhYmxlcmFuZ2U6NzJkNGQyMmQ0MTNiNDFiNTg4YzRiOTkyYmIwYThiOTVfNC0xLTEtMS02OTY1Mg_122b5f51-d94a-42a8-8f49-9332d93eb04e">2,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic24aec2bd2a146c0b2ceeb0af31c9a57_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjcyZDRkMjJkNDEzYjQxYjU4OGM0Yjk5MmJiMGE4Yjk1L3RhYmxlcmFuZ2U6NzJkNGQyMmQ0MTNiNDFiNTg4YzRiOTkyYmIwYThiOTVfNC0zLTEtMS02OTY1Mg_55984fbf-0c11-4cec-a4ca-b8c204c2d88e">2,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjcyZDRkMjJkNDEzYjQxYjU4OGM0Yjk5MmJiMGE4Yjk1L3RhYmxlcmFuZ2U6NzJkNGQyMmQ0MTNiNDFiNTg4YzRiOTkyYmIwYThiOTVfNS0xLTEtMS02OTY1Mg_07aace1a-78fa-4c24-8387-d2239598efa2">9,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjcyZDRkMjJkNDEzYjQxYjU4OGM0Yjk5MmJiMGE4Yjk1L3RhYmxlcmFuZ2U6NzJkNGQyMmQ0MTNiNDFiNTg4YzRiOTkyYmIwYThiOTVfNS0zLTEtMS02OTY1Mg_4cd45346-1cd2-4d09-a681-8c875713f298">9,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjcyZDRkMjJkNDEzYjQxYjU4OGM0Yjk5MmJiMGE4Yjk1L3RhYmxlcmFuZ2U6NzJkNGQyMmQ0MTNiNDFiNTg4YzRiOTkyYmIwYThiOTVfNi0xLTEtMS02OTY1Mg_0e2afac3-d301-4483-80c1-29cf4153a555">8,773</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjcyZDRkMjJkNDEzYjQxYjU4OGM0Yjk5MmJiMGE4Yjk1L3RhYmxlcmFuZ2U6NzJkNGQyMmQ0MTNiNDFiNTg4YzRiOTkyYmIwYThiOTVfNi0zLTEtMS02OTY1Mg_61b8341d-0440-461a-8dd9-268fa15a9fca">8,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjcyZDRkMjJkNDEzYjQxYjU4OGM0Yjk5MmJiMGE4Yjk1L3RhYmxlcmFuZ2U6NzJkNGQyMmQ0MTNiNDFiNTg4YzRiOTkyYmIwYThiOTVfNy0xLTEtMS02OTY1Mg_c7e09600-9dde-4da7-8de0-52dd1a05eecb">1,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjcyZDRkMjJkNDEzYjQxYjU4OGM0Yjk5MmJiMGE4Yjk1L3RhYmxlcmFuZ2U6NzJkNGQyMmQ0MTNiNDFiNTg4YzRiOTkyYmIwYThiOTVfNy0zLTEtMS02OTY1Mg_f1534948-a65d-4b56-bff2-ae83d68cd394">1,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended March&#160;31, 2023 and 2022 was less than $0.1 million and $<ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RleHRyZWdpb246ZWVlN2I1NDZjYWNiNDY1YWIwMzZiYjAxYTk3ZDIxZDBfMjY0_5b0735c8-5d9e-4250-b4f3-2b6a649ece14">0.1</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued Liabilities</span></div><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RleHRyZWdpb246ZWVlN2I1NDZjYWNiNDY1YWIwMzZiYjAxYTk3ZDIxZDBfNDc0_9bb95bcc-13db-4bf2-a49c-0955abc98263" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related expenses </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjZhNmIzMWExZDA3YjRlMWNhNGVkOGExZTk5ODY5MTFlL3RhYmxlcmFuZ2U6NmE2YjMxYTFkMDdiNGUxY2E0ZWQ4YTFlOTk4NjkxMWVfMi0xLTEtMS02OTY1Mg_215f150d-f259-4b04-8186-8262ef238213">5,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjZhNmIzMWExZDA3YjRlMWNhNGVkOGExZTk5ODY5MTFlL3RhYmxlcmFuZ2U6NmE2YjMxYTFkMDdiNGUxY2E0ZWQ4YTFlOTk4NjkxMWVfMi0zLTEtMS02OTY1Mg_aa5b9727-7903-4a4c-8cdf-b5316b1c85db">5,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory-raw materials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="npce:AccruedInventoryLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjZhNmIzMWExZDA3YjRlMWNhNGVkOGExZTk5ODY5MTFlL3RhYmxlcmFuZ2U6NmE2YjMxYTFkMDdiNGUxY2E0ZWQ4YTFlOTk4NjkxMWVfMy0xLTEtMS02OTY1Mg_e04bf6fe-c78e-4e7b-a73f-31f1ae2326ad">463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="npce:AccruedInventoryLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjZhNmIzMWExZDA3YjRlMWNhNGVkOGExZTk5ODY5MTFlL3RhYmxlcmFuZ2U6NmE2YjMxYTFkMDdiNGUxY2E0ZWQ4YTFlOTk4NjkxMWVfMy0zLTEtMS02OTY1Mg_8b1b50db-55e6-4915-9ac7-ded1ca8d425f">764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjZhNmIzMWExZDA3YjRlMWNhNGVkOGExZTk5ODY5MTFlL3RhYmxlcmFuZ2U6NmE2YjMxYTFkMDdiNGUxY2E0ZWQ4YTFlOTk4NjkxMWVfNC0xLTEtMS02OTY1Mg_ee9d472e-ac78-4b6b-bab1-0f62de4e7d79">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjZhNmIzMWExZDA3YjRlMWNhNGVkOGExZTk5ODY5MTFlL3RhYmxlcmFuZ2U6NmE2YjMxYTFkMDdiNGUxY2E0ZWQ4YTFlOTk4NjkxMWVfNC0zLTEtMS02OTY1Mg_726364af-09da-4f50-bce7-8f7be28fdf10">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjZhNmIzMWExZDA3YjRlMWNhNGVkOGExZTk5ODY5MTFlL3RhYmxlcmFuZ2U6NmE2YjMxYTFkMDdiNGUxY2E0ZWQ4YTFlOTk4NjkxMWVfNi0xLTEtMS02OTY1Mg_e645fc3d-4d8a-4fbd-a342-440cac3aa318">756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjZhNmIzMWExZDA3YjRlMWNhNGVkOGExZTk5ODY5MTFlL3RhYmxlcmFuZ2U6NmE2YjMxYTFkMDdiNGUxY2E0ZWQ4YTFlOTk4NjkxMWVfNi0zLTEtMS02OTY1Mg_a9ce57be-40ce-4354-8050-96614e25d8e8">675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="npce:AccruedAndEmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjZhNmIzMWExZDA3YjRlMWNhNGVkOGExZTk5ODY5MTFlL3RhYmxlcmFuZ2U6NmE2YjMxYTFkMDdiNGUxY2E0ZWQ4YTFlOTk4NjkxMWVfNy0xLTEtMS02OTY1Mg_bb0b0f2f-994e-43b5-9a5e-4baef5c54a5c">6,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="-3" name="npce:AccruedAndEmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjZhNmIzMWExZDA3YjRlMWNhNGVkOGExZTk5ODY5MTFlL3RhYmxlcmFuZ2U6NmE2YjMxYTFkMDdiNGUxY2E0ZWQ4YTFlOTk4NjkxMWVfNy0zLTEtMS02OTY1Mg_86e73d0a-43ad-4519-ac93-3bc87a51be63">7,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2a59f7ea1762416695eae3249a8f9ede_49"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfNzUxMQ_5fecfcf8-50de-4bf1-a441-8f6ce36fc02c" continuedAt="icea63a7fd124406aa755b5816a1083f7" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="icea63a7fd124406aa755b5816a1083f7" continuedAt="icadd2aa128ed4fe782035a0da1ae87ed"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Facility Lease</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August&#160;2011, the Company entered into a non-cancelable operating lease for combined office and manufacturing facilities in Mountain View, California. The lease was scheduled to expire in April&#160;2019 and was amended in May 2018 to extend it through June 2024. In August 2022, the Company amended the lease to extend it through June 2030. The second amendment contained a rent free period from September 2022 through December 2022. The Company has an option to extend the lease for a period of <ix:nonNumeric contextRef="if9a80d56ebf04d499b58bf88ca435e06_D20220801-20220831" name="npce:OperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMzg0ODI5MDcwOTY3OQ_d137c557-9cdf-48f2-9cc6-937b82b0f396">five years</ix:nonNumeric>, commencing on July 1, 2030 and expiring on June 30, 2035. In conjunction with the original lease agreement, the Company obtained a letter of credit </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NeuroPace, Inc.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Condensed Financial Statements</span></div></div><ix:continuation id="icadd2aa128ed4fe782035a0da1ae87ed" continuedAt="i3a4a5fd61ffa42de8a510e6248d89077"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for $<ix:nonFraction unitRef="usd" contextRef="ibea6fa1c91014c4b8d2577a5a84d2960_I20110831" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfNzE2_acc9e70f-9a98-4c8f-ae63-1cad6ec3c1cc">0.9</ix:nonFraction> million in lieu of a security deposit. In May 2019, the letter of credit was amended and reduced to $<ix:nonFraction unitRef="usd" contextRef="ic7e26e273c0b48a4b9d9a2e7d4b6b51f_I20190531" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfODEx_84fb9d34-4f3c-4e9d-aa81-60d952a2b289">0.7</ix:nonFraction> million. In June 2021, the letter of credit was amended and further reduced to $<ix:nonFraction unitRef="usd" contextRef="i855f72fe57c7466cb0fdbebf83edc239_I20210630" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfODg1_5bd36ee5-3560-4ebd-8b23-45dc751bd3b6">0.2</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the facility lease provide for rental payments on a graduated scale; however, rent expense is recognized on a straight-line basis over the lease term. Rental payments range from $<ix:nonFraction unitRef="usd" contextRef="i2356a93c7f0842d59386f834f8ca8c04_D20180501-20180531" decimals="-5" name="npce:OperatingLeasesAnnualRentalPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMTA4MA_a5d32ade-c4a1-4db9-9c4c-b32954c04052">2.8</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="ifffa9c7125464d7486ce57d0838a6f42_D20180501-20180531" decimals="-5" name="npce:OperatingLeasesAnnualRentalPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMTA4Ng_19e4ea2a-e8b3-434f-b07d-118f2b4ca9a4">3.3</ix:nonFraction> million per year over the extended term of the lease.</span></div><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfNzUxNQ_a92eadd4-45f0-452f-b606-a8430c7f20cf" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturities of operating lease liabilities as of March&#160;31, 2023 are as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining nine months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RhYmxlOjA5NDU0NzljMjM3NzQ1ZmRhNGVkZDBhYTAzZjRkYzcyL3RhYmxlcmFuZ2U6MDk0NTQ3OWMyMzc3NDVmZGE0ZWRkMGFhMDNmNGRjNzJfMS0xLTEtMS02OTY1Mg_e4ab02fa-6952-493d-a894-34d216a7a871">2,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RhYmxlOjA5NDU0NzljMjM3NzQ1ZmRhNGVkZDBhYTAzZjRkYzcyL3RhYmxlcmFuZ2U6MDk0NTQ3OWMyMzc3NDVmZGE0ZWRkMGFhMDNmNGRjNzJfMi0xLTEtMS02OTY1Mg_77a4df9d-f4d5-4928-b0be-b2d766167ebb">2,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RhYmxlOjA5NDU0NzljMjM3NzQ1ZmRhNGVkZDBhYTAzZjRkYzcyL3RhYmxlcmFuZ2U6MDk0NTQ3OWMyMzc3NDVmZGE0ZWRkMGFhMDNmNGRjNzJfMy0xLTEtMS02OTY1Mg_67daef7c-e4c2-4a9d-9e44-f37ffd7f93bf">2,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RhYmxlOjA5NDU0NzljMjM3NzQ1ZmRhNGVkZDBhYTAzZjRkYzcyL3RhYmxlcmFuZ2U6MDk0NTQ3OWMyMzc3NDVmZGE0ZWRkMGFhMDNmNGRjNzJfNC0xLTEtMS02OTY1Mg_73bb3d9f-7484-4196-8ec2-f60e041795f2">3,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RhYmxlOjA5NDU0NzljMjM3NzQ1ZmRhNGVkZDBhYTAzZjRkYzcyL3RhYmxlcmFuZ2U6MDk0NTQ3OWMyMzc3NDVmZGE0ZWRkMGFhMDNmNGRjNzJfNS0xLTEtMS02OTY1Mg_a53ef034-3aea-4215-9e26-ea688a82ff18">3,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="npce:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RhYmxlOjA5NDU0NzljMjM3NzQ1ZmRhNGVkZDBhYTAzZjRkYzcyL3RhYmxlcmFuZ2U6MDk0NTQ3OWMyMzc3NDVmZGE0ZWRkMGFhMDNmNGRjNzJfNi0xLTEtMS02OTY1Mg_a53ad52e-eeff-4843-82ef-a3fecb9bf874">8,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RhYmxlOjA5NDU0NzljMjM3NzQ1ZmRhNGVkZDBhYTAzZjRkYzcyL3RhYmxlcmFuZ2U6MDk0NTQ3OWMyMzc3NDVmZGE0ZWRkMGFhMDNmNGRjNzJfNy0xLTEtMS02OTY1Mg_fe496b35-f66a-4afd-b0cd-4d4719bae16c">22,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RhYmxlOjA5NDU0NzljMjM3NzQ1ZmRhNGVkZDBhYTAzZjRkYzcyL3RhYmxlcmFuZ2U6MDk0NTQ3OWMyMzc3NDVmZGE0ZWRkMGFhMDNmNGRjNzJfOC0xLTEtMS02OTY1Mg_6870e798-821b-443d-a381-435ea4a47aa0">5,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RhYmxlOjA5NDU0NzljMjM3NzQ1ZmRhNGVkZDBhYTAzZjRkYzcyL3RhYmxlcmFuZ2U6MDk0NTQ3OWMyMzc3NDVmZGE0ZWRkMGFhMDNmNGRjNzJfOS0xLTEtMS02OTY1Mg_616a86e5-e708-4c5b-b094-36a4e620c1b4">16,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RhYmxlOjA5NDU0NzljMjM3NzQ1ZmRhNGVkZDBhYTAzZjRkYzcyL3RhYmxlcmFuZ2U6MDk0NTQ3OWMyMzc3NDVmZGE0ZWRkMGFhMDNmNGRjNzJfMTAtMS0xLTEtNjk2NTI_cbb366de-e433-4402-8c12-6cb3750de5cd">1,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RhYmxlOjA5NDU0NzljMjM3NzQ1ZmRhNGVkZDBhYTAzZjRkYzcyL3RhYmxlcmFuZ2U6MDk0NTQ3OWMyMzc3NDVmZGE0ZWRkMGFhMDNmNGRjNzJfMTEtMS0xLTEtNjk2NTI_b17d0a26-2c35-4516-986e-7318229f19c2">15,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost was $<ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMTgzOA_a1ac83fc-299d-411b-b90d-b89e7fd1e8f3">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMTg0NQ_0529ae3c-1036-4d24-9ed3-616e0c85df30">0.7</ix:nonFraction> million for the three months ended March&#160;31, 2023 and 2022, respectively. As of March&#160;31, 2023, the remaining term for the operating lease in Mountain View, California was <ix:nonNumeric contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMjAwNA_20634561-5733-491c-b6a3-c430cecb9235">7.3</ix:nonNumeric> years, and the discount rate used to measure the lease liability for such operating lease upon recognition was <ix:nonFraction unitRef="number" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMjExMg_fe117bec-2494-4dd1-9ef8-29ad18bbff8c">8.5</ix:nonFraction>%.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, cash paid for amounts included in operating lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMjIxNA_3c576937-6eb9-46e8-8b7d-c75d018f519f">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMTA5OTUxMTYzNTk1MQ_3f95c729-60e3-4566-a48e-dd9775a58999">0.8</ix:nonFraction> million, respectively, was included in cash flows from operating activities on the condensed statements of cash flows.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Distribution Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company entered into an exclusive distribution agreement, or the Distribution Agreement, with DIXI Medical USA Corp, or DIXI Medical, pursuant to which the Company became the exclusive U.S. distributor of DIXI Medical&#8217;s product line. To maintain the exclusive distributor rights, the Company is committed to purchase a minimum of $<ix:nonFraction unitRef="usd" contextRef="ia4dd4f305a334652a40e5d347bc7628f_I20220831" decimals="-5" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMjY4Nw_34446e31-8d12-4156-a4c5-846ef7e32d55">2.4</ix:nonFraction>&#160;million of DIXI Medical&#8217;s products during the twelve months beginning October 2022, and increase the purchase minimum by <ix:nonFraction unitRef="number" contextRef="ia4dd4f305a334652a40e5d347bc7628f_I20220831" decimals="INF" name="npce:PurchaseObligationMinimumIncreasePercentageInNextTwoYears" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMjgxMg_e604b6aa-229a-4509-8e9e-a8463ee5ee89">10</ix:nonFraction>% for each of the two subsequent years.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnifications</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and may provide for indemnification of the counterparty. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against it in the future but have not yet been made. The Company may, from time to time, be subject to claims or be required to defend actions related to its indemnification obligations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director or officer is or was serving at the Company&#8217;s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws. The term of the indemnification period lasts as long as the director or officer may be subject to any proceeding arising out of acts or omissions of such individual in such capacity. The maximum amount of potential future indemnification is unlimited. The </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NeuroPace, Inc.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Condensed Financial Statements</span></div></div><ix:continuation id="i3a4a5fd61ffa42de8a510e6248d89077"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has <ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="INF" name="npce:IndemnificationLiabilityOfficersAndDirectors" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfNDAzOA_1a8d284b-610e-46ed-b051-8bb1b4851c9a"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="INF" name="npce:IndemnificationLiabilityOfficersAndDirectors" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfNDAzOA_8e308c99-561f-429c-b912-15c5dad4a605">no</ix:nonFraction></ix:nonFraction>t recognized any liabilities relating to these obligations as of March&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. The Company determined that <ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfNDQ0NQ_4286d3ee-44a7-499b-9dce-5fe2f87088b7"><ix:nonFraction unitRef="usd" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfNDQ0NQ_fad76563-4962-474f-9035-675b516b7e28">no</ix:nonFraction></ix:nonFraction> accrual related to contingencies was required as of March&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not involved in any pending legal proceedings that it believes could have a material adverse effect on its business, results of operations, financial condition, or cash flows. From time to time, the Company may pursue litigation to assert its legal rights and such litigation may be costly and divert the efforts and attention of its management and technical personnel which could adversely affect its business. The Company regularly evaluates current information to determine whether any accruals should be adjusted and whether new accruals are required. Such accruals, if any, reflect the estimable and probable costs that the Company may incur from the outcomes of its legal proceedings. Legal costs are expensed as incurred. There were <ix:nonFraction unitRef="usd" contextRef="i663f6b7d3d6c49a2bc184e2117245877_I20221231" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMjc0ODc3OTA4MTkyMg_98e4a42d-24e0-4417-b33b-696194dbf5e4"><ix:nonFraction unitRef="usd" contextRef="i7f4f2b14460d4ab894ce8ce881d1e8bf_I20230331" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMjc0ODc3OTA4MTkyMg_d67efb60-267a-43cc-a2a6-d62c68a089ec">no</ix:nonFraction></ix:nonFraction> contingent liabilities requiring accrual as of March&#160;31, 2023 and December&#160;31, 2022.</span></div></ix:continuation><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2a59f7ea1762416695eae3249a8f9ede_52"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfNDE3Mw_1e24100b-e457-4f30-9328-44b641451355" continuedAt="i61e306a0f86f4992b5e93ee8c4d476d2" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="i61e306a0f86f4992b5e93ee8c4d476d2" continuedAt="i4ef6207bb83349ce8e3397e2d735ae2e"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term Loan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company entered into a Term Loan Agreement with CRG Partners IV L.P. and its affiliates for total borrowings of up to $<ix:nonFraction unitRef="usd" contextRef="ief8e6ea33f5f49ba8c1945d7760420af_I20200930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMTY2_4cd18996-7524-4f36-836a-34fb5dd0ae23">60.0</ix:nonFraction> million, or the Term Loan, and borrowed $<ix:nonFraction unitRef="usd" contextRef="i82f97d12cf584623a6e5b81bd652ab53_D20200901-20200930" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMjAx_66fcf286-3ab3-4431-a230-757cad822b1d">50.0</ix:nonFraction> million. The remaining $<ix:nonFraction unitRef="usd" contextRef="i43f850c157d141ef9213ce882f01add9_I20200930" decimals="INF" name="us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMjE5_de8e27c9-7e90-4072-b8ea-5165c47a2ba2">10.0</ix:nonFraction> million of the Term Loan was available to the Company for borrowing until March 31, 2022 if the Company achieved a revenue-based milestone in 2021. The revenue-based milestone was not achieved, and the remaining $<ix:nonFraction unitRef="usd" contextRef="i43f850c157d141ef9213ce882f01add9_I20200930" decimals="INF" name="us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfNDI2_de8e27c9-7e90-4072-b8ea-5165c47a2ba2">10.0</ix:nonFraction> million of the Term Loan expired without being drawn.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan bore interest at a rate of <ix:nonFraction unitRef="number" contextRef="i43f850c157d141ef9213ce882f01add9_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfNTE3_3ec8a2dc-5d95-4d80-955d-66c90dd3afde">12.5</ix:nonFraction>% per year. In February 2023, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Term Loan was amended which increased the annual interest rate from <ix:nonFraction unitRef="number" contextRef="i7eeeb9a80b68476f81a32985be7b3bbb_I20230228" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMjc0ODc3OTA3NzE1NA_71c0d885-76ff-47a2-93fc-839f01e7ff59">12.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i936af4736e104ba1b78e04ecf51e9485_I20230301" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMjc0ODc3OTA3NzE2MQ_7739794a-c7b3-4e48-a9da-4d6cd365c3f5">13.5</ix:nonFraction>% effective March 1, 2023. The amendment was accounted as a debt modification and the Term Loan&#8217;s effective interest rate increased from <ix:nonFraction unitRef="number" contextRef="i52f87175f69a4d5ba7551816e3e6d9f9_I20230228" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMzg0ODI5MDcwNTk2Mg_7fd4d97c-0da9-4d83-a5b8-25c6d453f2d7">15.7</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="iff8d276c367b44d9b804890918cc832b_I20230301" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMzg0ODI5MDcwNTk3MQ_c49c0e75-84a2-45e0-a59e-1e39f1abae63">16.8</ix:nonFraction>%. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments under the Term Loan are made quarterly with payment dates fixed at the end of each calendar quarter. Through December 2020, the Company had the option to pay the entire interest paid-in-kind, or PIK, by increasing the principal of the Term Loan. From January 2021 through December 2022, the Company had the option to pay interest as follows: <ix:nonFraction unitRef="number" contextRef="ic717d133e94248aeb47643602e049d84_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMzg0ODI5MDcwNTY3MA_d3ef9e38-dfd8-48c3-b0e1-9361963c705d">7.5</ix:nonFraction>% per annum paid in cash and <ix:nonFraction unitRef="number" contextRef="i83b57f4259104d73b1aa83bc7764aa5d_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMzg0ODI5MDcwNTY3Ng_a5173795-f595-44d2-b0cc-c28399e2a037">5.0</ix:nonFraction>% per annum PIK by increasing the principal of the Term Loan. From January 2023 through June 2025, the Company has the option to pay interest as follows: <ix:nonFraction unitRef="number" contextRef="ieddb0b8aa4b949f1a6e2bed0558ca9c0_I20230131" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfODg4_934ee11a-1ae6-45be-a9db-bbdd381902bd">8.5</ix:nonFraction>% per annum paid in cash and <ix:nonFraction unitRef="number" contextRef="i9067c2fe52724e22a615ea36acafda17_I20230131" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfOTE4_f97eebd5-dc47-418e-bf25-8008669a596f">5.0</ix:nonFraction>% per annum PIK by increasing the principal of the Term Loan. For each payment date from April 2022 through March 2023, the Company elected the PIK option, increasing the principal of the Term Loan by $<ix:nonFraction unitRef="usd" contextRef="icabe16bffe8b4ea7bfe4bf0585864a95_I20230331" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMTEzMQ_ee4f1b07-803b-4c00-acdf-dfd40bcefada">2.6</ix:nonFraction> million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan was interest-only through September 2023, which could be extended through September 2025 at the Company&#8217;s option if the Company completed its IPO on or prior September 30, 2023. In connection with closing the IPO, the Company extended the interest-only period to September 30, 2025. Following the interest-only period, principal payment is due in <ix:nonFraction unitRef="installment" contextRef="ibfc06477076049948beb4962edceb579_D20230201-20230228" decimals="INF" name="npce:DebtInstrumentPrincipalPaymentNumberOfInstallment" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMTUwNA_8966a199-28e7-4107-be84-de2c4b601005">one</ix:nonFraction> installment on September 30, 2025. The Term Loan includes a fee upon repayment of the loan equal to <ix:nonFraction unitRef="number" contextRef="i7eeeb9a80b68476f81a32985be7b3bbb_I20230228" decimals="INF" name="npce:DebtInstrumentRedemptionFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMTYwNw_35a68a22-d348-492f-8067-3af5d4e34e8d">10</ix:nonFraction>% of the aggregate principal amount being prepaid or repaid, or the backend fee. As of March&#160;31, 2023, the Term Loan had an annual effective interest rate of <ix:nonFraction unitRef="number" contextRef="i112820749e8349ea97d447caf4294059_I20230331" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMTc1NA_81824820-8266-4c4a-a964-8325ba94e872">16.8</ix:nonFraction>% per year.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan is collateralized by substantially all of the Company&#8217;s assets. The Term Loan Agreement contains customary representations and warranties, covenants, events of default and termination provisions. The financial covenants require that the Company achieve minimum annual revenue thresholds commencing in 2021 and maintain a minimum balance of cash and cash equivalents (see Note 1). In February 2023, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Term Loan was amended to reduce the minimum annual net revenue covenant to $<ix:nonFraction unitRef="usd" contextRef="icfb0677a4b944e56b972e31d646b50b7_D20230201-20230228" decimals="INF" name="npce:DebtInstrumentCovenantMinimumAnnualNetRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMjI1NQ_ed0ebfad-9374-41d7-aed4-52655d9ba2c4">45.0</ix:nonFraction>&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the year ended December 31, 2023.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NeuroPace, Inc.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Condensed Financial Statements</span></div></div><ix:continuation id="i4ef6207bb83349ce8e3397e2d735ae2e"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $<ix:nonFraction unitRef="usd" contextRef="iad9b6795da0a45d5acf70ba4d680edb2_I20200930" decimals="-5" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMjMxMw_771ead73-90da-44fa-90d8-8dccae2263bb">1.0</ix:nonFraction> million in fees to the lender and third parties which is reflected as a discount on the loan and is being accreted over the life of the loan using the effective interest method. Also, the Company issued warrants to the lender for a total of <ix:nonFraction unitRef="shares" contextRef="i4e5845b14c67448eafe578cbd6b9e3fd_I20200924" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMjU0OQ_47ba0bf2-1f30-47e5-a676-071c274519e1">346,823</ix:nonFraction> shares of Series B&#8217; redeemable convertible preferred stock. The warrants had a fair value of $<ix:nonFraction unitRef="usd" contextRef="i4e5845b14c67448eafe578cbd6b9e3fd_I20200924" decimals="-5" name="npce:WarrantLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMjY0NQ_88938b01-3d8c-4970-afa6-eec9fdc4b8a4">0.6</ix:nonFraction> million as of the issuance date, which was accounted for as debt issuance costs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, the Company recorded interest expense related to debt discount and debt issuance costs of the Term Loan of $<ix:nonFraction unitRef="usd" contextRef="i814c00557d744141babf3f0e6dcf97a1_D20230101-20230331" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMjg4Mw_33171ce0-cb09-4942-a713-29a276b20e98">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i750b0ffd1c3643dca215a71011485722_D20220101-20220331" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMjg5MA_6bb93676-5291-42d0-9442-a707686b6303">0.1</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on the Term Loan was $<ix:nonFraction unitRef="usd" contextRef="i814c00557d744141babf3f0e6dcf97a1_D20230101-20230331" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMzExOA_70b3e89a-487a-4971-bf10-6ba41f1d024b">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i750b0ffd1c3643dca215a71011485722_D20220101-20220331" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMzEyNQ_1073a0dc-521f-4748-8fdc-63b0390502ad">1.8</ix:nonFraction> million during the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfNDE3Mg_d8f21244-39a0-4907-8ef0-dd0b03618bb8" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, future minimum payments for the Term Loan are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term Loan</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining nine months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i112820749e8349ea97d447caf4294059_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RhYmxlOmJhYTBlNjJkYWUzZjQ5NWY5OWYxOTI4NGM0ZmRhN2M1L3RhYmxlcmFuZ2U6YmFhMGU2MmRhZTNmNDk1Zjk5ZjE5Mjg0YzRmZGE3YzVfMS0xLTEtMS02OTY1Mg_1ded9af6-e1ed-405b-a4f4-2ccc78de1560">5,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i112820749e8349ea97d447caf4294059_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RhYmxlOmJhYTBlNjJkYWUzZjQ5NWY5OWYxOTI4NGM0ZmRhN2M1L3RhYmxlcmFuZ2U6YmFhMGU2MmRhZTNmNDk1Zjk5ZjE5Mjg0YzRmZGE3YzVfMi0xLTEtMS02OTY1Mg_3c8da58e-c37d-4416-8bc5-2b7e7455eb95">7,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i112820749e8349ea97d447caf4294059_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RhYmxlOmJhYTBlNjJkYWUzZjQ5NWY5OWYxOTI4NGM0ZmRhN2M1L3RhYmxlcmFuZ2U6YmFhMGU2MmRhZTNmNDk1Zjk5ZjE5Mjg0YzRmZGE3YzVfMy0xLTEtMS02OTY1Mg_401aa207-cc70-4d00-93d0-a8da6d67b517">63,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i112820749e8349ea97d447caf4294059_I20230331" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RhYmxlOmJhYTBlNjJkYWUzZjQ5NWY5OWYxOTI4NGM0ZmRhN2M1L3RhYmxlcmFuZ2U6YmFhMGU2MmRhZTNmNDk1Zjk5ZjE5Mjg0YzRmZGE3YzVfNS0xLTEtMS02OTY1Mg_72d5ca7d-0e0e-4fb5-b2bf-efef30961494">75,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized debt discount and issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i112820749e8349ea97d447caf4294059_I20230331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RhYmxlOmJhYTBlNjJkYWUzZjQ5NWY5OWYxOTI4NGM0ZmRhN2M1L3RhYmxlcmFuZ2U6YmFhMGU2MmRhZTNmNDk1Zjk5ZjE5Mjg0YzRmZGE3YzVfNi0xLTEtMS02OTY1Mg_61f8d7fc-2f12-4ee9-b845-5e8c77d6454c">840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unaccreted backend fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i112820749e8349ea97d447caf4294059_I20230331" decimals="-3" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RhYmxlOmJhYTBlNjJkYWUzZjQ5NWY5OWYxOTI4NGM0ZmRhN2M1L3RhYmxlcmFuZ2U6YmFhMGU2MmRhZTNmNDk1Zjk5ZjE5Mjg0YzRmZGE3YzVfNy0xLTEtMS02OTY1Mg_ce0d6aa3-8fe5-46d9-80e1-3f3a56cfbd9d">3,143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i112820749e8349ea97d447caf4294059_I20230331" decimals="-3" name="npce:DebtInstrumentUnamortizedInterestCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RhYmxlOmJhYTBlNjJkYWUzZjQ5NWY5OWYxOTI4NGM0ZmRhN2M1L3RhYmxlcmFuZ2U6YmFhMGU2MmRhZTNmNDk1Zjk5ZjE5Mjg0YzRmZGE3YzVfOC0xLTEtMS02OTY1Mg_484f0e0c-99cc-468d-aefc-3f0098b5ed6d">18,023</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i112820749e8349ea97d447caf4294059_I20230331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RhYmxlOmJhYTBlNjJkYWUzZjQ5NWY5OWYxOTI4NGM0ZmRhN2M1L3RhYmxlcmFuZ2U6YmFhMGU2MmRhZTNmNDk1Zjk5ZjE5Mjg0YzRmZGE3YzVfOS0xLTEtMS02OTY1Mg_22837221-7362-49b9-ac93-7606a09015ac">53,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2a59f7ea1762416695eae3249a8f9ede_61"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RleHRyZWdpb246MTZiZGM3MzcyYWQ1NDNlZGJjMWY1ZDI1NWVlYzhlYjdfNDc4_52de4b03-645f-4d21-af26-0b13d3fa242e" continuedAt="ib0ab83d8b794456281fe235e31a71cee" escape="true">Common Stock</ix:nonNumeric></span></div><ix:continuation id="ib0ab83d8b794456281fe235e31a71cee"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Amended and Restated Certificate of Incorporation authorizes the Company to issue <ix:nonFraction unitRef="shares" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RleHRyZWdpb246MTZiZGM3MzcyYWQ1NDNlZGJjMWY1ZDI1NWVlYzhlYjdfMTE3_be8f08a7-d93d-4212-97ea-d9d180697285">200,000,000</ix:nonFraction>&#160;shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RleHRyZWdpb246MTZiZGM3MzcyYWQ1NDNlZGJjMWY1ZDI1NWVlYzhlYjdfMTMw_be10861b-bcd3-4a69-a49b-27e9ef24cbb8">0.001</ix:nonFraction> par value common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of common stock are entitled to receive dividends whenever funds and assets are legally available and when declared by the Board of Directors. As of March&#160;31, 2023 and December 31, 2022, <ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="INF" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RleHRyZWdpb246MTZiZGM3MzcyYWQ1NDNlZGJjMWY1ZDI1NWVlYzhlYjdfMzQ0_3c07ece2-8222-4331-ac20-ea1eeca2f866"><ix:nonFraction unitRef="usd" contextRef="i03bae0452175488495225eda73e7fe90_D20220101-20221231" decimals="INF" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RleHRyZWdpb246MTZiZGM3MzcyYWQ1NDNlZGJjMWY1ZDI1NWVlYzhlYjdfMzQ0_f9fd3364-ea2d-4976-a185-66fd763aae13">no</ix:nonFraction></ix:nonFraction> dividends had been declared.</span></div><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RleHRyZWdpb246MTZiZGM3MzcyYWQ1NDNlZGJjMWY1ZDI1NWVlYzhlYjdfNDc5_9e37f59d-aac3-46dc-9da5-258f094816db" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December 31, 2022, the Company had reserved common stock for future issuance as follows:</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for future grant under the 2021 Plan</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7933e407f09241dcbaee799735452b05_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RhYmxlOjU4YTA1ZDM1MDk0NjQ3NmQ5MzM1MTRmMjYyM2Q5Njc1L3RhYmxlcmFuZ2U6NThhMDVkMzUwOTQ2NDc2ZDkzMzUxNGYyNjIzZDk2NzVfMi0xLTEtMS02OTY1Mg_7150fcee-b34e-4b72-816f-e75954110a47">959,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82a147b9aa3a438bbe5962d4d431b65a_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RhYmxlOjU4YTA1ZDM1MDk0NjQ3NmQ5MzM1MTRmMjYyM2Q5Njc1L3RhYmxlcmFuZ2U6NThhMDVkMzUwOTQ2NDc2ZDkzMzUxNGYyNjIzZDk2NzVfMi0zLTEtMS02OTY1Mg_ab8bbb04-8e09-4411-a380-f55f67601cc3">1,443,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding options under the 2021 Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9928356578b14783835e61b49e13bde7_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RhYmxlOjU4YTA1ZDM1MDk0NjQ3NmQ5MzM1MTRmMjYyM2Q5Njc1L3RhYmxlcmFuZ2U6NThhMDVkMzUwOTQ2NDc2ZDkzMzUxNGYyNjIzZDk2NzVfMy0xLTEtMS02OTY1Mg_6ff709d9-b006-4032-8b59-51f20564deff">3,531,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia780dfd625a04653a5d751d2bac0cd4e_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RhYmxlOjU4YTA1ZDM1MDk0NjQ3NmQ5MzM1MTRmMjYyM2Q5Njc1L3RhYmxlcmFuZ2U6NThhMDVkMzUwOTQ2NDc2ZDkzMzUxNGYyNjIzZDk2NzVfMy0zLTEtMS02OTY1Mg_a7c44de4-743d-4732-972c-15cea1463738">3,446,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding restricted stock units under the 2021 Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i106f4f143f4e47e38267866a576503c3_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RhYmxlOjU4YTA1ZDM1MDk0NjQ3NmQ5MzM1MTRmMjYyM2Q5Njc1L3RhYmxlcmFuZ2U6NThhMDVkMzUwOTQ2NDc2ZDkzMzUxNGYyNjIzZDk2NzVfNC0xLTEtMS02OTY1Mg_bb7632f8-c1dc-43d5-9aba-ed1b1fb63e10">3,099,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59a77cc78b754f55b5ff3d8bc740ad1b_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RhYmxlOjU4YTA1ZDM1MDk0NjQ3NmQ5MzM1MTRmMjYyM2Q5Njc1L3RhYmxlcmFuZ2U6NThhMDVkMzUwOTQ2NDc2ZDkzMzUxNGYyNjIzZDk2NzVfNC0zLTEtMS02OTY1Mg_52706421-4525-4f29-8fb6-dd23ebd9e1bf">1,756,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock available for ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1be39c24946144f8b22080563d21467c_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RhYmxlOjU4YTA1ZDM1MDk0NjQ3NmQ5MzM1MTRmMjYyM2Q5Njc1L3RhYmxlcmFuZ2U6NThhMDVkMzUwOTQ2NDc2ZDkzMzUxNGYyNjIzZDk2NzVfNS0xLTEtMS02OTY1Mg_bccc78de-4fe5-46bf-839e-c23041d316ca">680,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id847acf3ca4e4e02a9c3aaf18d3001eb_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RhYmxlOjU4YTA1ZDM1MDk0NjQ3NmQ5MzM1MTRmMjYyM2Q5Njc1L3RhYmxlcmFuZ2U6NThhMDVkMzUwOTQ2NDc2ZDkzMzUxNGYyNjIzZDk2NzVfNS0zLTEtMS02OTY1Mg_07f30962-fd77-449b-8348-c140f71b7c7b">429,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RhYmxlOjU4YTA1ZDM1MDk0NjQ3NmQ5MzM1MTRmMjYyM2Q5Njc1L3RhYmxlcmFuZ2U6NThhMDVkMzUwOTQ2NDc2ZDkzMzUxNGYyNjIzZDk2NzVfNi0xLTEtMS02OTY1Mg_1df618a0-22c8-4bab-a29e-40d0240e5071">8,271,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RhYmxlOjU4YTA1ZDM1MDk0NjQ3NmQ5MzM1MTRmMjYyM2Q5Njc1L3RhYmxlcmFuZ2U6NThhMDVkMzUwOTQ2NDc2ZDkzMzUxNGYyNjIzZDk2NzVfNi0zLTEtMS02OTY1Mg_1925b8b9-eba2-4201-9969-32e2a110afe0">7,076,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i2a59f7ea1762416695eae3249a8f9ede_64"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMzQ1MA_7f0658a2-0ce3-4ef6-a858-6c02fce1dd06" continuedAt="i1628a8e9897f46d9b8e3bbab7b3ce6ba" escape="true">Stock-Based Incentive Compensation Plans</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1628a8e9897f46d9b8e3bbab7b3ce6ba" continuedAt="i0531197535e3417f9dd8e3650d0c370c"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMzQ1NQ_e5e27fd6-d09e-4406-ae8c-7dc1d7fde496" continuedAt="i07693bb79b5b41f583a27885a27854e7" escape="true">A summary of shares available for grant under the Company&#8217;s 2021 Equity Incentive Plan, or the 2021 Plan, is as follows:</ix:nonNumeric></ix:continuation></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NeuroPace, Inc.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Condensed Financial Statements</span></div></div><ix:continuation id="i0531197535e3417f9dd8e3650d0c370c" continuedAt="i77870b65d30e4de6986f38c75e25d865"><div style="margin-bottom:9pt"><ix:continuation id="i07693bb79b5b41f583a27885a27854e7"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Available for Grant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant as of January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8968a5068c274de7a24aab2154e22af1_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ0MzA4YWFhMGNmZjRiMjc4MjU5NDliOTFlZTg1OGVkL3RhYmxlcmFuZ2U6NDQzMDhhYWEwY2ZmNGIyNzgyNTk0OWI5MWVlODU4ZWRfMS0xLTEtMS02OTY1Mg_b38ca0c1-16f2-44f6-91ba-4d931c994a08">1,443,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4072dc09d11d4232803ca241e4c4fd61_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ0MzA4YWFhMGNmZjRiMjc4MjU5NDliOTFlZTg1OGVkL3RhYmxlcmFuZ2U6NDQzMDhhYWEwY2ZmNGIyNzgyNTk0OWI5MWVlODU4ZWRfMi0xLTEtMS02OTY1Mg_a16d6e43-60a6-4f85-93bd-ca5fbf679f74">1,252,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted/Awarded</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4072dc09d11d4232803ca241e4c4fd61_D20230101-20230331" decimals="INF" name="npce:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ0MzA4YWFhMGNmZjRiMjc4MjU5NDliOTFlZTg1OGVkL3RhYmxlcmFuZ2U6NDQzMDhhYWEwY2ZmNGIyNzgyNTk0OWI5MWVlODU4ZWRfMy0xLTEtMS02OTY1Mg_73a1eaf7-6ccc-4f79-92fa-0d4cc6104dfa">1,821,762</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4072dc09d11d4232803ca241e4c4fd61_D20230101-20230331" decimals="INF" name="npce:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ0MzA4YWFhMGNmZjRiMjc4MjU5NDliOTFlZTg1OGVkL3RhYmxlcmFuZ2U6NDQzMDhhYWEwY2ZmNGIyNzgyNTk0OWI5MWVlODU4ZWRfNC0xLTEtMS02OTY1Mg_ccad54c4-85ce-43cf-b289-dbccef4e02a5">49,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Withheld for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4072dc09d11d4232803ca241e4c4fd61_D20230101-20230331" decimals="INF" name="npce:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ0MzA4YWFhMGNmZjRiMjc4MjU5NDliOTFlZTg1OGVkL3RhYmxlcmFuZ2U6NDQzMDhhYWEwY2ZmNGIyNzgyNTk0OWI5MWVlODU4ZWRfNS0xLTEtMS02OTY1Mg_eba9ab9d-cdb9-4d21-878a-f2c66359a83f">35,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant as of March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i898957e56f4f40b1800743493ec2650f_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ0MzA4YWFhMGNmZjRiMjc4MjU5NDliOTFlZTg1OGVkL3RhYmxlcmFuZ2U6NDQzMDhhYWEwY2ZmNGIyNzgyNTk0OWI5MWVlODU4ZWRfNi0xLTEtMS02OTY1Mg_2241c59f-86f0-4061-85f7-c1eecb63e14d">959,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMzQ1MQ_02378503-a22a-4b06-9a2f-7622411737b1" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the three months ended March&#160;31, 2023 is set forth below:</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances as of January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfMi0xLTEtMS02OTY1Mg_99d520d5-5eee-4e67-8d9c-e24c815f26f0">3,446,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfMi0zLTEtMS02OTY1Mg_0bab9256-b7b2-44b3-beba-6e29ce60e70e">3.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03bae0452175488495225eda73e7fe90_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfMi01LTEtMS02OTY1Mg_45145555-a08a-4ef0-a9a0-e51717611616">8.06</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfMy0xLTEtMS02OTY1Mg_9812b50c-f9f2-4c98-b77a-967a63ba4062">120,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfMy0zLTEtMS02OTY1Mg_4d2ba9f1-f2dd-41ad-9890-edc8d17f9b38">1.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfNC0xLTEtMS02OTY1Mg_5a3a0a30-fadf-42b4-bd59-3f0cd674e94f">17,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfNC0zLTEtMS02OTY1Mg_1c5a1ff0-0a99-4058-87a5-54e8bb386b9e">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfNS0xLTEtMS02OTY1Mg_0f253056-a6bd-4ebc-ad48-c35ab355b0a9">17,898</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfNS0zLTEtMS02OTY1Mg_c4c2d737-b271-4867-ae17-353c22c014ae">6.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances at March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfNi0xLTEtMS02OTY1Mg_08b8b168-8796-4718-9201-8fa202272b64">3,531,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfNi0zLTEtMS02OTY1Mg_484ed461-0a91-41b2-907b-63b884fb44a5">3.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfNi01LTEtMS02OTY1Mg_ae29a9de-680f-474c-a156-e146a0365e89">7.92</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfNy0xLTEtMS02OTY1Mg_61fdc863-6da3-419d-911e-d87b6d334abf">2,003,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfNy0zLTEtMS02OTY1Mg_15ee3216-7905-432b-8e9e-549d1a52ab53">2.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfNy01LTEtMS02OTY1Mg_f575bcf5-167c-4cad-b8bb-9ac6da60dbee">7.69</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfOC0xLTEtMS02OTY1Mg_30b50033-d938-442e-96c0-a67fd39cdec8">3,531,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfOC0zLTEtMS02OTY1Mg_e606d474-0666-425c-bf24-3afe0a453aee">3.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfOC01LTEtMS02OTY1Mg_288e2879-8bbd-424d-9239-0c0f21206c82">7.92</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Early Exercise of Stock Options </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the Company&#8217;s 2020 Stock Plan, or the 2020 Plan, and the 2021 Plan, permit the exercise of options granted under the plans prior to vesting, subject to required approvals. The shares of common stock issued from the early exercise of unvested stock options are restricted and continue to vest over the original implied service period. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. The shares purchased by the employees and non-employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be outstanding until those shares vest. The cash received in exchange for exercised and unvested shares related to stock options granted is recorded as a liability for the early exercise of stock options in accrued liabilities on the accompanying balance sheet and will be transferred into common stock and additional paid-in capital as the shares vest. As of March&#160;31, 2023 and December 31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="INF" name="npce:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMTMyMw_57c6b0ff-1b8f-4f0f-907d-6158c6ee2add">65,296</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i8daa853d90324638b7732e94aa400e74_I20221231" decimals="INF" name="npce:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMTMzMA_387802b1-b9f2-4386-ab0e-f9b69bc105ac">78,389</ix:nonFraction> shares of common stock, respectively, issued pursuant to early exercised options and subject to repurchase.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company adopted the 2021 Employee Stock Purchase Plan, or ESPP. The Company allows eligible employees to purchase shares of the Company's common stock through payroll deductions at a price equal to <ix:nonFraction unitRef="number" contextRef="i75e07d1256df491e837d1a678fa4841f_D20210401-20210430" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMTY4Nw_028cc0cc-deff-476c-9f77-f1a00c076223">85</ix:nonFraction>% of the lesser of the fair market value of the stock as of the first date or the ending date of each offering period, which is typically <ix:nonNumeric contextRef="i75e07d1256df491e837d1a678fa4841f_D20210401-20210430" name="npce:EmployeeStockPurchasePlanLengthOfOfferingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMTgyNg_3a71d3ed-ec84-4db9-9bbd-9e2aa112beb2">six months</ix:nonNumeric>. There were <ix:nonFraction unitRef="shares" contextRef="i881477cd12da4a8f82229279bbec5907_I20210430" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMTg0MQ_5b0fa6c8-eda7-478b-8ed9-f546aebaecc0">580,000</ix:nonFraction> shares of common stock initially reserved for issuance under the ESPP. In January 2023, the number of shares of common stock available for issuance under the ESPP was increased by <ix:nonFraction unitRef="shares" contextRef="ida17c9ecae0547af93d99c9010967769_D20210401-20210430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMjAyNA_2ec14d6d-41af-46fa-801c-f6337b3ed4ec">250,457</ix:nonFraction> shares as a result of the automatic increase provision in the ESPP.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="i06a5ce3c01de408795052e7b2448ca32_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMjU3Nw_0f3bf1b6-cbdc-4274-ba74-afda6ec48046">680,397</ix:nonFraction> shares under the ESPP remain available for purchase. The offering period and purchase period is determined by the board of directors. A new offering period of <ix:nonNumeric contextRef="i400dca35646848acb6a6f7c825c240c5_D20221207-20230606" name="npce:EmployeeStockPurchasePlanOfferingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMzQ1Mg_d6db8a5e-96fe-4374-8600-8e9c3384b716">six months</ix:nonNumeric> has been authorized beginning December 7, 2022 through June 6, 2023.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NeuroPace, Inc.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Condensed Financial Statements</span></div></div><ix:continuation id="i77870b65d30e4de6986f38c75e25d865"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMzQ1Mw_d8d4c1e1-6ec4-4917-a780-170cb40be5ce" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity with respect to restricted stock units was as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.619%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares Underlying Outstanding Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested, January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3a1293fb162241768174865fa0b18818_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjcwMTc2YzQ0ODY4MTRjMTFiMGE0Mzg2Yzc1MzFlZTBkL3RhYmxlcmFuZ2U6NzAxNzZjNDQ4NjgxNGMxMWIwYTQzODZjNzUzMWVlMGRfMS0xLTEtMS02OTY1Mg_c141ccb9-9fd3-4ec6-a10c-c9e5f21e5319">1,756,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3a1293fb162241768174865fa0b18818_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjcwMTc2YzQ0ODY4MTRjMTFiMGE0Mzg2Yzc1MzFlZTBkL3RhYmxlcmFuZ2U6NzAxNzZjNDQ4NjgxNGMxMWIwYTQzODZjNzUzMWVlMGRfMS0zLTEtMS02OTY1Mg_e959c5fc-8f1c-4414-bde5-b7309b097592">10.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="icf61601566c5496eaf799d95dd6d08ab_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjcwMTc2YzQ0ODY4MTRjMTFiMGE0Mzg2Yzc1MzFlZTBkL3RhYmxlcmFuZ2U6NzAxNzZjNDQ4NjgxNGMxMWIwYTQzODZjNzUzMWVlMGRfMi0xLTEtMS02OTY1Mg_47df6a65-3463-4a49-b1af-7b5beb7169a2">1,701,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="icf61601566c5496eaf799d95dd6d08ab_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjcwMTc2YzQ0ODY4MTRjMTFiMGE0Mzg2Yzc1MzFlZTBkL3RhYmxlcmFuZ2U6NzAxNzZjNDQ4NjgxNGMxMWIwYTQzODZjNzUzMWVlMGRfMi0zLTEtMS02OTY1Mg_c6b0e83f-b9c8-4e7a-9b1c-85cb3d90a31c">4.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="icf61601566c5496eaf799d95dd6d08ab_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjcwMTc2YzQ0ODY4MTRjMTFiMGE0Mzg2Yzc1MzFlZTBkL3RhYmxlcmFuZ2U6NzAxNzZjNDQ4NjgxNGMxMWIwYTQzODZjNzUzMWVlMGRfMy0xLTEtMS02OTY1Mg_9996893f-9b53-4380-92a3-e699443bfd5a">325,747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="icf61601566c5496eaf799d95dd6d08ab_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjcwMTc2YzQ0ODY4MTRjMTFiMGE0Mzg2Yzc1MzFlZTBkL3RhYmxlcmFuZ2U6NzAxNzZjNDQ4NjgxNGMxMWIwYTQzODZjNzUzMWVlMGRfMy0zLTEtMS02OTY1Mg_b0a79f0d-3248-45e6-9fd6-df0bb5c313fc">9.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="icf61601566c5496eaf799d95dd6d08ab_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjcwMTc2YzQ0ODY4MTRjMTFiMGE0Mzg2Yzc1MzFlZTBkL3RhYmxlcmFuZ2U6NzAxNzZjNDQ4NjgxNGMxMWIwYTQzODZjNzUzMWVlMGRfNC0xLTEtMS02OTY1Mg_69475871-5a9d-4387-982d-0847d55703b8">31,729</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="icf61601566c5496eaf799d95dd6d08ab_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjcwMTc2YzQ0ODY4MTRjMTFiMGE0Mzg2Yzc1MzFlZTBkL3RhYmxlcmFuZ2U6NzAxNzZjNDQ4NjgxNGMxMWIwYTQzODZjNzUzMWVlMGRfNC0zLTEtMS02OTY1Mg_8c23bd2c-6c0d-4958-a664-7a46df34b1a8">13.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested, March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4f6410c7ed884b1dac8048f069c34d10_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjcwMTc2YzQ0ODY4MTRjMTFiMGE0Mzg2Yzc1MzFlZTBkL3RhYmxlcmFuZ2U6NzAxNzZjNDQ4NjgxNGMxMWIwYTQzODZjNzUzMWVlMGRfNS0xLTEtMS02OTY1Mg_791f6a49-0e1c-4b5f-8f97-f45a037ec536">3,099,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4f6410c7ed884b1dac8048f069c34d10_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjcwMTc2YzQ0ODY4MTRjMTFiMGE0Mzg2Yzc1MzFlZTBkL3RhYmxlcmFuZ2U6NzAxNzZjNDQ4NjgxNGMxMWIwYTQzODZjNzUzMWVlMGRfNS0zLTEtMS02OTY1Mg_556e7f47-0961-4018-847e-bf156082da9e">7.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMzQ1NA_c971d886-510b-4326-9442-a36c28e46d19" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c03c7d6befd470b9c00ea069d4dec85_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ1MmNkOWNjMmIzZDRiMzNhNWZjMzgxMWFkNGYzMjY1L3RhYmxlcmFuZ2U6NDUyY2Q5Y2MyYjNkNGIzM2E1ZmMzODExYWQ0ZjMyNjVfMi01LTEtMS02OTY1Mg_420e0710-7041-4ac1-8f0f-523214ea3a8c">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie403128de0ed45939a20b7ba400d2deb_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ1MmNkOWNjMmIzZDRiMzNhNWZjMzgxMWFkNGYzMjY1L3RhYmxlcmFuZ2U6NDUyY2Q5Y2MyYjNkNGIzM2E1ZmMzODExYWQ0ZjMyNjVfMi03LTEtMS02OTY1Mg_67c152a4-c76b-48aa-9198-414b93feee77">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i639bac8ba3dc42db9ca14dffe873b9aa_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ1MmNkOWNjMmIzZDRiMzNhNWZjMzgxMWFkNGYzMjY1L3RhYmxlcmFuZ2U6NDUyY2Q5Y2MyYjNkNGIzM2E1ZmMzODExYWQ0ZjMyNjVfMy01LTEtMS02OTY1Mg_2a3bf5de-ac6e-4e27-a0e3-1a942caa2f49">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ab734a7b4054702ad1f354a8ba71a1a_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ1MmNkOWNjMmIzZDRiMzNhNWZjMzgxMWFkNGYzMjY1L3RhYmxlcmFuZ2U6NDUyY2Q5Y2MyYjNkNGIzM2E1ZmMzODExYWQ0ZjMyNjVfMy03LTEtMS02OTY1Mg_9adde79d-ae76-4002-9cf5-3e50c9441c2d">440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ed9f75a9df14b418c706ff213e1dc62_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ1MmNkOWNjMmIzZDRiMzNhNWZjMzgxMWFkNGYzMjY1L3RhYmxlcmFuZ2U6NDUyY2Q5Y2MyYjNkNGIzM2E1ZmMzODExYWQ0ZjMyNjVfNC01LTEtMS02OTY1Mg_ff29c43f-c85b-4823-a57d-d50f0df1e191">1,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id666fdb85ced40d196e685e2eb0efbb9_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ1MmNkOWNjMmIzZDRiMzNhNWZjMzgxMWFkNGYzMjY1L3RhYmxlcmFuZ2U6NDUyY2Q5Y2MyYjNkNGIzM2E1ZmMzODExYWQ0ZjMyNjVfNC03LTEtMS02OTY1Mg_4eaa18cf-cf40-4021-afcf-55f2b9a08286">938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ1MmNkOWNjMmIzZDRiMzNhNWZjMzgxMWFkNGYzMjY1L3RhYmxlcmFuZ2U6NDUyY2Q5Y2MyYjNkNGIzM2E1ZmMzODExYWQ0ZjMyNjVfNS01LTEtMS02OTY1Mg_be3fa5eb-bb6b-47fe-a901-64b63469b4ca">2,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ1MmNkOWNjMmIzZDRiMzNhNWZjMzgxMWFkNGYzMjY1L3RhYmxlcmFuZ2U6NDUyY2Q5Y2MyYjNkNGIzM2E1ZmMzODExYWQ0ZjMyNjVfNS03LTEtMS02OTY1Mg_f09ddae2-f080-46d8-8f66-e99c3672c38f">1,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above stock-based compensation expense related to the following equity-based awards (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options and restricted stock units</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8c8e2b0811a4c2085f3292fca112c80_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjBhYWRmYjg3NmRkMDRiMmQ5YTgxNWE5MmM2ZWY5ODljL3RhYmxlcmFuZ2U6MGFhZGZiODc2ZGQwNGIyZDlhODE1YTkyYzZlZjk4OWNfMi01LTEtMS02OTY1Mg_8e3a48ef-6337-431b-b65d-334118b26da3">2,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a901df324314e06b06d59f030123b5d_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjBhYWRmYjg3NmRkMDRiMmQ5YTgxNWE5MmM2ZWY5ODljL3RhYmxlcmFuZ2U6MGFhZGZiODc2ZGQwNGIyZDlhODE1YTkyYzZlZjk4OWNfMi03LTEtMS02OTY1Mg_e2dfe7c7-e55c-4d04-bf2a-89db32c48aa3">1,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22c77f84a8524a16aee5a4f8921601bc_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjBhYWRmYjg3NmRkMDRiMmQ5YTgxNWE5MmM2ZWY5ODljL3RhYmxlcmFuZ2U6MGFhZGZiODc2ZGQwNGIyZDlhODE1YTkyYzZlZjk4OWNfMy01LTEtMS02OTY1Mg_bb833b46-dbe6-4a53-b63c-045018c2e48d">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i387f9c0ddfda42738fd2f8d07cefdc23_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjBhYWRmYjg3NmRkMDRiMmQ5YTgxNWE5MmM2ZWY5ODljL3RhYmxlcmFuZ2U6MGFhZGZiODc2ZGQwNGIyZDlhODE1YTkyYzZlZjk4OWNfMy03LTEtMS02OTY1Mg_111bd1f6-9aea-4fb5-9001-36a6370823f9">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjBhYWRmYjg3NmRkMDRiMmQ5YTgxNWE5MmM2ZWY5ODljL3RhYmxlcmFuZ2U6MGFhZGZiODc2ZGQwNGIyZDlhODE1YTkyYzZlZjk4OWNfNC01LTEtMS02OTY1Mg_f88c7ffc-a87f-4868-9a56-f86feb644e92">2,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjBhYWRmYjg3NmRkMDRiMmQ5YTgxNWE5MmM2ZWY5ODljL3RhYmxlcmFuZ2U6MGFhZGZiODc2ZGQwNGIyZDlhODE1YTkyYzZlZjk4OWNfNC03LTEtMS02OTY1Mg_2f49e775-83e4-4bd6-9f38-a240fb75d4d5">1,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the total unrecognized stock-based compensation expense related to unvested stock options and restricted stock units was $<ix:nonFraction unitRef="usd" contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMzE1Nw_3a1fd8eb-00b6-4115-8914-b87b3ac59c8b">25.4</ix:nonFraction> million, which will be amortized on a straight-line basis over a weighted average remaining period of <ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMzI1NA_58eb3c02-39aa-43c8-94cb-505f310a9354">2.7</ix:nonNumeric> years.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company had unrecognized stock-based compensation expense relating to the ESPP awards of less than $<ix:nonFraction unitRef="usd" contextRef="i06a5ce3c01de408795052e7b2448ca32_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMzM3NQ_468d9977-5695-4f64-8e22-7f14d9b8a549">0.1</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i0a949f95a2434c7b8352d1c7ddbea5aa_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMzQ0OA_4f1bb785-9b7e-4a77-964f-bfd1a01285e7">0.2</ix:nonNumeric> years.</span></div></ix:continuation><div id="i2a59f7ea1762416695eae3249a8f9ede_67"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82Ny9mcmFnOjlhNDI4MTBkYTZmZTQ5ZmFiMzU2NjM5OTg5OGYwMDE2L3RleHRyZWdpb246OWE0MjgxMGRhNmZlNDlmYWIzNTY2Mzk5ODk4ZjAwMTZfNzg2_b70f6c82-f0df-4de9-9036-6fd4182bff51" continuedAt="i9e93e84a5eeb450e9595f99e4e04e13b" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i9e93e84a5eeb450e9595f99e4e04e13b"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did <ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82Ny9mcmFnOjlhNDI4MTBkYTZmZTQ5ZmFiMzU2NjM5OTg5OGYwMDE2L3RleHRyZWdpb246OWE0MjgxMGRhNmZlNDlmYWIzNTY2Mzk5ODk4ZjAwMTZfMzg_0f5156c1-1ee7-4ea2-84f2-eef215e70792"><ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82Ny9mcmFnOjlhNDI4MTBkYTZmZTQ5ZmFiMzU2NjM5OTg5OGYwMDE2L3RleHRyZWdpb246OWE0MjgxMGRhNmZlNDlmYWIzNTY2Mzk5ODk4ZjAwMTZfMzg_46b6f160-4340-4f07-8c2e-f3b79b8ca305">no</ix:nonFraction></ix:nonFraction>t record a federal or state income tax provision or benefit for the three months ended March&#160;31, 2023 and 2022 as it has incurred net losses since inception. In addition, the net deferred tax assets generated from net operating losses are fully offset by a valuation allowance as the Company believes it is not more likely than not that the benefit will be realized.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for the uncertainty in income taxes by utilizing a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or are expected to be taken on an income tax return. There has been no changes in the estimated uncertain tax benefits recorded as of December 31, 2022.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i2a59f7ea1762416695eae3249a8f9ede_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NeuroPace, Inc.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Condensed Financial Statements</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RleHRyZWdpb246MzZkMzg0ODFmYWJmNDcyYjlkYjFlM2I0MTMyYzZkYTJfNTE1_42f9740b-ca2b-4f8c-94e8-82aba06e8c5c" continuedAt="i2d3eb324b743428a92d7f4dce5dacd03" escape="true">Net Loss per Share Attributable to Common Stockholders</ix:nonNumeric></span></div><ix:continuation id="i2d3eb324b743428a92d7f4dce5dacd03"><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RleHRyZWdpb246MzZkMzg0ODFmYWJmNDcyYjlkYjFlM2I0MTMyYzZkYTJfNTEz_51b27c11-4038-4ccd-9aea-de34dfad7a37" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except for share and per share amounts):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOjZkM2Y2MTVjYmFkYzQyYTQ5YWZlM2YxMDFiMGRjOTU2L3RhYmxlcmFuZ2U6NmQzZjYxNWNiYWRjNDJhNDlhZmUzZjEwMWIwZGM5NTZfMy01LTEtMS02OTY1Mg_7d1d2ace-03b2-4023-8c3f-9f005ad2ba3f">10,375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOjZkM2Y2MTVjYmFkYzQyYTQ5YWZlM2YxMDFiMGRjOTU2L3RhYmxlcmFuZ2U6NmQzZjYxNWNiYWRjNDJhNDlhZmUzZjEwMWIwZGM5NTZfMy03LTEtMS02OTY1Mg_d4f9bfa1-1b67-4d69-8d3a-a019777cd724">11,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common stock outstanding used to compute basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOjZkM2Y2MTVjYmFkYzQyYTQ5YWZlM2YxMDFiMGRjOTU2L3RhYmxlcmFuZ2U6NmQzZjYxNWNiYWRjNDJhNDlhZmUzZjEwMWIwZGM5NTZfNS01LTEtMS02OTY1Mg_49cf71f5-b13e-4f68-a29f-1df224e00042"><ix:nonFraction unitRef="shares" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOjZkM2Y2MTVjYmFkYzQyYTQ5YWZlM2YxMDFiMGRjOTU2L3RhYmxlcmFuZ2U6NmQzZjYxNWNiYWRjNDJhNDlhZmUzZjEwMWIwZGM5NTZfNS01LTEtMS02OTY1Mg_bbc013d8-8c67-4d42-920a-6619afe98e06">25,097,262</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOjZkM2Y2MTVjYmFkYzQyYTQ5YWZlM2YxMDFiMGRjOTU2L3RhYmxlcmFuZ2U6NmQzZjYxNWNiYWRjNDJhNDlhZmUzZjEwMWIwZGM5NTZfNS03LTEtMS02OTY1Mg_a08304ee-4644-4050-b181-a4295e79c59a"><ix:nonFraction unitRef="shares" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOjZkM2Y2MTVjYmFkYzQyYTQ5YWZlM2YxMDFiMGRjOTU2L3RhYmxlcmFuZ2U6NmQzZjYxNWNiYWRjNDJhNDlhZmUzZjEwMWIwZGM5NTZfNS03LTEtMS02OTY1Mg_d22954e8-96b2-4873-a5a8-7bee026ae5f4">24,307,485</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOjZkM2Y2MTVjYmFkYzQyYTQ5YWZlM2YxMDFiMGRjOTU2L3RhYmxlcmFuZ2U6NmQzZjYxNWNiYWRjNDJhNDlhZmUzZjEwMWIwZGM5NTZfNi01LTEtMS02OTY1Mg_01793fe6-40fb-479e-8a65-8a19f9f3a16e"><ix:nonFraction unitRef="usdPerShare" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOjZkM2Y2MTVjYmFkYzQyYTQ5YWZlM2YxMDFiMGRjOTU2L3RhYmxlcmFuZ2U6NmQzZjYxNWNiYWRjNDJhNDlhZmUzZjEwMWIwZGM5NTZfNi01LTEtMS02OTY1Mg_c6a2fa90-de95-4041-a97a-4eccbf43b858">0.41</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOjZkM2Y2MTVjYmFkYzQyYTQ5YWZlM2YxMDFiMGRjOTU2L3RhYmxlcmFuZ2U6NmQzZjYxNWNiYWRjNDJhNDlhZmUzZjEwMWIwZGM5NTZfNi03LTEtMS02OTY1Mg_7d705f45-85a0-47fa-9e9c-f65aad1edae7"><ix:nonFraction unitRef="usdPerShare" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOjZkM2Y2MTVjYmFkYzQyYTQ5YWZlM2YxMDFiMGRjOTU2L3RhYmxlcmFuZ2U6NmQzZjYxNWNiYWRjNDJhNDlhZmUzZjEwMWIwZGM5NTZfNi03LTEtMS02OTY1Mg_a22f764b-7f22-42c1-876b-877fcf8abf4f">0.47</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RleHRyZWdpb246MzZkMzg0ODFmYWJmNDcyYjlkYjFlM2I0MTMyYzZkYTJfNTE0_b6aae07f-f63e-4bf6-a82d-b6e2363bc450" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company&#8217;s net loss, in common stock equivalent shares:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i660649a2805c490faa7479b8f8eb80f9_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOmRmZjZiNWExMzg0MTQ3YzNiZWQ2NjY1Mzc1ODI5MmNhL3RhYmxlcmFuZ2U6ZGZmNmI1YTEzODQxNDdjM2JlZDY2NjUzNzU4MjkyY2FfMi0xLTEtMS02OTY1Mg_15d74705-42c4-4284-aec4-e3b06499e0c5">3,531,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2dd75294bff941ef89454c5ed2eebd0a_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOmRmZjZiNWExMzg0MTQ3YzNiZWQ2NjY1Mzc1ODI5MmNhL3RhYmxlcmFuZ2U6ZGZmNmI1YTEzODQxNDdjM2JlZDY2NjUzNzU4MjkyY2FfMi0zLTEtMS02OTY1Mg_6861b0a7-6e82-45ff-9553-d828673f6b9c">3,543,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested early exercised common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad266dd548874ca7800f0d7408df01b3_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOmRmZjZiNWExMzg0MTQ3YzNiZWQ2NjY1Mzc1ODI5MmNhL3RhYmxlcmFuZ2U6ZGZmNmI1YTEzODQxNDdjM2JlZDY2NjUzNzU4MjkyY2FfMy0xLTEtMS02OTY1Mg_229283fe-7dec-4357-8997-48e19888a2b9">65,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51515b8cbea941149bc22fc10e0f86ab_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOmRmZjZiNWExMzg0MTQ3YzNiZWQ2NjY1Mzc1ODI5MmNhL3RhYmxlcmFuZ2U6ZGZmNmI1YTEzODQxNDdjM2JlZDY2NjUzNzU4MjkyY2FfMy0zLTEtMS02OTY1Mg_07f9a02a-75b1-4e5e-94d7-0607019ab3eb">143,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares committed under ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59a019c9f65548d59de82befb2acc22f_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOmRmZjZiNWExMzg0MTQ3YzNiZWQ2NjY1Mzc1ODI5MmNhL3RhYmxlcmFuZ2U6ZGZmNmI1YTEzODQxNDdjM2JlZDY2NjUzNzU4MjkyY2FfNC0xLTEtMS02OTY1Mg_f19066fc-d27d-4612-8711-7787648e6489">187,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4683af3b7a34481848a875e395fa408_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOmRmZjZiNWExMzg0MTQ3YzNiZWQ2NjY1Mzc1ODI5MmNhL3RhYmxlcmFuZ2U6ZGZmNmI1YTEzODQxNDdjM2JlZDY2NjUzNzU4MjkyY2FfNC0zLTEtMS02OTY1Mg_46dd8262-037b-4989-a9ca-0415503c9862">108,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9840aaee62a3402abc9cc764247cdcc3_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOmRmZjZiNWExMzg0MTQ3YzNiZWQ2NjY1Mzc1ODI5MmNhL3RhYmxlcmFuZ2U6ZGZmNmI1YTEzODQxNDdjM2JlZDY2NjUzNzU4MjkyY2FfNS0xLTEtMS02OTY1Mg_b33a89e8-aeca-4dca-b920-6da81e694355">3,099,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide54bdde89344a929a15191e91ab4bca_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOmRmZjZiNWExMzg0MTQ3YzNiZWQ2NjY1Mzc1ODI5MmNhL3RhYmxlcmFuZ2U6ZGZmNmI1YTEzODQxNDdjM2JlZDY2NjUzNzU4MjkyY2FfNS0zLTEtMS02OTY1Mg_a2403ea6-cd9f-4b4c-93e5-89cfef7639ff">1,848,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOmRmZjZiNWExMzg0MTQ3YzNiZWQ2NjY1Mzc1ODI5MmNhL3RhYmxlcmFuZ2U6ZGZmNmI1YTEzODQxNDdjM2JlZDY2NjUzNzU4MjkyY2FfNi0xLTEtMS02OTY1Mg_032e3232-6018-4875-ac4c-055b2cdbef38">6,884,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOmRmZjZiNWExMzg0MTQ3YzNiZWQ2NjY1Mzc1ODI5MmNhL3RhYmxlcmFuZ2U6ZGZmNmI1YTEzODQxNDdjM2JlZDY2NjUzNzU4MjkyY2FfNi0zLTEtMS02OTY1Mg_a6efa7e5-8ba2-4a79-bdba-806ec5f7d4ff">5,644,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i2a59f7ea1762416695eae3249a8f9ede_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our condensed financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q. This discussion and other parts of this report contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions, which are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this report entitled &#8220;Risk Factors,&#8221; under Part II, Item 1A of this report and those discussed in our other disclosures and filings.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2a59f7ea1762416695eae3249a8f9ede_79"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Our novel and differentiated RNS System is the first and only commercially available, brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. By continuously monitoring the brain&#8217;s electrical activity, recognizing patient-specific abnormal electrical patterns, and responding in real time with imperceptible electrical pulses to prevent seizures, our RNS System delivers the precise amount of therapy when and where it is needed and provides exceptional clinical outcomes with approximately three minutes of stimulation on average per day. Our RNS System is also the only commercially available device that records continuous brain activity data and allows clinicians to monitor patients not only in person, but also remotely, in order to make more informed treatment decisions, thus optimizing patient care. We believe the therapeutic advantages of our RNS System, combined with the insights obtained from our extensive brain data set, offer a significant leap forward in epilepsy treatment.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our RNS System is currently indicated in the United States for use in adult epilepsy patients, meaning patients who are 18 years of age or older, with drug-resistant focal epilepsy. As of March&#160;31, 2023, over 4,000 epilepsy patients have received our RNS System. We believe our compelling body of long-term clinical data, demonstrating continuous improvement in outcomes over time, will support the continued adoption of our RNS System among the approximately 575,000 adults in the United States with drug-resistant focal epilepsy. We continue seeking indication expansion to, over time, more broadly reach the entire approximately 1.2 million drug-resistant epilepsy patients in the United States and have begun enrollment in clinical studies to broaden our indication including into generalized epilepsy. We may additionally seek to expand our operations to reach the approximately 16.5 million drug-resistant epilepsy patients globally.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial efforts are focused on the comprehensive epilepsy centers, or CECs, including Level 4 CECs, that facilitate appropriate care for drug-resistant epilepsy patients. This may include implantation of epilepsy neuromodulation devices such as our RNS System or the ongoing treatment of patients with neuromodulation devices. While most drug-resistant epilepsy patients begin their care at physician offices or community hospitals, we estimate that approximately 24,000 adult drug-resistant focal epilepsy patients are treated in CECs in the United States each year. We estimate that this patient pool represents an annual core market opportunity of approximately $1.1 billion for initial RNS System implants, and we expect that it will continue to grow as the number of CECs and the number of epileptologists increase, as more patients are referred to these CECs, and as more care for RNS-implanted patients can happen outside of the CECs. In addition, the sale of replacement neuromodulation devices when the battery in our RNS neurostimulator approaches end of service provides a recurring revenue stream that is additive to our current $1.1 billion annual market opportunity for initial implants.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received Premarket Approval, or PMA, from the FDA for our RNS System in late 2013 and began the commercial rollout of our RNS System in early 2014. We market our RNS System in the United States through a direct sales organization primarily to the epileptologists and neurosurgeons who respectively prescribe and implant neuromodulation devices in the approximately 250 CECs in the United States. We have established a significant account base at these CECs. Given the concentrated and underpenetrated nature of our target market, we believe that through our sales force, there is a significant opportunity to efficiently drive higher utilization within these centers, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">grow our account base, and expand our referral channel to increase the number of drug-resistant patients referred to the CECs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The implant procedure for our RNS System and the ongoing patient treatment provided by clinicians, including monitoring and programming, are reimbursed under well-established physician and hospital codes. In addition, we believe that our RNS System is currently the only neuromodulation system for epilepsy with reimbursement available for periodic in-person or remote review of brain activity data. Given the relatively young average age of our patient population, our payor mix has historically been more heavily weighted towards commercial payors. As of March&#160;31, 2023, commercial payors have written positive coverage policies that address over 200 million covered lives in the United States. Medicare and Medicaid also routinely provide coverage for implantation of our RNS System and follow-up care. Based on our experience, less than 1% of potential RNS System patients have been unable to undergo an implant procedure with our RNS System due to lack of payor coverage. We believe the established, differentiated, and favorable reimbursement paradigm for our RNS System will continue to support its broad commercial adoption.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently manufacture our RNS System at and distribute our products from our approximately 53,000 square foot facility in Mountain View, California. This facility provides approximately 20,000 square feet of space for our production and distribution operations, including manufacturing, quality control and storage. We believe our existing facility will be sufficient to meet our current and near-term manufacturing needs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have generated significant losses. To date, we have financed our operations primarily through the sale of equity securities, debt financing arrangements and sales of our products. As of March&#160;31, 2023, we had an accumulated deficit of $481.2 million, cash, cash equivalents and short-term investments of $67.6 million, and $53.9 million of outstanding term loans, net of debt discount and issuance costs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested heavily and expect to continue to invest in research and development and commercial activities. Our research and development activities include clinical studies to demonstrate the safety and efficacy of our RNS System, including in expanded indications, and to obtain, as well as retain, FDA approval. We intend to continue making significant investments in research and development, clinical studies and regulatory affairs to support ongoing and future regulatory submissions for retaining and expanding indications of our RNS System, including to patients with drug-resistant generalized epilepsy and adolescent patients, ages 12-17, support continuous improvements to our RNS System, and develop future products that address neurological disorders. We have also made significant investments in building our field commercial team and intend to make significant investments in sales and marketing efforts in the future, including initiatives to drive awareness and expand our referral channel to increase the number of drug-resistant epilepsy patients referred to CECs. Moreover, we expect to continue to incur expenses associated with operating as a public company. We may in the future seek to acquire or invest in additional businesses, products, or technologies that we believe could complement or enhance our products, enhance our technical capabilities or otherwise offer growth opportunities, although we currently have no agreements or understandings with respect to any such acquisitions or investments. Because of these and other factors, we expect to continue to incur net losses and negative cash flows for the next several years. We may require additional funding to support operations and pay our obligations or may opportunistically seek to raise additional capital, which may include future equity or debt financings.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our existing cash, cash equivalents and short-term investments will allow us to continue our operations for at least the next 12 months.</span></div><div id="i2a59f7ea1762416695eae3249a8f9ede_82"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Pandemic Update</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business, financial condition and results of operations have been and may continue to be significantly impacted by the COVID-19 pandemic. Beginning in 2020, our revenue was negatively impacted and experienced volatility as hospitals delayed or canceled elective procedures in response to the pandemic, including procedures to implant our RNS System. In addition, hospitals delayed or canceled admissions for epilepsy diagnostic evaluations, which reduced and may continue to reduce our patient pipeline. By the second half of 2022, the impact of the COVID-19 pandemic on our revenue had diminished. However, the future impact of the COVID-19 pandemic on </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our business, financial condition and results of operations is dependent on future developments, including the potential emergence of new COVID-19 variants and spikes in COVID-19 cases, which remain highly uncertain and cannot be predicted. For further information, refer to &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DIXI Distribution Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we entered into an exclusive distribution agreement, or the Distribution Agreement, with DIXI Medical USA Corp., or DIXI Medical, pursuant to which we became the exclusive U.S. distributor of DIXI Medical&#8217;s product line beginning in October 2022. DIXI Medical is a subsidiary of a European company that pioneered the development of stereo electroencephalography, or Stereo EEG, electrodes and related products. These products are used in the epilepsy monitoring units, or EMUs, of comprehensive epilepsy centers to determine where epileptic seizures originate. In addition to providing us with an incremental revenue stream, the DIXI Medical partnership provides us with improved visibility of patients moving through the EMUs, many of whom may be candidates for our RNS System. This synergistic partnership leverages our field organization that is already calling on the same customers and supports our objective to engage earlier in the diagnostic and therapy selection process. DIXI Medical provides us with ongoing commercial support and supplies the DIXI Medical products we order.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for DIXI Medical&#8217;s ongoing commercial support, we paid DIXI Medical $2.0 million in the fourth quarter of 2022 and will pay $1.25 million in each of the fourth quarters of 2023 and 2024, for a total of $4.5 million. </span></div><div id="i2a59f7ea1762416695eae3249a8f9ede_85"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Factors Affecting Our Performance</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe there are several important factors that have impacted and that we expect will continue to impact our business and results of operations. These factors include:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinician, Hospital and Patient Awareness and Acceptance of Our RNS System</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to establish our RNS System as a standard of care for drug-resistant epilepsy. We intend to continue to promote awareness of our RNS System within existing and new accounts through additional investments in training and education of clinicians, epilepsy centers, hospitals and patients on the clinical benefits of our RNS System for the treatment of drug-resistant epilepsy. In addition, we intend to publish additional clinical data in scientific journals and to continue presenting at medical conferences. We plan to continue building patient awareness through direct-to-patient marketing initiatives, which include advertising, social media and online education. We also intend to continue supporting patient and referring clinician outreach efforts to help increase the number of appropriate patients with drug-resistant epilepsy being treated at CECs. These efforts require significant investment by our marketing and sales organization.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Ability to Retain Our Experienced Commercial Team and Increase its Productivity</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made significant investments in, and will continue to invest in, recruiting, training and retaining our experienced and specialized direct sales team, which includes Therapy Consultants and Field Clinical Engineers. Significant education and training is required for our team to achieve the level of technical competency with our products that is expected by clinicians and to gain experience building demand for our RNS System. Upon completion of initial training, our personnel typically require time in the field to grow their network of accounts, build relationships with clinicians and increase their productivity to the levels we expect. We believe successfully training, developing and retaining our Therapy Consultants and Field Clinical Engineers will be required to achieve growth. In addition, the loss of any productive sales personnel would have a negative impact on our ability to grow our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our industry is highly competitive and subject to rapid change from the introduction of new products and technologies and the marketing activities of industry participants. There are two primary treatment alternatives for adults with drug-resistant epilepsy: (i) an ablative or resective surgery; and (ii) implantation of a neuromodulation </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">device. Within neuromodulation, we currently compete with two manufacturers of neuromodulation devices. These companies have longer operating histories, significantly greater resources and name recognition, and established relationships with physicians and hospitals that treat patients with epilepsy. In addition to competing for market share, we also compete against these companies for personnel, including qualified sales and other personnel that are necessary to grow our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leveraging Our Manufacturing Capacity to Further Improve Our Gross Margin</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With our current operating model and infrastructure, we believe that we have the capacity to significantly increase our manufacturing production. If we grow our revenue and sell more RNS Systems, our fixed manufacturing costs will be spread over more units, which we believe will reduce our manufacturing costs on a per-unit basis and in turn improve our gross margin. In addition, we intend to continue investing in manufacturing efficiencies in order to reduce our overall manufacturing costs. However, other factors will continue to impact our gross margin such as the cost of materials, components and subassemblies, pricing, procedure mix, and geographic sales mix to the extent that we commercialize our RNS System outside of the United States.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing in Research and Development, Including Clinical Studies, to Expand Our Addressable Market</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue investing in clinical studies and existing and next generation technologies to further improve our RNS System and clinical outcomes, enhance the patient and provider experience and broaden the patient population that can be treated with our RNS System. In addition, we are continuing to leverage our extensive database of intracranial electroencephalogram, or iEEG, data and our advanced data analysis capabilities to equip clinicians with the data they need to establish optimal program settings for each patient.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While research and development and clinical studies are time consuming and costly, we believe that a pipeline of product enhancements and new products that improve efficacy, safety and ease of use is important for supporting increased adoption of our RNS System.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Product Mix</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue from sales of our RNS System to hospital facilities both for initial RNS System implant procedures and for replacement procedures when our implanted devices reach end of service. We launched our current neurostimulator model in 2018. This device has an average battery life of nearly eleven years, an increase from the previous model of the device. We expect that our revenue from replacement procedures will decrease over the next few years as a result of the extended replacement cycle of the newer device. In addition, a change in procedure mix between initial and replacement procedures may have a negative impact on our gross margin. Beginning in the fourth quarter of 2022, we also began to derive revenue from sales of DIXI Medical products. A change in product mix between sales of our RNS System and DIXI Medical products may have a negative impact on our gross margin.</span></div><div id="i2a59f7ea1762416695eae3249a8f9ede_88"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Our Results of Operations</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive most of our revenue from sales of our RNS System to hospital facilities (primarily Level 4 CECs) that implant our RNS System. We typically deliver our RNS System to a hospital on the date of the scheduled procedure. There is no commitment to purchase our RNS System until the delivery of the product, as the procedure may be canceled at any time.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue fluctuates primarily based on the volume of procedures performed and the procedure mix between initial and replacement implants. Our revenue also fluctuates and in the future will continue to fluctuate from quarter-to-quarter due to a variety of factors, including the success of our sales force in expanding adoption of our RNS System in new accounts and the number of physicians who are aware of and prescribe our RNS System.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the fourth quarter of 2022, we also derive revenue from sales of DIXI Medical products, primarily to our current customer base. Our revenue from the sale of DIXI Medical products will fluctuate in the future due to a variety of factors, including our ability to take market share from competitive Stereo EEG products.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold and Gross Margin</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold consists primarily of costs related to materials, components and subassemblies, personnel-related expenses for our manufacturing and quality assurance employees, including stock-based compensation, manufacturing overhead and charges for excess, obsolete and non-sellable inventories. Overhead costs include the cost of quality assurance, testing, material procurement, inventory control, operations supervision and management personnel, an allocation of facilities and information technology expenses, including rent and utilities, and equipment depreciation. Cost of goods sold also includes certain direct costs such as those incurred for shipping our RNS System. We record adjustments to our inventory valuation for estimated excess, obsolete and non-sellable inventories based on assumptions about future demand, past usage, changes to manufacturing processes and overall market conditions. Beginning in the fourth quarter of 2022, cost of goods sold also includes costs of procuring DIXI Medical products. We expect cost of goods sold to increase in absolute dollars as more of our RNS Systems and DIXI Medical products are sold.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate gross margin as gross profit divided by revenue. Our gross margin has been and will continue to be affected by a variety of factors, primarily by our manufacturing costs, pricing and product mix. Our gross margin may increase over the long term to the extent our production volume increases as our fixed manufacturing costs would be spread over a larger number of units, thereby reducing our per-unit manufacturing costs. We expect our gross margin to fluctuate from period to period, however, based upon the factors described above.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenses consist of research and development costs and selling, general and administrative costs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities primarily consist of engineering and research programs associated with our products under development and clinical studies. Research and development expenses include personnel-related costs for our research and development employees, including stock-based compensation, and expenses related to consulting services, clinical trials, regulatory activities, prototyping, testing, materials and supplies, and allocated overhead including facilities and information technology expenses. Our clinical trial expenses include costs associated with clinical trial design, clinical trial site development and study costs, data management costs, related travel expenses, the cost of products used for clinical activities, and costs associated with our regulatory compliance. We expense research and development costs as they are incurred. We expect our research and development expenses to increase in absolute dollars as we continue to develop new product offerings and product enhancements and conduct studies for expanded indications for use.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our selling, general and administrative expenses consist primarily of personnel-related costs for our sales and marketing employees, including stock-based compensation and sales-based variable compensation, travel expenses, consulting, public relations costs, direct marketing, customer training, trade show and promotional expenses and allocated facility and information technology expenses, and for administrative personnel that support our general operations such as executive management and information technology, finance, accounting, customer services, human resources and legal personnel. We expense sales variable compensation when revenue related to the underlying sale is recognized. Selling, general and administrative expenses also include costs attributable to professional fees for legal, accounting and tax services, insurance and recruiting fees.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to increase our sales and marketing spending to support increased adoption of our RNS System. We expect our sales and marketing expenses will increase in absolute dollars as we hire additional personnel and add programs in order to more fully penetrate the market opportunity. We expect our administrative expenses, including stock-based compensation expense, will increase as we increase our headcount to support our growth. Additionally, we may incur increased expenses related to audit, legal, regulatory and tax-related services, compliance with exchange listing and Securities and Exchange Commission, or SEC, requirements, and director and officer insurance premiums. Our selling, general and administrative expenses may fluctuate from period to period as we continue to grow.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense and Income</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists primarily of interest expense related to our term loan facility, including amortization of debt discount and issuance costs. Interest income is predominantly derived from investing surplus cash in money market funds and short-term marketable securities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net primarily consists of gain and loss from short-term investments.</span></div><div id="i2a59f7ea1762416695eae3249a8f9ede_91"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Three Months Ended March 31, 2023 and 2022</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the periods indicated (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,098&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,100</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,115</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,372</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,259</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,577</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(314)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,428</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,444</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,691</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,319)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,762)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,965)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,830)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(817)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(814)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,375)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,461)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">NM = Not meaningful</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased by $3.1 million, or 27%, to $14.5 million during the three months ended March&#160;31, 2023, compared to $11.4 million during the three months ended March&#160;31, 2022. The increase in revenue was primarily due to an increase in the number of units sold for initial implant procedures as well as an increase in pricing, and the addition of sales of DIXI Medical products which began in the fourth quarter of 2022, partially offset by a decrease in units sold for replacement implant procedures in the three months ended March&#160;31, 2023 as compared to the three months ended March&#160;31, 2022. Revenue from sales of our RNS System for replacement procedures represented less than 10% of our total revenue for the three months ended March&#160;31, 2023 as compared to approximately 23% for the three months ended March&#160;31, 2022. All of our revenue was generated from sales in the United States.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold and Gross Margin</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold increased by $1.0 million, or 32%, to $4.1 million during the three months ended March&#160;31, 2023, compared to $3.1 million during the three months ended March&#160;31, 2022. The increase was primarily due to costs associated with distribution of DIXI Medical products. Our gross margin decreased from 72.6% for the three months ended March&#160;31, 2022 to 71.7% for the three months ended March&#160;31, 2023 primarily due to lower gross margin for distribution of DIXI Medical products as compared to the gross margin for sales of our RNS System.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased by $0.3 million, or 6%, to $5.3 million during the three months ended March&#160;31, 2023, compared to $5.6 million during the three months ended March&#160;31, 2022. The decrease in research and development expenses was primarily due to a decrease of $0.1 million in personnel-related expenses associated with a reduction in personnel to support product development efforts and clinical studies, a decrease of $0.1 million in clinical study expenses, and a decrease of $0.1 million in regulatory affairs and quality assurance expenses.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased by $1.0 million, or 8%, to $13.4 million during the three months ended March&#160;31, 2023, compared to $12.4 million during the three months ended March&#160;31, 2022. The increase in selling, general and administrative expenses was primarily due to an increase of $1.2 million in personnel-related expenses primarily due to sales-based variable compensation as a result of the increase in revenue during the three months ended March&#160;31, 2023 compared to the three months ended March&#160;31, 2022 and stock-based compensation, and an increase of $0.5 million in expenses for ongoing commercial support provided by DIXI Medical in connection with distributing their products. The increases were offset in part by a decrease of $0.8 million in general and administrative costs, primarily outside services.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense and Income</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense increased to $2.0 million for the three months ended March&#160;31, 2023, compared to $1.8 million for the three months ended March&#160;31, 2022, due to an increase in average balances of our Term Loan as a result of using the paid-in-kind option for interest whereby we added part of the interest due to the Term Loan's principal balance instead of paying it in cash for the payment dates from April 2022 through March 2023. Interest income increased by $0.6 million for the three months ended March&#160;31, 2023 compared to the three months ended March&#160;31, 2022, primarily due to higher interest yields in the three months ended March&#160;31, 2023, partly offset by a decrease in average balances of our money market funds and short-term marketable securities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), net</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net decreased by $0.8 million to ($0.8) million during the three months ended March&#160;31, 2023, compared to less than ($0.1) million during the three months ended March&#160;31, 2022, primarily due to unrealized loss, net on short-term investments in the three months ended March&#160;31, 2023.</span></div><div style="text-align:center"><span style="background-color:#ffff00;color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2a59f7ea1762416695eae3249a8f9ede_94"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our IPO, we financed our operations primarily through the sale of equity securities, debt financing arrangements and sales of our RNS System. As of March&#160;31, 2023, we had cash, cash equivalents and short-term investments of $67.6 million, compared to $77.4 million at December 31, 2022, and $53.9 million outstanding under the Term Loan, net of debt discount and issuance costs, compared to $52.9 million at December 31, 2022. In September 2020, we entered into the Term Loan for total borrowings of up to $60.0 million and borrowed $50.0 mi</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">llion. In April 2021, we completed our IPO and received $105.5&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net proceeds after deducting underwriting discounts and commissions and offering costs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Term Loan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into the Term Loan with CRG Partners IV L.P. and its affiliates for total borrowings of up to $60 million and borrowed $50 million. The remaining $10.0 million was available to us for borrowing until March 31, 2022 if we achieved a revenue-based milestone in 2021. The revenue-based milestone was not met, and the remaining $10.0 million of the Term Loan expired without being drawn. The borrowings under the Term Loan are secured by substantially all of our properties, rights and assets, including intellectual property.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan bears interest at a rate of 13.5% per year. Payments under the loan are made quarterly with payment dates fixed at the end of each calendar quarter. Through December 2020, we had the option to pay the entire interest paid-in-kind, or PIK, by increasing the principal of the Term Loan. From January 2021 through </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 2022, we had the option to pay interest as follows: 7.5% per annum paid in cash and 5.0% per annum PIK by increasing the principal of the Term Loan. From January 2023 through June 2025, we have the option to pay interest as follows: 8.5% per annum paid in cash and 5.0% per annum PIK by increasing the principal of the Term Loan. For each payment date from April 2022 through March 2023, we elected the PIK option, increasing the principal of the Term Loan by $2.6 million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan was interest-only through September 30, 2023, which could be extended through September 30, 2025 at our option if we completed our IPO on or prior September 30, 2023. In connection with closing the IPO, we extended the interest-only period to September 30, 2025. Following the interest-only period, principal payment is due in one installment on September 30, 2025. The Term Loan includes a fee upon repayment of the loan equal to 10% of the aggregate principal amount being prepaid or repaid.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan is collateralized by substantially all of our assets. The loan agreement contains customary representations and warranties, covenants, events of default and termination provisions. The financial covenants require that we achieve minimum annual revenue thresholds commencing in 2021 and maintain a minimum balance of cash and cash equivalents. See Notes 1 and 6 to our unaudited interim condensed financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional information.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid $1.0 million in fees to the lender and third parties which is reflected as a discount on the loan and is being accreted over the life of the loan using the effective interest method.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur continued expenditures in the future in support of our commercialization efforts in the United States. In addition, we intend to continue to make investments in clinical studies, development of new products, and other ongoing research and development programs. We may incur additional expenses to expand our commercial organization to re-establish operations to pre-pandemic levels, and to plan for continued growth. We may incur additional expenses to further enhance our research and development efforts and to pursue commercial opportunities outside of the United States. We lease our office and manufacturing facilities in Mountain View, California under a non-cancelable operating lease which expires in June 2030. Future minimum lease payments under non-cancelable operating leases were $22.3 million as of March&#160;31, 2023. See &#8220;Facility Lease&#8221; in Note 5 to our condensed financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional information.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had cash, cash equivalents and short-term investments of $67.6 million. Based on our current planned operations, we ex</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pect that our cash, cash equivalents and short-term investments will enable us to fund our operating expenses for at least 12 months fr</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">om the issuance of our condensed financial statements as of and for the three months ended March 31, 2023. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with research, development and commercialization of medical devices, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on many factors, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of activities related to commercializing and marketing our RNS System in the United States and elsewhere, and manufacturing and distribution costs;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the research and development activities we intend to undertake, including product enhancements and clinical studies for indication expansions that we intend to pursue;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic on our business;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of obtaining, maintaining, defending, enforcing, and protecting any patents and other intellectual property rights;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether or not we pursue acquisitions or investments in businesses, products or technologies that are complementary to our current business;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree and rate of increased market acceptance of our RNS System in the United States and market acceptance elsewhere;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our revenue and cost projections related to the DIXI Medical distribution agreement;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need to implement additional infrastructure and internal systems; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to hire additional personnel to support our operations as a public company; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence of competing technologies or other adverse market developments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do raise additional capital through public or private equity or convertible debt offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may adversely affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Our ability to raise additional capital may be adversely impacted by global economic conditions and the recent disruptions to, and volatility in, the financial markets in the United States and worldwide. If we are unable to raise capital when needed, we will need to delay, limit, reduce or terminate planned commercialization or product development activities in order to reduce costs. In addition, COVID-19 has negatively impacted our business by decreasing and delaying procedures performed to implant our RNS System, and the pandemic may continue to negatively impact our business, which may negatively impact our future liquidity.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary Statements of Cash Flows</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the primary sources and uses of cash and cash equivalents for the periods presented below (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,698)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,393)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,698)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows Used in Operating Activities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $9.7 million for the three months ended March&#160;31, 2023. Cash used in operating activities was primarily a result of the net loss of $10.4 million, adjusted for non-cash charges of $4.3 million and change in operating assets and liabilities of $3.6 million. The non-cash charges primarily consisted of $2.1 million of stock-based compensation, $0.6 million of interest incurred but paid-in-kind, $0.3 million of amortization of right-of-use assets, $0.2 million of non-cash interest expense related to our term loan and $0.8 million of realized loss from sale of short-term investments. The change in operating assets and liabilities was due to an increase in accounts receivable of $1.7 million primarily due to an increase in sales of our products including DIXI Medical products and our RNS System, an increase in inventories of $1.1 million largely due to an increase in raw materials partially offset by a reduction in work-in-process inventory, a decrease in accrued liabilities of $0.8 million, a decrease in operating lease liabilities of $0.3 million, and a decrease in accounts payable of $0.2 million primarily due to the timing of payments to our vendors, offset in part by a decrease in prepaid expenses and other assets of $0.5 million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $11.4 million for the three months ended March 31, 2022. Cash used in operating activities was primarily a result of the net loss of $11.5 million, adjusted for non-cash charges of $2.6 million and change in operating assets and liabilities of $2.5 million. The non-cash charges primarily consisted of  $1.5 million of stock-based compensation, $0.7 million of amortization of right-of-use assets and $0.2 million of non-cash interest expense related to our term loan. The change in operating assets and liabilities was due to an </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase in accounts receivable of $2.0 million primarily due to an increase in sales of our products in March 2022 as COVID-19-related hospital restrictions eased, a decrease in accrued liabilities of $0.5 million, and a decrease in operating lease liabilities of $0.8 million offset in part by an increase in accounts payable of $0.8 million primarily due to the timing of payments to our vendors.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows Provided by (Used in) Investing Activities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $10.1 million for the three months ended March&#160;31, 2023, which primarily consisted of sales of short-term investments of $10.2 million, which amounts were partially offset by purchases of property and equipment of $0.1 million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $0.3 million for the three months ended March 31, 2022, which consisted of purchases of property and equipment of $0.3 million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows (Used in) Provided by Financing Activities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $0.3 million for the three months ended March&#160;31, 2023, which primarily relates to taxes withheld and paid related to net share settlement of equity awards of $0.1 million and payment of deferred offering costs of $0.1 million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was immaterial for the three months ended March 31, 2022, and primarily relates to receipt of proceeds from the exercise of stock options.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2a59f7ea1762416695eae3249a8f9ede_97"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial statements have been prepared in accordance with GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the amounts and disclosures in the financial statements. Our estimates are based on our historical experience, knowledge of current events and actions we may undertake in the future, and on various other factors that we believe are reasonable under the circumstances.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting policies and estimates are described in &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Estimates&#8221; in our Annual Report on Form 10-K filed with the SEC on March 2, 2023. There were no material changes to these accounting policies during the three months ended March 31, 2023.</span></div><div id="i2a59f7ea1762416695eae3249a8f9ede_100"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOBS Act Accounting Election</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The JOBS Act permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to use this extended transition period under the JOBS Act until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult.</span></div><div id="i2a59f7ea1762416695eae3249a8f9ede_103"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Recent Accounting Pronouncements&#8221; in Note 2 to our unaudited interim condensed financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional information.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i2a59f7ea1762416695eae3249a8f9ede_106"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Sensitivity </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates. As of March&#160;31, 2023, we had cash, cash equivalents and short-term investments of $67.6&#160;million, compared to $77.4&#160;million at December 31, 2022, consisting of interest-bearing money market funds and fixed income mutual funds for which the fair value would be affected by changes in the general level of U.S. interest rates. However, due to the short-term maturities and the low-risk profile of our cash equivalents and short-term investments, an immediate 10% change in interest rates would not have a material effect on the fair value of our cash equivalents and short-term investments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that inflation, interest rate changes or exchange rate fluctuations have had a significant impact on our results of operations for any periods presented herein.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i2a59f7ea1762416695eae3249a8f9ede_109"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e), as amended) as of March&#160;31, 2023, the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our principal executive officer and principal financial officer have concluded that, as of the end of the period covered by this quarterly report, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal control over financial reporting is subject to inherent limitations</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system will be met.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i2a59f7ea1762416695eae3249a8f9ede_112"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i2a59f7ea1762416695eae3249a8f9ede_115"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are, and from time to time may become, involved in legal proceedings in the ordinary course of business. The results of litigation and claims are inherently unpredictable and regardless of the outcome, such legal proceedings may negatively impact our business and financial position, result in brand or reputational harm, and divert the attention of our management from core operations of our business.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i2a59f7ea1762416695eae3249a8f9ede_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk and uncertainty. You should carefully read, consider, and evaluate the risks described below, as well as all of the other information contained in this Quarterly Report on Form 10-Q, including &#8220;Management&#8217;s Discussion and Analysis of Results of Operations,&#8221; our financial statements and related notes, and our other disclosures and filings. While we believe that the risks and uncertainties described below are the material risks currently facing us, additional risks that we do not yet know of or that we currently think are immaterial may also arise and materially affect our business. If any of the following risks materialize, our business, financial condition and results of operations could be materially and adversely affected. In that case, the market price of our common stock could decline, and you may lose some or all of your investment.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this Quarterly Report on Form 10-Q.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk because our business is subject to numerous risks and uncertainties, as fully described below. The principal factors and uncertainties that make investing in our common stock speculative or risky include, among others:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently rely on our RNS System, which can only be marketed in the United States for use in adults with drug-resistant focal epilepsy, as our primary source of revenue. Our RNS System is recommended as well as implanted primarily at Level 4 CECs. If we are not successful in enhancing awareness of our RNS System, driving adoption across our current target population, expanding referral pathways to increase referrals to Level 4 CECs, reaching beyond Level 4 CECs and expanding the population of eligible patients, our sales, business, financial condition and results of operations will be negatively affected;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our commercial success will continue to depend on attaining significant market acceptance of our RNS System among patients, clinicians and hospital facilities and increasing the number of patients treated. If we are unable to successfully achieve substantial market acceptance and adoption of our RNS System, our sales, business, financial condition and results of operations will be harmed; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our estimates of market opportunity and forecasts of market and revenue growth, including growth in the number of CECs, epileptologists and neurosurgeons, as well as our revenue and cost projections related to the distribution agreement with DIXI Medical USA Corp., may prove to be inaccurate, and even if the market in which we compete achieves the forecasted growth, our business could fail to grow at similar rates, if at all;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on a limited number of single-source suppliers and vendors in connection with the manufacture of our products, which makes us vulnerable to supply shortages and price fluctuations that could harm our business, financial condition, and results of operations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable to compete successfully with other treatment options for drug-resistant focal epilepsy, which could harm our sales, business, financial condition and results of operations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If adequate reimbursement becomes unavailable for the procedures to implant our RNS System and for clinicians to provide ongoing care for patients treated with our RNS System, it could diminish our sales or affect our ability to sell our RNS System profitably;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Use of our RNS System requires appropriate neurosurgeon training for implantation and epileptologist training for programming and ongoing patient care, and inadequate training may lead to negative patient outcomes, which could harm our business, financial condition, and results of operations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our sales, business, financial conditions and results of operations have been and continue to be impacted by the COVID-19 pandemic;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to achieve or maintain satisfactory pricing and margins for our RNS System, which could harm our business and results of operations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are seeking expanded FDA labeling for our RNS System to be able to treat patients with drug-resistant generalized epilepsy, as well as patients with drug-resistant focal epilepsy between the ages of 12 and 17, but if we are unable to broaden the indications for our RNS System to include these patients, our growth potential could be harmed;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to comply with U.S. federal and state laws and regulations, including fraud and abuse and other healthcare laws and regulations, such as those relating to kickbacks and false claims for reimbursement, we could face substantial penalties and our business, financial condition and results of operations could be harmed;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory compliance is expensive, complex and uncertain, and a failure to comply could lead to enforcement actions against us and other negative consequences for our business; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations are subject to pervasive and continuing FDA regulatory requirements, and failure to comply with these requirements could harm our business, financial condition and results of operations; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain, maintain, protect, enforce and defend patent or other intellectual property protection for our products, or if the scope of the patent and other intellectual property protection obtained is not sufficiently broad, or as a result of our existing or any future out-licenses of our intellectual property, our competitors could develop and commercialize products competitive with ours, and our ability to continue to commercialize our RNS System, or our other products, may be harmed;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our collection, use, storage, disclosure, transfer and other processing of sensitive and personal information could give rise to significant costs, liabilities and other risks, including as a result of investigations, inquiries, litigation, fines, legislative and regulatory action and negative press about our privacy and data protection practices, which may harm our business, financial conditions, results of operations and prospects;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a history of net losses, and we expect to continue to incur losses for the foreseeable future. If we do achieve profitability, we may not be able to sustain it;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we identify any material weaknesses or otherwise fail to maintain an effective system of internal control, we may not be able to accurately or timely report our financial condition or results of operations; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">To support our continued operations and the growth of our business, we may need access to our existing capital or to seek additional capital through new equity or debt financings, which sources of existing or additional capital may not be available to us on acceptable terms or at all. If we are unable to obtain, if needed, capital, adequate financing or financing on terms satisfactory to us, it could harm our business and growth prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to operational, commercial and manufacturing matters </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently rely on our RNS System, which can only be marketed in the United States for use in adults with drug-resistant focal epilepsy, as our primary source of revenue. Our RNS System is recommended as well as implanted primarily at Level 4 CECs. If we are not successful in enhancing awareness of our RNS System, driving adoption across our current target population, expanding referral pathways to increase referrals to Level 4 CECs, reaching beyond Level 4 CECs and expanding the population of eligible patients, our sales, business, financial condition and results of operations will be negatively affected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business currently depends primarily on our ability to successfully market our RNS System, which includes increasing the number of patients treated at CECs, increasing adoption of our RNS System across CECs, and driving utilization by clinicians within CECs. Currently, our RNS System can only be marketed for use in adults with drug-</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resistant focal epilepsy in the United States. Additionally, our RNS System is primarily recommended and implanted at Level 4 CECs, which provide advanced diagnosis and management of epilepsy. Therefore, we are dependent on widespread market adoption of our RNS System within a limited number of accounts. We are aiming to increase awareness about our RNS System, including earlier in the diagnostic process through our partnership with DIXI Medical, expand the population of patients we can treat with our RNS System, as well as the number of physicians that can prescribe and the number of centers at which neurosurgeons can implant our RNS System, but there can be no assurance that we will succeed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of our RNS System will continue to depend on a number of factors, including the following: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree to which drug-resistant epilepsy remains a chronic and debilitating condition;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the actual and perceived effectiveness, safety and reliability, and clinical benefit, of our RNS System, especially relative to alternative neuromodulation devices such as VNS or DBS; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any adverse patient events involving our RNS System;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to provide earlier awareness of and education about our RNS System to patients and clinicians, including through our partnership with DIXI Medical;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree to which clinicians, patients and hospital facilities adopt our RNS System;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continued effects of the COVID-19 pandemic; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability, relative cost and perceived advantages and disadvantages of alternative technologies or treatment methods for epilepsy; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of additional clinical and other studies relating to the health, safety, economic or other benefits of our RNS System; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether key thought leaders in the medical community accept that our clinical efficacy and safety results are sufficiently meaningful to influence their decision to adopt our RNS System over other neuromodulation therapies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we are successful in educating clinicians, patients, and hospital facilities about the benefits of our RNS System, including as a result of the extended battery life of the neurostimulator; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation among clinicians, patients and hospital facilities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to predict product performance; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of our marketing and distribution infrastructure, including our ability to drive adoption and utilization of our RNS System, our ability to develop and maintain relationships with programming centers, and our ability to expand referral pathways to CECs and beyond;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, maintain, protect, enforce and defend our intellectual property rights, including in and to our RNS System; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain compliance with all legal and regulatory requirements, including those applicable to our RNS System; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to continue to maintain a commercially viable manufacturing process at our manufacturing facility that is compliant with current Good Manufacturing Practices, or cGMP, and Quality Systems Regulations, or QSR; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain our contractual relationships with our vendors and component suppliers, including single-source vendors and suppliers, through which we obtain critical components for our RNS System; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continued coverage of and adequate payment for the implantation procedure and for clinicians to provide ongoing care for patients implanted with our RNS System by third party payors, including both private and government payors; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to continue to attract and retain key talent.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to successfully market and sell our RNS System cost-effectively and maintain and expand our market share, our sales, business, financial condition and results of operations will be negatively affected. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our commercial success will continue to depend on attaining significant market acceptance of our RNS System among patients, clinicians and hospital facilities and increasing the number of patients treated. If we are unable to successfully achieve substantial market acceptance and adoption of our RNS System, our sales, business, financial condition and results of operations would be harmed. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend in large part on the further acceptance by clinicians, patients and hospital facilities of our RNS System as safe, useful, and cost-effective, and increasing the number of patients treated at  CECs and other facilities. We cannot predict how quickly, if at all, additional clinicians, patients, and hospital facilities will adopt our RNS System over continued noninterventional therapies or competing neuromodulation devices or surgical treatment options at CECs and other facilities. For example, clinicians may be reluctant to use our RNS System due to familiarity with neuromodulation devices that are more established. Clinicians, patients, and hospital facilities may continue to prefer noninvasive therapeutic options, resective or ablative surgery, or alternative neuromodulation therapies such as VNS and DBS. Moreover, we cannot predict how quickly, if at all, those currently living with epilepsy but who are not being treated will seek treatment or utilize CECs for treatment. Our ability to grow sales of our RNS System and drive market acceptance will depend on successfully educating clinicians, patients, and hospital facilities of the relative benefits of our RNS System. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, patients rely on their healthcare providers, including epileptologists and neurosurgeons to recommend a course of treatment. If we are unable to successfully achieve substantial market acceptance and adoption of our RNS System by additional clinicians, patients, and hospital facilities, patients may be reluctant to use our products over alternative neuromodulation therapies. If we are unable to successfully drive patient interest in our RNS System, including through our partnership with DIXI Medical, our business, financial condition and results of operations would be harmed.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our commercial success will depend on a continued flow of patient referrals to CECs from treating primary care physicians, neurologists, and other healthcare providers and from caregiver support and encouragement around physician referrals and self-referrals to CECs. If we are unable to successfully expand our referral pathways to achieve an increased patient referral pipeline into CECs, our sales, business, financial condition and results of operations would be harmed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend in large part on continued referrals of appropriate patients from treating primary care physicians, neurologists, and other healthcare providers to epileptologists, neurosurgeons, and other clinicians, primarily at Level 4 CECs. We estimate that of the approximately 575,000 adults with drug-resistant focal epilepsy in the United States, approximately 24,000 adult drug-resistant focal epilepsy patients are treated in Level 4 CECs annually. We cannot predict how quickly, if at all, we can build that pipeline through our sales and marketing efforts and whether primary care physicians, neurologists, and other healthcare providers, as well as caregivers will support patient referrals to epileptologists and neurosurgeons at CECs over other therapy options.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Primary care physicians, neurologists, and other healthcare providers may continue to prefer traditional treatments, such as additional attempts to treat with new therapeutic drugs that become available from time to time, including for fear of losing management of the patient&#8217;s care. If we are unable to educate clinicians to follow national guidelines, which recommend that patients whose seizures have not been brought under control after three months of care by a primary care physician or after 12 months of seeing a general neurologist be referred to a CEC, we may be unable to successfully build our patient pipeline. This could harm our business, financial condition and results of operations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Various factors outside our direct control, including the COVID-19 pandemic, may negatively impact our manufacturing of our RNS System, which could harm our business, financial condition, and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture our RNS System at our manufacturing facility in Mountain View, California. This facility supports our production operations, including manufacturing, quality control, and raw material and finished goods storage. We believe that we currently have adequate manufacturing capacity and supplies for our products sufficient to meet our demand forecasts. If demand for our RNS System increases more rapidly than we anticipate, if we encounter problems with one or more of our suppliers, or if we secure regulatory approval to commercialize our products in additional geographies or indications, we may need to either expand our manufacturing capabilities, qualify new suppliers, or outsource to other manufacturers.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing and distribution operations are subject to regulatory requirements of the FDA&#8217;s Quality System Regulation, or QSR, for medical devices sold in the United States. Manufacturers of medical device products often encounter difficulties in production, including difficulties with production costs and yields, quality control, quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced FDA requirements, other federal and state regulatory requirements, and foreign regulations, to the extent applicable. If we fail to manufacture our products in compliance with QSR, or if our manufacturing facility suffers disruptions, supply chain issues, machine failures, slowdowns or disrepair, we may not be able to fulfill customer demand and our business would be harmed. Further, we typically do not maintain more than several months of inventory on hand and we manufacture our products using near term demand forecasts. As a result, deviations from our forecasts could cause us to fail to meet demand for our products.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we produce our products in one manufacturing facility, any contamination of the controlled environment, equipment malfunction, supply issues, personnel issues, including human error, or failure to strictly follow procedures can significantly reduce our yield. A drop in yield can increase our cost to manufacture our products or, in more severe cases, require us to halt the manufacture of our products until the problem is resolved. Identifying and resolving the cause of a drop in yield can require substantial time and resources. In addition, if demand for our products shifts such that our manufacturing facility is operated below our forecasts for an extended period, we may adjust our manufacturing operations to reduce fixed costs, which could lead to uncertainty and delays in manufacturing times and quality during any transition period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing, sterilization and distribution of our products are technically challenging. Changes that our suppliers may make, or additional requirements from regulatory agencies, outside of our direct control can have an impact on our processes, on quality and on the successful or timely delivery of our products to our customers. Mistakes and mishandling may occur, which can affect supply and delivery. As a result, our dependence on third-party, including single source, suppliers, subjects us to a number of risks that could impact our ability to manufacture our products and harm our business, financial condition, and results of operations, including: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of supply resulting from modifications to, or discontinuation of, a supplier&#8217;s operations, including due to the COVID-19 pandemic; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in product shipments resulting from uncorrected defects, reliability issues or a supplier&#8217;s failure to produce components that consistently meet our quality specifications; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in analytical results or failure of analytical techniques that we depend on for quality control and release of our products; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">price fluctuations due to a lack of long-term supply arrangements with our suppliers for key components; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to obtain adequate supply in a timely manner or on commercially reasonable terms; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty identifying and qualifying alternative suppliers for components in a timely manner; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability of suppliers to comply with applicable provisions of the QSR or other applicable laws or regulations enforced by the FDA and other Federal and state regulatory authorities; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in regulatory approvals of any changes to manufacturing, including the use of new suppliers;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">latent defects that may become apparent after our products have been released and that may result in an adverse event or a recall of such products; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inclusion of vendors of raw materials not in compliance with regulatory requirements; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">natural or other disasters, global pandemics, labor disputes, financial distress, lack of raw material supply, issues with facilities and equipment, international conflict or war, or other forms of disruption to business operations affecting our manufacturer or its suppliers; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production delays related to the evaluation and testing of our products or the use of components from alternative suppliers; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to complete sterilization on time or in compliance with the required regulatory standards; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in delivery by our suppliers of components, materials, or services due to changes in demand from us or their other customers. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of these issues could significantly harm our ability to manufacture our products and maintain sufficient quality standards, which would negatively impact our sales, business, financial condition, and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on a limited number of single-source suppliers and vendors in connection with the manufacture of our RNS System, which makes us vulnerable to supply shortages and price fluctuations that could harm our business, financial condition, and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We source and rely upon materials, components, and sub-assemblies of our RNS System, as well as manufacturing services from approved suppliers, most of which are single source suppliers. For example, Micro Systems Technologies Management AG and Greatbatch Ltd are single source suppliers of several key components of our products, including printed circuit assemblies and batteries. In addition, certain of our suppliers are not under long-term contracts with us.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These components, materials, and services, which also include silicone adhesive, integrated circuits, and other components, are critical and there are relatively few alternative sources of supply. We believe our single source suppliers are capable of continuing to meet our specifications and maintaining quality, but any significant problem experienced by one of our single source suppliers may result in a delay or interruption in the supply of components, materials, or services to us. Our suppliers may experience manufacturing delays or issues, stop producing our components, materials, or services, increase the prices they charge us, or elect to terminate their relationships with us. In any of these cases, we could face a delay of several months to identify, perform appropriate testing, and qualify alternative suppliers and service providers with regulatory authorities, as we do not currently have supplier transition plans. In addition, the failure of our third-party suppliers and service providers to maintain acceptable quality requirements could result in the recall of our products. If one of our suppliers fails to maintain acceptable quality requirements, we may have to identify and qualify a new supplier. Although we require our third-party suppliers to supply us with materials, components and services that meet our specifications and comply with applicable provisions of the FDA&#8217;s QSR and other applicable legal and regulatory requirements in our agreements and contracts, and we perform incoming inspection, testing or other acceptance activities to ensure the materials and components meet our requirements, there is a risk that our suppliers will not always act consistent with our best interests, and may not always supply components that meet our requirements or supply components in a timely manner. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of third-party suppliers with the necessary manufacturing and regulatory expertise and facilities is limited and certification of a new supplier may be complex and time consuming. Any delay or interruption would likely lead to a delay or interruption in our manufacturing operations. The inclusion of substitute components must meet our product specifications and could require us to qualify the new supplier with the appropriate regulatory authorities, including the FDA. The added time and cost to arrange for alternative suppliers could harm our business. New manufacturers of any planned product would be required to qualify under applicable regulatory requirements </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and would need to have sufficient rights under applicable intellectual property laws to the method of manufacturing the planned product. Obtaining the necessary FDA or international approvals or other qualifications under applicable regulatory requirements and ensuring non-infringement of third-party intellectual property or other proprietary rights could result in a significant interruption of supply and could require the new manufacturer to bear significant additional costs that may be passed on to us. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to optimize our sales and marketing capabilities and develop widespread brand awareness cost-effectively, our growth will be impeded and our business may suffer. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are actively expanding our presence in the United States through additional sales and education efforts to drive awareness of our RNS System amongst patients, clinicians and hospital facilities, to drive adoption of our RNS System at CECs and other facilities and increase utilization of our RNS System within new and existing accounts. We also plan to explore regulatory and reimbursement approval pathways to expand our presence in international territories. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We take a measured approach to optimize our sales infrastructure to grow our customer base and our business. Identifying and recruiting qualified personnel and training them on the use of our RNS System, on applicable federal and state laws and regulations and on our internal policies and procedures, requires significant time, expense and attention, particularly given our strategy of having each Therapy Consultant, or sales representative, cover many accounts. It can take significant time before our Therapy Consultants are fully trained and productive and before they have established relationships with their target accounts. Our business may be harmed if our efforts to optimize do not generate a corresponding increase in revenue or result in a decrease in our operating margin. In particular, if we are unable to hire, develop and retain talented sales personnel or if new sales personnel are unable to achieve desired productivity levels in a reasonable period of time, we may not be able to realize the expected benefits of this investment or increase our revenue. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We dedicate significant financial and other resources to our customer outreach and training programs, which may require us to incur significant upfront costs. For example, we may need to conduct additional physician trainings across hospital facilities, including CECs. Our sales force may also need to develop additional efficiencies and approaches to address potential growth as we expand referral pathways, expand into additional existing Level 4 CECs as well as new CECs, offer new products, including those distributed through our partnership with DIXI Medical, and increase the number of epileptologists recommending, and neurosurgeons implanting, our RNS System within each CEC. Our business would be harmed if our programs and associated expenditures do not generate a corresponding increase in revenue. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we believe that developing and maintaining awareness of our brand in a cost-effective manner is critical to achieving broad acceptance of our products and attracting new customers. Brand promotion activities may not generate customer awareness or increase revenue and, even if they do, any increase in revenue may not offset the costs and expenses we incur in building our brand. If we fail to successfully promote, maintain and protect our brand, we may fail to realize a sufficient return on our brand-building efforts, or to achieve the widespread brand awareness that is critical for broad adoption of our RNS System.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to compete successfully with other treatment options for drug-resistant focal epilepsy, which could harm our sales, business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our industry is competitive and has been evolving rapidly with not only existing treatment options, but also the introduction of new products and technologies as well as the market activities of industry participants. Our RNS System is indicated for adult patients with drug-resistant focal epilepsy in the United States and we primarily market our device to customers, primarily consisting of the clinicians within CECs that treat these patients. In our target patient population, there are two primary treatment options (i) an ablative or resective surgery, or (ii) implantation of a neuromodulation device. Patients may also choose not to actively seek additional treatment for epilepsy or may choose to try new therapeutic drugs that become available from time to time. We estimate that approximately 80% of drug-resistant focal epilepsy patients are either not ideal candidates for ablative or resective surgery or are unwilling to undergo a destructive surgical procedure and we compete primarily with two manufacturers of neuromodulation devices for the treatment of these patients. Our primary competitors are LivaNova plc, which </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufactures the VNS System, and Medtronic plc, which manufactures the DBS System. Third-party payors may encourage the use of competitors&#8217; products or other neuromodulation therapies due to lower costs of competing products or alternatives. Additionally, treating physicians, including epileptologists and neurosurgeons may promote the use of other competitors&#8217; products or alternative therapies. Further, as existing competitors and other companies develop new or improved products, we cannot predict what the standard of care will be in the future. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary competitors are large, well-capitalized companies with significant market share and resources. They have more established sales and marketing programs than we do and have greater name recognition. These competitors also have long operating histories and may have more established relationships with potential customers. In addition to competing for market share, competitors may develop or acquire patents or other rights that may limit our ability to compete. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry is intensely competitive, subject to rapid change and significantly affected by new product introductions and other market activities of industry participants. There can be no assurance that other companies or institutions will not succeed in developing or marketing devices and products that are more effective or safer than our RNS System or that would render our RNS System obsolete or noncompetitive. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the clinical advantages of our RNS System and our focus on neuromodulation will be important factors in our future success. Our continued success depends on, among other things, our ability to: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to demonstrate safety and efficacy in our Post-Approval Study and in ongoing commercial use;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our referral pathways;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand the number of CECs implanting our RNS System and increase utilization across these CECs; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">drive awareness to increase the number of drug-resistant epilepsy patients referred to CECs; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain adequate reimbursement for implant procedures and for clinicians to provide ongoing care of patients treated with our RNS System; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attract and retain skilled research, development, sales, marketing and clinical personnel; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to innovate in order to improve therapy effectiveness and enhance the patient and provider experience;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adequately predict product performance; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain and maintain regulatory clearances and approvals, including for expanded indications; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost-effectively manufacture, market and sell our RNS System;  </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain, maintain, protect, enforce and defend our intellectual property rights and operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of others;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire products or technologies complementary to or necessary for our business; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">source materials, components, and sub-assemblies from suppliers on a cost-effective and timely basis.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption of our RNS System depends on positive clinical data as well as clinician acceptance of the data and our products, and negative clinical data or perceptions among these clinicians would harm our sales, business, financial condition, and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rate of adoption and sales of our products are heavily influenced by clinical data. Although we have positive clinical data across four multi-center FDA approved prospective clinical studies going out as far as nine years, there can be no assurance that clinical data will continue to be positive for our ongoing studies, such as our Post-Approval Study. Additionally, there can be no assurance that future clinical studies, including those to continue demonstrating the efficacy of our products in currently approved patient populations and those to support label </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">retention and expansion for our products will demonstrate safety and effectiveness. Unfavorable or inconsistent clinical data from ongoing or future clinical studies conducted by us, our competitors, or third parties, the negative interpretation of our clinical data internally and externally, including by customers, competitors, patients, and regulators, or findings of new or more frequent adverse events, could harm our business, financial condition, and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rate of adoption and sales of our products are also influenced by clinician</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">perceptions. Negative perceptions of our products by clinicians, including due to negative clinical data, could result in decreased adoption or use of our products, which would harm our business, financial condition, and results of operations. Additionally, if key opinion leaders who support our products cease to recommend our products, our business, financial condition and results of operations will be harmed. Further, if we cannot maintain strong working relationships with clinicians and continue to receive their advice and input, the marketing of our products could suffer, which could harm our business, financial condition and results of operations. The COVID-19 pandemic and related restrictions on access to clinicians as well as hospital staffing shortages have impacted, and will likely continue to impact, our ability to maintain such relationships. Finally, although we have demonstrated the safety, effectiveness and clinical advantages of our products in pivotal clinical studies, neuromodulation is still a relatively new approach to treating drug-resistant focal epilepsy. The results of clinical studies of the products conducted to date and from commercial use do not necessarily predict future results. Any negative long-term results or adverse events from use of our products that arise in the future could harm our business, financial condition, and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success also depends upon patients having an understanding of how to properly use our RNS System and an experience with our products that meets their expectations in order to increase clinician demand for our products as a result of positive feedback and word-of-mouth. Patients may be dissatisfied if their expectations of the procedure and results are not met or if they are not adequately trained on use of our RNS System. Patients may be dissatisfied if they experience adverse events or insufficient reduction in frequency of seizures. If the results of our products do not meet the expectations of the patients, or the patient experiences adverse events, it could discourage the patient from continuing to use our device or referring our products to others. Dissatisfied patients may express negative opinions through social media, advocacy, or other publicity. Any failure to meet patient expectations and any resulting negative publicity could harm our reputation and future sales.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our sales, business, financial condition and results of operations have been and continue to be impacted by the COVID-19 pandemic.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global spread of the COVID-19 pandemic, including the different COVID-19 variants and measures introduced by local, state and federal governments to contain the virus and mitigate its public health effects have significantly impacted the global economy and negatively impacted our business. We have seen and may continue to be negatively impacted by decreased and delayed procedures being performed to implant our RNS System, hospital staffing shortages, delayed and decreased epilepsy diagnostic evaluations at epilepsy monitoring units, or EMUs, which create the majority of our pipeline for new RNS System implants and increased vacation demand by both patients and clinicians as a result of loosening travel restrictions. Given the uncertainty around the duration and extent of the COVID-19 pandemic, we expect continued, lingering, and far-reaching adverse impacts to our business, results of operations, financial condition, and liquidity, but cannot accurately predict at this time the extent of the future potential impacts.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The widespread pandemic has also had a significant negative effect on the U.S. and global economies and, if the COVID-19 pandemic results in a prolonged economic recession, it would continue to harm our sales, business, operating results, and financial condition. Additionally, quarantines or government reaction or shutdowns for COVID-19 have disrupted and may disrupt our supply chain, especially for components we source from single-source suppliers. Travel and cargo restrictions may also disrupt our ability to distribute our RNS System or engage with our customers in the ordinary course of business. Any cargo restrictions related to raw materials used to manufacture our RNS System or its components may restrict our ability to manufacture and ship devices and harm our sales, business, operating results, and financial condition.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If adequate reimbursement becomes unavailable for the procedures to implant our RNS System and for clinicians to provide ongoing care for patients treated with our RNS System, it could diminish our sales or affect our ability to sell our RNS System profitably.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The implant procedure for our RNS System and the ongoing patient care provided by clinicians, including monitoring and programming, are reimbursed under well-established physician and hospital codes. Our ability to increase sales of our RNS System depends, in significant part, on the availability of adequate financial coverage and reimbursement from third-party payors, including governmental payors (such as the Medicare and Medicaid programs in the United States), managed care organizations, and private health insurers. Third-party payors decide which treatments they will cover and establish reimbursement rates for those treatments. We do not bill any third-party payors for our RNS System. Instead, we invoice healthcare providers for our RNS System and the cost is bundled into the reimbursement received by healthcare providers for the procedures in which our RNS System is used.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our RNS System will continue to be purchased by hospital facilities, primarily CECs, and other providers who will then seek reimbursement from third-party payors for brain-responsive neuromodulation for drug resistant focal epilepsy. While third-party payors currently cover and provide reimbursement for both implant procedures of our RNS System as well as for clinicians providing ongoing patient care, we can give no assurance that these third-party payors will continue to provide coverage and adequate reimbursement, or that current reimbursement levels for implant procedures as well as clinician-provided ongoing patient care will continue.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the overall amount of reimbursement available for brain-responsive neuromodulation for drug resistant focal epilepsy could decrease in the future. Changes in reimbursement may not necessarily impact our sales. Additionally, we cannot be sure that the reimbursement amounts available for brain-responsive neuromodulation for drug resistant focal epilepsy will not reduce or otherwise negatively impact the demand for our marketed RNS System. Failure by CECs and other users of our RNS System to obtain coverage and adequate reimbursement for the implant procedures or for clinicians providing ongoing patient care would cause our business, financial condition, and results of operations to suffer.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of our RNS System requires appropriate neurosurgeon training for implantation and epileptologist training for programming and ongoing patient care, and inadequate training may lead to negative patient outcomes, which could harm our business, financial condition, and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful use of our RNS System depends in part on the training and skill of the neurosurgeon performing the implant procedure as well as the clinician, typically an epileptologist, performing the subsequent programming of our RNS System and monitoring the patient response. Clinicians could experience difficulty with the technique necessary to successfully implant and program our RNS System, and monitor patients if they do not receive appropriate training. Moreover, clinicians rely on their previous medical training and experience when recommending or implanting our RNS System, and we cannot guarantee that all neurosurgeons will have the necessary implantation skills to properly perform the procedure. We cannot be certain that physicians or healthcare providers that use our RNS System have received sufficient training, and physicians or healthcare providers who have not received adequate training may nonetheless attempt to use our RNS System with their patients. If clinicians implant or utilize our RNS System incorrectly, or without adhering to or completing all relevant training, their patient outcomes may not be consistent with the outcomes achieved in our clinical studies. Adverse safety outcomes that arise from improper or incorrect use of our RNS System may negatively impact the perception of patient benefit and safety of our RNS System, notwithstanding results from our clinical studies. These results could limit adoption of our RNS System in treatment for drug-resistant focal epilepsy, which would harm our sales, business, financial condition, and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on our senior management team and key personnel, and our business could be harmed if we are unable to attract and retain personnel necessary for our success.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on our senior management and key personnel. Our success will depend on our ability to retain senior management and to attract and retain qualified personnel in the future, including sales and marketing professionals, engineers, scientists, clinical trial specialists and other highly skilled personnel and to integrate </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">current and additional personnel in all departments. As part of our expense management initiatives, we recently implemented a pause on hiring for certain open positions and implemented or may implement additional cost saving measures that lead to reductions in force, furloughs, or altered job responsibilities across the entire organization. The pause on hiring, or turnover or reductions of members of our senior management, sales and marketing professionals, engineers, scientists and clinical trial specialists could impact decision-making as well as efficiency and could result in delays in product development and harm our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms, or at all. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have issued stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by fluctuations in our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management and other key personnel may terminate their employment with us on short notice. Our employment arrangements with our employees provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We also do not maintain &#8220;key man&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on our own direct sales force to market and sell our RNS System, and if we are unable to optimize our sales force, it could harm our business. Our operating results are directly dependent upon the sales and marketing efforts of our sales and customer support team. If our employees fail to adequately promote, market and sell our products, our sales could significantly decrease. As we launch new products, expand our product offerings and increase our marketing efforts with respect to existing products, we will need to expand the reach of our marketing and sales networks. Our future success will depend largely on our ability to continue to hire, train, retain and motivate skilled employees with significant technical knowledge in various areas. An inability to attract, hire, train and retain employees will harm our sales, business, financial condition, and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to increase the size of our organization in the future, and we may experience difficulties in managing the operational elements or timing of this growth. If we are unable to manage or appropriately time the anticipated growth of our business, our future revenue and operating results may be harmed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had 163 employees. As our sales and marketing strategies evolve and as we continue operating as a public company, we may need additional managerial, operational, sales, marketing, financial and other personnel. Future growth would impose significant added responsibilities on members of management, including: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identifying, recruiting, integrating, maintaining and motivating additional employees; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">managing our internal development efforts effectively, while complying with our contractual obligations to contractors and other third parties; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">improving our operational, financial and management controls, reporting systems and procedures. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to successfully market and sell our RNS System will depend, in part, on our ability to effectively manage or time any future growth, and our management may also have to divert a disproportionate amount of attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As demand for our RNS System increases, we will need to continue to scale our capacity at our manufacturing facility, expand customer service, billing and systems processes and enhance our internal quality assurance program. We cannot be certain that any increases in scale, related improvements and quality assurance will be successfully implemented or that appropriate personnel will be available to facilitate the growth of our business. If we encounter difficulty meeting market demand, quality standards or physician expectations, our reputation will be harmed and our business will suffer. Additionally, additional growth may result in higher fixed costs and may slow our ability to reduce costs in the face of a sudden decline in demand for our products.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to achieve or maintain satisfactory pricing and margins for our RNS System, which could harm our business and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers of medical devices have a history of price competition, and we can give no assurance that we will be able to maintain satisfactory prices for our RNS System at the levels we have historically achieved. The pricing of our products could be impacted by several factors, including pressure to reduce prices by our customers due to a decline in the amount that third-party payors reimburse for implant procedures using our RNS System for clinicians providing ongoing patient care. A decline in the amount that third-party payors reimburse our customers for ongoing patient care could also make it difficult for programming centers to conduct ongoing patient support without a corresponding reduction in prices for our products. If we are forced to lower or are unable to increase the price we charge for our RNS System, our gross margins will decrease, which will harm our ability to invest in and grow our business. If we are unable to maintain our prices, or if our costs increase and we are unable to offset such increase with an increase in our prices, our margins could erode, which could harm our business and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations may be harmed if we are unable to accurately forecast customer demand for our products. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not maintain large amounts of excess inventory at any given time. To ensure adequate supply, we must forecast inventory needs and manufacture our products based on our estimates of future demand. Our ability to accurately forecast demand for our products could be negatively affected by many factors, including our failure to accurately manage our expansion strategy, product introductions by competitors, our inability to forecast the lifecycle of our products, an increase or decrease in customer demand for our products or for competitor products, our failure to accurately forecast customer adoption of new products, unanticipated changes in general market conditions or regulatory matters and weakening of economic conditions or consumer confidence in future economic conditions, as well as the ongoing COVID-19 pandemic. Inventory levels in excess of customer demand may result in inventory write-downs or write-offs, which would cause our gross margin to be adversely affected and could impair the strength of our brand. Conversely, if we underestimate customer demand for our products, our manufacturing team may not be able to deliver products to meet our requirements, and this could result in damage to our reputation and customer relationships. In addition, if we experience a significant increase in demand, additional supplies of components, materials, or services, or additional manufacturing capacity may not be available when required on terms that are acceptable to us, or at all, which may negatively affect our business, financial condition, and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are seeking expanded FDA labeling for our RNS System to be able to treat patients with generalized drug-resistant epilepsy as well as patients between the age of 12 and 17 with drug-resistant focal epilepsy, but if we are unable to broaden the indications for our RNS System to include these patients, our growth potential could be harmed. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are subject to extensive regulation by the FDA in the United States. Before a new medical device or a new intended use for an existing medical device can be marketed in the United States, we must first submit and receive either 510(k) clearance pursuant to Section 510(k) of the Food, Drug and Cosmetic Act, or the FDCA, or approval of a PMA application from the FDA, unless an exemption applies.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If clinical studies do not produce results necessary to support regulatory clearance or approval to expand our indications to include patients with generalized drug-resistant epilepsy as well as patients age 12 to 17 with drug-resistant focal epilepsy, we will be unable to obtain and maintain necessary approvals to expand our indications to include these patients in accordance with our expected timelines, which could harm our growth potential. Furthermore, we could incur substantial costs and the attention of management could be diverted throughout this process.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expand sales of our RNS System internationally in the future, but we may experience difficulties in obtaining regulatory clearance or approval or in successfully marketing our RNS System internationally even if </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">approved. A variety of risks associated with marketing our RNS System internationally could harm our growth potential. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our RNS System is not yet approved for sale outside the United States, we may pursue regulatory and reimbursement approval pathways in markets outside of the United States. Sales of our RNS System outside of the United States will be subject to foreign regulatory requirements governing clinical studies and marketing approval, as well as additional post-approval requirements. We would incur substantial expenses in connection with any international expansion. Additional risks related to operating in foreign countries include: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing regulatory requirements in foreign countries, including with respect to data privacy and security; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing reimbursement regimes in foreign countries, including price controls; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign taxes, including withholding of payroll taxes; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency fluctuations, which could result in increased operating expenses or reduced revenue; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties staffing and managing foreign operations; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential liability under the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, or comparable foreign regulations; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges enforcing our contractual and intellectual property rights as well as intellectual property theft or compulsory licensing, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including tariffs, war and terrorism. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other risks associated with international operations may harm our ability to attain or maintain profitable operations internationally, which would harm our growth potential.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there can be no guarantee that we will receive approval to sell our RNS System in every international market we target, nor can there be any guarantee that any sales would result even if such approval is received. Approval in the United States, or in any other jurisdiction, does not ensure approval in other jurisdictions. Obtaining foreign approvals could result in significant delays, difficulties and costs for us and require additional studies and additional expenses. Regulatory requirements can vary widely from country to country and could delay the introduction of our RNS System in those countries. If we fail to comply with these regulatory requirements or to obtain and maintain required approvals, our target market will be reduced and our ability to generate revenue will be diminished. Our inability to successfully enter all our desired international markets and manage business on a global scale could harm our growth potential.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, there are foreign privacy laws and regulations that impose restrictions on the collection, use, storage, disclosure, transfer and other processing of personal data, including health information. For example, the European Union General Data Protection Regulation, or the GDPR, imposes stringent data protection requirements, including, for example, more robust disclosures to individuals, a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to special categories of data, such as health data, and additional obligations regarding third-party processors in connection with the processing of the personal data. Our failure to comply with the GDPR or other applicable </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">foreign privacy laws or regulations or significant changes in the laws and regulations restricting our ability to obtain or use required patient information could significantly impact our business and our future business plans.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to government regulation and our industry </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with U.S. federal and state laws and regulations, including fraud and abuse and other healthcare laws and regulations, such as those relating to kickbacks and false claims for reimbursement, we could face substantial penalties and our business, financial condition and results of operations could be harmed. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers play a primary role in the distribution, recommendation, ordering and purchasing of any medical device for which we have or obtain marketing clearance or approval. Through our arrangements with healthcare professionals and hospital facilities, we are exposed to broadly applicable anti-fraud and abuse, anti-kickback, false claims and other healthcare laws and regulations that may constrain our business, our arrangements and relationships with customers, and how we market, sell and distribute our marketed medical devices. We have a compliance program, code of conduct and associated policies and procedures, but it is not always possible to identify and deter misconduct by our employees, contractors, and other third parties, including our customers, and the precautions we take to detect and prevent noncompliance may not be effective in protecting us from governmental investigations for failure to comply with applicable fraud and abuse or other healthcare laws and regulations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we are subject to various state and federal anti-fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and federal civil False Claims Act, or the FCA. Our relationships with physicians, other health care professionals and hospitals are subject to scrutiny under these laws. There are also similar laws in other countries that we may become subject to if we expand internationally.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws that may affect our ability to operate include, among others: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Anti-Kickback Statute, which prohibits, among other things, knowingly and willingly soliciting, offering, receiving or paying remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual, or the purchase, order or recommendation of, items or services for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws, including the FCA, and civil monetary penalties laws, which prohibits, among other things, persons or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds and knowingly making, using or causing to be made or used, a false record or statement to get a false claim paid or to avoid, decrease or conceal an obligation to pay money to the federal government; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Health Insurance Portability &amp; Accountability Act of 1996, or HIPAA, which applies to our customers and some of their downstream vendors and contractors, imposes criminal and civil liability for, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, or knowingly and willfully falsifying, concealing or covering up a material fact or making a materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">various state laws governing the privacy and security of personal information, including the California Consumer Privacy Act, or the CCPA, which became effective on January 1, 2020, and California Privacy Rights Act of 2020, or the CPRA, which amends and expands the CCPA and goes into effect in January 2023, which regulates the processing of personal information of California residents and increases the privacy and security obligations of covered companies handling such personal information. The CCPA and the CRPA requires covered companies to, amongst other things, provide new and additional disclosures to California residents, and affords such residents new abilities to access their personal information and opt out of certain sales of personal information; and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payments Sunshine Act, also known as Open Payments, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually, with certain exceptions to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments or other &#8220;transfers of value&#8221; made to physicians, as defined by such law, other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, and requires applicable manufacturers and group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and federal regulatory and enforcement agencies continue to actively investigate violations of healthcare laws and regulations, and the U.S. Congress continues to strengthen the arsenal of enforcement tools. Most recently, the Bipartisan Budget Act of 2018, or the BBA, increased the criminal and civil penalties that can be imposed for violating certain federal health care laws, including the Anti-Kickback Statute. Enforcement agencies also continue to pursue novel theories of liability under these laws. In particular, government agencies have increased regulatory scrutiny and enforcement activity with respect to manufacturer reimbursement support activities and patient care programs, including bringing criminal charges or civil enforcement actions under the Anti-Kickback Statute, federal civil FCA and HIPAA&#8217;s healthcare fraud and privacy provisions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Achieving and sustaining compliance with applicable federal and state anti-fraud and abuse laws may prove costly. If we or our employees are found to have violated any of the above laws we may be subjected to substantial criminal, civil and administrative penalties, including imprisonment, exclusion from participation in federal healthcare programs, such as Medicare and Medicaid, and significant fines, monetary penalties, forfeiture, disgorgement and damages, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results. Any action or investigation against us for the violation of these healthcare fraud and abuse laws, even if successfully defended, could result in significant legal expenses and could divert our management&#8217;s attention from the operation of our business. Companies settling federal civil FCA, Anti-Kickback Statute or civil monetary penalties law cases also may be required to enter into a Corporate Integrity Agreement with the Office of Inspector General, or OIG, in order to avoid exclusion from participation (such as loss of coverage for their products) in federal healthcare programs such as Medicare and Medicaid. Corporate Integrity Agreements typically impose substantial costs and operational burdens on companies to ensure compliance. Defending against any such actions can be detrimental to our reputation and brand and can otherwise be costly, time-consuming and may require significant personnel resources, and may harm our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the medical device industry&#8217;s relationship with physicians is under increasing scrutiny by the OIG, the U.S. Department of Justice, or the DOJ, the state attorney generals and other foreign and domestic government agencies. Our failure to comply with requirements governing the industry&#8217;s relationships with physicians or an investigation into our compliance by the OIG, the DOJ, state attorney generals and other government agencies, could harm our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could harm our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, consultants, commercial partners and vendors may engage in fraudulent or illegal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violates: (i) the laws of the FDA and other similar foreign regulatory bodies, including those laws requiring the reporting of true, complete and accurate information to such regulators; (ii) manufacturing standards; (iii) healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws; or (iv) laws that require the true, complete and accurate reporting of financial information or data. These laws may impact, among other things, future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of pricing, discounting, marketing and promotion, structuring and commissions, certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical studies. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a code of conduct, employee handbook, and compliance policies, but it is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent these activities may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of significant fines or other sanctions, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, disgorgement, imprisonment, reporting and oversight obligations, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, diminished profits and future earnings and curtailment of operations, any of which could adversely affect our ability to operate our business and our results of operations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in integrity issues, or a negative impact to our reputation or brand. Whether or not we are successful in defending against any such actions or investigations, we could incur substantial costs, including legal fees, and divert the attention of management in defending ourselves against any of these claims or investigations, which could harm our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory compliance is expensive, complex and uncertain, and a failure to comply could lead to enforcement actions against us and other negative consequences for our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and similar agencies regulate our products as medical devices. Complying with these regulations is costly, time-consuming, complex and uncertain. For instance, before a new medical device, or a new intended use for an existing device, can be marketed in the United States, a company must first submit and receive either 510(k) clearance or approval of a PMA from the FDA, unless an exemption applies. FDA regulations and regulations of similar agencies are wide-ranging and include, among other things, oversight of: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product design, development, manufacturing (including suppliers) and testing; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laboratory, preclinical and clinical studies; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product safety and effectiveness; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product labeling; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product storage and shipping; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">record keeping; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pre-market clearance or approval; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">marketing, advertising and promotion; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product sales and distribution; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product changes; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-market surveillance and reporting of deaths or serious injuries and certain malfunctions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are subject to extensive regulation by the FDA and if we expand internationally in the future may be subject to extensive regulation by non-U.S. regulatory agencies. Further, improvements of our existing products, any potential new products, and new indications for use of our current products will be subject to extensive regulation, and we may require permission from regulatory agencies and ethics boards to conduct clinical studies, as </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">well as clearance or approval from the FDA prior to commercial sale. In order to commercialize and distribute our products in markets outside of the United States, it will require approval from non-U.S. regulatory agencies. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and foreign regulatory bodies can delay, limit or deny clearance or approval of a device for many reasons, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to demonstrate to the satisfaction of the FDA or the applicable regulatory entity or notified body that our products are safe or effective for their intended uses;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the disagreement of the FDA or the applicable foreign regulatory body with the design or implementation of our clinical studies or the interpretation of data from clinical studies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">serious and unexpected adverse device effects experienced by participants in our clinical studies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data from our preclinical studies and clinical studies may be insufficient to support clearance or approval, where required;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to demonstrate that the clinical and other benefits of the device outweigh the risks;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the manufacturing process or facilities we use may not meet applicable requirements; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory filings insufficient for clearance or approval.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable U.S. requirements regarding, for example, promoting, manufacturing or labeling our RNS System, may subject us to a variety of administrative or judicial actions and sanctions, such as Form 483 observations, warning letters, untitled letters, product recalls, product seizures, and total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution. Any enforcement action by the FDA and other comparable non-U.S. regulatory agencies could harm our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA or state agencies, which may include any of the following actions: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">removal from FDA&#8217;s Voluntary Improvement Program pilot;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated expenditures to address or defend such actions; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">form 483s, or other compliance or enforcement notices, communications or correspondence, including customer notifications for repair, replacement or refunds; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recall, detention or seizure of our RNS System; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating restrictions or partial suspension or total shutdown of production; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusing or delaying our requests for 510(k) clearance or PMA of new products or modified products; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating restrictions; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seizure or detention of products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawing 510(k) clearances or PMAs that have already been granted; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to grant export approval for our RNS System;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">criminal prosecution; or</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">civil penalties. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events were to occur, it would have a negative impact on our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also regulates the advertising and promotion of our RNS System to ensure that the claims we make are consistent with our regulatory clearances and approvals, that there are adequate and reasonable data to substantiate the claims and that our promotional labeling and advertising is neither false nor misleading in any respect. If the FDA determines that any of our advertising or promotional claims are misleading, not substantiated or not permissible, we may be subject to enforcement actions, including warning letters, and we may be required to revise our promotional claims and make other corrections or restitutions. Additionally, our manufacturing facility is required to comply with extensive requirements imposed by the FDA, including ensuring that quality control and manufacturing procedures conform to the QSR. As such, we will be subject to continual review and inspections to assess compliance with the QSR and adherence to commitments made in any 510(k) or PMA application. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 510(k) or PMA process can be expensive, lengthy and unpredictable and we will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. We may not be able to obtain necessary clearances or approvals or may be unduly delayed in doing so, which would negatively affect our business, financial condition and results of operations. Furthermore, even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for the product, which may limit the market for the product. Although we have obtained PMA approval to market our RNS System, our approval can be revoked if safety or efficacy problems develop.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations are subject to pervasive and continuing FDA regulatory requirements, and failure to comply with these requirements could harm our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before a new medical device or service, or a new intended use for an existing product or service, can be marketed in the United States, a company must first submit and receive either 510(k) clearance or PMA from the FDA, unless an exemption applies. In the 510(k) clearance process, before a device may be marketed, the FDA must determine that a proposed device is substantially equivalent to a legally-marketed predicate device, which includes a device that has been previously cleared through the 510(k) process, a device that was legally marketed prior to May 28, 1976 (pre-amendments device), a device that was originally on the U.S. market pursuant to an approved PMA and later down-classified, or a 510(k)-exempt device.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the process of obtaining PMA approval, which was required for our RNS System, the FDA must determine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including, but not limited to, technical, preclinical, clinical study, manufacturing and labeling data. The PMA process is typically required for devices that are deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable device.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and state and international authorities have broad enforcement powers. The medical device industry is now experiencing greater scrutiny and regulation by federal, state and foreign governmental authorities. Companies in our industry are subject to more frequent and more intensive reviews and investigations, often involving the marketing, business practices and product quality management. Such reviews and investigations may result in: civil and criminal proceedings; the imposition of substantial fines and penalties; the receipt of warning letters, untitled letters, demands for recalls or the seizure of our products; the requirement to enter into corporate integrity agreements, stipulated judgments or other administrative remedies; and result in our incurring substantial unanticipated costs and the diversion of key personnel and management&#8217;s attention from their regular duties, any of which may harm our business, financial condition and results of operations, and may result in greater and continuing governmental scrutiny of our business in the future.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, federal, state and foreign governments and entities have enacted laws and issued regulations and other standards requiring increased visibility and transparency of interactions with healthcare providers. For example, Open Payments requires us to annually report to CMS payments and other transfers of value to U.S. physicians and certain other clinicians and U.S. teaching hospitals, with the reported information made publicly available on a searchable website. Failure to comply with these legal and regulatory requirements could impact our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business, and we have had and will continue to spend substantial time and financial resources to develop and implement enhanced structures, policies, systems and processes to comply with these legal and regulatory requirements, which could harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Modifications to our products or products we sell may require new 510(k) clearances or PMAs or may require us to recall or cease marketing these products until clearances or approvals are obtained, which could harm our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, our RNS System is marketed pursuant to a PMA order issued by the FDA. Any modifications to a PMA-approved device that could significantly affect its safety or effectiveness, including significant design and manufacturing changes, or that would constitute a major change in its intended use, manufacture, design, components, or technology requires approval of a new PMA application or PMA supplement. For instance, we believe that the change in the expected average battery life of our RNS System requires a label change, and we have submitted this to the FDA as a PMA supplement for review. However, certain changes to a PMA-approved device do not require submission and approval of a new PMA or PMA supplement and may only require notice to FDA in a PMA 30-Day Notice, Special PMA Supplement - Changes Being Effected or PMA Annual Report. The FDA requires every manufacturer to make this determination in the first instance, but the FDA may review any manufacturer&#8217;s decision. The FDA may not agree with our decisions regarding whether new approvals are necessary. If the FDA disagrees with our determination and requires us to seek new PMA approvals for modifications to our previously approved products for which we have concluded that new approvals are unnecessary, we may be required to cease marketing or to recall the modified product until we obtain clearance or approval, and we may be subject to significant regulatory fines or penalties. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For products that have received 510(k) clearance, such as our Burr Hole Cover product, modifications that could significantly affect safety and effectiveness, such as changes to the intended use or technological characteristics, may require new 510(k) clearances or PMAs or require us to recall or cease marketing the modified devices until these clearances or approvals are obtained. Based on FDA published guidelines, the FDA requires device manufacturers to initially make and document a determination of whether or not a modification requires a new approval, supplemental approval or clearance; however, the FDA can review a manufacturer&#8217;s decision. Any modification to an FDA-cleared device that could significantly affect its safety or efficacy or that would constitute a major change in its intended use would require a new 510(k) clearance, or if such modification put the device into Class III, possibly a PMA. We may not be able to obtain additional 510(k) clearances or PMAs for new products or for modifications to, or additional indications for, our products in a timely fashion, or at all. Delays in obtaining required future clearances or approvals would adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn would harm our future growth.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made modifications to our RNS System in the past and expect to make additional modifications in the future that we believe do not or will not require additional clearances or approvals. If the FDA disagrees and requires new clearances or approvals for these modifications, we may be required to recall and to stop selling or marketing such products as modified, which could harm our operating results and require us to redesign such products. In these circumstances, we may be subject to significant enforcement actions. The FDA may also change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions which may impact our ability to modify our currently approved or cleared products on a timely basis. Any of these actions could harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products or products we sell may be subject to recalls after receiving FDA approval or clearance, which could divert managerial and financial resources, harm our reputation and our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has the authority to require the recall of our products or products we sell because of any failure to comply with applicable laws and regulations, or defects in design or manufacture. A government mandated or voluntary product recall by us could occur because of, for example, component failures, device malfunctions or other adverse events, such as serious injuries or deaths, or quality-related issues, such as manufacturing errors or design or labeling defects. Any future recalls of our products or products we sell could divert managerial and financial resources, harm our reputation and negatively impact our business. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we initiate a correction or removal of one of our products to reduce a risk to health posed by the device, we would be required to submit a publicly available Correction and Removal report to the FDA and, in many cases, similar reports to other regulatory agencies. This report could be classified by the FDA as a device recall which could lead to increased scrutiny by the FDA and our customers regarding the quality and safety of our products. Furthermore, the submission of these reports has been and could be used by competitors against us and could harm our reputation, which could cause customers to delay purchase decisions, cancel orders or decide not to purchase our products and could cause patients to lose trust in and decide not to implant our RNS System. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our products cause or contribute to a death or a serious injury or malfunction in certain ways, we will be required to report under applicable medical device reporting regulations, or MDRs, which can result in voluntary corrective actions or agency enforcement actions and harm our reputation, business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under MDRs, medical device manufacturers are required to report to the FDA information that a device has or may have caused or contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute to death or serious injury if the malfunction of the device or one of our similar devices were to recur. If we fail to report events required to be reported to the FDA within the required timeframes, or at all, the FDA could take enforcement action and impose sanctions against us. Any such adverse event involving our products also could result in future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection or enforcement action. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, would be costly, distract management from operating our business, could be used by competitors against us, and may harm our reputation, business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">From time to time, we engage outside parties to perform services related to certain of our clinical studies. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to complete our clinical studies on our planned timelines, or at all, and may incur significant additional costs. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we engage consultants to help design, monitor and analyze the results of certain of our clinical studies and trials. The consultants we engage may interact with clinical investigators to enroll patients in our clinical studies. We depend on these consultants and clinical investigators to conduct clinical studies and trials and monitor and analyze data from these studies and trials under the investigational plan and protocol for the study or trial and in compliance with applicable regulations and standards, such as the FDA&#8217;s Good Clinical Practice, or GCP, guidelines and FDA human subject protection regulations. We may face delays in completing our clinical studies if these parties do not perform their obligations in a timely, compliant or competent manner. If these third parties do not successfully carry out their duties or meet expected deadlines, or if the quality, completeness or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical study protocols or for other reasons, our clinical studies or trials may need to be extended, delayed or terminated or may otherwise prove to be unsuccessful, and we may have to conduct additional studies, which would significantly increase our costs. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare reform initiatives and other administrative and legislative proposals may harm our business, financial condition, results of operations and cash flows in our key markets. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been and continue to be proposals by the federal government, state governments, regulators and third-party payors to control or manage the increased costs of healthcare and, more generally, to reform the U.S. healthcare system. Certain of these proposals could limit the prices we are able to charge for our products or the coverage and reimbursement available for our products and could limit the acceptance and availability of our products. The adoption of proposals to control costs could harm our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There likely will continue to be legislative and regulatory proposals at the federal and state levels directed at containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future or their full impact. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may harm: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a price that we believe is fair for our products; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenue and achieve or maintain profitability; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal legislation designed to bring transparency to product pricing and reduce the cost of products and services under government healthcare programs, such as the recently enacted Inflation Reduction Act of 2022. Additionally, individual states in the United States have also increasingly passed legislation and implemented regulations designed to control product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. Moreover, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what products to purchase and which suppliers will be included in their healthcare programs. Adoption of price controls and other cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures may prevent or limit our ability to generate revenue and attain profitability. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various new healthcare reform proposals are emerging at the federal and state level. Any new federal and state healthcare initiatives that may be adopted could limit the amounts that federal and state governments will pay for healthcare products and services, and could harm our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our collection, use, storage, disclosure, transfer and other processing of sensitive and personal information subject us to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security that could give rise to significant costs, liabilities and other risks, including as a result of investigations, inquiries, litigation, fines, legislative and regulatory action and negative press about our privacy and data protection practices, which may disrupt our business operations and harm our business and reputation, financial conditions, results of operations and prospects and cause other adverse business consequences.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the course of our operations, we receive, collect, use, generate, store, disclose, transfer, make accessible, protect, secure, dispose of, transmit, share and otherwise process an increasing volume of sensitive, and personal information, including detailed recordings of iEEGs from patients as well as information from our employees and third parties with whom we conduct business. Our data processing activities may subject us to data privacy and security obligations, such as various laws, rules, regulations, guidance and industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security. When conducting clinical studies, we face risks associated with collecting trial participants&#8217; data, especially health data, in a manner consistent with applicable laws and regulations, such as GCP guidelines or FDA human subject protection regulations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to many diverse laws and regulations relating to data privacy and security. In the United States, various federal and state regulators have adopted, or are considering adopting, laws and regulations concerning personal information and data security. Additionally, our customers may be subject to additional federal and state privacy and security laws, rules, regulations and standards, including HIPAA, that they may require us to comply with through contractual obligations. This patchwork of legislation and regulation may give rise to conflicts or differing views of personal privacy rights. Additionally, new privacy rules are being enacted in the United States and globally, and existing ones are being updated and strengthened. For example, the CCPA applies to personal information of consumers, business representatives, and employees, and requires businesses to provide specific disclosures in privacy notices and honor requests of California residents to exercise certain privacy rights. The CCPA provides for civil penalties of up to $7,500 per violation and allows private litigants affected by certain data breaches to recover significant statutory damages. Although the CCPA exempts some data processed in the context of clinical trials, the CCPA increases compliance costs and potential liability with respect to other personal data we maintain about California residents. In addition, the California Privacy Rights Act of 2020, or CPRA, expands the CCPA&#8217;s requirements, including by adding a new right for individuals to correct their personal information and establishing a new regulatory agency to implement and enforce the law. Other states, such as Virginia and Colorado, have also passed comprehensive privacy laws, and similar laws are being considered in several other states, as well as at the federal and local levels. While these states, like the CCPA, also exempt some data processed in the context </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of clinical trials, these developments further complicate compliance efforts, and increase legal risk and compliance costs for us, the third parties upon whom we rely. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event we expand our operations internationally, we may become subject to additional foreign data privacy and security laws, rules, regulations, requirements, and standards, which in the European Union, for instance, have been significantly reformed. Outside the United States, an increasing number of laws, regulations, and industry standards may govern data privacy and security.  For example, the European Union&#8217;s General Data Protection Regulation, or EU GDPR, the United Kingdom&#8217;s GDPR, or UK GDPR, and Canada&#8217;s Personal Information Protection and Electronic Documents Act, or PIPEDA, impose strict requirements for processing personal data. Under the EU GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to &#8364;20 million Euros or four percent of annual global revenues, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also bound by contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. For example, certain privacy laws, such as the GDPR and the CCPA, require our customers to impose specific contractual restrictions on their service providers. We publish privacy policies, marketing materials, and other statements regarding data privacy and security.  If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make public statements about our use and disclosure of personal information through our privacy policies, information provided on our website and press statements. Although we endeavor to comply with our public statements and documentation, we may at times fail to do so or be alleged to have failed to do so. The publication of our privacy policies and other statements that provide promises and assurances about data privacy and security can subject us to potential government or legal action if they are found to be deceptive, unfair or misrepresentative of our actual practices. Any concerns about our data privacy and security practices, even if unfounded, could damage the reputation of our business and harm our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obligations related to data privacy and security are quickly changing, becoming increasingly stringent, and creating regulatory uncertainty.  Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions.  Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims); additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not use personal data. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant disruptions in our information technology systems or those of third parties upon which we rely, whether through breaches or failures of our systems, unauthorized access or otherwise, may result in both an adverse impact to our products, as well as the unauthorized use, disclosure, modification or misappropriation of patient personal information, the occurrence of fraudulent activity, or other data security-related incidents, all of which could result in adverse consequences, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">profits; loss of customers or sales; and other adverse consequences, which could have a material and adverse impact on our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent on complex information technology systems for the efficient functioning of our business, including the manufacture, distribution and maintenance of our products, as well as for accounting, data storage, compliance, purchasing and inventory management purposes. Further, our products collect, use, store, disclose, transfer, and otherwise process sensitive patient data, such as detailed recordings of iEEGs to help clinicians make more informed treatment decisions and optimize their patients&#8217; care. These data are recorded by our RNS System and can be viewed by the physician during regular patient visits using the Physician Tablet or on demand through a secure website. We also collect, use, store, disclose, transfer, and otherwise process a growing volume of other personal information and confidential, proprietary and sensitive data, which may include procedure-based information and sensitive healthcare data, credit card, and other financial information, insurance information, and other potentially personally identifiable information. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyber-attacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive data and information technology systems, and those of the third parties upon which we rely. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our services.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the third parties upon which we rely are subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks (such as credential stuffing), credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods, and other similar threats. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, loss of sensitive data and income, reputational harm, and diversion of funds.  Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our reliance on third-party service providers could introduce new cybersecurity risks and vulnerabilities, including supply-chain attacks, and other threats to our business operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party service providers and technologies to operate critical business systems to process sensitive data in a variety of contexts, such as and without limitation, cloud-based infrastructure, data center facilities, encryption and authentication technology, employee email, content delivery to customers, and other functions. We also rely on third-party service providers to provide other products, services, parts, or otherwise to operate our business. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">insufficient to cover our damages, or we may be unable to recover such award.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive data or our information technology systems, or those of the third parties upon whom we rely. A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to provide our services. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may expend significant resources or modify our business activities to try to protect against security incidents. Additionally, certain data privacy and security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive data.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We take steps to detect and remediate vulnerabilities, but we may not be able to detect and remediate all vulnerabilities because the threats and techniques used to exploit the vulnerability change frequently and are often sophisticated in nature. Therefore, such vulnerabilities could be exploited but may not be detected until after a security incident has occurred. These vulnerabilities pose material risks to our business. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause customers to stop using our services, deter new customers from using our services, and negatively impact our ability to grow and operate our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We currently maintain a cybersecurity insurance policy and business interruption coverage to mitigate certain potential losses but this insurance is limited in amount, and we cannot be certain that such potential losses will not exceed our policy limits, or will cover all potential claims to which we are exposed and may not be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims. Therefore, failure to maintain or protect our information systems and data integrity effectively could harm our business, financial condition, and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential liability related to the privacy of health information we obtain.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may maintain, use, and share sensitive health information that we receive directly from patients that use our products, throughout the clinical study process, in the course of our research collaborations, and from healthcare providers in the course of using our products and systems. Most healthcare providers, including hospitals from which we obtain patient health information, are subject to privacy and security regulations promulgated under </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health, or HITECH. We are not currently classified as a covered entity or business associate under HIPAA and thus are not subject to its requirements or penalties. However, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive, maintain, use, or transfer individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information. Furthermore, certain health privacy laws, data breach notification laws, consumer protection laws and genetic testing laws may apply directly to our operations or those of our collaborators and may impose restrictions on our collection, use and dissemination of individuals&#8217; health information As such, we may be subject to state laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, including certain health information, which is a broader class of information than the health information protected by HIPAA. To the extent we engage in clinical studies outside the United States, we may implicate foreign data privacy and security laws and regulations, including the GDPR and legislation of the European Union member states implementing it.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do business in international markets in the future, any failure by us or our third-party contractors to comply with the strict rules on the transfer of personal data outside of the European Union and the United Kingdom into the United States in accordance with such laws and regulations may result in the imposition of criminal and administrative sanctions on such contractors, which could adversely affect our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, patients about whom we or our contractors or collaborators obtain or share health information, as well as the providers who share this information with us or whom we share this data with, may have statutory or contractual rights that limit our ability to use and disclose the information. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we have violated individuals&#8217; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could negatively affect our business, financial condition and results of operations. If we or third-party contractors or consultants fail to comply with applicable federal, state or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our contractors&#8217; ability to develop and commercialize our products and could harm or prevent sales of our products, or could substantially increase the costs and expenses of developing, commercializing and marketing our products. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, data collection, privacy and security have become the subject of increasing public concern and changing preferences towards data collection, privacy and security could adversely affect patient willingness to consent to our collection of their health information. Patients may be reluctant or unwilling to consent to the collecting of their health information, and patients that have opted-in to the collection of their health information may revoke their consent at any time, including as a result of these concerns or as a result of changes to our data policies that we have implemented or may implement in the future. In particular, the success of our business depends in part on our ability to lawfully obtain health information from our patients. If patients choose not to consent to the collection of their health information as a result of these concerns, or our consent practices are found to be unlawful, this could negatively impact the growth potential for our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with environmental laws and regulations could be expensive, and the failure to comply with these laws and regulations could subject us to significant liability.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research, development and manufacturing operations involve the use of hazardous substances, and we are subject to a variety of federal, state and local environmental laws and regulations relating to the storage, use, handling, generation, manufacture, treatment, discharge and disposal of hazardous substances. Our products may also contain hazardous substances, and they are subject laws and regulations relating to labeling requirements and to their sale, collection, recycling, treatment, storage and disposal. Compliance with these laws and regulations may be expensive and noncompliance could result in substantial fines and penalties. Environmental laws and regulations also impose liability for the remediation of releases of hazardous substances into the environment and for personal injuries resulting from exposure to hazardous substances, and they can give rise to substantial remediation costs and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to third-party claims, including for property damage and personal injury. Liability under environmental laws and regulations can be joint and several and without regard to fault or negligence, and they tend to become more stringent over time, imposing greater compliance costs and increased risks and penalties associated with violations. We cannot be certain that violations of these laws and regulations, or releases of or exposure to hazardous substances, will not occur in the future or have not occurred in the past, including as a result of human error, accidents, equipment failure or other causes. The costs of complying with environmental laws and regulations, and liabilities that may be imposed for violating them, or for remediation obligations or responding to third-party claims, could negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical studies may be delayed, suspended or terminated for many reasons, which will increase our expenses and delay the time it takes to support label expansion for additional indications.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to continue to develop and execute clinical studies to support label retention for our products and label expansion for our products into additional epilepsy populations. We may also develop and execute clinical studies for new products or for label expansion for our current products into patient populations living with other neurologic conditions. We do not know whether future clinical studies will begin on time, need to be redesigned, enroll an adequate number of patients or be completed on schedule, if at all. The commencement and completion of clinical studies to support label retention and expansion for additional indications or for new products may be delayed, suspended or terminated as a result of many factors, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the delay or refusal of regulators or Institutional Review Boards, or IRBs, to authorize us to commence a clinical study at a prospective trial site;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulatory requirements, policies and guidelines;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or failure to reach agreement on acceptable terms with prospective clinical research organizations, or CROs, and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in patient enrollment and variability in the number and types of patients available for clinical studies, including due to COVID-19, and delays in or the inability to monitor enrolled patients, including due to COVID-19;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to enroll a sufficient number of patients in studies to observe statistically significant treatment effects in the trial;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">having clinical sites deviate from the trial protocol or dropping out of a study;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety or tolerability concerns that could cause us to suspend or terminate a trial if we find that the participants are being exposed to unacceptable health risks;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators or IRBs requiring that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or safety concerns, among others;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lower than anticipated retention rates of patients and volunteers in clinical studies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our CROs or clinical studies sites failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, deviating from the protocol or dropping out of a trial;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays relating to adding new clinical study sites; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exceeding budgeted costs due to difficulty in accurately predicting costs associated with clinical studies.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if a clinical study is suspended or terminated by us, by the IRBs or the Ethics Committees of institutions at which such studies are being conducted, by the Data Safety Monitoring Board for such trial or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical study due to a number of factors, including failure to conduct the clinical study in accordance with regulatory requirements, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including GCP regulations, or our clinical protocols, inspection of the clinical study operations or trial site by the FDA resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate safety and effectiveness, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical study.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may encounter delays if the FDA concludes that our financial relationships with investigators result in a perceived or actual conflict of interest that may have affected the interpretation of a study, the integrity of the data generated at the applicable clinical study site or the utility of the clinical study itself. Principal investigators for our clinical studies may serve as scientific advisors or consultants to us from time to time and receive cash compensation and/or stock options in connection with such services. If these relationships and any related compensation to or ownership interest by the clinical investigator carrying out the study result in perceived or actual conflicts of interest, or if the FDA concludes that the financial relationship may have affected interpretation of the study, the integrity of the data generated at the applicable clinical study site may be questioned and the utility of the clinical study itself may be jeopardized, which could result in the delay or rejection by the FDA. Any such delay or rejection could prevent us from supporting label retention and expansion for our RNS System.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our intellectual property</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain, maintain, protect, enforce and defend patent or other intellectual property protection for our products, or if the scope of the patent and other intellectual property protection obtained is not sufficiently broad, or as a result of our existing or any future out-licenses of our intellectual property, our competitors could develop and commercialize products similar to or competitive with our products, our ability to continue to commercialize our RNS System, or our other products, may be harmed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with other medical device companies, our success depends in large part on our ability to obtain, maintain, protect, enforce and defend a proprietary position for our products, which will depend upon our success in obtaining and maintaining effective patent and other intellectual property protection in the United States and other countries into which we may expand our business in the future that covers our RNS System and any other products, their manufacturing processes and their intended methods of use. Furthermore, our success will also depend on our ability to enforce and defend those patents, as well as our other intellectual property. In some cases, we may not be able to obtain patents covering our products which are sufficient to prevent third parties, such as our competitors, from utilizing our products, or our competitors may have rights under current or future out-licenses of our intellectual property, which could result in our competitors developing and commercializing products similar to or competitive with our products. Any failure to obtain, maintain, protect, enforce or defend patent and other intellectual property protection with respect to our RNS System or other aspects of our business could harm our business, competitive position, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain, protect, enforce, and defend our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our patents. Additionally, we cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors or other third parties. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection in one, several, or all geographies. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, suppliers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. Furthermore, the publication of discoveries in scientific literature often lags behind the actual discoveries, and patent applications in the United </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. As such, we cannot be certain that we were the first to make the inventions claimed in any of our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties, including by way of our cross-license with Medtronic, and we are therefore reliant on our licensors or licensees. Therefore, these and any of our patents and patent applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. Furthermore, our license agreements may be terminated by the licensor. Defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example, with respect to proper priority claims, inventorship and the like, although we are unaware of any such defects that we believe are of importance. If we or any of our current or future licensors or licensees fail to obtain, maintain, protect, enforce or defend such patents and other intellectual property rights, such rights may be reduced or eliminated. If any of our current or future licensors or licensees are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation or prosecution of our patents or patent applications, such patents or applications may be invalid and unenforceable. Any of these outcomes could impair our ability to prevent competition from third parties, which may harm our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The strength of patent rights generally, and particularly the patent position of medical device companies, involves complex legal and scientific questions, can be uncertain, and has been the subject of much litigation in recent years. This uncertainty includes changes to the patent laws through either legislative action to change statutory patent law or court action that may reinterpret existing law or rules in ways affecting the scope or validity of issued patents. Our current or future patent applications may fail to result in issued patents in the United States or foreign countries with claims that cover our products, including our RNS System. Even if patents do successfully issue from our patent applications, third parties may challenge the validity, enforceability or scope of such patents, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful challenge to our patents could deprive us of exclusive rights necessary for the successful commercialization of our products, including our RNS System. Furthermore, even if they are unchallenged, our patents may not adequately protect our RNS System or any other products we develop, provide exclusivity for these products or prevent others from designing around our claims. If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical products could be adversely affected. If the breadth or strength of protection provided by the patents we hold or pursue with respect to our products is challenged, it could dissuade companies from collaborating with us to develop, or threaten our ability to commercialize, our products. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, the natural expiration of a utility patent is generally 20 years after its effective filing date and the natural expiration of a design patent is generally 14 years after its issue date, unless the filing date occurred on or after May 13, 2015, in which case the natural expiration of a design patent is generally 15 years after its issue date. However, the actual protection afforded by a patent varies from country to country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Without patent protection for our products, we may be open to competition. Further, if we encounter delays in our development efforts, the period of time during which we could market our products under patent protection would be reduced and, given the amount of time required for the development, testing and regulatory review of planned or future products, patents protecting such products might expire before or shortly after such products are commercialized.  Our issued patents are expected to continue to expire through August 2038 without taking into account all possible patent term adjustments, extensions, or abandonments, and assuming payment of all appropriate maintenance, renewal, annuity, and other governmental fees. As our patents expire, the scope of our patent protection will be reduced, which may reduce or eliminate any competitive advantage afforded by our patent portfolio. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we license or own, currently or in the future, issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we own may be challenged, narrowed, circumvented or invalidated by third parties. Consequently, we do not know whether our RNS System or our other products will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative products in a non-infringing manner, which could harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our patents and patent applications may be co-owned or cross-licensed with third parties. If we give up, do not pursue, or are unable to obtain an exclusive license to any such third-party co-owners&#8217; or licensee&#8217;s interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining necessary rights to any products or processes we may develop through acquisitions and in-licenses.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may find it necessary or prudent to acquire or obtain licenses to intellectual property or proprietary rights held by third parties that we may identify as necessary or important to our business operations. However, we may be unable to acquire or secure such licenses to any or all intellectual property or proprietary rights from third parties that we identify as necessary for our RNS System or any future products we may develop. The acquisition or licensing of third-party intellectual property or proprietary rights is a competitive area, and our competitors may pursue strategies to acquire or license third party intellectual property or proprietary rights that we may consider attractive or necessary. Our competitors may have a competitive advantage over us due to their size, capital resources and greater development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to acquire or license third party intellectual property or proprietary rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully acquire or license required third-party intellectual property or proprietary rights or maintain the existing licenses to intellectual property rights we have, we may have to spend time and resources to develop intellectual property ourselves or abandon development of the relevant product, both of which could harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patents covering our products, including our RNS System could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, which could harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third-party preissuance submission of prior art to the U.S. Patent and Trademark Office, or the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant and inter partes review, or IPR, or interference proceedings or other similar proceedings challenging our patent rights. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, such patent rights, allow third parties to commercialize our products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our priority of invention or other features of patentability with respect to our patents and patent applications. Such challenges may result in loss of patent rights, in loss of exclusivity, or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical products or limit the duration of the patent protection of our products. Such proceedings also may result in substantial cost and require significant time from our management, even if the eventual outcome is favorable to us.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we initiate legal proceedings against a third party to enforce a patent covering our products, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Defenses of these types of claims, regardless of their merit, would involve substantial litigation expense, would result in reputational harm, and would be a substantial diversion of employee resources from our business. Third parties may also raise claims challenging the validity or enforceability of our patents before administrative bodies in the United States or abroad, even outside the context of litigation, including through re-examination, post-grant review, IPR, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (such as opposition proceedings). Such proceedings could result in the revocation of, cancellation of or amendment to our patents in such a way that they no longer cover our products. The outcome for any particular patent following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant or other third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection for the patents raised in such a claim. Such a loss of patent protection would harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The medical device industry is characterized by patent litigation and in the future we could become subject to patent or other intellectual property litigation that could be costly, result in the diversion of management&#8217;s time and efforts, require us to pay damages or prevent us from marketing our existing or future products.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent litigation is prevalent in the medical device and diagnostic sectors. Our commercial success depends in part upon our ability and that of our suppliers to manufacture, market, sell, and use our proprietary products without infringing, misappropriating or otherwise violating the intellectual property or proprietary rights of third parties. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our products. Additional third parties may assert infringement claims against us based on existing or future intellectual property rights, regardless of merit. If we are found to infringe a third party&#8217;s intellectual property rights, we could be required to incur costs to obtain a license from such third party to continue developing and marketing our products. We may also elect to enter into such a license in order to settle pending or threatened litigation. However, we may not be able to obtain any required license on commercially reasonable terms, or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us, and could require us to pay significant royalties and other fees. We could be forced, including by court order, to cease commercializing the infringing product. In addition, we could be found liable for monetary damages, which may be significant. If we are found to have willfully infringed a third-party patent, we could be required to pay treble damages and attorneys&#8217; fees. A finding of infringement could prevent us from commercializing our planned products in commercially important territories, or force us to cease some of our business operations, which could harm our business and cause brand and reputational harm. We could also be forced to redesign those products that contain the allegedly infringing intellectual property, which could be costly, disruptive and infeasible. Many of our employees were previously employed at, and many of our current advisors and consultants are employed by, universities or other biotechnology, medical device, healthcare, or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, advisors and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we, or these employees, have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Furthermore, although these agreements may be difficult to enforce, we may in the future be subject to claims that these individuals are violating non-compete agreements with their former employers. These and other claims that we have misappropriated the confidential information or trade secrets of third parties can have a similar negative impact on our business to the infringement claims discussed above.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in defending against intellectual property claims, litigation or other legal proceedings relating to such claims may cause us to incur significant expenses, cause reputational harm, and could distract our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technical and management personnel from their normal responsibilities. If we fail in defending any such claims, in addition to paying monetary damages or other settlements, we may lose valuable intellectual property rights or personnel, which could harm our business, financial condition and results of operations. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial negative impact on the price of our common shares. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of litigation or other intellectual property related proceedings could harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural measures, document submissions, fee payments and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and patent applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our patents and applications. The USPTO and various non-U.S. government agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in the abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain of our patents are, and our future owned and in-licensed patents may be, discovered through government funded programs and thus may subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our patents are, and our future owned and in-licensed patents may be, discovered through government funded programs. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future products pursuant to the Bayh-Dole Act of 1980, or the Bayh-Dole Act, and implementing regulations, which are amended from time to time. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us or our licensors to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations, which are also referred to as &#8220;march-in rights.&#8221; The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. These time limits have recently been changed by regulation, and may change in the future. Intellectual property generated under or in collaboration with a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This preference for U.S. manufacturers may limit our future ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. If the U.S. government decides to exercise these rights, it is not required to engage us as its contractor in connection with doing so. These rights may permit the U.S. government to disclose our confidential information to third parties. To the extent any of our current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. Any exercise by the government of any of the foregoing rights could harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in any current or future agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are and may become party to license or collaboration agreements with third parties to advance our research or allow commercialization of our products. Such agreements may impose numerous obligations, such as development, diligence, payment, commercialization, funding, milestone, royalty, sublicensing, insurance, patent prosecution, enforcement and other obligations on us and may require us to meet development timelines, or to exercise certain efforts to develop and commercialize licensed products, in order to maintain the licenses. In spite of our best efforts, our licensors might conclude that we have materially breached such license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technologies covered by these license agreements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any termination of these licenses could result in the loss of significant rights and could harm our ability to commercialize our products, and competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical to ours. We may further be required to cease our development and commercialization of certain of our products. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate intellectual property rights of the licensor that are not subject to the license agreement;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our products, and what activities satisfy those diligence obligations; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of any patented technology; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our future licensors and us and our partners.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreements under which we may license intellectual property or technology from third parties are likely to be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our sales, business, financial condition or results of operations. Moreover, if disputes over intellectual property that we may license prevent or impair our ability to maintain future license agreements on acceptable terms, we may be unable to successfully develop and commercialize the affected products, which could have a material adverse effect on our sales, business, financial conditions or results of operations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain patent term extension under the Hatch-Waxman Amendments, our business may be materially harmed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of FDA marketing approval of our products, one or more of the U.S. patents we own or license may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, even if, at the relevant time, we have an issued patent covering our product, we may not be granted an extension if we were, for example, to fail to exercise due diligence during the testing phase or regulatory review process, to fail to apply within applicable deadlines or prior to expiration of relevant patents or otherwise to fail to satisfy applicable requirements. Moreover, the time period of the extension or the scope of patent protection afforded could be less than we request. Only one patent per approved product can be extended, the extension cannot extend the total patent term beyond 14 years from approval and only those claims covering the approved product, a method for using it or a method for manufacturing it may be extended. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, the period during which we can enforce our patent rights for the applicable product will be shortened and our competitors may obtain approval of competing products following our patent expiration. As a result, our ability to generate revenues could be adversely affected. Further, if this occurs, our competitors may take advantage of our investment in development and studies by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case. If we do not have adequate patent protection or other exclusivity for our products, our business, financial condition or results of operations could be adversely affected</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited foreign intellectual property rights and may not be able to protect our intellectual property and proprietary rights throughout the world, which could harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited intellectual property rights outside the United States. Filing, prosecuting and defending patents on our products in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as in the United States. While we do not currently operate or sell our products outside of the United States, these products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries, which may impede on our ability to grow outside of the United States.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition and results of operations may be harmed.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act, or the America Invents Act, enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we could continue incurring costs without being certain that we were the first to file any patent application related to our products or invent any of the inventions claimed in our patents or patent applications.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The America Invents Act also includes a number of significant changes that affect the way patent applications are prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Additionally, USPTO proceedings provide a venue for challenging the validity of patents at a cost must lower than district court litigation and on much faster timelines. This lower-cost, faster and potentially more potent tribunal for challenging patents could itself increase the likelihood that our own patents will be challenged. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. In addition, future actions by the U.S. Congress, the federal courts and the USPTO could cause the laws and regulations governing patents to change in unpredictable ways. Any of the foregoing could harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. We cannot predict how this and future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. Any similar adverse changes in the patent laws of other jurisdictions could also harm our business, financial condition, results of operations and prospects.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims, including third-party claims of intellectual property infringement, misappropriation or other violations against us or our collaborators, challenging the ownership or inventorship of our intellectual property and, if unsuccessful in any of these proceedings, we may be required to obtain licenses from third parties, which may not be available on commercially reasonable terms, or at all, or to cease the development, manufacture and commercialization of one or more of our products.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry is highly competitive and dynamic. Due to the focused research and development that is taking place by several companies, including us and our competitors, in this field, the intellectual property landscape is in flux, and it may remain uncertain in the future. As such, we may be subject to claims that current or former employees, collaborators or other third parties have an interest in our patents, trade secrets or other intellectual property as an inventor or co-inventor. Additionally, we could become subject to significant intellectual property-related litigation and proceedings relating to our or third-party intellectual property and proprietary rights. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our products, or could face third-party claims of intellectual property infringement, misappropriation or other violations, including by a licensor from whom we&#8217;ve licensed certain intellectual property.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation may be necessary to defend against these and other claims challenging inventorship of our patents, trade secrets or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our products. If we were to lose exclusive ownership of such intellectual property, other owners may be able to license their rights to other third parties, including our competitors. We also may be required to obtain and maintain licenses from third parties, including parties involved in any such disputes. Such licenses may not be available on commercially reasonable terms, or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture and commercialization of one or more of our products. The loss of exclusivity or the narrowing of our patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our commercial success depends in part on our and any potential future collaborators&#8217; ability to develop, manufacture, market and sell any products that we may develop and use our proprietary technologies without infringing, misappropriating or otherwise violating the patents and other intellectual property or proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us or any potential collaborators to alter our development or commercial strategies, obtain licenses or cease certain activities. The medical device industry is characterized by extensive litigation regarding patents and other intellectual property rights, as well as administrative proceedings for challenging patents, including interference, inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or post-grant review, derivation and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties, including our competitors, may currently have patents or obtain patents in the future and claim that the manufacture, use or sale of our products infringes upon these patents. We have not conducted an extensive search of patents issued or assigned to other parties, including our competitors, and no assurance can be given that patents containing claims covering our products, parts of our products, technology or methods do not exist, have not been filed or could not be filed or issued. In addition, because patent applications can take many years to issue and because publication schedules for pending patent applications vary by jurisdiction, there may be applications now pending of which we are unaware and which may result in issued patents which our current or future products infringe. Also, because the claims of published patent applications can change between publication and patent grant, there may be published patent applications that may ultimately issue with claims that we infringe. Unintentionally abandoned patents or applications can also be revived, so there may be recently revived patents or applications of which we are unaware. As the number of competitors in our market grows and the number of patents issued in this area increases, the possibility of patent infringement claims against us escalates. Moreover, we may face claims from non-practicing entities, or NPEs, which have no relevant product revenue and against whom our own patent </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">portfolio may have no deterrent effect. Third parties, including NPEs, may in the future claim, that our products infringe or violate their patents or other intellectual property rights.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that any third-party claims that we infringe their patents or that we are otherwise employing their proprietary technology without authorization and initiates litigation against us, even if we believe such claims are without merit, there is no assurance that a court would find in our favor on questions of infringement, validity, enforceability or priority. A court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed by our products, which could harm our ability to commercialize any product we may develop and any other technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If we are found to infringe third-party intellectual property rights, including patents, and we are unsuccessful in demonstrating that such patents or other intellectual property rights are invalid or unenforceable, such third parties may be able to block our ability to commercialize the applicable products or technology unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be held invalid or unenforceable. Such a license may not be available on commercially reasonable terms, or at all. Even if we are able to obtain a license, the license would likely obligate us to pay significant license fees and/or royalties, and the rights granted to us might be non-exclusive, which could result in our competitors gaining access to the same technology. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, we may be unable to commercialize our products, or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defense of infringement claims, regardless of their merit or outcome, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business, and may impact our reputation. In the event of a successful claim of infringement against us, we may be enjoined from further developing or commercializing the infringing products and/or have to pay substantial damages for use of the asserted intellectual property, including treble damages and attorneys&#8217; fees were we found to willfully infringe such intellectual property. Claims that we have misappropriated the confidential information or trade secrets of third parties could harm our business, financial condition and results of operations. We also might have to redesign our infringing products or technologies, which may be impossible or require substantial time and monetary expenditure.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Engaging in litigation, including to defend against third-party infringement claims is very expensive, particularly for a company of our size, and time-consuming. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial negative impact on our common stock price. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings against us could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time-consuming and unsuccessful.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents, or the patents of any current or future licensing partners, or we may be required to defend against claims of infringement. Our ability to enforce our patent rights against competitors who infringe our patents depends on our ability to detect such infringement. It may be difficult to detect infringers who do not advertise the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our patents or the patents of our licensing partners also may become involved in inventorship, priority or validity disputes. For example, although we try to ensure that our employees, consultants and advisors are not in breach of any past contractual obligations and do not use the proprietary information or know-how of others in the work that they do for us, we may in the future become subject to claims that we or these individuals have, inadvertently or otherwise, used or disclosed intellectual property, including trade secrets or other proprietary information, of their former university or employer. Additionally, we may be subject to claims from third parties challenging intellectual property rights we regard as our own, based on claims that our agreements with employees or consultants obligating them to assign intellectual property to us are ineffective or in conflict with prior or competing contractual obligations to assign inventions to a previous employer, or to another person or entity. Furthermore, while it is our policy to require all employees and contractors to execute agreements assigning relevant intellectual property to us, we may also be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. These assignment agreements may not be self-executing or adequate in scope, and may be breached or challenged, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. We may not have adequate remedies for any such breaches, and such claims could harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To counter or defend against such claims can be expensive and time-consuming and it may be necessary or we may desire to enter into a license to settle any such claims; however, there can be no assurance that we would be able to obtain a license on commercially reasonable terms, if at all. In an infringement proceeding, a court may decide that our patent is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover such technology. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our management and other personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial negative impact on our common stock price. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could harm our ability to compete in the marketplace, including ability to hire new employees or contract with independent sales representatives. Additionally, we may lose valuable intellectual property rights or personnel. Any of the foregoing could harm our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be harmed. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered and unregistered trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be violating or infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build or sustain name recognition among potential partners, customers and patients in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to continue to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement or dilution claims brought by owners of other trademarks. Over the long term, if we are unable to establish name recognition based on our trademarks, trade names, domain names or other intellectual property, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names or other intellectual property may be ineffective, could result in </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantial costs, diversion of resources, or adverse impact to our brand and could harm our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats, and limitations in intellectual property rights could harm our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, may evolve, and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make products that are similar to our products or utilize similar technology but that are not covered by the claims of our patents or that incorporate certain technology in our products that is in the public domain; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intellectual property strategy may be limited, we may not seek protection for intellectual property that may ultimately become relevant to our business or our invention disclosure process may prove insufficient to encourage inventors to come forward with protectable intellectual property; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or our current or future licensors or collaborators, might not have been the first to make the inventions covered by the applicable issued patent or pending patent application that we own now or may own or license in the future; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or our current or future licensors or collaborators, might not have been the first to file patent applications covering certain of our or their inventions; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or our current or future licensors or collaborators, may fail to meet our obligations to the U.S. government regarding any future patents and patent applications funded by U.S. government grants, leading to the loss or unenforceability of patent rights; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our current or future pending patent applications will not lead to issued patents; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that there are prior public disclosures that could invalidate our patents, or parts of our patents; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our products or technology similar to ours; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our patents or patent applications omit individuals that should be listed as inventors or include individuals that should not be listed as inventors, which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the claims of our patents or patent applications, if and when issued, may not cover our products or technologies; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the laws of foreign countries may not protect our proprietary rights or the rights of current or future licensors or collaborators to the same extent as the laws of the United States; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inventors of our patents or patent applications may become involved with competitors, develop products or processes that design around our patents, or become hostile to us or the patents or patent applications on which they are named as inventors; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have engaged in scientific collaborations in the past and will continue to do so in the future and our collaborators may develop adjacent or competing products that are outside the scope of our patents; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may harm our business; or </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing could harm our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our other proprietary information, our business and competitive position may be harmed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, know-how and other confidential or proprietary information that is not patentable or that we elect not to patent. However, such information can be difficult to protect, and some courts, for instance, are less willing or unwilling to protect trade secrets. To maintain the confidentiality of our trade secrets and proprietary information, we rely heavily on confidentiality provisions that we have in contracts with our employees, consultants, collaborators, suppliers, customers, and others upon the commencement of their relationship with us. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Furthermore, we may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by such third parties, despite the existence generally of these confidentiality restrictions. These contracts may not provide meaningful protection or equitable remedies for our trade secrets, know-how, or other proprietary information in the event of any unauthorized use, misappropriation, or disclosure of such trade secrets, know-how, or other proprietary information. There can be no assurance that such third parties will not breach their agreements with us, that we will have adequate remedies for any breach, or that our trade secrets will not otherwise become known or independently developed by competitors. Despite the protections we do place on our intellectual property or other proprietary rights, monitoring unauthorized use and disclosure of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property or other proprietary rights have or will be adequate. Trade secret violations are often a matter of state law, and the criteria for protection of trade secrets can vary among different jurisdictions. In addition, the laws of many foreign countries will not protect our intellectual property or other proprietary rights to the same extent as the laws of the United States. Consequently, we may be unable to prevent our proprietary technology from being exploited abroad, which could affect our ability to expand to foreign markets or require costly efforts to protect our products.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also license rights to use certain proprietary information and technology from third parties. The use of such proprietary information and technology is therefore subject to the obligations of the applicable license agreement between us and the owner. For example, the software we developed for our RNS System includes the use of open source software that is subject to the terms and conditions of the applicable open source software licenses that grant us permission to use such software. The owner of any such proprietary information or technology also might not enforce or otherwise protect its rights in the proprietary information or technology with the same vigilance that we would, which would allow competitors to use such proprietary information and technology without having to adhere to a license agreement with the owner.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent our intellectual property or other proprietary information protection is incomplete, we are exposed to a greater risk of direct competition. A third party could, without authorization, copy or otherwise obtain and use our products or technology, or develop similar products or technology. Our competitors could purchase our products and attempt to reverse engineer or replicate some or all of the competitive advantages we derive from our development efforts or design around our protected products or technology. Our failure to secure, protect and enforce our intellectual property rights could substantially harm the value of our products, brand and business. The </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">theft or unauthorized use or publication of our trade secrets and other confidential business information could reduce the differentiation of our products, substantially and adversely impact our sales and commercial operations and harm our business. Additionally, the value of our investment in development or business acquisitions could be reduced and third parties might make claims against us related to losses of their confidential or proprietary information. Any of the foregoing could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, it is possible that others will independently develop the same or similar technology or product or otherwise obtain access to our unpatented technology, and in such cases, we could not assert any trade secret rights against such parties. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our trade secret rights and related confidentiality and nondisclosure provisions. If we fail to obtain or maintain trade secret protection, or if our competitors otherwise obtain our trade secrets or independently develop technology or products similar to and potentially competing with our products, our competitive market position could be materially and adversely affected. In addition, some courts are less willing or unwilling to protect trade secrets and agreement terms that address non-competition are difficult to enforce in many jurisdictions and might not be enforceable in certain cases.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations, systems and tools, agreements or security measures may be breached, whereby detecting the disclosure or misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our inability to use software licensed from third parties, or our use of open source software under license terms that interfere with our proprietary rights, could disrupt our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products, including our RNS System, includes the use of open source software that is subject to the terms and conditions of the applicable open source software licenses that grant us permission to use such software. Although we monitor our use of open source software, the terms of many open source licenses to which we are subject have not been interpreted by U.S. or foreign courts, and there is a risk that such licenses could be construed in a manner that imposes unanticipated conditions or restrictions on our ability to provide our technology to our customers. Moreover, we cannot ensure that we have not incorporated additional open source software in our products in a manner that is inconsistent with the terms of the applicable license or our current policies and procedures. In the future, we could be required to seek licenses from third parties in order to continue offering our solutions, which licenses may not be available on terms that are acceptable to us, or at all. Claims related to our use of open source software could also result in litigation, require us to purchase costly licenses or require us to devote additional research and development resources to change the software underlying our technology, any of which would have a negative effect on our business, financial condition and operating results and may not be possible in a timely manner. We and our customers may also be subject to suits by parties claiming infringement due to the reliance by our products on certain open source software, and such litigation could be costly for us to defend or subject us to injunctions enjoining us from the sale of our products that contain open source software.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alternatively, we may need to re-engineer our products or discontinue using portions of the functionality provided by our products. In addition, the terms of open source software licenses may require us to provide software that we develop using such software to others on unfavorable terms, such as by precluding us from charging license fees, requiring us to disclose our source code, requiring us to license certain of our own source code under the terms of the applicable open source license or requiring us to provide notice on our products using such code. Any such restriction on the use of our own software, or our inability to use open source or third-party software, could result in disruptions to our business or operations, or delays in our development of future products or enhancements of our existing products, such as our RNS System, which could impair our business.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to financial matters</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of net losses, and we expect to continue to incur losses for the foreseeable future. If we do achieve profitability, we may not be able to sustain it. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred losses since our inception and expect to continue to incur losses for the foreseeable future. For the three months ended March&#160;31, 2023 and 2022, we reported net losses of $10.4&#160;million and $11.5&#160;million, respectively. As a result of these losses, as of March&#160;31, 2023, we had an accumulated deficit of approximately $481.2&#160;million. We expect to continue to incur significant business expenses as we continue to enhance our efforts to promote our brand, increase sales, improve therapy effectiveness, enhance the patient and provider experience, and expand the population of eligible patients. In addition, we expect our selling, general and administrative expenses to increase as we continue to operate as a public company. The net losses that we incur may fluctuate significantly from period to period. We will need to generate significant additional revenue and improve our gross margins in order to achieve and sustain profitability. It is possible that we will not achieve profitability or that, even if we do achieve profitability, we may not remain profitable for any substantial period of time. Our failure to achieve or maintain profitability could negatively impact the value of our common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expected future capital requirements may and do depend on many factors including expanding our customer base, the expansion of our sales force, our efforts to manage our expenses, and the timing and extent of spending on updating our product to enhance our offering or expand our reach. We may need additional funding to fund our operations but additional funds may not be available to us on acceptable terms on a timely basis, if at all. We may seek funds through borrowings or through additional rounds of financing, including private or public equity or debt offerings. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay any dividends, repurchase our common stock, make certain investments, and engage in certain merger, consolidation or asset sale transactions. Any future debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. Furthermore, we cannot be certain that additional funding will be available on acceptable terms, if at all. If we are unable to raise additional capital or generate sufficient cash from operations to adequately fund our operations, we will need to curtail planned activities to reduce costs, which will likely harm our ability to execute on our business plan and continue operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are party to an existing Term Loan Agreement, which contains restrictive covenants as well as financial maintenance covenants, and if we are unable to comply with these covenants then the lenders could declare an event of default wherein we may need to immediately repay the amounts due under the Term Loan Agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a Term Loan Agreement, or the Term Loan, pursuant to which the lender has made available to us an aggregate principal amount not to exceed $60.0 million, of which, as of March&#160;31, 2023, we have drawn $50.0 million and the remainder was available to be drawn only if we met certain financial thresholds, which we did not meet. The Term Loan contains customary affirmative and restrictive covenants, including with respect to our ability to enter into fundamental transactions, incur additional indebtedness, grant liens, pay any dividend or make any distributions to our holders, make investments, merge or consolidate with any other person or engage in transactions with our affiliates, as well as financial maintenance covenants, including minimum liquidity and annual revenue covenants. In February 2023, the Term Loan was amended to reduce the minimum annual revenue covenant and increase the annual interest rate from 12.5% to 13.5%, effective March 1, 2023. If we fail to comply with the covenants or payments specified in the Term Loan, the lenders could declare an event of default, which would give it the right to terminate its commitment to provide additional loans and declare all borrowings outstanding, together with accrued and unpaid interest and fees, to be immediately due and payable. In addition, borrowings under the Term Loan are secured by substantially all of our properties, rights and assets, including intellectual property.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">To support our continued operations and the growth of our business, we may need access to our existing capital or to seek additional capital through new equity or debt financings, which sources of existing or additional capital may not be available to us on acceptable terms or at all. If we are unable to obtain, if needed, adequate financing or financing on terms satisfactory to us, it could harm our business and growth prospects. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed substantial amounts of cash since inception and we intend to continue to make significant investments to support our continued business operations and growth, respond to business challenges or opportunities, enhance our products, expand the population of eligible patients, and potentially acquire complementary businesses and technologies. For the three months ended March&#160;31, 2023 and 2022, our net cash used in operating activities was $9.7&#160;million and $11.4&#160;million, respectively. As of March&#160;31, 2023, we had $67.6&#160;million of cash, cash equivalents and short-term investments and $9.9&#160;million in current liabilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash is invested in major financial institutions in the United States and cash equivalents are invested in money market funds. Deposits in these financial institutions may exceed federally insured limits, and the Company may be exposed to credit risk on deposits in the event of default of the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements may be significantly different from our current estimates and will depend on many factors, including our growth rate, the growth of sales and marketing teams and activities, our expense management initiatives, the expansion of the population of eligible patients, geographies we may choose to enter and commercialize in, updates to our products, potential introduction of new products, either developed internally or acquired, the continued oversight of regulatory agencies, and the continuing market acceptance of our products. Accordingly, we may need to engage in equity or debt financings or collaborative arrangements to secure additional funds. If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences and privileges superior to those of holders of our common stock. Any debt financing secured by us in the future could involve additional restrictive covenants relating to our capital-raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. In addition, during times of economic instability, it has been difficult for many companies to obtain financing in the public markets or to obtain debt financing, and we may not be able to obtain additional financing, if needed, on commercially reasonable terms, if at all. If we are unable to access our existing capital or obtain adequate financing or financing on terms satisfactory to us, if needed, it could harm our business and growth prospects.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, under Section 382 of the U.S. Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change net operating losses, or NOLs, to offset future taxable income. A Section 382 &#8220;ownership change&#8221; generally occurs if one or more stockholders or groups of stockholders who own at least 5% of our stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Similar rules may apply under state tax laws. As of December 31, 2022, we had $151.6 million of federal net operating loss carryforwards and $142.6 million of state net operating loss carryforwards. The federal and state NOL carryforwards began expiring in 2022 and 2028, for federal and state purposes, respectively. As of December 31, 2022, the amount of federal NOL carryforwards that does not expire is $99.1 million (subject to certain utilization limitations). We have conducted Section 382 studies and determined that we experienced ownership changes in 2016 and in 2021 which resulted in permanent limitation of our pre-change NOL and research and development credit carryforwards. In addition, future changes in our stock ownership, some of which are outside of our control, could result in an additional ownership change under Section 382 of the Code, further limiting our ability to utilize NOLs arising prior to such ownership change in the future. There is also a risk that due to statutory or regulatory changes, such as suspensions on the use of NOLs (including California legislation enacted in June 2020 that limited the ability to use California net operating losses to offset California income for tax years beginning after 2019 and before 2023), or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to offset future income tax liabilities. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we identify any material weaknesses or otherwise fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately or timely report our financial condition or results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that the actions we may take in the future will prevent or avoid potential future material weaknesses. If we identify any material weaknesses in our internal control over financial reporting and are unable to successfully remediate them , the accuracy and timing of our financial reporting may be negatively impacted, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial reporting, and our stock price may decline as a result.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our history of recurring losses and anticipated expenditures as well as the significant amount of debt that we have incurred may affect our ability to operate our business and secure additional financing in the future. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred operating losses to date and it is possible we may never generate a profit. Additionally, our obligations under the Term Loan Agreement are collateralized by substantially all of our assets, including our material intellectual property, and we are subject to customary financial and operating covenants limiting our ability to engage in various activities, which management may deem important for the business. The covenants related to the Term Loan Agreement, as well as any future financing agreements into which we may enter, may restrict our ability to finance our operations and engage in, expand or otherwise pursue our business activities and strategies. While we have not previously breached and are not currently in breach of these or any other covenants contained in our Term Loan Agreement, there can be no guarantee that we will not breach these covenants in the future. Our ability to comply with these covenants may be affected by events beyond our control, and future breaches of any of these covenants could result in a default under the loan agreement. If not waived, future defaults could cause all of the outstanding indebtedness under the term loan agreement to become immediately due and payable and terminate commitments to extend further credit. If we do not have or are unable to generate sufficient cash available to repay our debt obligations when they become due and payable, either upon maturity or in the event of a default, our assets could be foreclosed upon and we may not be able to obtain additional debt or equity financing on favorable terms, if at all, which may negatively impact our ability to operate and continue our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other risks facing our company</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The estimates of market opportunity and forecasts of market and revenue growth included in this Quarterly Report on Form 10-Q, including growth in the number of CECs, epileptologists and neurosurgeons, as well as our projections related to the DIXI Medical distribution agreement, may prove to be inaccurate, and even if the market in which we compete achieves the forecasted growth, our business could fail to grow at similar rates, if at all. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market opportunity estimates and growth forecasts are subject to significant uncertainty. Our estimates of the annual total addressable markets for our RNS System are based on a number of internal and third-party estimates and assumptions, including, without limitation, our assumptions relative to the number of adults with drug-resistant focal epilepsy in the United States who are treated at CECs each year; the number of neuromodulation procedures annually in the United States; the growth in number of CECs, epileptologists, and neurosurgeons; the growth in number of patients referred to CECs; and the potential growth of our market opportunity with the expansion of treatment to patients under age 18 and with drug-resistant generalized epilepsy patients. In addition, our projections related to becoming the exclusive U.S. distributor of DIXI Medical products are based on a number of estimates and assumptions, including, without limitation, information obtained from DIXI Medical related to historical performance and future projections. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, including as a result of the COVID-19 pandemic, thereby reducing the predictive accuracy of these underlying factors. As a result, our estimates of the annual total addressable market for our RNS System may prove to be incorrect. If the actual annual total addressable market for our RNS System is smaller than we have estimated, it may impair our sales growth and have an adverse impact on our business. Alternatively, if the actual annual total addressable market for our RNS System is bigger than we have estimated, we may not be ready to manage such growth, which may impair our sales and have an adverse impact on our business.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit or halt the marketing and sale of our products. The expense and potential unavailability of insurance coverage for liabilities resulting from our products could harm our business and our ability to sell our products, including our RNS System.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the marketing and sale of our products. Although we have established internal procedures designed to minimize risks that may arise from quality issues, there can be no assurance that we will eliminate or mitigate occurrences of these issues and associated liabilities. For example, we may be sued if our RNS System causes or is perceived to cause injury or is found to be otherwise unsuitable during manufacturing, marketing, sale, or distribution. Any such product liability claim may include, but not be limited to, allegations of defects in manufacturing, defects in design, defects in clinical study design or performance, a failure to warn of dangers inherent in the product, negligence, strict liability or a potential breach of implied or expressed warranties. In addition, we may be subject to claims against us even if the apparent injury is due to the actions of others or the pre-existing health of the patient. For example, we rely on healthcare providers to determine appropriate patients for our products and to properly and correctly implant and use our RNS System as part of a patient&#8217;s treatment protocol. If these healthcare providers are not properly trained, do not properly screen the patient, are negligent in implanting or using our RNS System or implant or use our RNS System &#8220;off-label,&#8221; the capabilities or reputation of our RNS System may be diminished or the patient may suffer critical injury. While we believe that we clearly describe the limitations of our label, we cannot prevent an epileptologist from referring a patient for an RNS System implant for off-label indications, prevent a neurosurgeon from implanting our RNS System for off-label applications, or having our RNS System programmed based on off-label considerations. In addition, we cannot guarantee that healthcare providers are adequately trained prior to incorporating our RNS System into their practice. Complications resulting from the use of our products, including use of our RNS System off-label or use by healthcare providers who have not been trained appropriately, or at all, may expose us to product liability claims and harm our reputation. We may also be subject to claims that are caused by the activities of our suppliers and vendors, such as those who provide us with components, materials, or services, which may have an impact on our products and result in product liability claims brought against us.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or halt commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our products; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our brand or reputation; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiation of investigations by regulators; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to defend the related litigation; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased insurance premiums; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a diversion of management&#8217;s time and our resources; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to trial participants or patients; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exhaustion of any available insurance and our capital resources; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to market and sell our products. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have adequate product liability insurance, but it may not prove to be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We currently carry product liability </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">insurance in the amount of $7.0 million in the aggregate. In the future, we may not be able to maintain or obtain insurance at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Our insurance policy contains various exclusions, and we may be subject to a product liability claim for which we have no coverage. The potential inability to obtain sufficient product liability insurance at an acceptable cost to protect against product liability claims could prevent or inhibit the marketing and sale of products we may develop. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts, which would harm our business, financial condition and results of operations. In addition, any product liability claims brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing continuing coverage, harm our patient-focused brand, negatively impact our reputation in the industry, significantly increase our expenses and reduce product sales. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our customers may also have difficulty in procuring or maintaining liability insurance to cover their operations, including their use of our products. Medical malpractice carriers are withdrawing coverage in certain states or substantially increasing premiums. If this trend continues or worsens, our customers may discontinue using our products and potential additional customers may opt against purchasing our products due to the cost or inability to procure insurance coverage. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The failure of third parties to meet their contractual, regulatory and other obligations could adversely affect our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on suppliers, vendors, partners, consultants, and other third parties to research, develop, and partake in both the manufacturing and commercialization of our products, as well as manage certain parts of our business. In addition, in August 2022 we entered into a distribution agreement with DIXI Medical pursuant to which we became the exclusive U.S. distributor of DIXI Medical&#8217;s product line, under which DIXI Medical provides us with ongoing commercial support and supplies us with DIXI Medical products, as ordered by us. Using these third parties poses a number of risks, such as: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">they may not perform to our standards or legal requirements; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">they may not produce reliable results; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">they may not perform in a timely manner; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">they may not maintain confidentiality of our proprietary information; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise with respect to ownership of rights to products developed with our partners; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements could cause delays in, or termination of, the research, development or commercialization of our products or result in litigation or arbitration. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, some third parties may be located in markets subject to political and social risk, corruption, infrastructure problems and natural disasters, in addition to country-specific privacy and data security risk given current legal and regulatory environments. Failure of third parties to meet their contractual, regulatory and other obligations may materially affect our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future legislation, potential changes in federal regulatory agency leadership, and new policies and priorities under the Biden Administration may adversely impact our company.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Congress devoted substantial attention in 2021 to healthcare matters, through greater oversight of the FDA. Although the prospects for the imminent enactment of major legislation are not certain at this time, the enactment of more targeted measures may be more likely due to the increased possibility of bipartisan support for consideration of such measures. In addition, the Biden administration could impose new or modified COVID-19 programs and restrictions, and may propose additional fiscal or tax measures, or additional regulatory requirements that would apply to us or our customers, thereby impacting our business, operations and profitability. Moreover, changes in the leadership and senior staffs of the FDA could impact the rulemaking, supervision, examination and enforcement </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">priorities and policies of the agency. The potential impact of changes in agency personnel, policies and priorities on the medical device sector, including us, cannot be predicted at this time.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Biden administration has indicated an increased focus on enforcement of federal consumer protection laws and appoint consumer-oriented regulators. It is possible that regulators in the administration could promulgate rulemakings and bring enforcement actions that materially impact our business and the business of our customers. These regulators may, for example, augment requirements that apply to the medical device approval process, impose additional clinical studies requirements, or change privacy rules that impact how we maintain, use, and share sensitive healthcare data, and could otherwise revise or create new regulatory requirements that apply to us.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to respond quickly or effectively to regulatory, legislative, and other developments, and these changes may in turn impair our ability to offer our current or planned products, or increase our cost of doing business. In addition, if our practices are not consistent or viewed as not consistent with legal and regulatory requirements, we may become subject to audits, inquiries, whistleblower complaints, adverse media coverage, investigations, or criminal or civil sanctions, all of which may have an adverse effect on our reputation, business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to ownership of our common stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we sell shares of our common stock in future financings, stockholders may experience immediate dilution and, as a result, our stock price may decline.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may, from time to time, issue additional shares of common stock at a discount from the current trading price of our common stock. As a result, our stockholders would experience immediate dilution upon the purchase of any shares of our common stock sold at such discount. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preferred stock or common stock. If we issue common stock or securities convertible into common stock, our common stockholders would experience additional dilution and, as a result, our stock price may decline.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will continue to have broad discretion in the use of proceeds from our initial public offering and may invest or spend the proceeds in ways with which investors do not agree and in ways that may not yield a return. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to have broad discretion over the use of proceeds from our initial public offering. Investors may not agree with our decisions, and our use of the proceeds may not yield any return on your investment. We currently are using or intend to use the net proceeds from our initial public offering to expand our sales and marketing efforts, increase our research and development activities, conduct or sponsor clinical studies, expand internationally, and provide for working capital and other general corporate purposes. We also used a portion of the net proceeds we received from our initial public offering to repay approximately $4.0&#160;million of principal indebtedness, plus accrued interest, under our Paycheck Protection Program loan. Our failure to apply the net proceeds of our initial public offering effectively could impair our ability to pursue our growth strategy or could require us to raise additional capital. In addition, pending their use, the proceeds of our initial public offering may have been or could be placed in investments which may not produce income or that may lose value. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could cause the market price of our common stock to decline. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that such sales may have on the prevailing market price of our common stock. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had a total of approximately 25,352,204 shares outstanding of common stock, of which 15,572,446 shares are held by directors, executive officers and other affiliates. These shares will be subject to volume limitations under Rule 144 under the Securities Act, and may also be subject to vesting requirements. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">re were approximatel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y 8,271,629 shares</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of common stock subject to outstanding stock options and restricted stock units (RSUs) or reserved for future i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ssuance under our equity incentive plans. All of the shares of common stock issuable upon exercise of outstanding stock options, vesting and settlement of RSUs, and exercise of settlement of any options or other equity incentives are registered for public resale under the Securities Act. Accordingly, these shares will be able to be freely sold in the public market upon issuance as permitted by any applicable vesting requirements, subject to the lock-up agreements and, for our affiliates, volume limitations described above. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain of our stockholders have registration rights that would require us to file registration statements for the public resale of the common stock issuable upon conversion of such shares or to include such shares in registration statements that we may file on our behalf or for other stockholders.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of ownership of our common stock among our executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the number of shares of common stock outstanding as of March&#160;31, 2023, our executive officers, directors and current beneficial owners of 5% or more of our common stock, in the aggregate, beneficially own, approximately 84.7% of our common stock. These stockholders, acting together, will be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors and any merger or other significant corporate transactions. The interests of this group of stockholders may not coincide with the interests of other stockholders and they may want us to pursue strategies that deviate from the interests of other stockholders. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an emerging growth company and a smaller reporting company, and our compliance with the reduced reporting and disclosure requirements applicable to emerging growth companies and smaller reporting companies could make our common stock less attractive to investors. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an emerging growth company, as defined in the JOBS Act, and we expect to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including the auditor attestation requirements of Section 404, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved and extended adoption period for accounting pronouncements. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to continue to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in this Quarterly Report on Form 10-Q and our periodic reports and proxy statements. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict whether investors will find our common stock less attractive as a result of our reliance on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will remain an emerging growth company until the earliest of (i) December 31, 2026, (ii) the first fiscal year after our annual gross revenues exceed $1.235 billion, (iii) the date on which we have, during the immediately preceding three-year period, issued more than $1.00 billion in non-convertible debt securities, or (iv) the end of any fiscal year in which the market value of our common stock held by non-affiliates exceeds $700 million as of the end of the second quarter of that fiscal year.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-takeover provisions in our charter and under Delaware law could make an acquisition of our company more difficult, limit attempts by our stockholders to replace or remove our current management and limit the market price of our common stock. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may have the effect of delaying or preventing a change of control or changes in our management without the consent of our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">board of directors. Our amended and restated certificate of incorporation and amended and restated bylaws include provisions that: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide for a classified board of directors whose members serve staggered terms; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize our board of directors to issue, without further action by the stockholders, shares of undesignated convertible preferred stock with terms, rights, and preferences determined by our board of directors that may be senior to our common stock; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">specify that special meetings of our stockholders can be called only by our board of directors, the chairperson of our board of directors, or our chief executive officer; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish an advance notice procedure for stockholder proposals to be brought before an annual meeting, including proposed nominations of persons for election to our board of directors; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit cumulative voting in the election of directors; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that our directors may be removed for cause only upon the vote of the holders of at least 66 2/3% of our outstanding shares of common stock; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the approval of our board of directors or the holders of at least 66 2/3% of our outstanding shares of common stock entitled to vote at an election of directors to adopt, to amend our bylaws and certain provisions of our certificate of incorporation. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which generally, subject to certain exceptions, prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any &#8220;interested&#8221; stockholder for a period of three years following the date on which the stockholder became an &#8220;interested&#8221; stockholder. Any delay or prevention of a change of control transaction or changes in our management could cause the market price of our common stock to decline. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware or, under certain circumstances, the federal district courts of the United States of America be the exclusive forums for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) is the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law for: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any derivative action or proceeding brought on our behalf; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a breach of fiduciary duty; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation, or our amended and restated bylaws; and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim against us that is governed by the internal-affairs doctrine. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions do not apply to suits brought to enforce a duty or liability created by the Exchange Act or any claim for which the federal district courts of the United States of America have exclusive jurisdiction. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stockholders cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of, and consented to, the provisions of our amended and restated certificate of incorporation, including those described in the preceding sentences. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provide that the federal district courts of the United States be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid and several state trial courts have enforced such provisions and required that suits asserting Securities Act claims be filed in federal court, there is no guarantee that courts of appeal will affirm the enforceability of such provisions and a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions. If a court were to find either exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with litigating Securities Act claims in state court, or both state and federal court, which could harm our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could harm our business and financial condition. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General risk factors</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable U.S. and global economic conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the U.S. economy and financial markets and adverse geopolitical and macroeconomic developments. U.S. and global market and economic conditions have been, and continue to be, disrupted and volatile due to many factors, including component shortages and related supply chain challenges, geopolitical developments such as the ongoing COVID-19 pandemic and the conflict between Ukraine and Russia and related sanctions, and increasing inflation rates and the responses by central banking authorities to control such inflation, among others. General business and economic conditions that could affect our business, financial condition or results of operations include fluctuations in economic growth, debt and equity capital markets, liquidity of the global financial markets, the availability and cost of credit, investor and consumer confidence, and the strength of the economies in which we, our manufacturers and our suppliers operate. A severe or prolonged global economic downturn could result in a variety of risks to our business. For example, inflation rates, particularly in the United States, have increased recently to levels not seen in years, and increased inflation may result in increases in our operating costs (including our labor costs), reduced liquidity and limits on our ability to access credit or otherwise raise capital on acceptable terms, if at all. In addition, the U.S. Federal Reserve has raised, and may again raise, interest rates in response to concerns about inflation, which, coupled with reduced government spending and volatility in financial markets may have the effect of further increasing economic </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uncertainty and heightening these risks. Risks of a prolonged global economic downturn are particularly true in Europe, which is undergoing a continued severe economic crisis. A weak or declining economy could also strain our suppliers and manufacturers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, financial markets around the world experienced volatility following the recent invasion of Ukraine by Russia. Our operations could be disrupted by tariffs, international conflict or war. For example, in late February 2022, Russia initiated significant military action against Ukraine. In response, the United States and certain other countries imposed significant sanctions and trade actions against Russia, and the United States and certain other countries could impose further sanctions, trade restrictions and other retaliatory actions should the conflict continue or worsen. It is not possible to predict the broader consequences of the conflict, including related geopolitical tensions, and the measures and retaliatory actions that may be taken by the United States and other countries in respect thereof, as well as any counter measures or retaliatory actions by Russia in response. Such conflict may cause regional instability, geopolitical shifts and could materially adversely affect global trade, currency exchange rates, regional economies and the global economy. In particular, while it is difficult to anticipate the impact of any of the foregoing on us, the conflict and actions taken in response to the conflict could increase our costs, disrupt our supply chain, reduce our sales and earnings, impair our ability to raise additional capital when needed on acceptable terms, if at all, or otherwise adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics or pandemics, and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. Our ability to obtain components for our products could be disrupted if the operations of our suppliers were affected by a man-made or natural disaster or other business interruption. In addition, our corporate headquarters and manufacturing facility is located in Mountain View, California, near major earthquake faults and fire zones. Should our facilities be significantly damaged or destroyed, it could take months to relocate or rebuild, during which time our manufacturing would cease or be delayed and our RNS System may be unavailable. Moreover, the use of a new facility or new manufacturing, quality control, or environmental control equipment or systems generally requires FDA review and approval of a PMA supplement. Because of the time required to authorize manufacturing in a new facility under FDA regulatory requirements, we may not be able to resume production on a timely basis even if we are able to replace production capacity. While we maintain property and business interruption insurance, such insurance has limits and would only cover the cost of rebuilding and relocating and, to some extent, lost revenue, but not general damage or losses caused by earthquakes or losses we may suffer due to our products being replaced by competitors&#8217; products. The inability to perform our manufacturing activities, combined with our limited inventory of materials and components and manufactured products, may cause physicians to discontinue using our products or harm our reputation, and we may be unable to reestablish relationships with such physicians in the future. Consequently, a catastrophic event at our facility could harm our business, financial condition, and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation and other legal proceedings may harm our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in, and from time to time in the future we may become involved in, legal proceedings relating to patent and other intellectual property matters, product liability claims, employee matters, tort or contract claims, federal regulatory investigations, private rights of action, securities matters and class actions as well as other legal proceedings or investigations, which could have a negative impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation is inherently unpredictable and can result in excessive or unanticipated verdicts, judgements, and/or injunctive relief that affect how we operate our business. We could incur judgments or enter into settlements of claims for monetary damages or for agreements to change the way we operate our business, or both. We may fail to enter into settlements or to obtain rulings for matters we believe we have resolved. There may be an increase in the scope of these or other matters or there may be additional lawsuits, claims, proceedings or investigations in the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future, which could harm our business, financial condition and results of operations. Adverse publicity about regulatory or legal action against us, irrespective of outcome, could damage our reputation and brand image, undermine our customers&#8217; confidence and reduce long-term demand for our products, even if the regulatory or legal action is unfounded or not material to our operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price has been volatile, an active or liquid market in our common stock may not be sustainable and the value of our common stock may decline. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our stock price has been volatile. During the year ended December 31, 2022, our stock traded as high as $11.57 per share and as low as $1.29 per share. An active or liquid market in our common stock may not be sustainable and the market price of our common stock may continue to be highly volatile and may fluctuate or decline substantially as a result of a variety of factors, some of which are beyond our control or are related in complex ways, including: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated fluctuations in our financial condition and results of operations; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variance in our financial performance from expectations of securities analysts or investors; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the coverage decisions, reimbursement or pricing of our products; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our projected operating and financial results; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws or regulations applicable to our products; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant business developments, acquisitions, or new offerings; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publicity associated with issues related to our products; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our involvement in regulatory investigations or litigation; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future sales of our common stock or other securities, by us or our stockholders, as well as the anticipation of lock-up releases; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in senior management or key personnel; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the trading volume of our common stock; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the anticipated future size and growth rate of our market; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, regulatory, and market conditions, including economic recessions or slowdowns; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning our intellectual property or other proprietary rights. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Broad market and industry fluctuations, as well as general economic, political, regulatory, and market conditions, may negatively impact the market price of our common stock. In addition, given the relatively small public float of shares of our common stock on the Nasdaq Global Market, the trading market for our shares may be subject to increased volatility. In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us, because medical device companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our reputation and our business. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not continue to publish research or publish unfavorable or inaccurate research about our business, our common stock price and trading volume could decline. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price and trading volume will be heavily influenced by the way analysts and investors interpret our financial information and other disclosures. If securities or industry analysts do not continue to publish research or reports about our business, delay publishing reports about our business or publish negative or unfavorable reports about our business, regardless of accuracy, our common stock price and trading volume could decline. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock depends, in part, on the research and reports that securities or industry analysts publish about us or our business. We expect that only a limited number of analysts will cover our company and we do not have any control over these analysts.  If the number of analysts that cover us declines, demand for our common stock could decrease and our common stock price and trading volume may decline. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our common stock is actively covered by analysts, we do not have any control over the analysts or the measures that analysts or investors may rely upon to forecast our future results. Over-reliance by analysts or investors on any particular metric to forecast our future results may result in forecasts that differ significantly from our own. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of accuracy, unfavorable interpretations of our financial information and other public disclosures could have a negative impact on our stock price. If our financial performance fails to meet analyst estimates, for any of the reasons discussed above or otherwise, or one or more of the analysts who cover us downgrade our common&#160;stock or change their opinion of our common stock, our reputation may be adversely impacted and our stock price would likely decline. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are obligated to develop and maintain proper and effective internal control over financial reporting and any failure to maintain the adequacy of these internal controls may negatively impact investor confidence in our company and, as a result, the value of our common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required pursuant to Section 404 of the Sarbanes-Oxley Act to include in our annual reports, the first of which being for the year ending December 31, 2022, a report by management on, among other things, the effectiveness of our internal control over financial reporting. This assessment needs to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. In addition, our independent registered public accounting firm is required to attest to the effectiveness of our internal control over financial reporting in our first annual report required to be filed with the Securities and Exchange Commission, or the SEC, following the date we are no longer an emerging growth company. We have not yet commenced the costly and challenging process of compiling the system and process documentation necessary to perform the evaluation required under Section 404. We currently do not have an internal audit group, and we will need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge and compile the system and process documentation necessary to perform the evaluation needed to comply with Section 404. Any failure to maintain effective internal control over financial reporting could severely inhibit our ability to accurately report our financial condition or results of operations. If we are unable to conclude that our internal control over financial reporting is effective, or if we identify additional material weaknesses in our internal control over financial reporting, our reputation could be negatively impacted, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, we could be subject to sanctions or investigations by the Nasdaq Global Market, the SEC or other regulatory authorities and our access to the capital markets could be restricted in the future.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results may fluctuate across periods, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly and annual operating results may fluctuate across periods, which makes it difficult for us to predict our future operating results. Accordingly, the results of any one quarter or period should not be relied upon </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as an indication of future performance. Our quarterly and annual operating results may fluctuate due to a variety of factors, many of which are outside of our control, including, but not limited to:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of demand for our products and any future products, which may vary significantly from period to period;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenditures that we may incur to acquire, develop or commercialize additional products and technologies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and cost of obtaining regulatory approvals or clearances to expand our indications and get future approvals of any future products or features;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing pressures;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to expand the geographic reach of our commercial efforts;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree of competition in our industry and any change in the competitive landscape of our industry, including consolidation among our competitors or future partners;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">coverage and reimbursement policies with respect to our products, and potential future products that compete with our products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and success or failure of preclinical or clinical studies for expanding the indications of our RNS System or any future products we develop or competing products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">positive or negative coverage in the media or clinical publications of our products or products of our competitors or our industry;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of customer orders or scheduling of implants using our products and the number of available selling days in any quarterly period, which can be impacted by holidays, vacations, the mix of products sold and the geographic mix of where products are sold, including any related foreign currency impact; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of COVID-19 on procedure volume or otherwise; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and cost of, and level of investment in, research, development, licenses, regulatory approval, commercialization activities, acquisitions and other strategic transactions, or other significant events relating to our products, which may change from time to time;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our products, which may vary depending on the quantity of production and the terms of our agreements with third-party suppliers; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future accounting pronouncements or changes in our accounting policies.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative effects of these factors could result in fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Further, our historical results are not necessarily indicative of results expected for any future period, and quarterly results are not necessarily indicative of the results to be expected for the full year or any other period. Investors should not rely on our past results as an indication of our future performance. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, it could harm our business, financial condition, and results or operations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will continue to incur increased costs as a result of operating as a public company, and our management and board of directors will be required to devote substantial time to compliance with our public company responsibilities and corporate governance practices. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we have and will continue to incur significant legal, accounting, and other expenses. We expect such expenses to further increase after we are no longer an emerging growth company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Market, and other applicable securities rules and regulations impose various requirements on public companies. Furthermore, most senior members of our management team as well as our board of directors do not have significant experience with operating a public company. As a result, our management, board of directors, and other personnel will have to devote a substantial amount of time to compliance with these requirements. Moreover, these rules and regulations will drive high legal and financial compliance costs and will make some activities more time-consuming and costly. We cannot predict or estimate the amount of these additional costs or the timing of such costs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become subject to numerous laws and regulations related to anti-bribery and anti-corruption laws, such as the FCPA and the U.K. Bribery Act, in which violations of these laws could result in substantial penalties and prosecution. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not market and sell our products outside the United States. However, if we choose to conduct business outside the United States, our business will be subject to various heavily-enforced anti-bribery and anti-corruption laws, such as the FCPA and similar laws around the world. These laws generally prohibit U.S. companies and their employees and intermediaries from offering, promising, authorizing or making improper payments to foreign government officials for the purpose of obtaining or retaining business or gaining any advantage. We face significant risks if we, which includes our third-party business partners and intermediaries, fail to comply with the FCPA or other anti-corruption and anti-bribery laws. In many foreign countries, particularly in countries with developing economies, it may be a local custom that businesses engage in practices that are prohibited by the FCPA or other applicable laws and regulations. To that end, we may have to incur substantial costs to enhance our controls if we begin doing business outside the United States, and even so, such compliance measures ultimately may not be effective in prohibiting our employees, contractors, business partners, intermediaries or agents from violating or circumventing our policies and/or the law. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Responding to any enforcement action or related investigation may result in a significant diversion of management&#8217;s attention and resources and significant defense costs and other professional fees. Any violation of the FCPA or other applicable anti-bribery, anti-corruption or anti-money laundering laws to which we become subject could result in whistleblower complaints, adverse media coverage, investigations, loss of export privileges, severe criminal or civil sanctions and, in the case of the FCPA, suspension or debarment from U.S. government contracts, which could harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may partner with or acquire other businesses, which could require significant management attention, disrupt our business, dilute stockholder value and harm our results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we may in the future partner with, make acquisitions of or investments in complementary companies, products or technologies that we believe fit within our business model and can address the needs of our customers and the patients they serve. In the future, we may not be able to acquire and integrate other companies, products or technologies in a successful manner. We may not be able to find suitable partners or acquisition candidates, and we may not be able to complete such partnership or acquisitions in an appropriate timeframe and on favorable terms, if at all. In addition, the pursuit of potential acquisitions may divert the attention of management and cause us to incur additional expenses in identifying, investigating and pursuing suitable partnerships or acquisitions, whether or not they are consummated. If we do complete partnerships or acquisitions, we may not ultimately strengthen our competitive position or achieve our goals, including increases in revenue, and any acquisitions we complete could be viewed negatively by management, as well as our employees, customers, investors and industry analysts. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future partnerships or acquisitions may reduce our cash available for operations and other uses and could result in amortization expense related to identifiable assets acquired. We may have to pay cash, incur debt or issue equity securities to pay into or for any such partnerships or acquisition, each of which could adversely affect our financial condition or the value of our common stock. The sale or issuance of equity to finance any such partnerships or acquisitions would result in dilution to our stockholders. The incurrence of indebtedness to finance any such partnerships or acquisition would result in fixed obligations and could also include covenants or other restrictions that could impede our ability to manage our operations. In addition, our future results of operations may be harmed by the dilutive effect of an acquisition, performance earn-outs or contingent bonuses associated with an acquisition. Furthermore, partnerships or acquisitions may require large, one-time charges and can result in increased debt or contingent liabilities, a negative impact to our gross margins, adverse tax consequences, additional stock-based compensation expenses and the recording and subsequent amortization of amounts related to certain purchased intangible assets, any of which items could negatively affect our future results of operations. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i2a59f7ea1762416695eae3249a8f9ede_121"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Proceeds</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we closed our initial public offering of 6,900,000 shares of our common stock, including shares issued upon the exercise in full of the underwriters&#8217; option to purchase 900,000 additional shares of common stock, at a public offering price of $17.00 per share. We received gross proceeds of $117.3 million. All of the shares issued and sold in our initial public offering were registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-254663), which was declared effective by the SEC on April 21, 2021. J.P. Morgan Securities LLC and Morgan Stanley &amp; Co. LLC acted as joint lead book-running managers for the offering. Wells Fargo Securities, LLC and SVB Leerink LLC also acted as book-running managers for the offering. Shares of our common stock began trading on the Nasdaq Global Market on April 22, 2021 and, following the sale of all the shares upon the closing of the initial public offering on April 26, 2021, the offer terminated.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds to us after deducting underwriting discounts and commissions of $8.2 million and net offering expenses of approximately $3.6&#160;million were $105.5&#160;million. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates. There has been no material change in the planned use of proceeds from our initial public offering from those disclosed in the final prospectus for our initial public offering dated as of April 21, 2021 and filed with the SEC pursuant to Rule 424(b)(4) on April 23, 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i2a59f7ea1762416695eae3249a8f9ede_124"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i2a59f7ea1762416695eae3249a8f9ede_127"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i2a59f7ea1762416695eae3249a8f9ede_130"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="i2a59f7ea1762416695eae3249a8f9ede_133"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporation by Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description of Exhibit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1528287/000162828021007595/exhibit31-closing8xk.htm">Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-40377</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">April 26, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001528287/000162828021006852/exhibit34-sx1a1.htm">Amended and Restated Bylaws of the Registrant, as currently in effect</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">S-1/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">333-254663</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 14, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1528287/000162828021006852/exhibit41-sx1a1.htm">Form of common stock certificate of the Registrant.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">S-1/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">333-254663</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 14, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="npce-exhibit101q1202310xq.htm">Second Amendment to Term Loan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="npce-exhibit101q1202310xq.htm"> Agreement, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="npce-exhibit101q1202310xq.htm">February 28, 2023,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="npce-exhibit101q1202310xq.htm"> by </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="npce-exhibit101q1202310xq.htm">among the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="npce-exhibit101q1202310xq.htm">Company, the Subsidiary Guarantors from time to time party thereto,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="npce-exhibit101q1202310xq.htm"> the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="npce-exhibit101q1202310xq.htm">Lenders from time to time party</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="npce-exhibit101q1202310xq.htm"> thereto</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="npce-exhibit101q1202310xq.htm"> and CRG</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="npce-exhibit102q1202310xq.htm">Amendment 1 to Supply Agreement, dated November 16, 2022, by and between the Company and Micro Systems Technologies, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311-certificationsq.htm">Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312certificationsq1.htm">Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321certificationsq1.htm">Certification of Principal Executive Officer and Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBLR Instance Document - the instance document does not appear in the Interactive Data File because its XBLR tags are embedded within the Inline XBLR document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibits 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;The certification furnished in Exhibit 32.1 hereto is deemed to accompany this Quarterly Report on Form 10-Q and is not deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in such filing.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="i2a59f7ea1762416695eae3249a8f9ede_136"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Mountain View, State of California, on May 4, 2023. </span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.044%"><tr><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEUROPACE, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Michael Favet</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Favet</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Rebecca Kuhn</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebecca Kuhn</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Vice President, Finance and Administration (Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>npce-exhibit101q1202310xq.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i9c570eb6cce0415e9e97c6c154e770ef_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SECOND AMENDMENT TO TERM LOAN AGREEMENT</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THIS SECOND AMENDMENT TO TERM LOAN AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), dated as of February &#91;28&#93;, 2023, is entered into among NEUROPACE, INC., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the Lenders party hereto and CRG SERVICING LLC, as administrative agent and collateral agent (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  All capitalized terms used herein and not otherwise defined herein shall have the meanings given to such terms in the Term Loan Agreement (as defined below).</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">RECITALS</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, Borrower, the Subsidiary Guarantors from time to time party thereto, the Lenders from time to time party thereto and the Agent have entered into that certain Term Loan Agreement, dated as of September 24, 2020 (as amended, restated, supplemented or modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Term Loan Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Borrower has requested that the Lenders amend the Term Loan Agreement to provide for certain modifications thereto&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Lenders are willing to amend the Term Loan Agreement subject to the terms and conditions hereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Amendments to Term Loan Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Section 1.01 of the Term Loan Agreement is hereby amended by adding the following defined term in the appropriate alphabetical order&#58; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">DIXI Distribution Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means that certain Exclusive Distribution Agreement, effective as of August 9, 2022, by and between the Borrower and DIXI Medical USA Corp, a Delaware corporation.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Section 3.02(a) of the Term Loan Agreement is hereby amended by replacing the text &#8220;at a rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">per annum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> equal to twelve and one half of one percent (12.50%)&#8221; with the text &#8220;at a rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">per annum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> equal to thirteen and one half of one percent (13.50%)&#8221;.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Section 3.02(d) of the Term Loan Agreement is hereby amended by replacing the text &#8220;(ii) thereafter (A) seven and one half of one percent (7.50%) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">per annum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> interest in cash and (B) five percent (5.00%) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">per annum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> interest as a PIK Loan&#8221; with the text &#8220;(ii) thereafter (A) eight and one half of one percent (8.50%) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">per annum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> interest in cash and (B) five percent (5.00%) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">per annum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> interest as a PIK Loan&#8221;.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Section 10.02 of the Term Loan Agreement is hereby amended by replacing the text &#8220;annual consolidated Revenue from sales and usage of the Product&#8221; with the text &#8220;annual Revenue in the aggregate (x) from sales and usage of the Product and (y) under the DIXI Distribution Agreement&#8221;.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Section 10.02(c) of the Term Loan Agreement is hereby amended by replacing the text &#8220;$60,000,000&#8221; with the text &#8220;$45,000,000&#8221;.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Conditions Precedent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The effectiveness of this Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall be subject to the satisfaction of each of the following conditions precedent&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;receipt by the Agent of counterparts of this Agreement duly executed by the Obligors, the Majority Lenders and the Agent&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NEUROPACE, INC.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SECOND AMENDMENT TO TERM LOAN AGREEMENT</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;the representations and warranties in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 5(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall be true and correct on the date hereof.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Obligors agree to reimburse the Agent for all reasonable fees, charges and disbursements of the Agent in connection with the preparation, execution and delivery of this Agreement, including the reasonable fees, charges and disbursements of Moore &#38; Van Allen PLLC.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Reaffirmation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each of the Obligors acknowledges and reaffirms (a) that it is bound by all of the terms of the Loan Documents to which it is a party and (b) that it is responsible for the observance and full performance of all Obligations, including without limitation, the repayment of the Loans.  Furthermore, the Obligors acknowledge and confirm (i) that the Agent and the Lenders have performed fully all of their obligations under the Term Loan Agreement and the other Loan Documents arising on or before the date hereof other than their respective obligations specifically set forth in this Agreement and (ii) that by entering into this Agreement, the Agent and the Lenders do not, except as expressly set forth herein, waive or release any term or condition of the Term Loan Agreement or any of the other Loan Documents or any of their rights or remedies under such Loan Documents or any applicable law or any of the Obligations of the Obligors thereunder.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Term Loan Agreement and the Obligations of the Obligors thereunder and under the other Loan Documents, are hereby ratified and confirmed and shall remain in full force and effect according to their terms, as amended by this Agreement.  This Agreement is a Loan Document.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Each Guarantor (i) acknowledges and consents to all of the terms and conditions of this Agreement, (ii) affirms all of its Obligations under the Loan Documents and (iii) agrees that this Agreement and all documents executed in connection herewith do not operate to reduce or discharge its Obligations under the Term Loan Agreement or the other Loan Documents.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;The Obligors represent and warrant to the Agent and the Lenders that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;each Obligor has taken all necessary corporate, limited liability company or other organizational action to authorize the execution, delivery and performance of this Agreement&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;this Agreement has been duly executed and delivered by each Obligor and constitutes a legal, valid and binding obligation of each Obligor, enforceable against each such Obligor in accordance with its terms, subject to bankruptcy, insolvency and similar laws affecting enforceability of creditors&#8217; rights generally and to general principles of equity&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;no approval, consent, exemption, authorization or other action by, or notice to, or filing with, any Governmental Authority or any other Person is necessary or required in connection with the execution, delivery or performance by, or enforcement against, any Obligor of this Agreement other than (A) those that have already been obtained and are in full force and effect and (B) those that may be required under any applicable notices under securities laws&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;(A) the representations and warranties of each Obligor contained in Section 7 of the Term Loan Agreement or in any other Loan Document, or which are contained in any document furnished at any time under or in connection therewith, are true and correct in all material respects (and in all respects if any such representation and warranty is already qualified by materiality or reference to Material Adverse Change or Material Adverse Effect) on and as of the date hereof, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they are true and correct in all material respects (and in all respects if any such representation and warranty is already qualified by materiality or reference to Material Adverse Change or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Material Adverse Effect) as of such earlier date and (B) no event has occurred and is continuing which constitutes a Default or an Event of Default.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(d)&#160;&#160;&#160;&#160;Each of the Obligors hereby affirms the Liens created and granted in the Loan Documents in favor of the Agent, for the benefit of the Secured Parties, and agrees that this Agreement does not adversely affect or impair such Liens and security interests in any manner.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract.  Delivery of an executed counterpart of a signature page of this Agreement by facsimile or other electronic imaging means (e.g. &#8220;pdf&#8221; or &#8220;tif&#8221;) shall be effective as delivery of a manually executed counterpart of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;If any provision of this Agreement is held to be illegal, invalid or unenforceable, (i) the legality, validity and enforceability of the remaining provisions of this Agreement shall not be affected or impaired thereby and (ii) the parties shall endeavor in good faith negotiations to replace the illegal, invalid or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the illegal, invalid or unenforceable provisions.  The invalidity of a provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">THIS AGREEMENT AND ANY CLAIM, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY, SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;SIGNATURE PAGES FOLLOW&#93;IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the parties hereto have caused this Agreement to be duly executed as of the date first above written.</font></div><div style="padding-left:180pt;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BORROWER&#58;&#160;&#160;&#160;&#160;NEUROPACE, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Rebecca Kuhn</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:146.75pt;padding-right:2.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Rebecca Kuhn&#160;&#160;&#160;&#160; </font></div></td></tr></table></div><div style="margin-bottom:12pt;padding-left:216pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Chief Financial Officer and Vice President, Finance and Administration</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   </font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;   </font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AGENT&#58; &#160;&#160;&#160;&#160;CRG SERVICING LLC</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt;text-indent:-180pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Nathan Hukill</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Nathan Hukill</font></div><div style="margin-bottom:24pt;padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Title&#58;&#160;&#160;&#160;&#160;Authorized Signatory</font></div><div style="padding-left:180pt;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">LENDERS&#58;&#160;&#160;&#160;&#160;CRG PARTNERS IV L.P.</font></div><div style="padding-left:198pt;text-indent:-198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58; CRG PARTNERS IV GP L.P., its general partner</font></div><div style="padding-left:144pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; CRG PARTNERS IV GP LLC, its general partner</font></div><div style="padding-left:144pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Nathan Hukill</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58;&#160;&#160;&#160;&#160;Nathan Hukill</font></div><div style="margin-bottom:24pt;padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58;&#160;&#160;&#160;&#160;Authorized Signatory</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CRG PARTNERS IV &#8211; PARALLEL FUND &#8220;C&#8221; (CAYMAN) L.P.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;By&#58; CR GROUP L.P., its investment advisor</font></div><div style="margin-bottom:12pt;padding-left:198pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Nathan Hukill</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58;&#160;&#160;&#160;&#160;Nathan Hukill</font></div><div style="margin-bottom:24pt;padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58;&#160;&#160;&#160;&#160;Authorized Signatory</font></div><div style="padding-left:180pt;text-indent:-180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CRG PARTNERS IV &#8211; CAYMAN LEVERED L.P.</font></div><div style="padding-left:198pt;text-indent:-198pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58; CRG PARTNERS IV (CAYMAN) GP L.P., its general partner</font></div><div style="padding-left:144pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; CRG PARTNERS IV GP LLC, its general partner</font></div><div style="padding-left:144pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Nathan Hukill</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58;&#160;&#160;&#160;&#160;Nathan Hukill</font></div><div style="margin-bottom:24pt;padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58;&#160;&#160;&#160;&#160;Authorized Signatory</font></div><div style="margin-bottom:24pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>npce-exhibit102q1202310xq.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i89a63ee97b9d415a99fbd789c5499fec_1"></div><div style="min-height:21.6pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:173.9pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDMENT</font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1</font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TO</font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SUPPLY</font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AGREEMENT</font></div><div><font><br></font></div><div style="margin-top:10.85pt;padding-left:61pt;padding-right:10.95pt;text-indent:-0.05pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NeuroPace, Inc. a Delaware corporation located at 455 N. Bernardo Avenue, Mountain View, CA 940443 (&#8220;COMPANY&#8221;) and </font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12.5pt;font-weight:400;line-height:100%">Micro Systems Technologies, Inc., </font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">located at </font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12.5pt;font-weight:400;line-height:100%">6024 SW Jean Road, Lake Oswego, OR, USA </font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(&#8220;MST&#8221;) are parties to a Supply Agreement (&#8220;Supply Agreement&#8221;) dated November 16, 2022. COMPANY and MST may be individually referred to herein as &#8220;Party&#8221; and collectively as &#8220;Parties.&#8221;</font></div><div><font><br></font></div><div style="padding-left:61pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Whereas, the Parties now wish to amend the Supply Agreement as set forth herein.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61pt;text-indent:-0.05pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Now, therefore, MST and COMPANY, recognizing the receipt and sufficiency of the consideration herein, hereby agree as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97pt;padding-right:4.9pt;text-indent:-18pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Exhibit A2 of the Supply Agreement shall be replaced and completely superseded by Exhibit A2 attached hereto.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:97pt;text-indent:-18.05pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;The Effective Date of this Amendment shall be November 16, 2022.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:97pt;padding-right:12.95pt;text-indent:-18pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;All other terms of the Supply Agreement remain unchanged except and unless otherwise set forth herein.</font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:57.95pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:133%">The Parties have entered into this Supply Agreement effective as of the Effective Date. </font></div><div style="margin-top:4.55pt;padding-left:57.95pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Micro Systems Engineering, Inc.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;           NeuroPace, Inc.</font></div><div style="margin-top:0.05pt;padding-left:57.95pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:57.95pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:115%;text-decoration:underline">By&#58; </font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">&#47;s&#47; Juergen Lindner</font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:115%;text-decoration:underline">By&#58; </font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">&#47;s&#47; Rebecca Kuhn</font></div><div style="padding-left:57.95pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:117%">Juergen Lindner&#160;&#160;&#160;&#160;</font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">Rebecca Kuhn</font></div><div style="padding-left:285.65pt;padding-right:80.8pt;text-indent:-227.7pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">General Manager&#160;&#160;&#160;&#160;Chief Financial Officer &#38; Vice President Finance &#38; Administration</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="height:94.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:21.6pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.55pt;padding-left:231.07pt;padding-right:231.07pt;text-align:center"><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT A2</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:60.45pt;padding-right:10.95pt;text-indent:0.4pt"><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">This </font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">Exh</font><font style="color:#363d56;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">ib</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">i</font><font style="color:#363d56;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">t </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">A2 s</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">h</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">all a</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">ppl</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">y </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">to the purchase </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">of </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">Product designated in this Exhibit by NeuroPace</font><font style="color:#726b77;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">, </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">Inc.</font><font style="color:#726b77;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">, </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">a Delaware corporation located </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">at </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">455 N. Bernardo Avenue, Mountain </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">V</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">i</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">ew</font><font style="color:#726b77;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">, </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">Ca</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">liforni</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">a</font><font style="color:#726b77;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">, </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">94043 </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">USA </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">(''Ne</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">uroP</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">ace</font><font style="color:#726b77;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">,</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">&#34; </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">referred to as </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">&#34;COM</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">P</font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">ANY&#34; </font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">in </font><font style="color:#363d56;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">t</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">h</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">e S</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">uppl</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">y Ag</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">r</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">eement </font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">and </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">&#34;C</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">u</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">stomer&#34; </font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">in </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">the </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">Supp</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">lier </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">Quality Agreement) </font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">fr</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">o</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">m </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">the following </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">MST Com</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">pan</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">y&#58; </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">Micro </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">Systems </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">Engineering, Inc. </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">(MSEI)</font><font style="color:#726b77;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">, </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">6024 SW </font><font style="color:#363d56;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">Jea</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">n R</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">oad, </font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">L</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">ake </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">Oswego</font><font style="color:#726b77;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">, </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">OR, USA </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">(o</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">ne </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">of the </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">e</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">n</font><font style="color:#363d56;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">tities </font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">referred </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">to as an </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">&#34;MST </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">Affiliate&#34; in the </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">S</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">uppl</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">y </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">Agreement</font><font style="color:#726b77;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">, </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">a</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">n</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">d </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">as </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">&#34;S</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">upplier</font><font style="color:#595b74;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">&#34; </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">in the </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">S</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">uppli</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">er </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">Quality </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">Ag</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">re</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:139%">ement).</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:61.05pt;text-indent:-18.05pt"><font style="color:#3d333f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Product(s)&#58;</font></div><div style="margin-top:1.8pt;padding-left:74.55pt"><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:85%">Part </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:85%">Num</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:85%">b</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:85%">e</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:85%">r&#160;&#160;&#160;&#160;</font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:85%">Revision&#160;&#160;&#160;&#160;Description</font></div><div style="margin-top:1.8pt;padding-left:74.55pt"><font style="background-color:#07050a;color:#e2e6d8;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:98%">Redacted&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Redacted</font></div><div style="margin-top:7.65pt;padding-left:67.95pt"><font style="background-color:#07050a;color:#e2e6d8;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:96%">&#160;&#160;&#160;&#160;Redacted&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Redacted         Redacted</font></div><div style="margin-top:4.55pt;padding-left:60.75pt;text-indent:0.05pt"><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">The Parties </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">agree </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">that this Exhibit A2 </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">sha</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">ll in</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">clu</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">d</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">e </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">all </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">s</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">ub</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">seq</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">uent r</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">evisio</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">n</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">s</font><font style="color:#726b77;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">&#47;</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">vers</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">i</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">o</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">n</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">s of </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">the foregoing </font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">Produ</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">ct. </font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">Product r</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">ev</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">i</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">s</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">i</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">on c</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">han</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">ges </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">by NeuroPace must be accepted </font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">b</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">y MSEI. Acceptance </font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">b</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">y MSEI wi</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">ll b</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">e </font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">d</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">oc</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">ument</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">ed </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">in the </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">dev</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">i</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">ce </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">manufacturing </font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">r</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">ecord </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">and communicated through </font><font style="color:#363d56;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">t</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">he </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:143%">MSEI ECN process.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:60.8pt;text-indent:0.05pt"><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">The</font><font style="background-color:#07050a;color:#e2e6d8;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:95%"> Redacted</font><font style="color:#050508;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:95%"> </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">wi</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">ll </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">be manufactured </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">w</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">i</font><font style="color:#363d56;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">t</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">hin </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">the </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">MSEI </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">facilities at </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">6024 SW </font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">J</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">ea</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">n </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">Road</font><font style="color:#726b77;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">, </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">Lake Oswego</font><font style="color:#726b77;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">, </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">OR, USA</font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:95%">.</font><font style="background-color:#07050a;color:#e2e6d8;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:95%"> Redacted</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%"> to </font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">includ</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">e </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">pin &#38; </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">w</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">ir</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">e attac</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">h</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">, SM</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">T </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">assembly</font><font style="color:#726b77;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">, </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">functional test</font><font style="color:#726b77;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">, </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:95%">and rework for</font></div><div style="margin-top:1.8pt;padding-left:60.9pt;padding-right:10.95pt;text-indent:0.2pt"><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">workma</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">n</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">s</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">hip</font><font style="color:#363d56;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">. </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">MSEI wi</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">ll </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">de</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">li</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">ver a</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">ll produ</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">c</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">t </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">passing </font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">f</font></div><div style="margin-top:1.8pt;padding-left:60.9pt;padding-right:10.95pt;text-indent:0.2pt"><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">l</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">y</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">in</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">g </font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">probe </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">test and </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">vis</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">u</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">a</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">l in</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">s</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">p</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">ectio</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">n per IP</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">C-6</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">10E</font><font style="color:#363d56;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:137%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:59.1pt;padding-right:13pt"><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">The </font><font style="background-color:#07050a;color:#e2e6d8;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:99%">Redacted</font><font style="color:#050508;font-family:'Arial',sans-serif;font-size:15.5pt;font-weight:700;line-height:99%"> </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">w</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">ill </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">be manufactured </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">wit</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">hin </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">the Micro </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">Systems </font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">En</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">g</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">ine</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">ering </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">GmbH facility using the    N</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">e</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">ur</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">o</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">Pa</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">ce </font><font style="background-color:#07050a;color:#e2e6d8;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:99%">Redacted</font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%"> and</font><font style="color:#050508;font-family:'Arial',sans-serif;font-size:16.5pt;font-weight:700;line-height:99%;text-decoration:underline"> </font><font style="background-color:#07050a;color:#e2e6d8;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:99%">Redacted  </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%"> speci</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">fi</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">ed </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">by N</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">e</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">ur</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">oPace </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">and purchased by MSEI. </font><font style="background-color:#07050a;color:#e2e6d8;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:99%">Redacted</font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%"> will be </font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">so</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">ld </font><font style="color:#363d56;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">to </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:99%">MSEI by MSE GmbH.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61pt;text-indent:-18.15pt"><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Sta</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">ndar</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">d </font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Pri</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">c</font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">in</font><font style="color:#4b4452;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">g (Currency&#58; </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">USD)&#58;</font></div><div style="padding-left:61pt;text-indent:-18.15pt"><font><br></font></div><div style="padding-left:76.5pt;text-indent:-18.15pt"><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Part Number&#58; </font><font style="background-color:#07050a;color:#e2e6d8;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redacted</font></div><div style="padding-left:76.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.610%"><tr><td style="width:1.0%"></td><td style="width:48.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Annual</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cost </font><font style="color:#2a242a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">per </font><font style="color:#3d333f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unit</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#e2e6d8;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redacted</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#e2e6d8;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redacted</font></td></tr></table></div><div style="padding-left:76.5pt;text-indent:-18.15pt"><font><br></font></div><div style="padding-left:61pt;text-indent:-18.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:4.5pt;padding-left:61pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Part</font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Number&#58;</font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="background-color:#000000;color:#ffffff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Redacted&#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:91.85pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.690%"><tr><td style="width:1.0%"></td><td style="width:32.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.293%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-left:0.5pt solid #221f1f;border-top:0.5pt solid #221f1f;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.45pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Annual</font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Quantity</font></div></td><td colspan="9" style="border-left:0.5pt solid #221f1f;border-right:0.5pt solid #221f1f;border-top:0.5pt solid #221f1f;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12.35pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Cost</font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">per</font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Unit</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #221f1f;border-top:0.5pt solid #221f1f;padding:2px 1pt 2px 37.9pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Redacted</font></td><td colspan="3" style="background-color:#000000;border-bottom:0.5pt solid #221f1f;border-left:3pt solid #ffffff;border-top:0.5pt solid #221f1f;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #221f1f;border-top:0.5pt solid #221f1f;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;border-bottom:0.5pt solid #221f1f;border-top:0.5pt solid #221f1f;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-right:-0.25pt;text-align:center"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:5.5pt;font-weight:400;line-height:100%">Redacted</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #221f1f;border-right:0.5pt solid #221f1f;border-top:0.5pt solid #221f1f;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #221f1f;border-left:0.5pt solid #221f1f;border-top:0.5pt solid #221f1f;padding:2px 1pt 2px 31.9pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redacted</font></td><td colspan="9" style="border-left:0.5pt solid #221f1f;border-right:0.5pt solid #221f1f;border-top:0.5pt solid #221f1f;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:34.6pt;padding-right:34.6pt;text-align:center"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:5.5pt;font-weight:400;line-height:100%">Redacted</font></div></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #221f1f;border-left:0.5pt solid #221f1f;border-top:0.5pt solid #221f1f;padding:2px 1pt 2px 61.2pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Redacted</font></td><td colspan="3" style="border-bottom:0.5pt solid #221f1f;border-left:0.5pt solid #221f1f;border-top:0.5pt solid #221f1f;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;border-bottom:0.5pt solid #221f1f;border-top:0.5pt solid #221f1f;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-right:-0.25pt;text-align:center"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:5.5pt;font-weight:400;line-height:100%">Redacted</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #221f1f;border-right:0.5pt solid #221f1f;border-top:0.5pt solid #221f1f;padding:0 1pt"></td></tr></table></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:61pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pricing is based upon NeuroPace providing MSEI the following parts at no cost&#58;</font></div><div style="margin-top:2.15pt;padding-left:97pt;padding-right:135pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"></font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Part Number </font><font style="background-color:#000000;color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redacted Redacted&#160;&#160;&#160;&#160;</font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or subsequent revision (</font><font style="background-color:#000000;color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redacted&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">)</font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:61pt;text-indent:-18.1pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;Lead Times&#58;</font></div><div style="height:94.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:21.6pt;width:100%"><div><font><br></font></div></div><div style="padding-left:60.75pt"><font style="background-color:#000000;color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redacted&#160;&#160;&#160;&#160;</font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; 6 weeks from receipt of purchase order.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt;text-indent:-18.1pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;Forecast&#58;</font></div><div style="padding-left:112.5pt;text-indent:-18.05pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;A twelve (12) month rolling forecast will be provided quarterly.</font></div><div style="padding-left:112.5pt;text-indent:-18.05pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Binding Forecast is six (6) months.</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt;text-indent:-18.1pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;Inventory Management&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:61pt;padding-right:6.8pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">For other than </font><font style="background-color:#000000;color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Redacted </font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">, NeuroPace is liable for up to 6 months component inventory based on demand for the immediate next 6 months forecast. The target stocking level for each component is 12 weeks of safety stock with up to 14 weeks additional committed orders based upon 6 months binding forecast. Multiple components have 14-16 week lead times with additional incoming screening or lot based qualification lead time of 3+ weeks. For these exceptional components, NeuroPace will be liable for the order placed to support forecast within lead times at or exceeding the target stocking level. If NeuroPace cancels a purchase order, MSEI will undertake reasonable measures to attempt to cancel component open orders with suppliers and return stock on hand. If otherwise unusable components remain in MSEI inventory, NeuroPace will be liable for all return restocking, shipping, discounts and all other return expenses, non- returnable items and any disposition costs of non-returnable or non-usable components.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:61pt;padding-right:13pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">For </font><font style="background-color:#000000;color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Redacted </font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">, NeuroPace is liable for up to 9 months component inventory based on demand for the immediate next 9 months forecast.</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt;text-indent:-18.1pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;Yield Responsibility&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:9.25pt"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">All </font><font style="background-color:#000000;color:#ffffff;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:133%">Redacted</font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">tested through the functional test process, pass or fail, are sold to NeuroPace by MSEI at full value, assuming&#160;&#160;&#160;&#160;pass all other tests and inspections. The failed&#160;&#160;&#160;&#160;will ship to NeuroPace as mechanical </font><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%">Redacted</font><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:8.8pt;text-indent:-0.05pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:15px;margin-bottom:5pt;vertical-align:text-bottom;width:31px"><font style="color:#221f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">NeuroPace will pay full component value for NeuroPace-specified components or consigned components as follows&#58; (1) if the quality of the components adversely affects&#160;&#160;&#160;&#160;performance or acceptability&#59; (2) if there is any incoming quality yield loss&#59; and (3) if there is any manufacturing quality yield loss. NeuroPace-specified components or consigned-components will be used as-received, subject to an mutually agreed to acceptance process upon receipt.</font></div><div style="height:94.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exhibit311-certificationsq.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic19ff2451b7f4f0b8a0f14b08e2dd8d6_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael Favet, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Form 10-Q of NeuroPace, Inc.&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-34.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:1.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.429%"><tr><td style="width:1.0%"></td><td style="width:5.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 4, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Michael Favet</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael Favet</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:right;text-indent:0.36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exhibit312certificationsq1.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic629b27888244c69b8b713ddc835abe8_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Rebecca Kuhn, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Form 10-Q of NeuroPace, Inc.&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-34.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:1.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.750%"><tr><td style="width:1.0%"></td><td style="width:5.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 4, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Rebecca Kuhn</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebecca Kuhn</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer and Vice President, Finance and Administration (Principal Financial and Accounting Officer)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exhibit321certificationsq1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1044cb5b537c406da4378dd075b74e6b_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael Favet, Chief Executive Officer of NeuroPace, Inc. (the &#8220;Company&#8221;), and Rebecca Kuhn, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2023, to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; May 4, 2023</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In Witness Whereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the undersigned have set their hands hereto as of the 4th day of May 2023.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:1.4pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:1.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.903%"><tr><td style="width:1.0%"></td><td style="width:3.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Michael Favet</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Rebecca Kuhn</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael Favet</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebecca Kuhn</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer and Vice President, Finance and Administration (Principal Financial and Accounting Officer)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of NeuroPace, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>npce-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1fd4e094-c2e9-4b44-9de8-fd1ff4c54731,g:0a3c8fdc-3cf9-40a0-97f2-986b9fb768aa-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:npce="http://neuropace.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://neuropace.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="npce-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="npce-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="npce-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="npce-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://neuropace.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheetsunaudited" roleURI="http://neuropace.com/role/CondensedBalanceSheetsunaudited">
        <link:definition>0000002 - Statement - Condensed Balance Sheets (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheetsunauditedParenthetical" roleURI="http://neuropace.com/role/CondensedBalanceSheetsunauditedParenthetical">
        <link:definition>0000003 - Statement - Condensed Balance Sheets (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofOperationsandComprehensiveLossunaudited" roleURI="http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited">
        <link:definition>0000004 - Statement - Condensed Statements of Operations and Comprehensive Loss (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofStockholdersEquityunaudited" roleURI="http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited">
        <link:definition>0000005 - Statement - Condensed Statements of Stockholders&#8217; Equity (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofCashFlowsunaudited" roleURI="http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited">
        <link:definition>0000006 - Statement - Condensed Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompany" roleURI="http://neuropace.com/role/TheCompany">
        <link:definition>0000007 - Disclosure - The Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://neuropace.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://neuropace.com/role/FairValueMeasurements">
        <link:definition>0000009 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://neuropace.com/role/BalanceSheetComponents">
        <link:definition>0000010 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://neuropace.com/role/CommitmentsandContingencies">
        <link:definition>0000011 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://neuropace.com/role/Debt">
        <link:definition>0000012 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStock" roleURI="http://neuropace.com/role/CommonStock">
        <link:definition>0000013 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedIncentiveCompensationPlans" roleURI="http://neuropace.com/role/StockBasedIncentiveCompensationPlans">
        <link:definition>0000014 - Disclosure - Stock-Based Incentive Compensation Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://neuropace.com/role/IncomeTaxes">
        <link:definition>0000015 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareAttributabletoCommonStockholders" roleURI="http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholders">
        <link:definition>0000016 - Disclosure - Net Loss per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://neuropace.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000017 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://neuropace.com/role/FairValueMeasurementsTables">
        <link:definition>0000018 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://neuropace.com/role/BalanceSheetComponentsTables">
        <link:definition>0000019 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://neuropace.com/role/CommitmentsandContingenciesTables">
        <link:definition>0000020 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://neuropace.com/role/DebtTables">
        <link:definition>0000021 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockTables" roleURI="http://neuropace.com/role/CommonStockTables">
        <link:definition>0000022 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedIncentiveCompensationPlansTables" roleURI="http://neuropace.com/role/StockBasedIncentiveCompensationPlansTables">
        <link:definition>0000023 - Disclosure - Stock-Based Incentive Compensation Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareAttributabletoCommonStockholdersTables" roleURI="http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersTables">
        <link:definition>0000024 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompanyDetails" roleURI="http://neuropace.com/role/TheCompanyDetails">
        <link:definition>0000025 - Disclosure - The Company (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://neuropace.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>0000026 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" roleURI="http://neuropace.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails">
        <link:definition>0000027 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://neuropace.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>0000028 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofInventoryDetails" roleURI="http://neuropace.com/role/BalanceSheetComponentsScheduleofInventoryDetails">
        <link:definition>0000029 - Disclosure - Balance Sheet Components - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails" roleURI="http://neuropace.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails">
        <link:definition>0000030 - Disclosure - Balance Sheet Components -Schedule of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails" roleURI="http://neuropace.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails">
        <link:definition>0000031 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>0000032 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" roleURI="http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails">
        <link:definition>0000033 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1" roleURI="http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1">
        <link:definition>0000033 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://neuropace.com/role/DebtNarrativeDetails">
        <link:definition>0000034 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofMaturitiesofLongtermDebtDetails" roleURI="http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails">
        <link:definition>0000035 - Disclosure - Debt - Schedule of Maturities of Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockDetails" roleURI="http://neuropace.com/role/CommonStockDetails">
        <link:definition>0000036 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedIncentiveCompensationPlansScheduleofAvailableforGrantDetails" roleURI="http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofAvailableforGrantDetails">
        <link:definition>0000037 - Disclosure - Stock-Based Incentive Compensation Plans - Schedule of Available for Grant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails" roleURI="http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails">
        <link:definition>0000038 - Disclosure - Stock-Based Incentive Compensation Plans - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedIncentiveCompensationPlansNarrativeDetails" roleURI="http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails">
        <link:definition>0000039 - Disclosure - Stock-Based Incentive Compensation Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails" roleURI="http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails">
        <link:definition>0000040 - Disclosure - Stock-Based Incentive Compensation Plans - Schedule of Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedIncentiveCompensationPlansScheduleofRecognizedStockbasedCompensationDetails" roleURI="http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRecognizedStockbasedCompensationDetails">
        <link:definition>0000041 - Disclosure - Stock-Based Incentive Compensation Plans - Schedule of Recognized Stock-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://neuropace.com/role/IncomeTaxesDetails">
        <link:definition>0000042 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareAttributabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareDetails" roleURI="http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareDetails">
        <link:definition>0000043 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareAttributabletoCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesOutstandingDetails" roleURI="http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesOutstandingDetails">
        <link:definition>0000044 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Schedule of Potentially Dilutive Securities Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="npce_MachineryEquipmentFurnitureAndFixturesMember" abstract="true" name="MachineryEquipmentFurnitureAndFixturesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="npce_AccruedAndEmployeeRelatedLiabilitiesCurrent" abstract="false" name="AccruedAndEmployeeRelatedLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="npce_WarrantLiabilityNoncurrent" abstract="false" name="WarrantLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="npce_SeriesBRedeemableConvertiblePreferredStockMember" abstract="true" name="SeriesBRedeemableConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="npce_StockOptionsAndRestrictedStockUnitsMember" abstract="true" name="StockOptionsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="npce_A2021EquityIncentivePlanMember" abstract="true" name="A2021EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="npce_EmployeeStockPurchasePlanLengthOfOfferingPeriod" abstract="false" name="EmployeeStockPurchasePlanLengthOfOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="npce_AtTheMarketEquityOfferingMember" abstract="true" name="AtTheMarketEquityOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="npce_OptionsAvailableForGrant2021PlanMember" abstract="true" name="OptionsAvailableForGrant2021PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="npce_IncreaseDecreaseInNonCashInterestExpense" abstract="false" name="IncreaseDecreaseInNonCashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="npce_TermLoanMember" abstract="true" name="TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="npce_DebtInstrumentUnamortizedInterestCost" abstract="false" name="DebtInstrumentUnamortizedInterestCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="npce_OptionsRestrictedStockUnit2021PlanMember" abstract="true" name="OptionsRestrictedStockUnit2021PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="npce_ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember" abstract="true" name="ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTerm" abstract="false" name="ResearchAndDevelopmentArrangementWithFederalGovernmentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="npce_PurchaseObligationMinimumIncreasePercentageInNextTwoYears" abstract="false" name="PurchaseObligationMinimumIncreasePercentageInNextTwoYears" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="npce_EmployeeStockPurchasePlanOfferingPeriod" abstract="false" name="EmployeeStockPurchasePlanOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="npce_AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1" abstract="false" name="ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="npce_DebtInstrumentPrincipalPaymentNumberOfInstallment" abstract="false" name="DebtInstrumentPrincipalPaymentNumberOfInstallment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="npce_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="npce_PaymentInCashMember" abstract="true" name="PaymentInCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="npce_LeaseFacilityMember" abstract="true" name="LeaseFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="npce_OutstandingOptions2021PlanMember" abstract="true" name="OutstandingOptions2021PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="npce_A2021EmployeeStockPurchasePlanMember" abstract="true" name="A2021EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="npce_IndemnificationLiabilityOfficersAndDirectors" abstract="false" name="IndemnificationLiabilityOfficersAndDirectors" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="npce_ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards" abstract="false" name="ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="npce_SaleOfStockUnderwritingDiscounts" abstract="false" name="SaleOfStockUnderwritingDiscounts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="npce_IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions" abstract="false" name="IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="npce_DebtInstrumentRedemptionFeePercent" abstract="false" name="DebtInstrumentRedemptionFeePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="npce_OCIUnrealizedLossAdjustmentForShortTermInvestment" abstract="false" name="OCIUnrealizedLossAdjustmentForShortTermInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="npce_DebtInstrumentCovenantMinimumAnnualNetRevenue" abstract="false" name="DebtInstrumentCovenantMinimumAnnualNetRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="npce_OperatingLeaseRenewalTerm" abstract="false" name="OperatingLeaseRenewalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="npce_DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO" abstract="false" name="DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1" abstract="false" name="ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="npce_OperatingLeasesAnnualRentalPayments" abstract="false" name="OperatingLeasesAnnualRentalPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="npce_CommonStockAvailableForESPPMember" abstract="true" name="CommonStockAvailableForESPPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="npce_PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement" abstract="false" name="PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost" abstract="false" name="ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="npce_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="npce_SaleOfStockOfferingCosts" abstract="false" name="SaleOfStockOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2" abstract="false" name="ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2" abstract="false" name="ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="npce_AccruedInventoryLiabilityCurrent" abstract="false" name="AccruedInventoryLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>npce-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1fd4e094-c2e9-4b44-9de8-fd1ff4c54731,g:0a3c8fdc-3cf9-40a0-97f2-986b9fb768aa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://neuropace.com/role/CondensedBalanceSheetsunaudited" xlink:type="simple" xlink:href="npce-20230331.xsd#CondensedBalanceSheetsunaudited"/>
  <link:calculationLink xlink:role="http://neuropace.com/role/CondensedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_51e34c52-44eb-4499-98da-d545d560b826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c97a9ecb-118e-4ce3-aee9-c7cb80462db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_51e34c52-44eb-4499-98da-d545d560b826" xlink:to="loc_us-gaap_StockholdersEquity_c97a9ecb-118e-4ce3-aee9-c7cb80462db3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_10709cc1-7243-4d85-b717-8d56be0049d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_51e34c52-44eb-4499-98da-d545d560b826" xlink:to="loc_us-gaap_CommitmentsAndContingencies_10709cc1-7243-4d85-b717-8d56be0049d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_90546069-6f89-491e-8595-9e0ff174cc60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_51e34c52-44eb-4499-98da-d545d560b826" xlink:to="loc_us-gaap_Liabilities_90546069-6f89-491e-8595-9e0ff174cc60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_acb63b28-582f-420c-8462-dd9479abff97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_7dd591b4-6922-4b87-b53e-d0299d81d013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_acb63b28-582f-420c-8462-dd9479abff97" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_7dd591b4-6922-4b87-b53e-d0299d81d013" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f06a1899-f137-4c48-aa34-4544e5f0591e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_acb63b28-582f-420c-8462-dd9479abff97" xlink:to="loc_us-gaap_AssetsCurrent_f06a1899-f137-4c48-aa34-4544e5f0591e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_25160a43-3369-40b0-8894-f39763676728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_acb63b28-582f-420c-8462-dd9479abff97" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_25160a43-3369-40b0-8894-f39763676728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_411a5c12-75f8-4089-be9f-5d3ff84da72a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_acb63b28-582f-420c-8462-dd9479abff97" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_411a5c12-75f8-4089-be9f-5d3ff84da72a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_97cb4c87-2a50-40ba-b5ba-888b6e8398bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_acb63b28-582f-420c-8462-dd9479abff97" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_97cb4c87-2a50-40ba-b5ba-888b6e8398bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCosts_7819efc2-07d8-4478-bf50-79a9d12cb493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_acb63b28-582f-420c-8462-dd9479abff97" xlink:to="loc_us-gaap_DeferredCosts_7819efc2-07d8-4478-bf50-79a9d12cb493" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1b8b83be-52d3-4570-b3ff-f6559af369e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_61f0cdbb-5c61-426c-9106-978650148d91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1b8b83be-52d3-4570-b3ff-f6559af369e9" xlink:to="loc_us-gaap_AccountsPayableCurrent_61f0cdbb-5c61-426c-9106-978650148d91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_58a7449d-1960-4804-a5c4-7baa0df9465e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1b8b83be-52d3-4570-b3ff-f6559af369e9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_58a7449d-1960-4804-a5c4-7baa0df9465e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6a1792c7-c20b-4c4b-b849-2ada5297f4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1b8b83be-52d3-4570-b3ff-f6559af369e9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6a1792c7-c20b-4c4b-b849-2ada5297f4b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0e3c954c-5e3c-4d73-a527-50b1b5737fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a51d3126-ddfd-4fa1-b6ac-0b62ae7f6987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0e3c954c-5e3c-4d73-a527-50b1b5737fb8" xlink:to="loc_us-gaap_PreferredStockValue_a51d3126-ddfd-4fa1-b6ac-0b62ae7f6987" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f5c60735-fd34-42f6-ab96-0dc4b9c590ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0e3c954c-5e3c-4d73-a527-50b1b5737fb8" xlink:to="loc_us-gaap_CommonStockValue_f5c60735-fd34-42f6-ab96-0dc4b9c590ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c6bc35cf-d7c9-4275-b3f8-49df39c3728a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0e3c954c-5e3c-4d73-a527-50b1b5737fb8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c6bc35cf-d7c9-4275-b3f8-49df39c3728a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fd3df297-5cbd-45c3-ad63-03b64238e259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0e3c954c-5e3c-4d73-a527-50b1b5737fb8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fd3df297-5cbd-45c3-ad63-03b64238e259" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c30e2466-1ca5-469a-be3e-18ad900cfe85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0e3c954c-5e3c-4d73-a527-50b1b5737fb8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c30e2466-1ca5-469a-be3e-18ad900cfe85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e681eb29-4046-4d0e-99e9-f9a75fb4c192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ea2feb5d-a6f2-484e-8dcd-01db6cb95fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e681eb29-4046-4d0e-99e9-f9a75fb4c192" xlink:to="loc_us-gaap_LiabilitiesCurrent_ea2feb5d-a6f2-484e-8dcd-01db6cb95fb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_88d4dcb6-07c5-4c0f-9c8d-d8d930e4523d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e681eb29-4046-4d0e-99e9-f9a75fb4c192" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_88d4dcb6-07c5-4c0f-9c8d-d8d930e4523d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a7cf1f77-57c6-4bb4-8c37-a73eb3802974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e681eb29-4046-4d0e-99e9-f9a75fb4c192" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a7cf1f77-57c6-4bb4-8c37-a73eb3802974" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_23c4507b-dbf5-4aa5-9921-23f57763684b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6cc17db5-13ac-441d-81b2-c3581bb646a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_23c4507b-dbf5-4aa5-9921-23f57763684b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6cc17db5-13ac-441d-81b2-c3581bb646a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_55c64d59-e9d8-43bd-8051-20c8a0ad8cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_23c4507b-dbf5-4aa5-9921-23f57763684b" xlink:to="loc_us-gaap_ShortTermInvestments_55c64d59-e9d8-43bd-8051-20c8a0ad8cc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e9ecf958-e334-4328-b927-827633a2286b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_23c4507b-dbf5-4aa5-9921-23f57763684b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e9ecf958-e334-4328-b927-827633a2286b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_8c34e7d7-9ecc-45c2-ace4-ff38735a40b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_23c4507b-dbf5-4aa5-9921-23f57763684b" xlink:to="loc_us-gaap_InventoryNet_8c34e7d7-9ecc-45c2-ace4-ff38735a40b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3e7471bd-9c78-44ee-be32-77546a6814cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_23c4507b-dbf5-4aa5-9921-23f57763684b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3e7471bd-9c78-44ee-be32-77546a6814cf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="simple" xlink:href="npce-20230331.xsd#CondensedStatementsofOperationsandComprehensiveLossunaudited"/>
  <link:calculationLink xlink:role="http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_12aa277b-c1f0-4985-b695-45a66a038129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_06824026-3d35-4b90-81e4-72285e293813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_12aa277b-c1f0-4985-b695-45a66a038129" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_06824026-3d35-4b90-81e4-72285e293813" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_908bcbd4-11b0-4a00-ac6e-da88c2fa3bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_12aa277b-c1f0-4985-b695-45a66a038129" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_908bcbd4-11b0-4a00-ac6e-da88c2fa3bd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_20d4f74f-76e7-4204-b83f-fb3caadaf407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_21d5be4c-7623-4fbf-8c3e-d772c9d7dde0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_20d4f74f-76e7-4204-b83f-fb3caadaf407" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_21d5be4c-7623-4fbf-8c3e-d772c9d7dde0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0d49a1eb-1639-4737-80f5-8f6d5348e9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_20d4f74f-76e7-4204-b83f-fb3caadaf407" xlink:to="loc_us-gaap_NetIncomeLoss_0d49a1eb-1639-4737-80f5-8f6d5348e9ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_11abbe2b-51e2-4b16-a9cb-af6900d8c31b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d2767cb7-b6c2-4043-8f69-27100fd67ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_11abbe2b-51e2-4b16-a9cb-af6900d8c31b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d2767cb7-b6c2-4043-8f69-27100fd67ebc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a271b1ad-08d5-4c9e-ba82-f408993be662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_11abbe2b-51e2-4b16-a9cb-af6900d8c31b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a271b1ad-08d5-4c9e-ba82-f408993be662" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2700daba-4399-4571-8a62-5c3920adc76d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_563200d1-34eb-4b89-8c1e-19d8b28d9c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2700daba-4399-4571-8a62-5c3920adc76d" xlink:to="loc_us-gaap_OperatingIncomeLoss_563200d1-34eb-4b89-8c1e-19d8b28d9c0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_41e14a23-30ea-4926-8bf1-73e70977d27e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2700daba-4399-4571-8a62-5c3920adc76d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_41e14a23-30ea-4926-8bf1-73e70977d27e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_71e7306c-8d66-4b30-8f24-2e24dcb4ef02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2700daba-4399-4571-8a62-5c3920adc76d" xlink:to="loc_us-gaap_InterestExpense_71e7306c-8d66-4b30-8f24-2e24dcb4ef02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_106aad0c-84d2-49b6-ae4e-3d86c4e04223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2700daba-4399-4571-8a62-5c3920adc76d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_106aad0c-84d2-49b6-ae4e-3d86c4e04223" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="npce-20230331.xsd#CondensedStatementsofCashFlowsunaudited"/>
  <link:calculationLink xlink:role="http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_07774503-ea28-48e4-8110-c19e3152c3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_35ba47c0-930d-4d4b-acf6-f123252d4cde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_07774503-ea28-48e4-8110-c19e3152c3d3" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_35ba47c0-930d-4d4b-acf6-f123252d4cde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bbab3851-9de5-4883-bfba-1df30a68ea3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_07774503-ea28-48e4-8110-c19e3152c3d3" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bbab3851-9de5-4883-bfba-1df30a68ea3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d4cbf61b-363f-43c1-a0b3-971f5c2bb82d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f9c239a5-87ff-4def-aa8a-58d21ad3ff0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d4cbf61b-363f-43c1-a0b3-971f5c2bb82d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f9c239a5-87ff-4def-aa8a-58d21ad3ff0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bffb4469-834d-4df1-a2f4-f747d347645c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d4cbf61b-363f-43c1-a0b3-971f5c2bb82d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bffb4469-834d-4df1-a2f4-f747d347645c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87840f3d-197b-412a-bcea-f4bd5eafbb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d4cbf61b-363f-43c1-a0b3-971f5c2bb82d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87840f3d-197b-412a-bcea-f4bd5eafbb5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_779efcb5-c8b2-4478-8077-542e45b0b756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_17dc79e0-24ab-44d2-b395-250e691fed14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_779efcb5-c8b2-4478-8077-542e45b0b756" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_17dc79e0-24ab-44d2-b395-250e691fed14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_60757863-b14b-4331-a302-b101b910082f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_779efcb5-c8b2-4478-8077-542e45b0b756" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_60757863-b14b-4331-a302-b101b910082f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_e61ae306-382f-4157-a351-c9f106989790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_779efcb5-c8b2-4478-8077-542e45b0b756" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_e61ae306-382f-4157-a351-c9f106989790" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d07e8853-657a-4850-a7b5-8e109fbda6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_06a0898a-91f0-43bf-9f49-aeba177dc0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d07e8853-657a-4850-a7b5-8e109fbda6e3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_06a0898a-91f0-43bf-9f49-aeba177dc0fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_0f292b94-d42e-4bc9-b202-cf18ffe66852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d07e8853-657a-4850-a7b5-8e109fbda6e3" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_0f292b94-d42e-4bc9-b202-cf18ffe66852" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_f06ad0df-4e4c-4f41-931e-e957905a9eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d07e8853-657a-4850-a7b5-8e109fbda6e3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_f06ad0df-4e4c-4f41-931e-e957905a9eb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a10928ae-4cda-4b09-a8d8-73a2ef5aa70d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d07e8853-657a-4850-a7b5-8e109fbda6e3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a10928ae-4cda-4b09-a8d8-73a2ef5aa70d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_467ad28f-0788-4e15-9a48-760b7032acc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d07e8853-657a-4850-a7b5-8e109fbda6e3" xlink:to="loc_us-gaap_PaidInKindInterest_467ad28f-0788-4e15-9a48-760b7032acc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e8d61c2b-3413-44d9-a7ae-24b902989c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d07e8853-657a-4850-a7b5-8e109fbda6e3" xlink:to="loc_us-gaap_ShareBasedCompensation_e8d61c2b-3413-44d9-a7ae-24b902989c45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c4590479-4b7a-413a-b988-039c15d5c81f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d07e8853-657a-4850-a7b5-8e109fbda6e3" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c4590479-4b7a-413a-b988-039c15d5c81f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_0fc63cab-89e4-4912-9b95-f575210db72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d07e8853-657a-4850-a7b5-8e109fbda6e3" xlink:to="loc_us-gaap_InventoryWriteDown_0fc63cab-89e4-4912-9b95-f575210db72e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a3640511-7576-46b0-802d-9c29b7f61290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d07e8853-657a-4850-a7b5-8e109fbda6e3" xlink:to="loc_us-gaap_NetIncomeLoss_a3640511-7576-46b0-802d-9c29b7f61290" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a764223e-ca0d-49cd-8e0d-589e19002ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d07e8853-657a-4850-a7b5-8e109fbda6e3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a764223e-ca0d-49cd-8e0d-589e19002ea6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_13e01105-13ae-4876-9e7a-32ac7d698560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d07e8853-657a-4850-a7b5-8e109fbda6e3" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_13e01105-13ae-4876-9e7a-32ac7d698560" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_9ea4334e-5608-4f6d-b560-f0b4b0bf7477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d07e8853-657a-4850-a7b5-8e109fbda6e3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_9ea4334e-5608-4f6d-b560-f0b4b0bf7477" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a2abd8fa-8a0b-4f51-9d95-f9779c54eb59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d07e8853-657a-4850-a7b5-8e109fbda6e3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a2abd8fa-8a0b-4f51-9d95-f9779c54eb59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_IncreaseDecreaseInNonCashInterestExpense_b153d850-7572-42f1-afbe-9a54b36acd4d" xlink:href="npce-20230331.xsd#npce_IncreaseDecreaseInNonCashInterestExpense"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d07e8853-657a-4850-a7b5-8e109fbda6e3" xlink:to="loc_npce_IncreaseDecreaseInNonCashInterestExpense_b153d850-7572-42f1-afbe-9a54b36acd4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_25b32b21-95f8-4c55-b364-d7b3f7abd71c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d07e8853-657a-4850-a7b5-8e109fbda6e3" xlink:to="loc_us-gaap_Depreciation_25b32b21-95f8-4c55-b364-d7b3f7abd71c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_45388106-221b-45f4-ad14-009134fb6b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_00ae04eb-0696-4b4d-bf5e-ec3b6bb29623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_45388106-221b-45f4-ad14-009134fb6b97" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_00ae04eb-0696-4b4d-bf5e-ec3b6bb29623" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_32867064-190a-40af-afcd-6b71aafa4a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_45388106-221b-45f4-ad14-009134fb6b97" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_32867064-190a-40af-afcd-6b71aafa4a88" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neuropace.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:calculationLink xlink:role="http://neuropace.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_740bee05-6aef-441f-a0f9-e71a7a971912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_50d734c8-9aba-4fb4-abf5-94a438b78c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_740bee05-6aef-441f-a0f9-e71a7a971912" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_50d734c8-9aba-4fb4-abf5-94a438b78c57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_41150251-91d6-4145-82a6-06be1a334e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_740bee05-6aef-441f-a0f9-e71a7a971912" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_41150251-91d6-4145-82a6-06be1a334e69" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neuropace.com/role/BalanceSheetComponentsScheduleofInventoryDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#BalanceSheetComponentsScheduleofInventoryDetails"/>
  <link:calculationLink xlink:role="http://neuropace.com/role/BalanceSheetComponentsScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ae69c76e-e6b1-41e3-ad3d-cfe7f7d8d852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_295b43ce-aee9-47fe-8738-3f29965fe2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_ae69c76e-e6b1-41e3-ad3d-cfe7f7d8d852" xlink:to="loc_us-gaap_InventoryRawMaterials_295b43ce-aee9-47fe-8738-3f29965fe2e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_7313583a-cfae-4824-a7dd-09aa9453049e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_ae69c76e-e6b1-41e3-ad3d-cfe7f7d8d852" xlink:to="loc_us-gaap_InventoryWorkInProcess_7313583a-cfae-4824-a7dd-09aa9453049e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_68b3cb22-2955-401e-b8f9-7f80b4a9a4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_ae69c76e-e6b1-41e3-ad3d-cfe7f7d8d852" xlink:to="loc_us-gaap_InventoryFinishedGoods_68b3cb22-2955-401e-b8f9-7f80b4a9a4bc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neuropace.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://neuropace.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3172f32b-8711-4120-96c5-4547994d50f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_097dc13e-667c-4803-b905-887d83cd4f58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3172f32b-8711-4120-96c5-4547994d50f9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_097dc13e-667c-4803-b905-887d83cd4f58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_26bd9ff0-e095-402c-af8e-34acc4ae5b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3172f32b-8711-4120-96c5-4547994d50f9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_26bd9ff0-e095-402c-af8e-34acc4ae5b34" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neuropace.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://neuropace.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_npce_AccruedAndEmployeeRelatedLiabilitiesCurrent_9489df3f-69ef-49f9-a6d9-b313aee8a39a" xlink:href="npce-20230331.xsd#npce_AccruedAndEmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d75f39db-ccc3-451a-b563-7b289aa88036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_npce_AccruedAndEmployeeRelatedLiabilitiesCurrent_9489df3f-69ef-49f9-a6d9-b313aee8a39a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d75f39db-ccc3-451a-b563-7b289aa88036" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_AccruedInventoryLiabilityCurrent_7bd1e0ef-93e7-453d-8f4f-c4c972398905" xlink:href="npce-20230331.xsd#npce_AccruedInventoryLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_npce_AccruedAndEmployeeRelatedLiabilitiesCurrent_9489df3f-69ef-49f9-a6d9-b313aee8a39a" xlink:to="loc_npce_AccruedInventoryLiabilityCurrent_7bd1e0ef-93e7-453d-8f4f-c4c972398905" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_c0857858-9faa-4960-9cd2-0ff2435946ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_npce_AccruedAndEmployeeRelatedLiabilitiesCurrent_9489df3f-69ef-49f9-a6d9-b313aee8a39a" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_c0857858-9faa-4960-9cd2-0ff2435946ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4815f756-9256-4fe7-977b-8c2afda827fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_npce_AccruedAndEmployeeRelatedLiabilitiesCurrent_9489df3f-69ef-49f9-a6d9-b313aee8a39a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4815f756-9256-4fe7-977b-8c2afda827fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f258b9b8-5446-43c5-aa3e-b6d82bccf3df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_cd0940ef-4ac1-4e9a-b4e0-d524888fbeb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_f258b9b8-5446-43c5-aa3e-b6d82bccf3df" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_cd0940ef-4ac1-4e9a-b4e0-d524888fbeb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_970436b6-889b-4868-9b75-7e051ee6518b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_f258b9b8-5446-43c5-aa3e-b6d82bccf3df" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_970436b6-889b-4868-9b75-7e051ee6518b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_643b4230-22f7-4300-be22-3fb689763c21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bf78901a-4bbc-482b-a1a8-8134154311d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_643b4230-22f7-4300-be22-3fb689763c21" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bf78901a-4bbc-482b-a1a8-8134154311d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9f95c446-005e-4573-9aae-2de1586bd311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_643b4230-22f7-4300-be22-3fb689763c21" xlink:to="loc_us-gaap_OperatingLeaseLiability_9f95c446-005e-4573-9aae-2de1586bd311" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="npce-20230331.xsd#CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ad55e0ea-ed7c-41c5-bcf9-8102afcd3af8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_58eed180-567c-4b85-86ed-ee7730eeb86e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ad55e0ea-ed7c-41c5-bcf9-8102afcd3af8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_58eed180-567c-4b85-86ed-ee7730eeb86e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bab99095-be77-458a-909b-cdabaee142f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ad55e0ea-ed7c-41c5-bcf9-8102afcd3af8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bab99095-be77-458a-909b-cdabaee142f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6d59deab-343b-48de-8e1d-5a8e67d14f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ad55e0ea-ed7c-41c5-bcf9-8102afcd3af8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6d59deab-343b-48de-8e1d-5a8e67d14f8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_90a11167-9c86-45d6-8cc5-1f74436c9d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ad55e0ea-ed7c-41c5-bcf9-8102afcd3af8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_90a11167-9c86-45d6-8cc5-1f74436c9d43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3511f696-1f89-4b48-889a-e1226d87532b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ad55e0ea-ed7c-41c5-bcf9-8102afcd3af8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3511f696-1f89-4b48-889a-e1226d87532b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_1798192e-6a3e-4506-adaa-32aa5e2905ef" xlink:href="npce-20230331.xsd#npce_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ad55e0ea-ed7c-41c5-bcf9-8102afcd3af8" xlink:to="loc_npce_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_1798192e-6a3e-4506-adaa-32aa5e2905ef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#DebtScheduleofMaturitiesofLongtermDebtDetails"/>
  <link:calculationLink xlink:role="http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3b2e2703-11a9-4678-ba5f-49fac627ff0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_7a6c0aef-183f-407f-b7d1-3c26b13fae94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3b2e2703-11a9-4678-ba5f-49fac627ff0c" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_7a6c0aef-183f-407f-b7d1-3c26b13fae94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_c71a7038-b6ff-40bd-a975-3d8671b7b700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3b2e2703-11a9-4678-ba5f-49fac627ff0c" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_c71a7038-b6ff-40bd-a975-3d8671b7b700" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_21298ffb-3079-4691-bede-94ef69a83998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3b2e2703-11a9-4678-ba5f-49fac627ff0c" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_21298ffb-3079-4691-bede-94ef69a83998" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_DebtInstrumentUnamortizedInterestCost_1d3c74b4-a743-4071-a92d-13628fc01bfb" xlink:href="npce-20230331.xsd#npce_DebtInstrumentUnamortizedInterestCost"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3b2e2703-11a9-4678-ba5f-49fac627ff0c" xlink:to="loc_npce_DebtInstrumentUnamortizedInterestCost_1d3c74b4-a743-4071-a92d-13628fc01bfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c0fe9353-ac12-4841-9a05-6de0818caabf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_adaab086-4941-4b3f-b2f9-fd73cc4e8475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c0fe9353-ac12-4841-9a05-6de0818caabf" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_adaab086-4941-4b3f-b2f9-fd73cc4e8475" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_783c2f13-f0b3-4e0b-aa5e-f28a1184291c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c0fe9353-ac12-4841-9a05-6de0818caabf" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_783c2f13-f0b3-4e0b-aa5e-f28a1184291c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b48574cb-a7e9-4a07-8782-f9cc4a07102e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c0fe9353-ac12-4841-9a05-6de0818caabf" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b48574cb-a7e9-4a07-8782-f9cc4a07102e" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>npce-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1fd4e094-c2e9-4b44-9de8-fd1ff4c54731,g:0a3c8fdc-3cf9-40a0-97f2-986b9fb768aa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited" xlink:type="simple" xlink:href="npce-20230331.xsd#CondensedStatementsofStockholdersEquityunaudited"/>
  <link:definitionLink xlink:role="http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited" xlink:type="extended" id="i51320112a481442e9025e29334eff873_CondensedStatementsofStockholdersEquityunaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d082503e-2028-4034-b81b-2119b9ad44e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_a7888845-f815-4914-a0cc-de41411dd367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d082503e-2028-4034-b81b-2119b9ad44e4" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_a7888845-f815-4914-a0cc-de41411dd367" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_a7888845-f815-4914-a0cc-de41411dd367" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ef731ba4-3b13-4279-ad90-c58622c2bbae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ef731ba4-3b13-4279-ad90-c58622c2bbae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3565db98-8596-4bc7-b2a4-733cda7f5c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_us-gaap_StockholdersEquity_3565db98-8596-4bc7-b2a4-733cda7f5c2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4412486e-dbf6-457f-b2f2-62348953976a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_us-gaap_NetIncomeLoss_4412486e-dbf6-457f-b2f2-62348953976a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_OCIUnrealizedLossAdjustmentForShortTermInvestment_38954b1e-7b09-478e-abd7-f953dc6e8475" xlink:href="npce-20230331.xsd#npce_OCIUnrealizedLossAdjustmentForShortTermInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_npce_OCIUnrealizedLossAdjustmentForShortTermInvestment_38954b1e-7b09-478e-abd7-f953dc6e8475" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a85445c8-20e0-4278-980d-811be3968af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a85445c8-20e0-4278-980d-811be3968af9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b8ab758a-1456-4f85-9804-fe9c1892cd64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b8ab758a-1456-4f85-9804-fe9c1892cd64" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2c8aa286-eaa1-4bbe-9d8b-e44e2add59e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2c8aa286-eaa1-4bbe-9d8b-e44e2add59e4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_d84e1818-2c23-4ac0-b92e-acd772712101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_d84e1818-2c23-4ac0-b92e-acd772712101" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_f0d8955f-ddd1-4f9b-a04e-a06d722d2505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_f0d8955f-ddd1-4f9b-a04e-a06d722d2505" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_c4b29ec2-bcc9-44c3-8c8c-af7dc4b4b9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_c4b29ec2-bcc9-44c3-8c8c-af7dc4b4b9d1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_f01bf08d-811b-4462-8505-65c1d8350111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_f01bf08d-811b-4462-8505-65c1d8350111" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability_a523dab4-87ee-4a69-91cb-b75a99be447c" xlink:href="npce-20230331.xsd#npce_AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_npce_AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability_a523dab4-87ee-4a69-91cb-b75a99be447c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_a68cc6d3-8785-4b08-a3fe-e625400a9970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_a68cc6d3-8785-4b08-a3fe-e625400a9970" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8aaa0cc1-0976-4360-b6e5-ef01d98555eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7505286a-ce58-4073-8b6d-8e197a22a794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_60727d21-d513-4037-9365-cee6c839ab24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d082503e-2028-4034-b81b-2119b9ad44e4" xlink:to="loc_us-gaap_StatementTable_60727d21-d513-4037-9365-cee6c839ab24" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0ec9f8e0-f8ed-44f8-81b8-9a80988d86b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_60727d21-d513-4037-9365-cee6c839ab24" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0ec9f8e0-f8ed-44f8-81b8-9a80988d86b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0ec9f8e0-f8ed-44f8-81b8-9a80988d86b6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0ec9f8e0-f8ed-44f8-81b8-9a80988d86b6" xlink:to="loc_us-gaap_EquityComponentDomain_0ec9f8e0-f8ed-44f8-81b8-9a80988d86b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1e1785f8-82cd-4e78-89d0-15df512047fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0ec9f8e0-f8ed-44f8-81b8-9a80988d86b6" xlink:to="loc_us-gaap_EquityComponentDomain_1e1785f8-82cd-4e78-89d0-15df512047fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2c6e87eb-a5d0-4f5e-b2ba-5dbd047d94b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1e1785f8-82cd-4e78-89d0-15df512047fe" xlink:to="loc_us-gaap_CommonStockMember_2c6e87eb-a5d0-4f5e-b2ba-5dbd047d94b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_592d5068-ed84-4ab9-b25d-68afc2aab7be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1e1785f8-82cd-4e78-89d0-15df512047fe" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_592d5068-ed84-4ab9-b25d-68afc2aab7be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bd02b065-6ccb-4b25-9dea-9a37582baebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1e1785f8-82cd-4e78-89d0-15df512047fe" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bd02b065-6ccb-4b25-9dea-9a37582baebe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0b0e7822-0e93-45b4-99bf-9960c4de9dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1e1785f8-82cd-4e78-89d0-15df512047fe" xlink:to="loc_us-gaap_RetainedEarningsMember_0b0e7822-0e93-45b4-99bf-9960c4de9dd6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neuropace.com/role/TheCompanyDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#TheCompanyDetails"/>
  <link:definitionLink xlink:role="http://neuropace.com/role/TheCompanyDetails" xlink:type="extended" id="i8bc15b983033432886a8c583e7843b4e_TheCompanyDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c1ab1a57-130f-4dd2-a228-e1f6407f059a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c1ab1a57-130f-4dd2-a228-e1f6407f059a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_7c94ea88-5910-413e-acdb-5cd485de373e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_7c94ea88-5910-413e-acdb-5cd485de373e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2b5389f6-c360-479c-b12f-92685953e0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2b5389f6-c360-479c-b12f-92685953e0b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_29995820-2683-413b-93ef-9826e863e6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_29995820-2683-413b-93ef-9826e863e6c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_SaleOfStockUnderwritingDiscounts_81d3b63e-bd4b-45b5-a17a-d80351802757" xlink:href="npce-20230331.xsd#npce_SaleOfStockUnderwritingDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_npce_SaleOfStockUnderwritingDiscounts_81d3b63e-bd4b-45b5-a17a-d80351802757" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_SaleOfStockOfferingCosts_127bd882-f04f-45a0-92da-489e4eaf271a" xlink:href="npce-20230331.xsd#npce_SaleOfStockOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_npce_SaleOfStockOfferingCosts_127bd882-f04f-45a0-92da-489e4eaf271a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_b72d7e46-98c0-4093-a2bd-8d915a4df2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_b72d7e46-98c0-4093-a2bd-8d915a4df2f6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_65f0e65d-8bdb-43ad-a15b-f9440ecb2d97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_65f0e65d-8bdb-43ad-a15b-f9440ecb2d97" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement_31000dcd-898c-4865-aba9-84bf362d16b7" xlink:href="npce-20230331.xsd#npce_PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_npce_PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement_31000dcd-898c-4865-aba9-84bf362d16b7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_12b7f129-93aa-4697-88f8-347a139e7767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_12b7f129-93aa-4697-88f8-347a139e7767" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72dc64f3-b998-40f0-8752-4ef63435ca9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72dc64f3-b998-40f0-8752-4ef63435ca9b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_a56adbca-0022-49d2-9115-eb36657227bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_a56adbca-0022-49d2-9115-eb36657227bd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_DebtInstrumentCovenantMinimumAnnualNetRevenue_4eab9077-6150-4367-ac1e-6ac94e830319" xlink:href="npce-20230331.xsd#npce_DebtInstrumentCovenantMinimumAnnualNetRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_npce_DebtInstrumentCovenantMinimumAnnualNetRevenue_4eab9077-6150-4367-ac1e-6ac94e830319" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO_391af682-ae5f-4935-92a6-34c8f3b6856c" xlink:href="npce-20230331.xsd#npce_DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_npce_DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO_391af682-ae5f-4935-92a6-34c8f3b6856c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d69e12fc-b684-4a1c-9878-054fcc9a0274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d69e12fc-b684-4a1c-9878-054fcc9a0274" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8a18efe4-12b6-454c-8c23-7138904857fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d69e12fc-b684-4a1c-9878-054fcc9a0274" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8a18efe4-12b6-454c-8c23-7138904857fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8a18efe4-12b6-454c-8c23-7138904857fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8a18efe4-12b6-454c-8c23-7138904857fc" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8a18efe4-12b6-454c-8c23-7138904857fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_abf5efbd-5c2e-4b71-a76c-d9002f69de52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8a18efe4-12b6-454c-8c23-7138904857fc" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_abf5efbd-5c2e-4b71-a76c-d9002f69de52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_7de05c5e-db93-4743-a26b-5b7bdfc54367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_abf5efbd-5c2e-4b71-a76c-d9002f69de52" xlink:to="loc_us-gaap_IPOMember_7de05c5e-db93-4743-a26b-5b7bdfc54367" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_fc9ac400-f48b-462b-a91f-ea21747b2708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_abf5efbd-5c2e-4b71-a76c-d9002f69de52" xlink:to="loc_us-gaap_OverAllotmentOptionMember_fc9ac400-f48b-462b-a91f-ea21747b2708" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_AtTheMarketEquityOfferingMember_de9e12c4-0a1d-4b43-a849-6149c6cb0f40" xlink:href="npce-20230331.xsd#npce_AtTheMarketEquityOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_abf5efbd-5c2e-4b71-a76c-d9002f69de52" xlink:to="loc_npce_AtTheMarketEquityOfferingMember_de9e12c4-0a1d-4b43-a849-6149c6cb0f40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_9e61d9d1-ca37-4872-ac2e-4e8c2d7e40cb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d69e12fc-b684-4a1c-9878-054fcc9a0274" xlink:to="loc_srt_StatementScenarioAxis_9e61d9d1-ca37-4872-ac2e-4e8c2d7e40cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9e61d9d1-ca37-4872-ac2e-4e8c2d7e40cb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_9e61d9d1-ca37-4872-ac2e-4e8c2d7e40cb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9e61d9d1-ca37-4872-ac2e-4e8c2d7e40cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1c5a638d-42a6-46b0-a196-f16718a2834b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_9e61d9d1-ca37-4872-ac2e-4e8c2d7e40cb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1c5a638d-42a6-46b0-a196-f16718a2834b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_aa34938b-f1d8-4671-980f-0ae24b0d432a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1c5a638d-42a6-46b0-a196-f16718a2834b" xlink:to="loc_srt_ScenarioForecastMember_aa34938b-f1d8-4671-980f-0ae24b0d432a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neuropace.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://neuropace.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="i005e7e8c161a4093a9cb8e6693d4c5c4_SummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bc6552be-8a3b-4ecf-8353-f02cd71a66ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTerm_47536752-307c-422f-b8a7-f40252c73ac4" xlink:href="npce-20230331.xsd#npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bc6552be-8a3b-4ecf-8353-f02cd71a66ef" xlink:to="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTerm_47536752-307c-422f-b8a7-f40252c73ac4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost_f8a18c83-1395-4527-a1fc-eb2256f9a0c1" xlink:href="npce-20230331.xsd#npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bc6552be-8a3b-4ecf-8353-f02cd71a66ef" xlink:to="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost_f8a18c83-1395-4527-a1fc-eb2256f9a0c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards_f5376a31-cb32-4458-9a97-911cf0ab99bf" xlink:href="npce-20230331.xsd#npce_ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bc6552be-8a3b-4ecf-8353-f02cd71a66ef" xlink:to="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards_f5376a31-cb32-4458-9a97-911cf0ab99bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1_531fe0d7-5622-4de8-88ef-136cbd38a6f5" xlink:href="npce-20230331.xsd#npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bc6552be-8a3b-4ecf-8353-f02cd71a66ef" xlink:to="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1_531fe0d7-5622-4de8-88ef-136cbd38a6f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1_7ba07f24-3541-44ba-a098-226faec9a1eb" xlink:href="npce-20230331.xsd#npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bc6552be-8a3b-4ecf-8353-f02cd71a66ef" xlink:to="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1_7ba07f24-3541-44ba-a098-226faec9a1eb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2_a7a402d5-3a33-4926-89d5-f2e46af296bb" xlink:href="npce-20230331.xsd#npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bc6552be-8a3b-4ecf-8353-f02cd71a66ef" xlink:to="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2_a7a402d5-3a33-4926-89d5-f2e46af296bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2_a7f3e213-65ae-4f31-9208-10e1fd555abe" xlink:href="npce-20230331.xsd#npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bc6552be-8a3b-4ecf-8353-f02cd71a66ef" xlink:to="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2_a7f3e213-65ae-4f31-9208-10e1fd555abe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_4bc126e7-7e7a-4e28-bdfd-95f6cf3b98f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bc6552be-8a3b-4ecf-8353-f02cd71a66ef" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_4bc126e7-7e7a-4e28-bdfd-95f6cf3b98f5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_67a7930a-1c22-473c-809e-0c0f5b913ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bc6552be-8a3b-4ecf-8353-f02cd71a66ef" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_67a7930a-1c22-473c-809e-0c0f5b913ed2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_60ef6605-6db0-4ff3-8fc9-0f20fa724959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bc6552be-8a3b-4ecf-8353-f02cd71a66ef" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_60ef6605-6db0-4ff3-8fc9-0f20fa724959" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f7a244ff-e65d-40ea-bebf-0af4bcada087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_60ef6605-6db0-4ff3-8fc9-0f20fa724959" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f7a244ff-e65d-40ea-bebf-0af4bcada087" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f7a244ff-e65d-40ea-bebf-0af4bcada087_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f7a244ff-e65d-40ea-bebf-0af4bcada087" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f7a244ff-e65d-40ea-bebf-0af4bcada087_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a0ffcfb6-34c7-4bd7-9872-ff880891911c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f7a244ff-e65d-40ea-bebf-0af4bcada087" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a0ffcfb6-34c7-4bd7-9872-ff880891911c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFundingAgreementTermsMember_7e525a06-7ce7-44cb-8b69-c505e71d9239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFundingAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a0ffcfb6-34c7-4bd7-9872-ff880891911c" xlink:to="loc_us-gaap_AdditionalFundingAgreementTermsMember_7e525a06-7ce7-44cb-8b69-c505e71d9239" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neuropace.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://neuropace.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended" id="ic43a5d4fe89e46759e972c8634006fac_FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cde3e7f2-24be-42da-8d95-6eb1b0ee4ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_ebfcacae-7b1d-45d2-b3ed-40dcc0e967dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cde3e7f2-24be-42da-8d95-6eb1b0ee4ccb" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_ebfcacae-7b1d-45d2-b3ed-40dcc0e967dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_799057b6-77b7-445c-93b4-8839bc5a893d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ebfcacae-7b1d-45d2-b3ed-40dcc0e967dc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_799057b6-77b7-445c-93b4-8839bc5a893d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_aca0e239-2b44-441c-b312-33aab78826e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ebfcacae-7b1d-45d2-b3ed-40dcc0e967dc" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_aca0e239-2b44-441c-b312-33aab78826e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_aaf1bbb4-23dc-4708-8d8a-234c753c63cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ebfcacae-7b1d-45d2-b3ed-40dcc0e967dc" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_aaf1bbb4-23dc-4708-8d8a-234c753c63cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4e0c0ee-2ca6-4774-97cd-8d753d5ed41c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cde3e7f2-24be-42da-8d95-6eb1b0ee4ccb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4e0c0ee-2ca6-4774-97cd-8d753d5ed41c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1e0c0bb3-21d4-4ab3-9dd5-dbb2b730900b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4e0c0ee-2ca6-4774-97cd-8d753d5ed41c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1e0c0bb3-21d4-4ab3-9dd5-dbb2b730900b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e0c0bb3-21d4-4ab3-9dd5-dbb2b730900b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1e0c0bb3-21d4-4ab3-9dd5-dbb2b730900b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e0c0bb3-21d4-4ab3-9dd5-dbb2b730900b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d79dda3-bb48-43bd-ba6c-6faf743b8dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1e0c0bb3-21d4-4ab3-9dd5-dbb2b730900b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d79dda3-bb48-43bd-ba6c-6faf743b8dcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0e91c770-c188-4ebf-adaf-dce099bfc7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d79dda3-bb48-43bd-ba6c-6faf743b8dcd" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0e91c770-c188-4ebf-adaf-dce099bfc7f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_84596708-e349-45ad-b825-0657b164c43c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d79dda3-bb48-43bd-ba6c-6faf743b8dcd" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_84596708-e349-45ad-b825-0657b164c43c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_efa02f6d-f9d2-45b7-b648-a2936066682a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d79dda3-bb48-43bd-ba6c-6faf743b8dcd" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_efa02f6d-f9d2-45b7-b648-a2936066682a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neuropace.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://neuropace.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="icaec2f0eca3c4e5681cc4114ea6ee8bf_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b57349de-ed07-4e33-bec2-3363379776ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_eb5ddc0b-f0b3-4bf4-9f7a-271eb8472963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b57349de-ed07-4e33-bec2-3363379776ff" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_eb5ddc0b-f0b3-4bf4-9f7a-271eb8472963" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7c8432ca-c6eb-4e68-94da-08aab2f47680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b57349de-ed07-4e33-bec2-3363379776ff" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7c8432ca-c6eb-4e68-94da-08aab2f47680" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a01f143a-0f85-48cb-b624-f04cdb43388e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b57349de-ed07-4e33-bec2-3363379776ff" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a01f143a-0f85-48cb-b624-f04cdb43388e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_60df0cab-0067-4bef-a7e4-d393d57274ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b57349de-ed07-4e33-bec2-3363379776ff" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_60df0cab-0067-4bef-a7e4-d393d57274ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ed1b8569-3fa5-47c0-b623-234fcf83312c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b57349de-ed07-4e33-bec2-3363379776ff" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ed1b8569-3fa5-47c0-b623-234fcf83312c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8b70c02a-d908-4f2d-9c3a-e03b111bda20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b57349de-ed07-4e33-bec2-3363379776ff" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8b70c02a-d908-4f2d-9c3a-e03b111bda20" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_3278ac18-b520-435e-9b4e-ffc4a39afadd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8b70c02a-d908-4f2d-9c3a-e03b111bda20" xlink:to="loc_us-gaap_InvestmentTypeAxis_3278ac18-b520-435e-9b4e-ffc4a39afadd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_3278ac18-b520-435e-9b4e-ffc4a39afadd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_3278ac18-b520-435e-9b4e-ffc4a39afadd" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_3278ac18-b520-435e-9b4e-ffc4a39afadd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_73be657a-91e0-4bf1-9f11-47c7f569a86e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_3278ac18-b520-435e-9b4e-ffc4a39afadd" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_73be657a-91e0-4bf1-9f11-47c7f569a86e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_1a4ef6ef-40d9-494b-90cc-bcc8203d80fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_73be657a-91e0-4bf1-9f11-47c7f569a86e" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_1a4ef6ef-40d9-494b-90cc-bcc8203d80fb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neuropace.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://neuropace.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended" id="ic714e7d3121b483c91a2cc64b7e336d8_BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4ceeb294-e4c0-4b97-b16c-37ac959b6367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_a8a2d447-5a04-47c5-8f95-4a37b40f3296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4ceeb294-e4c0-4b97-b16c-37ac959b6367" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_a8a2d447-5a04-47c5-8f95-4a37b40f3296" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ddd832a8-ce6c-4435-bcb7-39534a6176a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4ceeb294-e4c0-4b97-b16c-37ac959b6367" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ddd832a8-ce6c-4435-bcb7-39534a6176a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_02cab6b5-387a-4ded-9668-c3a17abfb976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4ceeb294-e4c0-4b97-b16c-37ac959b6367" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_02cab6b5-387a-4ded-9668-c3a17abfb976" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c449a1d7-1d16-46b9-9062-3977e80a918c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4ceeb294-e4c0-4b97-b16c-37ac959b6367" xlink:to="loc_us-gaap_Depreciation_c449a1d7-1d16-46b9-9062-3977e80a918c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a85e4ecb-30cc-4cd1-bf73-08ddfea7656c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4ceeb294-e4c0-4b97-b16c-37ac959b6367" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a85e4ecb-30cc-4cd1-bf73-08ddfea7656c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_67cc3698-e793-4869-8d6f-14c170b56cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a85e4ecb-30cc-4cd1-bf73-08ddfea7656c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_67cc3698-e793-4869-8d6f-14c170b56cb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_67cc3698-e793-4869-8d6f-14c170b56cb8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_67cc3698-e793-4869-8d6f-14c170b56cb8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_67cc3698-e793-4869-8d6f-14c170b56cb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_95c34229-293e-437f-b4b3-7e38709ade25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_67cc3698-e793-4869-8d6f-14c170b56cb8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_95c34229-293e-437f-b4b3-7e38709ade25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_MachineryEquipmentFurnitureAndFixturesMember_e8aea221-3d5b-45f7-9288-34ffd3d16a1e" xlink:href="npce-20230331.xsd#npce_MachineryEquipmentFurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_95c34229-293e-437f-b4b3-7e38709ade25" xlink:to="loc_npce_MachineryEquipmentFurnitureAndFixturesMember_e8aea221-3d5b-45f7-9288-34ffd3d16a1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ComputerEquipmentAndSoftwareMember_11f385c1-b2bb-45bf-af0d-518d00e58eee" xlink:href="npce-20230331.xsd#npce_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_95c34229-293e-437f-b4b3-7e38709ade25" xlink:to="loc_npce_ComputerEquipmentAndSoftwareMember_11f385c1-b2bb-45bf-af0d-518d00e58eee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_a916cf00-bb6d-4891-ae61-b6790e0f8c87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_95c34229-293e-437f-b4b3-7e38709ade25" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_a916cf00-bb6d-4891-ae61-b6790e0f8c87" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="i1dfb4acc5429464fa921ff50a0c26db0_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_OperatingLeaseRenewalTerm_e390d264-40f7-4ab7-8f06-b19c57f0e415" xlink:href="npce-20230331.xsd#npce_OperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:to="loc_npce_OperatingLeaseRenewalTerm_e390d264-40f7-4ab7-8f06-b19c57f0e415" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e21bbc52-7855-4071-9673-980bd462dfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e21bbc52-7855-4071-9673-980bd462dfdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_OperatingLeasesAnnualRentalPayments_bc285f8c-6b50-40fd-b1c3-679d53c0cacc" xlink:href="npce-20230331.xsd#npce_OperatingLeasesAnnualRentalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:to="loc_npce_OperatingLeasesAnnualRentalPayments_bc285f8c-6b50-40fd-b1c3-679d53c0cacc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_b6ffcdfb-d473-4c42-8a01-63a4bb6844c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:to="loc_us-gaap_OperatingLeaseCost_b6ffcdfb-d473-4c42-8a01-63a4bb6844c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3c2b7fa9-f3f2-4d55-b58d-a87500b4cba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3c2b7fa9-f3f2-4d55-b58d-a87500b4cba7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f2bfbf2c-28aa-4301-9b8c-a252c5f42ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f2bfbf2c-28aa-4301-9b8c-a252c5f42ac1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_69fb7f66-ac9b-4b59-976c-9cc122cc41d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:to="loc_us-gaap_OperatingLeasePayments_69fb7f66-ac9b-4b59-976c-9cc122cc41d2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_83da115b-7211-418f-b42d-10bdc00af248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_83da115b-7211-418f-b42d-10bdc00af248" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_PurchaseObligationMinimumIncreasePercentageInNextTwoYears_36c93583-1d5d-4da5-855d-763df00a4a75" xlink:href="npce-20230331.xsd#npce_PurchaseObligationMinimumIncreasePercentageInNextTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:to="loc_npce_PurchaseObligationMinimumIncreasePercentageInNextTwoYears_36c93583-1d5d-4da5-855d-763df00a4a75" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_IndemnificationLiabilityOfficersAndDirectors_5842923d-abd3-45a3-9ab7-8852312028ad" xlink:href="npce-20230331.xsd#npce_IndemnificationLiabilityOfficersAndDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:to="loc_npce_IndemnificationLiabilityOfficersAndDirectors_5842923d-abd3-45a3-9ab7-8852312028ad" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_7bae85f7-8217-439a-a182-ab9164b8d93f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_7bae85f7-8217-439a-a182-ab9164b8d93f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_f6988a9e-033c-4eb8-85a8-1e0ee97bd2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:to="loc_us-gaap_LossContingenciesTable_f6988a9e-033c-4eb8-85a8-1e0ee97bd2aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_037e231f-94bc-4d72-b7d4-4e744d1a6707" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_f6988a9e-033c-4eb8-85a8-1e0ee97bd2aa" xlink:to="loc_srt_RangeAxis_037e231f-94bc-4d72-b7d4-4e744d1a6707" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_037e231f-94bc-4d72-b7d4-4e744d1a6707_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_037e231f-94bc-4d72-b7d4-4e744d1a6707" xlink:to="loc_srt_RangeMember_037e231f-94bc-4d72-b7d4-4e744d1a6707_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d632ba76-f29d-4157-8adb-86b6b9823ec7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_037e231f-94bc-4d72-b7d4-4e744d1a6707" xlink:to="loc_srt_RangeMember_d632ba76-f29d-4157-8adb-86b6b9823ec7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0a86372c-1a1c-4bad-bd8d-86cf599064aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d632ba76-f29d-4157-8adb-86b6b9823ec7" xlink:to="loc_srt_MinimumMember_0a86372c-1a1c-4bad-bd8d-86cf599064aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2a0482e0-d08d-4183-9156-11fa10a164ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d632ba76-f29d-4157-8adb-86b6b9823ec7" xlink:to="loc_srt_MaximumMember_2a0482e0-d08d-4183-9156-11fa10a164ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9e62bef2-f83c-405a-adb6-5ac44a65bea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_f6988a9e-033c-4eb8-85a8-1e0ee97bd2aa" xlink:to="loc_us-gaap_DebtInstrumentAxis_9e62bef2-f83c-405a-adb6-5ac44a65bea3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9e62bef2-f83c-405a-adb6-5ac44a65bea3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9e62bef2-f83c-405a-adb6-5ac44a65bea3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9e62bef2-f83c-405a-adb6-5ac44a65bea3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6a2d340c-7af8-40df-b751-0c84d021e30f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9e62bef2-f83c-405a-adb6-5ac44a65bea3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6a2d340c-7af8-40df-b751-0c84d021e30f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_LeaseFacilityMember_b9b5918c-504d-40e8-a825-6dcd2bcf573f" xlink:href="npce-20230331.xsd#npce_LeaseFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6a2d340c-7af8-40df-b751-0c84d021e30f" xlink:to="loc_npce_LeaseFacilityMember_b9b5918c-504d-40e8-a825-6dcd2bcf573f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_b05e7777-f0ee-47c9-9261-60f5358cfab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_f6988a9e-033c-4eb8-85a8-1e0ee97bd2aa" xlink:to="loc_us-gaap_LitigationStatusAxis_b05e7777-f0ee-47c9-9261-60f5358cfab3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_b05e7777-f0ee-47c9-9261-60f5358cfab3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_b05e7777-f0ee-47c9-9261-60f5358cfab3" xlink:to="loc_us-gaap_LitigationStatusDomain_b05e7777-f0ee-47c9-9261-60f5358cfab3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_f7f2ccb6-c1cf-49f8-a671-8464dba53c78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_b05e7777-f0ee-47c9-9261-60f5358cfab3" xlink:to="loc_us-gaap_LitigationStatusDomain_f7f2ccb6-c1cf-49f8-a671-8464dba53c78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_27159a46-3b54-4378-9bbb-9267554a45f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_f7f2ccb6-c1cf-49f8-a671-8464dba53c78" xlink:to="loc_us-gaap_PendingLitigationMember_27159a46-3b54-4378-9bbb-9267554a45f7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neuropace.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://neuropace.com/role/DebtNarrativeDetails" xlink:type="extended" id="i990ca4c4b12f43cc8c3eee9fa31319ef_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_054b0722-1186-47ca-b6ce-309f9e7212f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_054b0722-1186-47ca-b6ce-309f9e7212f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c1173822-86f1-49f6-8322-ce9cff1773c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c1173822-86f1-49f6-8322-ce9cff1773c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_14f80ff3-d326-4b9c-96c3-26f5d0ed3db0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_14f80ff3-d326-4b9c-96c3-26f5d0ed3db0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_00be21ac-c4ee-4e5c-8262-e20838d871c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_00be21ac-c4ee-4e5c-8262-e20838d871c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_80b96aff-7ab1-47c1-a62c-0bbe2921ff90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_80b96aff-7ab1-47c1-a62c-0bbe2921ff90" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_DebtInstrumentPrincipalPaymentNumberOfInstallment_42333c9a-fd10-4c95-9326-5b49d8058fae" xlink:href="npce-20230331.xsd#npce_DebtInstrumentPrincipalPaymentNumberOfInstallment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_npce_DebtInstrumentPrincipalPaymentNumberOfInstallment_42333c9a-fd10-4c95-9326-5b49d8058fae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_DebtInstrumentRedemptionFeePercent_fd679149-51f3-46be-a8ba-3f48be8a0a03" xlink:href="npce-20230331.xsd#npce_DebtInstrumentRedemptionFeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_npce_DebtInstrumentRedemptionFeePercent_fd679149-51f3-46be-a8ba-3f48be8a0a03" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_DebtInstrumentCovenantMinimumAnnualNetRevenue_be82118d-49d3-4f11-8f44-04f7ed91f07d" xlink:href="npce-20230331.xsd#npce_DebtInstrumentCovenantMinimumAnnualNetRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_npce_DebtInstrumentCovenantMinimumAnnualNetRevenue_be82118d-49d3-4f11-8f44-04f7ed91f07d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_fe78d196-ff85-48fe-90a6-1278b98c3e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_fe78d196-ff85-48fe-90a6-1278b98c3e2a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_c105dbe0-3d61-41ef-b466-33f735a082b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_c105dbe0-3d61-41ef-b466-33f735a082b5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_WarrantLiabilityNoncurrent_9ec79e94-9d33-4b34-b499-aa5a77d18ee7" xlink:href="npce-20230331.xsd#npce_WarrantLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_npce_WarrantLiabilityNoncurrent_9ec79e94-9d33-4b34-b499-aa5a77d18ee7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f4b332f7-097e-484c-9181-0c4209b19e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f4b332f7-097e-484c-9181-0c4209b19e5e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_7225b19b-3922-4b98-9196-aa6c18f8a09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_us-gaap_InterestExpenseDebt_7225b19b-3922-4b98-9196-aa6c18f8a09b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7b85aeb6-cfb4-4199-bc63-3784393c6a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_us-gaap_DebtInstrumentTable_7b85aeb6-cfb4-4199-bc63-3784393c6a48" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c33e72d7-b9d5-42dd-b76e-fd0bb3895c76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7b85aeb6-cfb4-4199-bc63-3784393c6a48" xlink:to="loc_us-gaap_DebtInstrumentAxis_c33e72d7-b9d5-42dd-b76e-fd0bb3895c76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c33e72d7-b9d5-42dd-b76e-fd0bb3895c76_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c33e72d7-b9d5-42dd-b76e-fd0bb3895c76" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c33e72d7-b9d5-42dd-b76e-fd0bb3895c76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a4827eae-62b7-4098-b606-277236344cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c33e72d7-b9d5-42dd-b76e-fd0bb3895c76" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a4827eae-62b7-4098-b606-277236344cf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_TermLoanMember_e2d719bc-e06a-487a-b000-8810d23014e9" xlink:href="npce-20230331.xsd#npce_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a4827eae-62b7-4098-b606-277236344cf5" xlink:to="loc_npce_TermLoanMember_e2d719bc-e06a-487a-b000-8810d23014e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1f0928ec-3d1a-4b09-ada7-c7bc8456ce4c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7b85aeb6-cfb4-4199-bc63-3784393c6a48" xlink:to="loc_srt_RangeAxis_1f0928ec-3d1a-4b09-ada7-c7bc8456ce4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1f0928ec-3d1a-4b09-ada7-c7bc8456ce4c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1f0928ec-3d1a-4b09-ada7-c7bc8456ce4c" xlink:to="loc_srt_RangeMember_1f0928ec-3d1a-4b09-ada7-c7bc8456ce4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f7695087-131e-4fc0-895e-af3f1b7c91f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1f0928ec-3d1a-4b09-ada7-c7bc8456ce4c" xlink:to="loc_srt_RangeMember_f7695087-131e-4fc0-895e-af3f1b7c91f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bfab2534-2ec1-4bbc-bfa4-616c0437dbb9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f7695087-131e-4fc0-895e-af3f1b7c91f3" xlink:to="loc_srt_MaximumMember_bfab2534-2ec1-4bbc-bfa4-616c0437dbb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f4587557-3eb8-4515-ba97-18231bf58001" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f7695087-131e-4fc0-895e-af3f1b7c91f3" xlink:to="loc_srt_MinimumMember_f4587557-3eb8-4515-ba97-18231bf58001" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_48678bc0-ec02-43ec-b88b-bf38ffb487f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7b85aeb6-cfb4-4199-bc63-3784393c6a48" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_48678bc0-ec02-43ec-b88b-bf38ffb487f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_48678bc0-ec02-43ec-b88b-bf38ffb487f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_48678bc0-ec02-43ec-b88b-bf38ffb487f2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_48678bc0-ec02-43ec-b88b-bf38ffb487f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5382b6a1-123c-4a82-a2c4-278337f42ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_48678bc0-ec02-43ec-b88b-bf38ffb487f2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5382b6a1-123c-4a82-a2c4-278337f42ae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_PaymentInCashMember_9023fc10-09d6-4bdb-9547-405646aece52" xlink:href="npce-20230331.xsd#npce_PaymentInCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5382b6a1-123c-4a82-a2c4-278337f42ae4" xlink:to="loc_npce_PaymentInCashMember_9023fc10-09d6-4bdb-9547-405646aece52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember_474eb13e-38be-4e68-8cbc-b93e1444c3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5382b6a1-123c-4a82-a2c4-278337f42ae4" xlink:to="loc_us-gaap_PaymentInKindPIKNoteMember_474eb13e-38be-4e68-8cbc-b93e1444c3b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_acef426a-c02e-43df-850e-42ac89b4730a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7b85aeb6-cfb4-4199-bc63-3784393c6a48" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_acef426a-c02e-43df-850e-42ac89b4730a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_acef426a-c02e-43df-850e-42ac89b4730a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_acef426a-c02e-43df-850e-42ac89b4730a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_acef426a-c02e-43df-850e-42ac89b4730a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3764172e-1366-4de8-bf8c-ab5581fd275e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_acef426a-c02e-43df-850e-42ac89b4730a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3764172e-1366-4de8-bf8c-ab5581fd275e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_SeriesBRedeemableConvertiblePreferredStockMember_e9c018cf-6b02-42b2-a371-7d85ec9fc77e" xlink:href="npce-20230331.xsd#npce_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3764172e-1366-4de8-bf8c-ab5581fd275e" xlink:to="loc_npce_SeriesBRedeemableConvertiblePreferredStockMember_e9c018cf-6b02-42b2-a371-7d85ec9fc77e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#DebtScheduleofMaturitiesofLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails" xlink:type="extended" id="i34217a7134ce4aecacf45358f132961e_DebtScheduleofMaturitiesofLongtermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fb10e5fc-0caa-4bce-9612-807ec1051239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_39c06912-46a7-498b-b787-5ceed0663d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fb10e5fc-0caa-4bce-9612-807ec1051239" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_39c06912-46a7-498b-b787-5ceed0663d29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ced26c20-6309-469c-84e4-7adb4bac63a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fb10e5fc-0caa-4bce-9612-807ec1051239" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ced26c20-6309-469c-84e4-7adb4bac63a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9bbfe825-7ddd-47b7-b32f-2a629ff129b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fb10e5fc-0caa-4bce-9612-807ec1051239" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9bbfe825-7ddd-47b7-b32f-2a629ff129b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0bde3815-4435-4fa7-a971-b7a0f0ee4063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fb10e5fc-0caa-4bce-9612-807ec1051239" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0bde3815-4435-4fa7-a971-b7a0f0ee4063" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_148cdde5-c1d6-4132-9226-f6b19617fb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fb10e5fc-0caa-4bce-9612-807ec1051239" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_148cdde5-c1d6-4132-9226-f6b19617fb2f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_9335a7e6-08df-414c-aa79-2f4494c61fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fb10e5fc-0caa-4bce-9612-807ec1051239" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_9335a7e6-08df-414c-aa79-2f4494c61fd3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_DebtInstrumentUnamortizedInterestCost_494d8774-18fd-42c5-8bc6-e11815e2b04a" xlink:href="npce-20230331.xsd#npce_DebtInstrumentUnamortizedInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fb10e5fc-0caa-4bce-9612-807ec1051239" xlink:to="loc_npce_DebtInstrumentUnamortizedInterestCost_494d8774-18fd-42c5-8bc6-e11815e2b04a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d9088885-0cfc-4adc-8b19-78fb7829ae5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fb10e5fc-0caa-4bce-9612-807ec1051239" xlink:to="loc_us-gaap_LongTermDebt_d9088885-0cfc-4adc-8b19-78fb7829ae5b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_61b7f742-2938-4ac9-9be4-2c064d0908fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fb10e5fc-0caa-4bce-9612-807ec1051239" xlink:to="loc_us-gaap_DebtInstrumentTable_61b7f742-2938-4ac9-9be4-2c064d0908fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_aa2a5767-b9aa-40df-b086-9eaaec894aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_61b7f742-2938-4ac9-9be4-2c064d0908fd" xlink:to="loc_us-gaap_DebtInstrumentAxis_aa2a5767-b9aa-40df-b086-9eaaec894aa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_aa2a5767-b9aa-40df-b086-9eaaec894aa9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_aa2a5767-b9aa-40df-b086-9eaaec894aa9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_aa2a5767-b9aa-40df-b086-9eaaec894aa9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f54dfe1a-59fb-474a-917d-5559b9970ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_aa2a5767-b9aa-40df-b086-9eaaec894aa9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f54dfe1a-59fb-474a-917d-5559b9970ed8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_TermLoanMember_c1b78f11-4c88-42d4-885a-9208bf02cb7b" xlink:href="npce-20230331.xsd#npce_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f54dfe1a-59fb-474a-917d-5559b9970ed8" xlink:to="loc_npce_TermLoanMember_c1b78f11-4c88-42d4-885a-9208bf02cb7b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neuropace.com/role/CommonStockDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#CommonStockDetails"/>
  <link:definitionLink xlink:role="http://neuropace.com/role/CommonStockDetails" xlink:type="extended" id="i47b4b1797fb04369b526ca67d5d94a20_CommonStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d56d84b2-cc11-4b6b-bd88-08d7fa0266db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9f54be57-4b24-4002-8523-415b56d6e581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d56d84b2-cc11-4b6b-bd88-08d7fa0266db" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9f54be57-4b24-4002-8523-415b56d6e581" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cc993ead-d145-415e-9944-235d7a1c2cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d56d84b2-cc11-4b6b-bd88-08d7fa0266db" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cc993ead-d145-415e-9944-235d7a1c2cd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_2cc89f3d-d8ff-4a25-8238-7981295cdad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d56d84b2-cc11-4b6b-bd88-08d7fa0266db" xlink:to="loc_us-gaap_DividendsCommonStockCash_2cc89f3d-d8ff-4a25-8238-7981295cdad1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_58a64ecc-47a9-462f-9e94-6c3c851cbbec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d56d84b2-cc11-4b6b-bd88-08d7fa0266db" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_58a64ecc-47a9-462f-9e94-6c3c851cbbec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b6d182c5-45bd-4745-9834-7d9bc972e6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_d56d84b2-cc11-4b6b-bd88-08d7fa0266db" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b6d182c5-45bd-4745-9834-7d9bc972e6ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6567795b-f7ce-4cbb-96cb-87d84acf7740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b6d182c5-45bd-4745-9834-7d9bc972e6ed" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6567795b-f7ce-4cbb-96cb-87d84acf7740" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6567795b-f7ce-4cbb-96cb-87d84acf7740_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6567795b-f7ce-4cbb-96cb-87d84acf7740" xlink:to="loc_us-gaap_ClassOfStockDomain_6567795b-f7ce-4cbb-96cb-87d84acf7740_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5bb92ca6-5a94-4742-9bf3-1b03f6c5d3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6567795b-f7ce-4cbb-96cb-87d84acf7740" xlink:to="loc_us-gaap_ClassOfStockDomain_5bb92ca6-5a94-4742-9bf3-1b03f6c5d3b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_OptionsAvailableForGrant2021PlanMember_25609fa3-6d0c-4ad2-bfac-1615191778c5" xlink:href="npce-20230331.xsd#npce_OptionsAvailableForGrant2021PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5bb92ca6-5a94-4742-9bf3-1b03f6c5d3b8" xlink:to="loc_npce_OptionsAvailableForGrant2021PlanMember_25609fa3-6d0c-4ad2-bfac-1615191778c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_OutstandingOptions2021PlanMember_86a8005a-c2f0-486e-809f-302e8e5a160e" xlink:href="npce-20230331.xsd#npce_OutstandingOptions2021PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5bb92ca6-5a94-4742-9bf3-1b03f6c5d3b8" xlink:to="loc_npce_OutstandingOptions2021PlanMember_86a8005a-c2f0-486e-809f-302e8e5a160e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_OptionsRestrictedStockUnit2021PlanMember_ddf40e20-f389-4399-ad0a-9d615d684509" xlink:href="npce-20230331.xsd#npce_OptionsRestrictedStockUnit2021PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5bb92ca6-5a94-4742-9bf3-1b03f6c5d3b8" xlink:to="loc_npce_OptionsRestrictedStockUnit2021PlanMember_ddf40e20-f389-4399-ad0a-9d615d684509" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_CommonStockAvailableForESPPMember_f2eb361c-0b78-46f3-a4df-fb97c604f635" xlink:href="npce-20230331.xsd#npce_CommonStockAvailableForESPPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5bb92ca6-5a94-4742-9bf3-1b03f6c5d3b8" xlink:to="loc_npce_CommonStockAvailableForESPPMember_f2eb361c-0b78-46f3-a4df-fb97c604f635" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofAvailableforGrantDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#StockBasedIncentiveCompensationPlansScheduleofAvailableforGrantDetails"/>
  <link:definitionLink xlink:role="http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofAvailableforGrantDetails" xlink:type="extended" id="i00f98e13864b43a39a9b474af36f65e6_StockBasedIncentiveCompensationPlansScheduleofAvailableforGrantDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72bdb770-7793-4ed9-a8d3-17dbab3348e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_a6a93d3a-615b-4ab3-9278-60ec2fef7d06" xlink:href="npce-20230331.xsd#npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72bdb770-7793-4ed9-a8d3-17dbab3348e2" xlink:to="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_a6a93d3a-615b-4ab3-9278-60ec2fef7d06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_651a79a7-4ae6-4528-a6ba-24b1197f82c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_a6a93d3a-615b-4ab3-9278-60ec2fef7d06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_651a79a7-4ae6-4528-a6ba-24b1197f82c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_249e606e-8680-42e5-9298-3247fe63b580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_a6a93d3a-615b-4ab3-9278-60ec2fef7d06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_249e606e-8680-42e5-9298-3247fe63b580" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod_e295dd23-6870-4f4d-b1b3-a99a32f17bd4" xlink:href="npce-20230331.xsd#npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_a6a93d3a-615b-4ab3-9278-60ec2fef7d06" xlink:to="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod_e295dd23-6870-4f4d-b1b3-a99a32f17bd4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod_d4ef6b79-1ae5-4244-887f-5bb7dae85c72" xlink:href="npce-20230331.xsd#npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_a6a93d3a-615b-4ab3-9278-60ec2fef7d06" xlink:to="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod_d4ef6b79-1ae5-4244-887f-5bb7dae85c72" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes_884efd04-0d66-49f3-9f3c-ccb02f6b51b5" xlink:href="npce-20230331.xsd#npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_a6a93d3a-615b-4ab3-9278-60ec2fef7d06" xlink:to="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes_884efd04-0d66-49f3-9f3c-ccb02f6b51b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a11c53ae-1983-4299-be36-2be5485f4eed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a39c660-08f2-43f9-8bd6-829db35f394a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72bdb770-7793-4ed9-a8d3-17dbab3348e2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a39c660-08f2-43f9-8bd6-829db35f394a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a443f7da-b2d9-4976-ba33-a57b318305e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a39c660-08f2-43f9-8bd6-829db35f394a" xlink:to="loc_us-gaap_PlanNameAxis_a443f7da-b2d9-4976-ba33-a57b318305e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a443f7da-b2d9-4976-ba33-a57b318305e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_a443f7da-b2d9-4976-ba33-a57b318305e8" xlink:to="loc_us-gaap_PlanNameDomain_a443f7da-b2d9-4976-ba33-a57b318305e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_94c15029-5eba-4ec1-82f8-f190573cff23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_a443f7da-b2d9-4976-ba33-a57b318305e8" xlink:to="loc_us-gaap_PlanNameDomain_94c15029-5eba-4ec1-82f8-f190573cff23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_A2021EquityIncentivePlanMember_d0275ecc-da73-4cc0-b4bf-b99d87ba083d" xlink:href="npce-20230331.xsd#npce_A2021EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_94c15029-5eba-4ec1-82f8-f190573cff23" xlink:to="loc_npce_A2021EquityIncentivePlanMember_d0275ecc-da73-4cc0-b4bf-b99d87ba083d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#StockBasedIncentiveCompensationPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails" xlink:type="extended" id="i95072278a9454c11a9294628d2eea47f_StockBasedIncentiveCompensationPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cda8b0f3-9faf-46bc-a5cf-581e07d44db9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase_e678c487-3a1e-4260-9043-9de885f5a04f" xlink:href="npce-20230331.xsd#npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cda8b0f3-9faf-46bc-a5cf-581e07d44db9" xlink:to="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase_e678c487-3a1e-4260-9043-9de885f5a04f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_9e9de6a9-371c-40b1-a05b-5c33ec0172ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cda8b0f3-9faf-46bc-a5cf-581e07d44db9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_9e9de6a9-371c-40b1-a05b-5c33ec0172ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_EmployeeStockPurchasePlanLengthOfOfferingPeriod_5224f660-f1cd-41b7-95b1-410c4655433d" xlink:href="npce-20230331.xsd#npce_EmployeeStockPurchasePlanLengthOfOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cda8b0f3-9faf-46bc-a5cf-581e07d44db9" xlink:to="loc_npce_EmployeeStockPurchasePlanLengthOfOfferingPeriod_5224f660-f1cd-41b7-95b1-410c4655433d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_74db27b5-00ce-4860-8c62-b1f02b20c842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cda8b0f3-9faf-46bc-a5cf-581e07d44db9" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_74db27b5-00ce-4860-8c62-b1f02b20c842" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_363c9036-8b6b-4558-a712-f216743dcc07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cda8b0f3-9faf-46bc-a5cf-581e07d44db9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_363c9036-8b6b-4558-a712-f216743dcc07" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8b2ffef5-e38e-43fe-b051-56dbc0f55543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cda8b0f3-9faf-46bc-a5cf-581e07d44db9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8b2ffef5-e38e-43fe-b051-56dbc0f55543" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_EmployeeStockPurchasePlanOfferingPeriod_8d6b3328-8a4d-4d92-9cef-ede7cc650cb2" xlink:href="npce-20230331.xsd#npce_EmployeeStockPurchasePlanOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cda8b0f3-9faf-46bc-a5cf-581e07d44db9" xlink:to="loc_npce_EmployeeStockPurchasePlanOfferingPeriod_8d6b3328-8a4d-4d92-9cef-ede7cc650cb2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_02cd325f-f7f8-4114-b5ba-cd48865dfaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cda8b0f3-9faf-46bc-a5cf-581e07d44db9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_02cd325f-f7f8-4114-b5ba-cd48865dfaf8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_475535e0-adde-4ed9-af68-0c1f2008bea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cda8b0f3-9faf-46bc-a5cf-581e07d44db9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_475535e0-adde-4ed9-af68-0c1f2008bea1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_f24f096c-a28b-46b1-9161-aba94a36cc22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cda8b0f3-9faf-46bc-a5cf-581e07d44db9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_f24f096c-a28b-46b1-9161-aba94a36cc22" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ade11c2e-724a-44c0-94eb-2aa28350a7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cda8b0f3-9faf-46bc-a5cf-581e07d44db9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ade11c2e-724a-44c0-94eb-2aa28350a7b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_30005ef5-098d-4f0e-964e-db935acc0775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ade11c2e-724a-44c0-94eb-2aa28350a7b4" xlink:to="loc_us-gaap_PlanNameAxis_30005ef5-098d-4f0e-964e-db935acc0775" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_30005ef5-098d-4f0e-964e-db935acc0775_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_30005ef5-098d-4f0e-964e-db935acc0775" xlink:to="loc_us-gaap_PlanNameDomain_30005ef5-098d-4f0e-964e-db935acc0775_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_66e02ff6-97c5-4f7a-9c68-3b16e6c6e5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_30005ef5-098d-4f0e-964e-db935acc0775" xlink:to="loc_us-gaap_PlanNameDomain_66e02ff6-97c5-4f7a-9c68-3b16e6c6e5f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_A2021EmployeeStockPurchasePlanMember_c8940d99-a567-4179-9575-17e896e5d068" xlink:href="npce-20230331.xsd#npce_A2021EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_66e02ff6-97c5-4f7a-9c68-3b16e6c6e5f4" xlink:to="loc_npce_A2021EmployeeStockPurchasePlanMember_c8940d99-a567-4179-9575-17e896e5d068" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_5382fef2-b8f9-4654-b3d6-b539611a5eeb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ade11c2e-724a-44c0-94eb-2aa28350a7b4" xlink:to="loc_srt_StatementScenarioAxis_5382fef2-b8f9-4654-b3d6-b539611a5eeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_5382fef2-b8f9-4654-b3d6-b539611a5eeb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_5382fef2-b8f9-4654-b3d6-b539611a5eeb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_5382fef2-b8f9-4654-b3d6-b539611a5eeb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_21af9b2e-75ba-4612-be74-212bc530d77c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_5382fef2-b8f9-4654-b3d6-b539611a5eeb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_21af9b2e-75ba-4612-be74-212bc530d77c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_86ee3e47-9a39-4ab1-9ca8-1922fe6fee7f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_21af9b2e-75ba-4612-be74-212bc530d77c" xlink:to="loc_srt_ScenarioForecastMember_86ee3e47-9a39-4ab1-9ca8-1922fe6fee7f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails" xlink:type="extended" id="ibffdcab19e814f98b0c7587c7533cf64_StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5730c9c3-90fa-42ef-876b-1e9a0eca63ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04dcdc5c-2a2d-4f11-9851-165d6798ef1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5730c9c3-90fa-42ef-876b-1e9a0eca63ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04dcdc5c-2a2d-4f11-9851-165d6798ef1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_78c8d004-9f2a-4202-8fe7-547ba11eaa54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04dcdc5c-2a2d-4f11-9851-165d6798ef1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_78c8d004-9f2a-4202-8fe7-547ba11eaa54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_929a265a-33f9-49d5-90dd-209b0402cb95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04dcdc5c-2a2d-4f11-9851-165d6798ef1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_929a265a-33f9-49d5-90dd-209b0402cb95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_752f6608-c3d2-431e-a3b0-3d8ce01da755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04dcdc5c-2a2d-4f11-9851-165d6798ef1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_752f6608-c3d2-431e-a3b0-3d8ce01da755" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6fe1b52a-50b9-4824-ad59-3efa5991f9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04dcdc5c-2a2d-4f11-9851-165d6798ef1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6fe1b52a-50b9-4824-ad59-3efa5991f9c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ae9c250-38ec-4ec2-b9d0-31b74481ac36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3034f7ba-e271-4370-804e-e659acaf5d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5730c9c3-90fa-42ef-876b-1e9a0eca63ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3034f7ba-e271-4370-804e-e659acaf5d54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e260c41d-252d-45d7-8365-48b71c1f5b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3034f7ba-e271-4370-804e-e659acaf5d54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e260c41d-252d-45d7-8365-48b71c1f5b1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b2047d5e-4dbd-438e-96b1-9b5dcf2fcd35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3034f7ba-e271-4370-804e-e659acaf5d54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b2047d5e-4dbd-438e-96b1-9b5dcf2fcd35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b4652620-9386-472c-bc1e-ecf9579306df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3034f7ba-e271-4370-804e-e659acaf5d54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b4652620-9386-472c-bc1e-ecf9579306df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d17e1281-2dda-4238-ad92-746596c360ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3034f7ba-e271-4370-804e-e659acaf5d54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d17e1281-2dda-4238-ad92-746596c360ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a9f677df-da0d-4722-8053-820b4780c888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3ea51695-dd1d-478c-954c-51d91a3c4c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5730c9c3-90fa-42ef-876b-1e9a0eca63ca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3ea51695-dd1d-478c-954c-51d91a3c4c4d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_39b4a0dd-eef0-478a-aa80-d95053a83882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3ea51695-dd1d-478c-954c-51d91a3c4c4d" xlink:to="loc_us-gaap_AwardTypeAxis_39b4a0dd-eef0-478a-aa80-d95053a83882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39b4a0dd-eef0-478a-aa80-d95053a83882_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_39b4a0dd-eef0-478a-aa80-d95053a83882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39b4a0dd-eef0-478a-aa80-d95053a83882_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f61bb268-51fe-469a-87e8-21adaffb61cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_39b4a0dd-eef0-478a-aa80-d95053a83882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f61bb268-51fe-469a-87e8-21adaffb61cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_81c8f059-6cdf-4c50-a229-a122054944ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f61bb268-51fe-469a-87e8-21adaffb61cf" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_81c8f059-6cdf-4c50-a229-a122054944ea" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRecognizedStockbasedCompensationDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#StockBasedIncentiveCompensationPlansScheduleofRecognizedStockbasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRecognizedStockbasedCompensationDetails" xlink:type="extended" id="i83bf7aca1cdb467187538002d4f91dd8_StockBasedIncentiveCompensationPlansScheduleofRecognizedStockbasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffa518db-a958-4f38-acfd-2ce63fc5d903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b277bf2e-ff91-48d9-a6b5-b7cdfb40779a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffa518db-a958-4f38-acfd-2ce63fc5d903" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b277bf2e-ff91-48d9-a6b5-b7cdfb40779a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ce600f7-33a9-4c54-978e-14cb7509b4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffa518db-a958-4f38-acfd-2ce63fc5d903" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ce600f7-33a9-4c54-978e-14cb7509b4de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1d9a8185-6928-45b7-ae66-beb36d995efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ce600f7-33a9-4c54-978e-14cb7509b4de" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1d9a8185-6928-45b7-ae66-beb36d995efd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1d9a8185-6928-45b7-ae66-beb36d995efd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1d9a8185-6928-45b7-ae66-beb36d995efd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1d9a8185-6928-45b7-ae66-beb36d995efd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_568e1305-85ae-44ce-868b-873e3076a9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1d9a8185-6928-45b7-ae66-beb36d995efd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_568e1305-85ae-44ce-868b-873e3076a9c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_ec877bae-c33e-4853-bab7-491857e1b226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_568e1305-85ae-44ce-868b-873e3076a9c6" xlink:to="loc_us-gaap_CostOfSalesMember_ec877bae-c33e-4853-bab7-491857e1b226" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c5952993-8ff9-45c7-afd5-7987e5c68e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_568e1305-85ae-44ce-868b-873e3076a9c6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c5952993-8ff9-45c7-afd5-7987e5c68e4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_db9045e2-3dd9-4983-8459-9d11ec61644a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_568e1305-85ae-44ce-868b-873e3076a9c6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_db9045e2-3dd9-4983-8459-9d11ec61644a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_abb7ece6-e8ce-43c2-aa19-e5a112b5d91a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ce600f7-33a9-4c54-978e-14cb7509b4de" xlink:to="loc_us-gaap_AwardTypeAxis_abb7ece6-e8ce-43c2-aa19-e5a112b5d91a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abb7ece6-e8ce-43c2-aa19-e5a112b5d91a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_abb7ece6-e8ce-43c2-aa19-e5a112b5d91a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abb7ece6-e8ce-43c2-aa19-e5a112b5d91a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b7870e33-fefa-4e3c-8f9d-371160921010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_abb7ece6-e8ce-43c2-aa19-e5a112b5d91a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b7870e33-fefa-4e3c-8f9d-371160921010" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_StockOptionsAndRestrictedStockUnitsMember_b33b34e3-905f-4c9c-a7c7-7ea0dd8a5c5f" xlink:href="npce-20230331.xsd#npce_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b7870e33-fefa-4e3c-8f9d-371160921010" xlink:to="loc_npce_StockOptionsAndRestrictedStockUnitsMember_b33b34e3-905f-4c9c-a7c7-7ea0dd8a5c5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_0504b83a-8636-4a6d-a068-9e4d15225988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b7870e33-fefa-4e3c-8f9d-371160921010" xlink:to="loc_us-gaap_EmployeeStockMember_0504b83a-8636-4a6d-a068-9e4d15225988" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesOutstandingDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#NetLossperShareAttributabletoCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesOutstandingDetails"/>
  <link:definitionLink xlink:role="http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesOutstandingDetails" xlink:type="extended" id="iecf710a14bd942d080092739c785cf10_NetLossperShareAttributabletoCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aee82482-11e1-461b-a053-1e2432fa84b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_35b9a0c8-1d25-4087-9eb7-ba46a71cae64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aee82482-11e1-461b-a053-1e2432fa84b6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_35b9a0c8-1d25-4087-9eb7-ba46a71cae64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_50a98c5d-7310-4368-ab95-9819cbc4ae97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aee82482-11e1-461b-a053-1e2432fa84b6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_50a98c5d-7310-4368-ab95-9819cbc4ae97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0bc22ad4-b49b-417d-ba9a-dac43a5b02f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_50a98c5d-7310-4368-ab95-9819cbc4ae97" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0bc22ad4-b49b-417d-ba9a-dac43a5b02f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0bc22ad4-b49b-417d-ba9a-dac43a5b02f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0bc22ad4-b49b-417d-ba9a-dac43a5b02f9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0bc22ad4-b49b-417d-ba9a-dac43a5b02f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c00a9b56-b05d-4e94-b572-bd8086277de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0bc22ad4-b49b-417d-ba9a-dac43a5b02f9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c00a9b56-b05d-4e94-b572-bd8086277de7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e2b0c59b-0c96-4627-8471-13d5daa434cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c00a9b56-b05d-4e94-b572-bd8086277de7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e2b0c59b-0c96-4627-8471-13d5daa434cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember_f4265edc-f8f0-48dd-8737-f05492fa554a" xlink:href="npce-20230331.xsd#npce_ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c00a9b56-b05d-4e94-b572-bd8086277de7" xlink:to="loc_npce_ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember_f4265edc-f8f0-48dd-8737-f05492fa554a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_2e410424-ffc2-4559-b61b-8b72b338c7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c00a9b56-b05d-4e94-b572-bd8086277de7" xlink:to="loc_us-gaap_EmployeeStockMember_2e410424-ffc2-4559-b61b-8b72b338c7ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8d6f803e-903a-48ab-b877-8f6d5607c7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c00a9b56-b05d-4e94-b572-bd8086277de7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8d6f803e-903a-48ab-b877-8f6d5607c7f9" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>npce-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1fd4e094-c2e9-4b44-9de8-fd1ff4c54731,g:0a3c8fdc-3cf9-40a0-97f2-986b9fb768aa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_npce_DebtInstrumentPrincipalPaymentNumberOfInstallment_4ac2c103-45af-4e16-8dae-0795caeb65ff_terseLabel_en-US" xlink:label="lab_npce_DebtInstrumentPrincipalPaymentNumberOfInstallment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payment number of installment</link:label>
    <link:label id="lab_npce_DebtInstrumentPrincipalPaymentNumberOfInstallment_label_en-US" xlink:label="lab_npce_DebtInstrumentPrincipalPaymentNumberOfInstallment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Principal Payment Number of Installment</link:label>
    <link:label id="lab_npce_DebtInstrumentPrincipalPaymentNumberOfInstallment_documentation_en-US" xlink:label="lab_npce_DebtInstrumentPrincipalPaymentNumberOfInstallment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Principal Payment Number of Installment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_DebtInstrumentPrincipalPaymentNumberOfInstallment" xlink:href="npce-20230331.xsd#npce_DebtInstrumentPrincipalPaymentNumberOfInstallment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_DebtInstrumentPrincipalPaymentNumberOfInstallment" xlink:to="lab_npce_DebtInstrumentPrincipalPaymentNumberOfInstallment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCosts_f0408a60-f8ad-4950-9719-81e86042bb9f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredCosts_label_en-US" xlink:label="lab_us-gaap_DeferredCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCosts" xlink:to="lab_us-gaap_DeferredCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1a0abea4-64eb-4ff3-812d-150e899ab926_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e8d9a720-a4ea-4d38-9e7b-d96db453e0cc_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_579183e8-7276-4cfe-8c72-97784a1db8ff_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_a1fa111d-9833-49f6-9226-cdb14e3e3f9f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation earned</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_dcdeb9e0-30bf-47a6-88c8-a06746c8c62b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_dd020c0b-af5b-42bd-a76e-1b54f654b5bd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_655c8271-768f-41e3-9ba4-141b8d6a4dbe_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTerm_a7610509-ffc2-4a6b-9066-548cb456fa4f_terseLabel_en-US" xlink:label="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant period (in years)</link:label>
    <link:label id="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTerm_label_en-US" xlink:label="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement with Federal Government, Term</link:label>
    <link:label id="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTerm_documentation_en-US" xlink:label="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement with Federal Government, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTerm" xlink:href="npce-20230331.xsd#npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTerm" xlink:to="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_10eb469a-2a7d-43cc-bc48-06842ac53fbd_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed income mutual fund, included in short-term investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_34fda9ed-ce3f-4106-b140-00dea4b63eec_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_accdd6ba-b1d4-41df-a0fe-eb54609f9d9c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO_8634b08b-c4bb-4e29-93eb-822ad9d7fd44_terseLabel_en-US" xlink:label="lab_npce_DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum cash and cash equivalents required after completion of IPO</link:label>
    <link:label id="lab_npce_DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO_label_en-US" xlink:label="lab_npce_DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Minimum Cash and Cash Equivalents Required After Completion of IPO</link:label>
    <link:label id="lab_npce_DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO_documentation_en-US" xlink:label="lab_npce_DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Minimum Cash and Cash Equivalents Required After Completion of IPO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO" xlink:href="npce-20230331.xsd#npce_DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO" xlink:to="lab_npce_DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_7f686385-91bc-45fb-8455-63acc27f1662_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_79a2a5f5-b670-41bd-969f-996b01bb96e0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_f40ed57c-80ae-4fe8-9f13-cb61cbee13ae_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance or sale by company of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_60bcedee-3bba-436a-8319-8c408e1ae52e_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_dcaf1390-675c-4c1d-aedf-347403232f0e_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_583dc513-f81c-4de1-9eb0-853a17383a45_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation (less than $0.1 million for both periods)</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_PaymentInCashMember_639ea748-9440-430d-8e2d-805e5bf27614_terseLabel_en-US" xlink:label="lab_npce_PaymentInCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment In Cash</link:label>
    <link:label id="lab_npce_PaymentInCashMember_label_en-US" xlink:label="lab_npce_PaymentInCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment In Cash [Member]</link:label>
    <link:label id="lab_npce_PaymentInCashMember_documentation_en-US" xlink:label="lab_npce_PaymentInCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment In Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_PaymentInCashMember" xlink:href="npce-20230331.xsd#npce_PaymentInCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_PaymentInCashMember" xlink:to="lab_npce_PaymentInCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1eee3c09-051d-46be-b523-bda62d6d8a26_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock pursuant to stock option exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2ab44c41-9153-48f2-a568-810f2edab4e4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_b5dabe58-aa90-4c26-9452-1e4257fab42b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_32293824-635d-450c-b37e-ade04497e3db_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6fb749e2-ab43-4d99-8df8-de355b978b33_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_OptionsAvailableForGrant2021PlanMember_c0d59203-505c-46c3-9dfe-7ed7454483de_terseLabel_en-US" xlink:label="lab_npce_OptionsAvailableForGrant2021PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future grant under the 2021 Plan</link:label>
    <link:label id="lab_npce_OptionsAvailableForGrant2021PlanMember_label_en-US" xlink:label="lab_npce_OptionsAvailableForGrant2021PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Available for Grant, 2021 Plan [Member]</link:label>
    <link:label id="lab_npce_OptionsAvailableForGrant2021PlanMember_documentation_en-US" xlink:label="lab_npce_OptionsAvailableForGrant2021PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Available for Grant, 2021 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_OptionsAvailableForGrant2021PlanMember" xlink:href="npce-20230331.xsd#npce_OptionsAvailableForGrant2021PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_OptionsAvailableForGrant2021PlanMember" xlink:to="lab_npce_OptionsAvailableForGrant2021PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f442d022-3a6e-4a25-8781-0ff16633abef_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_a50a07d2-4642-4968-8db2-702664c610f7_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a38ebfd5-5845-4046-a6c4-594c11e4a5c0_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_82457fd0-4024-4e77-8e6b-0c4c67fc3fb3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_27499144-4cae-4d53-af98-e95ae83b80ee_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_84fdb41a-3ac4-497f-a02d-0298aa44f740_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_a2f1377e-ffed-4391-ba92-5f7c73951a3d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_faa8073c-bbe9-4be6-a185-cb1913507f59_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_8bd096f8-f02c-4b0c-bcc5-22424ffa206b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_SaleOfStockUnderwritingDiscounts_056eba30-7de7-4fc8-9b7e-1c5578048382_terseLabel_en-US" xlink:label="lab_npce_SaleOfStockUnderwritingDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, underwriting discounts</link:label>
    <link:label id="lab_npce_SaleOfStockUnderwritingDiscounts_label_en-US" xlink:label="lab_npce_SaleOfStockUnderwritingDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Underwriting Discounts</link:label>
    <link:label id="lab_npce_SaleOfStockUnderwritingDiscounts_documentation_en-US" xlink:label="lab_npce_SaleOfStockUnderwritingDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Underwriting Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_SaleOfStockUnderwritingDiscounts" xlink:href="npce-20230331.xsd#npce_SaleOfStockUnderwritingDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_SaleOfStockUnderwritingDiscounts" xlink:to="lab_npce_SaleOfStockUnderwritingDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_OperatingLeaseRenewalTerm_1352e682-13ce-4e23-ab60-699dcad87819_terseLabel_en-US" xlink:label="lab_npce_OperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_npce_OperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_npce_OperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Renewal term</link:label>
    <link:label id="lab_npce_OperatingLeaseRenewalTerm_documentation_en-US" xlink:label="lab_npce_OperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Renewal term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_OperatingLeaseRenewalTerm" xlink:href="npce-20230331.xsd#npce_OperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_OperatingLeaseRenewalTerm" xlink:to="lab_npce_OperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_9f11d9f6-1673-4cc2-b9d6-bca0faa03bb3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_19fec3c6-de6d-45b6-8f2a-69fcd433fae3_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_OptionsRestrictedStockUnit2021PlanMember_0e03e401-8722-488e-bc56-ec696d7551a3_terseLabel_en-US" xlink:label="lab_npce_OptionsRestrictedStockUnit2021PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding restricted stock units under the 2021 Plan</link:label>
    <link:label id="lab_npce_OptionsRestrictedStockUnit2021PlanMember_label_en-US" xlink:label="lab_npce_OptionsRestrictedStockUnit2021PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Restricted Stock Unit, 2021 Plan [Member]</link:label>
    <link:label id="lab_npce_OptionsRestrictedStockUnit2021PlanMember_documentation_en-US" xlink:label="lab_npce_OptionsRestrictedStockUnit2021PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Restricted Stock Unit, 2021 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_OptionsRestrictedStockUnit2021PlanMember" xlink:href="npce-20230331.xsd#npce_OptionsRestrictedStockUnit2021PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_OptionsRestrictedStockUnit2021PlanMember" xlink:to="lab_npce_OptionsRestrictedStockUnit2021PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0ff6070f-3e52-43a6-bcf1-e41fbe78b1a8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_AccruedInventoryLiabilityCurrent_fde5fa0e-1a05-454c-9431-234a94d9975f_terseLabel_en-US" xlink:label="lab_npce_AccruedInventoryLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory-raw materials</link:label>
    <link:label id="lab_npce_AccruedInventoryLiabilityCurrent_label_en-US" xlink:label="lab_npce_AccruedInventoryLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Inventory Liability, Current</link:label>
    <link:label id="lab_npce_AccruedInventoryLiabilityCurrent_documentation_en-US" xlink:label="lab_npce_AccruedInventoryLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Inventory Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_AccruedInventoryLiabilityCurrent" xlink:href="npce-20230331.xsd#npce_AccruedInventoryLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_AccruedInventoryLiabilityCurrent" xlink:to="lab_npce_AccruedInventoryLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_31809037-0319-4065-9471-14c3b9177ff1_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_9f20e69c-8c3a-4dbf-a375-68aeaf697f3f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost not yet recognized, amount</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_2fc329e5-8ab5-424d-bc09-0c5b7e2781ec_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2d507636-6bf4-42ed-9b7f-c954aeb0c181_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 (remaining nine months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_39618511-c780-4f50-8e20-e8cd53e77fca_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_51665284-4b89-4cf5-a4a3-2c49ef62c33a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_5f73bdd4-7c8b-43e4-87c2-768ad6314832_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_eb4cdfa3-47c5-48c2-99f3-6354c2c43284_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_2f09844b-51f4-4e2c-b794-464f90f60b8d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares committed under ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70734dfe-a837-4a08-80ac-aee8212a62c3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_1d85d0ea-b325-453e-a789-8a2b61beb534_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e98b362-e77f-45e8-b017-426ffda543a6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_be7b56d1-ba14-42f9-98e9-21eb1f0c4009_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_68227663-d5ec-40d4-b1b7-cf5dcad9ec04_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_5dca9a18-3dbe-41d1-8786-1b3f4e93efbf_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3f4e0adb-f03d-44ea-ba2e-5f13523c7893_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_9bb979ad-aa1b-4bda-8ac0-a6d135b3e832_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_a3678293-5ab3-41fc-bccb-a913a87df1b0_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7be3657f-bf1f-48d8-aed2-5bee5753f8a0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39ec174d-d344-4b92-93b0-dc5586d20f83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_80f8361d-7544-4e5e-8918-b61093ac9dc7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8b688345-d0d6-4dcf-875f-84c408b8c368_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_0c57fa6d-5274-4aab-9364-09c6c94f47f7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_badb87ec-51ef-4be9-a083-3d094e7adc77_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_e1bd78a0-e106-4f49-8636-edc2469ebadc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_b5ca9158-04a7-4c22-91aa-9d1413d192bc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6868e237-937d-43e0-9d2d-94c8f838bd01_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dc7b4958-3c3c-4878-8d4d-bb12ca1c32c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_eb13471d-7e5c-4e14-a972-d3570211bb70_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares Underlying Outstanding Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_f7cecedf-a466-4596-a909-4c9cfa2385cc_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_a548e930-c701-4d4d-834b-11e92b7cda35_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a01c867a-33e3-429d-9983-131b1a25526a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5cc244e0-cc91-4873-bfbe-ffcde071790f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_5676f6a0-a44d-4a7d-b313-4d9a3372e55d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_6d576353-aa86-46d2-852d-f6235acb6228_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_65f03e8b-8ff1-4a1d-a989-c11a8ba7944f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8386ff6c-2154-44f1-8d4d-1b26888b172f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_06a5fbf5-513d-404c-8459-f16608305b4f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_AtTheMarketEquityOfferingMember_63ac17de-db36-4be0-bd7f-8c291cdb7d22_terseLabel_en-US" xlink:label="lab_npce_AtTheMarketEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-Market Equity Offering</link:label>
    <link:label id="lab_npce_AtTheMarketEquityOfferingMember_label_en-US" xlink:label="lab_npce_AtTheMarketEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-Market Equity Offering [Member]</link:label>
    <link:label id="lab_npce_AtTheMarketEquityOfferingMember_documentation_en-US" xlink:label="lab_npce_AtTheMarketEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-Market Equity Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_AtTheMarketEquityOfferingMember" xlink:href="npce-20230331.xsd#npce_AtTheMarketEquityOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_AtTheMarketEquityOfferingMember" xlink:to="lab_npce_AtTheMarketEquityOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_57d05d91-6d15-4919-90d1-b6e5bad985d0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on short-term investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_d50300c1-7904-4cf2-90ec-8241fa9c9cbc_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_b92bfc36-038b-43ef-90db-39900d327054_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_b78418be-9d89-4191-ba7c-02528472e021_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share of Class A common stock:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_b48fc9bb-5306-4e58-93a6-4365ae13dc42_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_2701cf7d-ad3c-404a-9ff5-4faf53d41f85_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFundingAgreementTermsMember_6692c2b1-b7f4-4cea-9bf0-9b4d6890cc89_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFundingAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Funding Agreement Terms</link:label>
    <link:label id="lab_us-gaap_AdditionalFundingAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_AdditionalFundingAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Funding Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFundingAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFundingAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFundingAgreementTermsMember" xlink:to="lab_us-gaap_AdditionalFundingAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_f369fbb1-94c2-488e-ae2f-56962b76c342_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities, Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ce6a3f41-fadb-452e-9fa7-2a783dfe424f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3b706c32-ddbf-4a98-b2f5-b0d548038229_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_4d170989-f9d3-462b-ad34-1b666bf6bcd4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ee68ccea-f0c8-4aa9-8cdd-5b7f7dc0b218_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a2c57394-bd5d-4653-bf29-8dd96411ee73_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_917f13a9-ee4c-430f-ad65-400cff20790e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_1cc28fb0-3a05-4336-aaeb-a2afbb227e74_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_0aa8f9ee-ba4e-4d50-8cd6-8890f45383b3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused borrowing capacity</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unused Borrowing Capacity, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:to="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_bc67f26d-7a6f-47f3-a649-0539208f7523_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_cca2e58a-62b9-41ef-b436-d034c6198177_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_27c08110-eb88-4eaa-bed2-db20b5b0103d_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4a38ec04-3381-4f1c-a840-70a50a82386b_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_bb6cc62d-ae21-4460-a305-2192e58b9daa_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_aa6d011d-fdd4-42d3-958d-44b9ccf751f8_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available for Grant</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_47876c22-0955-4abd-b225-65ad4623f11c_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_52d7397d-74a6-4fbd-aa00-67419ebac8ae_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_ef3b6b0d-1b64-4975-a7e3-3f9e38504f80_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_49b5b854-2996-4f79-8d0c-4df34b93a1aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0ba56eeb-faeb-4977-aae4-fb597c815ec6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5967a259-3f9a-44a9-befe-57f4ae80f8a3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_dfff337d-cffe-43eb-8ab7-605df09ac42e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_53bb518d-3404-4b90-af90-a76bc1027f9e_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_98b5f1e8-75a7-4082-a9ba-474d0ca34dbc_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2ef556a6-61b6-410f-9cd7-83c188b07c98_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_59528f12-023f-42dc-a7a4-facee073b9fb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_bf076b93-7f1e-41bb-baa2-ef93fdf9f75a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_8f0ae682-2ae5-4018-80ce-648089a207b3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_0b4dabcf-1c95-423c-ac41-2fc5a23f936d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_6db2225f-0dac-4df7-9c8c-8c5b77af9571_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_637b66e2-6344-4ba5-81aa-8872f4813e16_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ac9bbca5-dbe1-4666-b74a-91a787c8062e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_1d0e0626-8b98-44ec-a3c0-5d6e91e1b076_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-downs</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fd10c167-8924-4268-b772-672305339a8e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_e1c635fc-735d-47cf-a8e7-0edc2d9dc597_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_acf3e464-a8eb-4429-baa7-2c60c6d59f37_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_fa7be806-fa78-4187-902d-2981a643195e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4eb28fbd-0aac-43a4-8258-43adeff90b30_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_d00d1a53-c352-4695-aa2c-7915916312b5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember_5a1d7af7-9e30-40ff-8377-88481f57fd1b_terseLabel_en-US" xlink:label="lab_npce_ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested early exercised common stock options</link:label>
    <link:label id="lab_npce_ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember_label_en-US" xlink:label="lab_npce_ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Unvested Early Exercised Common Stock Option [Member]</link:label>
    <link:label id="lab_npce_ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember_documentation_en-US" xlink:label="lab_npce_ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Unvested Early Exercised Common Stock Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember" xlink:href="npce-20230331.xsd#npce_ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember" xlink:to="lab_npce_ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_069033f6-9305-42e9-8b1e-57de883e95dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_941ee83d-9038-4005-9cd8-f2ea3b15bab5_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_88493d5e-d161-474c-bf19-36b2716150cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_ea46b9bf-f128-4539-b471-24c1760875e2_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_06007c85-cfda-415e-9d43-fa94967151ba_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds, included in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_ee03b49f-f242-4222-8059-26b78a79d3dc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_73756c38-f58a-498c-b131-d1c8539c9c20_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_16d5286e-f6cb-4aae-9376-14260589917b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_c9ded539-6110-47ed-a1f2-7fba273bc02c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Backend fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_224d5258-bdf5-4b64-8add-b2423b2b4b14_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Unaccreted backend fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_416719d7-a7e0-46a2-b1ee-1c38a37dcbb0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_a3887f5a-c138-4861-9ee2-0b044fb3e384_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_a23d9e89-13a9-46ea-b90f-355588203b1f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_63344236-cb11-4b52-b5d4-3e1bf0746028_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_354fd306-f55b-4b84-8e8e-163129011fcc_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_a4aecc3b-d541-4d4f-b731-8eefb84cec08_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_f52f4a8c-5143-4819-8a6e-0b1afe2667eb_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_29c1c666-e689-4443-b689-1bf9d286622d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_49e0c3c8-3a75-4f40-862d-7f852489cf35_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of preferred stock, preference stock, and warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_047accc6-4991-4169-8bb0-a18d46647e3c_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_78e4857b-508f-4e37-93d8-ebaa9c9a0230_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ad62d448-8740-4b70-8b37-5dad1e70feac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aee8319b-3d60-4a31-a588-61df20048efc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_214c9215-0452-452b-bfc6-8360bf397d85_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a50c11e3-bef9-4aff-b5e9-0cbb262e6f6c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_ec684a01-8d91-45f8-9e96-f86a7cfe9279_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared cash</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_55529f1a-62d0-4c6f-ae99-caeb6641e161_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_0af5a375-cc35-42da-99b5-fc42550d93b9_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_dc6d41a3-4241-4b24-a991-b9477f208e85_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_37aa2b28-865b-4d6d-b288-94114a957cb6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5dafc3d0-756a-4db3-9f4d-bcd024724be3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9350cd52-c6a0-49ec-a3f8-2ef103890b1f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2e56a8a7-46c8-4466-b90f-713a9dcc6128_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_ec03d241-3d0e-4907-9b32-e6d8946ad372_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_IncreaseDecreaseInNonCashInterestExpense_936b6b6e-cc9c-4b66-8077-76f55ea196b5_verboseLabel_en-US" xlink:label="lab_npce_IncreaseDecreaseInNonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_npce_IncreaseDecreaseInNonCashInterestExpense_label_en-US" xlink:label="lab_npce_IncreaseDecreaseInNonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Non-cash Interest Expense</link:label>
    <link:label id="lab_npce_IncreaseDecreaseInNonCashInterestExpense_documentation_en-US" xlink:label="lab_npce_IncreaseDecreaseInNonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Non-cash Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_IncreaseDecreaseInNonCashInterestExpense" xlink:href="npce-20230331.xsd#npce_IncreaseDecreaseInNonCashInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_IncreaseDecreaseInNonCashInterestExpense" xlink:to="lab_npce_IncreaseDecreaseInNonCashInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_8f8d66d8-5f15-4328-9710-c3abfd020520_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_1b076067-c27a-4c19-a54d-cbe463a544b5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_4bfce8e3-faa7-4f60-8ba9-48cc316a21de_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6ecf197f-93fd-45e7-b7c8-77db1e052b0a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2c8da43c-daab-4e0c-97b1-382a7f951eeb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_0ab6f0ae-a046-4597-8f90-7c30ff3ada0d_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_44b3c556-bacb-4586-ac31-4603487e60d3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_928627d7-cbf2-426e-998c-3a872c1780f2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0f0dfd56-3c2f-4cf2-8623-7a5e95b8aa68_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_dbec0edb-f7a9-4d22-bbd0-c4cb06cb7f92_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_6c6a72e7-fdf0-4971-b155-2f694e89f368_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0338318b-94e7-4006-8d2f-e7ecb128c0a6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6a994a58-a6e0-4d57-9a3a-f8307b72baca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2_d15a190b-bf2a-48a1-8a36-83590ba62423_terseLabel_en-US" xlink:label="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approval for funding, including subawards, year two</link:label>
    <link:label id="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2_label_en-US" xlink:label="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement with Federal Government, Approval for Funding Subawards, Year 2</link:label>
    <link:label id="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2_documentation_en-US" xlink:label="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement with Federal Government, Approval for Funding Subawards, Year 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2" xlink:href="npce-20230331.xsd#npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2" xlink:to="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_2392453a-d5fb-4e1d-be31-639095887a7d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_d66d3f37-da5c-4607-afa1-0953532f54b9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_063ea0a0-4907-4d48-90e8-7ffe6d52144e_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_ComputerEquipmentAndSoftwareMember_b45d1e43-b8a3-45a1-885e-ce3b1c60d324_terseLabel_en-US" xlink:label="lab_npce_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_npce_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_npce_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_npce_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_npce_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ComputerEquipmentAndSoftwareMember" xlink:href="npce-20230331.xsd#npce_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_ComputerEquipmentAndSoftwareMember" xlink:to="lab_npce_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6ed3bd1f-543b-4a66-b050-6d914c665b1b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6e2103bb-dba3-4ab1-8d30-172144b5f08f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6e25786c-91cf-467d-a241-8ea0708972a3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ec0ee16c-8be4-474c-9d55-61074cca3a42_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_109e8eb4-7dc6-4c49-905e-f33af0bbd864_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4ecfd640-b0e3-4b88-9445-8ded99253ecc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_d0f8c897-5211-493e-98db-61cda91568dd_terseLabel_en-US" xlink:label="lab_npce_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_npce_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_npce_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, After Year Four</link:label>
    <link:label id="lab_npce_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_npce_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="npce-20230331.xsd#npce_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_npce_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_PurchaseObligationMinimumIncreasePercentageInNextTwoYears_d038fdda-73c8-4c7a-b1e4-d8192953c883_terseLabel_en-US" xlink:label="lab_npce_PurchaseObligationMinimumIncreasePercentageInNextTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage increase in purchase commitment</link:label>
    <link:label id="lab_npce_PurchaseObligationMinimumIncreasePercentageInNextTwoYears_label_en-US" xlink:label="lab_npce_PurchaseObligationMinimumIncreasePercentageInNextTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Minimum Increase Percentage In Next Two years</link:label>
    <link:label id="lab_npce_PurchaseObligationMinimumIncreasePercentageInNextTwoYears_documentation_en-US" xlink:label="lab_npce_PurchaseObligationMinimumIncreasePercentageInNextTwoYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Minimum Increase Percentage In Next Two years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_PurchaseObligationMinimumIncreasePercentageInNextTwoYears" xlink:href="npce-20230331.xsd#npce_PurchaseObligationMinimumIncreasePercentageInNextTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_PurchaseObligationMinimumIncreasePercentageInNextTwoYears" xlink:to="lab_npce_PurchaseObligationMinimumIncreasePercentageInNextTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_cb6ac37d-880e-450f-8c69-cc34c5720ff8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_d8422f01-2426-4b13-bea4-34aea4122116_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_f651495e-1817-45cc-8a0c-d679156fa6e9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_56867ee3-bda7-4291-a082-2319c326baad_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_b3efb68d-625a-4eb3-ae47-864e157443ac_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3cda7455-a8d9-4cee-90f4-e4520575ddaa_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_5104d802-45ef-4a34-950a-ba7a13ee8dfb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_de2a62eb-af85-403f-b59c-92e983aae255_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_52d3c4e4-96bd-4f56-8fef-7ce660e35239_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30c21ff5-979c-45c8-8628-5e28dcd610d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_cf98ccaf-5145-429e-a4d0-01afdb8e8a40_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_f67abb27-8008-4006-bcec-de9f3ea6cf3a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7ea074b0-6499-46ff-9333-1aad8e0f84d3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_e9326269-0176-460c-a544-f587ed79aa00_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_EmployeeStockPurchasePlanLengthOfOfferingPeriod_0d77aaf5-a688-4818-ae01-fea8949b5fd0_terseLabel_en-US" xlink:label="lab_npce_EmployeeStockPurchasePlanLengthOfOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP, length of offering period</link:label>
    <link:label id="lab_npce_EmployeeStockPurchasePlanLengthOfOfferingPeriod_label_en-US" xlink:label="lab_npce_EmployeeStockPurchasePlanLengthOfOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Length of Offering Period</link:label>
    <link:label id="lab_npce_EmployeeStockPurchasePlanLengthOfOfferingPeriod_documentation_en-US" xlink:label="lab_npce_EmployeeStockPurchasePlanLengthOfOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Length of Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_EmployeeStockPurchasePlanLengthOfOfferingPeriod" xlink:href="npce-20230331.xsd#npce_EmployeeStockPurchasePlanLengthOfOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_EmployeeStockPurchasePlanLengthOfOfferingPeriod" xlink:to="lab_npce_EmployeeStockPurchasePlanLengthOfOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7d719a2a-5498-4c72-b503-44414651c1e6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_09d04b2f-3e3c-487f-9cbe-c025d713c74e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_089822a0-4dfe-4162-9dbb-0a3e0b35b406_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_aa97b331-ff7d-43a4-9a05-c077ab392fba_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4cd3e38b-e1e3-4fd0-ae46-f5e5c1db60a0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_825ff073-d7e9-4412-a319-a014538ae414_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value disclosure</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_52258dcd-39a1-4b6f-b63a-a6a20e7e07f8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_30b32b98-3081-4fa2-aa98-6d80260261a7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9a41dd3b-e520-496c-8f58-2300f673f4fc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_74298917-cc3e-449b-a3b8-54107d57134a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_0c9d5e57-5a9f-4507-8ea9-4b6efc47e3b4_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_d5452c2e-8041-4a4d-ad12-38493a4a4dd6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3834019c-c329-4385-98a0-24b3762468c8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_4bcee199-9938-4c31-82a3-1f01b1066d59_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f9f37e43-44ae-4fba-9a5b-fdac33322b3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_57de2393-40a2-43b9-93df-9fbc79b2f5f3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_a4b722f2-361a-4218-b2da-49a899a11842_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_f47ebe88-d5ad-4b0e-9f94-0f9f92525103_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_b9688603-0c53-4720-be61-4be2665d7025_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_30cfabc0-6868-4ce8-84f0-233845eb1875_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5b2ba2a2-3fee-4563-b99f-8933300b33e4_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_28f0c157-9713-4c8a-90a0-c31f3375b9c5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common stock outstanding used to compute diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c882e654-6122-445c-9f20-696b50dc38dc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_e3967793-0021-4f61-a3f5-fafc3457d218_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_e72d3cef-9b36-4a3e-bb79-e83b6f72c0d8_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_SaleOfStockOfferingCosts_99f3bcca-74ee-4081-8d62-82a160269317_terseLabel_en-US" xlink:label="lab_npce_SaleOfStockOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, offering costs</link:label>
    <link:label id="lab_npce_SaleOfStockOfferingCosts_label_en-US" xlink:label="lab_npce_SaleOfStockOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Offering Costs</link:label>
    <link:label id="lab_npce_SaleOfStockOfferingCosts_documentation_en-US" xlink:label="lab_npce_SaleOfStockOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_SaleOfStockOfferingCosts" xlink:href="npce-20230331.xsd#npce_SaleOfStockOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_SaleOfStockOfferingCosts" xlink:to="lab_npce_SaleOfStockOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_d2abe4bb-7d83-42b9-a41b-c62bd2555e59_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, 200,000,000 shares authorized as of March&#160;31, 2023 and December&#160;31, 2022; 25,352,204 and 25,045,751 shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_30221d17-b05a-488f-a36c-67a1099106a4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_DebtInstrumentUnamortizedInterestCost_eaa12d04-7720-453f-938f-ddf7f3853340_negatedTerseLabel_en-US" xlink:label="lab_npce_DebtInstrumentUnamortizedInterestCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_npce_DebtInstrumentUnamortizedInterestCost_label_en-US" xlink:label="lab_npce_DebtInstrumentUnamortizedInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Interest Cost</link:label>
    <link:label id="lab_npce_DebtInstrumentUnamortizedInterestCost_documentation_en-US" xlink:label="lab_npce_DebtInstrumentUnamortizedInterestCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_DebtInstrumentUnamortizedInterestCost" xlink:href="npce-20230331.xsd#npce_DebtInstrumentUnamortizedInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_DebtInstrumentUnamortizedInterestCost" xlink:to="lab_npce_DebtInstrumentUnamortizedInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_0c75c243-7999-427e-b636-75bcb3ac7e08_terseLabel_en-US" xlink:label="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Available for Grant [Roll Forward]</link:label>
    <link:label id="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_label_en-US" xlink:label="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Available for Grant [Roll Forward]</link:label>
    <link:label id="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_documentation_en-US" xlink:label="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" xlink:href="npce-20230331.xsd#npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" xlink:to="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bab9d157-f91b-46ef-8d20-c7b3cb92917c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_60114745-ee99-4e58-8f1f-0fc00e38455b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f43a4d5a-8792-486f-bdc8-db860831bd18_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e929e1fe-2cdd-475b-97e3-3ea40af0380c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_47c2e9d2-3855-462a-883e-9bb748789f42_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16eea63a-3f64-4098-9ca2-c1d47a55f919_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash in balance sheets</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_de07872f-e4a4-4452-94f6-cf30e7d73e9d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_91d6c509-95cb-4041-98c6-bf937df42e77_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7408462b-a647-4120-a2cc-a782115d32e2_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_b7f84515-2903-44de-a5b6-c1fe3f349298_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from long term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_08872db4-9632-48fd-99cc-a61df532eab6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_3626a3f6-0fb2-485b-b8d3-a77e57ee316b_verboseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation, to be paid in the next twelve months</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_3617e76f-6ed6-4cd3-83c9-1f70e2d5a941_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment included in accounts payable</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_000a14c3-047f-4059-9b62-d60d48575e9b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1d72714-a982-42d9-b492-cbe2b1e74dc5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_1665455b-1a52-45ca-b694-3c07eb8425a3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_405943f8-af59-4db8-82f2-21efb4d92778_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_de6cc5f3-41bf-476a-965b-f09091eaca08_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_5f9dd041-d741-4b9c-bfd0-56f64f4225ba_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_CommonStockAvailableForESPPMember_1350985d-4e4e-44c1-93c8-0cfdd7ed4686_terseLabel_en-US" xlink:label="lab_npce_CommonStockAvailableForESPPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for ESPP</link:label>
    <link:label id="lab_npce_CommonStockAvailableForESPPMember_label_en-US" xlink:label="lab_npce_CommonStockAvailableForESPPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Available for ESPP [Member]</link:label>
    <link:label id="lab_npce_CommonStockAvailableForESPPMember_documentation_en-US" xlink:label="lab_npce_CommonStockAvailableForESPPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Available for ESPP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_CommonStockAvailableForESPPMember" xlink:href="npce-20230331.xsd#npce_CommonStockAvailableForESPPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_CommonStockAvailableForESPPMember" xlink:to="lab_npce_CommonStockAvailableForESPPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_e749ad40-7e7c-4062-b923-bf044defa805_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_7284a3be-5b35-4eb5-84c4-ae7fcf96db49_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_daf71304-65a7-4466-be37-d308f5b8c0e6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under employee plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_81a68a08-e0bf-433a-95a3-6d96354d67ac_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5cb3e02d-ea00-4f32-9c37-cf29e5b0dee4_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_d3e81789-7934-4656-9502-20c45d9dc652_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f1b9d493-2e55-434f-8857-3ba1840e3f15_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (in Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_82b316a0-bbba-4599-b5f5-d537f6b464d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_597b0fef-9fb0-43c2-acb5-b93233b43726_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP discount percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions_20cf7897-29e9-4b09-8290-d9f1722d0087_terseLabel_en-US" xlink:label="lab_npce_IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in accrued liabilities from early exercise of options</link:label>
    <link:label id="lab_npce_IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions_label_en-US" xlink:label="lab_npce_IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Liabilities, Early Exercise Of Options</link:label>
    <link:label id="lab_npce_IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions_documentation_en-US" xlink:label="lab_npce_IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Liabilities, Early Exercise Of Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions" xlink:href="npce-20230331.xsd#npce_IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions" xlink:to="lab_npce_IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6b99b78c-89c0-4791-91ae-0cf79b76fa98_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_df345a05-c021-49cf-a363-4ddc77939b0f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_OutstandingOptions2021PlanMember_afc06dac-ab7f-44a1-84f4-d8515432dc83_terseLabel_en-US" xlink:label="lab_npce_OutstandingOptions2021PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding options under the 2021 Plan</link:label>
    <link:label id="lab_npce_OutstandingOptions2021PlanMember_label_en-US" xlink:label="lab_npce_OutstandingOptions2021PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Options, 2021 Plan [Member]</link:label>
    <link:label id="lab_npce_OutstandingOptions2021PlanMember_documentation_en-US" xlink:label="lab_npce_OutstandingOptions2021PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Options, 2021 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_OutstandingOptions2021PlanMember" xlink:href="npce-20230331.xsd#npce_OutstandingOptions2021PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_OutstandingOptions2021PlanMember" xlink:to="lab_npce_OutstandingOptions2021PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_10f71f55-679c-486a-9f59-bec173ae464d_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Unamortized debt discount and issuance cost</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_db867c5b-b0a8-4146-85a7-49e80c6b1449_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_9a50a8fa-c4fe-4931-9a5d-ddf0a5f11097_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_591a188d-acb1-44ad-8520-d0d0d5cf78b2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_72df8251-2089-45df-95d5-837bdd4d41c9_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Unaudited Interim Financial Information</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4b496f99-63fa-4d09-9c41-de032f8030c2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_532b5984-9b6f-4198-80ff-24b2519d7d93_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_f3f62e1a-980c-4188-bde8-1c9d142c7cb0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_e936d886-2bb9-4d3f-9265-ee48456449e3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_OperatingLeasesAnnualRentalPayments_fb5c0c93-b565-48ac-b271-a6afe4d8f053_terseLabel_en-US" xlink:label="lab_npce_OperatingLeasesAnnualRentalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual rental payments</link:label>
    <link:label id="lab_npce_OperatingLeasesAnnualRentalPayments_label_en-US" xlink:label="lab_npce_OperatingLeasesAnnualRentalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Annual Rental Payments</link:label>
    <link:label id="lab_npce_OperatingLeasesAnnualRentalPayments_documentation_en-US" xlink:label="lab_npce_OperatingLeasesAnnualRentalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Annual Rental Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_OperatingLeasesAnnualRentalPayments" xlink:href="npce-20230331.xsd#npce_OperatingLeasesAnnualRentalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_OperatingLeasesAnnualRentalPayments" xlink:to="lab_npce_OperatingLeasesAnnualRentalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b691dfe7-eccd-45b9-b6bd-71daff3a1e70_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock pursuant to stock option exercises</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_21b9de37-05a4-46a4-a792-346cf48a1dfe_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_0d216979-d6f6-411d-8a6b-99cd702e4183_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_33f8fffb-b5d3-473d-aa24-0460ce9e7ff5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_20b39470-5fef-4107-892e-2ef141eedd45_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Company</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_c159a692-4c05-4cc4-905f-8620d158f029_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7e53b608-ea72-4cf2-9dcb-d3c2101fefd9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_f1eccc03-67e7-43f8-90d4-32b848d0ed15_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3ccfb069-0486-4430-b59b-67b2d51c035d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_9d12e68a-0c53-4536-99a4-95bd2e7052f2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_12439fb2-0b13-4358-8593-e0201742b771_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_4f140b4e-b826-4ac0-96f4-c0ec59c67aa3_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_98a79225-1220-4c12-8450-b59d85e247a2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod_ae0480fc-b425-48cd-afe0-6adb3b19419d_negatedLabel_en-US" xlink:label="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted/Awarded (in shares)</link:label>
    <link:label id="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod_label_en-US" xlink:label="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Granted During Period</link:label>
    <link:label id="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod_documentation_en-US" xlink:label="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Granted During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod" xlink:href="npce-20230331.xsd#npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod" xlink:to="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_83c0c3c7-67f0-4d31-8c91-583aa84d87d3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4ce67b35-f755-4410-b925-75e613fcc9e2_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_6154537a-a76e-4a05-909a-b7c00f1d94b0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f6ae02d1-99b4-457b-a6ea-2abc50fdec1d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_02558126-c7af-47bd-b337-4ab21b7c0f17_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_39f2108f-8e8e-4c37-8e81-85cf07c71eb3_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_SeriesBRedeemableConvertiblePreferredStockMember_e319614f-421a-4fba-919d-2d1958f6d334_terseLabel_en-US" xlink:label="lab_npce_SeriesBRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_npce_SeriesBRedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_npce_SeriesBRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_npce_SeriesBRedeemableConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_npce_SeriesBRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_SeriesBRedeemableConvertiblePreferredStockMember" xlink:href="npce-20230331.xsd#npce_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="lab_npce_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1_9db248df-5259-4149-a872-b8e74c255b36_terseLabel_en-US" xlink:label="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approved funding, including subawards, first year</link:label>
    <link:label id="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1_label_en-US" xlink:label="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement with Federal Government, Approved Funding Subawards, Year 1</link:label>
    <link:label id="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1_documentation_en-US" xlink:label="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement with Federal Government, Approved Funding Subawards, Year 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1" xlink:href="npce-20230331.xsd#npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1" xlink:to="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_DebtInstrumentCovenantMinimumAnnualNetRevenue_5912edf4-aca4-466a-8b2e-e196d9a99609_terseLabel_en-US" xlink:label="lab_npce_DebtInstrumentCovenantMinimumAnnualNetRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum annual net revenue</link:label>
    <link:label id="lab_npce_DebtInstrumentCovenantMinimumAnnualNetRevenue_label_en-US" xlink:label="lab_npce_DebtInstrumentCovenantMinimumAnnualNetRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Minimum Annual Net Revenue</link:label>
    <link:label id="lab_npce_DebtInstrumentCovenantMinimumAnnualNetRevenue_documentation_en-US" xlink:label="lab_npce_DebtInstrumentCovenantMinimumAnnualNetRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Minimum Annual Net Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_DebtInstrumentCovenantMinimumAnnualNetRevenue" xlink:href="npce-20230331.xsd#npce_DebtInstrumentCovenantMinimumAnnualNetRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_DebtInstrumentCovenantMinimumAnnualNetRevenue" xlink:to="lab_npce_DebtInstrumentCovenantMinimumAnnualNetRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ebca7dc5-ec91-4d33-8b2c-ec2015ed30be_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_37197089-3e76-4f6c-af60-95b94daedc6e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards_7716bc8f-7abd-445c-a222-d37a57cae6e7_terseLabel_en-US" xlink:label="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development arrangement with federal government, funding for subawards</link:label>
    <link:label id="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards_label_en-US" xlink:label="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement with Federal Government, Estimated Cost for Subawards</link:label>
    <link:label id="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards_documentation_en-US" xlink:label="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement with Federal Government, Estimated Cost for Subawards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards" xlink:href="npce-20230331.xsd#npce_ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards" xlink:to="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_242a9f4b-f626-4274-9627-298928cdbfec_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_59cb0666-f7f7-46c6-9bf8-3612e39fbff5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_842bc7ae-c9cb-4ae5-83a1-c58351b5b7e8_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PIK interest incurred but not paid on term loan</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_OCIUnrealizedLossAdjustmentForShortTermInvestment_14e5c5aa-7d07-4e68-b62b-dc6a105f3d47_terseLabel_en-US" xlink:label="lab_npce_OCIUnrealizedLossAdjustmentForShortTermInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss adjustment for short-term investment</link:label>
    <link:label id="lab_npce_OCIUnrealizedLossAdjustmentForShortTermInvestment_label_en-US" xlink:label="lab_npce_OCIUnrealizedLossAdjustmentForShortTermInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Unrealized Loss Adjustment for Short-term Investment</link:label>
    <link:label id="lab_npce_OCIUnrealizedLossAdjustmentForShortTermInvestment_documentation_en-US" xlink:label="lab_npce_OCIUnrealizedLossAdjustmentForShortTermInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Unrealized Loss Adjustment for Short-term Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_OCIUnrealizedLossAdjustmentForShortTermInvestment" xlink:href="npce-20230331.xsd#npce_OCIUnrealizedLossAdjustmentForShortTermInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_OCIUnrealizedLossAdjustmentForShortTermInvestment" xlink:to="lab_npce_OCIUnrealizedLossAdjustmentForShortTermInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d8bb10e-81a9-41ec-a1d8-832c5512744f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_c0578b09-2aec-4a5f-8e45-ad4af406a45a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a8b18b03-fbbd-4b02-b20d-235e46342ee7_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement_71397526-2019-43a2-b8cc-64af5f4f4802_terseLabel_en-US" xlink:label="lab_npce_PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of shares of common stock sold under sales agreement</link:label>
    <link:label id="lab_npce_PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement_label_en-US" xlink:label="lab_npce_PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Shares of Common Stock Sold under the Sales Agreement</link:label>
    <link:label id="lab_npce_PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement_documentation_en-US" xlink:label="lab_npce_PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Shares of Common Stock Sold under the Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement" xlink:href="npce-20230331.xsd#npce_PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement" xlink:to="lab_npce_PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_8aa5e5d5-e329-40f6-b6b2-23828b7ffb4f_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_1a6cc33b-baf3-4c50-99be-f8eb22e42343_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_6addb484-e2ab-4d3f-9bd0-c4ffc876a8b5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_d6978e66-9de3-4ed4-8584-31b6ecd27bd1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2e3dbb09-80c9-4e50-8bc4-81119a6f2f17_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2_e2905db5-3cb7-465f-9571-3df90f79c12a_terseLabel_en-US" xlink:label="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approval for funding, year two</link:label>
    <link:label id="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2_label_en-US" xlink:label="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement with Federal Government, Approval for Funding, Year 2</link:label>
    <link:label id="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2_documentation_en-US" xlink:label="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement with Federal Government, Approval for Funding, Year 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2" xlink:href="npce-20230331.xsd#npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2" xlink:to="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_896d9615-9bd2-4ec3-8c0e-017b3eda247b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ac9c9432-5fe8-4495-adf7-e52b7e060d8a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8f91763d-2061-4dae-9398-340d53b072cf_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5f99f067-02f8-4222-9791-ee232f9ca1a8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_d991c05e-047c-41c7-97d9-c46276beda08_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options cancelled (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_948707f1-5f52-4352-b048-5b041cfc3fe9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_9632b05c-b846-4893-b660-f1bd5b7c5a64_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 (remaining nine months)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_42fee35b-8dec-4f64-a6e7-0b307af51cd9_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_c733a945-66c5-49b2-ac64-dbd9f3e3edae_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_77b08f28-5fed-4e66-8e18-581001178dc6_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_139a2fd0-0b4d-44ef-9987-175c15cff173_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost_d8953fb8-092b-4181-9992-a00e5545e367_terseLabel_en-US" xlink:label="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development arrangement with federal government, total budget</link:label>
    <link:label id="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost_label_en-US" xlink:label="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement with Federal Government, Total Estimated Cost</link:label>
    <link:label id="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost_documentation_en-US" xlink:label="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement with Federal Government, Total Estimated Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost" xlink:href="npce-20230331.xsd#npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost" xlink:to="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ba3eda57-a5be-4524-9a9c-cf1a69d6d78d_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_A2021EquityIncentivePlanMember_0e616d39-9565-4050-8868-f70598acbaf3_terseLabel_en-US" xlink:label="lab_npce_A2021EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Equity Incentive Plan</link:label>
    <link:label id="lab_npce_A2021EquityIncentivePlanMember_label_en-US" xlink:label="lab_npce_A2021EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_npce_A2021EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_npce_A2021EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_A2021EquityIncentivePlanMember" xlink:href="npce-20230331.xsd#npce_A2021EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_A2021EquityIncentivePlanMember" xlink:to="lab_npce_A2021EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6f12e0fc-0384-4a80-bfee-151590737dbf_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9de80d3d-5d21-4322-a9c9-6dbb58257612_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common stock outstanding used to compute basic net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_TermLoanMember_1abdf1e6-2193-4350-8a36-b231657f8d1a_terseLabel_en-US" xlink:label="lab_npce_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_npce_TermLoanMember_label_en-US" xlink:label="lab_npce_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_npce_TermLoanMember_documentation_en-US" xlink:label="lab_npce_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_TermLoanMember" xlink:href="npce-20230331.xsd#npce_TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_TermLoanMember" xlink:to="lab_npce_TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_a36ca0e9-ce48-4f54-ab9f-ebe9379b2737_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for contingent liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_69df7b95-9524-4fb2-a477-34cd20b46b5c_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_5e1e7beb-cc04-46f6-b589-eefa253250e5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c8644702-8ad8-4249-b4e1-b9cf530b60b1_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d0a5013b-feb2-461a-8064-8784e29144a8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1a6b2136-63c1-44ee-9c86-051186c53aaa_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_5e7ab508-6b58-4654-aa86-3f189f14f02a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_MachineryEquipmentFurnitureAndFixturesMember_772fd146-bf6d-4106-9580-7cfbae58773a_terseLabel_en-US" xlink:label="lab_npce_MachineryEquipmentFurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery, equipment, furniture and fixtures</link:label>
    <link:label id="lab_npce_MachineryEquipmentFurnitureAndFixturesMember_label_en-US" xlink:label="lab_npce_MachineryEquipmentFurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery, Equipment, Furniture, and Fixtures [Member]</link:label>
    <link:label id="lab_npce_MachineryEquipmentFurnitureAndFixturesMember_documentation_en-US" xlink:label="lab_npce_MachineryEquipmentFurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery, Equipment, Furniture, and Fixtures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_MachineryEquipmentFurnitureAndFixturesMember" xlink:href="npce-20230331.xsd#npce_MachineryEquipmentFurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_MachineryEquipmentFurnitureAndFixturesMember" xlink:to="lab_npce_MachineryEquipmentFurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_StockOptionsAndRestrictedStockUnitsMember_ed0a15ef-8e99-44e7-96f4-7482d3c9255c_terseLabel_en-US" xlink:label="lab_npce_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and restricted stock units</link:label>
    <link:label id="lab_npce_StockOptionsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_npce_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_npce_StockOptionsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_npce_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_StockOptionsAndRestrictedStockUnitsMember" xlink:href="npce-20230331.xsd#npce_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_StockOptionsAndRestrictedStockUnitsMember" xlink:to="lab_npce_StockOptionsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_36f0d6d9-d589-4792-a0e7-96b5c029726a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability_385aa1e3-700b-4ff5-9f55-d9e979344f1c_negatedTerseLabel_en-US" xlink:label="lab_npce_AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in early exercise liability</link:label>
    <link:label id="lab_npce_AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability_label_en-US" xlink:label="lab_npce_AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Change In Early Exercise Liability</link:label>
    <link:label id="lab_npce_AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability_documentation_en-US" xlink:label="lab_npce_AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Change In Early Exercise Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability" xlink:href="npce-20230331.xsd#npce_AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability" xlink:to="lab_npce_AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_a0fd07ef-e865-4aba-a2dc-e8de5a582d46_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ca455999-2e2c-444c-9a51-cd7ec961ec20_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_A2021EmployeeStockPurchasePlanMember_701d7f91-f435-4ad2-9021-7a6fa1c2451b_terseLabel_en-US" xlink:label="lab_npce_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_npce_A2021EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_npce_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_npce_A2021EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_npce_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_A2021EmployeeStockPurchasePlanMember" xlink:href="npce-20230331.xsd#npce_A2021EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_A2021EmployeeStockPurchasePlanMember" xlink:to="lab_npce_A2021EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f0383ab5-3236-42cc-8fe2-6b921503e984_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_e45a2688-2231-46b0-acef-f64a22189661_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_4ebf1834-8ad1-4ead-8967-0f54cae884bb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_14654e59-86e3-46e4-9901-6912570ef1f4_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_ac1ae83c-955c-4b53-abc6-95da30da46a0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3585d2e9-6bd0-417c-8530-6420886dc5c1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Incentive Compensation Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_d30d5974-7137-4af5-8cbc-3d2cd1e68aab_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1_6420c744-5bcd-4e18-a54d-ded64f52134a_terseLabel_en-US" xlink:label="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approved funding, first year</link:label>
    <link:label id="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1_label_en-US" xlink:label="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement with Federal Government, Approved Funding, Year 1</link:label>
    <link:label id="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1_documentation_en-US" xlink:label="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement with Federal Government, Approved Funding, Year 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1" xlink:href="npce-20230331.xsd#npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1" xlink:to="lab_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_2e9b8c80-0d7f-4479-8abd-7bf86834eaa1_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a799496a-ddda-42df-a5d4-8a598617f583_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes withheld and paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_d3cc598e-15d2-435b-b8e7-9f1776a0d70f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_a9a1365b-0971-48ec-bfbd-756c5eb3d654_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5a1022eb-0f7f-4796-b77f-f1ed04b0870c_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_LeaseFacilityMember_6750832d-bade-426b-be4f-06b41eb18e46_terseLabel_en-US" xlink:label="lab_npce_LeaseFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Facility</link:label>
    <link:label id="lab_npce_LeaseFacilityMember_label_en-US" xlink:label="lab_npce_LeaseFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Facility [Member]</link:label>
    <link:label id="lab_npce_LeaseFacilityMember_documentation_en-US" xlink:label="lab_npce_LeaseFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_LeaseFacilityMember" xlink:href="npce-20230331.xsd#npce_LeaseFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_LeaseFacilityMember" xlink:to="lab_npce_LeaseFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_df2e1f96-6076-4605-bd9a-7d609849d3fe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_c16060a7-e9c4-4b38-9438-367ee3459d60_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c17ce40e-45b6-4ce9-a9f3-7559c9bff169_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_311ab8fb-da35-434a-9835-004236681bac_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_79360761-7fc5-41a4-9da0-aeae9b1ef70d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_AccruedAndEmployeeRelatedLiabilitiesCurrent_63cce473-22af-4bf7-b6d1-ec7ef83bf526_totalLabel_en-US" xlink:label="lab_npce_AccruedAndEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_npce_AccruedAndEmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_npce_AccruedAndEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and Employee-related Liabilities, Current</link:label>
    <link:label id="lab_npce_AccruedAndEmployeeRelatedLiabilitiesCurrent_documentation_en-US" xlink:label="lab_npce_AccruedAndEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_AccruedAndEmployeeRelatedLiabilitiesCurrent" xlink:href="npce-20230331.xsd#npce_AccruedAndEmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_AccruedAndEmployeeRelatedLiabilitiesCurrent" xlink:to="lab_npce_AccruedAndEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_4a79bc7b-579b-479f-929e-31f3ebeaabb7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_55ce0505-436f-4a6a-b541-90b43ba98b29_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of deferred offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_79761ec6-274f-449a-bf7f-2be6de8c2c7b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_a671e3e4-bbd8-49b0-8aa4-ca2f448bb296_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod_75a0e19f-5c96-4819-9477-188dce891a6b_terseLabel_en-US" xlink:label="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod_label_en-US" xlink:label="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Canceled During Period</link:label>
    <link:label id="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod_documentation_en-US" xlink:label="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Canceled During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod" xlink:href="npce-20230331.xsd#npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod" xlink:to="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ed7e4585-b4ee-4147-980b-d7a85eabc33d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_8ad35f7e-a8f8-47ff-bd88-454211272c7f_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4a7aa908-8147-41e1-9b4a-e25b973af4ef_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_575cd88a-fa57-468e-8874-8dab337e8a6a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_d9c681cc-9055-4b74-8d07-ca22e2105a84_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_c838bec8-bf5e-4d7a-b8e6-81e1aee18c89_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_4c04dcbb-ec59-4d3a-8535-f68e7d4ef607_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase_1ca8d472-6d3a-4bdf-b4e8-68edf4d94731_terseLabel_en-US" xlink:label="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, subject to repurchase (in shares)</link:label>
    <link:label id="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase_label_en-US" xlink:label="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Subject to Repurchase</link:label>
    <link:label id="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase_documentation_en-US" xlink:label="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Subject to Repurchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase" xlink:href="npce-20230331.xsd#npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase" xlink:to="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_ee8dc8b1-2f09-4620-82b7-182fce6fe0bd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_557040df-64cf-4e06-b68b-730fe10b2a42_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_23e5e314-d2e9-4cc8-b9fb-f2e9b98866de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_51d3ade1-17b0-4188-b4df-85e0a08ad355_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash to balance sheets:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_e59feaf8-dd1e-4052-b25d-1bbeda0f9a79_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a7262ccf-3023-4aad-a5a3-cf17e66f6464_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a7b24b32-4084-4983-a822-1d0a34599dc9_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes_87608431-613d-4da6-9b9b-56bd2bce7173_terseLabel_en-US" xlink:label="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Withheld for taxes (in shares)</link:label>
    <link:label id="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes_label_en-US" xlink:label="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares, Withheld for Taxes</link:label>
    <link:label id="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes_documentation_en-US" xlink:label="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares, Withheld for Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes" xlink:href="npce-20230331.xsd#npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes" xlink:to="lab_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_DebtInstrumentRedemptionFeePercent_f8a44735-5e2e-4144-8424-23ad495547f0_terseLabel_en-US" xlink:label="lab_npce_DebtInstrumentRedemptionFeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption fee, percent</link:label>
    <link:label id="lab_npce_DebtInstrumentRedemptionFeePercent_label_en-US" xlink:label="lab_npce_DebtInstrumentRedemptionFeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Fee, Percent</link:label>
    <link:label id="lab_npce_DebtInstrumentRedemptionFeePercent_documentation_en-US" xlink:label="lab_npce_DebtInstrumentRedemptionFeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Fee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_DebtInstrumentRedemptionFeePercent" xlink:href="npce-20230331.xsd#npce_DebtInstrumentRedemptionFeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_DebtInstrumentRedemptionFeePercent" xlink:to="lab_npce_DebtInstrumentRedemptionFeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_06d0de86-1769-44f7-ac7d-8d84879be1ae_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_b87f6220-000a-48a7-bcc5-d9585f45e592_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares withheld for taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9b623f39-d5a5-43eb-8622-bd4e1a026f3a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_WarrantLiabilityNoncurrent_1791b1b8-8555-41a8-84b3-fe5fb44ebd71_terseLabel_en-US" xlink:label="lab_npce_WarrantLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability, noncurrent</link:label>
    <link:label id="lab_npce_WarrantLiabilityNoncurrent_label_en-US" xlink:label="lab_npce_WarrantLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability, Noncurrent</link:label>
    <link:label id="lab_npce_WarrantLiabilityNoncurrent_documentation_en-US" xlink:label="lab_npce_WarrantLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_WarrantLiabilityNoncurrent" xlink:href="npce-20230331.xsd#npce_WarrantLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_WarrantLiabilityNoncurrent" xlink:to="lab_npce_WarrantLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentInKindPIKNoteMember_233f6b92-673d-4080-a0d2-670bc72e7702_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment in Kind (PIK) Note</link:label>
    <link:label id="lab_us-gaap_PaymentInKindPIKNoteMember_label_en-US" xlink:label="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment in Kind (PIK) Note [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentInKindPIKNoteMember" xlink:to="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_dd48bc62-fa06-4be6-9da8-1de505f83b41_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_a4769d88-e02a-43a7-860c-47fd7f5d175d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_65eb49ae-207f-43fd-a106-f106b7b3ac47_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_95d0d333-26d9-49b3-9a9f-151bccd492ac_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Programs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bc792e54-a40a-4300-9ce0-570bd11be7b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_f3f411e9-c2f9-488c-9807-dcf819e69830_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares withheld for taxes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c186c258-fe91-450f-8c74-be0ef91c7de6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_119c932c-0be2-4c6f-a961-003db724ddbd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk, and Other Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_b17f9aa6-d4cb-41de-8527-6d96b961dc5b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f2266868-0c10-432b-8dd6-ef1ffb4de9b4_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_5194f703-445f-4d02-8ec3-7a99a73df2c5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_1c0bf621-c890-44d0-aa70-6958fb13190c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_7626000b-4deb-442e-837b-a74d9abdcbe5_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_a77addc0-3a65-4479-a0bb-8cc55cf5277f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_7eaf2869-12a3-442f-b5a7-97fc33ac3301_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_EmployeeStockPurchasePlanOfferingPeriod_f2d512ce-7b81-4c7a-adc8-c367216eb83e_terseLabel_en-US" xlink:label="lab_npce_EmployeeStockPurchasePlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering period</link:label>
    <link:label id="lab_npce_EmployeeStockPurchasePlanOfferingPeriod_label_en-US" xlink:label="lab_npce_EmployeeStockPurchasePlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Offering Period</link:label>
    <link:label id="lab_npce_EmployeeStockPurchasePlanOfferingPeriod_documentation_en-US" xlink:label="lab_npce_EmployeeStockPurchasePlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_EmployeeStockPurchasePlanOfferingPeriod" xlink:href="npce-20230331.xsd#npce_EmployeeStockPurchasePlanOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_EmployeeStockPurchasePlanOfferingPeriod" xlink:to="lab_npce_EmployeeStockPurchasePlanOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a2bbbb16-9800-496d-903d-76526d213ecb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_c853a835-6706-4910-b3a3-b8b77ea70fd0_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance initial public offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_f50914f0-3804-4024-84d2-c6ce31101cd8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_819b8cd2-dc76-4d0b-b598-8e16b2645b89_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_9068d318-41e8-4a5c-9e95-e0ac4013298b_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing information:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_72a97223-b383-40a5-8e32-7101e9cdb176_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_b2b90496-5b0a-4963-943f-1c6b96d5da65_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_npce_IndemnificationLiabilityOfficersAndDirectors_e9c521e2-c9d0-43fc-a14a-404675ed62e5_terseLabel_en-US" xlink:label="lab_npce_IndemnificationLiabilityOfficersAndDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification liability accrued for officers and directors</link:label>
    <link:label id="lab_npce_IndemnificationLiabilityOfficersAndDirectors_label_en-US" xlink:label="lab_npce_IndemnificationLiabilityOfficersAndDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Liability, Officers and Directors</link:label>
    <link:label id="lab_npce_IndemnificationLiabilityOfficersAndDirectors_documentation_en-US" xlink:label="lab_npce_IndemnificationLiabilityOfficersAndDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Liability, Officers and Directors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_npce_IndemnificationLiabilityOfficersAndDirectors" xlink:href="npce-20230331.xsd#npce_IndemnificationLiabilityOfficersAndDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_npce_IndemnificationLiabilityOfficersAndDirectors" xlink:to="lab_npce_IndemnificationLiabilityOfficersAndDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_10532530-4214-4b08-81de-3dd7d3e1fb46_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_3825ff4a-567b-414f-824b-73aaaacc34b2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_70eb315d-f12f-43ca-b839-82331a9c25af_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_ff54f3af-b1be-4705-980a-d8c1a07da53c_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>npce-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1fd4e094-c2e9-4b44-9de8-fd1ff4c54731,g:0a3c8fdc-3cf9-40a0-97f2-986b9fb768aa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://neuropace.com/role/Cover" xlink:type="simple" xlink:href="npce-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d0a48c08-bedb-49a2-a18b-92f8019acb48" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_DocumentType_d0a48c08-bedb-49a2-a18b-92f8019acb48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_5aa91e4d-38b7-4d73-b88a-7aee4d690141" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_DocumentQuarterlyReport_5aa91e4d-38b7-4d73-b88a-7aee4d690141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_cabb9ec7-bff5-44d1-a752-59d83c0deb82" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_DocumentPeriodEndDate_cabb9ec7-bff5-44d1-a752-59d83c0deb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c8a293fa-e14b-4264-a04f-6cdd0061166f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_DocumentTransitionReport_c8a293fa-e14b-4264-a04f-6cdd0061166f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_6d41a987-9277-48d4-ad50-0f4840356ba4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_EntityFileNumber_6d41a987-9277-48d4-ad50-0f4840356ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e1eac5b3-9f2c-4892-95b9-8a702ace4849" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_EntityRegistrantName_e1eac5b3-9f2c-4892-95b9-8a702ace4849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f568b300-a5b4-40ab-87b2-2969615911ee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f568b300-a5b4-40ab-87b2-2969615911ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d58edf02-dd46-4ae5-a1ef-be2b51f4067c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_EntityTaxIdentificationNumber_d58edf02-dd46-4ae5-a1ef-be2b51f4067c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1355ca24-2d15-48e9-95e4-9ea438a57afa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_EntityAddressAddressLine1_1355ca24-2d15-48e9-95e4-9ea438a57afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_29975db5-5d61-4d39-9b14-6a1e193cf2a7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_EntityAddressCityOrTown_29975db5-5d61-4d39-9b14-6a1e193cf2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ac7f2b7a-cd0f-42fd-bc75-263dda2f154e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_EntityAddressStateOrProvince_ac7f2b7a-cd0f-42fd-bc75-263dda2f154e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a8d8e638-ee16-426e-a737-f29da706ef8e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_EntityAddressPostalZipCode_a8d8e638-ee16-426e-a737-f29da706ef8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ce9f694a-92eb-4296-86d7-d93fd66667ed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_CityAreaCode_ce9f694a-92eb-4296-86d7-d93fd66667ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4a099031-2620-42c0-a37a-5af9564265ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_LocalPhoneNumber_4a099031-2620-42c0-a37a-5af9564265ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c450c233-45ae-4abd-a808-41f53e088a06" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_Security12bTitle_c450c233-45ae-4abd-a808-41f53e088a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2a3051e8-ca58-4f9b-ab17-89986f28468f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_TradingSymbol_2a3051e8-ca58-4f9b-ab17-89986f28468f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4dfc7339-be4d-46aa-bbb9-952b6431b2a6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_SecurityExchangeName_4dfc7339-be4d-46aa-bbb9-952b6431b2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9bc27a28-d11d-467c-b092-7ed89628cea1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_EntityCurrentReportingStatus_9bc27a28-d11d-467c-b092-7ed89628cea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f5f3be61-28dd-47d7-9031-1287ada98325" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_EntityInteractiveDataCurrent_f5f3be61-28dd-47d7-9031-1287ada98325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_611b0794-fe6d-4a1e-b933-86b46207b52a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_EntityFilerCategory_611b0794-fe6d-4a1e-b933-86b46207b52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e1b0109d-fe37-4817-92cf-f0bfb0e8d46f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_EntitySmallBusiness_e1b0109d-fe37-4817-92cf-f0bfb0e8d46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_467d8671-deb9-4d3a-adcd-981503fe0883" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_EntityEmergingGrowthCompany_467d8671-deb9-4d3a-adcd-981503fe0883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_a2c92b7d-efdf-459e-8b6f-eb8f5ae0a779" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_EntityExTransitionPeriod_a2c92b7d-efdf-459e-8b6f-eb8f5ae0a779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_5df378aa-7618-43dd-b3ca-8575b3f9807a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_EntityShellCompany_5df378aa-7618-43dd-b3ca-8575b3f9807a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ca72b947-afa6-4ff7-a665-7cd6d7f93edb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ca72b947-afa6-4ff7-a665-7cd6d7f93edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_7e9a02f7-1cbb-4c13-bed7-5c94d9f4a919" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_AmendmentFlag_7e9a02f7-1cbb-4c13-bed7-5c94d9f4a919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ee7991be-f5b9-411e-8941-864df900aaae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_EntityCentralIndexKey_ee7991be-f5b9-411e-8941-864df900aaae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_3ab5f04b-879a-473f-8049-00936786a552" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_CurrentFiscalYearEndDate_3ab5f04b-879a-473f-8049-00936786a552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_5f0bf013-2f8a-436d-9c13-537baecd1fc2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_DocumentFiscalYearFocus_5f0bf013-2f8a-436d-9c13-537baecd1fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b88516ed-37b8-4ccb-9613-5d816153a39b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e89f9cc1-f4a4-400d-895a-e8378195086c" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b88516ed-37b8-4ccb-9613-5d816153a39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/CondensedBalanceSheetsunaudited" xlink:type="simple" xlink:href="npce-20230331.xsd#CondensedBalanceSheetsunaudited"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/CondensedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_446cf0c5-39ab-44dc-bf70-58579b4eff3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_8d01478b-9e61-4269-9980-7c59d3a2cf3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_446cf0c5-39ab-44dc-bf70-58579b4eff3a" xlink:to="loc_us-gaap_AssetsAbstract_8d01478b-9e61-4269-9980-7c59d3a2cf3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9bc48413-f444-4ee4-b650-ed2f159a5250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8d01478b-9e61-4269-9980-7c59d3a2cf3a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9bc48413-f444-4ee4-b650-ed2f159a5250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6ff72f39-bc62-4c08-ab1c-8d0999eb176f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9bc48413-f444-4ee4-b650-ed2f159a5250" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6ff72f39-bc62-4c08-ab1c-8d0999eb176f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_f6b83cf8-f2e8-426a-a94f-b9ef91bb59e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9bc48413-f444-4ee4-b650-ed2f159a5250" xlink:to="loc_us-gaap_ShortTermInvestments_f6b83cf8-f2e8-426a-a94f-b9ef91bb59e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a1a74ad9-dd43-4394-a3e9-3083b2d5fae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9bc48413-f444-4ee4-b650-ed2f159a5250" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a1a74ad9-dd43-4394-a3e9-3083b2d5fae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a40ea73b-87c2-47e1-a8f2-c1b99fa2665c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9bc48413-f444-4ee4-b650-ed2f159a5250" xlink:to="loc_us-gaap_InventoryNet_a40ea73b-87c2-47e1-a8f2-c1b99fa2665c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_668feadf-0e3a-4d89-aa69-1432b027c254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9bc48413-f444-4ee4-b650-ed2f159a5250" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_668feadf-0e3a-4d89-aa69-1432b027c254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3a7778a4-940a-44a6-8a13-96b3549e5fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9bc48413-f444-4ee4-b650-ed2f159a5250" xlink:to="loc_us-gaap_AssetsCurrent_3a7778a4-940a-44a6-8a13-96b3549e5fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f45d4250-f964-484f-bcfa-29cefebcdef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8d01478b-9e61-4269-9980-7c59d3a2cf3a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f45d4250-f964-484f-bcfa-29cefebcdef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b89dce75-72a2-4ae0-b1b5-1aa8489abe48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8d01478b-9e61-4269-9980-7c59d3a2cf3a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b89dce75-72a2-4ae0-b1b5-1aa8489abe48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_bc3cf31d-9d3b-4458-8172-cc382193724e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8d01478b-9e61-4269-9980-7c59d3a2cf3a" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_bc3cf31d-9d3b-4458-8172-cc382193724e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCosts_e6eb9270-a10e-4dd1-8edb-20d2b43a49cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8d01478b-9e61-4269-9980-7c59d3a2cf3a" xlink:to="loc_us-gaap_DeferredCosts_e6eb9270-a10e-4dd1-8edb-20d2b43a49cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e7f40d06-9968-41b1-abc3-d74b8aeb465d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8d01478b-9e61-4269-9980-7c59d3a2cf3a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e7f40d06-9968-41b1-abc3-d74b8aeb465d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_dcb97647-ecc8-4dbc-bc3b-2d0131b87698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8d01478b-9e61-4269-9980-7c59d3a2cf3a" xlink:to="loc_us-gaap_Assets_dcb97647-ecc8-4dbc-bc3b-2d0131b87698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8fc6c72e-aa7d-401a-b294-262c326df4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_446cf0c5-39ab-44dc-bf70-58579b4eff3a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8fc6c72e-aa7d-401a-b294-262c326df4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2aa3059d-c073-426e-8d55-d7f3be950ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8fc6c72e-aa7d-401a-b294-262c326df4e7" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2aa3059d-c073-426e-8d55-d7f3be950ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0baa9fa4-fc1e-4979-8e49-9bd8ee58e6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2aa3059d-c073-426e-8d55-d7f3be950ac4" xlink:to="loc_us-gaap_AccountsPayableCurrent_0baa9fa4-fc1e-4979-8e49-9bd8ee58e6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_877aa5c9-f22b-4b54-88ec-b7f2bf3220fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2aa3059d-c073-426e-8d55-d7f3be950ac4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_877aa5c9-f22b-4b54-88ec-b7f2bf3220fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c28ccc68-2030-402d-b5f4-a038acd4cc67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2aa3059d-c073-426e-8d55-d7f3be950ac4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c28ccc68-2030-402d-b5f4-a038acd4cc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a7269f53-5daa-40cc-97fc-836b8d511411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2aa3059d-c073-426e-8d55-d7f3be950ac4" xlink:to="loc_us-gaap_LiabilitiesCurrent_a7269f53-5daa-40cc-97fc-836b8d511411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d39966b7-e9aa-400b-b950-0bdd02093f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8fc6c72e-aa7d-401a-b294-262c326df4e7" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d39966b7-e9aa-400b-b950-0bdd02093f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b6b13816-5d78-4a17-9d05-c3cc3c1d5934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8fc6c72e-aa7d-401a-b294-262c326df4e7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b6b13816-5d78-4a17-9d05-c3cc3c1d5934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7542e03f-6d83-409c-b49c-3fc8ccf0c90a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8fc6c72e-aa7d-401a-b294-262c326df4e7" xlink:to="loc_us-gaap_Liabilities_7542e03f-6d83-409c-b49c-3fc8ccf0c90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4038b9a3-d716-45fe-86ab-7d6f7ca0d456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8fc6c72e-aa7d-401a-b294-262c326df4e7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4038b9a3-d716-45fe-86ab-7d6f7ca0d456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_9d7afec7-9315-4541-b710-e78ff43f3cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8fc6c72e-aa7d-401a-b294-262c326df4e7" xlink:to="loc_us-gaap_StockholdersEquityAbstract_9d7afec7-9315-4541-b710-e78ff43f3cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e87ff5de-1e8f-4009-842e-5a8cf5f14282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9d7afec7-9315-4541-b710-e78ff43f3cb7" xlink:to="loc_us-gaap_PreferredStockValue_e87ff5de-1e8f-4009-842e-5a8cf5f14282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7cff2ea8-046f-40f1-b8de-d162a059af11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9d7afec7-9315-4541-b710-e78ff43f3cb7" xlink:to="loc_us-gaap_CommonStockValue_7cff2ea8-046f-40f1-b8de-d162a059af11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_09c52da0-0adb-4b19-8d2a-ed42f0c4dec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9d7afec7-9315-4541-b710-e78ff43f3cb7" xlink:to="loc_us-gaap_AdditionalPaidInCapital_09c52da0-0adb-4b19-8d2a-ed42f0c4dec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b1455fbf-4477-4ae3-8956-6769b2e6c7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9d7afec7-9315-4541-b710-e78ff43f3cb7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b1455fbf-4477-4ae3-8956-6769b2e6c7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0ea3b232-8243-42a3-b687-0d4aabbe3807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9d7afec7-9315-4541-b710-e78ff43f3cb7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0ea3b232-8243-42a3-b687-0d4aabbe3807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2a9d2703-4ec6-4e8a-89dc-3b4b44272f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9d7afec7-9315-4541-b710-e78ff43f3cb7" xlink:to="loc_us-gaap_StockholdersEquity_2a9d2703-4ec6-4e8a-89dc-3b4b44272f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d9072be0-c572-4a40-b872-48c258208953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8fc6c72e-aa7d-401a-b294-262c326df4e7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d9072be0-c572-4a40-b872-48c258208953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/CondensedBalanceSheetsunauditedParenthetical" xlink:type="simple" xlink:href="npce-20230331.xsd#CondensedBalanceSheetsunauditedParenthetical"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/CondensedBalanceSheetsunauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_17e924c3-2020-4c9d-afcc-1d2e3020ef08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_891b478f-4676-40c7-9aa4-5ad5686f9727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_17e924c3-2020-4c9d-afcc-1d2e3020ef08" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_891b478f-4676-40c7-9aa4-5ad5686f9727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_780e4fd6-71b0-4533-81a0-00c209e2d9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_17e924c3-2020-4c9d-afcc-1d2e3020ef08" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_780e4fd6-71b0-4533-81a0-00c209e2d9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_62e06bde-874d-4835-aad9-fb5d566faea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_17e924c3-2020-4c9d-afcc-1d2e3020ef08" xlink:to="loc_us-gaap_PreferredStockSharesIssued_62e06bde-874d-4835-aad9-fb5d566faea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f05fd822-598e-45e3-acc8-2e01c8a072cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_17e924c3-2020-4c9d-afcc-1d2e3020ef08" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f05fd822-598e-45e3-acc8-2e01c8a072cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_99ac46e3-a407-4b6a-9fc8-9f0b0f35e547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_17e924c3-2020-4c9d-afcc-1d2e3020ef08" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_99ac46e3-a407-4b6a-9fc8-9f0b0f35e547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1c180c07-4931-4b70-a3ae-bb37a56f7151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_17e924c3-2020-4c9d-afcc-1d2e3020ef08" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1c180c07-4931-4b70-a3ae-bb37a56f7151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_240fef33-2566-4473-9fcf-b248b6fc2404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_17e924c3-2020-4c9d-afcc-1d2e3020ef08" xlink:to="loc_us-gaap_CommonStockSharesIssued_240fef33-2566-4473-9fcf-b248b6fc2404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e4c31b74-6176-433b-aa84-77b96dc56214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_17e924c3-2020-4c9d-afcc-1d2e3020ef08" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e4c31b74-6176-433b-aa84-77b96dc56214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="simple" xlink:href="npce-20230331.xsd#CondensedStatementsofOperationsandComprehensiveLossunaudited"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_10023bba-9caa-4503-99b0-75eec48971fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0e348716-3dde-4d6e-91a7-50fbdb338922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_10023bba-9caa-4503-99b0-75eec48971fd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0e348716-3dde-4d6e-91a7-50fbdb338922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d6575f39-8f91-4e14-9a1d-18df2f3ba62b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_10023bba-9caa-4503-99b0-75eec48971fd" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d6575f39-8f91-4e14-9a1d-18df2f3ba62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_3cc0b7bc-26d4-483c-93fa-f81879aaf97b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_10023bba-9caa-4503-99b0-75eec48971fd" xlink:to="loc_us-gaap_GrossProfit_3cc0b7bc-26d4-483c-93fa-f81879aaf97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7357e676-78bb-41ba-99a2-e52ba6741d87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_10023bba-9caa-4503-99b0-75eec48971fd" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7357e676-78bb-41ba-99a2-e52ba6741d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c681a1a1-452c-454d-a461-7c901f15289a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7357e676-78bb-41ba-99a2-e52ba6741d87" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c681a1a1-452c-454d-a461-7c901f15289a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8067c2b0-4cdd-4611-8fd1-7895b004e89d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7357e676-78bb-41ba-99a2-e52ba6741d87" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8067c2b0-4cdd-4611-8fd1-7895b004e89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_47e64ef4-796b-4a59-8bed-84f6ed8484c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7357e676-78bb-41ba-99a2-e52ba6741d87" xlink:to="loc_us-gaap_OperatingExpenses_47e64ef4-796b-4a59-8bed-84f6ed8484c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_53f9b4ed-40e5-419f-800c-db5dea9de164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_10023bba-9caa-4503-99b0-75eec48971fd" xlink:to="loc_us-gaap_OperatingIncomeLoss_53f9b4ed-40e5-419f-800c-db5dea9de164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_3f52e95a-1d22-47ce-b09e-ddd40b24cda8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_10023bba-9caa-4503-99b0-75eec48971fd" xlink:to="loc_us-gaap_InvestmentIncomeInterest_3f52e95a-1d22-47ce-b09e-ddd40b24cda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9def675d-955b-4346-abfa-5e07ce253623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_10023bba-9caa-4503-99b0-75eec48971fd" xlink:to="loc_us-gaap_InterestExpense_9def675d-955b-4346-abfa-5e07ce253623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_41d49458-1c16-4e05-9afc-b1fc12cb7243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_10023bba-9caa-4503-99b0-75eec48971fd" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_41d49458-1c16-4e05-9afc-b1fc12cb7243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_61108b49-bad8-4836-b66d-8742c0e7072a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_10023bba-9caa-4503-99b0-75eec48971fd" xlink:to="loc_us-gaap_NetIncomeLoss_61108b49-bad8-4836-b66d-8742c0e7072a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3d67df61-45e0-4a52-8849-2d403dd159ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_10023bba-9caa-4503-99b0-75eec48971fd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3d67df61-45e0-4a52-8849-2d403dd159ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b6065200-b439-4179-ba92-7079450c62d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_10023bba-9caa-4503-99b0-75eec48971fd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_b6065200-b439-4179-ba92-7079450c62d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_651d10f7-097d-473d-abe6-a27cd7763c97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_10023bba-9caa-4503-99b0-75eec48971fd" xlink:to="loc_us-gaap_EarningsPerShareBasic_651d10f7-097d-473d-abe6-a27cd7763c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9e82c295-de70-4136-9d32-c40b2ac6dc85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_10023bba-9caa-4503-99b0-75eec48971fd" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9e82c295-de70-4136-9d32-c40b2ac6dc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dec0e87b-4288-43ee-8d37-a890bb9e05e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_10023bba-9caa-4503-99b0-75eec48971fd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dec0e87b-4288-43ee-8d37-a890bb9e05e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f779258d-6910-4be1-a86d-bc3b230d21e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_10023bba-9caa-4503-99b0-75eec48971fd" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f779258d-6910-4be1-a86d-bc3b230d21e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited" xlink:type="simple" xlink:href="npce-20230331.xsd#CondensedStatementsofStockholdersEquityunaudited"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_385f462e-425c-4ca6-90b3-5cdc3d2b1c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_60727d21-d513-4037-9365-cee6c839ab24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_385f462e-425c-4ca6-90b3-5cdc3d2b1c57" xlink:to="loc_us-gaap_StatementTable_60727d21-d513-4037-9365-cee6c839ab24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0ec9f8e0-f8ed-44f8-81b8-9a80988d86b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_60727d21-d513-4037-9365-cee6c839ab24" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0ec9f8e0-f8ed-44f8-81b8-9a80988d86b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1e1785f8-82cd-4e78-89d0-15df512047fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0ec9f8e0-f8ed-44f8-81b8-9a80988d86b6" xlink:to="loc_us-gaap_EquityComponentDomain_1e1785f8-82cd-4e78-89d0-15df512047fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2c6e87eb-a5d0-4f5e-b2ba-5dbd047d94b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1e1785f8-82cd-4e78-89d0-15df512047fe" xlink:to="loc_us-gaap_CommonStockMember_2c6e87eb-a5d0-4f5e-b2ba-5dbd047d94b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_592d5068-ed84-4ab9-b25d-68afc2aab7be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1e1785f8-82cd-4e78-89d0-15df512047fe" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_592d5068-ed84-4ab9-b25d-68afc2aab7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bd02b065-6ccb-4b25-9dea-9a37582baebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1e1785f8-82cd-4e78-89d0-15df512047fe" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bd02b065-6ccb-4b25-9dea-9a37582baebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0b0e7822-0e93-45b4-99bf-9960c4de9dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1e1785f8-82cd-4e78-89d0-15df512047fe" xlink:to="loc_us-gaap_RetainedEarningsMember_0b0e7822-0e93-45b4-99bf-9960c4de9dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d082503e-2028-4034-b81b-2119b9ad44e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_60727d21-d513-4037-9365-cee6c839ab24" xlink:to="loc_us-gaap_StatementLineItems_d082503e-2028-4034-b81b-2119b9ad44e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_a7888845-f815-4914-a0cc-de41411dd367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d082503e-2028-4034-b81b-2119b9ad44e4" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_a7888845-f815-4914-a0cc-de41411dd367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_a7888845-f815-4914-a0cc-de41411dd367" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ef731ba4-3b13-4279-ad90-c58622c2bbae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ef731ba4-3b13-4279-ad90-c58622c2bbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3565db98-8596-4bc7-b2a4-733cda7f5c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_us-gaap_StockholdersEquity_3565db98-8596-4bc7-b2a4-733cda7f5c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4412486e-dbf6-457f-b2f2-62348953976a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_us-gaap_NetIncomeLoss_4412486e-dbf6-457f-b2f2-62348953976a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_OCIUnrealizedLossAdjustmentForShortTermInvestment_38954b1e-7b09-478e-abd7-f953dc6e8475" xlink:href="npce-20230331.xsd#npce_OCIUnrealizedLossAdjustmentForShortTermInvestment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_npce_OCIUnrealizedLossAdjustmentForShortTermInvestment_38954b1e-7b09-478e-abd7-f953dc6e8475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a85445c8-20e0-4278-980d-811be3968af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a85445c8-20e0-4278-980d-811be3968af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b8ab758a-1456-4f85-9804-fe9c1892cd64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b8ab758a-1456-4f85-9804-fe9c1892cd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2c8aa286-eaa1-4bbe-9d8b-e44e2add59e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2c8aa286-eaa1-4bbe-9d8b-e44e2add59e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_d84e1818-2c23-4ac0-b92e-acd772712101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_d84e1818-2c23-4ac0-b92e-acd772712101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_f0d8955f-ddd1-4f9b-a04e-a06d722d2505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_f0d8955f-ddd1-4f9b-a04e-a06d722d2505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_c4b29ec2-bcc9-44c3-8c8c-af7dc4b4b9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_c4b29ec2-bcc9-44c3-8c8c-af7dc4b4b9d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_f01bf08d-811b-4462-8505-65c1d8350111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_f01bf08d-811b-4462-8505-65c1d8350111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability_a523dab4-87ee-4a69-91cb-b75a99be447c" xlink:href="npce-20230331.xsd#npce_AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_npce_AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability_a523dab4-87ee-4a69-91cb-b75a99be447c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_a68cc6d3-8785-4b08-a3fe-e625400a9970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_a68cc6d3-8785-4b08-a3fe-e625400a9970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8aaa0cc1-0976-4360-b6e5-ef01d98555eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8aaa0cc1-0976-4360-b6e5-ef01d98555eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7505286a-ce58-4073-8b6d-8e197a22a794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a74525fe-2983-41c7-8419-566df3db99e4" xlink:to="loc_us-gaap_StockholdersEquity_7505286a-ce58-4073-8b6d-8e197a22a794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="npce-20230331.xsd#CondensedStatementsofCashFlowsunaudited"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6870575b-7f9d-4fc4-b69a-314ef7975c74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_52fe9247-351c-4935-a725-0a810f0ae12e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6870575b-7f9d-4fc4-b69a-314ef7975c74" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_52fe9247-351c-4935-a725-0a810f0ae12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6513dad2-839b-4991-925d-ea213d05a96e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_52fe9247-351c-4935-a725-0a810f0ae12e" xlink:to="loc_us-gaap_NetIncomeLoss_6513dad2-839b-4991-925d-ea213d05a96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e69f3541-49d4-4056-a6ff-dcf95bb3a972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_52fe9247-351c-4935-a725-0a810f0ae12e" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e69f3541-49d4-4056-a6ff-dcf95bb3a972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_51487cc8-3145-4d53-80f0-13b81580a0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e69f3541-49d4-4056-a6ff-dcf95bb3a972" xlink:to="loc_us-gaap_ShareBasedCompensation_51487cc8-3145-4d53-80f0-13b81580a0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_fd298197-26d3-4971-bbe9-c18ff350e9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e69f3541-49d4-4056-a6ff-dcf95bb3a972" xlink:to="loc_us-gaap_Depreciation_fd298197-26d3-4971-bbe9-c18ff350e9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_9b9bf0ae-0c81-4553-a2bf-deaeabe09842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e69f3541-49d4-4056-a6ff-dcf95bb3a972" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_9b9bf0ae-0c81-4553-a2bf-deaeabe09842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_IncreaseDecreaseInNonCashInterestExpense_de09335c-d8f9-4a8c-a7e5-9251d5740425" xlink:href="npce-20230331.xsd#npce_IncreaseDecreaseInNonCashInterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e69f3541-49d4-4056-a6ff-dcf95bb3a972" xlink:to="loc_npce_IncreaseDecreaseInNonCashInterestExpense_de09335c-d8f9-4a8c-a7e5-9251d5740425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_4593b2a8-f455-4980-a852-7f4fd28727e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e69f3541-49d4-4056-a6ff-dcf95bb3a972" xlink:to="loc_us-gaap_PaidInKindInterest_4593b2a8-f455-4980-a852-7f4fd28727e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d94866af-f6c0-4201-a09b-fe23671019e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e69f3541-49d4-4056-a6ff-dcf95bb3a972" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d94866af-f6c0-4201-a09b-fe23671019e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_0cedea2a-de8d-4f76-9764-a3a69cb5e1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e69f3541-49d4-4056-a6ff-dcf95bb3a972" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_0cedea2a-de8d-4f76-9764-a3a69cb5e1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_9b398b6a-5984-4c6d-9896-df636503dd90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e69f3541-49d4-4056-a6ff-dcf95bb3a972" xlink:to="loc_us-gaap_InventoryWriteDown_9b398b6a-5984-4c6d-9896-df636503dd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e179a9f8-9fe1-4b00-9d8d-3adafe783ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e69f3541-49d4-4056-a6ff-dcf95bb3a972" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e179a9f8-9fe1-4b00-9d8d-3adafe783ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_82d04dc9-f153-4077-8dfa-6979c0e7c835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e179a9f8-9fe1-4b00-9d8d-3adafe783ac6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_82d04dc9-f153-4077-8dfa-6979c0e7c835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_e62db830-ed7b-47e2-9393-1363989150e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e179a9f8-9fe1-4b00-9d8d-3adafe783ac6" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_e62db830-ed7b-47e2-9393-1363989150e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5aacb6a0-7f8f-48b2-af34-4b1ac3db8841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e179a9f8-9fe1-4b00-9d8d-3adafe783ac6" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5aacb6a0-7f8f-48b2-af34-4b1ac3db8841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_df335a91-b335-445b-ad82-4474f987781d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e179a9f8-9fe1-4b00-9d8d-3adafe783ac6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_df335a91-b335-445b-ad82-4474f987781d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_169b322f-160b-400e-842b-1ac8ec6c27be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e179a9f8-9fe1-4b00-9d8d-3adafe783ac6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_169b322f-160b-400e-842b-1ac8ec6c27be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_19087faf-0285-4817-80bd-9714a2196346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e179a9f8-9fe1-4b00-9d8d-3adafe783ac6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_19087faf-0285-4817-80bd-9714a2196346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94d8faaf-ee96-4c02-9469-6b242391332d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_52fe9247-351c-4935-a725-0a810f0ae12e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94d8faaf-ee96-4c02-9469-6b242391332d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f3e83e2e-c80d-4022-9278-a6da318e555a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6870575b-7f9d-4fc4-b69a-314ef7975c74" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f3e83e2e-c80d-4022-9278-a6da318e555a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_22afbe6d-16f1-4089-b010-2f1c10d9b8be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f3e83e2e-c80d-4022-9278-a6da318e555a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_22afbe6d-16f1-4089-b010-2f1c10d9b8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_230f2eb1-f5a8-43d1-9853-7230019858f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f3e83e2e-c80d-4022-9278-a6da318e555a" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_230f2eb1-f5a8-43d1-9853-7230019858f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3804337b-ff97-4fa3-97f7-b14aab477e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f3e83e2e-c80d-4022-9278-a6da318e555a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3804337b-ff97-4fa3-97f7-b14aab477e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6d12be06-6a66-4423-b6a4-ef5379258ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6870575b-7f9d-4fc4-b69a-314ef7975c74" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6d12be06-6a66-4423-b6a4-ef5379258ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f4fd7abe-6f0d-4d6d-9cba-a5ad71832e61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6d12be06-6a66-4423-b6a4-ef5379258ff9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f4fd7abe-6f0d-4d6d-9cba-a5ad71832e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_49a4be0b-d305-4eb2-b409-a7b0e0d6db80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6d12be06-6a66-4423-b6a4-ef5379258ff9" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_49a4be0b-d305-4eb2-b409-a7b0e0d6db80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_a8c34aba-8cc9-496f-8cdf-2e1d609b2a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6d12be06-6a66-4423-b6a4-ef5379258ff9" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_a8c34aba-8cc9-496f-8cdf-2e1d609b2a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_57d452f3-f6e7-4def-85c0-91dac50d8e11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6d12be06-6a66-4423-b6a4-ef5379258ff9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_57d452f3-f6e7-4def-85c0-91dac50d8e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ea91f0cb-4c11-44c0-a039-19ca9434278e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6870575b-7f9d-4fc4-b69a-314ef7975c74" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ea91f0cb-4c11-44c0-a039-19ca9434278e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_515cdaf8-97a8-4d1a-ab39-074d84b61232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6870575b-7f9d-4fc4-b69a-314ef7975c74" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_515cdaf8-97a8-4d1a-ab39-074d84b61232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_722c4cf4-f7fe-4389-9fcd-e2d0130ee393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_515cdaf8-97a8-4d1a-ab39-074d84b61232" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_722c4cf4-f7fe-4389-9fcd-e2d0130ee393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3a506181-0e8e-46fa-a794-18fdbac31a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_515cdaf8-97a8-4d1a-ab39-074d84b61232" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3a506181-0e8e-46fa-a794-18fdbac31a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_d08928d3-2818-4b36-8b5b-d7a9ba65f896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6870575b-7f9d-4fc4-b69a-314ef7975c74" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_d08928d3-2818-4b36-8b5b-d7a9ba65f896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_566c34d1-9b0d-4d7b-80e3-205cd58e018a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_d08928d3-2818-4b36-8b5b-d7a9ba65f896" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_566c34d1-9b0d-4d7b-80e3-205cd58e018a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_8b512d0f-0e1a-468b-bb64-8a9f3cb8c096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_d08928d3-2818-4b36-8b5b-d7a9ba65f896" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_8b512d0f-0e1a-468b-bb64-8a9f3cb8c096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2735c2b7-7770-4a5c-9c8a-2c79af8f1244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_d08928d3-2818-4b36-8b5b-d7a9ba65f896" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2735c2b7-7770-4a5c-9c8a-2c79af8f1244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_15520201-27ef-4db0-8586-0c731c3b00a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6870575b-7f9d-4fc4-b69a-314ef7975c74" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_15520201-27ef-4db0-8586-0c731c3b00a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_6426d476-1b77-4c31-896c-4d29accc909c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_15520201-27ef-4db0-8586-0c731c3b00a9" xlink:to="loc_us-gaap_InterestPaidNet_6426d476-1b77-4c31-896c-4d29accc909c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_effa6e01-dd98-4b6b-ad0d-4db45669e5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6870575b-7f9d-4fc4-b69a-314ef7975c74" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_effa6e01-dd98-4b6b-ad0d-4db45669e5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions_ee151958-0c20-4cff-a3a1-e5ecc548c6c6" xlink:href="npce-20230331.xsd#npce_IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_effa6e01-dd98-4b6b-ad0d-4db45669e5c6" xlink:to="loc_npce_IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions_ee151958-0c20-4cff-a3a1-e5ecc548c6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a13814d2-d22c-46df-9c8e-0092d27aeaca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_effa6e01-dd98-4b6b-ad0d-4db45669e5c6" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a13814d2-d22c-46df-9c8e-0092d27aeaca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/TheCompany" xlink:type="simple" xlink:href="npce-20230331.xsd#TheCompany"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/TheCompany" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_259a2ac1-33e2-4287-b194-d396ef2bee1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_caa9fccb-f243-407e-99e5-c8e1a218c8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_259a2ac1-33e2-4287-b194-d396ef2bee1f" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_caa9fccb-f243-407e-99e5-c8e1a218c8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="npce-20230331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_df7cafce-30e3-4ff5-b1b2-bc00e044004a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_900da7ab-3406-4359-b221-9edba36fe446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df7cafce-30e3-4ff5-b1b2-bc00e044004a" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_900da7ab-3406-4359-b221-9edba36fe446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="npce-20230331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_804984e4-08fe-490d-83ea-c40923bcbf1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_0388c5a0-75dd-41db-bc42-3d0a23ecdacb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_804984e4-08fe-490d-83ea-c40923bcbf1b" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_0388c5a0-75dd-41db-bc42-3d0a23ecdacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="npce-20230331.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dc1b33d9-96af-40e8-a5ee-43b6dcb1d2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_5687ce04-f83a-4b1b-975d-4b0e9dcc381c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dc1b33d9-96af-40e8-a5ee-43b6dcb1d2f0" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_5687ce04-f83a-4b1b-975d-4b0e9dcc381c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="npce-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0165dab-d67b-4f40-9599-25b7ff0a37c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0c7c529b-d199-4e85-8c1a-9ccbdf1df265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0165dab-d67b-4f40-9599-25b7ff0a37c1" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0c7c529b-d199-4e85-8c1a-9ccbdf1df265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/Debt" xlink:type="simple" xlink:href="npce-20230331.xsd#Debt"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_554230a9-d9d1-4698-84d2-ee302e03d1a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4e85db85-9aa4-4191-9ea2-feb7e3f1cbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_554230a9-d9d1-4698-84d2-ee302e03d1a8" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_4e85db85-9aa4-4191-9ea2-feb7e3f1cbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/CommonStock" xlink:type="simple" xlink:href="npce-20230331.xsd#CommonStock"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/CommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b38eda1f-af20-4206-9d4e-9e74ae6df01b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_fd0e73c0-7da8-4095-998f-0a3e553b472c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b38eda1f-af20-4206-9d4e-9e74ae6df01b" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_fd0e73c0-7da8-4095-998f-0a3e553b472c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/StockBasedIncentiveCompensationPlans" xlink:type="simple" xlink:href="npce-20230331.xsd#StockBasedIncentiveCompensationPlans"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/StockBasedIncentiveCompensationPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5244f2fb-6841-42de-8933-917de22f9d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a5822191-af4c-4903-8a45-b1a3a3e7f50e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5244f2fb-6841-42de-8933-917de22f9d31" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a5822191-af4c-4903-8a45-b1a3a3e7f50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/IncomeTaxes" xlink:type="simple" xlink:href="npce-20230331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b83c2ce0-0a91-4d5d-9195-2dafd2fe2178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_109f573d-eb4a-4d90-9775-5c74f4497b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b83c2ce0-0a91-4d5d-9195-2dafd2fe2178" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_109f573d-eb4a-4d90-9775-5c74f4497b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholders" xlink:type="simple" xlink:href="npce-20230331.xsd#NetLossperShareAttributabletoCommonStockholders"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholders" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_faa2e01c-95ff-499d-bbff-a696d6d605a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_3561044c-a10b-4026-ae09-36d20f1bf711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_faa2e01c-95ff-499d-bbff-a696d6d605a0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_3561044c-a10b-4026-ae09-36d20f1bf711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="npce-20230331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_336de67a-c53f-451d-9381-c729cc117a00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ed23bb01-9bc7-42e4-ab61-9a48940c23e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336de67a-c53f-451d-9381-c729cc117a00" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ed23bb01-9bc7-42e4-ab61-9a48940c23e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_95bbdc3c-0b08-4fcd-8e86-31d6c7c84f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336de67a-c53f-451d-9381-c729cc117a00" xlink:to="loc_us-gaap_UseOfEstimates_95bbdc3c-0b08-4fcd-8e86-31d6c7c84f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_06f33856-5d73-4987-89ee-c9ffeda53997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336de67a-c53f-451d-9381-c729cc117a00" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_06f33856-5d73-4987-89ee-c9ffeda53997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_264198af-d513-496f-8e83-9d0fbe2caeee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336de67a-c53f-451d-9381-c729cc117a00" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_264198af-d513-496f-8e83-9d0fbe2caeee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_5883bd9a-5142-48bf-b9b6-af954cd1af82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336de67a-c53f-451d-9381-c729cc117a00" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_5883bd9a-5142-48bf-b9b6-af954cd1af82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_4b0cbc4c-5056-42f9-a43f-ab7a46136cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336de67a-c53f-451d-9381-c729cc117a00" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_4b0cbc4c-5056-42f9-a43f-ab7a46136cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_243a78f6-11c0-487c-8266-88c522acf038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336de67a-c53f-451d-9381-c729cc117a00" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_243a78f6-11c0-487c-8266-88c522acf038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3e29ec29-7cb0-40e2-92eb-00dd7d2d11a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336de67a-c53f-451d-9381-c729cc117a00" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3e29ec29-7cb0-40e2-92eb-00dd7d2d11a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="npce-20230331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a4343db2-2aaa-4359-8645-0f99fada6586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_e45ff003-6082-4fd5-8611-ee11d1e04e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a4343db2-2aaa-4359-8645-0f99fada6586" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_e45ff003-6082-4fd5-8611-ee11d1e04e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="npce-20230331.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9399d92d-1d40-4f97-9cd2-a29d905251ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c3cff390-ac93-4b13-a2ff-68a6ac38f8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9399d92d-1d40-4f97-9cd2-a29d905251ef" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c3cff390-ac93-4b13-a2ff-68a6ac38f8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9f7dea18-ca4e-4249-bfbb-0de42f36314e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9399d92d-1d40-4f97-9cd2-a29d905251ef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9f7dea18-ca4e-4249-bfbb-0de42f36314e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d0db78c9-d7f6-4280-bb9a-9506fa425c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9399d92d-1d40-4f97-9cd2-a29d905251ef" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d0db78c9-d7f6-4280-bb9a-9506fa425c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="npce-20230331.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5213a766-c39c-42ce-abf1-4ff838fdb2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_dc4a62eb-5b89-41d2-805e-c2fd2047ffb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5213a766-c39c-42ce-abf1-4ff838fdb2ea" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_dc4a62eb-5b89-41d2-805e-c2fd2047ffb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/DebtTables" xlink:type="simple" xlink:href="npce-20230331.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fd069364-bd63-4e03-a350-7c8de9ed3291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_f4b90469-847a-4000-9dbf-5ec690c3e6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fd069364-bd63-4e03-a350-7c8de9ed3291" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_f4b90469-847a-4000-9dbf-5ec690c3e6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/CommonStockTables" xlink:type="simple" xlink:href="npce-20230331.xsd#CommonStockTables"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/CommonStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2be019a8-303d-4a33-af07-1f4aed1264fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_bba0c943-3c96-457a-ad19-63c3fe358fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2be019a8-303d-4a33-af07-1f4aed1264fb" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_bba0c943-3c96-457a-ad19-63c3fe358fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/StockBasedIncentiveCompensationPlansTables" xlink:type="simple" xlink:href="npce-20230331.xsd#StockBasedIncentiveCompensationPlansTables"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/StockBasedIncentiveCompensationPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e6288878-d874-4526-8869-0ef2e5c855ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_04c5cd01-4d1f-491e-9f2a-7f742e18342a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e6288878-d874-4526-8869-0ef2e5c855ad" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_04c5cd01-4d1f-491e-9f2a-7f742e18342a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_c94c4e96-1810-4327-9ef7-461b7d047ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e6288878-d874-4526-8869-0ef2e5c855ad" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_c94c4e96-1810-4327-9ef7-461b7d047ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_0572720d-0b5f-4e7c-8bf8-0a3a22babb5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e6288878-d874-4526-8869-0ef2e5c855ad" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_0572720d-0b5f-4e7c-8bf8-0a3a22babb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_51e1daf0-7ba1-4b56-83e5-90007d51ce17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e6288878-d874-4526-8869-0ef2e5c855ad" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_51e1daf0-7ba1-4b56-83e5-90007d51ce17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersTables" xlink:type="simple" xlink:href="npce-20230331.xsd#NetLossperShareAttributabletoCommonStockholdersTables"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_29e7e912-acf5-4fed-95fb-bfa383df09f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_722902ec-bbc4-4087-889d-a8e6e8138e12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_29e7e912-acf5-4fed-95fb-bfa383df09f4" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_722902ec-bbc4-4087-889d-a8e6e8138e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_954f39e3-c8db-4a6f-b759-154aa2c51333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_29e7e912-acf5-4fed-95fb-bfa383df09f4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_954f39e3-c8db-4a6f-b759-154aa2c51333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/TheCompanyDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#TheCompanyDetails"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/TheCompanyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_21a95f97-a22d-497b-bb31-40754a51a947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d69e12fc-b684-4a1c-9878-054fcc9a0274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_21a95f97-a22d-497b-bb31-40754a51a947" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d69e12fc-b684-4a1c-9878-054fcc9a0274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8a18efe4-12b6-454c-8c23-7138904857fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d69e12fc-b684-4a1c-9878-054fcc9a0274" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8a18efe4-12b6-454c-8c23-7138904857fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_abf5efbd-5c2e-4b71-a76c-d9002f69de52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8a18efe4-12b6-454c-8c23-7138904857fc" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_abf5efbd-5c2e-4b71-a76c-d9002f69de52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_7de05c5e-db93-4743-a26b-5b7bdfc54367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_abf5efbd-5c2e-4b71-a76c-d9002f69de52" xlink:to="loc_us-gaap_IPOMember_7de05c5e-db93-4743-a26b-5b7bdfc54367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_fc9ac400-f48b-462b-a91f-ea21747b2708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_abf5efbd-5c2e-4b71-a76c-d9002f69de52" xlink:to="loc_us-gaap_OverAllotmentOptionMember_fc9ac400-f48b-462b-a91f-ea21747b2708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_AtTheMarketEquityOfferingMember_de9e12c4-0a1d-4b43-a849-6149c6cb0f40" xlink:href="npce-20230331.xsd#npce_AtTheMarketEquityOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_abf5efbd-5c2e-4b71-a76c-d9002f69de52" xlink:to="loc_npce_AtTheMarketEquityOfferingMember_de9e12c4-0a1d-4b43-a849-6149c6cb0f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_9e61d9d1-ca37-4872-ac2e-4e8c2d7e40cb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d69e12fc-b684-4a1c-9878-054fcc9a0274" xlink:to="loc_srt_StatementScenarioAxis_9e61d9d1-ca37-4872-ac2e-4e8c2d7e40cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1c5a638d-42a6-46b0-a196-f16718a2834b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_9e61d9d1-ca37-4872-ac2e-4e8c2d7e40cb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1c5a638d-42a6-46b0-a196-f16718a2834b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_aa34938b-f1d8-4671-980f-0ae24b0d432a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1c5a638d-42a6-46b0-a196-f16718a2834b" xlink:to="loc_srt_ScenarioForecastMember_aa34938b-f1d8-4671-980f-0ae24b0d432a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d69e12fc-b684-4a1c-9878-054fcc9a0274" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c1ab1a57-130f-4dd2-a228-e1f6407f059a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c1ab1a57-130f-4dd2-a228-e1f6407f059a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_7c94ea88-5910-413e-acdb-5cd485de373e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_7c94ea88-5910-413e-acdb-5cd485de373e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2b5389f6-c360-479c-b12f-92685953e0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2b5389f6-c360-479c-b12f-92685953e0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_29995820-2683-413b-93ef-9826e863e6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_29995820-2683-413b-93ef-9826e863e6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_SaleOfStockUnderwritingDiscounts_81d3b63e-bd4b-45b5-a17a-d80351802757" xlink:href="npce-20230331.xsd#npce_SaleOfStockUnderwritingDiscounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_npce_SaleOfStockUnderwritingDiscounts_81d3b63e-bd4b-45b5-a17a-d80351802757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_SaleOfStockOfferingCosts_127bd882-f04f-45a0-92da-489e4eaf271a" xlink:href="npce-20230331.xsd#npce_SaleOfStockOfferingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_npce_SaleOfStockOfferingCosts_127bd882-f04f-45a0-92da-489e4eaf271a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_b72d7e46-98c0-4093-a2bd-8d915a4df2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_b72d7e46-98c0-4093-a2bd-8d915a4df2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_65f0e65d-8bdb-43ad-a15b-f9440ecb2d97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_65f0e65d-8bdb-43ad-a15b-f9440ecb2d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement_31000dcd-898c-4865-aba9-84bf362d16b7" xlink:href="npce-20230331.xsd#npce_PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_npce_PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement_31000dcd-898c-4865-aba9-84bf362d16b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_12b7f129-93aa-4697-88f8-347a139e7767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_12b7f129-93aa-4697-88f8-347a139e7767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72dc64f3-b998-40f0-8752-4ef63435ca9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72dc64f3-b998-40f0-8752-4ef63435ca9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_a56adbca-0022-49d2-9115-eb36657227bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_a56adbca-0022-49d2-9115-eb36657227bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_DebtInstrumentCovenantMinimumAnnualNetRevenue_4eab9077-6150-4367-ac1e-6ac94e830319" xlink:href="npce-20230331.xsd#npce_DebtInstrumentCovenantMinimumAnnualNetRevenue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_npce_DebtInstrumentCovenantMinimumAnnualNetRevenue_4eab9077-6150-4367-ac1e-6ac94e830319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO_391af682-ae5f-4935-92a6-34c8f3b6856c" xlink:href="npce-20230331.xsd#npce_DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6b1cb5f7-9142-45ff-9f0b-76c2a6986a5a" xlink:to="loc_npce_DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO_391af682-ae5f-4935-92a6-34c8f3b6856c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c0599e70-d7ed-45a1-bff4-89937a4afe10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_60ef6605-6db0-4ff3-8fc9-0f20fa724959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c0599e70-d7ed-45a1-bff4-89937a4afe10" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_60ef6605-6db0-4ff3-8fc9-0f20fa724959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f7a244ff-e65d-40ea-bebf-0af4bcada087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_60ef6605-6db0-4ff3-8fc9-0f20fa724959" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f7a244ff-e65d-40ea-bebf-0af4bcada087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a0ffcfb6-34c7-4bd7-9872-ff880891911c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f7a244ff-e65d-40ea-bebf-0af4bcada087" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a0ffcfb6-34c7-4bd7-9872-ff880891911c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFundingAgreementTermsMember_7e525a06-7ce7-44cb-8b69-c505e71d9239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFundingAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a0ffcfb6-34c7-4bd7-9872-ff880891911c" xlink:to="loc_us-gaap_AdditionalFundingAgreementTermsMember_7e525a06-7ce7-44cb-8b69-c505e71d9239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bc6552be-8a3b-4ecf-8353-f02cd71a66ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_60ef6605-6db0-4ff3-8fc9-0f20fa724959" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bc6552be-8a3b-4ecf-8353-f02cd71a66ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTerm_47536752-307c-422f-b8a7-f40252c73ac4" xlink:href="npce-20230331.xsd#npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bc6552be-8a3b-4ecf-8353-f02cd71a66ef" xlink:to="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTerm_47536752-307c-422f-b8a7-f40252c73ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost_f8a18c83-1395-4527-a1fc-eb2256f9a0c1" xlink:href="npce-20230331.xsd#npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bc6552be-8a3b-4ecf-8353-f02cd71a66ef" xlink:to="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost_f8a18c83-1395-4527-a1fc-eb2256f9a0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards_f5376a31-cb32-4458-9a97-911cf0ab99bf" xlink:href="npce-20230331.xsd#npce_ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bc6552be-8a3b-4ecf-8353-f02cd71a66ef" xlink:to="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards_f5376a31-cb32-4458-9a97-911cf0ab99bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1_531fe0d7-5622-4de8-88ef-136cbd38a6f5" xlink:href="npce-20230331.xsd#npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bc6552be-8a3b-4ecf-8353-f02cd71a66ef" xlink:to="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1_531fe0d7-5622-4de8-88ef-136cbd38a6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1_7ba07f24-3541-44ba-a098-226faec9a1eb" xlink:href="npce-20230331.xsd#npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bc6552be-8a3b-4ecf-8353-f02cd71a66ef" xlink:to="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1_7ba07f24-3541-44ba-a098-226faec9a1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2_a7a402d5-3a33-4926-89d5-f2e46af296bb" xlink:href="npce-20230331.xsd#npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bc6552be-8a3b-4ecf-8353-f02cd71a66ef" xlink:to="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2_a7a402d5-3a33-4926-89d5-f2e46af296bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2_a7f3e213-65ae-4f31-9208-10e1fd555abe" xlink:href="npce-20230331.xsd#npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bc6552be-8a3b-4ecf-8353-f02cd71a66ef" xlink:to="loc_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2_a7f3e213-65ae-4f31-9208-10e1fd555abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_4bc126e7-7e7a-4e28-bdfd-95f6cf3b98f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bc6552be-8a3b-4ecf-8353-f02cd71a66ef" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_4bc126e7-7e7a-4e28-bdfd-95f6cf3b98f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_67a7930a-1c22-473c-809e-0c0f5b913ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bc6552be-8a3b-4ecf-8353-f02cd71a66ef" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_67a7930a-1c22-473c-809e-0c0f5b913ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c6f9e491-7ef6-481e-a6b3-ae9a1e3b90cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4e0c0ee-2ca6-4774-97cd-8d753d5ed41c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c6f9e491-7ef6-481e-a6b3-ae9a1e3b90cc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4e0c0ee-2ca6-4774-97cd-8d753d5ed41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1e0c0bb3-21d4-4ab3-9dd5-dbb2b730900b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4e0c0ee-2ca6-4774-97cd-8d753d5ed41c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1e0c0bb3-21d4-4ab3-9dd5-dbb2b730900b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d79dda3-bb48-43bd-ba6c-6faf743b8dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1e0c0bb3-21d4-4ab3-9dd5-dbb2b730900b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d79dda3-bb48-43bd-ba6c-6faf743b8dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0e91c770-c188-4ebf-adaf-dce099bfc7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d79dda3-bb48-43bd-ba6c-6faf743b8dcd" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0e91c770-c188-4ebf-adaf-dce099bfc7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_84596708-e349-45ad-b825-0657b164c43c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d79dda3-bb48-43bd-ba6c-6faf743b8dcd" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_84596708-e349-45ad-b825-0657b164c43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_efa02f6d-f9d2-45b7-b648-a2936066682a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d79dda3-bb48-43bd-ba6c-6faf743b8dcd" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_efa02f6d-f9d2-45b7-b648-a2936066682a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cde3e7f2-24be-42da-8d95-6eb1b0ee4ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4e0c0ee-2ca6-4774-97cd-8d753d5ed41c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cde3e7f2-24be-42da-8d95-6eb1b0ee4ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_ebfcacae-7b1d-45d2-b3ed-40dcc0e967dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cde3e7f2-24be-42da-8d95-6eb1b0ee4ccb" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_ebfcacae-7b1d-45d2-b3ed-40dcc0e967dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_799057b6-77b7-445c-93b4-8839bc5a893d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ebfcacae-7b1d-45d2-b3ed-40dcc0e967dc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_799057b6-77b7-445c-93b4-8839bc5a893d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_aca0e239-2b44-441c-b312-33aab78826e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ebfcacae-7b1d-45d2-b3ed-40dcc0e967dc" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_aca0e239-2b44-441c-b312-33aab78826e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_aaf1bbb4-23dc-4708-8d8a-234c753c63cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_ebfcacae-7b1d-45d2-b3ed-40dcc0e967dc" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_aaf1bbb4-23dc-4708-8d8a-234c753c63cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d8bf8435-6b7a-4ecd-a32c-8d9c15d93fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8b70c02a-d908-4f2d-9c3a-e03b111bda20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d8bf8435-6b7a-4ecd-a32c-8d9c15d93fe0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8b70c02a-d908-4f2d-9c3a-e03b111bda20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_3278ac18-b520-435e-9b4e-ffc4a39afadd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8b70c02a-d908-4f2d-9c3a-e03b111bda20" xlink:to="loc_us-gaap_InvestmentTypeAxis_3278ac18-b520-435e-9b4e-ffc4a39afadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_73be657a-91e0-4bf1-9f11-47c7f569a86e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_3278ac18-b520-435e-9b4e-ffc4a39afadd" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_73be657a-91e0-4bf1-9f11-47c7f569a86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_1a4ef6ef-40d9-494b-90cc-bcc8203d80fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_73be657a-91e0-4bf1-9f11-47c7f569a86e" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_1a4ef6ef-40d9-494b-90cc-bcc8203d80fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b57349de-ed07-4e33-bec2-3363379776ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8b70c02a-d908-4f2d-9c3a-e03b111bda20" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b57349de-ed07-4e33-bec2-3363379776ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_eb5ddc0b-f0b3-4bf4-9f7a-271eb8472963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b57349de-ed07-4e33-bec2-3363379776ff" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_eb5ddc0b-f0b3-4bf4-9f7a-271eb8472963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7c8432ca-c6eb-4e68-94da-08aab2f47680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b57349de-ed07-4e33-bec2-3363379776ff" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7c8432ca-c6eb-4e68-94da-08aab2f47680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a01f143a-0f85-48cb-b624-f04cdb43388e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b57349de-ed07-4e33-bec2-3363379776ff" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a01f143a-0f85-48cb-b624-f04cdb43388e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_60df0cab-0067-4bef-a7e4-d393d57274ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b57349de-ed07-4e33-bec2-3363379776ff" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_60df0cab-0067-4bef-a7e4-d393d57274ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ed1b8569-3fa5-47c0-b623-234fcf83312c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b57349de-ed07-4e33-bec2-3363379776ff" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ed1b8569-3fa5-47c0-b623-234fcf83312c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/BalanceSheetComponentsScheduleofInventoryDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#BalanceSheetComponentsScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/BalanceSheetComponentsScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ca3e2629-3ecc-4ed3-a3a3-370e54fd2875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_a2849d07-f49b-4b6c-912d-f7f74b0d5019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ca3e2629-3ecc-4ed3-a3a3-370e54fd2875" xlink:to="loc_us-gaap_InventoryRawMaterials_a2849d07-f49b-4b6c-912d-f7f74b0d5019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_6d90148c-4768-4574-a813-8468fd8c542a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ca3e2629-3ecc-4ed3-a3a3-370e54fd2875" xlink:to="loc_us-gaap_InventoryWorkInProcess_6d90148c-4768-4574-a813-8468fd8c542a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_c7839f14-b261-45a5-8a85-d89ffb0432b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ca3e2629-3ecc-4ed3-a3a3-370e54fd2875" xlink:to="loc_us-gaap_InventoryFinishedGoods_c7839f14-b261-45a5-8a85-d89ffb0432b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5a8bacd6-adb1-4aba-8414-3f0aa12dd005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ca3e2629-3ecc-4ed3-a3a3-370e54fd2875" xlink:to="loc_us-gaap_InventoryNet_5a8bacd6-adb1-4aba-8414-3f0aa12dd005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_49aa7e1f-51ac-43b0-a2fc-3e332885b433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a85e4ecb-30cc-4cd1-bf73-08ddfea7656c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_49aa7e1f-51ac-43b0-a2fc-3e332885b433" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a85e4ecb-30cc-4cd1-bf73-08ddfea7656c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_67cc3698-e793-4869-8d6f-14c170b56cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a85e4ecb-30cc-4cd1-bf73-08ddfea7656c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_67cc3698-e793-4869-8d6f-14c170b56cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_95c34229-293e-437f-b4b3-7e38709ade25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_67cc3698-e793-4869-8d6f-14c170b56cb8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_95c34229-293e-437f-b4b3-7e38709ade25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_MachineryEquipmentFurnitureAndFixturesMember_e8aea221-3d5b-45f7-9288-34ffd3d16a1e" xlink:href="npce-20230331.xsd#npce_MachineryEquipmentFurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_95c34229-293e-437f-b4b3-7e38709ade25" xlink:to="loc_npce_MachineryEquipmentFurnitureAndFixturesMember_e8aea221-3d5b-45f7-9288-34ffd3d16a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ComputerEquipmentAndSoftwareMember_11f385c1-b2bb-45bf-af0d-518d00e58eee" xlink:href="npce-20230331.xsd#npce_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_95c34229-293e-437f-b4b3-7e38709ade25" xlink:to="loc_npce_ComputerEquipmentAndSoftwareMember_11f385c1-b2bb-45bf-af0d-518d00e58eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_a916cf00-bb6d-4891-ae61-b6790e0f8c87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_95c34229-293e-437f-b4b3-7e38709ade25" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_a916cf00-bb6d-4891-ae61-b6790e0f8c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4ceeb294-e4c0-4b97-b16c-37ac959b6367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a85e4ecb-30cc-4cd1-bf73-08ddfea7656c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4ceeb294-e4c0-4b97-b16c-37ac959b6367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_a8a2d447-5a04-47c5-8f95-4a37b40f3296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4ceeb294-e4c0-4b97-b16c-37ac959b6367" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_a8a2d447-5a04-47c5-8f95-4a37b40f3296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ddd832a8-ce6c-4435-bcb7-39534a6176a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4ceeb294-e4c0-4b97-b16c-37ac959b6367" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ddd832a8-ce6c-4435-bcb7-39534a6176a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_02cab6b5-387a-4ded-9668-c3a17abfb976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4ceeb294-e4c0-4b97-b16c-37ac959b6367" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_02cab6b5-387a-4ded-9668-c3a17abfb976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c449a1d7-1d16-46b9-9062-3977e80a918c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4ceeb294-e4c0-4b97-b16c-37ac959b6367" xlink:to="loc_us-gaap_Depreciation_c449a1d7-1d16-46b9-9062-3977e80a918c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d0ac744d-20be-4382-912c-a525f636e1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_16187757-5f59-4c16-b4a3-cb4cb3b65f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d0ac744d-20be-4382-912c-a525f636e1fe" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_16187757-5f59-4c16-b4a3-cb4cb3b65f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_AccruedInventoryLiabilityCurrent_fe1d14e3-294d-4639-a612-ae5be93fd553" xlink:href="npce-20230331.xsd#npce_AccruedInventoryLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d0ac744d-20be-4382-912c-a525f636e1fe" xlink:to="loc_npce_AccruedInventoryLiabilityCurrent_fe1d14e3-294d-4639-a612-ae5be93fd553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_19dbc886-24db-4553-9181-06f186b75dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d0ac744d-20be-4382-912c-a525f636e1fe" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_19dbc886-24db-4553-9181-06f186b75dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9e86c4f8-3dd1-418e-99fe-ff203c48f284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d0ac744d-20be-4382-912c-a525f636e1fe" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9e86c4f8-3dd1-418e-99fe-ff203c48f284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_AccruedAndEmployeeRelatedLiabilitiesCurrent_5e4f54a1-53ad-43d1-b088-a3606eb10347" xlink:href="npce-20230331.xsd#npce_AccruedAndEmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d0ac744d-20be-4382-912c-a525f636e1fe" xlink:to="loc_npce_AccruedAndEmployeeRelatedLiabilitiesCurrent_5e4f54a1-53ad-43d1-b088-a3606eb10347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7e36f43c-92e4-46b5-9002-f175dc0cae13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_f6988a9e-033c-4eb8-85a8-1e0ee97bd2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7e36f43c-92e4-46b5-9002-f175dc0cae13" xlink:to="loc_us-gaap_LossContingenciesTable_f6988a9e-033c-4eb8-85a8-1e0ee97bd2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_037e231f-94bc-4d72-b7d4-4e744d1a6707" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f6988a9e-033c-4eb8-85a8-1e0ee97bd2aa" xlink:to="loc_srt_RangeAxis_037e231f-94bc-4d72-b7d4-4e744d1a6707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d632ba76-f29d-4157-8adb-86b6b9823ec7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_037e231f-94bc-4d72-b7d4-4e744d1a6707" xlink:to="loc_srt_RangeMember_d632ba76-f29d-4157-8adb-86b6b9823ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0a86372c-1a1c-4bad-bd8d-86cf599064aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d632ba76-f29d-4157-8adb-86b6b9823ec7" xlink:to="loc_srt_MinimumMember_0a86372c-1a1c-4bad-bd8d-86cf599064aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2a0482e0-d08d-4183-9156-11fa10a164ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d632ba76-f29d-4157-8adb-86b6b9823ec7" xlink:to="loc_srt_MaximumMember_2a0482e0-d08d-4183-9156-11fa10a164ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9e62bef2-f83c-405a-adb6-5ac44a65bea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f6988a9e-033c-4eb8-85a8-1e0ee97bd2aa" xlink:to="loc_us-gaap_DebtInstrumentAxis_9e62bef2-f83c-405a-adb6-5ac44a65bea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6a2d340c-7af8-40df-b751-0c84d021e30f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9e62bef2-f83c-405a-adb6-5ac44a65bea3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6a2d340c-7af8-40df-b751-0c84d021e30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_LeaseFacilityMember_b9b5918c-504d-40e8-a825-6dcd2bcf573f" xlink:href="npce-20230331.xsd#npce_LeaseFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6a2d340c-7af8-40df-b751-0c84d021e30f" xlink:to="loc_npce_LeaseFacilityMember_b9b5918c-504d-40e8-a825-6dcd2bcf573f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_b05e7777-f0ee-47c9-9261-60f5358cfab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f6988a9e-033c-4eb8-85a8-1e0ee97bd2aa" xlink:to="loc_us-gaap_LitigationStatusAxis_b05e7777-f0ee-47c9-9261-60f5358cfab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_f7f2ccb6-c1cf-49f8-a671-8464dba53c78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_b05e7777-f0ee-47c9-9261-60f5358cfab3" xlink:to="loc_us-gaap_LitigationStatusDomain_f7f2ccb6-c1cf-49f8-a671-8464dba53c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_27159a46-3b54-4378-9bbb-9267554a45f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_f7f2ccb6-c1cf-49f8-a671-8464dba53c78" xlink:to="loc_us-gaap_PendingLitigationMember_27159a46-3b54-4378-9bbb-9267554a45f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f6988a9e-033c-4eb8-85a8-1e0ee97bd2aa" xlink:to="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_OperatingLeaseRenewalTerm_e390d264-40f7-4ab7-8f06-b19c57f0e415" xlink:href="npce-20230331.xsd#npce_OperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:to="loc_npce_OperatingLeaseRenewalTerm_e390d264-40f7-4ab7-8f06-b19c57f0e415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e21bbc52-7855-4071-9673-980bd462dfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e21bbc52-7855-4071-9673-980bd462dfdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_OperatingLeasesAnnualRentalPayments_bc285f8c-6b50-40fd-b1c3-679d53c0cacc" xlink:href="npce-20230331.xsd#npce_OperatingLeasesAnnualRentalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:to="loc_npce_OperatingLeasesAnnualRentalPayments_bc285f8c-6b50-40fd-b1c3-679d53c0cacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_b6ffcdfb-d473-4c42-8a01-63a4bb6844c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:to="loc_us-gaap_OperatingLeaseCost_b6ffcdfb-d473-4c42-8a01-63a4bb6844c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3c2b7fa9-f3f2-4d55-b58d-a87500b4cba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3c2b7fa9-f3f2-4d55-b58d-a87500b4cba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f2bfbf2c-28aa-4301-9b8c-a252c5f42ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f2bfbf2c-28aa-4301-9b8c-a252c5f42ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_69fb7f66-ac9b-4b59-976c-9cc122cc41d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:to="loc_us-gaap_OperatingLeasePayments_69fb7f66-ac9b-4b59-976c-9cc122cc41d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_83da115b-7211-418f-b42d-10bdc00af248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_83da115b-7211-418f-b42d-10bdc00af248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_PurchaseObligationMinimumIncreasePercentageInNextTwoYears_36c93583-1d5d-4da5-855d-763df00a4a75" xlink:href="npce-20230331.xsd#npce_PurchaseObligationMinimumIncreasePercentageInNextTwoYears"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:to="loc_npce_PurchaseObligationMinimumIncreasePercentageInNextTwoYears_36c93583-1d5d-4da5-855d-763df00a4a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_IndemnificationLiabilityOfficersAndDirectors_5842923d-abd3-45a3-9ab7-8852312028ad" xlink:href="npce-20230331.xsd#npce_IndemnificationLiabilityOfficersAndDirectors"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:to="loc_npce_IndemnificationLiabilityOfficersAndDirectors_5842923d-abd3-45a3-9ab7-8852312028ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_7bae85f7-8217-439a-a182-ab9164b8d93f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d14dd60e-21c1-4b19-9fc1-6479c9d40f4d" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_7bae85f7-8217-439a-a182-ab9164b8d93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2abd7fbe-7ef0-431e-87e6-6322ab0f4d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b3ae409c-ba46-4990-8557-5d7f47efefa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2abd7fbe-7ef0-431e-87e6-6322ab0f4d25" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b3ae409c-ba46-4990-8557-5d7f47efefa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f7b45b32-7128-443f-8a69-abc128dd27fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2abd7fbe-7ef0-431e-87e6-6322ab0f4d25" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f7b45b32-7128-443f-8a69-abc128dd27fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1e4eba0d-f5db-4dfb-8680-3cb06e241d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2abd7fbe-7ef0-431e-87e6-6322ab0f4d25" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1e4eba0d-f5db-4dfb-8680-3cb06e241d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a56d1b70-ff11-4b31-839b-ea3edcba7214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2abd7fbe-7ef0-431e-87e6-6322ab0f4d25" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a56d1b70-ff11-4b31-839b-ea3edcba7214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9d0f604b-fd30-415d-91c3-d9bcf651aef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2abd7fbe-7ef0-431e-87e6-6322ab0f4d25" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9d0f604b-fd30-415d-91c3-d9bcf651aef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_0dcc75a2-566e-456a-bd57-3b8d5d12c1fe" xlink:href="npce-20230331.xsd#npce_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2abd7fbe-7ef0-431e-87e6-6322ab0f4d25" xlink:to="loc_npce_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_0dcc75a2-566e-456a-bd57-3b8d5d12c1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0c47f7d4-67e1-4efe-a83e-b7371ef60d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2abd7fbe-7ef0-431e-87e6-6322ab0f4d25" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0c47f7d4-67e1-4efe-a83e-b7371ef60d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_86e1884b-278f-4604-acf6-17a94bb292a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2abd7fbe-7ef0-431e-87e6-6322ab0f4d25" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_86e1884b-278f-4604-acf6-17a94bb292a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_767ab2c0-95bb-47c8-bf24-c5e8529b24de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2abd7fbe-7ef0-431e-87e6-6322ab0f4d25" xlink:to="loc_us-gaap_OperatingLeaseLiability_767ab2c0-95bb-47c8-bf24-c5e8529b24de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_54783c2a-8c30-445d-aed3-d03ccaa8ab15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2abd7fbe-7ef0-431e-87e6-6322ab0f4d25" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_54783c2a-8c30-445d-aed3-d03ccaa8ab15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1d696e66-11b3-4145-820d-2e7170260c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2abd7fbe-7ef0-431e-87e6-6322ab0f4d25" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1d696e66-11b3-4145-820d-2e7170260c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="npce-20230331.xsd#CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://neuropace.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_148e4245-7b45-423b-bf55-8c11fa8133cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7b85aeb6-cfb4-4199-bc63-3784393c6a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_148e4245-7b45-423b-bf55-8c11fa8133cb" xlink:to="loc_us-gaap_DebtInstrumentTable_7b85aeb6-cfb4-4199-bc63-3784393c6a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c33e72d7-b9d5-42dd-b76e-fd0bb3895c76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7b85aeb6-cfb4-4199-bc63-3784393c6a48" xlink:to="loc_us-gaap_DebtInstrumentAxis_c33e72d7-b9d5-42dd-b76e-fd0bb3895c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a4827eae-62b7-4098-b606-277236344cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c33e72d7-b9d5-42dd-b76e-fd0bb3895c76" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a4827eae-62b7-4098-b606-277236344cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_TermLoanMember_e2d719bc-e06a-487a-b000-8810d23014e9" xlink:href="npce-20230331.xsd#npce_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a4827eae-62b7-4098-b606-277236344cf5" xlink:to="loc_npce_TermLoanMember_e2d719bc-e06a-487a-b000-8810d23014e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1f0928ec-3d1a-4b09-ada7-c7bc8456ce4c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7b85aeb6-cfb4-4199-bc63-3784393c6a48" xlink:to="loc_srt_RangeAxis_1f0928ec-3d1a-4b09-ada7-c7bc8456ce4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f7695087-131e-4fc0-895e-af3f1b7c91f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1f0928ec-3d1a-4b09-ada7-c7bc8456ce4c" xlink:to="loc_srt_RangeMember_f7695087-131e-4fc0-895e-af3f1b7c91f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bfab2534-2ec1-4bbc-bfa4-616c0437dbb9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f7695087-131e-4fc0-895e-af3f1b7c91f3" xlink:to="loc_srt_MaximumMember_bfab2534-2ec1-4bbc-bfa4-616c0437dbb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f4587557-3eb8-4515-ba97-18231bf58001" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f7695087-131e-4fc0-895e-af3f1b7c91f3" xlink:to="loc_srt_MinimumMember_f4587557-3eb8-4515-ba97-18231bf58001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_48678bc0-ec02-43ec-b88b-bf38ffb487f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7b85aeb6-cfb4-4199-bc63-3784393c6a48" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_48678bc0-ec02-43ec-b88b-bf38ffb487f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5382b6a1-123c-4a82-a2c4-278337f42ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_48678bc0-ec02-43ec-b88b-bf38ffb487f2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5382b6a1-123c-4a82-a2c4-278337f42ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_PaymentInCashMember_9023fc10-09d6-4bdb-9547-405646aece52" xlink:href="npce-20230331.xsd#npce_PaymentInCashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5382b6a1-123c-4a82-a2c4-278337f42ae4" xlink:to="loc_npce_PaymentInCashMember_9023fc10-09d6-4bdb-9547-405646aece52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember_474eb13e-38be-4e68-8cbc-b93e1444c3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5382b6a1-123c-4a82-a2c4-278337f42ae4" xlink:to="loc_us-gaap_PaymentInKindPIKNoteMember_474eb13e-38be-4e68-8cbc-b93e1444c3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_acef426a-c02e-43df-850e-42ac89b4730a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7b85aeb6-cfb4-4199-bc63-3784393c6a48" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_acef426a-c02e-43df-850e-42ac89b4730a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3764172e-1366-4de8-bf8c-ab5581fd275e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_acef426a-c02e-43df-850e-42ac89b4730a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3764172e-1366-4de8-bf8c-ab5581fd275e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_SeriesBRedeemableConvertiblePreferredStockMember_e9c018cf-6b02-42b2-a371-7d85ec9fc77e" xlink:href="npce-20230331.xsd#npce_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3764172e-1366-4de8-bf8c-ab5581fd275e" xlink:to="loc_npce_SeriesBRedeemableConvertiblePreferredStockMember_e9c018cf-6b02-42b2-a371-7d85ec9fc77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7b85aeb6-cfb4-4199-bc63-3784393c6a48" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_054b0722-1186-47ca-b6ce-309f9e7212f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_054b0722-1186-47ca-b6ce-309f9e7212f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c1173822-86f1-49f6-8322-ce9cff1773c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c1173822-86f1-49f6-8322-ce9cff1773c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_14f80ff3-d326-4b9c-96c3-26f5d0ed3db0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_14f80ff3-d326-4b9c-96c3-26f5d0ed3db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_00be21ac-c4ee-4e5c-8262-e20838d871c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_00be21ac-c4ee-4e5c-8262-e20838d871c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_80b96aff-7ab1-47c1-a62c-0bbe2921ff90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_80b96aff-7ab1-47c1-a62c-0bbe2921ff90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_DebtInstrumentPrincipalPaymentNumberOfInstallment_42333c9a-fd10-4c95-9326-5b49d8058fae" xlink:href="npce-20230331.xsd#npce_DebtInstrumentPrincipalPaymentNumberOfInstallment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_npce_DebtInstrumentPrincipalPaymentNumberOfInstallment_42333c9a-fd10-4c95-9326-5b49d8058fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_DebtInstrumentRedemptionFeePercent_fd679149-51f3-46be-a8ba-3f48be8a0a03" xlink:href="npce-20230331.xsd#npce_DebtInstrumentRedemptionFeePercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_npce_DebtInstrumentRedemptionFeePercent_fd679149-51f3-46be-a8ba-3f48be8a0a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_DebtInstrumentCovenantMinimumAnnualNetRevenue_be82118d-49d3-4f11-8f44-04f7ed91f07d" xlink:href="npce-20230331.xsd#npce_DebtInstrumentCovenantMinimumAnnualNetRevenue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_npce_DebtInstrumentCovenantMinimumAnnualNetRevenue_be82118d-49d3-4f11-8f44-04f7ed91f07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_fe78d196-ff85-48fe-90a6-1278b98c3e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_fe78d196-ff85-48fe-90a6-1278b98c3e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_c105dbe0-3d61-41ef-b466-33f735a082b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_c105dbe0-3d61-41ef-b466-33f735a082b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_WarrantLiabilityNoncurrent_9ec79e94-9d33-4b34-b499-aa5a77d18ee7" xlink:href="npce-20230331.xsd#npce_WarrantLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_npce_WarrantLiabilityNoncurrent_9ec79e94-9d33-4b34-b499-aa5a77d18ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f4b332f7-097e-484c-9181-0c4209b19e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f4b332f7-097e-484c-9181-0c4209b19e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_7225b19b-3922-4b98-9196-aa6c18f8a09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c323ac01-3305-47c3-9037-070e7dbfeb52" xlink:to="loc_us-gaap_InterestExpenseDebt_7225b19b-3922-4b98-9196-aa6c18f8a09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#DebtScheduleofMaturitiesofLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7b9d7407-460d-46e3-b28e-b8aec7b48b45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_61b7f742-2938-4ac9-9be4-2c064d0908fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7b9d7407-460d-46e3-b28e-b8aec7b48b45" xlink:to="loc_us-gaap_DebtInstrumentTable_61b7f742-2938-4ac9-9be4-2c064d0908fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_aa2a5767-b9aa-40df-b086-9eaaec894aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_61b7f742-2938-4ac9-9be4-2c064d0908fd" xlink:to="loc_us-gaap_DebtInstrumentAxis_aa2a5767-b9aa-40df-b086-9eaaec894aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f54dfe1a-59fb-474a-917d-5559b9970ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_aa2a5767-b9aa-40df-b086-9eaaec894aa9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f54dfe1a-59fb-474a-917d-5559b9970ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_TermLoanMember_c1b78f11-4c88-42d4-885a-9208bf02cb7b" xlink:href="npce-20230331.xsd#npce_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f54dfe1a-59fb-474a-917d-5559b9970ed8" xlink:to="loc_npce_TermLoanMember_c1b78f11-4c88-42d4-885a-9208bf02cb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fb10e5fc-0caa-4bce-9612-807ec1051239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_61b7f742-2938-4ac9-9be4-2c064d0908fd" xlink:to="loc_us-gaap_DebtInstrumentLineItems_fb10e5fc-0caa-4bce-9612-807ec1051239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_39c06912-46a7-498b-b787-5ceed0663d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fb10e5fc-0caa-4bce-9612-807ec1051239" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_39c06912-46a7-498b-b787-5ceed0663d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ced26c20-6309-469c-84e4-7adb4bac63a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fb10e5fc-0caa-4bce-9612-807ec1051239" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ced26c20-6309-469c-84e4-7adb4bac63a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9bbfe825-7ddd-47b7-b32f-2a629ff129b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fb10e5fc-0caa-4bce-9612-807ec1051239" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9bbfe825-7ddd-47b7-b32f-2a629ff129b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0bde3815-4435-4fa7-a971-b7a0f0ee4063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fb10e5fc-0caa-4bce-9612-807ec1051239" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0bde3815-4435-4fa7-a971-b7a0f0ee4063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_148cdde5-c1d6-4132-9226-f6b19617fb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fb10e5fc-0caa-4bce-9612-807ec1051239" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_148cdde5-c1d6-4132-9226-f6b19617fb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_9335a7e6-08df-414c-aa79-2f4494c61fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fb10e5fc-0caa-4bce-9612-807ec1051239" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_9335a7e6-08df-414c-aa79-2f4494c61fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_DebtInstrumentUnamortizedInterestCost_494d8774-18fd-42c5-8bc6-e11815e2b04a" xlink:href="npce-20230331.xsd#npce_DebtInstrumentUnamortizedInterestCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fb10e5fc-0caa-4bce-9612-807ec1051239" xlink:to="loc_npce_DebtInstrumentUnamortizedInterestCost_494d8774-18fd-42c5-8bc6-e11815e2b04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d9088885-0cfc-4adc-8b19-78fb7829ae5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fb10e5fc-0caa-4bce-9612-807ec1051239" xlink:to="loc_us-gaap_LongTermDebt_d9088885-0cfc-4adc-8b19-78fb7829ae5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/CommonStockDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#CommonStockDetails"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/CommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5939efcb-d767-412b-8e8c-2f2b99c61811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b6d182c5-45bd-4745-9834-7d9bc972e6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5939efcb-d767-412b-8e8c-2f2b99c61811" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b6d182c5-45bd-4745-9834-7d9bc972e6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6567795b-f7ce-4cbb-96cb-87d84acf7740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b6d182c5-45bd-4745-9834-7d9bc972e6ed" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6567795b-f7ce-4cbb-96cb-87d84acf7740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5bb92ca6-5a94-4742-9bf3-1b03f6c5d3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6567795b-f7ce-4cbb-96cb-87d84acf7740" xlink:to="loc_us-gaap_ClassOfStockDomain_5bb92ca6-5a94-4742-9bf3-1b03f6c5d3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_OptionsAvailableForGrant2021PlanMember_25609fa3-6d0c-4ad2-bfac-1615191778c5" xlink:href="npce-20230331.xsd#npce_OptionsAvailableForGrant2021PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5bb92ca6-5a94-4742-9bf3-1b03f6c5d3b8" xlink:to="loc_npce_OptionsAvailableForGrant2021PlanMember_25609fa3-6d0c-4ad2-bfac-1615191778c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_OutstandingOptions2021PlanMember_86a8005a-c2f0-486e-809f-302e8e5a160e" xlink:href="npce-20230331.xsd#npce_OutstandingOptions2021PlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5bb92ca6-5a94-4742-9bf3-1b03f6c5d3b8" xlink:to="loc_npce_OutstandingOptions2021PlanMember_86a8005a-c2f0-486e-809f-302e8e5a160e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_OptionsRestrictedStockUnit2021PlanMember_ddf40e20-f389-4399-ad0a-9d615d684509" xlink:href="npce-20230331.xsd#npce_OptionsRestrictedStockUnit2021PlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5bb92ca6-5a94-4742-9bf3-1b03f6c5d3b8" xlink:to="loc_npce_OptionsRestrictedStockUnit2021PlanMember_ddf40e20-f389-4399-ad0a-9d615d684509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_CommonStockAvailableForESPPMember_f2eb361c-0b78-46f3-a4df-fb97c604f635" xlink:href="npce-20230331.xsd#npce_CommonStockAvailableForESPPMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5bb92ca6-5a94-4742-9bf3-1b03f6c5d3b8" xlink:to="loc_npce_CommonStockAvailableForESPPMember_f2eb361c-0b78-46f3-a4df-fb97c604f635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d56d84b2-cc11-4b6b-bd88-08d7fa0266db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b6d182c5-45bd-4745-9834-7d9bc972e6ed" xlink:to="loc_us-gaap_ClassOfStockLineItems_d56d84b2-cc11-4b6b-bd88-08d7fa0266db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9f54be57-4b24-4002-8523-415b56d6e581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d56d84b2-cc11-4b6b-bd88-08d7fa0266db" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9f54be57-4b24-4002-8523-415b56d6e581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cc993ead-d145-415e-9944-235d7a1c2cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d56d84b2-cc11-4b6b-bd88-08d7fa0266db" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cc993ead-d145-415e-9944-235d7a1c2cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_2cc89f3d-d8ff-4a25-8238-7981295cdad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d56d84b2-cc11-4b6b-bd88-08d7fa0266db" xlink:to="loc_us-gaap_DividendsCommonStockCash_2cc89f3d-d8ff-4a25-8238-7981295cdad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_58a64ecc-47a9-462f-9e94-6c3c851cbbec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d56d84b2-cc11-4b6b-bd88-08d7fa0266db" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_58a64ecc-47a9-462f-9e94-6c3c851cbbec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofAvailableforGrantDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#StockBasedIncentiveCompensationPlansScheduleofAvailableforGrantDetails"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofAvailableforGrantDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6255df70-4b12-4ed6-8836-3a65bd4dc3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a39c660-08f2-43f9-8bd6-829db35f394a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6255df70-4b12-4ed6-8836-3a65bd4dc3e5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a39c660-08f2-43f9-8bd6-829db35f394a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a443f7da-b2d9-4976-ba33-a57b318305e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a39c660-08f2-43f9-8bd6-829db35f394a" xlink:to="loc_us-gaap_PlanNameAxis_a443f7da-b2d9-4976-ba33-a57b318305e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_94c15029-5eba-4ec1-82f8-f190573cff23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_a443f7da-b2d9-4976-ba33-a57b318305e8" xlink:to="loc_us-gaap_PlanNameDomain_94c15029-5eba-4ec1-82f8-f190573cff23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_A2021EquityIncentivePlanMember_d0275ecc-da73-4cc0-b4bf-b99d87ba083d" xlink:href="npce-20230331.xsd#npce_A2021EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_94c15029-5eba-4ec1-82f8-f190573cff23" xlink:to="loc_npce_A2021EquityIncentivePlanMember_d0275ecc-da73-4cc0-b4bf-b99d87ba083d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72bdb770-7793-4ed9-a8d3-17dbab3348e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a39c660-08f2-43f9-8bd6-829db35f394a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72bdb770-7793-4ed9-a8d3-17dbab3348e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_a6a93d3a-615b-4ab3-9278-60ec2fef7d06" xlink:href="npce-20230331.xsd#npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_72bdb770-7793-4ed9-a8d3-17dbab3348e2" xlink:to="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_a6a93d3a-615b-4ab3-9278-60ec2fef7d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_651a79a7-4ae6-4528-a6ba-24b1197f82c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_a6a93d3a-615b-4ab3-9278-60ec2fef7d06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_651a79a7-4ae6-4528-a6ba-24b1197f82c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_249e606e-8680-42e5-9298-3247fe63b580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_a6a93d3a-615b-4ab3-9278-60ec2fef7d06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_249e606e-8680-42e5-9298-3247fe63b580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod_e295dd23-6870-4f4d-b1b3-a99a32f17bd4" xlink:href="npce-20230331.xsd#npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_a6a93d3a-615b-4ab3-9278-60ec2fef7d06" xlink:to="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod_e295dd23-6870-4f4d-b1b3-a99a32f17bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod_d4ef6b79-1ae5-4244-887f-5bb7dae85c72" xlink:href="npce-20230331.xsd#npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_a6a93d3a-615b-4ab3-9278-60ec2fef7d06" xlink:to="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod_d4ef6b79-1ae5-4244-887f-5bb7dae85c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes_884efd04-0d66-49f3-9f3c-ccb02f6b51b5" xlink:href="npce-20230331.xsd#npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_a6a93d3a-615b-4ab3-9278-60ec2fef7d06" xlink:to="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes_884efd04-0d66-49f3-9f3c-ccb02f6b51b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a11c53ae-1983-4299-be36-2be5485f4eed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_a6a93d3a-615b-4ab3-9278-60ec2fef7d06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a11c53ae-1983-4299-be36-2be5485f4eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb368062-6252-4a6c-802b-6e21808141ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_07182573-febf-4249-a26a-9acd4eebb4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb368062-6252-4a6c-802b-6e21808141ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_07182573-febf-4249-a26a-9acd4eebb4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1a61561f-62c9-431d-89a3-8dfd9ddfcc33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_07182573-febf-4249-a26a-9acd4eebb4ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1a61561f-62c9-431d-89a3-8dfd9ddfcc33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_37e80459-8ce9-4517-b105-23e379646ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_07182573-febf-4249-a26a-9acd4eebb4ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_37e80459-8ce9-4517-b105-23e379646ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_06802885-b886-4b26-9a02-021d65fb84d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_07182573-febf-4249-a26a-9acd4eebb4ea" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_06802885-b886-4b26-9a02-021d65fb84d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9d0aa57d-7038-40e3-9b20-3a03c3cb8a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_07182573-febf-4249-a26a-9acd4eebb4ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9d0aa57d-7038-40e3-9b20-3a03c3cb8a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_65ef4863-645f-4b83-8cf9-e2c54c3bfef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_07182573-febf-4249-a26a-9acd4eebb4ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_65ef4863-645f-4b83-8cf9-e2c54c3bfef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3aa9b806-454c-48e1-ac9f-eb3b9d746edc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb368062-6252-4a6c-802b-6e21808141ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3aa9b806-454c-48e1-ac9f-eb3b9d746edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_6c87c62d-f3e3-4751-96aa-383a6d01ee91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb368062-6252-4a6c-802b-6e21808141ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_6c87c62d-f3e3-4751-96aa-383a6d01ee91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3b4d190b-8d70-42a7-a8e4-3aa4b33ddd53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb368062-6252-4a6c-802b-6e21808141ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3b4d190b-8d70-42a7-a8e4-3aa4b33ddd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c1a5ee05-f3fc-407c-bedd-80524bddd267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3b4d190b-8d70-42a7-a8e4-3aa4b33ddd53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c1a5ee05-f3fc-407c-bedd-80524bddd267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2e0b8cd7-77aa-4161-bd65-f01758cdba82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3b4d190b-8d70-42a7-a8e4-3aa4b33ddd53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2e0b8cd7-77aa-4161-bd65-f01758cdba82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4434c702-49a4-4e76-9758-b284a0aa6d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3b4d190b-8d70-42a7-a8e4-3aa4b33ddd53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4434c702-49a4-4e76-9758-b284a0aa6d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_562f3b60-c37d-4195-89e5-699b805dc206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3b4d190b-8d70-42a7-a8e4-3aa4b33ddd53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_562f3b60-c37d-4195-89e5-699b805dc206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_85e8c8b8-6841-44b6-8673-90af82acc1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3b4d190b-8d70-42a7-a8e4-3aa4b33ddd53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_85e8c8b8-6841-44b6-8673-90af82acc1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_84d82722-1bdf-40f2-8367-439d7791320d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb368062-6252-4a6c-802b-6e21808141ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_84d82722-1bdf-40f2-8367-439d7791320d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4e5c0737-0e5d-47c1-9377-6af20df76e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb368062-6252-4a6c-802b-6e21808141ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4e5c0737-0e5d-47c1-9377-6af20df76e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_80440608-6371-4fef-a1ac-a3ca253e59b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb368062-6252-4a6c-802b-6e21808141ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_80440608-6371-4fef-a1ac-a3ca253e59b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_74ef87ac-47a4-44b1-b8d5-cbd78a578d51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_80440608-6371-4fef-a1ac-a3ca253e59b9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_74ef87ac-47a4-44b1-b8d5-cbd78a578d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_fd97c0fc-1141-4e49-b9bd-925059cc39f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_80440608-6371-4fef-a1ac-a3ca253e59b9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_fd97c0fc-1141-4e49-b9bd-925059cc39f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_3be6ec64-e170-490a-a096-67caaa406a00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_80440608-6371-4fef-a1ac-a3ca253e59b9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_3be6ec64-e170-490a-a096-67caaa406a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#StockBasedIncentiveCompensationPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_66b1434a-a9e0-45a5-8447-6a97f9c3bc11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ade11c2e-724a-44c0-94eb-2aa28350a7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_66b1434a-a9e0-45a5-8447-6a97f9c3bc11" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ade11c2e-724a-44c0-94eb-2aa28350a7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_30005ef5-098d-4f0e-964e-db935acc0775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ade11c2e-724a-44c0-94eb-2aa28350a7b4" xlink:to="loc_us-gaap_PlanNameAxis_30005ef5-098d-4f0e-964e-db935acc0775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_66e02ff6-97c5-4f7a-9c68-3b16e6c6e5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_30005ef5-098d-4f0e-964e-db935acc0775" xlink:to="loc_us-gaap_PlanNameDomain_66e02ff6-97c5-4f7a-9c68-3b16e6c6e5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_A2021EmployeeStockPurchasePlanMember_c8940d99-a567-4179-9575-17e896e5d068" xlink:href="npce-20230331.xsd#npce_A2021EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_66e02ff6-97c5-4f7a-9c68-3b16e6c6e5f4" xlink:to="loc_npce_A2021EmployeeStockPurchasePlanMember_c8940d99-a567-4179-9575-17e896e5d068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_5382fef2-b8f9-4654-b3d6-b539611a5eeb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ade11c2e-724a-44c0-94eb-2aa28350a7b4" xlink:to="loc_srt_StatementScenarioAxis_5382fef2-b8f9-4654-b3d6-b539611a5eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_21af9b2e-75ba-4612-be74-212bc530d77c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_5382fef2-b8f9-4654-b3d6-b539611a5eeb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_21af9b2e-75ba-4612-be74-212bc530d77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_86ee3e47-9a39-4ab1-9ca8-1922fe6fee7f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_21af9b2e-75ba-4612-be74-212bc530d77c" xlink:to="loc_srt_ScenarioForecastMember_86ee3e47-9a39-4ab1-9ca8-1922fe6fee7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cda8b0f3-9faf-46bc-a5cf-581e07d44db9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ade11c2e-724a-44c0-94eb-2aa28350a7b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cda8b0f3-9faf-46bc-a5cf-581e07d44db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase_e678c487-3a1e-4260-9043-9de885f5a04f" xlink:href="npce-20230331.xsd#npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cda8b0f3-9faf-46bc-a5cf-581e07d44db9" xlink:to="loc_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase_e678c487-3a1e-4260-9043-9de885f5a04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_9e9de6a9-371c-40b1-a05b-5c33ec0172ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cda8b0f3-9faf-46bc-a5cf-581e07d44db9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_9e9de6a9-371c-40b1-a05b-5c33ec0172ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_EmployeeStockPurchasePlanLengthOfOfferingPeriod_5224f660-f1cd-41b7-95b1-410c4655433d" xlink:href="npce-20230331.xsd#npce_EmployeeStockPurchasePlanLengthOfOfferingPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cda8b0f3-9faf-46bc-a5cf-581e07d44db9" xlink:to="loc_npce_EmployeeStockPurchasePlanLengthOfOfferingPeriod_5224f660-f1cd-41b7-95b1-410c4655433d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_74db27b5-00ce-4860-8c62-b1f02b20c842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cda8b0f3-9faf-46bc-a5cf-581e07d44db9" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_74db27b5-00ce-4860-8c62-b1f02b20c842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_363c9036-8b6b-4558-a712-f216743dcc07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cda8b0f3-9faf-46bc-a5cf-581e07d44db9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_363c9036-8b6b-4558-a712-f216743dcc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8b2ffef5-e38e-43fe-b051-56dbc0f55543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cda8b0f3-9faf-46bc-a5cf-581e07d44db9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8b2ffef5-e38e-43fe-b051-56dbc0f55543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_EmployeeStockPurchasePlanOfferingPeriod_8d6b3328-8a4d-4d92-9cef-ede7cc650cb2" xlink:href="npce-20230331.xsd#npce_EmployeeStockPurchasePlanOfferingPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cda8b0f3-9faf-46bc-a5cf-581e07d44db9" xlink:to="loc_npce_EmployeeStockPurchasePlanOfferingPeriod_8d6b3328-8a4d-4d92-9cef-ede7cc650cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_02cd325f-f7f8-4114-b5ba-cd48865dfaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cda8b0f3-9faf-46bc-a5cf-581e07d44db9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_02cd325f-f7f8-4114-b5ba-cd48865dfaf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_475535e0-adde-4ed9-af68-0c1f2008bea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cda8b0f3-9faf-46bc-a5cf-581e07d44db9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_475535e0-adde-4ed9-af68-0c1f2008bea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_f24f096c-a28b-46b1-9161-aba94a36cc22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cda8b0f3-9faf-46bc-a5cf-581e07d44db9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_f24f096c-a28b-46b1-9161-aba94a36cc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_782be1f5-1b3a-4058-9685-59776b74b22e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3ea51695-dd1d-478c-954c-51d91a3c4c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_782be1f5-1b3a-4058-9685-59776b74b22e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3ea51695-dd1d-478c-954c-51d91a3c4c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_39b4a0dd-eef0-478a-aa80-d95053a83882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3ea51695-dd1d-478c-954c-51d91a3c4c4d" xlink:to="loc_us-gaap_AwardTypeAxis_39b4a0dd-eef0-478a-aa80-d95053a83882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f61bb268-51fe-469a-87e8-21adaffb61cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_39b4a0dd-eef0-478a-aa80-d95053a83882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f61bb268-51fe-469a-87e8-21adaffb61cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_81c8f059-6cdf-4c50-a229-a122054944ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f61bb268-51fe-469a-87e8-21adaffb61cf" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_81c8f059-6cdf-4c50-a229-a122054944ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5730c9c3-90fa-42ef-876b-1e9a0eca63ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3ea51695-dd1d-478c-954c-51d91a3c4c4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5730c9c3-90fa-42ef-876b-1e9a0eca63ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04dcdc5c-2a2d-4f11-9851-165d6798ef1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5730c9c3-90fa-42ef-876b-1e9a0eca63ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04dcdc5c-2a2d-4f11-9851-165d6798ef1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_78c8d004-9f2a-4202-8fe7-547ba11eaa54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04dcdc5c-2a2d-4f11-9851-165d6798ef1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_78c8d004-9f2a-4202-8fe7-547ba11eaa54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_929a265a-33f9-49d5-90dd-209b0402cb95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04dcdc5c-2a2d-4f11-9851-165d6798ef1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_929a265a-33f9-49d5-90dd-209b0402cb95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_752f6608-c3d2-431e-a3b0-3d8ce01da755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04dcdc5c-2a2d-4f11-9851-165d6798ef1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_752f6608-c3d2-431e-a3b0-3d8ce01da755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6fe1b52a-50b9-4824-ad59-3efa5991f9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04dcdc5c-2a2d-4f11-9851-165d6798ef1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6fe1b52a-50b9-4824-ad59-3efa5991f9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ae9c250-38ec-4ec2-b9d0-31b74481ac36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_04dcdc5c-2a2d-4f11-9851-165d6798ef1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ae9c250-38ec-4ec2-b9d0-31b74481ac36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3034f7ba-e271-4370-804e-e659acaf5d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5730c9c3-90fa-42ef-876b-1e9a0eca63ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3034f7ba-e271-4370-804e-e659acaf5d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e260c41d-252d-45d7-8365-48b71c1f5b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3034f7ba-e271-4370-804e-e659acaf5d54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e260c41d-252d-45d7-8365-48b71c1f5b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b2047d5e-4dbd-438e-96b1-9b5dcf2fcd35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3034f7ba-e271-4370-804e-e659acaf5d54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b2047d5e-4dbd-438e-96b1-9b5dcf2fcd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b4652620-9386-472c-bc1e-ecf9579306df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3034f7ba-e271-4370-804e-e659acaf5d54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b4652620-9386-472c-bc1e-ecf9579306df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d17e1281-2dda-4238-ad92-746596c360ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3034f7ba-e271-4370-804e-e659acaf5d54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d17e1281-2dda-4238-ad92-746596c360ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a9f677df-da0d-4722-8053-820b4780c888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3034f7ba-e271-4370-804e-e659acaf5d54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a9f677df-da0d-4722-8053-820b4780c888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRecognizedStockbasedCompensationDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#StockBasedIncentiveCompensationPlansScheduleofRecognizedStockbasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRecognizedStockbasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7655f00c-bd4e-45a4-9797-7b25c8b7a761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ce600f7-33a9-4c54-978e-14cb7509b4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7655f00c-bd4e-45a4-9797-7b25c8b7a761" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ce600f7-33a9-4c54-978e-14cb7509b4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1d9a8185-6928-45b7-ae66-beb36d995efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ce600f7-33a9-4c54-978e-14cb7509b4de" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1d9a8185-6928-45b7-ae66-beb36d995efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_568e1305-85ae-44ce-868b-873e3076a9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1d9a8185-6928-45b7-ae66-beb36d995efd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_568e1305-85ae-44ce-868b-873e3076a9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_ec877bae-c33e-4853-bab7-491857e1b226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_568e1305-85ae-44ce-868b-873e3076a9c6" xlink:to="loc_us-gaap_CostOfSalesMember_ec877bae-c33e-4853-bab7-491857e1b226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c5952993-8ff9-45c7-afd5-7987e5c68e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_568e1305-85ae-44ce-868b-873e3076a9c6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c5952993-8ff9-45c7-afd5-7987e5c68e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_db9045e2-3dd9-4983-8459-9d11ec61644a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_568e1305-85ae-44ce-868b-873e3076a9c6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_db9045e2-3dd9-4983-8459-9d11ec61644a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_abb7ece6-e8ce-43c2-aa19-e5a112b5d91a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ce600f7-33a9-4c54-978e-14cb7509b4de" xlink:to="loc_us-gaap_AwardTypeAxis_abb7ece6-e8ce-43c2-aa19-e5a112b5d91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b7870e33-fefa-4e3c-8f9d-371160921010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_abb7ece6-e8ce-43c2-aa19-e5a112b5d91a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b7870e33-fefa-4e3c-8f9d-371160921010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_StockOptionsAndRestrictedStockUnitsMember_b33b34e3-905f-4c9c-a7c7-7ea0dd8a5c5f" xlink:href="npce-20230331.xsd#npce_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b7870e33-fefa-4e3c-8f9d-371160921010" xlink:to="loc_npce_StockOptionsAndRestrictedStockUnitsMember_b33b34e3-905f-4c9c-a7c7-7ea0dd8a5c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_0504b83a-8636-4a6d-a068-9e4d15225988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b7870e33-fefa-4e3c-8f9d-371160921010" xlink:to="loc_us-gaap_EmployeeStockMember_0504b83a-8636-4a6d-a068-9e4d15225988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffa518db-a958-4f38-acfd-2ce63fc5d903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2ce600f7-33a9-4c54-978e-14cb7509b4de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffa518db-a958-4f38-acfd-2ce63fc5d903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b277bf2e-ff91-48d9-a6b5-b7cdfb40779a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffa518db-a958-4f38-acfd-2ce63fc5d903" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b277bf2e-ff91-48d9-a6b5-b7cdfb40779a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e46b9909-7bbe-4e63-a904-244cb170ef07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_259c136e-411f-4c4e-8071-51d4ba1a4389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e46b9909-7bbe-4e63-a904-244cb170ef07" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_259c136e-411f-4c4e-8071-51d4ba1a4389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#NetLossperShareAttributabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2e5ce3d4-fa7e-4498-bebd-63eb60e2302e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1d587c71-7831-4226-bb1b-68707dce18d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2e5ce3d4-fa7e-4498-bebd-63eb60e2302e" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1d587c71-7831-4226-bb1b-68707dce18d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e565dc5f-9baa-4e3b-8502-866dc3d1eccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1d587c71-7831-4226-bb1b-68707dce18d1" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e565dc5f-9baa-4e3b-8502-866dc3d1eccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f50c169e-2071-45fb-8de6-aee0c58e7d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2e5ce3d4-fa7e-4498-bebd-63eb60e2302e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f50c169e-2071-45fb-8de6-aee0c58e7d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0f454629-6bb5-465a-9770-f208d2b67b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f50c169e-2071-45fb-8de6-aee0c58e7d4d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0f454629-6bb5-465a-9770-f208d2b67b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7c94e840-989b-498e-b6f2-ee62f6577ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f50c169e-2071-45fb-8de6-aee0c58e7d4d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7c94e840-989b-498e-b6f2-ee62f6577ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7e542166-4e99-4040-a2fc-8c13cbe9ac4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2e5ce3d4-fa7e-4498-bebd-63eb60e2302e" xlink:to="loc_us-gaap_EarningsPerShareBasic_7e542166-4e99-4040-a2fc-8c13cbe9ac4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_07c0fff3-a309-4001-ba89-56ba18f7cbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2e5ce3d4-fa7e-4498-bebd-63eb60e2302e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_07c0fff3-a309-4001-ba89-56ba18f7cbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesOutstandingDetails" xlink:type="simple" xlink:href="npce-20230331.xsd#NetLossperShareAttributabletoCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesOutstandingDetails"/>
  <link:presentationLink xlink:role="http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_dbb64e0c-b754-45db-af74-612250d013aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_50a98c5d-7310-4368-ab95-9819cbc4ae97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dbb64e0c-b754-45db-af74-612250d013aa" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_50a98c5d-7310-4368-ab95-9819cbc4ae97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0bc22ad4-b49b-417d-ba9a-dac43a5b02f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_50a98c5d-7310-4368-ab95-9819cbc4ae97" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0bc22ad4-b49b-417d-ba9a-dac43a5b02f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c00a9b56-b05d-4e94-b572-bd8086277de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0bc22ad4-b49b-417d-ba9a-dac43a5b02f9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c00a9b56-b05d-4e94-b572-bd8086277de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e2b0c59b-0c96-4627-8471-13d5daa434cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c00a9b56-b05d-4e94-b572-bd8086277de7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e2b0c59b-0c96-4627-8471-13d5daa434cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_npce_ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember_f4265edc-f8f0-48dd-8737-f05492fa554a" xlink:href="npce-20230331.xsd#npce_ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c00a9b56-b05d-4e94-b572-bd8086277de7" xlink:to="loc_npce_ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember_f4265edc-f8f0-48dd-8737-f05492fa554a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_2e410424-ffc2-4559-b61b-8b72b338c7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c00a9b56-b05d-4e94-b572-bd8086277de7" xlink:to="loc_us-gaap_EmployeeStockMember_2e410424-ffc2-4559-b61b-8b72b338c7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8d6f803e-903a-48ab-b877-8f6d5607c7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c00a9b56-b05d-4e94-b572-bd8086277de7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8d6f803e-903a-48ab-b877-8f6d5607c7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aee82482-11e1-461b-a053-1e2432fa84b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_50a98c5d-7310-4368-ab95-9819cbc4ae97" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aee82482-11e1-461b-a053-1e2432fa84b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_35b9a0c8-1d25-4087-9eb7-ba46a71cae64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aee82482-11e1-461b-a053-1e2432fa84b6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_35b9a0c8-1d25-4087-9eb7-ba46a71cae64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
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MW+ESI<(&MJ-'CQX5%_G+6NSIA95C2:.9@FZCN_JU@GGSYI$8>WSGCT7\ QQ
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&3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929068737808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROPACE, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-3550230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">455 N. Bernardo Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Mountain View<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">237-2700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NPCE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,405,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001528287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929067637536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,720<span></span>
</td>
<td class="nump">$ 6,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">60,895<span></span>
</td>
<td class="nump">70,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">9,194<span></span>
</td>
<td class="nump">7,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">10,750<span></span>
</td>
<td class="nump">9,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,597<span></span>
</td>
<td class="nump">3,111<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">90,156<span></span>
</td>
<td class="nump">97,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,024<span></span>
</td>
<td class="nump">1,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">14,491<span></span>
</td>
<td class="nump">14,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="nump">457<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">106,271<span></span>
</td>
<td class="nump">114,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,829<span></span>
</td>
<td class="nump">2,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">6,580<span></span>
</td>
<td class="nump">7,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">1,466<span></span>
</td>
<td class="nump">1,415<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,875<span></span>
</td>
<td class="nump">10,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">53,859<span></span>
</td>
<td class="nump">52,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">15,047<span></span>
</td>
<td class="nump">15,440<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">78,781<span></span>
</td>
<td class="nump">79,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 200,000,000 shares authorized as of March&#160;31, 2023 and December&#160;31, 2022; 25,352,204 and 25,045,751 shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">508,693<span></span>
</td>
<td class="nump">506,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,108)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(481,228)<span></span>
</td>
<td class="num">(470,853)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">27,490<span></span>
</td>
<td class="nump">34,777<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 106,271<span></span>
</td>
<td class="nump">$ 114,106<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929067556384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="nump">25,352,204<span></span>
</td>
<td class="nump">25,045,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="nump">25,352,204<span></span>
</td>
<td class="nump">25,045,751<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929067157792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations and Comprehensive Loss (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 14,472<span></span>
</td>
<td class="nump">$ 11,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="nump">3,115<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">10,372<span></span>
</td>
<td class="nump">8,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">5,263<span></span>
</td>
<td class="nump">5,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">13,428<span></span>
</td>
<td class="nump">12,444<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">18,691<span></span>
</td>
<td class="nump">18,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(8,319)<span></span>
</td>
<td class="num">(9,762)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">726<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,965)<span></span>
</td>
<td class="num">(1,830)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(817)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(10,375)<span></span>
</td>
<td class="num">(11,461)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(710)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (10,375)<span></span>
</td>
<td class="num">$ (12,171)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic (in dollars per share)</a></td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted (in dollars per share)</a></td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)</a></td>
<td class="nump">25,097,262<span></span>
</td>
<td class="nump">24,307,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)</a></td>
<td class="nump">25,097,262<span></span>
</td>
<td class="nump">24,307,485<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929064511696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Stockholders&#8217; Equity (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,452,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 73,503<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 497,522<span></span>
</td>
<td class="num">$ (272)<span></span>
</td>
<td class="num">$ (423,771)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(11,461)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on available-for-sale debt securities</a></td>
<td class="num">(710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to stock option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to stock option exercises</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,454)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability', window );">Change in early exercise liability</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">1,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,477,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 62,823<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">499,013<span></span>
</td>
<td class="num">(982)<span></span>
</td>
<td class="num">(435,232)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">25,045,751<span></span>
</td>
<td class="nump">25,045,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 34,777<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">506,713<span></span>
</td>
<td class="num">(1,108)<span></span>
</td>
<td class="num">(470,853)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(10,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_OCIUnrealizedLossAdjustmentForShortTermInvestment', window );">Unrealized loss adjustment for short-term investment</a></td>
<td class="nump">1,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on available-for-sale debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to stock option exercises (in shares)</a></td>
<td class="nump">17,608<span></span>
</td>
<td class="nump">17,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to stock option exercises</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,562)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld for taxes</a></td>
<td class="num">(146)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(146)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 2,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">25,352,204<span></span>
</td>
<td class="nump">25,352,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 27,490<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 508,693<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (481,228)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Change In Early Exercise Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_OCIUnrealizedLossAdjustmentForShortTermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>OCI, Unrealized Loss Adjustment for Short-term Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_OCIUnrealizedLossAdjustmentForShortTermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929067535728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (10,375)<span></span>
</td>
<td class="num">$ (11,461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,125<span></span>
</td>
<td class="nump">1,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_IncreaseDecreaseInNonCashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">PIK interest incurred but not paid on term loan</a></td>
<td class="nump">649<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use asset</a></td>
<td class="nump">347<span></span>
</td>
<td class="nump">672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Loss on short-term investments</a></td>
<td class="nump">817<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-downs</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,713)<span></span>
</td>
<td class="num">(1,970)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(1,072)<span></span>
</td>
<td class="num">(362)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">514<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(193)<span></span>
</td>
<td class="nump">820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(834)<span></span>
</td>
<td class="num">(472)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(343)<span></span>
</td>
<td class="num">(777)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) operating activities</a></td>
<td class="num">(9,698)<span></span>
</td>
<td class="num">(11,393)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Acquisition of property and equipment</a></td>
<td class="num">(132)<span></span>
</td>
<td class="num">(306)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale of short-term investments</a></td>
<td class="nump">10,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">10,068<span></span>
</td>
<td class="num">(306)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under employee plans</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes withheld and paid related to net share settlement of equity awards</a></td>
<td class="num">(146)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of deferred offering costs</a></td>
<td class="num">(110)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(255)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">115<span></span>
</td>
<td class="num">(11,698)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract', window );"><strong>Cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Beginning of the period</a></td>
<td class="nump">6,727<span></span>
</td>
<td class="nump">19,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">End of the period</a></td>
<td class="nump">6,842<span></span>
</td>
<td class="nump">7,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash to balance sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">6,720<span></span>
</td>
<td class="nump">7,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash in balance sheets</a></td>
<td class="nump">6,842<span></span>
</td>
<td class="nump">7,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">1,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions', window );">Net change in accrued liabilities from early exercise of options</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment included in accounts payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Liabilities, Early Exercise Of Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_IncreaseDecreaseInNonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Non-cash Interest Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_IncreaseDecreaseInNonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929069880816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">The Company</a></td>
<td class="text">The Company<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NeuroPace, Inc., or the Company, was incorporated in the state of Delaware on November 19, 1997. The Company is a commercial-stage medical device company that has developed the RNS System, the only commercially available brain-responsive neuromodulation system designed for treating medically refractory focal epilepsy by delivering personalized, real-time treatment at the seizure source. The Company began commercializing its products in the United States in 2014.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Initial Public Offering</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2021, the Company&#8217;s registration statement on Form S-1 (File No. 333-254663) relating to its initial public offering, or IPO, of common stock became effective. The IPO closed on April 26, 2021, at which time the Company issued 6,900,000 shares of its common stock at a price of $17.00 per share, which included the issuance of shares in connection with the exercise by the underwriters of their option to purchase up to 900,000 additional shares. The Company received an aggregate of $117.3 million in gross proceeds, before underwriting discounts and commissions and offering costs, and approximately $105.5 million in net proceeds after deducting $8.2&#160;million in underwriting discounts and commissions and $3.6&#160;million in offering costs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At-the-Market Equity Offering</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company filed a Registration Statement on Form S-3, or Shelf, with the Securities and Exchange Commission in relation to the registration of common stock, preferred stock, debt securities, warrants or any combination thereof for up to an aggregate of $150.0&#160;million, of which $50.0&#160;million may be issued and sold pursuant to an at-the-market, or ATM, offering program for sales of the Company&#8217;s common stock under a sales agreement, or Sales Agreement, with SVB Securities LLC, or SVB. The Company agreed to pay SVB up to 3.0% of the gross proceeds of sales of common stock made through the Sales Agreement. The Company&#8217;s common stock would be sold at prevailing market prices at the time of the sale and, as a result, prices may vary. The Company has not issued or sold any securities pursuant to the Shelf or ATM offering program.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred operating losses and negative cash flows from operations since its inception and has an accumulated deficit of $481.2 million as of March&#160;31, 2023. For the three months ended March&#160;31, 2023 and 2022, the Company used $9.7 million and $11.4 million of cash, respectively, in its operating activities. As of March&#160;31, 2023, the Company had cash, cash equivalents and short-term investments of $67.6 million. Historically, the Company has funded its operations principally through the sales of its products, issuance of redeemable convertible preferred stock and debt financing.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed financial statements have been prepared on the basis of the Company continuing as a going concern for the next 12 months. Management believes that the Company&#8217;s cash, cash equivalents and short-term investments will allow the Company to continue its planned operations for at least the next 12 months from the date of the issuance of these unaudited interim condensed financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Term Loan described in Note 6, the Company will need to be in compliance with a minimum annual net revenue covenant determined in accordance with generally accepted accounting principles of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$45.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the year ended December 31, 2023, and maintain a minimum cash and cash equivalents balance of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If the Company cannot generate sufficient revenue in the future, the Company may not be in compliance with the annual net revenue covenant and the lender may call the debt resulting in the Company immediately needing additional capital, and resulting in a going concern. The Company&#8217;s ability to raise additional capital may be adversely impacted by global economic conditions and the recent disruptions to, and volatility in, the financial markets in the United States and worldwide. If the Company is unable to raise capital when needed, it will need to delay, limit, reduce or terminate planned commercialization or product development activities in order to reduce costs. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company was in compliance with all covenants of the Term Loan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global spread of the COVID-19 pandemic, including the different COVID-19 variants and measures introduced by local, state and federal governments to contain the pandemic and mitigate its public health effects, </span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have significantly impacted the global economy and negatively impacted our business. Beginning in March 2020, the Company&#8217;s net sales were negatively impacted by the COVID-19 pandemic as hospitals delayed or canceled elective procedures. The decrease in hospital admission rates and elective surgeries reduced both the number of patients being evaluated for treatment with and demand for elective procedures using the Company's RNS System. By the second half of 2022, the impact of the pandemic on the Company&#8217;s revenue had diminished. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, the future impact of the COVID-19 pandemic on the Company&#8217;s business, financial condition and results of operations is dependent on future developments, including the potential emergence of new COVID-19 variants and spikes in COVID-19 cases, which </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remain highly uncertain and cannot be predicted.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929069895088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed financial statements have been prepared in conformity with generally accepted accounting principles in the United States, or GAAP, as defined by the Financial Accounting Standards Board, or the FASB.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed balance sheet as of December 31, 2022 was derived from the Company&#8217;s audited financial statements, but does not include all disclosures required by GAAP. The accompanying unaudited condensed financial statements as of March 31, 2023 and for the three months ended March 31, 2023 and 2022, have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC, for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. Accordingly, these financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2022 and notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the SEC on March 2, 2023. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company&#8217;s condensed financial position as of March 31, 2023 and condensed results of operations and condensed cash flows for the three months ended March 31, 2023 and 2022 have been made. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2023.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited interim condensed financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. The Company uses significant judgment when making estimates related to the valuation of deferred tax assets and related valuation allowances and provision for excess and obsolete inventories. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amounts of certain of the Company&#8217;s financial instruments, including cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value because of the short-term nature of these instruments. The Company has a short-term investment in a fixed income mutual fund, which is classified as equity security and carried at fair value based on quoted market prices. Changes in the fair value of the short-term investment are recorded in income or loss. The Company believes that its borrowings bear interest at the prevailing market rates for instruments with similar characteristics; accordingly, the carrying value of this instrument approximates its fair value. The Company determines the fair value of financial and non-financial assets and </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities using the fair value hierarchy which establishes three levels of inputs that may be used to measure fair value (see Note 3).</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk, and Other Risks and Uncertainties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, short-term investments and accounts receivable to the extent of the amounts recorded on the balance sheets. The Company&#8217;s cash is invested in major financial institutions in the United States. Deposits in these financial institutions may exceed federally insured limits, and the Company is exposed to credit risk on deposits in the event of default of the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation. The Company&#8217;s cash equivalents are invested in money market funds.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable are due from a variety of health care organizations in the United States. For the three months ended March&#160;31, 2023 and 2022, there were no customers that represented 10% or more of revenue. As of March&#160;31, 2023 and December&#160;31, 2022, no customer represented 10% or more of the Company&#8217;s accounts receivable.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain risks, including that its devices may not be approved or cleared or continue to be approved or cleared for marketing by governmental authorities or be successfully marketed for expanded indications. There can be no assurance that the Company&#8217;s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and speed and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence on healthcare providers to prescribe initial implants and replacements, dependence upon third-party payors to provide adequate coverage and reimbursement, dependence on key personnel, single-source suppliers and vendors in connection with the manufacture of its products, concentration of CECs and epileptologists, obtaining, maintaining, protecting, enforcing, and defending intellectual property rights and proprietary technology, product liability claims, legal proceedings, and compliance with government regulations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s medical devices require approvals or clearances from the U.S. Food and Drug Administration, or the FDA, or international regulatory agencies. In addition, in order to continue the Company&#8217;s operations, compliance with various federal and state laws is required. If approvals or clearances were withdrawn by the FDA for the Company&#8217;s current products or if such approvals or clearances were denied or delayed for future products, product updates, or expanded indications for use, it would have a material adverse impact on the Company.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company makes estimates on the collectability of customer accounts based primarily on analysis of historical trends and experience, the age of the receivable and changes in customers&#8217; financial condition. The Company uses its judgment, based on the best available facts and circumstances, and records an allowance against amounts due to reduce the receivable to the amount that is expected to be collected. The Company determined that no allowance was required as of March&#160;31, 2023 and December 31, 2022. To date, the Company has not experienced any credit-related losses.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Programs</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company was awarded a grant by the National Institutes of Health, or NIH, to support research of thalamocortical responsive neurostimulation for the treatment of Lennox-Gastaut Syndrome, a type of epilepsy. The award was issued for a five-year period and has a total budget of over $9.3&#160;million, which includes approximately $5.5&#160;million in funding for subawards to third party academic epilepsy centers that are collaborating on the study and are subinvestigators on the study funded by NIH. The subawardees are determined by NIH. The Company&#8217;s responsibility for the subawards is to submit the funding requests on behalf of the subawardees. The funding of subawards does not have any impact on the Company&#8217;s condensed financial statements. Initially funding was approved for the first year beginning June 1, 2021 and provides for reimbursement of qualified direct and indirect expenses in the amount of $0.8&#160;million, including $0.4&#160;million for subawards. Approvals of funds for years </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">two through five are subject to the completion of certain milestones. On July 30, 2022, the Company received funding approval for year two in the amount of $2.6&#160;million, which includes $1.6&#160;million for subawards.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For funds received under the NIH funding agreement, the Company recognizes a reduction in research and development expenses in an amount equal to the qualifying expenses incurred in each period up to the amount awarded by the NIH. Qualifying expenses incurred by the Company in advance of funding by the NIH are recorded within prepaid expenses and other current assets on the balance sheets. Through March&#160;31, 2023, $1.0&#160;million of qualifying expenses have been incurred and funded by the NIH related to the first and second year funding. As of March&#160;31, 2023, the Company recorded prepaid expenses and other current assets of $0.1&#160;million related to the second year funding.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss per Share Attributable to Common Stockholders</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, stock options, common stock subject to repurchase related to early exercise of stock options, and restricted stock units are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities. The Company considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of the shares issued upon early exercise of stock options subject to repurchase do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends existing guidance on the impairment of financial assets and adds an impairment model that is based on expected losses rather than incurred losses and requires an entity to recognize as an allowance its estimate of expected credit losses for its financial assets. An entity will apply this guidance through a cumulative-effect adjustment to retained earnings upon adoption (a modified-retrospective approach) while a prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. For public business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, adoption is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. For SEC filers that are eligible to be smaller reporting companies and for all other entities, this ASU is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company adopted this ASU effective January 1, 2023. The adoption of this ASU did not have a material effect on the Company&#8217;s financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929069895088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.77pt">Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.77pt">Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.77pt">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the market approach to measure fair value for its financial assets and liabilities. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the&#160;Company&#8217;s financial assets (cash equivalents and marketable securities) at fair value as of March&#160;31, 2023 (in thousands):</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.694%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.723%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of March&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis for Fair Value Measurements</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income mutual fund, included in short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,696&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,696&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the&#160;Company&#8217;s financial assets (cash equivalents and marketable securities) at fair value as of December&#160;31, 2022 (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.694%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.723%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of December&#160;31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis for Fair Value Measurements</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income mutual fund, included in short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,879&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,879&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no liabilities measured at fair value on a recurring and non-recurring basis as of March&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The money market funds are highly liquid and primarily invest in short-term fixed income securities issued by the U.S. government and U.S. government agencies. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s available-for-sale investment comprises a short-term investment in a fixed income mutual fund, which primarily invests in debt securities issued by the U.S. government and U.S. government agencies and corporate bonds and notes. Interest income from its short-term investment is recorded in interest income.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of December 31, 2022, the Company&#8217;s short-term investment had a fair value of $70.8&#160;million, a cost basis of $71.9&#160;million, and an unrealized loss of $1.1&#160;million, which was recorded in accumulated other comprehensive loss.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the three months ended March 31, 2023, the Company recognized $0.4&#160;million in unrealized gains from its short-term investment. As of March 31, 2023, the Company&#8217;s short-term investment had a cumulative unrealized net loss of $0.7&#160;million, which included an adjustment of $1.1&#160;million unrealized loss recorded </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in other income (expense), net in the three months ended March 31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adjustment was not material to any previously issued financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929067277600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,750&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,712&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery, equipment, furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,797&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,788&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,773)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,724)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended March&#160;31, 2023 and 2022 was less than $0.1 million and $0.1 million, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued Liabilities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related expenses </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,748&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory-raw materials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,580&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,414&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929070482432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Facility Lease</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August&#160;2011, the Company entered into a non-cancelable operating lease for combined office and manufacturing facilities in Mountain View, California. The lease was scheduled to expire in April&#160;2019 and was amended in May 2018 to extend it through June 2024. In August 2022, the Company amended the lease to extend it through June 2030. The second amendment contained a rent free period from September 2022 through December 2022. The Company has an option to extend the lease for a period of five years, commencing on July 1, 2030 and expiring on June 30, 2035. In conjunction with the original lease agreement, the Company obtained a letter of credit </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for $0.9 million in lieu of a security deposit. In May 2019, the letter of credit was amended and reduced to $0.7 million. In June 2021, the letter of credit was amended and further reduced to $0.2&#160;million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the facility lease provide for rental payments on a graduated scale; however, rent expense is recognized on a straight-line basis over the lease term. Rental payments range from $2.8 million to $3.3 million per year over the extended term of the lease.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturities of operating lease liabilities as of March&#160;31, 2023 are as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining nine months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,047&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost was $0.7 million and $0.7 million for the three months ended March&#160;31, 2023 and 2022, respectively. As of March&#160;31, 2023, the remaining term for the operating lease in Mountain View, California was 7.3 years, and the discount rate used to measure the lease liability for such operating lease upon recognition was 8.5%.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, cash paid for amounts included in operating lease liabilities of $0.7 million and $0.8 million, respectively, was included in cash flows from operating activities on the condensed statements of cash flows.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Distribution Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company entered into an exclusive distribution agreement, or the Distribution Agreement, with DIXI Medical USA Corp, or DIXI Medical, pursuant to which the Company became the exclusive U.S. distributor of DIXI Medical&#8217;s product line. To maintain the exclusive distributor rights, the Company is committed to purchase a minimum of $2.4&#160;million of DIXI Medical&#8217;s products during the twelve months beginning October 2022, and increase the purchase minimum by 10% for each of the two subsequent years.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnifications</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and may provide for indemnification of the counterparty. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against it in the future but have not yet been made. The Company may, from time to time, be subject to claims or be required to defend actions related to its indemnification obligations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director or officer is or was serving at the Company&#8217;s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws. The term of the indemnification period lasts as long as the director or officer may be subject to any proceeding arising out of acts or omissions of such individual in such capacity. The maximum amount of potential future indemnification is unlimited. The </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations as of March&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. The Company determined that no accrual related to contingencies was required as of March&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not involved in any pending legal proceedings that it believes could have a material adverse effect on its business, results of operations, financial condition, or cash flows. From time to time, the Company may pursue litigation to assert its legal rights and such litigation may be costly and divert the efforts and attention of its management and technical personnel which could adversely affect its business. The Company regularly evaluates current information to determine whether any accruals should be adjusted and whether new accruals are required. Such accruals, if any, reflect the estimable and probable costs that the Company may incur from the outcomes of its legal proceedings. Legal costs are expensed as incurred. There were no contingent liabilities requiring accrual as of March&#160;31, 2023 and December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929069553712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term Loan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company entered into a Term Loan Agreement with CRG Partners IV L.P. and its affiliates for total borrowings of up to $60.0 million, or the Term Loan, and borrowed $50.0 million. The remaining $10.0 million of the Term Loan was available to the Company for borrowing until March 31, 2022 if the Company achieved a revenue-based milestone in 2021. The revenue-based milestone was not achieved, and the remaining $10.0 million of the Term Loan expired without being drawn.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan bore interest at a rate of 12.5% per year. In February 2023, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Term Loan was amended which increased the annual interest rate from 12.5% to 13.5% effective March 1, 2023. The amendment was accounted as a debt modification and the Term Loan&#8217;s effective interest rate increased from 15.7% to 16.8%. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments under the Term Loan are made quarterly with payment dates fixed at the end of each calendar quarter. Through December 2020, the Company had the option to pay the entire interest paid-in-kind, or PIK, by increasing the principal of the Term Loan. From January 2021 through December 2022, the Company had the option to pay interest as follows: 7.5% per annum paid in cash and 5.0% per annum PIK by increasing the principal of the Term Loan. From January 2023 through June 2025, the Company has the option to pay interest as follows: 8.5% per annum paid in cash and 5.0% per annum PIK by increasing the principal of the Term Loan. For each payment date from April 2022 through March 2023, the Company elected the PIK option, increasing the principal of the Term Loan by $2.6 million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan was interest-only through September 2023, which could be extended through September 2025 at the Company&#8217;s option if the Company completed its IPO on or prior September 30, 2023. In connection with closing the IPO, the Company extended the interest-only period to September 30, 2025. Following the interest-only period, principal payment is due in one installment on September 30, 2025. The Term Loan includes a fee upon repayment of the loan equal to 10% of the aggregate principal amount being prepaid or repaid, or the backend fee. As of March&#160;31, 2023, the Term Loan had an annual effective interest rate of 16.8% per year.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan is collateralized by substantially all of the Company&#8217;s assets. The Term Loan Agreement contains customary representations and warranties, covenants, events of default and termination provisions. The financial covenants require that the Company achieve minimum annual revenue thresholds commencing in 2021 and maintain a minimum balance of cash and cash equivalents (see Note 1). In February 2023, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Term Loan was amended to reduce the minimum annual net revenue covenant to $45.0&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the year ended December 31, 2023.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $1.0 million in fees to the lender and third parties which is reflected as a discount on the loan and is being accreted over the life of the loan using the effective interest method. Also, the Company issued warrants to the lender for a total of 346,823 shares of Series B&#8217; redeemable convertible preferred stock. The warrants had a fair value of $0.6 million as of the issuance date, which was accounted for as debt issuance costs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, the Company recorded interest expense related to debt discount and debt issuance costs of the Term Loan of $0.1 million and $0.1 million, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on the Term Loan was $2.0 million and $1.8 million during the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, future minimum payments for the Term Loan are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term Loan</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining nine months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,865&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized debt discount and issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(840)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unaccreted backend fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,023)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,859&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929073150048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">Common Stock<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Amended and Restated Certificate of Incorporation authorizes the Company to issue 200,000,000&#160;shares of $0.001 par value common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of common stock are entitled to receive dividends whenever funds and assets are legally available and when declared by the Board of Directors. As of March&#160;31, 2023 and December 31, 2022, no dividends had been declared.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December 31, 2022, the Company had reserved common stock for future issuance as follows:</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for future grant under the 2021 Plan</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding options under the 2021 Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,531,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,446,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding restricted stock units under the 2021 Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,099,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,756,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock available for ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,271,629&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,076,678&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929157658544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Incentive Compensation Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Incentive Compensation Plans</a></td>
<td class="text">Stock-Based Incentive Compensation PlansA summary of shares available for grant under the Company&#8217;s 2021 Equity Incentive Plan, or the 2021 Plan, is as follows:<div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Available for Grant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant as of January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,252,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted/Awarded</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,821,762)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Withheld for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant as of March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959,660&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the three months ended March&#160;31, 2023 is set forth below:</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances as of January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,446,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.06</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,608)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,898)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances at March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,531,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.92</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,003,254&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.69</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,531,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.92</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Early Exercise of Stock Options </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the Company&#8217;s 2020 Stock Plan, or the 2020 Plan, and the 2021 Plan, permit the exercise of options granted under the plans prior to vesting, subject to required approvals. The shares of common stock issued from the early exercise of unvested stock options are restricted and continue to vest over the original implied service period. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. The shares purchased by the employees and non-employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be outstanding until those shares vest. The cash received in exchange for exercised and unvested shares related to stock options granted is recorded as a liability for the early exercise of stock options in accrued liabilities on the accompanying balance sheet and will be transferred into common stock and additional paid-in capital as the shares vest. As of March&#160;31, 2023 and December 31, 2022, there were 65,296 and 78,389 shares of common stock, respectively, issued pursuant to early exercised options and subject to repurchase.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company adopted the 2021 Employee Stock Purchase Plan, or ESPP. The Company allows eligible employees to purchase shares of the Company's common stock through payroll deductions at a price equal to 85% of the lesser of the fair market value of the stock as of the first date or the ending date of each offering period, which is typically six months. There were 580,000 shares of common stock initially reserved for issuance under the ESPP. In January 2023, the number of shares of common stock available for issuance under the ESPP was increased by 250,457 shares as a result of the automatic increase provision in the ESPP.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, 680,397 shares under the ESPP remain available for purchase. The offering period and purchase period is determined by the board of directors. A new offering period of six months has been authorized beginning December 7, 2022 through June 6, 2023.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity with respect to restricted stock units was as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.619%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares Underlying Outstanding Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested, January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,756,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,701,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(325,747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31,729)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested, March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,099,974&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,125&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,488&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above stock-based compensation expense related to the following equity-based awards (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options and restricted stock units</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,125&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,488&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the total unrecognized stock-based compensation expense related to unvested stock options and restricted stock units was $25.4 million, which will be amortized on a straight-line basis over a weighted average remaining period of 2.7 years.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company had unrecognized stock-based compensation expense relating to the ESPP awards of less than $0.1 million, which is expected to be recognized over a weighted-average period of 0.2 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929069553712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not record a federal or state income tax provision or benefit for the three months ended March&#160;31, 2023 and 2022 as it has incurred net losses since inception. In addition, the net deferred tax assets generated from net operating losses are fully offset by a valuation allowance as the Company believes it is not more likely than not that the benefit will be realized.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for the uncertainty in income taxes by utilizing a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or are expected to be taken on an income tax return. There has been no changes in the estimated uncertain tax benefits recorded as of December 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929073212480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text">Net Loss per Share Attributable to Common Stockholders<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except for share and per share amounts):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,375)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,461)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common stock outstanding used to compute basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,097,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,307,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.41)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.47)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company&#8217;s net loss, in common stock equivalent shares:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,531,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,543,716&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested early exercised common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares committed under ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,099,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,848,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,884,069&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,644,197&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929067528080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Unaudited Interim Financial Information</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed financial statements have been prepared in conformity with generally accepted accounting principles in the United States, or GAAP, as defined by the Financial Accounting Standards Board, or the FASB.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed balance sheet as of December 31, 2022 was derived from the Company&#8217;s audited financial statements, but does not include all disclosures required by GAAP. The accompanying unaudited condensed financial statements as of March 31, 2023 and for the three months ended March 31, 2023 and 2022, have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC, for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. Accordingly, these financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2022 and notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the SEC on March 2, 2023. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company&#8217;s condensed financial position as of March 31, 2023 and condensed results of operations and condensed cash flows for the three months ended March 31, 2023 and 2022 have been made. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited interim condensed financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. The Company uses significant judgment when making estimates related to the valuation of deferred tax assets and related valuation allowances and provision for excess and obsolete inventories. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments and Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amounts of certain of the Company&#8217;s financial instruments, including cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value because of the short-term nature of these instruments. The Company has a short-term investment in a fixed income mutual fund, which is classified as equity security and carried at fair value based on quoted market prices. Changes in the fair value of the short-term investment are recorded in income or loss. The Company believes that its borrowings bear interest at the prevailing market rates for instruments with similar characteristics; accordingly, the carrying value of this instrument approximates its fair value. The Company determines the fair value of financial and non-financial assets and </span></div>liabilities using the fair value hierarchy which establishes three levels of inputs that may be used to measure fair value (see Note 3).<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.77pt">Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.77pt">Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.77pt">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the market approach to measure fair value for its financial assets and liabilities. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk, and Other Risks and Uncertainties</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk, and Other Risks and Uncertainties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, short-term investments and accounts receivable to the extent of the amounts recorded on the balance sheets. The Company&#8217;s cash is invested in major financial institutions in the United States. Deposits in these financial institutions may exceed federally insured limits, and the Company is exposed to credit risk on deposits in the event of default of the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation. The Company&#8217;s cash equivalents are invested in money market funds.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable are due from a variety of health care organizations in the United States. For the three months ended March&#160;31, 2023 and 2022, there were no customers that represented 10% or more of revenue. As of March&#160;31, 2023 and December&#160;31, 2022, no customer represented 10% or more of the Company&#8217;s accounts receivable.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain risks, including that its devices may not be approved or cleared or continue to be approved or cleared for marketing by governmental authorities or be successfully marketed for expanded indications. There can be no assurance that the Company&#8217;s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and speed and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence on healthcare providers to prescribe initial implants and replacements, dependence upon third-party payors to provide adequate coverage and reimbursement, dependence on key personnel, single-source suppliers and vendors in connection with the manufacture of its products, concentration of CECs and epileptologists, obtaining, maintaining, protecting, enforcing, and defending intellectual property rights and proprietary technology, product liability claims, legal proceedings, and compliance with government regulations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s medical devices require approvals or clearances from the U.S. Food and Drug Administration, or the FDA, or international regulatory agencies. In addition, in order to continue the Company&#8217;s operations, compliance with various federal and state laws is required. If approvals or clearances were withdrawn by the FDA for the Company&#8217;s current products or if such approvals or clearances were denied or delayed for future products, product updates, or expanded indications for use, it would have a material adverse impact on the Company.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company makes estimates on the collectability of customer accounts based primarily on analysis of historical trends and experience, the age of the receivable and changes in customers&#8217; financial condition. The Company uses its judgment, based on the best available facts and circumstances, and records an allowance against amounts due to reduce the receivable to the amount that is expected to be collected. The Company determined that no allowance was required as of March&#160;31, 2023 and December 31, 2022. To date, the Company has not experienced any credit-related losses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Government Programs</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Programs</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company was awarded a grant by the National Institutes of Health, or NIH, to support research of thalamocortical responsive neurostimulation for the treatment of Lennox-Gastaut Syndrome, a type of epilepsy. The award was issued for a five-year period and has a total budget of over $9.3&#160;million, which includes approximately $5.5&#160;million in funding for subawards to third party academic epilepsy centers that are collaborating on the study and are subinvestigators on the study funded by NIH. The subawardees are determined by NIH. The Company&#8217;s responsibility for the subawards is to submit the funding requests on behalf of the subawardees. The funding of subawards does not have any impact on the Company&#8217;s condensed financial statements. Initially funding was approved for the first year beginning June 1, 2021 and provides for reimbursement of qualified direct and indirect expenses in the amount of $0.8&#160;million, including $0.4&#160;million for subawards. Approvals of funds for years </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">two through five are subject to the completion of certain milestones. On July 30, 2022, the Company received funding approval for year two in the amount of $2.6&#160;million, which includes $1.6&#160;million for subawards.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For funds received under the NIH funding agreement, the Company recognizes a reduction in research and development expenses in an amount equal to the qualifying expenses incurred in each period up to the amount awarded by the NIH. Qualifying expenses incurred by the Company in advance of funding by the NIH are recorded within prepaid expenses and other current assets on the balance sheets. Through March&#160;31, 2023, $1.0&#160;million of qualifying expenses have been incurred and funded by the NIH related to the first and second year funding. As of March&#160;31, 2023, the Company recorded prepaid expenses and other current assets of $0.1&#160;million related to the second year funding.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss per Share Attributable to Common Stockholders</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, stock options, common stock subject to repurchase related to early exercise of stock options, and restricted stock units are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities. The Company considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of the shares issued upon early exercise of stock options subject to repurchase do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends existing guidance on the impairment of financial assets and adds an impairment model that is based on expected losses rather than incurred losses and requires an entity to recognize as an allowance its estimate of expected credit losses for its financial assets. An entity will apply this guidance through a cumulative-effect adjustment to retained earnings upon adoption (a modified-retrospective approach) while a prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. For public business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, adoption is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. For SEC filers that are eligible to be smaller reporting companies and for all other entities, this ASU is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company adopted this ASU effective January 1, 2023. The adoption of this ASU did not have a material effect on the Company&#8217;s financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929069470992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities, Measured at Fair Value</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the&#160;Company&#8217;s financial assets (cash equivalents and marketable securities) at fair value as of March&#160;31, 2023 (in thousands):</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.694%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.723%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of March&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis for Fair Value Measurements</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income mutual fund, included in short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,696&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,696&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the&#160;Company&#8217;s financial assets (cash equivalents and marketable securities) at fair value as of December&#160;31, 2022 (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.694%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.723%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of December&#160;31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis for Fair Value Measurements</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income mutual fund, included in short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,879&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,879&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929072105744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,750&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,712&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery, equipment, furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,797&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,788&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,773)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,724)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related expenses </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,748&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory-raw materials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,580&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,414&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929069417952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturities of operating lease liabilities as of March&#160;31, 2023 are as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining nine months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,047&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929069410592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, future minimum payments for the Term Loan are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term Loan</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining nine months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,865&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized debt discount and issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(840)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unaccreted backend fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,023)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,859&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929069463792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Stock by Class</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December 31, 2022, the Company had reserved common stock for future issuance as follows:</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for future grant under the 2021 Plan</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding options under the 2021 Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,531,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,446,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding restricted stock units under the 2021 Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,099,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,756,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock available for ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,271,629&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,076,678&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929069883504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Incentive Compensation Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Available for Grant</a></td>
<td class="text">A summary of shares available for grant under the Company&#8217;s 2021 Equity Incentive Plan, or the 2021 Plan, is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Available for Grant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant as of January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,252,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted/Awarded</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,821,762)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Withheld for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant as of March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959,660&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the three months ended March&#160;31, 2023 is set forth below:</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances as of January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,446,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.06</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,608)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,898)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances at March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,531,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.92</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,003,254&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.69</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,531,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.92</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Units</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity with respect to restricted stock units was as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.619%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares Underlying Outstanding Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested, January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,756,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,701,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(325,747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31,729)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested, March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,099,974&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-based Payment Arrangement, Expensed and Capitalized, Amount</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,125&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,488&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above stock-based compensation expense related to the following equity-based awards (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options and restricted stock units</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,125&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,488&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929067102352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except for share and per share amounts):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,375)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,461)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common stock outstanding used to compute basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,097,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,307,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.41)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.47)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Outstanding</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company&#8217;s net loss, in common stock equivalent shares:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,531,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,543,716&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested early exercised common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares committed under ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,099,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,848,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,884,069&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,644,197&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929063138000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2021</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 481,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 470,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,698<span></span>
</td>
<td class="nump">$ 11,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_DebtInstrumentCovenantMinimumAnnualNetRevenue', window );">Minimum annual net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO', window );">Minimum cash and cash equivalents required after completion of IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock (in dollars per share)</a></td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance initial public offering</a></td>
<td class="nump">$ 117,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="nump">105,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_SaleOfStockUnderwritingDiscounts', window );">Sale of stock, underwriting discounts</a></td>
<td class="nump">8,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_SaleOfStockOfferingCosts', window );">Sale of stock, offering costs</a></td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=npce_AtTheMarketEquityOfferingMember', window );">At-the-Market Equity Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from issuance of preferred stock, preference stock, and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance or sale by company of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement', window );">Percentage of shares of common stock sold under sales agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_DebtInstrumentCovenantMinimumAnnualNetRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Minimum Annual Net Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_DebtInstrumentCovenantMinimumAnnualNetRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Minimum Cash and Cash Equivalents Required After Completion of IPO</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Shares of Common Stock Sold under the Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_SaleOfStockOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Offering Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_SaleOfStockOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_SaleOfStockUnderwritingDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Underwriting Discounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_SaleOfStockUnderwritingDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=npce_AtTheMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=npce_AtTheMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929069371936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 30, 2022</div></th>
<th class="th"><div>Jun. 01, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTerm', window );">Grant period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost', window );">Research and development arrangement with federal government, total budget</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards', window );">Research and development arrangement with federal government, funding for subawards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1', window );">Approved funding, first year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1', window );">Approved funding, including subawards, first year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2', window );">Approval for funding, year two</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2', window );">Approval for funding, including subawards, year two</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,597<span></span>
</td>
<td class="nump">$ 3,111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_AdditionalFundingAgreementTermsMember', window );">Additional Funding Agreement Terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Compensation earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement with Federal Government, Approval for Funding Subawards, Year 2</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement with Federal Government, Approval for Funding, Year 2</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement with Federal Government, Approved Funding Subawards, Year 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement with Federal Government, Approved Funding, Year 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement with Federal Government, Estimated Cost for Subawards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement with Federal Government, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement with Federal Government, Total Estimated Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_AdditionalFundingAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_AdditionalFundingAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929069206128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">$ 6,801<span></span>
</td>
<td class="nump">$ 6,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fixed income mutual fund, included in short-term investments</a></td>
<td class="nump">60,895<span></span>
</td>
<td class="nump">70,804<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">67,696<span></span>
</td>
<td class="nump">76,879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">6,801<span></span>
</td>
<td class="nump">6,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fixed income mutual fund, included in short-term investments</a></td>
<td class="nump">60,895<span></span>
</td>
<td class="nump">70,804<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">67,696<span></span>
</td>
<td class="nump">76,879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fixed income mutual fund, included in short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fixed income mutual fund, included in short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929069391408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value disclosure</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized loss</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-Term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized loss</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gain</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929072065936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 4,575<span></span>
</td>
<td class="nump">$ 2,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">592<span></span>
</td>
<td class="nump">1,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">5,583<span></span>
</td>
<td class="nump">5,371<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">$ 10,750<span></span>
</td>
<td class="nump">$ 9,712<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929067170208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components -Schedule of Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 9,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(8,773)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,724)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation (less than $0.1 million for both periods)</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=npce_MachineryEquipmentFurnitureAndFixturesMember', window );">Machinery, equipment, furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">4,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=npce_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,952<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,402<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=npce_MachineryEquipmentFurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=npce_MachineryEquipmentFurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=npce_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=npce_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929069001632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">$ 5,190<span></span>
</td>
<td class="nump">$ 5,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_AccruedInventoryLiabilityCurrent', window );">Inventory-raw materials</a></td>
<td class="nump">463<span></span>
</td>
<td class="nump">764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">756<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_AccruedAndEmployeeRelatedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 6,580<span></span>
</td>
<td class="nump">$ 7,414<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_AccruedAndEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued and Employee-related Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_AccruedAndEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_AccruedInventoryLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Inventory Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_AccruedInventoryLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929062922528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Aug. 31, 2011</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_OperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Purchase obligation, to be paid in the next twelve months</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_PurchaseObligationMinimumIncreasePercentageInNextTwoYears', window );">Percentage increase in purchase commitment</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_IndemnificationLiabilityOfficersAndDirectors', window );">Indemnification liability accrued for officers and directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Accrual for contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Accrual for contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=npce_LeaseFacilityMember', window );">Lease Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_OperatingLeasesAnnualRentalPayments', window );">Annual rental payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_OperatingLeasesAnnualRentalPayments', window );">Annual rental payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_IndemnificationLiabilityOfficersAndDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indemnification Liability, Officers and Directors</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_IndemnificationLiabilityOfficersAndDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_OperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Renewal term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_OperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_OperatingLeasesAnnualRentalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Annual Rental Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_OperatingLeasesAnnualRentalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_PurchaseObligationMinimumIncreasePercentageInNextTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation, Minimum Increase Percentage In Next Two years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_PurchaseObligationMinimumIncreasePercentageInNextTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=npce_LeaseFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=npce_LeaseFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929069268080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023 (remaining nine months)</a></td>
<td class="nump">$ 2,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">2,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">2,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">3,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">3,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">8,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">22,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">5,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">16,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="nump">1,466<span></span>
</td>
<td class="nump">$ 1,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">$ 15,047<span></span>
</td>
<td class="nump">$ 15,440<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929067912896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 01, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th">
<div>Sep. 24, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_DebtInstrumentPrincipalPaymentNumberOfInstallment', window );">Principal payment number of installment | installment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="nump">$ 67,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=npce_TermLoanMember', window );">Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Unused borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective percentage</a></td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_DebtInstrumentRedemptionFeePercent', window );">Redemption fee, percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_DebtInstrumentCovenantMinimumAnnualNetRevenue', window );">Minimum annual net revenue</a></td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Backend fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,143,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=npce_TermLoanMember', window );">Term Loan | Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Backend fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_WarrantLiabilityNoncurrent', window );">Warrant liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=npce_TermLoanMember', window );">Term Loan | Payment In Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=npce_TermLoanMember', window );">Term Loan | Payment in Kind (PIK) Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=npce_TermLoanMember', window );">Term Loan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=npce_TermLoanMember', window );">Term Loan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective percentage</a></td>
<td class="nump">15.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_DebtInstrumentCovenantMinimumAnnualNetRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Minimum Annual Net Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_DebtInstrumentCovenantMinimumAnnualNetRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_DebtInstrumentPrincipalPaymentNumberOfInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Principal Payment Number of Installment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_DebtInstrumentPrincipalPaymentNumberOfInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_DebtInstrumentRedemptionFeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Fee, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_DebtInstrumentRedemptionFeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_WarrantLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_WarrantLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=npce_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=npce_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=npce_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=npce_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=npce_PaymentInCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=npce_PaymentInCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929069007632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Maturities of Long-term Debt (Details) - Term Loan<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2023 (remaining nine months)</a></td>
<td class="nump">$ 5,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">7,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">63,225<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">75,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized debt discount and issuance cost</a></td>
<td class="num">(840)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Less: Unaccreted backend fee</a></td>
<td class="num">(3,143)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_DebtInstrumentUnamortizedInterestCost', window );">Less: Interest</a></td>
<td class="num">(18,023)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Term Loan</a></td>
<td class="nump">$ 53,859<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_DebtInstrumentUnamortizedInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Unamortized Interest Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_DebtInstrumentUnamortizedInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=npce_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=npce_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929062907328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared cash</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">8,271,629<span></span>
</td>
<td class="nump">7,076,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=npce_OptionsAvailableForGrant2021PlanMember', window );">Shares available for future grant under the 2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">959,660<span></span>
</td>
<td class="nump">1,443,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=npce_OutstandingOptions2021PlanMember', window );">Outstanding options under the 2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">3,531,598<span></span>
</td>
<td class="nump">3,446,583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=npce_OptionsRestrictedStockUnit2021PlanMember', window );">Outstanding restricted stock units under the 2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">3,099,974<span></span>
</td>
<td class="nump">1,756,209<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=npce_CommonStockAvailableForESPPMember', window );">Common stock available for ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">680,397<span></span>
</td>
<td class="nump">429,940<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=npce_OptionsAvailableForGrant2021PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=npce_OptionsAvailableForGrant2021PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=npce_OutstandingOptions2021PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=npce_OutstandingOptions2021PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=npce_OptionsRestrictedStockUnit2021PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=npce_OptionsRestrictedStockUnit2021PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=npce_CommonStockAvailableForESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=npce_CommonStockAvailableForESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929069262880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Incentive Compensation Plans - Schedule of Available for Grant (Details) - 2021 Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Available for Grant [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant, beginning balance (in shares)</a></td>
<td class="nump">1,443,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">1,252,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod', window );">Granted/Awarded (in shares)</a></td>
<td class="num">(1,821,762)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod', window );">Cancelled (in shares)</a></td>
<td class="nump">49,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes', window );">Withheld for taxes (in shares)</a></td>
<td class="nump">35,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant, ending balance (in shares)</a></td>
<td class="nump">959,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Canceled During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Granted During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares, Withheld for Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Available for Grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=npce_A2021EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=npce_A2021EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929069211536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Incentive Compensation Plans - Schedule of Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, beginning balance (in shares)</a></td>
<td class="nump">3,446,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">120,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(17,608)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options cancelled (in shares)</a></td>
<td class="num">(17,898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, ending balance (in shares)</a></td>
<td class="nump">3,531,598<span></span>
</td>
<td class="nump">3,446,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested and exercisable (in shares)</a></td>
<td class="nump">2,003,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">3,531,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 3.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollar per share)</a></td>
<td class="nump">1.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollar per share)</a></td>
<td class="nump">0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options cancelled (in dollar per share)</a></td>
<td class="nump">6.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">3.54<span></span>
</td>
<td class="nump">$ 3.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Vested and exercisable (in dollars per share)</a></td>
<td class="nump">2.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 3.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (in Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance</a></td>
<td class="text">7 years 11 months 1 day<span></span>
</td>
<td class="text">8 years 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable</a></td>
<td class="text">7 years 8 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">7 years 11 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929067838704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Incentive Compensation Plans - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 06, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase', window );">Options, subject to repurchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">ESPP discount percent</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_EmployeeStockPurchasePlanLengthOfOfferingPeriod', window );">ESPP, length of offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,271,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,076,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=npce_A2021EmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">250,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">680,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Cost not yet recognized, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=npce_A2021EmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_npce_EmployeeStockPurchasePlanOfferingPeriod', window );">Offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_EmployeeStockPurchasePlanLengthOfOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Length of Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_EmployeeStockPurchasePlanLengthOfOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_EmployeeStockPurchasePlanOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_EmployeeStockPurchasePlanOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Subject to Repurchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>npce_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=npce_A2021EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=npce_A2021EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929068964800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Incentive Compensation Plans - Schedule of Restricted Stock Units (Details) - Unvested restricted stock units<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares Underlying Outstanding Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, beginning balance (in shares) | shares</a></td>
<td class="nump">1,756,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,701,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(325,747)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled (in shares) | shares</a></td>
<td class="num">(31,729)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, ending balance (in shares) | shares</a></td>
<td class="nump">3,099,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">4.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">9.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">13.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929064511296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Incentive Compensation Plans - Schedule of Recognized Stock-based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 2,125<span></span>
</td>
<td class="nump">$ 1,488<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=npce_StockOptionsAndRestrictedStockUnitsMember', window );">Stock options and restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">2,071<span></span>
</td>
<td class="nump">1,352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 1,479<span></span>
</td>
<td class="nump">$ 938<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=npce_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=npce_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929068721936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929072025184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (10,375)<span></span>
</td>
<td class="num">$ (11,461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common stock outstanding used to compute basic net loss per share (in shares)</a></td>
<td class="nump">25,097,262<span></span>
</td>
<td class="nump">24,307,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common stock outstanding used to compute diluted net loss per share (in shares)</a></td>
<td class="nump">25,097,262<span></span>
</td>
<td class="nump">24,307,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic (in dollars per share)</a></td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted (in dollars per share)</a></td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.47)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139929062785136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders - Schedule of Potentially Dilutive Securities Outstanding (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares (in shares)</a></td>
<td class="nump">6,884,069<span></span>
</td>
<td class="nump">5,644,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares (in shares)</a></td>
<td class="nump">3,531,598<span></span>
</td>
<td class="nump">3,543,716<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=npce_ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember', window );">Unvested early exercised common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares (in shares)</a></td>
<td class="nump">65,296<span></span>
</td>
<td class="nump">143,156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Shares committed under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares (in shares)</a></td>
<td class="nump">187,201<span></span>
</td>
<td class="nump">108,681<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares (in shares)</a></td>
<td class="nump">3,099,974<span></span>
</td>
<td class="nump">1,848,644<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=npce_ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=npce_ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>npce-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:npce="http://neuropace.com/20230331"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="npce-20230331.xsd" xlink:type="simple"/>
    <context id="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i537cbbe5a2c74417929006a9f9320b26_I20230501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="i2c6bb8e9b196490ba7de396051e5fc52_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8daa853d90324638b7732e94aa400e74_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i67198705cd5b4be6a83655c796893924_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i61be63c82dfc4be78e2f9d68b4f11019_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i98a7716fe4f8442ea99bfcffe232e221_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie8d9bf075ca645be8dba336153887c29_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i98bf413ba1ce4032a1cdf3cbddd33acd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7809dc429fd8495f9d069ad7b000facc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i62099d19b5164e1a965faa8cb79f62df_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6b89c6fbb19942c7ba5917a6174e4e08_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iac806c35c4c94cfbabaf3bf0aac255e4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3ad874e29bb74c679f513a76324f85d3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8e12eed5884041b78d03f7d55c84255f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i63642277a31a4e158aa8e35fc5614bf2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie4f3a4d01eb64c3d99f32042d0306005_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2672791bd16a4560ac4e6349ada7df02_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb6c3879fe2843cb86d6b11e28b0ece0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i583edd3895a14ca5acca2fc71f20f802_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieb3a188a2ef045108bee1a5e3cdc8bf7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i17c2f30808f842e79b03a1b5e2dc3a74_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie317d529e039488fa3e2b724a267f0af_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5ebcbcb47ad845b58adc86041e6d3e95_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i83cf5939e5774de68da51a47ab212e1f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5cf5d7f0fdf14d358770256db90ddb08_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i073cd7dafa2f45088fbdd34201842f90_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i50b17b8c21b8445ebb59d9b3575ecf6f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7a126628dbb0405eb5c4b1f67cdd87ab_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1616f745a37b421a8451f51495269b96_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4d497eb241564565aff73765a48fe320_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic31468e5e435455380b814e3c2061589_D20210426-20210426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-26</startDate>
            <endDate>2021-04-26</endDate>
        </period>
    </context>
    <context id="if0b1b62330d2427a92e83025c46122d5_I20210426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-26</instant>
        </period>
    </context>
    <context id="i6f49f5b3c47d4ba1ac4f833941af6ad6_D20210426-20210426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-26</startDate>
            <endDate>2021-04-26</endDate>
        </period>
    </context>
    <context id="ibd6ab3a83420410da0927243af8d2e90_D20221101-20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">npce:AtTheMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="id1b89218f85e4970ba94327f3911df2b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">npce:AtTheMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i34fc98c3b9124df39be5fbc449566961_D20230101-20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i2fb4e476763541a694ffb3eb2be6c4dd_I20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="iea9e5bc642294c36a2e9ce408258fa44_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="ie20e4646b6c64bd484f8b50c7fcb7a1e_D20210601-20210601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="id750435b22204579ab914565baeecdcc_D20220730-20220730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
        </entity>
        <period>
            <startDate>2022-07-30</startDate>
            <endDate>2022-07-30</endDate>
        </period>
    </context>
    <context id="i63da6b904e2e4e799b8f63827d7dd2ec_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8548ff80a4ad42a7bc8f521cc07045af_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:AdditionalFundingAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7320c8ff5d5a4db38fdb65660cdbc124_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9b3e368885a4412aa08f736e786122f7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5504ee5ca136427291328b9cdbfd9ac2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i089087e88c2f4e4594e265ef1eac9189_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i733ca2b6b6c1414dac92793e9704c260_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7b0dc4d765154685b20215349253bb6d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i50fbc717732e47c78990b648a1fb6851_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i56aad41cb82348889b805e52158fbf37_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie13bfccbf66c4ecab838a9cd17475bc2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">npce:MachineryEquipmentFurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i72b74226bce34ccd820c481519df8f32_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">npce:MachineryEquipmentFurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i92e875b8476a417484c9e720466e1c5c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">npce:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i15f6bae5515b42c08088c9d68db5f5d6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">npce:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3d52095ad0ee44e7b2c4a5bc8d88dcfb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic24aec2bd2a146c0b2ceeb0af31c9a57_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if9a80d56ebf04d499b58bf88ca435e06_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="ibea6fa1c91014c4b8d2577a5a84d2960_I20110831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:LeaseFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-08-31</instant>
        </period>
    </context>
    <context id="ic7e26e273c0b48a4b9d9a2e7d4b6b51f_I20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:LeaseFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="i855f72fe57c7466cb0fdbebf83edc239_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:LeaseFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2356a93c7f0842d59386f834f8ca8c04_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="ifffa9c7125464d7486ce57d0838a6f42_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="ia4dd4f305a334652a40e5d347bc7628f_I20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="i663f6b7d3d6c49a2bc184e2117245877_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7f4f2b14460d4ab894ce8ce881d1e8bf_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ief8e6ea33f5f49ba8c1945d7760420af_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i82f97d12cf584623a6e5b81bd652ab53_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i43f850c157d141ef9213ce882f01add9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7eeeb9a80b68476f81a32985be7b3bbb_I20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="i936af4736e104ba1b78e04ecf51e9485_I20230301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-01</instant>
        </period>
    </context>
    <context id="i52f87175f69a4d5ba7551816e3e6d9f9_I20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="iff8d276c367b44d9b804890918cc832b_I20230301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-01</instant>
        </period>
    </context>
    <context id="ic717d133e94248aeb47643602e049d84_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">npce:PaymentInCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i83b57f4259104d73b1aa83bc7764aa5d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieddb0b8aa4b949f1a6e2bed0558ca9c0_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">npce:PaymentInCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i9067c2fe52724e22a615ea36acafda17_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="icabe16bffe8b4ea7bfe4bf0585864a95_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibfc06477076049948beb4962edceb579_D20230201-20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="i112820749e8349ea97d447caf4294059_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icfb0677a4b944e56b972e31d646b50b7_D20230201-20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="iad9b6795da0a45d5acf70ba4d680edb2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">npce:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4e5845b14c67448eafe578cbd6b9e3fd_I20200924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">npce:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-24</instant>
        </period>
    </context>
    <context id="i814c00557d744141babf3f0e6dcf97a1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i750b0ffd1c3643dca215a71011485722_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">npce:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i03bae0452175488495225eda73e7fe90_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7933e407f09241dcbaee799735452b05_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">npce:OptionsAvailableForGrant2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i82a147b9aa3a438bbe5962d4d431b65a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">npce:OptionsAvailableForGrant2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9928356578b14783835e61b49e13bde7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">npce:OutstandingOptions2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia780dfd625a04653a5d751d2bac0cd4e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">npce:OutstandingOptions2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i106f4f143f4e47e38267866a576503c3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">npce:OptionsRestrictedStockUnit2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i59a77cc78b754f55b5ff3d8bc740ad1b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">npce:OptionsRestrictedStockUnit2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1be39c24946144f8b22080563d21467c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">npce:CommonStockAvailableForESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id847acf3ca4e4e02a9c3aaf18d3001eb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">npce:CommonStockAvailableForESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8968a5068c274de7a24aab2154e22af1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">npce:A2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4072dc09d11d4232803ca241e4c4fd61_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">npce:A2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i898957e56f4f40b1800743493ec2650f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">npce:A2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i75e07d1256df491e837d1a678fa4841f_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i881477cd12da4a8f82229279bbec5907_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">npce:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="ida17c9ecae0547af93d99c9010967769_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">npce:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i06a5ce3c01de408795052e7b2448ca32_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">npce:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i400dca35646848acb6a6f7c825c240c5_D20221207-20230606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">npce:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-07</startDate>
            <endDate>2023-06-06</endDate>
        </period>
    </context>
    <context id="i3a1293fb162241768174865fa0b18818_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icf61601566c5496eaf799d95dd6d08ab_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4f6410c7ed884b1dac8048f069c34d10_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5c03c7d6befd470b9c00ea069d4dec85_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie403128de0ed45939a20b7ba400d2deb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i639bac8ba3dc42db9ca14dffe873b9aa_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8ab734a7b4054702ad1f354a8ba71a1a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0ed9f75a9df14b418c706ff213e1dc62_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id666fdb85ced40d196e685e2eb0efbb9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic8c8e2b0811a4c2085f3292fca112c80_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">npce:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3a901df324314e06b06d59f030123b5d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">npce:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i22c77f84a8524a16aee5a4f8921601bc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i387f9c0ddfda42738fd2f8d07cefdc23_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0a949f95a2434c7b8352d1c7ddbea5aa_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">npce:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i660649a2805c490faa7479b8f8eb80f9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2dd75294bff941ef89454c5ed2eebd0a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iad266dd548874ca7800f0d7408df01b3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">npce:ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i51515b8cbea941149bc22fc10e0f86ab_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">npce:ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i59a019c9f65548d59de82befb2acc22f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia4683af3b7a34481848a875e395fa408_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9840aaee62a3402abc9cc764247cdcc3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ide54bdde89344a929a15191e91ab4bca_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="installment">
        <measure>npce:installment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80L2ZyYWc6YzkzNGJmYTUzMTllNDA4N2E3MWJmMzUxYzU2OWNjY2MvdGFibGU6M2VhYzNhOGJlOWZjNGY3Y2E3ODcwZjcyNWNlYWM3NjIvdGFibGVyYW5nZTozZWFjM2E4YmU5ZmM0ZjdjYTc4NzBmNzI1Y2VhYzc2Ml8wLTEtMS0xLTY5NjUy_2f573a6b-4d5c-4bac-8299-5bb31afa122b">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80L2ZyYWc6YzkzNGJmYTUzMTllNDA4N2E3MWJmMzUxYzU2OWNjY2MvdGFibGU6M2VhYzNhOGJlOWZjNGY3Y2E3ODcwZjcyNWNlYWM3NjIvdGFibGVyYW5nZTozZWFjM2E4YmU5ZmM0ZjdjYTc4NzBmNzI1Y2VhYzc2Ml8xLTEtMS0xLTY5NjUy_5078182d-4890-4390-8b49-42a9f7769a31">0001528287</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80L2ZyYWc6YzkzNGJmYTUzMTllNDA4N2E3MWJmMzUxYzU2OWNjY2MvdGFibGU6M2VhYzNhOGJlOWZjNGY3Y2E3ODcwZjcyNWNlYWM3NjIvdGFibGVyYW5nZTozZWFjM2E4YmU5ZmM0ZjdjYTc4NzBmNzI1Y2VhYzc2Ml8yLTEtMS0xLTY5NjUy_8c833692-2772-4b52-84ca-924f5a6e1868">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80L2ZyYWc6YzkzNGJmYTUzMTllNDA4N2E3MWJmMzUxYzU2OWNjY2MvdGFibGU6M2VhYzNhOGJlOWZjNGY3Y2E3ODcwZjcyNWNlYWM3NjIvdGFibGVyYW5nZTozZWFjM2E4YmU5ZmM0ZjdjYTc4NzBmNzI1Y2VhYzc2Ml8zLTEtMS0xLTY5NjUy_c272ef31-5a3e-49e4-aaf5-dab17bbc334b">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80L2ZyYWc6YzkzNGJmYTUzMTllNDA4N2E3MWJmMzUxYzU2OWNjY2MvdGFibGU6M2VhYzNhOGJlOWZjNGY3Y2E3ODcwZjcyNWNlYWM3NjIvdGFibGVyYW5nZTozZWFjM2E4YmU5ZmM0ZjdjYTc4NzBmNzI1Y2VhYzc2Ml80LTEtMS0xLTY5NjUy_55a0bf4f-1c29-4eb6-b5fd-3a44554d345f">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDUx_38d31432-516c-4a7b-8fe5-d1014e1e95b2">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGFibGU6OTk1MTg2ODNmZWNhNDEwMmFjOWY0ZjRkMDU5Y2U1MzYvdGFibGVyYW5nZTo5OTUxODY4M2ZlY2E0MTAyYWM5ZjRmNGQwNTljZTUzNl8wLTAtMS0xLTY5NjUy_eca7b092-c4a2-4fa3-b6d7-1bee14f08448">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8xMzc_44fda687-1129-4137-b356-032d93846f0d">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGFibGU6MjcxZGU5MmQ3ZGQxNDhlZmFhN2I3NDA3YzU4MzcwYmIvdGFibGVyYW5nZToyNzFkZTkyZDdkZDE0OGVmYWE3Yjc0MDdjNTgzNzBiYl8wLTAtMS0xLTY5NjUy_41ff42e0-ed4f-4532-bbac-69075a5ef03d">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDU1_3ed6cc3d-b00a-4732-97b2-83e636c685d9">001-40337</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDU2_64c62421-0ecb-45bb-bbf2-014896fb4a92">NEUROPACE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGFibGU6ZDdjYzQ3YTM3YzlmNGY1MTgyYWJiY2Y2Y2ViMWFkZTgvdGFibGVyYW5nZTpkN2NjNDdhMzdjOWY0ZjUxODJhYmJjZjZjZWIxYWRlOF8wLTAtMS0xLTY5NjUy_33a987fe-623e-4af6-97fe-86f90220f358">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGFibGU6ZDdjYzQ3YTM3YzlmNGY1MTgyYWJiY2Y2Y2ViMWFkZTgvdGFibGVyYW5nZTpkN2NjNDdhMzdjOWY0ZjUxODJhYmJjZjZjZWIxYWRlOF8wLTItMS0xLTY5NjUy_7c2c035b-4791-4ff4-9606-2a4f710ff08a">22-3550230</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDU0_d6df6ea0-f234-4564-a9cb-76f30718d421">455 N. Bernardo Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDUy_7a2d2664-36fe-4585-98da-d57a59c30e2e">Mountain View</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDQ2_9da113df-f4df-48d8-a3cf-ff62dc7812de">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDU3_b6880ba1-e069-429d-b692-70eb1ec2443c">94043</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDQ3_03a66675-9da6-4de0-9923-ae843af4d922">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDU4_a952b728-4ff0-4bb7-81a5-84807b5f5974">237-2700</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGFibGU6YjlkNjY5MTRkMTkwNDY5YjhjYjE3ZTVkNjg0MmU2NGMvdGFibGVyYW5nZTpiOWQ2NjkxNGQxOTA0NjliOGNiMTdlNWQ2ODQyZTY0Y18xLTAtMS0xLTY5NjUy_fb663a60-3e00-4b3b-80b8-9c886c387b01">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGFibGU6YjlkNjY5MTRkMTkwNDY5YjhjYjE3ZTVkNjg0MmU2NGMvdGFibGVyYW5nZTpiOWQ2NjkxNGQxOTA0NjliOGNiMTdlNWQ2ODQyZTY0Y18xLTItMS0xLTY5NjUy_b73426b6-7d8d-41c9-90d3-9a21a4de2d81">NPCE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGFibGU6YjlkNjY5MTRkMTkwNDY5YjhjYjE3ZTVkNjg0MmU2NGMvdGFibGVyYW5nZTpiOWQ2NjkxNGQxOTA0NjliOGNiMTdlNWQ2ODQyZTY0Y18xLTQtMS0xLTY5NjUy_952cb14c-37a3-4716-ad1d-3dfdbc8e3621">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDUz_94ef3c27-9d19-42a1-a5b7-3e569f84b378">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDQ4_26f5e8b3-d365-4e72-86c8-9f7865ccfa6c">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGFibGU6MjQxYmNiODUwNjNlNGE2ZmFhNmUzYjgxYWI1ODFhYTAvdGFibGVyYW5nZToyNDFiY2I4NTA2M2U0YTZmYWE2ZTNiODFhYjU4MWFhMF8xLTAtMS0xLTY5NjUy_d5b557bd-74a6-40da-b80c-d8a585f3f75a">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGFibGU6MjQxYmNiODUwNjNlNGE2ZmFhNmUzYjgxYWI1ODFhYTAvdGFibGVyYW5nZToyNDFiY2I4NTA2M2U0YTZmYWE2ZTNiODFhYjU4MWFhMF8xLTMtMS0xLTY5NjUy_cb8b90ba-2f58-4920-9a98-29c8accd1447">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGFibGU6MjQxYmNiODUwNjNlNGE2ZmFhNmUzYjgxYWI1ODFhYTAvdGFibGVyYW5nZToyNDFiY2I4NTA2M2U0YTZmYWE2ZTNiODFhYjU4MWFhMF8yLTMtMS0xLTY5NjUy_18c8d097-be36-4ac3-9776-b34d6daac388">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDQ5_195d05e0-8097-49cb-bcf2-141a3500f524">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8yMDUw_ded6f431-cac9-4e44-add0-cd05d8a84175">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i537cbbe5a2c74417929006a9f9320b26_I20230501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xL2ZyYWc6NTQxZmI4ZmJmYTIzNGNhNmIxZTEzNTBlYjdkYTFjNzgvdGV4dHJlZ2lvbjo1NDFmYjhmYmZhMjM0Y2E2YjFlMTM1MGViN2RhMWM3OF8xOTkw_d47c8177-325f-4889-a58f-7ee99fa308b7"
      unitRef="shares">25405362</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfNC0xLTEtMS02OTY1Mg_1cbb5718-1a56-4152-b39f-1ede5dcb2c29"
      unitRef="usd">6720000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfNC0zLTEtMS02OTY1Mg_66ef8fb2-6451-4766-950d-935d4317ff61"
      unitRef="usd">6605000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfNS0xLTEtMS02OTY1Mg_30fa3071-0c7a-4dc4-b19f-c62d7665a269"
      unitRef="usd">60895000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfNS0zLTEtMS02OTY1Mg_7d7ee053-72a4-4257-9eb5-bc8fbb2724a4"
      unitRef="usd">70804000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfNi0xLTEtMS02OTY1Mg_2385e115-a575-4db3-9f9e-96a6b052f255"
      unitRef="usd">9194000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfNi0zLTEtMS02OTY1Mg_eb384855-eb5a-43fb-a04d-745d3f5d0a48"
      unitRef="usd">7482000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfNy0xLTEtMS02OTY1Mg_1c7c3da2-f070-4a74-8e1e-6710b481feb9"
      unitRef="usd">10750000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfNy0zLTEtMS02OTY1Mg_3ea8d240-03b3-43d2-9eba-75b89c21dda6"
      unitRef="usd">9712000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfOC0xLTEtMS02OTY1Mg_909433ab-5b61-4246-8a41-4a4e289caebe"
      unitRef="usd">2597000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfOC0zLTEtMS02OTY1Mg_e658197c-1089-4fb0-9a5f-de99b64deb3a"
      unitRef="usd">3111000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfOS0xLTEtMS02OTY1Mg_9818c9e4-3d64-46b1-881a-f2b7c38fa426"
      unitRef="usd">90156000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfOS0zLTEtMS02OTY1Mg_63d397f8-2362-49b8-9e17-a83afca4daf8"
      unitRef="usd">97714000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTAtMS0xLTEtNjk2NTI_e3081a2c-e5be-4d6d-a992-c0826e2589fd"
      unitRef="usd">1024000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTAtMy0xLTEtNjk2NTI_08c65df7-b6e0-459a-9273-22f84d9e1614"
      unitRef="usd">1064000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTEtMS0xLTEtNjk2NTI_af5dd0db-586a-4ffe-bd66-1a9c6a7160c2"
      unitRef="usd">14491000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTEtMy0xLTEtNjk2NTI_54c0d955-5adf-40ca-9581-3b08f02a6c7b"
      unitRef="usd">14838000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTItMS0xLTEtNjk2NTI_c5048dfb-c048-48f8-aaef-35c6dfededab"
      unitRef="usd">122000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTItMy0xLTEtNjk2NTI_fb285d2c-96b1-4164-bbe4-395eaad45700"
      unitRef="usd">122000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:DeferredCosts
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTMtMS0xLTEtNjk3Njg_0c213807-2d02-444b-9e03-98e1318433c8"
      unitRef="usd">457000</us-gaap:DeferredCosts>
    <us-gaap:DeferredCosts
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTMtMy0xLTEtNjk3Njg_9238ac54-739c-4db8-ad44-7063c59ca798"
      unitRef="usd">347000</us-gaap:DeferredCosts>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTMtMS0xLTEtNjk2NTI_f079cf07-6953-4fd9-93b8-d767154d871b"
      unitRef="usd">21000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTMtMy0xLTEtNjk2NTI_8156a877-c446-4f97-9093-453707b06d10"
      unitRef="usd">21000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTQtMS0xLTEtNjk2NTI_e65180ab-2221-42ce-b137-bca2e5efb8e3"
      unitRef="usd">106271000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTQtMy0xLTEtNjk2NTI_d665a8ff-a883-4001-9eb0-294f3daf4340"
      unitRef="usd">114106000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTctMS0xLTEtNjk2NTI_5dceb4d4-5db5-4365-a7c0-d84ddd0d4ac1"
      unitRef="usd">1829000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTctMy0xLTEtNjk2NTI_01b66908-51d8-4c82-9fdf-61c0842c1af4"
      unitRef="usd">2147000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTgtMS0xLTEtNjk2NTI_b24f88d2-c74b-4aea-b041-68edd6893ed8"
      unitRef="usd">6580000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTgtMy0xLTEtNjk2NTI_390487ce-ce38-4a07-843a-a1c447300997"
      unitRef="usd">7414000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTktMS0xLTEtNjk2NTI_771d2cc8-1bdc-4fc7-bc97-61db1d5f0ade"
      unitRef="usd">1466000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMTktMy0xLTEtNjk2NTI_fca28e1e-d95a-473a-b8a8-2c4faac40dd9"
      unitRef="usd">1415000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjAtMS0xLTEtNjk2NTI_ea550a65-eb59-41a7-b607-308c3ca201cc"
      unitRef="usd">9875000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjAtMy0xLTEtNjk2NTI_17b1fcdb-56b3-4473-a327-687a2d1ae426"
      unitRef="usd">10976000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjItMS0xLTEtNjk2NTI_44adc49b-f898-41c0-8c96-84e4bbd7c9b4"
      unitRef="usd">53859000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjItMy0xLTEtNjk2NTI_e69e655c-d6a3-4235-8bf3-c08e8960ef51"
      unitRef="usd">52913000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjMtMS0xLTEtNjk2NTI_12cb8be1-01ce-4059-98d2-ce834635a319"
      unitRef="usd">15047000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjMtMy0xLTEtNjk2NTI_d9399477-2e02-4b65-92a4-c5d42526166c"
      unitRef="usd">15440000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjQtMS0xLTEtNjk2NTI_4aa9ca07-0fb2-44d3-a83e-c4b63aca6995"
      unitRef="usd">78781000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjQtMy0xLTEtNjk2NTI_4a0882cd-be08-4344-a940-f4625589c875"
      unitRef="usd">79329000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjUtMS0xLTEtNjk2NTI_fe24f917-9c72-4933-af69-dc6ae35b35a1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjUtMy0xLTEtNjk2NTI_7af3983c-75d9-4271-8093-46aa0e8a3a2c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjctMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjo5ODI5MzY2NjJiNjQ0M2RlODQyMjJmNWNmOGI0OGE0NF8yMQ_23e4b545-0a93-4125-bf3e-c7462c404a04"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjctMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjo5ODI5MzY2NjJiNjQ0M2RlODQyMjJmNWNmOGI0OGE0NF8yMQ_abedb2fb-0caf-49f9-bd5f-4ae7e323b36a"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjctMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjo5ODI5MzY2NjJiNjQ0M2RlODQyMjJmNWNmOGI0OGE0NF8zNQ_735fbd7b-da20-4663-baae-a409e3705bd8"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjctMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjo5ODI5MzY2NjJiNjQ0M2RlODQyMjJmNWNmOGI0OGE0NF8zNQ_d2a24ed1-cfb7-428c-98e4-2e9ad07bc1ef"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjctMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjo5ODI5MzY2NjJiNjQ0M2RlODQyMjJmNWNmOGI0OGE0NF82MA_38de2480-4708-442b-a598-5f1f304e7f63"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjctMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjo5ODI5MzY2NjJiNjQ0M2RlODQyMjJmNWNmOGI0OGE0NF82MA_87ea88d2-6131-4f91-8ee7-aa23b6deb233"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjctMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjo5ODI5MzY2NjJiNjQ0M2RlODQyMjJmNWNmOGI0OGE0NF82MA_cb6cad34-b607-452a-a5dd-2a8137021f78"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjctMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjo5ODI5MzY2NjJiNjQ0M2RlODQyMjJmNWNmOGI0OGE0NF82MA_d0bf7283-f08c-46cc-8c5d-32a384a44b5c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjctMS0xLTEtNjk2NTI_efa55fc4-e7fa-4b76-83af-fb5d9909c837"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjctMy0xLTEtNjk2NTI_36bd9c3e-38c0-4fcd-a2de-cf199d9a1c2e"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjgtMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjoyZTQ2NmM0NGUwN2Y0ZDQzYjc5MDk2YTIwZjgyYzEyOF8xOA_41358eac-1505-4ba6-aff2-c02fffa48d9c"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjgtMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjoyZTQ2NmM0NGUwN2Y0ZDQzYjc5MDk2YTIwZjgyYzEyOF8xOA_95e35bfa-c065-4802-9d1c-7c6454cfbbfd"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjgtMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjoyZTQ2NmM0NGUwN2Y0ZDQzYjc5MDk2YTIwZjgyYzEyOF8zMg_9151bfd8-e1b3-4d8f-81c4-9afdfa4fdb3a"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjgtMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjoyZTQ2NmM0NGUwN2Y0ZDQzYjc5MDk2YTIwZjgyYzEyOF8zMg_e9b354a6-95d1-403c-8577-72b4e594bb2d"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjgtMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjoyZTQ2NmM0NGUwN2Y0ZDQzYjc5MDk2YTIwZjgyYzEyOF83MA_1b22bc4f-3ea0-4f8d-b12d-f2e31395e863"
      unitRef="shares">25352204</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjgtMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjoyZTQ2NmM0NGUwN2Y0ZDQzYjc5MDk2YTIwZjgyYzEyOF83MA_a922b099-0ef1-46a1-a313-8d4d83036d62"
      unitRef="shares">25352204</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjgtMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjoyZTQ2NmM0NGUwN2Y0ZDQzYjc5MDk2YTIwZjgyYzEyOF83Nw_44e2ca63-0d35-4aa5-8e37-45408a739532"
      unitRef="shares">25045751</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjgtMC0xLTEtNjk2NTIvdGV4dHJlZ2lvbjoyZTQ2NmM0NGUwN2Y0ZDQzYjc5MDk2YTIwZjgyYzEyOF83Nw_47a6b247-8392-4b91-a831-392a8f914cd2"
      unitRef="shares">25045751</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjgtMS0xLTEtNjk2NTI_1611562e-783c-402b-97f1-8bc03bc82ae8"
      unitRef="usd">25000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjgtMy0xLTEtNjk2NTI_dd0137bc-f162-4084-b4e4-3f4da05e923d"
      unitRef="usd">25000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjktMS0xLTEtNjk2NTI_4d33e54b-bda2-47e5-8dd1-020dfa676062"
      unitRef="usd">508693000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMjktMy0xLTEtNjk2NTI_921ab6ec-1b45-4560-91c4-760d3cffdfdc"
      unitRef="usd">506713000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMzAtMS0xLTEtNjk2NTI_43e705a8-662f-45cb-bb1b-59e5b86bc3c3"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMzAtMy0xLTEtNjk2NTI_72ed50b0-8d32-4d3f-b6ab-11075b503945"
      unitRef="usd">-1108000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMzEtMS0xLTEtNjk2NTI_fe963c06-5741-4b5f-8490-908fb0cc84d2"
      unitRef="usd">-481228000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMzEtMy0xLTEtNjk2NTI_c2ad1ccd-e106-4322-93df-25c416eaaa06"
      unitRef="usd">-470853000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMzItMS0xLTEtNjk2NTI_d281aac1-d216-46dd-b84f-c2d2be24cc68"
      unitRef="usd">27490000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMzItMy0xLTEtNjk2NTI_52ceaa2c-a87c-4989-89ea-5e870658f40b"
      unitRef="usd">34777000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMzMtMS0xLTEtNjk2NTI_dd861c8e-b648-4d52-9812-a0c1fccddbe9"
      unitRef="usd">106271000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8xOS9mcmFnOjJiMmQxYWQ4MDI5YzQ3ZWE5YmYyMjU2ZDMzODExOGFjL3RhYmxlOjc0ODMyYTgzNzEzODRlMTNhZjZiM2E4YmEzYmVhYzEzL3RhYmxlcmFuZ2U6NzQ4MzJhODM3MTM4NGUxM2FmNmIzYThiYTNiZWFjMTNfMzMtMy0xLTEtNjk2NTI_e04fd38b-2f17-41d8-aea0-baafa4686e8f"
      unitRef="usd">114106000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMi02LTEtMS02OTY1Mg_d6a053bc-3ea2-40b0-96f4-75c7fec90fc3"
      unitRef="usd">14472000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMi04LTEtMS02OTY1Mg_a52d6fc2-5484-47d7-8c98-617d04f55be0"
      unitRef="usd">11374000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMy02LTEtMS02OTY1Mg_dd361db9-7c64-4244-b436-fe29b23f44c2"
      unitRef="usd">4100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMy04LTEtMS02OTY1Mg_79e7c685-a31b-4c15-81b3-e6343455c5a0"
      unitRef="usd">3115000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfNC02LTEtMS02OTY1Mg_1908baef-13d7-4e14-be3b-bfcf82413723"
      unitRef="usd">10372000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfNC04LTEtMS02OTY1Mg_7b4a718c-c0c9-48a7-a725-ad987b11f463"
      unitRef="usd">8259000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfNi02LTEtMS02OTY1Mg_95e02a78-69a2-40c6-b1fb-53de306e848b"
      unitRef="usd">5263000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfNi04LTEtMS02OTY1Mg_e9cabc31-ebf8-4019-947a-e6af0ec31295"
      unitRef="usd">5577000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfNy02LTEtMS02OTY1Mg_e646c0ac-7f47-4aed-8ad6-7c0db2579249"
      unitRef="usd">13428000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfNy04LTEtMS02OTY1Mg_32fcd9b8-1db2-4d5b-84ac-304f8656c4f8"
      unitRef="usd">12444000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfOC02LTEtMS02OTY1Mg_a7a4b6be-6d85-4cc7-8307-1c638aa8a9ff"
      unitRef="usd">18691000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfOC04LTEtMS02OTY1Mg_7d3fe5de-c5e9-48c3-9689-cc0b3e2e0e98"
      unitRef="usd">18021000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfOS02LTEtMS02OTY1Mg_451efff9-a5c9-42e2-b6c8-7e57ad87ac85"
      unitRef="usd">-8319000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfOS04LTEtMS02OTY1Mg_c492114c-3870-45cb-a6b5-a1d82c2cfb0c"
      unitRef="usd">-9762000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTAtNi0xLTEtNjk2NTI_2377e6fe-39ca-4567-9137-62e1effa0c27"
      unitRef="usd">726000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTAtOC0xLTEtNjk2NTI_57906853-5807-47ce-9d43-d27aa12b9de0"
      unitRef="usd">134000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTEtNi0xLTEtNjk2NTI_5fa13a6f-83cf-423d-bdd9-22c5d1aa40e5"
      unitRef="usd">1965000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTEtOC0xLTEtNjk2NTI_f450905e-0152-4d14-88c7-25077f4da48f"
      unitRef="usd">1830000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTItNi0xLTEtNjk2NTI_49ec50a8-512e-49cb-be56-22d80abc1fb5"
      unitRef="usd">-817000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTItOC0xLTEtNjk2NTI_07910e84-6133-43a3-b788-a99a50d75000"
      unitRef="usd">-3000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTMtNi0xLTEtNjk2NTI_17c5addb-c199-4638-a627-e977cda0bc50"
      unitRef="usd">-10375000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTMtOC0xLTEtNjk2NTI_2ad5a319-b4cf-441a-ba59-aa26ed882481"
      unitRef="usd">-11461000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTQtNi0xLTEtNjk2NTI_06cd4e44-2fed-4260-b2c5-72881f2f1ef3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTQtOC0xLTEtNjk2NTI_d6e41c10-741f-450a-a3d5-38a8caffee8a"
      unitRef="usd">-710000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTUtNi0xLTEtNjk2NTI_168773fd-6a56-4748-892a-bdf851380397"
      unitRef="usd">-10375000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTUtOC0xLTEtNjk2NTI_77a88e08-b988-40a2-9b71-8bfb6159bd41"
      unitRef="usd">-12171000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTYtNi0xLTEtNjk2NTI_6302e956-d4ad-47e7-bfc2-592bf9bdfec7"
      unitRef="usdPerShare">-0.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTYtNi0xLTEtNjk2NTI_f089392a-55da-4e44-afa3-54eca2bb58b9"
      unitRef="usdPerShare">-0.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTYtOC0xLTEtNjk2NTI_42b963fd-2ce9-48c5-b06b-c738191daa9d"
      unitRef="usdPerShare">-0.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTYtOC0xLTEtNjk2NTI_6e36456c-b860-43e8-99a0-f9ac82ec6484"
      unitRef="usdPerShare">-0.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTctNi0xLTEtNjk2NTI_52fae933-8a5a-4cf7-9b9d-49bb0a2915a1"
      unitRef="shares">25097262</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTctNi0xLTEtNjk2NTI_93185e30-5cee-4104-9a41-2468988e1226"
      unitRef="shares">25097262</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTctOC0xLTEtNjk2NTI_84e3ba43-8981-4e29-a431-4c9fd84e6ab2"
      unitRef="shares">24307485</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yMi9mcmFnOmYxNjAyODZkOTY4MDRjZWNiNjdmZTkyM2JjMDhmY2E5L3RhYmxlOjUxNzk1ZmFhZmE2NzQxYzI5ZDg5YjU1Y2Y3OWUzMTM4L3RhYmxlcmFuZ2U6NTE3OTVmYWFmYTY3NDFjMjlkODliNTVjZjc5ZTMxMzhfMTctOC0xLTEtNjk2NTI_dcb47b59-7079-4515-94d2-7a5ad42243f3"
      unitRef="shares">24307485</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i61be63c82dfc4be78e2f9d68b4f11019_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfMi0xLTEtMS02OTk5MQ_69ae5fed-5b9c-43d3-9cdf-55c942bb87d4"
      unitRef="shares">25045751</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i61be63c82dfc4be78e2f9d68b4f11019_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfMi0zLTEtMS02OTk5MQ_9333a54d-84c1-49dd-b69c-bfeaf1c7e446"
      unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i98a7716fe4f8442ea99bfcffe232e221_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfMi01LTEtMS02OTk5MQ_2aa08d6b-8530-4d54-8ed4-2da71cd11b46"
      unitRef="usd">506713000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie8d9bf075ca645be8dba336153887c29_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfMi03LTEtMS02OTk5MQ_783bb4b0-4891-417b-a1bf-81ed3e26cb5c"
      unitRef="usd">-1108000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i98bf413ba1ce4032a1cdf3cbddd33acd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfMi05LTEtMS02OTk5MQ_acf3491c-0808-4a6f-b84f-022aabf449f7"
      unitRef="usd">-470853000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfMi0xMS0xLTEtNzE2ODA_068bd5c1-7544-494c-9af2-ff977565e5c5"
      unitRef="usd">34777000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i7809dc429fd8495f9d069ad7b000facc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfMy05LTEtMS02OTk5MQ_42a4b1b4-6863-4f38-93cc-e7a1f4b9fd2d"
      unitRef="usd">-10375000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfMy0xMS0xLTEtNzE2ODI_c6855882-0999-42ad-bd8b-8713f7f064ba"
      unitRef="usd">-10375000</us-gaap:NetIncomeLoss>
    <npce:OCIUnrealizedLossAdjustmentForShortTermInvestment
      contextRef="i62099d19b5164e1a965faa8cb79f62df_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfNC03LTEtMS03MDA2NA_670485ba-7461-4bfb-a949-c173e691182b"
      unitRef="usd">1108000</npce:OCIUnrealizedLossAdjustmentForShortTermInvestment>
    <npce:OCIUnrealizedLossAdjustmentForShortTermInvestment
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfNC0xMS0xLTEtNzE2ODQ_75f6221b-f8f7-4885-aee3-c55ef12a8a06"
      unitRef="usd">1108000</npce:OCIUnrealizedLossAdjustmentForShortTermInvestment>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6b89c6fbb19942c7ba5917a6174e4e08_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfNC0xLTEtMS02OTk5MQ_5f6f247a-7146-4e0f-a9c8-c8edb8cec439"
      unitRef="shares">17608</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iac806c35c4c94cfbabaf3bf0aac255e4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfNC01LTEtMS02OTk5MQ_3686fce4-84ed-48e5-9f4c-194867c89b3b"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfNS0xMS0xLTEtNzE2ODY_334054a8-a86d-46ab-987c-a7bc8842c6bd"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i6b89c6fbb19942c7ba5917a6174e4e08_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfNi0xLTEtMS03MDA4Ng_1cec9d79-4335-40a9-80c0-df54546c4501"
      unitRef="shares">325747</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i6b89c6fbb19942c7ba5917a6174e4e08_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfNy0xLTEtMS03MDA4Ng_48afad77-0624-4c22-986f-9afd6321d53b"
      unitRef="shares">35562</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iac806c35c4c94cfbabaf3bf0aac255e4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfNy01LTEtMS03MDA4Ng_86098738-04c1-4316-91d9-570679699fa6"
      unitRef="usd">146000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfNy0xMS0xLTEtNzE3MDI_c09c83c7-1e0b-4af3-a2fc-bcf871141a2f"
      unitRef="usd">146000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i6b89c6fbb19942c7ba5917a6174e4e08_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfOC0xLTEtMS03Mjg4NA_eb608bab-d8ce-400e-8615-660f14a3be16"
      unitRef="shares">1340</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="iac806c35c4c94cfbabaf3bf0aac255e4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfNS01LTEtMS02OTk5MQ_13198603-f4b8-45ae-b81f-1062fdde1b56"
      unitRef="usd">2125000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfOC0xMS0xLTEtNzE3MDQ_d54da244-a714-4838-a8e9-e471b73742c1"
      unitRef="usd">2125000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3ad874e29bb74c679f513a76324f85d3_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfOS0xLTEtMS03MTY4OA_8abdd006-a745-4431-a6d3-1e4d8636ade1"
      unitRef="shares">25352204</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3ad874e29bb74c679f513a76324f85d3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfOS0zLTEtMS03MTY5MA_aa67b9bc-affe-423a-8136-8e08570e52ae"
      unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8e12eed5884041b78d03f7d55c84255f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfOS01LTEtMS03MTY5Mg_cbb2781c-702e-49c2-a892-98b2c4978132"
      unitRef="usd">508693000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i63642277a31a4e158aa8e35fc5614bf2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfOS03LTEtMS03MTY5NA_ab9f4e06-7294-4ebc-bb6d-88d8549d8cba"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie4f3a4d01eb64c3d99f32042d0306005_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfOS05LTEtMS03MTY5Ng_4649a67e-9ae3-44fe-b18a-89c0323b39cd"
      unitRef="usd">-481228000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjUzNmM1NjEzMjI5MzRjYWI4M2MwYjlmNDljNjI5ZDE1L3RhYmxlcmFuZ2U6NTM2YzU2MTMyMjkzNGNhYjgzYzBiOWY0OWM2MjlkMTVfOS0xMS0xLTEtNzE2OTg_5a7a2cf9-7b51-4cba-814b-82d239ef00fa"
      unitRef="usd">27490000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2672791bd16a4560ac4e6349ada7df02_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfMi0xLTEtMS02OTY1Mg_5a4cd9b9-35bc-45e9-a3f0-2e0c3dc39b80"
      unitRef="shares">24452999</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2672791bd16a4560ac4e6349ada7df02_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfMi0zLTEtMS02OTY1Mg_37453252-3c7b-468c-8625-978d8081a964"
      unitRef="usd">24000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icb6c3879fe2843cb86d6b11e28b0ece0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfMi01LTEtMS02OTY1Mg_e7f94abc-f817-4ad1-afd5-44c31c3dc5eb"
      unitRef="usd">497522000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i583edd3895a14ca5acca2fc71f20f802_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfMi03LTEtMS02OTY1Mg_3ab4f886-fd7f-48d1-95dc-86b12d297bad"
      unitRef="usd">-272000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ieb3a188a2ef045108bee1a5e3cdc8bf7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfMi05LTEtMS02OTY1Mg_53f2ae7e-1a78-4088-a0dd-3bf725916c1f"
      unitRef="usd">-423771000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i17c2f30808f842e79b03a1b5e2dc3a74_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfMi0xMS0xLTEtNjk2NTI_b4fe318a-ca24-433b-91a3-ac661f2836df"
      unitRef="usd">73503000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ie317d529e039488fa3e2b724a267f0af_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfMy05LTEtMS02OTY1Mg_75ecdd71-9e60-45bc-91d8-53e2e1bd79ca"
      unitRef="usd">-11461000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfMy0xMS0xLTEtNjk2NTI_1c42d22a-25cf-4afc-ba16-07c51fb04e7b"
      unitRef="usd">-11461000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i5ebcbcb47ad845b58adc86041e6d3e95_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfNC03LTEtMS02OTY1Mg_b0d2d0e4-5f55-4822-a8be-d1b71b84a8a0"
      unitRef="usd">-710000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfNC0xMS0xLTEtNjk2NTI_804cbbf8-85c8-40a1-9dfc-4f023ca5fd68"
      unitRef="usd">-710000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i83cf5939e5774de68da51a47ab212e1f_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfNS0xLTEtMS02OTY1Mg_dd748899-cc7f-4be3-8b5d-70bcb17bb835"
      unitRef="shares">38635</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5cf5d7f0fdf14d358770256db90ddb08_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfNS01LTEtMS02OTY1Mg_33c0abbd-bd1f-418b-aa1b-031eaba3ee92"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfNS0xMS0xLTEtNjk2NTI_9ba62b59-ae2a-4661-a804-ac4d49879652"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i83cf5939e5774de68da51a47ab212e1f_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfNi0xLTEtMS02OTY1Mg_bc632ebb-f196-4d83-8be4-aa89767ca863"
      unitRef="shares">14454</us-gaap:StockRepurchasedDuringPeriodShares>
    <npce:AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability
      contextRef="i5cf5d7f0fdf14d358770256db90ddb08_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfNy01LTEtMS02OTY1Mg_d4c34534-11bd-483c-bd9a-eb09ffebbd99"
      unitRef="usd">-2000</npce:AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability>
    <npce:AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfNy0xMS0xLTEtNjk2NTI_33993bc7-9f58-440e-a04c-07614ff7e037"
      unitRef="usd">-2000</npce:AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i5cf5d7f0fdf14d358770256db90ddb08_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfOC01LTEtMS02OTY1Mg_c1d6a3d0-feb6-4380-8029-79074e790b7b"
      unitRef="usd">1488000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfOC0xMS0xLTEtNjk2NTI_ac220d39-df5b-46f0-9b03-268fc4d7f0e9"
      unitRef="usd">1488000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i073cd7dafa2f45088fbdd34201842f90_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfOS0xLTEtMS02OTY1Mg_4c540bb8-a28c-4792-8d9b-6cf857da4913"
      unitRef="shares">24477180</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i073cd7dafa2f45088fbdd34201842f90_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfOS0zLTEtMS02OTY1Mg_81854a12-5756-4808-8d9b-1178edb2a911"
      unitRef="usd">24000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i50b17b8c21b8445ebb59d9b3575ecf6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfOS01LTEtMS02OTY1Mg_2e242411-baa6-4fa1-a6f5-51c393475dd7"
      unitRef="usd">499013000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7a126628dbb0405eb5c4b1f67cdd87ab_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfOS03LTEtMS02OTY1Mg_23296e07-3b6f-41f6-8bce-859b7d6245f7"
      unitRef="usd">-982000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1616f745a37b421a8451f51495269b96_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfOS05LTEtMS02OTY1Mg_39002524-ae6f-4050-870d-16b63440731b"
      unitRef="usd">-435232000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4d497eb241564565aff73765a48fe320_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yNS9mcmFnOjMxNmZiYTg5NmM3NDRiMzY5M2IxNzZmZWM0ZDcwNjY0L3RhYmxlOjg2OGRmNTU0ODJmMzQ5NDc4MWMxZDkxMjkyYTYyMzBhL3RhYmxlcmFuZ2U6ODY4ZGY1NTQ4MmYzNDk0NzgxYzFkOTEyOTJhNjIzMGFfOS0xMS0xLTEtNjk2NTI_e3e7fe1b-4d41-4352-9a15-2c98267090f4"
      unitRef="usd">62823000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMy0xLTEtMS02OTY1Mg_a4924d46-8bd4-4184-8f89-bd2eea3a8aae"
      unitRef="usd">-10375000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMy0zLTEtMS02OTY1Mg_98dfb3c3-b1fa-4d7e-8028-64b99fd469c1"
      unitRef="usd">-11461000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNS0xLTEtMS02OTY1Mg_2e12822b-87ce-46ac-bc75-8198fe64cdfa"
      unitRef="usd">2125000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNS0zLTEtMS02OTY1Mg_8fd85596-e874-4e86-b011-1248bb9e58e7"
      unitRef="usd">1488000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNi0xLTEtMS02OTY1Mg_96854885-65a7-49f1-b221-b112a6c9214d"
      unitRef="usd">48000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNi0zLTEtMS02OTY1Mg_0ad25b42-e60c-44c9-82dc-916131af39a2"
      unitRef="usd">80000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNy0xLTEtMS02OTY1Mg_8b19a20c-988e-4754-98a2-63c1f1c0dcba"
      unitRef="usd">64000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNy0zLTEtMS02OTY1Mg_f6761497-5340-4268-a666-67f20c2e22be"
      unitRef="usd">67000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <npce:IncreaseDecreaseInNonCashInterestExpense
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfOC0xLTEtMS02OTY1Mg_5ee7030e-1eb9-480c-9c9a-0b4f75b1fc6c"
      unitRef="usd">234000</npce:IncreaseDecreaseInNonCashInterestExpense>
    <npce:IncreaseDecreaseInNonCashInterestExpense
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfOC0zLTEtMS02OTY1Mg_284b20db-4e42-4d52-a753-35d66ec06377"
      unitRef="usd">201000</npce:IncreaseDecreaseInNonCashInterestExpense>
    <us-gaap:PaidInKindInterest
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfOS0xLTEtMS02OTY1Mg_dc1fa72a-f204-483a-85ae-3d80637c8619"
      unitRef="usd">649000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfOS0zLTEtMS02OTY1Mg_92272bf8-d5d9-4f5d-8db5-0296e6ac86d1"
      unitRef="usd">0</us-gaap:PaidInKindInterest>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTAtMS0xLTEtNjk2NTI_b564b676-28c6-4b05-affd-f540603836d1"
      unitRef="usd">347000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTAtMy0xLTEtNjk2NTI_e541c01e-351f-4c5e-ad22-44b6acbe509f"
      unitRef="usd">672000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTEtMS0xLTEtNjk2NTI_d69993af-41bc-419f-a1eb-73c5f4f7889c"
      unitRef="usd">-817000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTEtMy0xLTEtNjk2NTI_2f2caf01-b17f-41a4-bdce-3da6faf7d1cf"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:InventoryWriteDown
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTItMS0xLTEtNjk2NTI_2bc82c2e-470f-4b90-ba2d-266362a68217"
      unitRef="usd">34000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTItMy0xLTEtNjk2NTI_4c190786-8f2c-44cd-8122-58a21eefc61a"
      unitRef="usd">82000</us-gaap:InventoryWriteDown>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTUtMS0xLTEtNjk2NTI_23d9542c-dda6-4af0-9032-6021c4600f95"
      unitRef="usd">1713000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTUtMy0xLTEtNjk2NTI_44dc326e-5e9e-48b6-8f6b-f09be4bc0947"
      unitRef="usd">1970000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTYtMS0xLTEtNjk2NTI_a61b34c3-988e-4986-b821-ac3cea25089f"
      unitRef="usd">1072000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTYtMy0xLTEtNjk2NTI_551b5166-c006-400b-b209-15d7e179c5cb"
      unitRef="usd">362000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTctMS0xLTEtNjk2NTI_f7a70944-640d-444d-a889-6e0276b76e2b"
      unitRef="usd">-514000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTctMy0xLTEtNjk2NTI_bb1975cd-9ea5-4521-b4ec-5b86fbf76ba5"
      unitRef="usd">-239000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTgtMS0xLTEtNjk2NTI_f3c331af-ee5b-4652-9c80-ecf5ac340bb9"
      unitRef="usd">-193000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTgtMy0xLTEtNjk2NTI_52eb8615-5d65-4126-acc3-dc07217b2fbc"
      unitRef="usd">820000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTktMS0xLTEtNjk2NTI_0c826607-d6ea-49a0-a75f-1c878bbf1b23"
      unitRef="usd">-834000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMTktMy0xLTEtNjk2NTI_763e96a7-1f1a-4aa5-9892-4a1f704bc4e1"
      unitRef="usd">-472000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMjAtMS0xLTEtNjk2NTI_b3902141-a3eb-4ef8-bb28-a5865946e33b"
      unitRef="usd">-343000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMjAtMy0xLTEtNjk2NTI_3bf3512f-b938-4e67-b280-a91e12622bc3"
      unitRef="usd">-777000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMjItMS0xLTEtNjk2NTI_6ac1d466-9013-4802-b907-387da34992e5"
      unitRef="usd">-9698000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMjItMy0xLTEtNjk2NTI_ecface9f-03c7-439c-9e45-a67490395daf"
      unitRef="usd">-11393000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMjQtMS0xLTEtNjk2NTI_1250ccc3-3cd6-41ca-9c2d-d20540b79a42"
      unitRef="usd">132000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMjQtMy0xLTEtNjk2NTI_e266d588-3156-4acb-9725-121dd108f8b9"
      unitRef="usd">306000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMjUtMS0xLTEtNjk2NTI_d65edd19-6597-41a2-8edb-5984602f48b1"
      unitRef="usd">10200000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMjUtMy0xLTEtNjk2NTI_36ba756e-6bfe-4509-af42-04115d1ba74a"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMjctMS0xLTEtNjk2NTI_0744c968-1cd2-44af-910d-da615ac1213b"
      unitRef="usd">10068000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMjctMy0xLTEtNjk2NTI_52be434a-02c9-453e-8ae7-744a486618ce"
      unitRef="usd">-306000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMjktMS0xLTEtNjk2NTI_b677caaa-7a78-4be1-a853-59b3e605d5cc"
      unitRef="usd">1000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMjktMy0xLTEtNjk2NTI_042a3f0b-8045-4b20-8a06-aec4b7580bc7"
      unitRef="usd">1000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMzAtMS0xLTEtNjk2NTI_ee567736-ac10-4c51-aa73-a308c3948208"
      unitRef="usd">146000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMzAtMy0xLTEtNjk2NTI_c26ada38-50de-4ed3-81a8-3d1beea293eb"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMzItMS0xLTEtNjk2NTI_fa293d56-ba01-4b99-a63e-33b303a69908"
      unitRef="usd">110000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMzItMy0xLTEtNjk2NTI_a154644c-d85c-47fd-8a8f-dbade56aed48"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMzQtMS0xLTEtNjk2NTI_b7af4930-6da3-45e9-a969-abebb534ec02"
      unitRef="usd">-255000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMzQtMy0xLTEtNjk2NTI_fedd080e-cfe1-42ea-ba8d-24562e6b23a6"
      unitRef="usd">1000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMzUtMS0xLTEtNjk2NTI_3dd14ac6-214c-4ab4-bb46-ad596975dfb2"
      unitRef="usd">115000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMzUtMy0xLTEtNjk2NTI_5228a26a-cf21-4a58-834b-42dbf237a753"
      unitRef="usd">-11698000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMzctMS0xLTEtNjk2NTI_f1a53a80-fe57-4356-9de6-ace88dbcfeee"
      unitRef="usd">6727000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i17c2f30808f842e79b03a1b5e2dc3a74_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMzctMy0xLTEtNjk2NTI_f2c36109-44b6-4889-b241-14bc662eeb7f"
      unitRef="usd">19309000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMzgtMS0xLTEtNjk2NTI_0e448521-41f2-41ba-bec8-9d4bdd239794"
      unitRef="usd">6842000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4d497eb241564565aff73765a48fe320_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfMzgtMy0xLTEtNjk2NTI_9dc37fa0-823c-40a2-b96a-15f39dd83a2b"
      unitRef="usd">7611000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNDAtMS0xLTEtNjk2NTI_1cbb5718-1a56-4152-b39f-1ede5dcb2c29"
      unitRef="usd">6720000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4d497eb241564565aff73765a48fe320_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNDAtMy0xLTEtNjk2NTI_7cbcf31c-54ec-42ee-ac02-6eec0f82a345"
      unitRef="usd">7489000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNDEtMS0xLTEtNjk2NTI_c5048dfb-c048-48f8-aaef-35c6dfededab"
      unitRef="usd">122000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i4d497eb241564565aff73765a48fe320_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNDEtMy0xLTEtNjk2NTI_b2a1dd18-9c3a-4981-ab95-1f3d57d51321"
      unitRef="usd">122000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNDItMS0xLTEtNjk2NTI_92f2503f-3c22-4723-80cd-588816a6ef32"
      unitRef="usd">6842000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4d497eb241564565aff73765a48fe320_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNDItMy0xLTEtNjk2NTI_35c8162e-bb65-412e-84e3-808afec5821b"
      unitRef="usd">7611000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNDUtMS0xLTEtNjk2NTI_497a08b2-2725-4be9-9246-3cfc4ef036d7"
      unitRef="usd">1018000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNDUtMy0xLTEtNjk2NTI_179f63d7-3ca6-42a8-baa0-039456d7042b"
      unitRef="usd">1563000</us-gaap:InterestPaidNet>
    <npce:IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNDgtMS0xLTEtNjk2NTI_c4079a16-7f6f-49e8-a1b3-99863414520e"
      unitRef="usd">0</npce:IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions>
    <npce:IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNDgtMy0xLTEtNjk2NTI_bf8ba494-a422-4764-942b-cd57ab473881"
      unitRef="usd">-2000</npce:IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNDktMS0xLTEtNjk2NTI_f1402a39-1086-4b6c-82ce-eb1d55a632e2"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8yOC9mcmFnOmQzMGFlODEyMGQ4ZjQ2YWU5ODhjZDk3MjQwYTZiNTJkL3RhYmxlOmZkNDk0M2E4MTY5OTRmN2RhMWNkMDkxMGM4ZTU4YjZiL3RhYmxlcmFuZ2U6ZmQ0OTQzYTgxNjk5NGY3ZGExY2QwOTEwYzhlNThiNmJfNDktMy0xLTEtNjk2NTI_8fa8e32c-cb36-4e3b-be01-2941baed61d3"
      unitRef="usd">31000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfNTE0MA_f498c945-73cd-4bba-86ac-f51706b739e0">The Company&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NeuroPace, Inc., or the Company, was incorporated in the state of Delaware on November 19, 1997. The Company is a commercial-stage medical device company that has developed the RNS System, the only commercially available brain-responsive neuromodulation system designed for treating medically refractory focal epilepsy by delivering personalized, real-time treatment at the seizure source. The Company began commercializing its products in the United States in 2014.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Initial Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 21, 2021, the Company&#x2019;s registration statement on Form S-1 (File No. 333-254663) relating to its initial public offering, or IPO, of common stock became effective. The IPO closed on April 26, 2021, at which time the Company issued 6,900,000 shares of its common stock at a price of $17.00 per share, which included the issuance of shares in connection with the exercise by the underwriters of their option to purchase up to 900,000 additional shares. The Company received an aggregate of $117.3 million in gross proceeds, before underwriting discounts and commissions and offering costs, and approximately $105.5 million in net proceeds after deducting $8.2&#160;million in underwriting discounts and commissions and $3.6&#160;million in offering costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;At-the-Market Equity Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, the Company filed a Registration Statement on Form S-3, or Shelf, with the Securities and Exchange Commission in relation to the registration of common stock, preferred stock, debt securities, warrants or any combination thereof for up to an aggregate of $150.0&#160;million, of which $50.0&#160;million may be issued and sold pursuant to an at-the-market, or ATM, offering program for sales of the Company&#x2019;s common stock under a sales agreement, or Sales Agreement, with SVB Securities LLC, or SVB. The Company agreed to pay SVB up to 3.0% of the gross proceeds of sales of common stock made through the Sales Agreement. The Company&#x2019;s common stock would be sold at prevailing market prices at the time of the sale and, as a result, prices may vary. The Company has not issued or sold any securities pursuant to the Shelf or ATM offering program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred operating losses and negative cash flows from operations since its inception and has an accumulated deficit of $481.2 million as of March&#160;31, 2023. For the three months ended March&#160;31, 2023 and 2022, the Company used $9.7 million and $11.4 million of cash, respectively, in its operating activities. As of March&#160;31, 2023, the Company had cash, cash equivalents and short-term investments of $67.6 million. Historically, the Company has funded its operations principally through the sales of its products, issuance of redeemable convertible preferred stock and debt financing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s condensed financial statements have been prepared on the basis of the Company continuing as a going concern for the next 12 months. Management believes that the Company&#x2019;s cash, cash equivalents and short-term investments will allow the Company to continue its planned operations for at least the next 12 months from the date of the issuance of these unaudited interim condensed financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Term Loan described in Note 6, the Company will need to be in compliance with a minimum annual net revenue covenant determined in accordance with generally accepted accounting principles of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$45.0 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the year ended December 31, 2023, and maintain a minimum cash and cash equivalents balance of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$5.0 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. If the Company cannot generate sufficient revenue in the future, the Company may not be in compliance with the annual net revenue covenant and the lender may call the debt resulting in the Company immediately needing additional capital, and resulting in a going concern. The Company&#x2019;s ability to raise additional capital may be adversely impacted by global economic conditions and the recent disruptions to, and volatility in, the financial markets in the United States and worldwide. If the Company is unable to raise capital when needed, it will need to delay, limit, reduce or terminate planned commercialization or product development activities in order to reduce costs. As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company was in compliance with all covenants of the Term Loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The global spread of the COVID-19 pandemic, including the different COVID-19 variants and measures introduced by local, state and federal governments to contain the pandemic and mitigate its public health effects, &lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;have significantly impacted the global economy and negatively impacted our business. Beginning in March 2020, the Company&#x2019;s net sales were negatively impacted by the COVID-19 pandemic as hospitals delayed or canceled elective procedures. The decrease in hospital admission rates and elective surgeries reduced both the number of patients being evaluated for treatment with and demand for elective procedures using the Company's RNS System. By the second half of 2022, the impact of the pandemic on the Company&#x2019;s revenue had diminished. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;However, the future impact of the COVID-19 pandemic on the Company&#x2019;s business, financial condition and results of operations is dependent on future developments, including the potential emergence of new COVID-19 variants and spikes in COVID-19 cases, which &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;remain highly uncertain and cannot be predicted.&lt;/span&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ic31468e5e435455380b814e3c2061589_D20210426-20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfNzQ4_d23ff48b-4164-4dc7-85e7-ce23ce4c7a70"
      unitRef="shares">6900000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="if0b1b62330d2427a92e83025c46122d5_I20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfNzky_6de51c61-addd-482c-9764-f64db5dec0fe"
      unitRef="usdPerShare">17.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i6f49f5b3c47d4ba1ac4f833941af6ad6_D20210426-20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfOTMw_f65482b5-0c94-4945-a6b0-ba2483089ce0"
      unitRef="shares">900000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="ic31468e5e435455380b814e3c2061589_D20210426-20210426"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfOTg5_1b3fb74c-f4ff-4507-a3a1-b9e98e0ed327"
      unitRef="usd">117300000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ic31468e5e435455380b814e3c2061589_D20210426-20210426"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfMTA5NQ_2c66ab3f-9433-404c-af15-941e7a84a1a9"
      unitRef="usd">105500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <npce:SaleOfStockUnderwritingDiscounts
      contextRef="ic31468e5e435455380b814e3c2061589_D20210426-20210426"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfMTEzMA_9d8f2545-c971-46ec-9af6-0f5f64b3869a"
      unitRef="usd">8200000</npce:SaleOfStockUnderwritingDiscounts>
    <npce:SaleOfStockOfferingCosts
      contextRef="ic31468e5e435455380b814e3c2061589_D20210426-20210426"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfMTE3OQ_389ffa0c-4628-421e-bd28-c3c49424df85"
      unitRef="usd">3600000</npce:SaleOfStockOfferingCosts>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
      contextRef="ibd6ab3a83420410da0927243af8d2e90_D20221101-20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfNTQ5NzU1ODIwMzgz_e3c576c8-cf57-4c25-b476-601ae63ffe0a"
      unitRef="usd">150000000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="ibd6ab3a83420410da0927243af8d2e90_D20221101-20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfNTQ5NzU1ODIwNDAy_140c3312-1a29-4d45-a474-5a3b48c72f0d"
      unitRef="usd">50000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <npce:PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement
      contextRef="ibd6ab3a83420410da0927243af8d2e90_D20221101-20221130"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfMjc0ODc3OTA3OTEzMA_d82585a2-9255-4ec5-a562-085859665028"
      unitRef="number">0.030</npce:PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="id1b89218f85e4970ba94327f3911df2b_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfMjc0ODc3OTA3OTEzNQ_60526a88-96f0-408e-91ef-03b63cca4a6f"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfMjExNw_723920d0-aff7-48c1-8b61-0100eff3710b"
      unitRef="usd">-481200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfMjE4NA_2b18bef7-5d4d-49e8-8010-b39c8aed6643"
      unitRef="usd">-9700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfMjE5MQ_9ba568d4-e00e-45e9-b5b5-12164193ae82"
      unitRef="usd">-11400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfMjMyNQ_cc975419-9f1c-461b-b6c4-ac3e1fcb34bf"
      unitRef="usd">67600000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <npce:DebtInstrumentCovenantMinimumAnnualNetRevenue
      contextRef="i34fc98c3b9124df39be5fbc449566961_D20230101-20231231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfMzI5Mw_7c0c256d-df67-43da-85d8-10bbf2b440a2"
      unitRef="usd">45000000</npce:DebtInstrumentCovenantMinimumAnnualNetRevenue>
    <npce:DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO
      contextRef="i2fb4e476763541a694ffb3eb2be6c4dd_I20231231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNC9mcmFnOjQ0MmQwNjMxYTVmMTQxMjk4MTk5ZmMwNzM4OTc4OWNjL3RleHRyZWdpb246NDQyZDA2MzFhNWYxNDEyOTgxOTlmYzA3Mzg5Nzg5Y2NfMzM5Mw_a89631da-c8be-4f1f-b2e9-554d663462cc"
      unitRef="usd">5000000</npce:DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTcyMjM_d3b19c4a-4679-4d8f-8bdb-6094bcbf02ce">Summary of Significant Accounting Policies&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited interim condensed financial statements have been prepared in conformity with generally accepted accounting principles in the United States, or GAAP, as defined by the Financial Accounting Standards Board, or the FASB.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed balance sheet as of December 31, 2022 was derived from the Company&#x2019;s audited financial statements, but does not include all disclosures required by GAAP. The accompanying unaudited condensed financial statements as of March 31, 2023 and for the three months ended March 31, 2023 and 2022, have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC, for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. Accordingly, these financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2022 and notes thereto, which are included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the SEC on March 2, 2023. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company&#x2019;s condensed financial position as of March 31, 2023 and condensed results of operations and condensed cash flows for the three months ended March 31, 2023 and 2022 have been made. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of unaudited interim condensed financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. The Company uses significant judgment when making estimates related to the valuation of deferred tax assets and related valuation allowances and provision for excess and obsolete inventories. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Carrying amounts of certain of the Company&#x2019;s financial instruments, including cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value because of the short-term nature of these instruments. The Company has a short-term investment in a fixed income mutual fund, which is classified as equity security and carried at fair value based on quoted market prices. Changes in the fair value of the short-term investment are recorded in income or loss. The Company believes that its borrowings bear interest at the prevailing market rates for instruments with similar characteristics; accordingly, the carrying value of this instrument approximates its fair value. The Company determines the fair value of financial and non-financial assets and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;liabilities using the fair value hierarchy which establishes three levels of inputs that may be used to measure fair value (see Note 3).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk, and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, short-term investments and accounts receivable to the extent of the amounts recorded on the balance sheets. The Company&#x2019;s cash is invested in major financial institutions in the United States. Deposits in these financial institutions may exceed federally insured limits, and the Company is exposed to credit risk on deposits in the event of default of the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation. The Company&#x2019;s cash equivalents are invested in money market funds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts receivable are due from a variety of health care organizations in the United States. For the three months ended March&#160;31, 2023 and 2022, there were no customers that represented 10% or more of revenue. As of March&#160;31, 2023 and December&#160;31, 2022, no customer represented 10% or more of the Company&#x2019;s accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to certain risks, including that its devices may not be approved or cleared or continue to be approved or cleared for marketing by governmental authorities or be successfully marketed for expanded indications. There can be no assurance that the Company&#x2019;s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and speed and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence on healthcare providers to prescribe initial implants and replacements, dependence upon third-party payors to provide adequate coverage and reimbursement, dependence on key personnel, single-source suppliers and vendors in connection with the manufacture of its products, concentration of CECs and epileptologists, obtaining, maintaining, protecting, enforcing, and defending intellectual property rights and proprietary technology, product liability claims, legal proceedings, and compliance with government regulations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s medical devices require approvals or clearances from the U.S. Food and Drug Administration, or the FDA, or international regulatory agencies. In addition, in order to continue the Company&#x2019;s operations, compliance with various federal and state laws is required. If approvals or clearances were withdrawn by the FDA for the Company&#x2019;s current products or if such approvals or clearances were denied or delayed for future products, product updates, or expanded indications for use, it would have a material adverse impact on the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company makes estimates on the collectability of customer accounts based primarily on analysis of historical trends and experience, the age of the receivable and changes in customers&#x2019; financial condition. The Company uses its judgment, based on the best available facts and circumstances, and records an allowance against amounts due to reduce the receivable to the amount that is expected to be collected. The Company determined that no allowance was required as of March&#160;31, 2023 and December 31, 2022. To date, the Company has not experienced any credit-related losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Government Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company was awarded a grant by the National Institutes of Health, or NIH, to support research of thalamocortical responsive neurostimulation for the treatment of Lennox-Gastaut Syndrome, a type of epilepsy. The award was issued for a five-year period and has a total budget of over $9.3&#160;million, which includes approximately $5.5&#160;million in funding for subawards to third party academic epilepsy centers that are collaborating on the study and are subinvestigators on the study funded by NIH. The subawardees are determined by NIH. The Company&#x2019;s responsibility for the subawards is to submit the funding requests on behalf of the subawardees. The funding of subawards does not have any impact on the Company&#x2019;s condensed financial statements. Initially funding was approved for the first year beginning June 1, 2021 and provides for reimbursement of qualified direct and indirect expenses in the amount of $0.8&#160;million, including $0.4&#160;million for subawards. Approvals of funds for years &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;two through five are subject to the completion of certain milestones. On July 30, 2022, the Company received funding approval for year two in the amount of $2.6&#160;million, which includes $1.6&#160;million for subawards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For funds received under the NIH funding agreement, the Company recognizes a reduction in research and development expenses in an amount equal to the qualifying expenses incurred in each period up to the amount awarded by the NIH. Qualifying expenses incurred by the Company in advance of funding by the NIH are recorded within prepaid expenses and other current assets on the balance sheets. Through March&#160;31, 2023, $1.0&#160;million of qualifying expenses have been incurred and funded by the NIH related to the first and second year funding. As of March&#160;31, 2023, the Company recorded prepaid expenses and other current assets of $0.1&#160;million related to the second year funding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Loss per Share Attributable to Common Stockholders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, stock options, common stock subject to repurchase related to early exercise of stock options, and restricted stock units are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities. The Company considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of the shares issued upon early exercise of stock options subject to repurchase do not have a contractual obligation to share in the Company&#x2019;s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends existing guidance on the impairment of financial assets and adds an impairment model that is based on expected losses rather than incurred losses and requires an entity to recognize as an allowance its estimate of expected credit losses for its financial assets. An entity will apply this guidance through a cumulative-effect adjustment to retained earnings upon adoption (a modified-retrospective approach) while a prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. For public business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, adoption is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. For SEC filers that are eligible to be smaller reporting companies and for all other entities, this ASU is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company adopted this ASU effective January 1, 2023. The adoption of this ASU did not have a material effect on the Company&#x2019;s financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTcyMzA_04ffeffe-62a4-4387-a3b4-b63c3c9120fb">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited interim condensed financial statements have been prepared in conformity with generally accepted accounting principles in the United States, or GAAP, as defined by the Financial Accounting Standards Board, or the FASB.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed balance sheet as of December 31, 2022 was derived from the Company&#x2019;s audited financial statements, but does not include all disclosures required by GAAP. The accompanying unaudited condensed financial statements as of March 31, 2023 and for the three months ended March 31, 2023 and 2022, have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC, for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. Accordingly, these financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2022 and notes thereto, which are included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the SEC on March 2, 2023. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company&#x2019;s condensed financial position as of March 31, 2023 and condensed results of operations and condensed cash flows for the three months ended March 31, 2023 and 2022 have been made. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTcyMjI_d55a7243-d4be-4296-9d0f-b2576173bdce">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of unaudited interim condensed financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. The Company uses significant judgment when making estimates related to the valuation of deferred tax assets and related valuation allowances and provision for excess and obsolete inventories. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTcyMzE_b3bc1aaa-4669-40cb-9320-043a840423d5">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Carrying amounts of certain of the Company&#x2019;s financial instruments, including cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value because of the short-term nature of these instruments. The Company has a short-term investment in a fixed income mutual fund, which is classified as equity security and carried at fair value based on quoted market prices. Changes in the fair value of the short-term investment are recorded in income or loss. The Company believes that its borrowings bear interest at the prevailing market rates for instruments with similar characteristics; accordingly, the carrying value of this instrument approximates its fair value. The Company determines the fair value of financial and non-financial assets and &lt;/span&gt;&lt;/div&gt;liabilities using the fair value hierarchy which establishes three levels of inputs that may be used to measure fair value (see Note 3).&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.77pt"&gt;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.77pt"&gt;Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.77pt"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the market approach to measure fair value for its financial assets and liabilities. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTcyMzI_57d452b5-2930-4298-94da-ca7e9df65103">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk, and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, short-term investments and accounts receivable to the extent of the amounts recorded on the balance sheets. The Company&#x2019;s cash is invested in major financial institutions in the United States. Deposits in these financial institutions may exceed federally insured limits, and the Company is exposed to credit risk on deposits in the event of default of the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation. The Company&#x2019;s cash equivalents are invested in money market funds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts receivable are due from a variety of health care organizations in the United States. For the three months ended March&#160;31, 2023 and 2022, there were no customers that represented 10% or more of revenue. As of March&#160;31, 2023 and December&#160;31, 2022, no customer represented 10% or more of the Company&#x2019;s accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to certain risks, including that its devices may not be approved or cleared or continue to be approved or cleared for marketing by governmental authorities or be successfully marketed for expanded indications. There can be no assurance that the Company&#x2019;s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and speed and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence on healthcare providers to prescribe initial implants and replacements, dependence upon third-party payors to provide adequate coverage and reimbursement, dependence on key personnel, single-source suppliers and vendors in connection with the manufacture of its products, concentration of CECs and epileptologists, obtaining, maintaining, protecting, enforcing, and defending intellectual property rights and proprietary technology, product liability claims, legal proceedings, and compliance with government regulations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s medical devices require approvals or clearances from the U.S. Food and Drug Administration, or the FDA, or international regulatory agencies. In addition, in order to continue the Company&#x2019;s operations, compliance with various federal and state laws is required. If approvals or clearances were withdrawn by the FDA for the Company&#x2019;s current products or if such approvals or clearances were denied or delayed for future products, product updates, or expanded indications for use, it would have a material adverse impact on the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMjc0ODc3OTA5NzYxNw_48d99562-0202-4373-a572-dad8dba686ee">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company makes estimates on the collectability of customer accounts based primarily on analysis of historical trends and experience, the age of the receivable and changes in customers&#x2019; financial condition. The Company uses its judgment, based on the best available facts and circumstances, and records an allowance against amounts due to reduce the receivable to the amount that is expected to be collected. The Company determined that no allowance was required as of March&#160;31, 2023 and December 31, 2022. To date, the Company has not experienced any credit-related losses.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTcyMjc_2b77f7a8-1dad-4624-aa8e-259c545e90f4">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Government Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company was awarded a grant by the National Institutes of Health, or NIH, to support research of thalamocortical responsive neurostimulation for the treatment of Lennox-Gastaut Syndrome, a type of epilepsy. The award was issued for a five-year period and has a total budget of over $9.3&#160;million, which includes approximately $5.5&#160;million in funding for subawards to third party academic epilepsy centers that are collaborating on the study and are subinvestigators on the study funded by NIH. The subawardees are determined by NIH. The Company&#x2019;s responsibility for the subawards is to submit the funding requests on behalf of the subawardees. The funding of subawards does not have any impact on the Company&#x2019;s condensed financial statements. Initially funding was approved for the first year beginning June 1, 2021 and provides for reimbursement of qualified direct and indirect expenses in the amount of $0.8&#160;million, including $0.4&#160;million for subawards. Approvals of funds for years &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;two through five are subject to the completion of certain milestones. On July 30, 2022, the Company received funding approval for year two in the amount of $2.6&#160;million, which includes $1.6&#160;million for subawards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For funds received under the NIH funding agreement, the Company recognizes a reduction in research and development expenses in an amount equal to the qualifying expenses incurred in each period up to the amount awarded by the NIH. Qualifying expenses incurred by the Company in advance of funding by the NIH are recorded within prepaid expenses and other current assets on the balance sheets. Through March&#160;31, 2023, $1.0&#160;million of qualifying expenses have been incurred and funded by the NIH related to the first and second year funding. As of March&#160;31, 2023, the Company recorded prepaid expenses and other current assets of $0.1&#160;million related to the second year funding.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <npce:ResearchAndDevelopmentArrangementWithFederalGovernmentTerm
      contextRef="iea9e5bc642294c36a2e9ce408258fa44_D20210501-20210531"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTcyMjQ_4cb5a518-aa10-4208-8cf0-29fe7128c6ce">P5Y</npce:ResearchAndDevelopmentArrangementWithFederalGovernmentTerm>
    <npce:ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost
      contextRef="iea9e5bc642294c36a2e9ce408258fa44_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfOTk1Mw_480dbf6c-bd51-4870-b169-66f76959c882"
      unitRef="usd">9300000</npce:ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost>
    <npce:ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards
      contextRef="iea9e5bc642294c36a2e9ce408258fa44_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfOTk4Ng_34f3d941-438a-421a-b4e4-b1e74e4946f2"
      unitRef="usd">5500000</npce:ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards>
    <npce:ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1
      contextRef="ie20e4646b6c64bd484f8b50c7fcb7a1e_D20210601-20210601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTA1NTY_ecf0f39e-d0f4-4ce3-9e18-26eafcedb2e5"
      unitRef="usd">800000</npce:ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1>
    <npce:ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1
      contextRef="ie20e4646b6c64bd484f8b50c7fcb7a1e_D20210601-20210601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTA1NzA_8256c804-3132-44e7-8604-e2e5abc6dbc8"
      unitRef="usd">400000</npce:ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1>
    <npce:ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2
      contextRef="id750435b22204579ab914565baeecdcc_D20220730-20220730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTA3NzM_2df62113-9288-4875-932b-28ad18df14e6"
      unitRef="usd">2600000</npce:ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2>
    <npce:ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2
      contextRef="id750435b22204579ab914565baeecdcc_D20220730-20220730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTA3OTI_ef136b26-a85d-4cf7-99db-b4cd8f1fa232"
      unitRef="usd">1600000</npce:ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i63da6b904e2e4e799b8f63827d7dd2ec_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTEyMTU_23821f73-d8f9-40dc-beb7-ae84d54737f1"
      unitRef="usd">1000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i8548ff80a4ad42a7bc8f521cc07045af_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTE0MTQ_54b70142-4228-45f5-b2ad-4d96303772cc"
      unitRef="usd">100000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTcyMjg_a365b108-f7fd-44a4-b806-672612f536f3">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Loss per Share Attributable to Common Stockholders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, stock options, common stock subject to repurchase related to early exercise of stock options, and restricted stock units are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities. The Company considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of the shares issued upon early exercise of stock options subject to repurchase do not have a contractual obligation to share in the Company&#x2019;s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV8zNy9mcmFnOjFlYmUxMDUwMmFlNTQ3YmRhYzQwOWYyOWZmYWMwZWNkL3RleHRyZWdpb246MWViZTEwNTAyYWU1NDdiZGFjNDA5ZjI5ZmZhYzBlY2RfMTcyMjk_b1d5f148-de63-43a1-8850-7e936ca0f3f7">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends existing guidance on the impairment of financial assets and adds an impairment model that is based on expected losses rather than incurred losses and requires an entity to recognize as an allowance its estimate of expected credit losses for its financial assets. An entity will apply this guidance through a cumulative-effect adjustment to retained earnings upon adoption (a modified-retrospective approach) while a prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. For public business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, adoption is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. For SEC filers that are eligible to be smaller reporting companies and for all other entities, this ASU is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company adopted this ASU effective January 1, 2023. The adoption of this ASU did not have a material effect on the Company&#x2019;s financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RleHRyZWdpb246MGM2NTE4NDAyOGU1NGQzYmJmYmRkNTliNmQ0ZDJjNjVfMjk3Ng_a2c03ed4-b52c-4f0f-8ef6-d10fb13e63c4">Fair Value Measurements&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.77pt"&gt;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.77pt"&gt;Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.77pt"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the market approach to measure fair value for its financial assets and liabilities. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the&#160;Company&#x2019;s financial assets (cash equivalents and marketable securities) at fair value as of March&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basis for Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 2) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income mutual fund, included in short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the&#160;Company&#x2019;s financial assets (cash equivalents and marketable securities) at fair value as of December&#160;31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basis for Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 2) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income mutual fund, included in short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no liabilities measured at fair value on a recurring and non-recurring basis as of March&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The money market funds are highly liquid and primarily invest in short-term fixed income securities issued by the U.S. government and U.S. government agencies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s available-for-sale investment comprises a short-term investment in a fixed income mutual fund, which primarily invests in debt securities issued by the U.S. government and U.S. government agencies and corporate bonds and notes. Interest income from its short-term investment is recorded in interest income.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of December 31, 2022, the Company&#x2019;s short-term investment had a fair value of $70.8&#160;million, a cost basis of $71.9&#160;million, and an unrealized loss of $1.1&#160;million, which was recorded in accumulated other comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; During the three months ended March 31, 2023, the Company recognized $0.4&#160;million in unrealized gains from its short-term investment. As of March 31, 2023, the Company&#x2019;s short-term investment had a cumulative unrealized net loss of $0.7&#160;million, which included an adjustment of $1.1&#160;million unrealized loss recorded &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in other income (expense), net in the three months ended March 31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The adjustment was not material to any previously issued financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RleHRyZWdpb246MGM2NTE4NDAyOGU1NGQzYmJmYmRkNTliNmQ0ZDJjNjVfMjk3Mw_24e22aa3-d825-4fb6-9da4-68757bb64590">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the&#160;Company&#x2019;s financial assets (cash equivalents and marketable securities) at fair value as of March&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basis for Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 2) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income mutual fund, included in short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the&#160;Company&#x2019;s financial assets (cash equivalents and marketable securities) at fair value as of December&#160;31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basis for Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 2) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income mutual fund, included in short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjdjZGVkMjQyYzBjMzQ3MGY4MWE2MTg1YzNjMzc5MWNiL3RhYmxlcmFuZ2U6N2NkZWQyNDJjMGMzNDcwZjgxYTYxODVjM2MzNzkxY2JfMy0xLTEtMS02OTY1Mg_56f2ef12-f14e-4bd1-b3a7-04ae303552bd"
      unitRef="usd">6801000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7320c8ff5d5a4db38fdb65660cdbc124_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjdjZGVkMjQyYzBjMzQ3MGY4MWE2MTg1YzNjMzc5MWNiL3RhYmxlcmFuZ2U6N2NkZWQyNDJjMGMzNDcwZjgxYTYxODVjM2MzNzkxY2JfMy0zLTEtMS02OTY1Mg_0cdd7444-49a2-4aa1-bbe9-e3c3db15caaf"
      unitRef="usd">6801000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9b3e368885a4412aa08f736e786122f7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjdjZGVkMjQyYzBjMzQ3MGY4MWE2MTg1YzNjMzc5MWNiL3RhYmxlcmFuZ2U6N2NkZWQyNDJjMGMzNDcwZjgxYTYxODVjM2MzNzkxY2JfMy01LTEtMS02OTY1Mg_a9a5af3c-4017-4ff6-8285-5756aff5bf83"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5504ee5ca136427291328b9cdbfd9ac2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjdjZGVkMjQyYzBjMzQ3MGY4MWE2MTg1YzNjMzc5MWNiL3RhYmxlcmFuZ2U6N2NkZWQyNDJjMGMzNDcwZjgxYTYxODVjM2MzNzkxY2JfMy03LTEtMS02OTY1Mg_5091123d-88a8-42fd-84d9-8e3136f331bf"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjdjZGVkMjQyYzBjMzQ3MGY4MWE2MTg1YzNjMzc5MWNiL3RhYmxlcmFuZ2U6N2NkZWQyNDJjMGMzNDcwZjgxYTYxODVjM2MzNzkxY2JfNC0xLTEtMS02OTY1Mg_cf59c0a7-b9b4-462b-8515-f71adf506de8"
      unitRef="usd">60895000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7320c8ff5d5a4db38fdb65660cdbc124_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjdjZGVkMjQyYzBjMzQ3MGY4MWE2MTg1YzNjMzc5MWNiL3RhYmxlcmFuZ2U6N2NkZWQyNDJjMGMzNDcwZjgxYTYxODVjM2MzNzkxY2JfNC0zLTEtMS02OTY1Mg_eb08c8ed-32f5-4d0f-a6a4-e917ae27140c"
      unitRef="usd">60895000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i9b3e368885a4412aa08f736e786122f7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjdjZGVkMjQyYzBjMzQ3MGY4MWE2MTg1YzNjMzc5MWNiL3RhYmxlcmFuZ2U6N2NkZWQyNDJjMGMzNDcwZjgxYTYxODVjM2MzNzkxY2JfNC01LTEtMS02OTY1Mg_d7a134c6-ae80-45f4-b7ee-58d9d9212b70"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i5504ee5ca136427291328b9cdbfd9ac2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjdjZGVkMjQyYzBjMzQ3MGY4MWE2MTg1YzNjMzc5MWNiL3RhYmxlcmFuZ2U6N2NkZWQyNDJjMGMzNDcwZjgxYTYxODVjM2MzNzkxY2JfNC03LTEtMS02OTY1Mg_79b10691-c5ca-4324-8b3c-2aad91529bdb"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjdjZGVkMjQyYzBjMzQ3MGY4MWE2MTg1YzNjMzc5MWNiL3RhYmxlcmFuZ2U6N2NkZWQyNDJjMGMzNDcwZjgxYTYxODVjM2MzNzkxY2JfNS0xLTEtMS02OTY1Mg_88508f43-2709-4b10-9b0b-afe5d24a71bf"
      unitRef="usd">67696000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7320c8ff5d5a4db38fdb65660cdbc124_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjdjZGVkMjQyYzBjMzQ3MGY4MWE2MTg1YzNjMzc5MWNiL3RhYmxlcmFuZ2U6N2NkZWQyNDJjMGMzNDcwZjgxYTYxODVjM2MzNzkxY2JfNS0zLTEtMS02OTY1Mg_4fb860bc-23d2-4aab-b487-587af7c67a83"
      unitRef="usd">67696000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9b3e368885a4412aa08f736e786122f7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjdjZGVkMjQyYzBjMzQ3MGY4MWE2MTg1YzNjMzc5MWNiL3RhYmxlcmFuZ2U6N2NkZWQyNDJjMGMzNDcwZjgxYTYxODVjM2MzNzkxY2JfNS01LTEtMS02OTY1Mg_4dd7292e-2f7e-4ee7-8c17-19f00a6feb93"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5504ee5ca136427291328b9cdbfd9ac2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjdjZGVkMjQyYzBjMzQ3MGY4MWE2MTg1YzNjMzc5MWNiL3RhYmxlcmFuZ2U6N2NkZWQyNDJjMGMzNDcwZjgxYTYxODVjM2MzNzkxY2JfNS03LTEtMS02OTY1Mg_2c16325c-d391-4349-8555-7129d561a8ce"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjA2MDc5MWUzNWQ2MDRiOGNiNGVlYjg1NGVhMDZkODA1L3RhYmxlcmFuZ2U6MDYwNzkxZTM1ZDYwNGI4Y2I0ZWViODU0ZWEwNmQ4MDVfMy0xLTEtMS02OTY1Mg_9597ac2e-62fc-4c04-bb6f-3303ceae44c1"
      unitRef="usd">6075000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i089087e88c2f4e4594e265ef1eac9189_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjA2MDc5MWUzNWQ2MDRiOGNiNGVlYjg1NGVhMDZkODA1L3RhYmxlcmFuZ2U6MDYwNzkxZTM1ZDYwNGI4Y2I0ZWViODU0ZWEwNmQ4MDVfMy0zLTEtMS02OTY1Mg_63d8358b-f0d0-4d43-9c60-4d18f18ce4f6"
      unitRef="usd">6075000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i733ca2b6b6c1414dac92793e9704c260_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjA2MDc5MWUzNWQ2MDRiOGNiNGVlYjg1NGVhMDZkODA1L3RhYmxlcmFuZ2U6MDYwNzkxZTM1ZDYwNGI4Y2I0ZWViODU0ZWEwNmQ4MDVfMy01LTEtMS02OTY1Mg_90a7005c-1945-48c7-b4ca-b4706f74af2f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7b0dc4d765154685b20215349253bb6d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjA2MDc5MWUzNWQ2MDRiOGNiNGVlYjg1NGVhMDZkODA1L3RhYmxlcmFuZ2U6MDYwNzkxZTM1ZDYwNGI4Y2I0ZWViODU0ZWEwNmQ4MDVfMy03LTEtMS02OTY1Mg_d751fd92-2b4d-4959-9077-89a42f80b5ed"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjA2MDc5MWUzNWQ2MDRiOGNiNGVlYjg1NGVhMDZkODA1L3RhYmxlcmFuZ2U6MDYwNzkxZTM1ZDYwNGI4Y2I0ZWViODU0ZWEwNmQ4MDVfNC0xLTEtMS02OTY1Mg_52dc218c-2854-4ee2-aa90-32b6f65d4886"
      unitRef="usd">70804000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i089087e88c2f4e4594e265ef1eac9189_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjA2MDc5MWUzNWQ2MDRiOGNiNGVlYjg1NGVhMDZkODA1L3RhYmxlcmFuZ2U6MDYwNzkxZTM1ZDYwNGI4Y2I0ZWViODU0ZWEwNmQ4MDVfNC0zLTEtMS02OTY1Mg_cfc848b2-aeaa-419f-9c63-56da2cbfa03b"
      unitRef="usd">70804000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i733ca2b6b6c1414dac92793e9704c260_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjA2MDc5MWUzNWQ2MDRiOGNiNGVlYjg1NGVhMDZkODA1L3RhYmxlcmFuZ2U6MDYwNzkxZTM1ZDYwNGI4Y2I0ZWViODU0ZWEwNmQ4MDVfNC01LTEtMS02OTY1Mg_6489949f-8b64-42fe-ab03-b73558d7e5ab"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7b0dc4d765154685b20215349253bb6d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjA2MDc5MWUzNWQ2MDRiOGNiNGVlYjg1NGVhMDZkODA1L3RhYmxlcmFuZ2U6MDYwNzkxZTM1ZDYwNGI4Y2I0ZWViODU0ZWEwNmQ4MDVfNC03LTEtMS02OTY1Mg_d7d86762-b23a-4379-b2e8-5d8bc331c7ee"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjA2MDc5MWUzNWQ2MDRiOGNiNGVlYjg1NGVhMDZkODA1L3RhYmxlcmFuZ2U6MDYwNzkxZTM1ZDYwNGI4Y2I0ZWViODU0ZWEwNmQ4MDVfNS0xLTEtMS02OTY1Mg_58fe88d2-b357-4f74-bf36-7559fbfec488"
      unitRef="usd">76879000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i089087e88c2f4e4594e265ef1eac9189_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjA2MDc5MWUzNWQ2MDRiOGNiNGVlYjg1NGVhMDZkODA1L3RhYmxlcmFuZ2U6MDYwNzkxZTM1ZDYwNGI4Y2I0ZWViODU0ZWEwNmQ4MDVfNS0zLTEtMS02OTY1Mg_ac6e7067-e23e-4644-87eb-5159aa38241a"
      unitRef="usd">76879000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i733ca2b6b6c1414dac92793e9704c260_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjA2MDc5MWUzNWQ2MDRiOGNiNGVlYjg1NGVhMDZkODA1L3RhYmxlcmFuZ2U6MDYwNzkxZTM1ZDYwNGI4Y2I0ZWViODU0ZWEwNmQ4MDVfNS01LTEtMS02OTY1Mg_0fe92432-9d8d-4582-b280-7c32286e3d75"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7b0dc4d765154685b20215349253bb6d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RhYmxlOjA2MDc5MWUzNWQ2MDRiOGNiNGVlYjg1NGVhMDZkODA1L3RhYmxlcmFuZ2U6MDYwNzkxZTM1ZDYwNGI4Y2I0ZWViODU0ZWEwNmQ4MDVfNS03LTEtMS02OTY1Mg_2aa24e3f-66b5-4476-8e27-27ef58b7f891"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RleHRyZWdpb246MGM2NTE4NDAyOGU1NGQzYmJmYmRkNTliNmQ0ZDJjNjVfMTc0NA_67d36670-7c9f-467c-8b69-164e19776995"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RleHRyZWdpb246MGM2NTE4NDAyOGU1NGQzYmJmYmRkNTliNmQ0ZDJjNjVfMTc0NA_a020bb2d-d487-493f-a8fd-1c6801f8df4d"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i50fbc717732e47c78990b648a1fb6851_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RleHRyZWdpb246MGM2NTE4NDAyOGU1NGQzYmJmYmRkNTliNmQ0ZDJjNjVfNjQzNg_a02daf5e-ff83-4127-942e-f6ae2dc94e61"
      unitRef="usd">70800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RleHRyZWdpb246MGM2NTE4NDAyOGU1NGQzYmJmYmRkNTliNmQ0ZDJjNjVfNjQ0MA_350adfb5-7479-48e5-b20c-57d532715eab"
      unitRef="usd">71900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i50fbc717732e47c78990b648a1fb6851_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RleHRyZWdpb246MGM2NTE4NDAyOGU1NGQzYmJmYmRkNTliNmQ0ZDJjNjVfNjQ0NA_00d31fcb-f65c-458f-b444-b0c473b2b87f"
      unitRef="usd">1100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i56aad41cb82348889b805e52158fbf37_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RleHRyZWdpb246MGM2NTE4NDAyOGU1NGQzYmJmYmRkNTliNmQ0ZDJjNjVfMjE5OTAyMzI2MjE2MA_a44e1b91-d079-4a33-81cf-d4a52d7c0543"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RleHRyZWdpb246MGM2NTE4NDAyOGU1NGQzYmJmYmRkNTliNmQ0ZDJjNjVfOTM0NTg0ODg0MTY1MA_aa2aed75-411e-45c4-bb5f-5535e1f6b789"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i56aad41cb82348889b805e52158fbf37_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80My9mcmFnOjBjNjUxODQwMjhlNTRkM2JiZmJkZDU5YjZkNGQyYzY1L3RleHRyZWdpb246MGM2NTE4NDAyOGU1NGQzYmJmYmRkNTliNmQ0ZDJjNjVfOTM0NTg0ODg0MTY2NA_5902c99c-c23c-4b45-9315-3cac0d44a6a4"
      unitRef="usd">1100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RleHRyZWdpb246ZWVlN2I1NDZjYWNiNDY1YWIwMzZiYjAxYTk3ZDIxZDBfMzg0ODI5MDY5ODA1OQ_4b056f61-5528-4cff-b069-2bb88536dd83">Balance Sheet Components&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery, equipment, furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the three months ended March&#160;31, 2023 and 2022 was less than $0.1 million and $0.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related expenses &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory-raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RleHRyZWdpb246ZWVlN2I1NDZjYWNiNDY1YWIwMzZiYjAxYTk3ZDIxZDBfNDcy_21411611-2b19-491c-bead-c2d608dd2ccd">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjI5MmZkZjhlMTJkYjQ3Mzg5ZTI3YjIwNzk1NTNhZDRjL3RhYmxlcmFuZ2U6MjkyZmRmOGUxMmRiNDczODllMjdiMjA3OTU1M2FkNGNfMi0xLTEtMS02OTY1Mg_c242e786-82fa-4bb1-a6ce-6612f2332b6e"
      unitRef="usd">4575000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjI5MmZkZjhlMTJkYjQ3Mzg5ZTI3YjIwNzk1NTNhZDRjL3RhYmxlcmFuZ2U6MjkyZmRmOGUxMmRiNDczODllMjdiMjA3OTU1M2FkNGNfMi0zLTEtMS02OTY1Mg_0e6ee3ce-9886-4442-af3e-b3a05f6aed30"
      unitRef="usd">2818000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjI5MmZkZjhlMTJkYjQ3Mzg5ZTI3YjIwNzk1NTNhZDRjL3RhYmxlcmFuZ2U6MjkyZmRmOGUxMmRiNDczODllMjdiMjA3OTU1M2FkNGNfMy0xLTEtMS02OTY1Mg_5cdb7ac9-9997-4572-a27b-b4b1b025c013"
      unitRef="usd">592000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjI5MmZkZjhlMTJkYjQ3Mzg5ZTI3YjIwNzk1NTNhZDRjL3RhYmxlcmFuZ2U6MjkyZmRmOGUxMmRiNDczODllMjdiMjA3OTU1M2FkNGNfMy0zLTEtMS02OTY1Mg_166fdbb7-69da-454a-b2b4-e01f0cb50a38"
      unitRef="usd">1523000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjI5MmZkZjhlMTJkYjQ3Mzg5ZTI3YjIwNzk1NTNhZDRjL3RhYmxlcmFuZ2U6MjkyZmRmOGUxMmRiNDczODllMjdiMjA3OTU1M2FkNGNfNC0xLTEtMS02OTY1Mg_95365f49-1d53-4141-bd08-677030ad9699"
      unitRef="usd">5583000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjI5MmZkZjhlMTJkYjQ3Mzg5ZTI3YjIwNzk1NTNhZDRjL3RhYmxlcmFuZ2U6MjkyZmRmOGUxMmRiNDczODllMjdiMjA3OTU1M2FkNGNfNC0zLTEtMS02OTY1Mg_3be11e0c-6915-4568-b0d9-c31ac697b3eb"
      unitRef="usd">5371000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjI5MmZkZjhlMTJkYjQ3Mzg5ZTI3YjIwNzk1NTNhZDRjL3RhYmxlcmFuZ2U6MjkyZmRmOGUxMmRiNDczODllMjdiMjA3OTU1M2FkNGNfNS0xLTEtMS02OTY1Mg_3846cab3-52b6-4040-a95c-65d969d46b8d"
      unitRef="usd">10750000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjI5MmZkZjhlMTJkYjQ3Mzg5ZTI3YjIwNzk1NTNhZDRjL3RhYmxlcmFuZ2U6MjkyZmRmOGUxMmRiNDczODllMjdiMjA3OTU1M2FkNGNfNS0zLTEtMS02OTY1Mg_8c58120d-e913-4bb0-9990-9985c13e4bb7"
      unitRef="usd">9712000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RleHRyZWdpb246ZWVlN2I1NDZjYWNiNDY1YWIwMzZiYjAxYTk3ZDIxZDBfNDcz_1d2b21d1-f8c4-4800-86e9-3561e17f1366">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery, equipment, furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie13bfccbf66c4ecab838a9cd17475bc2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjcyZDRkMjJkNDEzYjQxYjU4OGM0Yjk5MmJiMGE4Yjk1L3RhYmxlcmFuZ2U6NzJkNGQyMmQ0MTNiNDFiNTg4YzRiOTkyYmIwYThiOTVfMi0xLTEtMS02OTY1Mg_a064b471-e7b1-4401-8496-dc56f6e89c5f"
      unitRef="usd">4443000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i72b74226bce34ccd820c481519df8f32_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjcyZDRkMjJkNDEzYjQxYjU4OGM0Yjk5MmJiMGE4Yjk1L3RhYmxlcmFuZ2U6NzJkNGQyMmQ0MTNiNDFiNTg4YzRiOTkyYmIwYThiOTVfMi0zLTEtMS02OTY1Mg_82227c79-783e-439e-90c4-849dcf46bc98"
      unitRef="usd">4434000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i92e875b8476a417484c9e720466e1c5c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjcyZDRkMjJkNDEzYjQxYjU4OGM0Yjk5MmJiMGE4Yjk1L3RhYmxlcmFuZ2U6NzJkNGQyMmQ0MTNiNDFiNTg4YzRiOTkyYmIwYThiOTVfMy0xLTEtMS02OTY1Mg_5dcdc41f-b7b7-4698-a029-b5e02001310b"
      unitRef="usd">2952000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i15f6bae5515b42c08088c9d68db5f5d6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjcyZDRkMjJkNDEzYjQxYjU4OGM0Yjk5MmJiMGE4Yjk1L3RhYmxlcmFuZ2U6NzJkNGQyMmQ0MTNiNDFiNTg4YzRiOTkyYmIwYThiOTVfMy0zLTEtMS02OTY1Mg_4b556bad-88dd-4dbb-aea5-508ddaf38ac4"
      unitRef="usd">2952000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3d52095ad0ee44e7b2c4a5bc8d88dcfb_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjcyZDRkMjJkNDEzYjQxYjU4OGM0Yjk5MmJiMGE4Yjk1L3RhYmxlcmFuZ2U6NzJkNGQyMmQ0MTNiNDFiNTg4YzRiOTkyYmIwYThiOTVfNC0xLTEtMS02OTY1Mg_122b5f51-d94a-42a8-8f49-9332d93eb04e"
      unitRef="usd">2402000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic24aec2bd2a146c0b2ceeb0af31c9a57_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjcyZDRkMjJkNDEzYjQxYjU4OGM0Yjk5MmJiMGE4Yjk1L3RhYmxlcmFuZ2U6NzJkNGQyMmQ0MTNiNDFiNTg4YzRiOTkyYmIwYThiOTVfNC0zLTEtMS02OTY1Mg_55984fbf-0c11-4cec-a4ca-b8c204c2d88e"
      unitRef="usd">2402000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjcyZDRkMjJkNDEzYjQxYjU4OGM0Yjk5MmJiMGE4Yjk1L3RhYmxlcmFuZ2U6NzJkNGQyMmQ0MTNiNDFiNTg4YzRiOTkyYmIwYThiOTVfNS0xLTEtMS02OTY1Mg_07aace1a-78fa-4c24-8387-d2239598efa2"
      unitRef="usd">9797000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjcyZDRkMjJkNDEzYjQxYjU4OGM0Yjk5MmJiMGE4Yjk1L3RhYmxlcmFuZ2U6NzJkNGQyMmQ0MTNiNDFiNTg4YzRiOTkyYmIwYThiOTVfNS0zLTEtMS02OTY1Mg_4cd45346-1cd2-4d09-a681-8c875713f298"
      unitRef="usd">9788000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjcyZDRkMjJkNDEzYjQxYjU4OGM0Yjk5MmJiMGE4Yjk1L3RhYmxlcmFuZ2U6NzJkNGQyMmQ0MTNiNDFiNTg4YzRiOTkyYmIwYThiOTVfNi0xLTEtMS02OTY1Mg_0e2afac3-d301-4483-80c1-29cf4153a555"
      unitRef="usd">8773000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjcyZDRkMjJkNDEzYjQxYjU4OGM0Yjk5MmJiMGE4Yjk1L3RhYmxlcmFuZ2U6NzJkNGQyMmQ0MTNiNDFiNTg4YzRiOTkyYmIwYThiOTVfNi0zLTEtMS02OTY1Mg_61b8341d-0440-461a-8dd9-268fa15a9fca"
      unitRef="usd">8724000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjcyZDRkMjJkNDEzYjQxYjU4OGM0Yjk5MmJiMGE4Yjk1L3RhYmxlcmFuZ2U6NzJkNGQyMmQ0MTNiNDFiNTg4YzRiOTkyYmIwYThiOTVfNy0xLTEtMS02OTY1Mg_c7e09600-9dde-4da7-8de0-52dd1a05eecb"
      unitRef="usd">1024000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjcyZDRkMjJkNDEzYjQxYjU4OGM0Yjk5MmJiMGE4Yjk1L3RhYmxlcmFuZ2U6NzJkNGQyMmQ0MTNiNDFiNTg4YzRiOTkyYmIwYThiOTVfNy0zLTEtMS02OTY1Mg_f1534948-a65d-4b56-bff2-ae83d68cd394"
      unitRef="usd">1064000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RleHRyZWdpb246ZWVlN2I1NDZjYWNiNDY1YWIwMzZiYjAxYTk3ZDIxZDBfMjY0_5b0735c8-5d9e-4250-b4f3-2b6a649ece14"
      unitRef="usd">100000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RleHRyZWdpb246ZWVlN2I1NDZjYWNiNDY1YWIwMzZiYjAxYTk3ZDIxZDBfNDc0_9bb95bcc-13db-4bf2-a49c-0955abc98263">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related expenses &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory-raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjZhNmIzMWExZDA3YjRlMWNhNGVkOGExZTk5ODY5MTFlL3RhYmxlcmFuZ2U6NmE2YjMxYTFkMDdiNGUxY2E0ZWQ4YTFlOTk4NjkxMWVfMi0xLTEtMS02OTY1Mg_215f150d-f259-4b04-8186-8262ef238213"
      unitRef="usd">5190000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjZhNmIzMWExZDA3YjRlMWNhNGVkOGExZTk5ODY5MTFlL3RhYmxlcmFuZ2U6NmE2YjMxYTFkMDdiNGUxY2E0ZWQ4YTFlOTk4NjkxMWVfMi0zLTEtMS02OTY1Mg_aa5b9727-7903-4a4c-8cdf-b5316b1c85db"
      unitRef="usd">5748000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <npce:AccruedInventoryLiabilityCurrent
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjZhNmIzMWExZDA3YjRlMWNhNGVkOGExZTk5ODY5MTFlL3RhYmxlcmFuZ2U6NmE2YjMxYTFkMDdiNGUxY2E0ZWQ4YTFlOTk4NjkxMWVfMy0xLTEtMS02OTY1Mg_e04bf6fe-c78e-4e7b-a73f-31f1ae2326ad"
      unitRef="usd">463000</npce:AccruedInventoryLiabilityCurrent>
    <npce:AccruedInventoryLiabilityCurrent
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjZhNmIzMWExZDA3YjRlMWNhNGVkOGExZTk5ODY5MTFlL3RhYmxlcmFuZ2U6NmE2YjMxYTFkMDdiNGUxY2E0ZWQ4YTFlOTk4NjkxMWVfMy0zLTEtMS02OTY1Mg_8b1b50db-55e6-4915-9ac7-ded1ca8d425f"
      unitRef="usd">764000</npce:AccruedInventoryLiabilityCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjZhNmIzMWExZDA3YjRlMWNhNGVkOGExZTk5ODY5MTFlL3RhYmxlcmFuZ2U6NmE2YjMxYTFkMDdiNGUxY2E0ZWQ4YTFlOTk4NjkxMWVfNC0xLTEtMS02OTY1Mg_ee9d472e-ac78-4b6b-bab1-0f62de4e7d79"
      unitRef="usd">171000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjZhNmIzMWExZDA3YjRlMWNhNGVkOGExZTk5ODY5MTFlL3RhYmxlcmFuZ2U6NmE2YjMxYTFkMDdiNGUxY2E0ZWQ4YTFlOTk4NjkxMWVfNC0zLTEtMS02OTY1Mg_726364af-09da-4f50-bce7-8f7be28fdf10"
      unitRef="usd">227000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjZhNmIzMWExZDA3YjRlMWNhNGVkOGExZTk5ODY5MTFlL3RhYmxlcmFuZ2U6NmE2YjMxYTFkMDdiNGUxY2E0ZWQ4YTFlOTk4NjkxMWVfNi0xLTEtMS02OTY1Mg_e645fc3d-4d8a-4fbd-a342-440cac3aa318"
      unitRef="usd">756000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjZhNmIzMWExZDA3YjRlMWNhNGVkOGExZTk5ODY5MTFlL3RhYmxlcmFuZ2U6NmE2YjMxYTFkMDdiNGUxY2E0ZWQ4YTFlOTk4NjkxMWVfNi0zLTEtMS02OTY1Mg_a9ce57be-40ce-4354-8050-96614e25d8e8"
      unitRef="usd">675000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <npce:AccruedAndEmployeeRelatedLiabilitiesCurrent
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjZhNmIzMWExZDA3YjRlMWNhNGVkOGExZTk5ODY5MTFlL3RhYmxlcmFuZ2U6NmE2YjMxYTFkMDdiNGUxY2E0ZWQ4YTFlOTk4NjkxMWVfNy0xLTEtMS02OTY1Mg_bb0b0f2f-994e-43b5-9a5e-4baef5c54a5c"
      unitRef="usd">6580000</npce:AccruedAndEmployeeRelatedLiabilitiesCurrent>
    <npce:AccruedAndEmployeeRelatedLiabilitiesCurrent
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80Ni9mcmFnOmVlZTdiNTQ2Y2FjYjQ2NWFiMDM2YmIwMWE5N2QyMWQwL3RhYmxlOjZhNmIzMWExZDA3YjRlMWNhNGVkOGExZTk5ODY5MTFlL3RhYmxlcmFuZ2U6NmE2YjMxYTFkMDdiNGUxY2E0ZWQ4YTFlOTk4NjkxMWVfNy0zLTEtMS02OTY1Mg_86e73d0a-43ad-4519-ac93-3bc87a51be63"
      unitRef="usd">7414000</npce:AccruedAndEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfNzUxMQ_5fecfcf8-50de-4bf1-a441-8f6ce36fc02c">Commitments and Contingencies&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Facility Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August&#160;2011, the Company entered into a non-cancelable operating lease for combined office and manufacturing facilities in Mountain View, California. The lease was scheduled to expire in April&#160;2019 and was amended in May 2018 to extend it through June 2024. In August 2022, the Company amended the lease to extend it through June 2030. The second amendment contained a rent free period from September 2022 through December 2022. The Company has an option to extend the lease for a period of five years, commencing on July 1, 2030 and expiring on June 30, 2035. In conjunction with the original lease agreement, the Company obtained a letter of credit &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for $0.9 million in lieu of a security deposit. In May 2019, the letter of credit was amended and reduced to $0.7 million. In June 2021, the letter of credit was amended and further reduced to $0.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the facility lease provide for rental payments on a graduated scale; however, rent expense is recognized on a straight-line basis over the lease term. Rental payments range from $2.8 million to $3.3 million per year over the extended term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maturities of operating lease liabilities as of March&#160;31, 2023 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost was $0.7 million and $0.7 million for the three months ended March&#160;31, 2023 and 2022, respectively. As of March&#160;31, 2023, the remaining term for the operating lease in Mountain View, California was 7.3 years, and the discount rate used to measure the lease liability for such operating lease upon recognition was 8.5%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023 and 2022, cash paid for amounts included in operating lease liabilities of $0.7 million and $0.8 million, respectively, was included in cash flows from operating activities on the condensed statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Distribution Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, the Company entered into an exclusive distribution agreement, or the Distribution Agreement, with DIXI Medical USA Corp, or DIXI Medical, pursuant to which the Company became the exclusive U.S. distributor of DIXI Medical&#x2019;s product line. To maintain the exclusive distributor rights, the Company is committed to purchase a minimum of $2.4&#160;million of DIXI Medical&#x2019;s products during the twelve months beginning October 2022, and increase the purchase minimum by 10% for each of the two subsequent years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and may provide for indemnification of the counterparty. The Company&#x2019;s exposure under these agreements is unknown because it involves claims that may be made against it in the future but have not yet been made. The Company may, from time to time, be subject to claims or be required to defend actions related to its indemnification obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director or officer is or was serving at the Company&#x2019;s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws. The term of the indemnification period lasts as long as the director or officer may be subject to any proceeding arising out of acts or omissions of such individual in such capacity. The maximum amount of potential future indemnification is unlimited. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations as of March&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. The Company determined that no accrual related to contingencies was required as of March&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not involved in any pending legal proceedings that it believes could have a material adverse effect on its business, results of operations, financial condition, or cash flows. From time to time, the Company may pursue litigation to assert its legal rights and such litigation may be costly and divert the efforts and attention of its management and technical personnel which could adversely affect its business. The Company regularly evaluates current information to determine whether any accruals should be adjusted and whether new accruals are required. Such accruals, if any, reflect the estimable and probable costs that the Company may incur from the outcomes of its legal proceedings. Legal costs are expensed as incurred. There were no contingent liabilities requiring accrual as of March&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <npce:OperatingLeaseRenewalTerm
      contextRef="if9a80d56ebf04d499b58bf88ca435e06_D20220801-20220831"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMzg0ODI5MDcwOTY3OQ_d137c557-9cdf-48f2-9cc6-937b82b0f396">P5Y</npce:OperatingLeaseRenewalTerm>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ibea6fa1c91014c4b8d2577a5a84d2960_I20110831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfNzE2_acc9e70f-9a98-4c8f-ae63-1cad6ec3c1cc"
      unitRef="usd">900000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic7e26e273c0b48a4b9d9a2e7d4b6b51f_I20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfODEx_84fb9d34-4f3c-4e9d-aa81-60d952a2b289"
      unitRef="usd">700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i855f72fe57c7466cb0fdbebf83edc239_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfODg1_5bd36ee5-3560-4ebd-8b23-45dc751bd3b6"
      unitRef="usd">200000</us-gaap:DebtInstrumentFaceAmount>
    <npce:OperatingLeasesAnnualRentalPayments
      contextRef="i2356a93c7f0842d59386f834f8ca8c04_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMTA4MA_a5d32ade-c4a1-4db9-9c4c-b32954c04052"
      unitRef="usd">2800000</npce:OperatingLeasesAnnualRentalPayments>
    <npce:OperatingLeasesAnnualRentalPayments
      contextRef="ifffa9c7125464d7486ce57d0838a6f42_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMTA4Ng_19e4ea2a-e8b3-434f-b07d-118f2b4ca9a4"
      unitRef="usd">3300000</npce:OperatingLeasesAnnualRentalPayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfNzUxNQ_a92eadd4-45f0-452f-b606-a8430c7f20cf">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maturities of operating lease liabilities as of March&#160;31, 2023 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RhYmxlOjA5NDU0NzljMjM3NzQ1ZmRhNGVkZDBhYTAzZjRkYzcyL3RhYmxlcmFuZ2U6MDk0NTQ3OWMyMzc3NDVmZGE0ZWRkMGFhMDNmNGRjNzJfMS0xLTEtMS02OTY1Mg_e4ab02fa-6952-493d-a894-34d216a7a871"
      unitRef="usd">2080000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RhYmxlOjA5NDU0NzljMjM3NzQ1ZmRhNGVkZDBhYTAzZjRkYzcyL3RhYmxlcmFuZ2U6MDk0NTQ3OWMyMzc3NDVmZGE0ZWRkMGFhMDNmNGRjNzJfMi0xLTEtMS02OTY1Mg_77a4df9d-f4d5-4928-b0be-b2d766167ebb"
      unitRef="usd">2857000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RhYmxlOjA5NDU0NzljMjM3NzQ1ZmRhNGVkZDBhYTAzZjRkYzcyL3RhYmxlcmFuZ2U6MDk0NTQ3OWMyMzc3NDVmZGE0ZWRkMGFhMDNmNGRjNzJfMy0xLTEtMS02OTY1Mg_67daef7c-e4c2-4a9d-9e44-f37ffd7f93bf"
      unitRef="usd">2942000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RhYmxlOjA5NDU0NzljMjM3NzQ1ZmRhNGVkZDBhYTAzZjRkYzcyL3RhYmxlcmFuZ2U6MDk0NTQ3OWMyMzc3NDVmZGE0ZWRkMGFhMDNmNGRjNzJfNC0xLTEtMS02OTY1Mg_73bb3d9f-7484-4196-8ec2-f60e041795f2"
      unitRef="usd">3031000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RhYmxlOjA5NDU0NzljMjM3NzQ1ZmRhNGVkZDBhYTAzZjRkYzcyL3RhYmxlcmFuZ2U6MDk0NTQ3OWMyMzc3NDVmZGE0ZWRkMGFhMDNmNGRjNzJfNS0xLTEtMS02OTY1Mg_a53ef034-3aea-4215-9e26-ea688a82ff18"
      unitRef="usd">3122000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <npce:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RhYmxlOjA5NDU0NzljMjM3NzQ1ZmRhNGVkZDBhYTAzZjRkYzcyL3RhYmxlcmFuZ2U6MDk0NTQ3OWMyMzc3NDVmZGE0ZWRkMGFhMDNmNGRjNzJfNi0xLTEtMS02OTY1Mg_a53ad52e-eeff-4843-82ef-a3fecb9bf874"
      unitRef="usd">8232000</npce:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RhYmxlOjA5NDU0NzljMjM3NzQ1ZmRhNGVkZDBhYTAzZjRkYzcyL3RhYmxlcmFuZ2U6MDk0NTQ3OWMyMzc3NDVmZGE0ZWRkMGFhMDNmNGRjNzJfNy0xLTEtMS02OTY1Mg_fe496b35-f66a-4afd-b0cd-4d4719bae16c"
      unitRef="usd">22264000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RhYmxlOjA5NDU0NzljMjM3NzQ1ZmRhNGVkZDBhYTAzZjRkYzcyL3RhYmxlcmFuZ2U6MDk0NTQ3OWMyMzc3NDVmZGE0ZWRkMGFhMDNmNGRjNzJfOC0xLTEtMS02OTY1Mg_6870e798-821b-443d-a381-435ea4a47aa0"
      unitRef="usd">5751000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RhYmxlOjA5NDU0NzljMjM3NzQ1ZmRhNGVkZDBhYTAzZjRkYzcyL3RhYmxlcmFuZ2U6MDk0NTQ3OWMyMzc3NDVmZGE0ZWRkMGFhMDNmNGRjNzJfOS0xLTEtMS02OTY1Mg_616a86e5-e708-4c5b-b094-36a4e620c1b4"
      unitRef="usd">16513000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RhYmxlOjA5NDU0NzljMjM3NzQ1ZmRhNGVkZDBhYTAzZjRkYzcyL3RhYmxlcmFuZ2U6MDk0NTQ3OWMyMzc3NDVmZGE0ZWRkMGFhMDNmNGRjNzJfMTAtMS0xLTEtNjk2NTI_cbb366de-e433-4402-8c12-6cb3750de5cd"
      unitRef="usd">1466000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RhYmxlOjA5NDU0NzljMjM3NzQ1ZmRhNGVkZDBhYTAzZjRkYzcyL3RhYmxlcmFuZ2U6MDk0NTQ3OWMyMzc3NDVmZGE0ZWRkMGFhMDNmNGRjNzJfMTEtMS0xLTEtNjk2NTI_b17d0a26-2c35-4516-986e-7318229f19c2"
      unitRef="usd">15047000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseCost
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMTgzOA_a1ac83fc-299d-411b-b90d-b89e7fd1e8f3"
      unitRef="usd">700000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMTg0NQ_0529ae3c-1036-4d24-9ed3-616e0c85df30"
      unitRef="usd">700000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMjAwNA_20634561-5733-491c-b6a3-c430cecb9235">P7Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMjExMg_fe117bec-2494-4dd1-9ef8-29ad18bbff8c"
      unitRef="number">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMjIxNA_3c576937-6eb9-46e8-8b7d-c75d018f519f"
      unitRef="usd">700000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMTA5OTUxMTYzNTk1MQ_3f95c729-60e3-4566-a48e-dd9775a58999"
      unitRef="usd">800000</us-gaap:OperatingLeasePayments>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths
      contextRef="ia4dd4f305a334652a40e5d347bc7628f_I20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMjY4Nw_34446e31-8d12-4156-a4c5-846ef7e32d55"
      unitRef="usd">2400000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <npce:PurchaseObligationMinimumIncreasePercentageInNextTwoYears
      contextRef="ia4dd4f305a334652a40e5d347bc7628f_I20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMjgxMg_e604b6aa-229a-4509-8e9e-a8463ee5ee89"
      unitRef="number">0.10</npce:PurchaseObligationMinimumIncreasePercentageInNextTwoYears>
    <npce:IndemnificationLiabilityOfficersAndDirectors
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfNDAzOA_1a8d284b-610e-46ed-b051-8bb1b4851c9a"
      unitRef="usd">0</npce:IndemnificationLiabilityOfficersAndDirectors>
    <npce:IndemnificationLiabilityOfficersAndDirectors
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfNDAzOA_8e308c99-561f-429c-b912-15c5dad4a605"
      unitRef="usd">0</npce:IndemnificationLiabilityOfficersAndDirectors>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfNDQ0NQ_4286d3ee-44a7-499b-9dce-5fe2f87088b7"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfNDQ0NQ_fad76563-4962-474f-9035-675b516b7e28"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i663f6b7d3d6c49a2bc184e2117245877_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMjc0ODc3OTA4MTkyMg_98e4a42d-24e0-4417-b33b-696194dbf5e4"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i7f4f2b14460d4ab894ce8ce881d1e8bf_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV80OS9mcmFnOjgwZTMwMzFkNmRjNDRhMjRiZGIwNjk5YTU3MzY4YTQ4L3RleHRyZWdpb246ODBlMzAzMWQ2ZGM0NGEyNGJkYjA2OTlhNTczNjhhNDhfMjc0ODc3OTA4MTkyMg_d67efb60-267a-43cc-a2a6-d62c68a089ec"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfNDE3Mw_1e24100b-e457-4f30-9328-44b641451355">Debt&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company entered into a Term Loan Agreement with CRG Partners IV L.P. and its affiliates for total borrowings of up to $60.0 million, or the Term Loan, and borrowed $50.0 million. The remaining $10.0 million of the Term Loan was available to the Company for borrowing until March 31, 2022 if the Company achieved a revenue-based milestone in 2021. The revenue-based milestone was not achieved, and the remaining $10.0 million of the Term Loan expired without being drawn.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Term Loan bore interest at a rate of 12.5% per year. In February 2023, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Term Loan was amended which increased the annual interest rate from 12.5% to 13.5% effective March 1, 2023. The amendment was accounted as a debt modification and the Term Loan&#x2019;s effective interest rate increased from 15.7% to 16.8%. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments under the Term Loan are made quarterly with payment dates fixed at the end of each calendar quarter. Through December 2020, the Company had the option to pay the entire interest paid-in-kind, or PIK, by increasing the principal of the Term Loan. From January 2021 through December 2022, the Company had the option to pay interest as follows: 7.5% per annum paid in cash and 5.0% per annum PIK by increasing the principal of the Term Loan. From January 2023 through June 2025, the Company has the option to pay interest as follows: 8.5% per annum paid in cash and 5.0% per annum PIK by increasing the principal of the Term Loan. For each payment date from April 2022 through March 2023, the Company elected the PIK option, increasing the principal of the Term Loan by $2.6 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Term Loan was interest-only through September 2023, which could be extended through September 2025 at the Company&#x2019;s option if the Company completed its IPO on or prior September 30, 2023. In connection with closing the IPO, the Company extended the interest-only period to September 30, 2025. Following the interest-only period, principal payment is due in one installment on September 30, 2025. The Term Loan includes a fee upon repayment of the loan equal to 10% of the aggregate principal amount being prepaid or repaid, or the backend fee. As of March&#160;31, 2023, the Term Loan had an annual effective interest rate of 16.8% per year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Term Loan is collateralized by substantially all of the Company&#x2019;s assets. The Term Loan Agreement contains customary representations and warranties, covenants, events of default and termination provisions. The financial covenants require that the Company achieve minimum annual revenue thresholds commencing in 2021 and maintain a minimum balance of cash and cash equivalents (see Note 1). In February 2023, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Term Loan was amended to reduce the minimum annual net revenue covenant to $45.0&#160;million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company paid $1.0 million in fees to the lender and third parties which is reflected as a discount on the loan and is being accreted over the life of the loan using the effective interest method. Also, the Company issued warrants to the lender for a total of 346,823 shares of Series B&#x2019; redeemable convertible preferred stock. The warrants had a fair value of $0.6 million as of the issuance date, which was accounted for as debt issuance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023 and 2022, the Company recorded interest expense related to debt discount and debt issuance costs of the Term Loan of $0.1 million and $0.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense on the Term Loan was $2.0 million and $1.8 million during the three months ended March&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, future minimum payments for the Term Loan are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Term Loan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized debt discount and issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unaccreted backend fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ief8e6ea33f5f49ba8c1945d7760420af_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMTY2_4cd18996-7524-4f36-836a-34fb5dd0ae23"
      unitRef="usd">60000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i82f97d12cf584623a6e5b81bd652ab53_D20200901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMjAx_66fcf286-3ab3-4431-a230-757cad822b1d"
      unitRef="usd">50000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="i43f850c157d141ef9213ce882f01add9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMjE5_de8e27c9-7e90-4072-b8ea-5165c47a2ba2"
      unitRef="usd">10000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="i43f850c157d141ef9213ce882f01add9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfNDI2_de8e27c9-7e90-4072-b8ea-5165c47a2ba2"
      unitRef="usd">10000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i43f850c157d141ef9213ce882f01add9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfNTE3_3ec8a2dc-5d95-4d80-955d-66c90dd3afde"
      unitRef="number">0.125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i7eeeb9a80b68476f81a32985be7b3bbb_I20230228"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMjc0ODc3OTA3NzE1NA_71c0d885-76ff-47a2-93fc-839f01e7ff59"
      unitRef="number">0.125</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i936af4736e104ba1b78e04ecf51e9485_I20230301"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMjc0ODc3OTA3NzE2MQ_7739794a-c7b3-4e48-a9da-4d6cd365c3f5"
      unitRef="number">0.135</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i52f87175f69a4d5ba7551816e3e6d9f9_I20230228"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMzg0ODI5MDcwNTk2Mg_7fd4d97c-0da9-4d83-a5b8-25c6d453f2d7"
      unitRef="number">0.157</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="iff8d276c367b44d9b804890918cc832b_I20230301"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMzg0ODI5MDcwNTk3MQ_c49c0e75-84a2-45e0-a59e-1e39f1abae63"
      unitRef="number">0.168</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic717d133e94248aeb47643602e049d84_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMzg0ODI5MDcwNTY3MA_d3ef9e38-dfd8-48c3-b0e1-9361963c705d"
      unitRef="number">0.075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i83b57f4259104d73b1aa83bc7764aa5d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMzg0ODI5MDcwNTY3Ng_a5173795-f595-44d2-b0cc-c28399e2a037"
      unitRef="number">0.050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ieddb0b8aa4b949f1a6e2bed0558ca9c0_I20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfODg4_934ee11a-1ae6-45be-a9db-bbdd381902bd"
      unitRef="number">0.085</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9067c2fe52724e22a615ea36acafda17_I20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfOTE4_f97eebd5-dc47-418e-bf25-8008669a596f"
      unitRef="number">0.050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="icabe16bffe8b4ea7bfe4bf0585864a95_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMTEzMQ_ee4f1b07-803b-4c00-acdf-dfd40bcefada"
      unitRef="usd">2600000</us-gaap:DebtInstrumentFaceAmount>
    <npce:DebtInstrumentPrincipalPaymentNumberOfInstallment
      contextRef="ibfc06477076049948beb4962edceb579_D20230201-20230228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMTUwNA_8966a199-28e7-4107-be84-de2c4b601005"
      unitRef="installment">1</npce:DebtInstrumentPrincipalPaymentNumberOfInstallment>
    <npce:DebtInstrumentRedemptionFeePercent
      contextRef="i7eeeb9a80b68476f81a32985be7b3bbb_I20230228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMTYwNw_35a68a22-d348-492f-8067-3af5d4e34e8d"
      unitRef="number">0.10</npce:DebtInstrumentRedemptionFeePercent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i112820749e8349ea97d447caf4294059_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMTc1NA_81824820-8266-4c4a-a964-8325ba94e872"
      unitRef="number">0.168</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <npce:DebtInstrumentCovenantMinimumAnnualNetRevenue
      contextRef="icfb0677a4b944e56b972e31d646b50b7_D20230201-20230228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMjI1NQ_ed0ebfad-9374-41d7-aed4-52655d9ba2c4"
      unitRef="usd">45000000</npce:DebtInstrumentCovenantMinimumAnnualNetRevenue>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="iad9b6795da0a45d5acf70ba4d680edb2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMjMxMw_771ead73-90da-44fa-90d8-8dccae2263bb"
      unitRef="usd">1000000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i4e5845b14c67448eafe578cbd6b9e3fd_I20200924"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMjU0OQ_47ba0bf2-1f30-47e5-a676-071c274519e1"
      unitRef="shares">346823</us-gaap:ClassOfWarrantOrRightOutstanding>
    <npce:WarrantLiabilityNoncurrent
      contextRef="i4e5845b14c67448eafe578cbd6b9e3fd_I20200924"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMjY0NQ_88938b01-3d8c-4970-afa6-eec9fdc4b8a4"
      unitRef="usd">600000</npce:WarrantLiabilityNoncurrent>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i814c00557d744141babf3f0e6dcf97a1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMjg4Mw_33171ce0-cb09-4942-a713-29a276b20e98"
      unitRef="usd">100000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i750b0ffd1c3643dca215a71011485722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMjg5MA_6bb93676-5291-42d0-9442-a707686b6303"
      unitRef="usd">100000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:InterestExpenseDebt
      contextRef="i814c00557d744141babf3f0e6dcf97a1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMzExOA_70b3e89a-487a-4971-bf10-6ba41f1d024b"
      unitRef="usd">2000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i750b0ffd1c3643dca215a71011485722_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfMzEyNQ_1073a0dc-521f-4748-8fdc-63b0390502ad"
      unitRef="usd">1800000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RleHRyZWdpb246ZjVkNmNhYzRiMWY4NGFhZjg0M2I2OWI3NzJlOTI1OGVfNDE3Mg_d8f21244-39a0-4907-8ef0-dd0b03618bb8">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, future minimum payments for the Term Loan are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Term Loan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized debt discount and issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unaccreted backend fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i112820749e8349ea97d447caf4294059_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RhYmxlOmJhYTBlNjJkYWUzZjQ5NWY5OWYxOTI4NGM0ZmRhN2M1L3RhYmxlcmFuZ2U6YmFhMGU2MmRhZTNmNDk1Zjk5ZjE5Mjg0YzRmZGE3YzVfMS0xLTEtMS02OTY1Mg_1ded9af6-e1ed-405b-a4f4-2ccc78de1560"
      unitRef="usd">5423000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i112820749e8349ea97d447caf4294059_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RhYmxlOmJhYTBlNjJkYWUzZjQ5NWY5OWYxOTI4NGM0ZmRhN2M1L3RhYmxlcmFuZ2U6YmFhMGU2MmRhZTNmNDk1Zjk5ZjE5Mjg0YzRmZGE3YzVfMi0xLTEtMS02OTY1Mg_3c8da58e-c37d-4416-8bc5-2b7e7455eb95"
      unitRef="usd">7217000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i112820749e8349ea97d447caf4294059_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RhYmxlOmJhYTBlNjJkYWUzZjQ5NWY5OWYxOTI4NGM0ZmRhN2M1L3RhYmxlcmFuZ2U6YmFhMGU2MmRhZTNmNDk1Zjk5ZjE5Mjg0YzRmZGE3YzVfMy0xLTEtMS02OTY1Mg_401aa207-cc70-4d00-93d0-a8da6d67b517"
      unitRef="usd">63225000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i112820749e8349ea97d447caf4294059_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RhYmxlOmJhYTBlNjJkYWUzZjQ5NWY5OWYxOTI4NGM0ZmRhN2M1L3RhYmxlcmFuZ2U6YmFhMGU2MmRhZTNmNDk1Zjk5ZjE5Mjg0YzRmZGE3YzVfNS0xLTEtMS02OTY1Mg_72d5ca7d-0e0e-4fb5-b2bf-efef30961494"
      unitRef="usd">75865000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i112820749e8349ea97d447caf4294059_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RhYmxlOmJhYTBlNjJkYWUzZjQ5NWY5OWYxOTI4NGM0ZmRhN2M1L3RhYmxlcmFuZ2U6YmFhMGU2MmRhZTNmNDk1Zjk5ZjE5Mjg0YzRmZGE3YzVfNi0xLTEtMS02OTY1Mg_61f8d7fc-2f12-4ee9-b845-5e8c77d6454c"
      unitRef="usd">840000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="i112820749e8349ea97d447caf4294059_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RhYmxlOmJhYTBlNjJkYWUzZjQ5NWY5OWYxOTI4NGM0ZmRhN2M1L3RhYmxlcmFuZ2U6YmFhMGU2MmRhZTNmNDk1Zjk5ZjE5Mjg0YzRmZGE3YzVfNy0xLTEtMS02OTY1Mg_ce0d6aa3-8fe5-46d9-80e1-3f3a56cfbd9d"
      unitRef="usd">3143000</us-gaap:DebtInstrumentFeeAmount>
    <npce:DebtInstrumentUnamortizedInterestCost
      contextRef="i112820749e8349ea97d447caf4294059_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RhYmxlOmJhYTBlNjJkYWUzZjQ5NWY5OWYxOTI4NGM0ZmRhN2M1L3RhYmxlcmFuZ2U6YmFhMGU2MmRhZTNmNDk1Zjk5ZjE5Mjg0YzRmZGE3YzVfOC0xLTEtMS02OTY1Mg_484f0e0c-99cc-468d-aefc-3f0098b5ed6d"
      unitRef="usd">18023000</npce:DebtInstrumentUnamortizedInterestCost>
    <us-gaap:LongTermDebt
      contextRef="i112820749e8349ea97d447caf4294059_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV81Mi9mcmFnOmY1ZDZjYWM0YjFmODRhYWY4NDNiNjliNzcyZTkyNThlL3RhYmxlOmJhYTBlNjJkYWUzZjQ5NWY5OWYxOTI4NGM0ZmRhN2M1L3RhYmxlcmFuZ2U6YmFhMGU2MmRhZTNmNDk1Zjk5ZjE5Mjg0YzRmZGE3YzVfOS0xLTEtMS02OTY1Mg_22837221-7362-49b9-ac93-7606a09015ac"
      unitRef="usd">53859000</us-gaap:LongTermDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RleHRyZWdpb246MTZiZGM3MzcyYWQ1NDNlZGJjMWY1ZDI1NWVlYzhlYjdfNDc4_52de4b03-645f-4d21-af26-0b13d3fa242e">Common Stock&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Amended and Restated Certificate of Incorporation authorizes the Company to issue 200,000,000&#160;shares of $0.001 par value common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The holders of common stock are entitled to receive dividends whenever funds and assets are legally available and when declared by the Board of Directors. As of March&#160;31, 2023 and December 31, 2022, no dividends had been declared.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023 and December 31, 2022, the Company had reserved common stock for future issuance as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for future grant under the 2021 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,443,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding options under the 2021 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,531,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,446,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding restricted stock units under the 2021 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,099,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,756,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock available for ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,271,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,076,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RleHRyZWdpb246MTZiZGM3MzcyYWQ1NDNlZGJjMWY1ZDI1NWVlYzhlYjdfMTE3_be8f08a7-d93d-4212-97ea-d9d180697285"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RleHRyZWdpb246MTZiZGM3MzcyYWQ1NDNlZGJjMWY1ZDI1NWVlYzhlYjdfMTMw_be10861b-bcd3-4a69-a49b-27e9ef24cbb8"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:DividendsCommonStockCash
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RleHRyZWdpb246MTZiZGM3MzcyYWQ1NDNlZGJjMWY1ZDI1NWVlYzhlYjdfMzQ0_3c07ece2-8222-4331-ac20-ea1eeca2f866"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i03bae0452175488495225eda73e7fe90_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RleHRyZWdpb246MTZiZGM3MzcyYWQ1NDNlZGJjMWY1ZDI1NWVlYzhlYjdfMzQ0_f9fd3364-ea2d-4976-a185-66fd763aae13"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RleHRyZWdpb246MTZiZGM3MzcyYWQ1NDNlZGJjMWY1ZDI1NWVlYzhlYjdfNDc5_9e37f59d-aac3-46dc-9da5-258f094816db">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023 and December 31, 2022, the Company had reserved common stock for future issuance as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for future grant under the 2021 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,443,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding options under the 2021 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,531,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,446,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding restricted stock units under the 2021 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,099,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,756,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock available for ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,271,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,076,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i7933e407f09241dcbaee799735452b05_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RhYmxlOjU4YTA1ZDM1MDk0NjQ3NmQ5MzM1MTRmMjYyM2Q5Njc1L3RhYmxlcmFuZ2U6NThhMDVkMzUwOTQ2NDc2ZDkzMzUxNGYyNjIzZDk2NzVfMi0xLTEtMS02OTY1Mg_7150fcee-b34e-4b72-816f-e75954110a47"
      unitRef="shares">959660</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i82a147b9aa3a438bbe5962d4d431b65a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RhYmxlOjU4YTA1ZDM1MDk0NjQ3NmQ5MzM1MTRmMjYyM2Q5Njc1L3RhYmxlcmFuZ2U6NThhMDVkMzUwOTQ2NDc2ZDkzMzUxNGYyNjIzZDk2NzVfMi0zLTEtMS02OTY1Mg_ab8bbb04-8e09-4411-a380-f55f67601cc3"
      unitRef="shares">1443946</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i9928356578b14783835e61b49e13bde7_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RhYmxlOjU4YTA1ZDM1MDk0NjQ3NmQ5MzM1MTRmMjYyM2Q5Njc1L3RhYmxlcmFuZ2U6NThhMDVkMzUwOTQ2NDc2ZDkzMzUxNGYyNjIzZDk2NzVfMy0xLTEtMS02OTY1Mg_6ff709d9-b006-4032-8b59-51f20564deff"
      unitRef="shares">3531598</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ia780dfd625a04653a5d751d2bac0cd4e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RhYmxlOjU4YTA1ZDM1MDk0NjQ3NmQ5MzM1MTRmMjYyM2Q5Njc1L3RhYmxlcmFuZ2U6NThhMDVkMzUwOTQ2NDc2ZDkzMzUxNGYyNjIzZDk2NzVfMy0zLTEtMS02OTY1Mg_a7c44de4-743d-4732-972c-15cea1463738"
      unitRef="shares">3446583</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i106f4f143f4e47e38267866a576503c3_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RhYmxlOjU4YTA1ZDM1MDk0NjQ3NmQ5MzM1MTRmMjYyM2Q5Njc1L3RhYmxlcmFuZ2U6NThhMDVkMzUwOTQ2NDc2ZDkzMzUxNGYyNjIzZDk2NzVfNC0xLTEtMS02OTY1Mg_bb7632f8-c1dc-43d5-9aba-ed1b1fb63e10"
      unitRef="shares">3099974</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i59a77cc78b754f55b5ff3d8bc740ad1b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RhYmxlOjU4YTA1ZDM1MDk0NjQ3NmQ5MzM1MTRmMjYyM2Q5Njc1L3RhYmxlcmFuZ2U6NThhMDVkMzUwOTQ2NDc2ZDkzMzUxNGYyNjIzZDk2NzVfNC0zLTEtMS02OTY1Mg_52706421-4525-4f29-8fb6-dd23ebd9e1bf"
      unitRef="shares">1756209</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i1be39c24946144f8b22080563d21467c_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RhYmxlOjU4YTA1ZDM1MDk0NjQ3NmQ5MzM1MTRmMjYyM2Q5Njc1L3RhYmxlcmFuZ2U6NThhMDVkMzUwOTQ2NDc2ZDkzMzUxNGYyNjIzZDk2NzVfNS0xLTEtMS02OTY1Mg_bccc78de-4fe5-46bf-839e-c23041d316ca"
      unitRef="shares">680397</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="id847acf3ca4e4e02a9c3aaf18d3001eb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RhYmxlOjU4YTA1ZDM1MDk0NjQ3NmQ5MzM1MTRmMjYyM2Q5Njc1L3RhYmxlcmFuZ2U6NThhMDVkMzUwOTQ2NDc2ZDkzMzUxNGYyNjIzZDk2NzVfNS0zLTEtMS02OTY1Mg_07f30962-fd77-449b-8348-c140f71b7c7b"
      unitRef="shares">429940</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RhYmxlOjU4YTA1ZDM1MDk0NjQ3NmQ5MzM1MTRmMjYyM2Q5Njc1L3RhYmxlcmFuZ2U6NThhMDVkMzUwOTQ2NDc2ZDkzMzUxNGYyNjIzZDk2NzVfNi0xLTEtMS02OTY1Mg_1df618a0-22c8-4bab-a29e-40d0240e5071"
      unitRef="shares">8271629</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82MS9mcmFnOjE2YmRjNzM3MmFkNTQzZWRiYzFmNWQyNTVlZWM4ZWI3L3RhYmxlOjU4YTA1ZDM1MDk0NjQ3NmQ5MzM1MTRmMjYyM2Q5Njc1L3RhYmxlcmFuZ2U6NThhMDVkMzUwOTQ2NDc2ZDkzMzUxNGYyNjIzZDk2NzVfNi0zLTEtMS02OTY1Mg_1925b8b9-eba2-4201-9969-32e2a110afe0"
      unitRef="shares">7076678</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMzQ1MA_7f0658a2-0ce3-4ef6-a858-6c02fce1dd06">Stock-Based Incentive Compensation PlansA summary of shares available for grant under the Company&#x2019;s 2021 Equity Incentive Plan, or the 2021 Plan, is as follows:&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Available for Grant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for grant as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,443,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,252,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted/Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,821,762)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Withheld for taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for grant as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity for the three months ended March&#160;31, 2023 is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term (in Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balances as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,446,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balances at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,531,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,003,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.69&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,531,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Early Exercise of Stock Options &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the Company&#x2019;s 2020 Stock Plan, or the 2020 Plan, and the 2021 Plan, permit the exercise of options granted under the plans prior to vesting, subject to required approvals. The shares of common stock issued from the early exercise of unvested stock options are restricted and continue to vest over the original implied service period. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. The shares purchased by the employees and non-employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be outstanding until those shares vest. The cash received in exchange for exercised and unvested shares related to stock options granted is recorded as a liability for the early exercise of stock options in accrued liabilities on the accompanying balance sheet and will be transferred into common stock and additional paid-in capital as the shares vest. As of March&#160;31, 2023 and December 31, 2022, there were 65,296 and 78,389 shares of common stock, respectively, issued pursuant to early exercised options and subject to repurchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company adopted the 2021 Employee Stock Purchase Plan, or ESPP. The Company allows eligible employees to purchase shares of the Company's common stock through payroll deductions at a price equal to 85% of the lesser of the fair market value of the stock as of the first date or the ending date of each offering period, which is typically six months. There were 580,000 shares of common stock initially reserved for issuance under the ESPP. In January 2023, the number of shares of common stock available for issuance under the ESPP was increased by 250,457 shares as a result of the automatic increase provision in the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, 680,397 shares under the ESPP remain available for purchase. The offering period and purchase period is determined by the board of directors. A new offering period of six months has been authorized beginning December 7, 2022 through June 6, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity with respect to restricted stock units was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares Underlying Outstanding Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested, January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,756,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,701,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(325,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(31,729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested, March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,099,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized stock-based compensation as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The above stock-based compensation expense related to the following equity-based awards (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options and restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the total unrecognized stock-based compensation expense related to unvested stock options and restricted stock units was $25.4 million, which will be amortized on a straight-line basis over a weighted average remaining period of 2.7 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the Company had unrecognized stock-based compensation expense relating to the ESPP awards of less than $0.1 million, which is expected to be recognized over a weighted-average period of 0.2 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMzQ1NQ_e5e27fd6-d09e-4406-ae8c-7dc1d7fde496">A summary of shares available for grant under the Company&#x2019;s 2021 Equity Incentive Plan, or the 2021 Plan, is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Available for Grant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for grant as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,443,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,252,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted/Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,821,762)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Withheld for taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for grant as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i8968a5068c274de7a24aab2154e22af1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ0MzA4YWFhMGNmZjRiMjc4MjU5NDliOTFlZTg1OGVkL3RhYmxlcmFuZ2U6NDQzMDhhYWEwY2ZmNGIyNzgyNTk0OWI5MWVlODU4ZWRfMS0xLTEtMS02OTY1Mg_b38ca0c1-16f2-44f6-91ba-4d931c994a08"
      unitRef="shares">1443946</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i4072dc09d11d4232803ca241e4c4fd61_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ0MzA4YWFhMGNmZjRiMjc4MjU5NDliOTFlZTg1OGVkL3RhYmxlcmFuZ2U6NDQzMDhhYWEwY2ZmNGIyNzgyNTk0OWI5MWVlODU4ZWRfMi0xLTEtMS02OTY1Mg_a16d6e43-60a6-4f85-93bd-ca5fbf679f74"
      unitRef="shares">1252287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <npce:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod
      contextRef="i4072dc09d11d4232803ca241e4c4fd61_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ0MzA4YWFhMGNmZjRiMjc4MjU5NDliOTFlZTg1OGVkL3RhYmxlcmFuZ2U6NDQzMDhhYWEwY2ZmNGIyNzgyNTk0OWI5MWVlODU4ZWRfMy0xLTEtMS02OTY1Mg_73a1eaf7-6ccc-4f79-92fa-0d4cc6104dfa"
      unitRef="shares">1821762</npce:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod>
    <npce:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod
      contextRef="i4072dc09d11d4232803ca241e4c4fd61_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ0MzA4YWFhMGNmZjRiMjc4MjU5NDliOTFlZTg1OGVkL3RhYmxlcmFuZ2U6NDQzMDhhYWEwY2ZmNGIyNzgyNTk0OWI5MWVlODU4ZWRfNC0xLTEtMS02OTY1Mg_ccad54c4-85ce-43cf-b289-dbccef4e02a5"
      unitRef="shares">49627</npce:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod>
    <npce:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes
      contextRef="i4072dc09d11d4232803ca241e4c4fd61_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ0MzA4YWFhMGNmZjRiMjc4MjU5NDliOTFlZTg1OGVkL3RhYmxlcmFuZ2U6NDQzMDhhYWEwY2ZmNGIyNzgyNTk0OWI5MWVlODU4ZWRfNS0xLTEtMS02OTY1Mg_eba9ab9d-cdb9-4d21-878a-f2c66359a83f"
      unitRef="shares">35562</npce:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i898957e56f4f40b1800743493ec2650f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ0MzA4YWFhMGNmZjRiMjc4MjU5NDliOTFlZTg1OGVkL3RhYmxlcmFuZ2U6NDQzMDhhYWEwY2ZmNGIyNzgyNTk0OWI5MWVlODU4ZWRfNi0xLTEtMS02OTY1Mg_2241c59f-86f0-4061-85f7-c1eecb63e14d"
      unitRef="shares">959660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMzQ1MQ_02378503-a22a-4b06-9a2f-7622411737b1">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity for the three months ended March&#160;31, 2023 is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term (in Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balances as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,446,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balances at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,531,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,003,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.69&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,531,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfMi0xLTEtMS02OTY1Mg_99d520d5-5eee-4e67-8d9c-e24c815f26f0"
      unitRef="shares">3446583</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfMi0zLTEtMS02OTY1Mg_0bab9256-b7b2-44b3-beba-6e29ce60e70e"
      unitRef="usdPerShare">3.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i03bae0452175488495225eda73e7fe90_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfMi01LTEtMS02OTY1Mg_45145555-a08a-4ef0-a9a0-e51717611616">P8Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfMy0xLTEtMS02OTY1Mg_9812b50c-f9f2-4c98-b77a-967a63ba4062"
      unitRef="shares">120521</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfMy0zLTEtMS02OTY1Mg_4d2ba9f1-f2dd-41ad-9890-edc8d17f9b38"
      unitRef="usdPerShare">1.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfNC0xLTEtMS02OTY1Mg_5a3a0a30-fadf-42b4-bd59-3f0cd674e94f"
      unitRef="shares">17608</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfNC0zLTEtMS02OTY1Mg_1c5a1ff0-0a99-4058-87a5-54e8bb386b9e"
      unitRef="usdPerShare">0.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfNS0xLTEtMS02OTY1Mg_0f253056-a6bd-4ebc-ad48-c35ab355b0a9"
      unitRef="shares">17898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfNS0zLTEtMS02OTY1Mg_c4c2d737-b271-4867-ae17-353c22c014ae"
      unitRef="usdPerShare">6.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfNi0xLTEtMS02OTY1Mg_08b8b168-8796-4718-9201-8fa202272b64"
      unitRef="shares">3531598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfNi0zLTEtMS02OTY1Mg_484ed461-0a91-41b2-907b-63b884fb44a5"
      unitRef="usdPerShare">3.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfNi01LTEtMS02OTY1Mg_ae29a9de-680f-474c-a156-e146a0365e89">P7Y11M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfNy0xLTEtMS02OTY1Mg_61fdc863-6da3-419d-911e-d87b6d334abf"
      unitRef="shares">2003254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfNy0zLTEtMS02OTY1Mg_15ee3216-7905-432b-8e9e-549d1a52ab53"
      unitRef="usdPerShare">2.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfNy01LTEtMS02OTY1Mg_f575bcf5-167c-4cad-b8bb-9ac6da60dbee">P7Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfOC0xLTEtMS02OTY1Mg_30b50033-d938-442e-96c0-a67fd39cdec8"
      unitRef="shares">3531598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfOC0zLTEtMS02OTY1Mg_e606d474-0666-425c-bf24-3afe0a453aee"
      unitRef="usdPerShare">3.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjhmZTUzMDFjOTg1MjRhYTA5YjcxYTk1MjhiYzBlZDQ1L3RhYmxlcmFuZ2U6OGZlNTMwMWM5ODUyNGFhMDliNzFhOTUyOGJjMGVkNDVfOC01LTEtMS02OTY1Mg_288e2879-8bbd-424d-9239-0c0f21206c82">P7Y11M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <npce:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMTMyMw_57c6b0ff-1b8f-4f0f-907d-6158c6ee2add"
      unitRef="shares">65296</npce:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase>
    <npce:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase
      contextRef="i8daa853d90324638b7732e94aa400e74_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMTMzMA_387802b1-b9f2-4386-ab0e-f9b69bc105ac"
      unitRef="shares">78389</npce:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i75e07d1256df491e837d1a678fa4841f_D20210401-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMTY4Nw_028cc0cc-deff-476c-9f77-f1a00c076223"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <npce:EmployeeStockPurchasePlanLengthOfOfferingPeriod
      contextRef="i75e07d1256df491e837d1a678fa4841f_D20210401-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMTgyNg_3a71d3ed-ec84-4db9-9bbd-9e2aa112beb2">P6M</npce:EmployeeStockPurchasePlanLengthOfOfferingPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i881477cd12da4a8f82229279bbec5907_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMTg0MQ_5b0fa6c8-eda7-478b-8ed9-f546aebaecc0"
      unitRef="shares">580000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ida17c9ecae0547af93d99c9010967769_D20210401-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMjAyNA_2ec14d6d-41af-46fa-801c-f6337b3ed4ec"
      unitRef="shares">250457</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i06a5ce3c01de408795052e7b2448ca32_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMjU3Nw_0f3bf1b6-cbdc-4274-ba74-afda6ec48046"
      unitRef="shares">680397</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <npce:EmployeeStockPurchasePlanOfferingPeriod
      contextRef="i400dca35646848acb6a6f7c825c240c5_D20221207-20230606"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMzQ1Mg_d6db8a5e-96fe-4374-8600-8e9c3384b716">P6M</npce:EmployeeStockPurchasePlanOfferingPeriod>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMzQ1Mw_d8d4c1e1-6ec4-4917-a780-170cb40be5ce">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity with respect to restricted stock units was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares Underlying Outstanding Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested, January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,756,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,701,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(325,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(31,729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested, March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,099,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i3a1293fb162241768174865fa0b18818_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjcwMTc2YzQ0ODY4MTRjMTFiMGE0Mzg2Yzc1MzFlZTBkL3RhYmxlcmFuZ2U6NzAxNzZjNDQ4NjgxNGMxMWIwYTQzODZjNzUzMWVlMGRfMS0xLTEtMS02OTY1Mg_c141ccb9-9fd3-4ec6-a10c-c9e5f21e5319"
      unitRef="shares">1756209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i3a1293fb162241768174865fa0b18818_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjcwMTc2YzQ0ODY4MTRjMTFiMGE0Mzg2Yzc1MzFlZTBkL3RhYmxlcmFuZ2U6NzAxNzZjNDQ4NjgxNGMxMWIwYTQzODZjNzUzMWVlMGRfMS0zLTEtMS02OTY1Mg_e959c5fc-8f1c-4414-bde5-b7309b097592"
      unitRef="usdPerShare">10.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="icf61601566c5496eaf799d95dd6d08ab_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjcwMTc2YzQ0ODY4MTRjMTFiMGE0Mzg2Yzc1MzFlZTBkL3RhYmxlcmFuZ2U6NzAxNzZjNDQ4NjgxNGMxMWIwYTQzODZjNzUzMWVlMGRfMi0xLTEtMS02OTY1Mg_47df6a65-3463-4a49-b1af-7b5beb7169a2"
      unitRef="shares">1701241</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="icf61601566c5496eaf799d95dd6d08ab_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjcwMTc2YzQ0ODY4MTRjMTFiMGE0Mzg2Yzc1MzFlZTBkL3RhYmxlcmFuZ2U6NzAxNzZjNDQ4NjgxNGMxMWIwYTQzODZjNzUzMWVlMGRfMi0zLTEtMS02OTY1Mg_c6b0e83f-b9c8-4e7a-9b1c-85cb3d90a31c"
      unitRef="usdPerShare">4.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="icf61601566c5496eaf799d95dd6d08ab_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjcwMTc2YzQ0ODY4MTRjMTFiMGE0Mzg2Yzc1MzFlZTBkL3RhYmxlcmFuZ2U6NzAxNzZjNDQ4NjgxNGMxMWIwYTQzODZjNzUzMWVlMGRfMy0xLTEtMS02OTY1Mg_9996893f-9b53-4380-92a3-e699443bfd5a"
      unitRef="shares">325747</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="icf61601566c5496eaf799d95dd6d08ab_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjcwMTc2YzQ0ODY4MTRjMTFiMGE0Mzg2Yzc1MzFlZTBkL3RhYmxlcmFuZ2U6NzAxNzZjNDQ4NjgxNGMxMWIwYTQzODZjNzUzMWVlMGRfMy0zLTEtMS02OTY1Mg_b0a79f0d-3248-45e6-9fd6-df0bb5c313fc"
      unitRef="usdPerShare">9.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="icf61601566c5496eaf799d95dd6d08ab_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjcwMTc2YzQ0ODY4MTRjMTFiMGE0Mzg2Yzc1MzFlZTBkL3RhYmxlcmFuZ2U6NzAxNzZjNDQ4NjgxNGMxMWIwYTQzODZjNzUzMWVlMGRfNC0xLTEtMS02OTY1Mg_69475871-5a9d-4387-982d-0847d55703b8"
      unitRef="shares">31729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="icf61601566c5496eaf799d95dd6d08ab_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjcwMTc2YzQ0ODY4MTRjMTFiMGE0Mzg2Yzc1MzFlZTBkL3RhYmxlcmFuZ2U6NzAxNzZjNDQ4NjgxNGMxMWIwYTQzODZjNzUzMWVlMGRfNC0zLTEtMS02OTY1Mg_8c23bd2c-6c0d-4958-a664-7a46df34b1a8"
      unitRef="usdPerShare">13.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4f6410c7ed884b1dac8048f069c34d10_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjcwMTc2YzQ0ODY4MTRjMTFiMGE0Mzg2Yzc1MzFlZTBkL3RhYmxlcmFuZ2U6NzAxNzZjNDQ4NjgxNGMxMWIwYTQzODZjNzUzMWVlMGRfNS0xLTEtMS02OTY1Mg_791f6a49-0e1c-4b5f-8f97-f45a037ec536"
      unitRef="shares">3099974</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i4f6410c7ed884b1dac8048f069c34d10_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjcwMTc2YzQ0ODY4MTRjMTFiMGE0Mzg2Yzc1MzFlZTBkL3RhYmxlcmFuZ2U6NzAxNzZjNDQ4NjgxNGMxMWIwYTQzODZjNzUzMWVlMGRfNS0zLTEtMS02OTY1Mg_556e7f47-0961-4018-847e-bf156082da9e"
      unitRef="usdPerShare">7.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMzQ1NA_c971d886-510b-4326-9442-a36c28e46d19">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized stock-based compensation as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The above stock-based compensation expense related to the following equity-based awards (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options and restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5c03c7d6befd470b9c00ea069d4dec85_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ1MmNkOWNjMmIzZDRiMzNhNWZjMzgxMWFkNGYzMjY1L3RhYmxlcmFuZ2U6NDUyY2Q5Y2MyYjNkNGIzM2E1ZmMzODExYWQ0ZjMyNjVfMi01LTEtMS02OTY1Mg_420e0710-7041-4ac1-8f0f-523214ea3a8c"
      unitRef="usd">146000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie403128de0ed45939a20b7ba400d2deb_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ1MmNkOWNjMmIzZDRiMzNhNWZjMzgxMWFkNGYzMjY1L3RhYmxlcmFuZ2U6NDUyY2Q5Y2MyYjNkNGIzM2E1ZmMzODExYWQ0ZjMyNjVfMi03LTEtMS02OTY1Mg_67c152a4-c76b-48aa-9198-414b93feee77"
      unitRef="usd">110000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i639bac8ba3dc42db9ca14dffe873b9aa_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ1MmNkOWNjMmIzZDRiMzNhNWZjMzgxMWFkNGYzMjY1L3RhYmxlcmFuZ2U6NDUyY2Q5Y2MyYjNkNGIzM2E1ZmMzODExYWQ0ZjMyNjVfMy01LTEtMS02OTY1Mg_2a3bf5de-ac6e-4e27-a0e3-1a942caa2f49"
      unitRef="usd">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8ab734a7b4054702ad1f354a8ba71a1a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ1MmNkOWNjMmIzZDRiMzNhNWZjMzgxMWFkNGYzMjY1L3RhYmxlcmFuZ2U6NDUyY2Q5Y2MyYjNkNGIzM2E1ZmMzODExYWQ0ZjMyNjVfMy03LTEtMS02OTY1Mg_9adde79d-ae76-4002-9cf5-3e50c9441c2d"
      unitRef="usd">440000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0ed9f75a9df14b418c706ff213e1dc62_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ1MmNkOWNjMmIzZDRiMzNhNWZjMzgxMWFkNGYzMjY1L3RhYmxlcmFuZ2U6NDUyY2Q5Y2MyYjNkNGIzM2E1ZmMzODExYWQ0ZjMyNjVfNC01LTEtMS02OTY1Mg_ff29c43f-c85b-4823-a57d-d50f0df1e191"
      unitRef="usd">1479000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id666fdb85ced40d196e685e2eb0efbb9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ1MmNkOWNjMmIzZDRiMzNhNWZjMzgxMWFkNGYzMjY1L3RhYmxlcmFuZ2U6NDUyY2Q5Y2MyYjNkNGIzM2E1ZmMzODExYWQ0ZjMyNjVfNC03LTEtMS02OTY1Mg_4eaa18cf-cf40-4021-afcf-55f2b9a08286"
      unitRef="usd">938000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ1MmNkOWNjMmIzZDRiMzNhNWZjMzgxMWFkNGYzMjY1L3RhYmxlcmFuZ2U6NDUyY2Q5Y2MyYjNkNGIzM2E1ZmMzODExYWQ0ZjMyNjVfNS01LTEtMS02OTY1Mg_be3fa5eb-bb6b-47fe-a901-64b63469b4ca"
      unitRef="usd">2125000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjQ1MmNkOWNjMmIzZDRiMzNhNWZjMzgxMWFkNGYzMjY1L3RhYmxlcmFuZ2U6NDUyY2Q5Y2MyYjNkNGIzM2E1ZmMzODExYWQ0ZjMyNjVfNS03LTEtMS02OTY1Mg_f09ddae2-f080-46d8-8f66-e99c3672c38f"
      unitRef="usd">1488000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic8c8e2b0811a4c2085f3292fca112c80_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjBhYWRmYjg3NmRkMDRiMmQ5YTgxNWE5MmM2ZWY5ODljL3RhYmxlcmFuZ2U6MGFhZGZiODc2ZGQwNGIyZDlhODE1YTkyYzZlZjk4OWNfMi01LTEtMS02OTY1Mg_8e3a48ef-6337-431b-b65d-334118b26da3"
      unitRef="usd">2071000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3a901df324314e06b06d59f030123b5d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjBhYWRmYjg3NmRkMDRiMmQ5YTgxNWE5MmM2ZWY5ODljL3RhYmxlcmFuZ2U6MGFhZGZiODc2ZGQwNGIyZDlhODE1YTkyYzZlZjk4OWNfMi03LTEtMS02OTY1Mg_e2dfe7c7-e55c-4d04-bf2a-89db32c48aa3"
      unitRef="usd">1352000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i22c77f84a8524a16aee5a4f8921601bc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjBhYWRmYjg3NmRkMDRiMmQ5YTgxNWE5MmM2ZWY5ODljL3RhYmxlcmFuZ2U6MGFhZGZiODc2ZGQwNGIyZDlhODE1YTkyYzZlZjk4OWNfMy01LTEtMS02OTY1Mg_bb833b46-dbe6-4a53-b63c-045018c2e48d"
      unitRef="usd">54000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i387f9c0ddfda42738fd2f8d07cefdc23_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjBhYWRmYjg3NmRkMDRiMmQ5YTgxNWE5MmM2ZWY5ODljL3RhYmxlcmFuZ2U6MGFhZGZiODc2ZGQwNGIyZDlhODE1YTkyYzZlZjk4OWNfMy03LTEtMS02OTY1Mg_111bd1f6-9aea-4fb5-9001-36a6370823f9"
      unitRef="usd">136000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjBhYWRmYjg3NmRkMDRiMmQ5YTgxNWE5MmM2ZWY5ODljL3RhYmxlcmFuZ2U6MGFhZGZiODc2ZGQwNGIyZDlhODE1YTkyYzZlZjk4OWNfNC01LTEtMS02OTY1Mg_f88c7ffc-a87f-4868-9a56-f86feb644e92"
      unitRef="usd">2125000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RhYmxlOjBhYWRmYjg3NmRkMDRiMmQ5YTgxNWE5MmM2ZWY5ODljL3RhYmxlcmFuZ2U6MGFhZGZiODc2ZGQwNGIyZDlhODE1YTkyYzZlZjk4OWNfNC03LTEtMS02OTY1Mg_2f49e775-83e4-4bd6-9f38-a240fb75d4d5"
      unitRef="usd">1488000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i2c6bb8e9b196490ba7de396051e5fc52_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMzE1Nw_3a1fd8eb-00b6-4115-8914-b87b3ac59c8b"
      unitRef="usd">25400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMzI1NA_58eb3c02-39aa-43c8-94cb-505f310a9354">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i06a5ce3c01de408795052e7b2448ca32_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMzM3NQ_468d9977-5695-4f64-8e22-7f14d9b8a549"
      unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i0a949f95a2434c7b8352d1c7ddbea5aa_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82NC9mcmFnOjUzNDZhYzJiZTE3NDQ2ZDg5ZGZlN2MxZjQ4NGYyMjQzL3RleHRyZWdpb246NTM0NmFjMmJlMTc0NDZkODlkZmU3YzFmNDg0ZjIyNDNfMzQ0OA_4f1bb785-9b7e-4a77-964f-bfd1a01285e7">P0Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82Ny9mcmFnOjlhNDI4MTBkYTZmZTQ5ZmFiMzU2NjM5OTg5OGYwMDE2L3RleHRyZWdpb246OWE0MjgxMGRhNmZlNDlmYWIzNTY2Mzk5ODk4ZjAwMTZfNzg2_b70f6c82-f0df-4de9-9036-6fd4182bff51">Income Taxes&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not record a federal or state income tax provision or benefit for the three months ended March&#160;31, 2023 and 2022 as it has incurred net losses since inception. In addition, the net deferred tax assets generated from net operating losses are fully offset by a valuation allowance as the Company believes it is not more likely than not that the benefit will be realized.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for the uncertainty in income taxes by utilizing a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or are expected to be taken on an income tax return. There has been no changes in the estimated uncertain tax benefits recorded as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82Ny9mcmFnOjlhNDI4MTBkYTZmZTQ5ZmFiMzU2NjM5OTg5OGYwMDE2L3RleHRyZWdpb246OWE0MjgxMGRhNmZlNDlmYWIzNTY2Mzk5ODk4ZjAwMTZfMzg_0f5156c1-1ee7-4ea2-84f2-eef215e70792"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV82Ny9mcmFnOjlhNDI4MTBkYTZmZTQ5ZmFiMzU2NjM5OTg5OGYwMDE2L3RleHRyZWdpb246OWE0MjgxMGRhNmZlNDlmYWIzNTY2Mzk5ODk4ZjAwMTZfMzg_46b6f160-4340-4f07-8c2e-f3b79b8ca305"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RleHRyZWdpb246MzZkMzg0ODFmYWJmNDcyYjlkYjFlM2I0MTMyYzZkYTJfNTE1_42f9740b-ca2b-4f8c-94e8-82aba06e8c5c">Net Loss per Share Attributable to Common Stockholders&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except for share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common stock outstanding used to compute basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,097,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,307,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share attributable to common stockholders, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company&#x2019;s net loss, in common stock equivalent shares:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,531,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,543,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested early exercised common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares committed under ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,099,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,848,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,884,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,644,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RleHRyZWdpb246MzZkMzg0ODFmYWJmNDcyYjlkYjFlM2I0MTMyYzZkYTJfNTEz_51b27c11-4038-4ccd-9aea-de34dfad7a37">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except for share and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common stock outstanding used to compute basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,097,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,307,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share attributable to common stockholders, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOjZkM2Y2MTVjYmFkYzQyYTQ5YWZlM2YxMDFiMGRjOTU2L3RhYmxlcmFuZ2U6NmQzZjYxNWNiYWRjNDJhNDlhZmUzZjEwMWIwZGM5NTZfMy01LTEtMS02OTY1Mg_7d1d2ace-03b2-4023-8c3f-9f005ad2ba3f"
      unitRef="usd">-10375000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOjZkM2Y2MTVjYmFkYzQyYTQ5YWZlM2YxMDFiMGRjOTU2L3RhYmxlcmFuZ2U6NmQzZjYxNWNiYWRjNDJhNDlhZmUzZjEwMWIwZGM5NTZfMy03LTEtMS02OTY1Mg_d4f9bfa1-1b67-4d69-8d3a-a019777cd724"
      unitRef="usd">-11461000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOjZkM2Y2MTVjYmFkYzQyYTQ5YWZlM2YxMDFiMGRjOTU2L3RhYmxlcmFuZ2U6NmQzZjYxNWNiYWRjNDJhNDlhZmUzZjEwMWIwZGM5NTZfNS01LTEtMS02OTY1Mg_49cf71f5-b13e-4f68-a29f-1df224e00042"
      unitRef="shares">25097262</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOjZkM2Y2MTVjYmFkYzQyYTQ5YWZlM2YxMDFiMGRjOTU2L3RhYmxlcmFuZ2U6NmQzZjYxNWNiYWRjNDJhNDlhZmUzZjEwMWIwZGM5NTZfNS01LTEtMS02OTY1Mg_bbc013d8-8c67-4d42-920a-6619afe98e06"
      unitRef="shares">25097262</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOjZkM2Y2MTVjYmFkYzQyYTQ5YWZlM2YxMDFiMGRjOTU2L3RhYmxlcmFuZ2U6NmQzZjYxNWNiYWRjNDJhNDlhZmUzZjEwMWIwZGM5NTZfNS03LTEtMS02OTY1Mg_a08304ee-4644-4050-b181-a4295e79c59a"
      unitRef="shares">24307485</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOjZkM2Y2MTVjYmFkYzQyYTQ5YWZlM2YxMDFiMGRjOTU2L3RhYmxlcmFuZ2U6NmQzZjYxNWNiYWRjNDJhNDlhZmUzZjEwMWIwZGM5NTZfNS03LTEtMS02OTY1Mg_d22954e8-96b2-4873-a5a8-7bee026ae5f4"
      unitRef="shares">24307485</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOjZkM2Y2MTVjYmFkYzQyYTQ5YWZlM2YxMDFiMGRjOTU2L3RhYmxlcmFuZ2U6NmQzZjYxNWNiYWRjNDJhNDlhZmUzZjEwMWIwZGM5NTZfNi01LTEtMS02OTY1Mg_01793fe6-40fb-479e-8a65-8a19f9f3a16e"
      unitRef="usdPerShare">-0.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOjZkM2Y2MTVjYmFkYzQyYTQ5YWZlM2YxMDFiMGRjOTU2L3RhYmxlcmFuZ2U6NmQzZjYxNWNiYWRjNDJhNDlhZmUzZjEwMWIwZGM5NTZfNi01LTEtMS02OTY1Mg_c6a2fa90-de95-4041-a97a-4eccbf43b858"
      unitRef="usdPerShare">-0.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOjZkM2Y2MTVjYmFkYzQyYTQ5YWZlM2YxMDFiMGRjOTU2L3RhYmxlcmFuZ2U6NmQzZjYxNWNiYWRjNDJhNDlhZmUzZjEwMWIwZGM5NTZfNi03LTEtMS02OTY1Mg_7d705f45-85a0-47fa-9e9c-f65aad1edae7"
      unitRef="usdPerShare">-0.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOjZkM2Y2MTVjYmFkYzQyYTQ5YWZlM2YxMDFiMGRjOTU2L3RhYmxlcmFuZ2U6NmQzZjYxNWNiYWRjNDJhNDlhZmUzZjEwMWIwZGM5NTZfNi03LTEtMS02OTY1Mg_a22f764b-7f22-42c1-876b-877fcf8abf4f"
      unitRef="usdPerShare">-0.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RleHRyZWdpb246MzZkMzg0ODFmYWJmNDcyYjlkYjFlM2I0MTMyYzZkYTJfNTE0_b6aae07f-f63e-4bf6-a82d-b6e2363bc450">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company&#x2019;s net loss, in common stock equivalent shares:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,531,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,543,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested early exercised common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares committed under ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,099,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,848,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,884,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,644,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i660649a2805c490faa7479b8f8eb80f9_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOmRmZjZiNWExMzg0MTQ3YzNiZWQ2NjY1Mzc1ODI5MmNhL3RhYmxlcmFuZ2U6ZGZmNmI1YTEzODQxNDdjM2JlZDY2NjUzNzU4MjkyY2FfMi0xLTEtMS02OTY1Mg_15d74705-42c4-4284-aec4-e3b06499e0c5"
      unitRef="shares">3531598</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2dd75294bff941ef89454c5ed2eebd0a_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOmRmZjZiNWExMzg0MTQ3YzNiZWQ2NjY1Mzc1ODI5MmNhL3RhYmxlcmFuZ2U6ZGZmNmI1YTEzODQxNDdjM2JlZDY2NjUzNzU4MjkyY2FfMi0zLTEtMS02OTY1Mg_6861b0a7-6e82-45ff-9553-d828673f6b9c"
      unitRef="shares">3543716</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iad266dd548874ca7800f0d7408df01b3_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOmRmZjZiNWExMzg0MTQ3YzNiZWQ2NjY1Mzc1ODI5MmNhL3RhYmxlcmFuZ2U6ZGZmNmI1YTEzODQxNDdjM2JlZDY2NjUzNzU4MjkyY2FfMy0xLTEtMS02OTY1Mg_229283fe-7dec-4357-8997-48e19888a2b9"
      unitRef="shares">65296</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i51515b8cbea941149bc22fc10e0f86ab_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOmRmZjZiNWExMzg0MTQ3YzNiZWQ2NjY1Mzc1ODI5MmNhL3RhYmxlcmFuZ2U6ZGZmNmI1YTEzODQxNDdjM2JlZDY2NjUzNzU4MjkyY2FfMy0zLTEtMS02OTY1Mg_07f9a02a-75b1-4e5e-94d7-0607019ab3eb"
      unitRef="shares">143156</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i59a019c9f65548d59de82befb2acc22f_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOmRmZjZiNWExMzg0MTQ3YzNiZWQ2NjY1Mzc1ODI5MmNhL3RhYmxlcmFuZ2U6ZGZmNmI1YTEzODQxNDdjM2JlZDY2NjUzNzU4MjkyY2FfNC0xLTEtMS02OTY1Mg_f19066fc-d27d-4612-8711-7787648e6489"
      unitRef="shares">187201</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia4683af3b7a34481848a875e395fa408_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOmRmZjZiNWExMzg0MTQ3YzNiZWQ2NjY1Mzc1ODI5MmNhL3RhYmxlcmFuZ2U6ZGZmNmI1YTEzODQxNDdjM2JlZDY2NjUzNzU4MjkyY2FfNC0zLTEtMS02OTY1Mg_46dd8262-037b-4989-a9ca-0415503c9862"
      unitRef="shares">108681</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9840aaee62a3402abc9cc764247cdcc3_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOmRmZjZiNWExMzg0MTQ3YzNiZWQ2NjY1Mzc1ODI5MmNhL3RhYmxlcmFuZ2U6ZGZmNmI1YTEzODQxNDdjM2JlZDY2NjUzNzU4MjkyY2FfNS0xLTEtMS02OTY1Mg_b33a89e8-aeca-4dca-b920-6da81e694355"
      unitRef="shares">3099974</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ide54bdde89344a929a15191e91ab4bca_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOmRmZjZiNWExMzg0MTQ3YzNiZWQ2NjY1Mzc1ODI5MmNhL3RhYmxlcmFuZ2U6ZGZmNmI1YTEzODQxNDdjM2JlZDY2NjUzNzU4MjkyY2FfNS0zLTEtMS02OTY1Mg_a2403ea6-cd9f-4b4c-93e5-89cfef7639ff"
      unitRef="shares">1848644</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i50cc9fc35ae54c0da85087af70824030_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOmRmZjZiNWExMzg0MTQ3YzNiZWQ2NjY1Mzc1ODI5MmNhL3RhYmxlcmFuZ2U6ZGZmNmI1YTEzODQxNDdjM2JlZDY2NjUzNzU4MjkyY2FfNi0xLTEtMS02OTY1Mg_032e3232-6018-4875-ac4c-055b2cdbef38"
      unitRef="shares">6884069</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i67198705cd5b4be6a83655c796893924_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJhNTlmN2VhMTc2MjQxNjY5NWVhZTMyNDlhOGY5ZWRlL3NlYzoyYTU5ZjdlYTE3NjI0MTY2OTVlYWUzMjQ5YThmOWVkZV83MC9mcmFnOjM2ZDM4NDgxZmFiZjQ3MmI5ZGIxZTNiNDEzMmM2ZGEyL3RhYmxlOmRmZjZiNWExMzg0MTQ3YzNiZWQ2NjY1Mzc1ODI5MmNhL3RhYmxlcmFuZ2U6ZGZmNmI1YTEzODQxNDdjM2JlZDY2NjUzNzU4MjkyY2FfNi0zLTEtMS02OTY1Mg_a6efa7e5-8ba2-4a79-bdba-806ec5f7d4ff"
      unitRef="shares">5644197</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>58
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M.0NXU _ _;D0:G^B_T&Y03_\#U!+ P04    " "%B*16-<\#+AP&  "U&0
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M6SH$$"?C'/((17$Z@7(@'Q)FGT]=FD]GSU[]*+^=]QN4.08V\ T)$\XNO0/
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MGYQO4%L<G*G;'S2@5MR(1D-;M09%?)I"%-3N-X+=C9';[IC]6AHCZ^YRPQF
MMP+P?"VE>;BQ)_?]+S6K?P!02P,$%     @ A8BD5ECEUAW^ @  -@H  !@
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M]@%+E!<<Y8OB67%'L.9*\:1X#!F%TF@#^'W+N3J^Z ;J:Z;E7U!+ P04
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M:2!^7Q8%_WDACZOO_\?$[#]02P,$%     @ A8BD5JT:R!C5!P   R0  !@
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M3CKW3GXD_:^2][<WBX^J=O8.9B;BUJ3C1%@GPNY[(C;2"VU2ZRKK$)@,#[S
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M(GOPL;Z9U!2SL#+HCV!=$!W9!20\1(@)!R.D6%F'_A!.Q(]4&QC3L741.!K
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M/14CCG.B4\ N!N)[&024:+A=^-'2'&O0@17.K1*&1]ZG,Q!P&ZQP+4$$P>\
M$A;&)EB(/?Q0$MM=#W4=PR;L@O11K=0W:8*8[OS,7@)3IX=A1>)"$KMIQ'!H
M, A9#277*^IGRRV50YJ%:[EL0,=JF4W%8!(QNEJ5FCSE^#@)#](:)CXX53^$
MICB:DII=+!/FESX-4E=4-="\L=W0;@]K8H9.J(-JPRB2,Z*T5)410KZCE*:?
MN.BRY<$AB"N!W?.TA*0Y*,*/XD+5WN;!P4&!4YJ&\-<6,J8S(R%I=,5-A*A
MKD#4NGT61S(8I+AA*&2\@]7TKNAUN6UM;3>\@VE;>R]>7!  4C:2R-2L<'9S
M<G,G5'':61[]E,ZLZ%S3,PPV\$J;VBIV46"FV99#Q]7$N.H4#0$0!-S3QBUY
M_W'L5%)XJHT..YIF-3@?QA]3*>^ :[ U^J!6UZB"Q&STJ?07L&G7@68YD0R
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M)?&=$'JF,E5>K=(X."36D4G#_-N[V4MXV>N"R[F_G#C+_N"ET6[#?]9##!=
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MK2E>#'N4&@C+^10^DEOOH2$<YLH6@<>A;@9^(T/D8<HX\B0\Z78#JE[8*"^
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MJRQ=_'Y8T4N+VCG0^DXI^V*X )>W>_$O4$L#!!0    ( (6(I%:QH&C7K@@
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MYC]?V!C/YAM.@1Q_P23V%8C86=N8#B%E_C3:W*F]&(VR^80Y1\39^-QSGY5
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M%\)5WQA?CO>?%Q3E+2>W*]R0J7\YH8:L^I;=3XQLNC:YEH::;C<LZ2L'E3U
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;,U6VV[;.!#]E8&Z*&+
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M@H9GT[$'NILMG6%5W?;S6EF:#NVRI'&,V@60OU#*[@V7H!_PZ3]02P,$%
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MI0'4+2N:^*B= YUOE+*'C0LP_(?,_P)02P,$%     @ A8BD5DD."I9F!0
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M'S/\UA**#N#^0DJS?2$#W=?;Z!]02P,$%     @ A8BD5HJJ/<L;!   R0D
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M#2$L,=,&@='?(]YB61H@HO&SQW0&E\;P>'Q _\W&3K%LF,);4?[@N2X63NI
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MG[;'C-?5X9J[*UZ?4=YAOB14H P62NJ=G:N&\OK8K[Z1K*B.J1Z9E"RO+E>
M4^"Z@'J_8$QN;W0%[>'K[&]02P,$%     @ A8BD5H293]ZJ P  >A(  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULO5AM;YLZ&/TK%G>Z:J6M8))
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MF0))0)@"_7S-N7H9F..'^K@I^@]02P,$%     @ A8BD5E:M"=CY @  '@L
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MQ9V@.T)+SG+:%*#(R52!1K>:!;3IF@ETDU%.9K@(9>WDC\NY-@KK]6>?'XV
ML%^ _8<O=$4S&#F5W4NMP4G?O_/BP:<^=_X3V2NO@LZKX!![.J7/2G)>^Z*
M8_HY@2?L-AIZ"Z%ABVLVVVO6:>1]' S=]79"/4%)>-X%O1(:=D+#@T)OQ!K/
M1:KG4T4W^"\94'ABO1H;HFAK^S .=B3NQR1QV*\PZA1&AZU4L@!M&R564@']
M_D5[^WJ)MZ-M/\;WDWYM<:<M/JCMUBQ!]>F)]WV(XAT]^S%Q$O7K23H]R4$]
M]]*@2;3M3_QO?^K3F.R54QR=[];<?E 2>KLGZFZU7'O=8>-:,*$)AP)A@[,$
MDU3-%=),C*SJ+CR7!GMZ/5SBK0O*!N#W0DKS,K&-O;O'TS]02P,$%     @
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M=0=>#[0HJB9V*S2VQ-5E@G\M(,T"G-\)H>\&IB]N_X-6?P%02P,$%     @
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MJ)NY'1;Z^@1I O3[A1"XFYB.WE[(Z1]02P,$%     @ A8BD5GN3\6(/!
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MV'T=;)UF;M%T:=>$-M;>=RM0V11HM+-S85/'<Z 7SL[]/!'HNKXW<Z[XN>]
MH+H%&?I9TA2,1$**:;25.1&WVUNYT-V/6!/:N"Q]>P,]K?96=DMW:]>$-M;>
MMT=0W1_IL[=_Z5HK#,/ /;?W92 ,/-^VPBOV[ILI>$<W->Y%WF\WFTG62L2[
MGZ4FM+'^O@F#,ZT^UMILZ4(;:^_;+:CL:C3Z.+RPIS^SG# XM_%EG&N'H7O^
MB\ <'$YDF.WK,QL.(EKFHCFGZ&:[<Z%W]6F(V8<WATKRA_R>R!8DQ3N9:CT&
M<G'6G-,T T&+^JCCA0I!L_HRP4ANZ%6 O+^C5)P&U0+=:=GR/U!+ P04
M" "%B*163XUM=08#   7"   &0   'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6R=EEUOVC 4AO^*E4E3*Y6&!!*@ R2@W=:+:JAHZ\6T"Y,<B%7'IK:!LE^_
M8R=D='QMNR&Q<SZ>\_K8IKN6ZEEG (:\YESHGI<9L[CQ?9UDD%-]+1<@\,M,
MJIP:'*JYKQ<*:.J<<NZ']7KLYY0)K]]U<V/5[\JEX4S 6!&]S'.J-D/@<MWS
M F\[\<CFF;$3?K^[H'.8@/FZ&"L<^564E.4@-)."*)CUO$%P,^Q8>V?PC<%:
M[[P36\E4RF<[N$][7MT" 8?$V @4'RL8 ><V$&*\E#&]*J5UW'W?1O_H:L=:
MIE3#2/(GEIJLY[4]DL*,+KEYE.O/4-83V7B)Y-K]DG5I6_=(LM1&YJ4S$N1,
M%$_Z6NJPXQ &1QS"TB%TW$4B1WE+#>UWE5P39:TQFGUQI3IOA&/"+LK$*/S*
MT,_T)T8FS[4AUI62>Y& L"*1D<QQU35UPHTY%9K4R 0;(EUR(')&!BO*.)WB
M /N"?%)4&')Q"P9G]27:AO4P('<O2V8V.V%MI*YO$-LF]Y,2<5@@AD<0&^1!
M"I-I<B=22-_Z^UAN57.XK7D8G@SX0-4U:017EK)!=$85Z!-A&Y64#1>V<4Q*
M&Z@V=5*^$7"@4)\Y8"L;,MV07;LQW;CIP9JJ](I\65@'?750W^^/DG."O6AM
M?QS2L>!K'N:SV_M&+V@"/0_WKP:U J___ET0US^<J+Y95=\\%;VH7A/Z!GQN
MP:_(%.9,"";FN(&P!1(@%TR4PE\>*J1(%;E4]EA9]8-FL]%IQEU_=8 QJABC
MOV)<FDPJ]A/U/\,1[7.$41BV6X<YXHHC/LGAUA-2WZWZ>8IXCZ(6M,.@%8>'
M,5H51NLDQL@N!>?G 5I[ ,U.'!X1H5UE;Y_,_L1,E@%/7:,8^HH+<P:CO8?1
MB*)C(G0JC,Y_]RV(]!^:MK.'UXDZ<5S_@\_?.:QS4'-W)6F2R*4PQ;E=S5:W
MWJ X['^;%U<F'F2XL33A,$/7^G4+DZOB&BH&1B[<T3^5!B\2]YKAS0W*&N#W
MF91F.[ )JO\"_5]02P,$%     @ A8BD5E*\G'F$!   #!8  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S@N>&ULM9AM;^(X$,>_BI5;G7:E+8D="&D/D KM
MZO9%[ZIV;U?WTB0#1$UBSC;0?ONSG9!0$@Q%[1O(@V<\/X^'^>/!AO$GL0"0
MZ#E+<S%T%E(NKUQ71 O(J.BP)>3JS8SQC$IUR^>N6'*@L3'*4I=X7N!F-,F=
MT< \N^>C 5O)-,GAGB.QRC+*7\:0LLW0P<[VP4,R7TC]P!T-EG0.CR#_6=YS
M=>=67N(D@UPD+$<<9D/G&E]-"-$&9L3/!#9BYQIIE"EC3_KF>SQT/!T1I!!)
M[8*JKS5,($VU)Q7'?Z53IYI3&^Y>;[U_,_ *9DH%3%CZ*XGE8NB$#HIA1E>I
M?&";/Z$$ZFE_$4N%^42;<JSGH&@E),M*8Q5!EN3%-WTN%V+'@'0/&)#2@.P9
MX." @5\:^ :TB,Q@W5!)1P/.-HCKT<J;OC!K8ZP539+K-#Y*KMXFRDZ.'B6+
MGB[&:B%B]#V/(->KBB8L4_M$4+/2]RG-!;I CVH+Q:L4$)LA8X;^7IH!USH5
MB7Q!GV] TB057]3H3\A%8D$YB($K5:!Z.C<J@QH709$#0?GHCN5R(=!M'D/<
M8C^QVV-B<>"J%:J6B6R7:4RL'N\H[R ??T7$(WY;0';S&X@J<V()QZ^RYAM_
M_@%_?ZVR*7"3B(-+7'CHMGO0OPY78DDC&#JJ_ 7P-3BCWW_#@?='&]X[.7L%
MVZU@NS;O.[#%?OJ*IC!/\CS)YZJ"U>:, 'U.\O+ME[:U*";HF0GT#]MZY'>[
M02]4J5SO8EH#.1.S5V'VK)A%,0DTYS27JAJ/(/4:2)AX/8+WB*QSGDD45$3!
M243P##Q*Q'&FH,%T@?N!%^XQ66<]DZE?,?5/8HKTMDO3XTS]-J;P<I_).NN9
M3&'%%+ZQP""/WU!=8;.Z>C[N-1A;QNU5X:OP+ZOP+ZWA_P2AZX7F\7:GT6EZ
M-.C+1C!*^?BDU]T+VCKWF8G!7MV=O=/9EDKZJ!O)T%H]/@98>CZ>%GL(YR+N
M"!!L[66_C-*"^.)Z#5PI1W1;_ER@>YY$T(J&W[.WO9>WU_RDYB?6%(];FUG,
MTI1R@9:J,$V2VW-<N YW<]P)]GN /8!S 6NM@JWJH+6Q%7C'Z J_&.\VN4ZC
M0NW3GXM7JQ-LER?M7>XTP&X3T.MX^ZK$'L"Y@+4NP:<)D]<M[S3 7A,PZ#02
M^!$B!=<J!=MERFVSV9U8?4&3SF_9GX&]2%^'70L1;%<BEK9W8OC]9OBD$P3[
MX7^$-,&U-L%V<7*L Y[(&K;DH)DI:RCGHM8Z!E^>U G1MA,^@#Z(T9MSHO[.
M<AK)%4W1#^"90?\7%'@[[CNIEG)9/D(#D5H#$;L&&A>%V<9YQ+*/7O02(8Q1
M5IP'8!33E];_[W9/8>F)& ?"QE4+'V(5%@<*N!73[FB+&6XIPY8@2\R/T#JD
MUCK$KG4LQ=S*;??VEO2^JP1R=\[;,N!S<PRI&B1;Y;(X>JN>5D>=U^: SZV'
M%^>D=Y0K^2=0"C-EZG7ZJA?RXNBQN)%L:4[OIDQ*EIG+!= 8N!Z@WL\8D]L;
M/4%U #SZ'U!+ P04    " "%B*16A'PP6$,%  "Q'P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6S%66U/ZS88_2N/LJL))&A>VJ8I*Y6@R=68QKW5
M16P?IGUP$[?-2.+.=BF=]N-G.R%M2G"I9.TB!'D[Y['/<1[[B4<;0I_8$F,.
M+WE6L&MKR?GJRK99O,0Y8AVRPH6X,R<T1UR<TH7-5A2C1('RS/8<Q[=SE!;6
M>*2N3>EX1-8\2PL\I<#6>8[H]A9G9'-MN=;KA6_I8LGE!7L\6J$%?L#\<36E
MXLRN69(TQP5+20$4SZ^M&_<J<H<2H)[X+<4;MG<,LBLS0I[DR5UR;3FR13C#
M,9<42/Q[QA.<99))M./OBM2J8TK@_O$K^V?5>=&9&6)X0K+?TX0OKZW @@3/
MT3KCW\CF9UQUJ"_Y8I(Q]1<VU;..!?&:<9)78-&"/"W*_^BE$F(/('C: 5X%
M\ X WGN ;@7H?C1"KP+T#@&]=P#]"J"Z;I=]5\*%B*/QB)(-4/FT8),'2GV%
M%GJEA1PH#YR*NZG \?$#)_'3Y:V0.H&[(L:%] TF)!<CD2'EY31#!8-+^((H
M1>KV68@Y2C-V+JX^/H1P]ND</D%:P'V:90+"1C87;9,1[+AJQVW9#N^==KAP
M3PJ^9! 5"4Y:\!,]OGL,'^KQO@9O"TUK8;U786\]+>'-BG:@ZUR YWAN6W_T
M\'LDX:Z"=]NZHX?_LBXZX/COPB,]/,1Q'=W3B-&M1UE7\77?&V5+1/'E3(VR
MQMBZ$4.J6&"1>3C,MK#_W!1MU>6;#:()_/&KH(0[CG/V9]OH*N/WVN/+;'O%
M5BC&UY9(IPS39VR-?_S!]9V?VJPQ21::)(L,D35,[-4F]G3LXZ\K:1F[$)/*
M["^1YX$3,56LUC1>"L/@3+S_3/K'SML,TG*?:E!)UE=D<BI\'OM];^B/[.=]
MY4V&C-Z&' 3=8%B';$C:KR7M:R6-'J932%(6D[48Z2M,90)N4Z^D&>Y%=SI!
MO]G?B3;6J</6)%EDB*RAL5]K[!_5^ (R7"SX$LA<_,XQ38N%E#LE;5/%K9[0
MAUQ-%6T#4XL\U0*39)$ALH8%@]J"@58QD?*%9,#D6@,J^@3$*A?F:[ZF&%+&
MUDBL/HXE$6V84Y/(X,T;'7@#U_>&!VG$9-#H;="!,_#]0=">2():X4"K\&-!
M<4P61?J/$%;I7,VB\?YLBU_D,6Y35DM_JK(EF>OM]=+K=WH'NIH,&1DB:X@_
MK,4?:L6?JD2BQG/E@E2[364MSZDJZQOEP18CRB"HLA6X'B1HVY:U0I/-B@R1
M-9QPG5TYX^B[+5;;$.6KC&PQ!E7=P/1UB2(KF=;21,MYJB]&V4*C;)$IMJ8[
M>\6F^YWK@*H!IJPTR18:98M,L36M]'96>O_/G%[%V9\2^X$C?@Y6M_KVG.R%
M2;;(%%O3BUUU[6KKOO*U8H#6?$FH6@(<T[S[1G.O[_3Z@T/-C5;"1MDB4VQ-
MS7?%L*NOAK^L\QFFLJ!@E?K/*,W0+,/J)5B(?,:/VF"T*'9;JN+ Z0X/3 V-
M1HU,L35MV!70KKZ"_OC:2T]TLMCZ9GD?6'49;5!DBJWIPZ[(=O5%\80P#@7A
M8M7)85>+7 #*Y;>-5D-,UK>3BJU1=#@=]W#L&ZVI3;$U-=]5U:Z^K#ZZUH5_
MX3,19B#6;H#1<MHH6VB4+3+%UC1J5YR[P?=>]AJMWXVRA4;9(E-L32MWI;ZK
M+ZN_'O]ZJ&<XV0N3;.&1WFD^;4:F&E(*;^]M6>:8+M1>,0/U(;S<O:ROUOO1
M-VH7UMX]7FYFWR.Z2 L&&9X+J-,9B)F0EOO#Y0DG*[4!.B.<DUP=+C%*,)4/
MB/MS0OCKB0Q0[]*/_P-02P,$%     @ A8BD5H*(: 5S P  1PL  !D   !X
M;"]W;W)K<VAE971S+W-H965T-# N>&ULM99?CZ,V$,"_BD6KZDZZ#=A "-L$
M:;/7N][#M:N-=N_9@4F"UMBI;9([J1^^MB$DO1"4VZIY"!CFSV_&GF&F>R%?
MU 9 HZ\5XVKF;;3>WOJ^RC=043426^#FS4K(BFJSE&M?;270PBE5S"=!,/8K
M6G(OF[IG#S*;BEJSDL.#1*JN*BJ_S8&)_<S#WN'!8[G>:/O SZ9;NH8%Z*?M
M@S0KO[-2E!5P50J.)*QFWAV^G>/(*CB)YQ+VZN0>V5"60KS8Q:=BY@66"!CD
MVIJ@YK*#>V#,6C(<?[5&O<ZG53R]/UC_X((WP2RI@GO!OI2%WLR\B8<*6-&:
MZ4>Q_QW:@&)K+Q=,N7^T;V4##^6UTJ)JE0U!5?+F2K^VB3A1",D%!=(J$,?=
M.'*4[ZFFV52*/9)6VEBS-RY4IVW@2FYW9:&E>5L:/9TMM,A?;N8FK@)]XCEP
MFR1T+RJS[8JZQ#TPRA6Z00MS(HJ: 1(K] A*RS+71LM90$^\U J]>0^:EDR]
M->)/?&>$C( \RBHG6UO9J:\-OH7P\Q9UWJ"2"Z@A^BRXWBCT&R^@^+>^;\+N
M8B>'V.=DT.!G*D<HQ.\0"4B(?D8^4AMJ:-O+@(>PRV[H/(07//Q15TN0-F&+
MQO*309?L6\G7Z,]:*TUY8>_[T]F7HL9?U._/EO"MVM(<9IZI405R!U[VRT]X
M'/PZ$$W411,-6<\.._H.+6%=<F[)E]2<CAS0FY*W:7N+_NY-8,/?>(B=!]LQ
M=AE.XC$)TJF_ZT&+.[1X$.VCI-QF[UJ,N <CP"3"_1CC#F,\B/'<G/AK*<9G
M%#<AB9,HZ:=(.HIDD.+>[@AC/P"2](#@A%S8E$G',;GRO$!SS'_TL$S.L,(@
M3=,DZN=*.ZYTL"J_N%9MTG.W VD^/<B='F3Z)Z /M)3HF;(:^H#2_Z'Z<'!L
MU<%_JK]",$:E0EO3<EQ2;7:/;:VWXS8>)Z>%$(QPW)]@?/)5P5?7XVNPVH\6
M/N&*1N,+U8G)$8M<6Y^OH2+G5.DH#M/3WP7$XQ<##[;P[XKW-93A.24.1YA<
M(#MV?WQM^^\IY]> 1F=G+QGA[VO;/YEM*I!K-\$IE(N:ZV;,Z9YV4^)=,QL=
MQ9L1TWSO3=DHQ&!E5(-18CJ+;*:V9J'%UDU*2Z'-W.5N-V;2!6D%S/N5$/JP
ML ZZV3G[!U!+ P04    " "%B*16@OP,( 4$   ]%   &0   'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6S%6%V/FS@4_2L6K:I6:@<,^9PFD2:9KG:D'2F:
MM+L/JWUPX ;0@)W:3M+97[^V8?A("-J,D/*2@+GW<.[QP;KVY,#XLX@ )/J5
M)E1,K4C*[:UM"S^"E(@;M@6JGFP83XE4MSRTQ98#"4Q2FMBNXPSLE,34FDW,
MV)+/)FPGDYC"DB.Q2U/"7^:0L,/4PM;KP%,<1E(/V+/)EH2P OECN^3JSBY0
M@C@%*F)&$8?-U+K#MPL\U@DFXL\8#J)RC70I:\:>]<U#,+4<S0@2\*6&(.IO
M#PM($HVD>/S,0:WBG3JQ>OV*_ILI7A6S)@(6+/DK#F0TM486"F!#=HE\8H??
M(2^HK_%\E@CSBPYYK&,A?R<D2_-DQ2"-:?9/?N5"5!(43G."FR>XQPF],PE>
MGN"90C-FIJQ[(LELPMD!<1VMT/2%T<9DJVIBJJ=Q);EZ&JL\.5M)YC]_F2LA
M O1 ?:!:5;1@J?*)($;I94*H0%_02EDHV"6 V 8]@<]"&O^KLC*$M4&HY7V\
M!TGB1'Q2N3]6]^CC^T_H/8HI^AZQG2 T$!-;JA(T$=O/Z<XSNNX9NAYZ9%1&
M GVC 03U?%N57M3OOM8_=UL!'PF_01[^C%S']1KX+/Y_NMM"QRNFPS-XWKGI
MB B')C'O."<T!/4!2;1^0=6X)7DQPW<'P@/T]Q\*$CU(2,4_3?IF[^\UOU\O
M&K=B2WR86FI5$,#W8,T^O,,#YVN3.!V!U:3J%5+UVM!GWYDD"1(5]_D5P9I*
MS_ &!D\O;_N9B]W^Q-Y72SH-PKW1J BJ4>T75/NM5,TG@MA6$Q-(.5\M@$+R
MV)>*M:D [6@L&[^'5N1+YZLCL)H(@T*$P96M/>A2JH[ :E(-"ZF&'5L[P^M7
MK>T,\9&U3X.PUW>;K3TJJ(Y:J7Y;+9=-A%JS+IV+CL!J!8Z+ L=7MNVX2ZDZ
M JM)A9VRF7 Z-FX.6#5EOW?DVX88[ V:?8LKC0]NY;I@0NI6)F0L$$BP)&CD
MUPIRZ>QTA58OV2U+=J_LY9Q 5W)UA%:7J^S%<&O_\A8W>Z=.[0V.[=P0A)TS
M=BZ[(=S>#CTI 0CW(]->!+!7&[2MGKA&FJU0%\]21VCUPLO>"O>O;>I.>["N
MT.IRE5T8;NU<WF+JP>D2[3C'ICX-ZO7.F;KL@W![([12V_N8AI]1"!2XXJW-
M30*U#XY5_TST7K61<2OJQ1/6$5I=@[+!PJ-K^[O39JTKM+I<9;N&6UN<M_A[
MW+#E&XZ/#7X:-?:.]X5VY2 F!1Z:\RFA&.RHS,XDBM'B#.S.G/P<C<_UV9@Y
MX"EALH.U1\+#6.TB$]@H2.=FJ#XYGIU593>2;<UQSYI)R5)S&0$)@.L ]7S#
MF'R]T2\H3@QG_P%02P,$%     @ A8BD5M]1!FE$ @  D04  !D   !X;"]W
M;W)K<VAE971S+W-H965T-#(N>&ULK91-C],P$(;_BA40ZDJP29-24$DB]0/$
M'E:JMBP<$ <WF336.G:PW:;\>\9.&KJK;.' I?''O(_G=3T3-U(]Z!+ D&/%
MA4Z\TIAZYOLZ*Z&B^EK6('"GD*JB!J=JY^M: <V=J.)^& 13OZ),>&GLUM8J
MC>7><"9@K8C>5Q55OQ; 99-X8^^T<,=VI;$+?AK7= <;,/?U6N',[RDYJT!H
M)@514"3>?#Q;3FR\"_C*H-%G8V*=;*5\L).;//$"FQ!PR(PE4/P<8 F<6Q"F
M\;-C>OV15G@^/M$_.>_H94LU+"7_QG)3)MY[C^10T#TW=[+Y#)V?MY:72:[=
M+VG:V"CR2+;71E:=&#.HF&B_]-C=PYD .<."L!.$3P639P11)XB<T38S9VM%
M#4UC)1NB;#32[,#=C5.C&R;LO[@Q"G<9ZDQZ(S)9 ?E"CZ#): 6&,JZOR!MR
MOUF1T<NKV#=XBHWULXZX:(GA,\2(W$IA2DT^BASRQWH?L^M3#$\I+L*+P%NJ
MKDDT?DW"((P&\EG^NSR\D$[4WUCD>-%?;XRLF,ZXU'L%Y/M\JXW"1_ECZ,9:
MXF28: MUIFN:0>)A)6I0!_#25R_&T^##D-W_!'MD?M*;GURBG\P;- ]'["0:
MR&@+ @IF!I]*2YLZFFTHAS2(_<.YFTL1;8K^V>NN0.U<T6N2R;TP[2OJ5_N^
M,G?E]&1]@?VF;0]_,&VSPC>R8T(3#@4B@^MW6*VJ;0#MQ,C:U=!6&JQ(-RRQ
M9X*R ;A?2&E.$WM WX73WU!+ P04    " "%B*16+<.*?%,#  "^"@  &0
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M&.:M[T7Z**>/<AS+AXSM!\OCYZ3F\L\T3>,X2; 5'8^]#L;8NB4)_/C5,&_
MP/) IC];:WRW\0K97P?8GNZK$&RF>"5B,\77&A#_N@$C3?V[C>4!!K8+6.U
M?G\>J"D_)XYA5S%OV!.,(VF*(5"+_AI-$F1U$OCX]P=[2N(X3?T(8'X'<8PA
M\#3B".8 /&!('-OWX,[[*%J]IZ+U__=&OP%02P,$%     @ A8BD5I>*NQS
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M7>-:E<W1GW6_L.:?4$L! A0#%     @ A8BD5@=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "%B*16
M$)+^M.\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " "%B*16F5R<(Q &  "<)P  $P              @ '-
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( (6(I%9PK;/5WP4
M *P?   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " "%B*16-<\#+AP&  "U&0  &               @($C
M#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ A8BD5ECE
MUAW^ @  -@H  !@              ("!=10  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( (6(I%:D6!LO[00  '(2   8
M  " @:D7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "%
MB*167/1OV1@'   ],0  &               @(','   >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ A8BD5JT:R!C5!P   R0  !@
M         ("!&B0  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( (6(I%:8Z:@D>@H  ,T9   8              " @24L  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "%B*16!IV^6K(2  !;-0
M&               @('5-@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ A8BD5O@5-;6Z!@  1Q,  !@              ("!O4D  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( (6(I%:0[Q</UP,
M ,\(   9              " @:U0  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ A8BD5JVRI9?["0  >QD  !D              ("!
MNU0  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " "%B*16
MJ*_Z:YH'  #=$P  &0              @('M7@  >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( (6(I%:,U!Q(? ,  ,<'   9
M      " @;YF  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ A8BD5K&@:->N"   .18  !D              ("!<6H  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "%B*16W+>O'&\#  "2!P
M&0              @(%6<P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( (6(I%8*5F]HY@,  $,)   9              " @?QV  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ A8BD5O(%KJ.\
M%   @CX  !D              ("!&7L  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    " "%B*16I4'[(#0#  #&"   &0
M@($,D   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( (6(
MI%8\@*N7U ,  &0)   9              " @7>3  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ A8BD5E82T&GL @  @P8  !D
M         ("!@I<  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    " "%B*16?+.:9\H"  #L!0  &0              @(&EF@  >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( (6(I%;30-THY (  $\&
M   9              " @::=  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ A8BD5DD."I9F!0  R0T  !D              ("!P:
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " "%B*16BJH]
MRQL$  #)"0  &0              @(%>I@  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( (6(I%90T),/)P<  +<[   9
M  " @;"J  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
MA8BD5LK[> /)!   B!T  !D              ("!#K(  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    " "%B*16A)E/WJH#  !Z$@  &0
M            @($.MP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( (6(I%96K0G8^0(  !X+   9              " @>^Z  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ A8BD5OB5Z8FY @
M$P<  !D              ("!'[X  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    " "%B*16D:1K,QX$  #1%   &0              @($/
MP0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( (6(I%9P
MFAO+[ (  -,'   9              " @63%  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ A8BD5N91^0F=!@  P4$  !D
M     ("!A\@  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (6(I%9/C6UU!@,  !<(   9              "
M@4'C  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ A8BD
M5E*\G'F$!   #!8  !D              ("!?N8  'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    " "%B*16A'PP6$,%  "Q'P  &0
M        @($YZP  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( (6(I%:"B&@%<P,  $<+   9              " @;/P  !X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ A8BD5H+\#" %!   /10
M !D              ("!7?0  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    " "%B*16WU$&:40"  "1!0  &0              @(&9^
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( (6(I%8MPXI\
M4P,  +X*   9              " @13[  !X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @ A8BD5G7;;F_U P  LQ$  !D
M ("!GOX  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " "%
MB*161U9_U#P#  #L$P  #0              @ '* @$ >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( (6(I%:7BKL<P    !,"   +              "  3$&
M 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( (6(I%98:ZBOO@,  'P=   /
M          "  1H' 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "%B*16
M1QQ@N:0!  ";&@  &@              @ $%"P$ >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " "%B*16+M+XP*X!  #*&@  $P
M        @ 'A# $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     -  T ",.
(  # #@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>124</ContextCount>
  <ElementCount>264</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>40</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Balance Sheets (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/CondensedBalanceSheetsunaudited</Role>
      <ShortName>Condensed Balance Sheets (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Balance Sheets (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/CondensedBalanceSheetsunauditedParenthetical</Role>
      <ShortName>Condensed Balance Sheets (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Statements of Operations and Comprehensive Loss (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited</Role>
      <ShortName>Condensed Statements of Operations and Comprehensive Loss (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Statements of Stockholders??? Equity (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited</Role>
      <ShortName>Condensed Statements of Stockholders??? Equity (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited</Role>
      <ShortName>Condensed Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - The Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/TheCompany</Role>
      <ShortName>The Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Stock-Based Incentive Compensation Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/StockBasedIncentiveCompensationPlans</Role>
      <ShortName>Stock-Based Incentive Compensation Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Net Loss per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholders</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://neuropace.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuropace.com/role/FairValueMeasurements</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuropace.com/role/BalanceSheetComponents</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuropace.com/role/CommitmentsandContingencies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuropace.com/role/Debt</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/CommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuropace.com/role/CommonStock</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Stock-Based Incentive Compensation Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/StockBasedIncentiveCompensationPlansTables</Role>
      <ShortName>Stock-Based Incentive Compensation Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuropace.com/role/StockBasedIncentiveCompensationPlans</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersTables</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholders</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - The Company (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/TheCompanyDetails</Role>
      <ShortName>The Company (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuropace.com/role/TheCompany</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuropace.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Balance Sheet Components - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/BalanceSheetComponentsScheduleofInventoryDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Balance Sheet Components -Schedule of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Balance Sheet Components -Schedule of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Debt - Schedule of Maturities of Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails</Role>
      <ShortName>Debt - Schedule of Maturities of Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/CommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuropace.com/role/CommonStockTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Stock-Based Incentive Compensation Plans - Schedule of Available for Grant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofAvailableforGrantDetails</Role>
      <ShortName>Stock-Based Incentive Compensation Plans - Schedule of Available for Grant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Stock-Based Incentive Compensation Plans - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Incentive Compensation Plans - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Stock-Based Incentive Compensation Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails</Role>
      <ShortName>Stock-Based Incentive Compensation Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Stock-Based Incentive Compensation Plans - Schedule of Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-Based Incentive Compensation Plans - Schedule of Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Stock-Based Incentive Compensation Plans - Schedule of Recognized Stock-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRecognizedStockbasedCompensationDetails</Role>
      <ShortName>Stock-Based Incentive Compensation Plans - Schedule of Recognized Stock-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuropace.com/role/IncomeTaxes</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="npce-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Schedule of Potentially Dilutive Securities Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesOutstandingDetails</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders - Schedule of Potentially Dilutive Securities Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="npce-20230331.htm">npce-20230331.htm</File>
    <File>exhibit311-certificationsq.htm</File>
    <File>exhibit312certificationsq1.htm</File>
    <File>exhibit321certificationsq1.htm</File>
    <File>npce-20230331.xsd</File>
    <File>npce-20230331_cal.xml</File>
    <File>npce-20230331_def.xml</File>
    <File>npce-20230331_lab.xml</File>
    <File>npce-20230331_pre.xml</File>
    <File>npce-exhibit101q1202310xq.htm</File>
    <File>npce-exhibit102q1202310xq.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="455">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>63
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "npce-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 17,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 455,
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "contextCount": 124,
   "dts": {
    "calculationLink": {
     "local": [
      "npce-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "npce-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "npce-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "npce-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "npce-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "npce-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 396,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 33,
   "keyStandard": 231,
   "memberCustom": 15,
   "memberStandard": 23,
   "nsprefix": "npce",
   "nsuri": "http://neuropace.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://neuropace.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Balance Sheet Components",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://neuropace.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://neuropace.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://neuropace.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Common Stock",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://neuropace.com/role/CommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Stock-Based Incentive Compensation Plans",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://neuropace.com/role/StockBasedIncentiveCompensationPlans",
     "shortName": "Stock-Based Incentive Compensation Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://neuropace.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Net Loss per Share Attributable to Common Stockholders",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholders",
     "shortName": "Net Loss per Share Attributable to Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "17",
     "role": "http://neuropace.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://neuropace.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Balance Sheet Components (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://neuropace.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i2c6bb8e9b196490ba7de396051e5fc52_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Balance Sheets (unaudited)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://neuropace.com/role/CondensedBalanceSheetsunaudited",
     "shortName": "Condensed Balance Sheets (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i2c6bb8e9b196490ba7de396051e5fc52_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://neuropace.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Debt (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://neuropace.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Common Stock (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://neuropace.com/role/CommonStockTables",
     "shortName": "Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Stock-Based Incentive Compensation Plans (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://neuropace.com/role/StockBasedIncentiveCompensationPlansTables",
     "shortName": "Stock-Based Incentive Compensation Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersTables",
     "shortName": "Net Loss per Share Attributable to Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i2c6bb8e9b196490ba7de396051e5fc52_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - The Company (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://neuropace.com/role/TheCompanyDetails",
     "shortName": "The Company (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i2c6bb8e9b196490ba7de396051e5fc52_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ResearchAndDevelopmentExpensePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "iea9e5bc642294c36a2e9ce408258fa44_D20210501-20210531",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "npce:ResearchAndDevelopmentArrangementWithFederalGovernmentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://neuropace.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ResearchAndDevelopmentExpensePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "iea9e5bc642294c36a2e9ce408258fa44_D20210501-20210531",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "npce:ResearchAndDevelopmentArrangementWithFederalGovernmentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i2c6bb8e9b196490ba7de396051e5fc52_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://neuropace.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails",
     "shortName": "Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i2c6bb8e9b196490ba7de396051e5fc52_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LiabilitiesFairValueDisclosure",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i2c6bb8e9b196490ba7de396051e5fc52_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://neuropace.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LiabilitiesFairValueDisclosure",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i2c6bb8e9b196490ba7de396051e5fc52_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i2c6bb8e9b196490ba7de396051e5fc52_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Balance Sheet Components - Schedule of Inventory (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://neuropace.com/role/BalanceSheetComponentsScheduleofInventoryDetails",
     "shortName": "Balance Sheet Components - Schedule of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i2c6bb8e9b196490ba7de396051e5fc52_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i2c6bb8e9b196490ba7de396051e5fc52_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Balance Sheets (unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://neuropace.com/role/CondensedBalanceSheetsunauditedParenthetical",
     "shortName": "Condensed Balance Sheets (unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i2c6bb8e9b196490ba7de396051e5fc52_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i2c6bb8e9b196490ba7de396051e5fc52_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Balance Sheet Components -Schedule of Property, Plant and Equipment (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://neuropace.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails",
     "shortName": "Balance Sheet Components -Schedule of Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i2c6bb8e9b196490ba7de396051e5fc52_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i2c6bb8e9b196490ba7de396051e5fc52_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://neuropace.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails",
     "shortName": "Balance Sheet Components - Schedule of Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i2c6bb8e9b196490ba7de396051e5fc52_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "if9a80d56ebf04d499b58bf88ca435e06_D20220801-20220831",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "npce:OperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "if9a80d56ebf04d499b58bf88ca435e06_D20220801-20220831",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "npce:OperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i2c6bb8e9b196490ba7de396051e5fc52_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails",
     "shortName": "Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i2c6bb8e9b196490ba7de396051e5fc52_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "ibfc06477076049948beb4962edceb579_D20230201-20230228",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "npce:DebtInstrumentPrincipalPaymentNumberOfInstallment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "installment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Debt - Narrative (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://neuropace.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "ibfc06477076049948beb4962edceb579_D20230201-20230228",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "npce:DebtInstrumentPrincipalPaymentNumberOfInstallment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "installment",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i112820749e8349ea97d447caf4294059_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Debt - Schedule of Maturities of Long-term Debt (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails",
     "shortName": "Debt - Schedule of Maturities of Long-term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i112820749e8349ea97d447caf4294059_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i2c6bb8e9b196490ba7de396051e5fc52_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Common Stock (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://neuropace.com/role/CommonStockDetails",
     "shortName": "Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DividendsCommonStockCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i8968a5068c274de7a24aab2154e22af1_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Stock-Based Incentive Compensation Plans - Schedule of Available for Grant (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofAvailableforGrantDetails",
     "shortName": "Stock-Based Incentive Compensation Plans - Schedule of Available for Grant (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i8968a5068c274de7a24aab2154e22af1_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i8daa853d90324638b7732e94aa400e74_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Stock-Based Incentive Compensation Plans - Schedule of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails",
     "shortName": "Stock-Based Incentive Compensation Plans - Schedule of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i2c6bb8e9b196490ba7de396051e5fc52_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "npce:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Stock-Based Incentive Compensation Plans - Narrative (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails",
     "shortName": "Stock-Based Incentive Compensation Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i2c6bb8e9b196490ba7de396051e5fc52_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "npce:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Statements of Operations and Comprehensive Loss (unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited",
     "shortName": "Condensed Statements of Operations and Comprehensive Loss (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i3a1293fb162241768174865fa0b18818_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Stock-Based Incentive Compensation Plans - Schedule of Restricted Stock Units (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails",
     "shortName": "Stock-Based Incentive Compensation Plans - Schedule of Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i3a1293fb162241768174865fa0b18818_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Stock-Based Incentive Compensation Plans - Schedule of Recognized Stock-based Compensation (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRecognizedStockbasedCompensationDetails",
     "shortName": "Stock-Based Incentive Compensation Plans - Schedule of Recognized Stock-based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://neuropace.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareDetails",
     "shortName": "Net Loss per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Schedule of Potentially Dilutive Securities Outstanding (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesOutstandingDetails",
     "shortName": "Net Loss per Share Attributable to Common Stockholders - Schedule of Potentially Dilutive Securities Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i2672791bd16a4560ac4e6349ada7df02_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Statements of Stockholders\u2019 Equity (unaudited)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited",
     "shortName": "Condensed Statements of Stockholders\u2019 Equity (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i2672791bd16a4560ac4e6349ada7df02_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Statements of Cash Flows (unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited",
     "shortName": "Condensed Statements of Cash Flows (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - The Company",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://neuropace.com/role/TheCompany",
     "shortName": "The Company",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://neuropace.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://neuropace.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "npce-20230331.htm",
      "contextRef": "i50cc9fc35ae54c0da85087af70824030_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 40,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://neuropace.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "npce_A2021EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Employee Stock Purchase Plan",
        "label": "2021 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2021 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "A2021EmployeeStockPurchasePlanMember",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "npce_A2021EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Equity Incentive Plan",
        "label": "2021 Equity Incentive Plan [Member]",
        "terseLabel": "2021 Equity Incentive Plan"
       }
      }
     },
     "localname": "A2021EquityIncentivePlanMember",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofAvailableforGrantDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "npce_AccruedAndEmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued and Employee-related Liabilities, Current",
        "label": "Accrued and Employee-related Liabilities, Current",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedAndEmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "npce_AccruedInventoryLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "npce_AccruedAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Inventory Liability, Current",
        "label": "Accrued Inventory Liability, Current",
        "terseLabel": "Inventory-raw materials"
       }
      }
     },
     "localname": "AccruedInventoryLiabilityCurrent",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "npce_AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Change In Early Exercise Liability",
        "label": "Adjustments to Additional Paid in Capital, Change In Early Exercise Liability",
        "negatedTerseLabel": "Change in early exercise liability"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "npce_AtTheMarketEquityOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-Market Equity Offering",
        "label": "At-the-Market Equity Offering [Member]",
        "terseLabel": "At-the-Market Equity Offering"
       }
      }
     },
     "localname": "AtTheMarketEquityOfferingMember",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/TheCompanyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "npce_CommonStockAvailableForESPPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Available for ESPP",
        "label": "Common Stock Available for ESPP [Member]",
        "terseLabel": "Common stock available for ESPP"
       }
      }
     },
     "localname": "CommonStockAvailableForESPPMember",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "npce_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Equipment and Software",
        "label": "Computer Equipment and Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "npce_DebtInstrumentCovenantMinimumAnnualNetRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Minimum Annual Net Revenue",
        "label": "Debt Instrument, Covenant, Minimum Annual Net Revenue",
        "terseLabel": "Minimum annual net revenue"
       }
      }
     },
     "localname": "DebtInstrumentCovenantMinimumAnnualNetRevenue",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/DebtNarrativeDetails",
      "http://neuropace.com/role/TheCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "npce_DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Minimum Cash and Cash Equivalents Required After Completion of IPO",
        "label": "Debt Instrument, Covenant, Minimum Cash and Cash Equivalents Required After Completion of IPO",
        "terseLabel": "Minimum cash and cash equivalents required after completion of IPO"
       }
      }
     },
     "localname": "DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/TheCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "npce_DebtInstrumentPrincipalPaymentNumberOfInstallment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Principal Payment Number of Installment",
        "label": "Debt Instrument, Principal Payment Number of Installment",
        "terseLabel": "Principal payment number of installment"
       }
      }
     },
     "localname": "DebtInstrumentPrincipalPaymentNumberOfInstallment",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "npce_DebtInstrumentRedemptionFeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption Fee, Percent",
        "label": "Debt Instrument, Redemption Fee, Percent",
        "terseLabel": "Redemption fee, percent"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionFeePercent",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "npce_DebtInstrumentUnamortizedInterestCost": {
     "auth_ref": [],
     "calculation": {
      "http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Unamortized Interest Cost",
        "label": "Debt Instrument, Unamortized Interest Cost",
        "negatedTerseLabel": "Less: Interest"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedInterestCost",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "npce_EmployeeStockPurchasePlanLengthOfOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, Length of Offering Period",
        "label": "Employee Stock Purchase Plan, Length of Offering Period",
        "terseLabel": "ESPP, length of offering period"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanLengthOfOfferingPeriod",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "npce_EmployeeStockPurchasePlanOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, Offering Period",
        "label": "Employee Stock Purchase Plan, Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanOfferingPeriod",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "npce_IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accrued Liabilities, Early Exercise Of Options",
        "label": "Increase (Decrease) In Accrued Liabilities, Early Exercise Of Options",
        "terseLabel": "Net change in accrued liabilities from early exercise of options"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "npce_IncreaseDecreaseInNonCashInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Non-cash Interest Expense",
        "label": "Increase (Decrease) in Non-cash Interest Expense",
        "verboseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "IncreaseDecreaseInNonCashInterestExpense",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "npce_IndemnificationLiabilityOfficersAndDirectors": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indemnification Liability, Officers and Directors",
        "label": "Indemnification Liability, Officers and Directors",
        "terseLabel": "Indemnification liability accrued for officers and directors"
       }
      }
     },
     "localname": "IndemnificationLiabilityOfficersAndDirectors",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "npce_LeaseFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Facility",
        "label": "Lease Facility [Member]",
        "terseLabel": "Lease Facility"
       }
      }
     },
     "localname": "LeaseFacilityMember",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "npce_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "npce_MachineryEquipmentFurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Machinery, Equipment, Furniture, and Fixtures",
        "label": "Machinery, Equipment, Furniture, and Fixtures [Member]",
        "terseLabel": "Machinery, equipment, furniture and fixtures"
       }
      }
     },
     "localname": "MachineryEquipmentFurnitureAndFixturesMember",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "npce_OCIUnrealizedLossAdjustmentForShortTermInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OCI, Unrealized Loss Adjustment for Short-term Investment",
        "label": "OCI, Unrealized Loss Adjustment for Short-term Investment",
        "terseLabel": "Unrealized loss adjustment for short-term investment"
       }
      }
     },
     "localname": "OCIUnrealizedLossAdjustmentForShortTermInvestment",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "npce_OperatingLeaseRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Renewal term",
        "label": "Operating Lease, Renewal term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "OperatingLeaseRenewalTerm",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "npce_OperatingLeasesAnnualRentalPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases, Annual Rental Payments",
        "label": "Operating Leases, Annual Rental Payments",
        "terseLabel": "Annual rental payments"
       }
      }
     },
     "localname": "OperatingLeasesAnnualRentalPayments",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "npce_OptionsAvailableForGrant2021PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options Available for Grant, 2021 Plan",
        "label": "Options Available for Grant, 2021 Plan [Member]",
        "terseLabel": "Shares available for future grant under the 2021 Plan"
       }
      }
     },
     "localname": "OptionsAvailableForGrant2021PlanMember",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "npce_OptionsRestrictedStockUnit2021PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options Restricted Stock Unit, 2021 Plan",
        "label": "Options Restricted Stock Unit, 2021 Plan [Member]",
        "terseLabel": "Outstanding restricted stock units under the 2021 Plan"
       }
      }
     },
     "localname": "OptionsRestrictedStockUnit2021PlanMember",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "npce_OutstandingOptions2021PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding Options, 2021 Plan",
        "label": "Outstanding Options, 2021 Plan [Member]",
        "terseLabel": "Outstanding options under the 2021 Plan"
       }
      }
     },
     "localname": "OutstandingOptions2021PlanMember",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "npce_PaymentInCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment In Cash",
        "label": "Payment In Cash [Member]",
        "terseLabel": "Payment In Cash"
       }
      }
     },
     "localname": "PaymentInCashMember",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "npce_PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Shares of Common Stock Sold under the Sales Agreement",
        "label": "Percentage of Shares of Common Stock Sold under the Sales Agreement",
        "terseLabel": "Percentage of shares of common stock sold under sales agreement"
       }
      }
     },
     "localname": "PercentageOfSharesOfCommonStockSoldUnderTheSalesAgreement",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/TheCompanyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "npce_PurchaseObligationMinimumIncreasePercentageInNextTwoYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Obligation, Minimum Increase Percentage In Next Two years",
        "label": "Purchase Obligation, Minimum Increase Percentage In Next Two years",
        "terseLabel": "Percentage increase in purchase commitment"
       }
      }
     },
     "localname": "PurchaseObligationMinimumIncreasePercentageInNextTwoYears",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Arrangement with Federal Government, Approval for Funding Subawards, Year 2",
        "label": "Research and Development Arrangement with Federal Government, Approval for Funding Subawards, Year 2",
        "terseLabel": "Approval for funding, including subawards, year two"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Arrangement with Federal Government, Approval for Funding, Year 2",
        "label": "Research and Development Arrangement with Federal Government, Approval for Funding, Year 2",
        "terseLabel": "Approval for funding, year two"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Arrangement with Federal Government, Approved Funding Subawards, Year 1",
        "label": "Research and Development Arrangement with Federal Government, Approved Funding Subawards, Year 1",
        "terseLabel": "Approved funding, including subawards, first year"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "npce_ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Arrangement with Federal Government, Approved Funding, Year 1",
        "label": "Research and Development Arrangement with Federal Government, Approved Funding, Year 1",
        "terseLabel": "Approved funding, first year"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "npce_ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Arrangement with Federal Government, Estimated Cost for Subawards",
        "label": "Research and Development Arrangement with Federal Government, Estimated Cost for Subawards",
        "terseLabel": "Research and development arrangement with federal government, funding for subawards"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Arrangement with Federal Government, Term",
        "label": "Research and Development Arrangement with Federal Government, Term",
        "terseLabel": "Grant period (in years)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentTerm",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "npce_ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Arrangement with Federal Government, Total Estimated Cost",
        "label": "Research and Development Arrangement with Federal Government, Total Estimated Cost",
        "terseLabel": "Research and development arrangement with federal government, total budget"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "npce_SaleOfStockOfferingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Offering Costs",
        "label": "Sale of Stock, Offering Costs",
        "terseLabel": "Sale of stock, offering costs"
       }
      }
     },
     "localname": "SaleOfStockOfferingCosts",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/TheCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "npce_SaleOfStockUnderwritingDiscounts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Underwriting Discounts",
        "label": "Sale of Stock, Underwriting Discounts",
        "terseLabel": "Sale of stock, underwriting discounts"
       }
      }
     },
     "localname": "SaleOfStockUnderwritingDiscounts",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/TheCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "npce_SeriesBRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B Redeemable Convertible Preferred Stock",
        "label": "Series B Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Canceled During Period",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Canceled During Period",
        "terseLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceledDuringPeriod",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofAvailableforGrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Granted During Period",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Granted During Period",
        "negatedLabel": "Granted/Awarded (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedDuringPeriod",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofAvailableforGrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares, Withheld for Taxes",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares, Withheld for Taxes",
        "terseLabel": "Withheld for taxes (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithheldForTaxes",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofAvailableforGrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Available for Grant",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Available for Grant [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Available for Grant [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofAvailableforGrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "npce_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Subject to Repurchase",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Subject to Repurchase",
        "terseLabel": "Options, subject to repurchase (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "npce_ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Unvested Early Exercised Common Stock Option",
        "label": "Share-based Payment Arrangement, Unvested Early Exercised Common Stock Option [Member]",
        "terseLabel": "Unvested early exercised common stock options"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementUnvestedEarlyExercisedCommonStockOptionMember",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "npce_StockOptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options And Restricted Stock Units",
        "label": "Stock Options And Restricted Stock Units [Member]",
        "terseLabel": "Stock options and restricted stock units"
       }
      }
     },
     "localname": "StockOptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRecognizedStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "npce_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/DebtNarrativeDetails",
      "http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "npce_WarrantLiabilityNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Liability, Noncurrent",
        "label": "Warrant Liability, Noncurrent",
        "terseLabel": "Warrant liability, noncurrent"
       }
      }
     },
     "localname": "WarrantLiabilityNoncurrent",
     "nsuri": "http://neuropace.com/20230331",
     "presentation": [
      "http://neuropace.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r322",
      "r410",
      "r420",
      "r444",
      "r445",
      "r457",
      "r461",
      "r465",
      "r509",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://neuropace.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r322",
      "r410",
      "r420",
      "r444",
      "r445",
      "r457",
      "r461",
      "r465",
      "r509",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://neuropace.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r315",
      "r322",
      "r349",
      "r350",
      "r351",
      "r409",
      "r410",
      "r420",
      "r444",
      "r445",
      "r457",
      "r461",
      "r465",
      "r502",
      "r509",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://neuropace.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r315",
      "r322",
      "r349",
      "r350",
      "r351",
      "r409",
      "r410",
      "r420",
      "r444",
      "r445",
      "r457",
      "r461",
      "r465",
      "r502",
      "r509",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://neuropace.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r323",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails",
      "http://neuropace.com/role/TheCompanyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r194",
      "r323",
      "r475",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails",
      "http://neuropace.com/role/TheCompanyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r194",
      "r323",
      "r475",
      "r476",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails",
      "http://neuropace.com/role/TheCompanyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r15",
      "r464"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r235",
      "r236"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "npce_AccruedAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r66",
      "r146"
     ],
     "calculation": {
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r153",
      "r416",
      "r425",
      "r426"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r25",
      "r28",
      "r102",
      "r405",
      "r421",
      "r422",
      "r484",
      "r485",
      "r486",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFundingAgreementTermsMember": {
     "auth_ref": [
      "r100",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of commitments to provide additional funding under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Additional Funding Agreement Terms [Member]",
        "terseLabel": "Additional Funding Agreement Terms"
       }
      }
     },
     "localname": "AdditionalFundingAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r7",
      "r464"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r495",
      "r496",
      "r497",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Shares withheld for taxes"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r353"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRecognizedStockbasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r286",
      "r395",
      "r455",
      "r456",
      "r489"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited",
      "http://neuropace.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r115",
      "r129",
      "r148",
      "r177",
      "r223",
      "r226",
      "r230",
      "r242",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r375",
      "r377",
      "r387",
      "r464",
      "r507",
      "r508",
      "r541"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r142",
      "r155",
      "r177",
      "r242",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r375",
      "r377",
      "r387",
      "r464",
      "r507",
      "r508",
      "r541"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://neuropace.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Unrealized loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r241",
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Cost basis"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r61",
      "r240",
      "r244",
      "r412"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRecognizedStockbasedCompensationDetails",
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Unaudited Interim Financial Information"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r48",
      "r49",
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchase of property and equipment included in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r47",
      "r144",
      "r447"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited",
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://neuropace.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds, included in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r482"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/TheCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r42",
      "r47",
      "r51"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "End of the period",
        "periodStartLabel": "Beginning of the period",
        "totalLabel": "Cash, cash equivalents and restricted cash in balance sheets"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash to balance sheets:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r42",
      "r109"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect [Abstract]",
        "terseLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash investing and financing information:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r177",
      "r198",
      "r199",
      "r202",
      "r204",
      "r211",
      "r212",
      "r242",
      "r255",
      "r257",
      "r258",
      "r259",
      "r262",
      "r263",
      "r296",
      "r297",
      "r300",
      "r304",
      "r311",
      "r387",
      "r446",
      "r474",
      "r491",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r86",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r22",
      "r121",
      "r134"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r68",
      "r248",
      "r249",
      "r443",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommonStockDetails",
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r495",
      "r496",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommonStockDetails",
      "http://neuropace.com/role/CondensedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommonStockDetails",
      "http://neuropace.com/role/CondensedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r6",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunauditedParenthetical",
      "http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r6",
      "r464"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, 200,000,000 shares authorized as of March\u00a031, 2023 and December\u00a031, 2022; 25,352,204 and 25,045,751 shares issued and outstanding as of March\u00a031, 2023 and December\u00a031, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r29",
      "r160",
      "r162",
      "r167",
      "r413",
      "r417"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r125",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk, and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r32",
      "r411"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRecognizedStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r73",
      "r175",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r280",
      "r287",
      "r288",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r116",
      "r117",
      "r126",
      "r180",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r396",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://neuropace.com/role/DebtNarrativeDetails",
      "http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r3",
      "r117",
      "r126",
      "r291"
     ],
     "calculation": {
      "http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r111",
      "r113",
      "r264",
      "r396",
      "r453",
      "r454"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://neuropace.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "negatedLabel": "Less: Unaccreted backend fee",
        "terseLabel": "Backend fee"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/DebtNarrativeDetails",
      "http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r19",
      "r111",
      "r294",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r19",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/DebtNarrativeDetails",
      "http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r21",
      "r180",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r396",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://neuropace.com/role/DebtNarrativeDetails",
      "http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r21",
      "r79",
      "r82",
      "r83",
      "r84",
      "r110",
      "r111",
      "r113",
      "r124",
      "r180",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r289",
      "r396",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/DebtNarrativeDetails",
      "http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r112",
      "r276",
      "r292",
      "r453",
      "r454"
     ],
     "calculation": {
      "http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Less: Unamortized debt discount and issuance cost"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": {
     "auth_ref": [
      "r20"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.",
        "label": "Debt Instrument, Unused Borrowing Capacity, Amount",
        "terseLabel": "Unused borrowing capacity"
       }
      }
     },
     "localname": "DebtInstrumentUnusedBorrowingCapacityAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCosts": {
     "auth_ref": [
      "r114",
      "r128",
      "r477"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.",
        "label": "Deferred Costs, Noncurrent",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r45",
      "r64"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation (less than $0.1 million for both periods)"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails",
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r326",
      "r354",
      "r355",
      "r357",
      "r361",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Incentive Compensation Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r89",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "terseLabel": "Schedule of Available for Grant"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "terseLabel": "Dividends declared cash"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings (loss) per share of Class A common stock:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r168",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r195",
      "r198",
      "r202",
      "r203",
      "r204",
      "r208",
      "r381",
      "r382",
      "r414",
      "r418",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to common stockholders, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited",
      "http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r168",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r198",
      "r202",
      "r203",
      "r204",
      "r208",
      "r381",
      "r382",
      "r414",
      "r418",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited",
      "http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r54",
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "npce_AccruedAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r536"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Cost not yet recognized, amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r536"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Shares committed under ESPP",
        "verboseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesOutstandingDetails",
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRecognizedStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r78",
      "r140",
      "r163",
      "r164",
      "r165",
      "r181",
      "r182",
      "r183",
      "r185",
      "r191",
      "r193",
      "r210",
      "r243",
      "r312",
      "r358",
      "r359",
      "r360",
      "r366",
      "r367",
      "r380",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r405",
      "r421",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/FairValueMeasurementsNarrativeDetails",
      "http://neuropace.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r383",
      "r384",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/FairValueMeasurementsNarrativeDetails",
      "http://neuropace.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities, Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r278",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r384",
      "r406",
      "r407",
      "r408",
      "r453",
      "r454",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r278",
      "r316",
      "r321",
      "r384",
      "r406",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "(Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r278",
      "r316",
      "r321",
      "r384",
      "r407",
      "r453",
      "r454",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "(Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r278",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r384",
      "r408",
      "r453",
      "r454",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "(Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments and Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r278",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r406",
      "r407",
      "r408",
      "r453",
      "r454",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/TheCompanyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.",
        "label": "Gain (Loss) on Sale of Investments",
        "negatedTerseLabel": "Loss on short-term investments"
       }
      }
     },
     "localname": "GainLossOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r31",
      "r177",
      "r223",
      "r225",
      "r229",
      "r231",
      "r242",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r387",
      "r451",
      "r507"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/TheCompanyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r246",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRecognizedStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRecognizedStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r178",
      "r363",
      "r364",
      "r365",
      "r368",
      "r370",
      "r372",
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r179",
      "r192",
      "r193",
      "r222",
      "r362",
      "r369",
      "r371",
      "r419"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r488",
      "r539"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r112",
      "r123",
      "r166",
      "r221",
      "r394"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r35",
      "r284",
      "r295",
      "r455",
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r170",
      "r172",
      "r173"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r478"
     ],
     "calculation": {
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r154",
      "r448",
      "r464"
     ],
     "calculation": {
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofInventoryDetails",
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r480"
     ],
     "calculation": {
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r479"
     ],
     "calculation": {
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r245"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-downs"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r34",
      "r220"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r383"
     ],
     "calculation": {
      "http://neuropace.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Fixed income mutual fund, included in short-term investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2023 (remaining nine months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r16",
      "r177",
      "r242",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r376",
      "r377",
      "r378",
      "r387",
      "r450",
      "r507",
      "r541",
      "r542"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r11",
      "r118",
      "r132",
      "r464",
      "r493",
      "r501",
      "r538"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r143",
      "r177",
      "r242",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r376",
      "r377",
      "r378",
      "r387",
      "r464",
      "r507",
      "r541",
      "r542"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Fair value disclosure"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r3",
      "r117",
      "r130",
      "r277",
      "r293",
      "r453",
      "r454"
     ],
     "calculation": {
      "http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Term Loan"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r71",
      "r180",
      "r282"
     ],
     "calculation": {
      "http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r71",
      "r180",
      "r282"
     ],
     "calculation": {
      "http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r494"
     ],
     "calculation": {
      "http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2023 (remaining nine months)"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r21",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r69",
      "r70",
      "r250",
      "r251",
      "r252",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r250",
      "r475"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Accrual for contingent liabilities"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r42",
      "r43",
      "r46"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedTerseLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited",
      "http://neuropace.com/role/TheCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r30",
      "r46",
      "r122",
      "r135",
      "r141",
      "r159",
      "r161",
      "r165",
      "r177",
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r192",
      "r193",
      "r200",
      "r223",
      "r225",
      "r229",
      "r231",
      "r242",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r382",
      "r387",
      "r451",
      "r507"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited",
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited",
      "http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r195",
      "r196",
      "r201",
      "r204",
      "r223",
      "r225",
      "r229",
      "r231",
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r223",
      "r225",
      "r229",
      "r231",
      "r451"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r400",
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability",
        "verboseLabel": "Less: current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails",
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion",
        "verboseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails",
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r399",
      "r401"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease, payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r489"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r403",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r402",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r52",
      "r53",
      "r59",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "The Company"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/TheCompany"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "npce_AccruedAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r156",
      "r157",
      "r158"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized loss on available-for-sale debt securities",
        "verboseLabel": "Unrealized gain (loss) on available-for-sale debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited",
      "http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/TheCompanyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "PIK interest incurred but not paid on term loan"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentInKindPIKNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A payment in kind note accrues interest over the term of the note and is repaid at maturity or upon refinancing. A PIK loan is typically unsecured.",
        "label": "Payment in Kind (PIK) Note [Member]",
        "terseLabel": "Payment in Kind (PIK) Note"
       }
      }
     },
     "localname": "PaymentInKindPIKNoteMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payment of deferred offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r169"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Taxes withheld and paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Acquisition of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails",
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofAvailableforGrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails",
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofAvailableforGrantDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r5",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r5",
      "r464"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued and outstanding as of March\u00a031, 2023 and December\u00a031, 2022"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited",
      "http://neuropace.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "verboseLabel": "Proceeds from issuance initial public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/TheCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from long term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants": {
     "auth_ref": [
      "r487"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.",
        "label": "Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants",
        "terseLabel": "Proceeds from issuance of preferred stock, preference stock, and warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/TheCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r39",
      "r97"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock under employee plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from issuance or sale by company of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/TheCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-Term Investments",
        "terseLabel": "Proceeds from sale of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r65",
      "r145"
     ],
     "calculation": {
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r67",
      "r133",
      "r415",
      "r464"
     ],
     "calculation": {
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails",
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year One",
        "verboseLabel": "Purchase obligation, to be paid in the next twelve months"
       }
      }
     },
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r100",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r99",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "terseLabel": "Compensation earned"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r100",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r98",
      "r136",
      "r549"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRecognizedStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Government Programs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r442",
      "r477",
      "r490"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited",
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesOutstandingDetails",
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r8",
      "r85",
      "r131",
      "r424",
      "r426",
      "r464"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited",
      "http://neuropace.com/role/TheCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r140",
      "r181",
      "r182",
      "r183",
      "r185",
      "r191",
      "r193",
      "r243",
      "r358",
      "r359",
      "r360",
      "r366",
      "r367",
      "r380",
      "r421",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r218",
      "r219",
      "r224",
      "r227",
      "r228",
      "r232",
      "r233",
      "r234",
      "r313",
      "r314",
      "r411"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/TheCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/TheCompanyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/TheCompanyDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/TheCompanyDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Arrangement, Expensed and Capitalized, Amount"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r0",
      "r12",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Units"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r100",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r324",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails",
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofAvailableforGrantDetails",
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRecognizedStockbasedCompensationDetails",
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r90",
      "r92",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r74",
      "r76",
      "r77",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r85",
      "r150",
      "r151",
      "r152",
      "r211",
      "r296",
      "r297",
      "r298",
      "r300",
      "r304",
      "r309",
      "r311",
      "r457",
      "r474",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r75",
      "r76",
      "r77",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Stock by Class"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRecognizedStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested, ending balance (in shares)",
        "periodStartLabel": "Unvested, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares Underlying Outstanding Restricted Stock Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested, ending balance (in dollars per share)",
        "periodStartLabel": "Unvested, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails",
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofAvailableforGrantDetails",
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRecognizedStockbasedCompensationDetails",
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails",
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofAvailableforGrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Shares available for grant, ending balance (in shares)",
        "periodStartLabel": "Shares available for grant, beginning balance (in shares)",
        "verboseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails",
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofAvailableforGrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (in Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Vested and exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested and exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Options cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options cancelled (in dollar per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of shares, ending balance (in shares)",
        "periodStartLabel": "Number of shares, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRecognizedStockbasedCompensationDetails",
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in dollar per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollar per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "ESPP discount percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedTerseLabel": "Shares withheld for taxes (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r119",
      "r120",
      "r127",
      "r481"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r439",
      "r440",
      "r441",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-Term Investments [Member]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r52",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r177",
      "r198",
      "r199",
      "r202",
      "r204",
      "r211",
      "r212",
      "r242",
      "r255",
      "r257",
      "r258",
      "r259",
      "r262",
      "r263",
      "r296",
      "r297",
      "r300",
      "r304",
      "r311",
      "r387",
      "r446",
      "r474",
      "r491",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r24",
      "r78",
      "r140",
      "r163",
      "r164",
      "r165",
      "r181",
      "r182",
      "r183",
      "r185",
      "r191",
      "r193",
      "r210",
      "r243",
      "r312",
      "r358",
      "r359",
      "r360",
      "r366",
      "r367",
      "r380",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r405",
      "r421",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r210",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r5",
      "r6",
      "r78",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r5",
      "r6",
      "r78",
      "r85",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options exercised (in shares)",
        "terseLabel": "Issuance of common stock pursuant to stock option exercises (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited",
      "http://neuropace.com/role/StockBasedIncentiveCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r24",
      "r78",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock pursuant to stock option exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r5",
      "r6",
      "r78",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedTerseLabel": "Repurchase of common stock (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r6",
      "r9",
      "r10",
      "r60",
      "r464",
      "r493",
      "r501",
      "r538"
     ],
     "calculation": {
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited",
      "http://neuropace.com/role/CondensedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r87",
      "r176",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r312",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Sale of Stock [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/TheCompanyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/TheCompanyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r237",
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r56",
      "r57",
      "r58",
      "r213",
      "r214",
      "r216",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r197",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common stock outstanding used to compute diluted net loss per share (in shares)",
        "verboseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited",
      "http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r195",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common stock outstanding used to compute basic net loss per share (in shares)",
        "verboseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://neuropace.com/role/CondensedStatementsofOperationsandComprehensiveLossunaudited",
      "http://neuropace.com/role/NetLossperShareAttributabletoCommonStockholdersScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r467": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r468": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r469": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r471": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r472": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r473": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>64
<FILENAME>0001528287-23-000026-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001528287-23-000026-xbrl.zip
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M/8T(O)[YI(;B>[_4;NLSVDW/HH_&W6<'/=1W_[G^;GK-]3WW[!XXJ*H#'!Y
MEOB'LL2Y>?H[P/2PHE\W[=&#]UMD\-&(/OIL?- XB;E=[X\O%V/!4W)URY/2
MM:[D?3CF;V:IY3NCE?YLGS9YCQ\9;>&AOSOPK1UX*_R"S/^6[?S_4$L#!!0
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MZK:N;[$"6M^XP5KN4U:NMYQ"(]BL2G-SRA<NO>IG=?]F;P+W_P-02P,$%
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M_WEYHEU,A+")$ERV<?F2%^5,/'"JXTNGUZ$/O6)S^H( S)<&W<G;H\W_;H!
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M$U9B(5)*>#P;+%6JN0RI\%ZIH"F2!BPIPM<9XNLT(U-FGA+XU3B.LS]%K$O
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M(9483!*E@P,L"\Y0_6RNIHJIEI.I@/24,U@7%7<X98C:5'(A4D$,\UPQ8PB
M&T&_N.OW$VZDEX_$Q_FQ\KTNTXJ7%X:7:6WK"S:$&,M"2KV.=IYTJ<'$I8%X
MBBDLX_+Q.X7SXZJ[]G4JAEHHAM(*& HIE2(?< S'QJD&3DJE@]47B)ZYC  X
M\G7*R3I!MQ/8W\;&9XQ_J#APR3BP_NT+8YY8G=$4.0JVA]8\E9[&C4:&I!8
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MZ6]6=>LM;!X").@X9SV I%9W9>8OWYD-"C8H.$9!(;%6,N/.<\ML$$91P4%
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MHRA2#CF761I(R()62> R\@N!>U'CU&.C="LO>V<CO=_K/GGZYOG SVV&.J]
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ME$-*$(ZT5%YE"ALM6 2P!K@:X'J!P.6L<%1)G0>B&'56"2\LQO";S8(+V7V
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MCMO9DH3[)D_U;<3Y,6V,&7%N)/9V$CMG/W".+<="()=EX!5DF4669!IA[F7
M4CON[-8V%6LBKR\J9/&^#*EOI^X&K@)3O<%I*.M(U0L+8*Q%><PB'-5DV@UY
MB#U7=>G>3M<?1E*ETKX&IVZ'4V[!LLBED>#+,"18YA$#MP<9I302(2-26"D"
M 9SBN$E\/6.I?K@1^XU4/XY4SUD?UF(M@9Q(!\,1XW$J(0L.<:M$;G,0;,/C
M0(![-_(U 8Q[9DW.S>6=4R8OP_%Y3)-C1);W%54:'+H5#ITL6A?4T3AI$87
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M-279=%J^Z+M.KS\LPZAH(2T5 9^B0B:0A;M5([R@]J_*(*!K0_:?%!BDV=E
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M*5,"J+[/>%=1(-LM$W.XP###SJ ]^D"4V^^FO)SE^YB[O5V0UF.K-,$*S.#
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ML!ZEDZ*,T\OORCH!%?DJ\EKEFLU,&I[(QB]D8JJ"MC53#)O_HGZVM:1T=HF
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M_DB/4<W-J78]5,7I/P.,8#1PI1.,$,T<%88$[0++XF:5W#!6+R7D%6# #Q/
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MP=>5D3.Q[_@0_QV:3E4QZL&]<I5#'0-AZ9=0N1GC1$'MV]URL4(@66"""2L
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MCGD$<!P,$=2XX%91C>\I86>E0Y*E[^]M8S!UXE-=6\%@>L/@-%=JE.2GFR5
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M8 %:8$[>6D@>"C?FA,3[T^/3'FP0X>T01OEY.N@_X;??(PA,W+;?&LFY2G+
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M"_2 6Y;NIZ:3A%' 7"Q#8QRM1JH,63^P=*3#6 *0B'<+6P^8O:Z8_78L'IB
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MB"=K"0P!.J%O-)8(D:BC463HQE#7=HT-;DPL;DS5N3']4B@30(2H_1!2E6/
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M6F.>T9AG-.89W5#3E94_44@M:KA?K.K'@MTHE.OV;4KWSR2PHRO6,SPG9%8
MBJ 3&BECOH/5H=* 1X&1AKN&[=P2(1]3TO(C<-'.WLX^??Z4G7YX\151],G[
M/^R/WTZS3Q_^L&".YLFWV'S]_)5[,CN=#O7(3[]_FIW.7IDPQV^OG\.:GB<P
M@W_FGYY_A&?__';Z[4_GY/.7RX_62VSI^778CLM-X(@-%U5(!_X3.#KC\!>W
M(R2%D!NQ^^2I/7%!@+GA'7<7V&];Z\@SMN(95I+XKA6""I>&CLG3('1 M79Y
M8G$>)0;;-7QCY!G[QC.^#7B&%WAF9#!?]WA@Z8Z;IGKHNK:>!%;@^7;J16%,
M/,.Q)[YYZT9^8RO@.[K7?ZJ6(9R5^:7&O_(RSF2M^4X4O8!68S#\%3R/)9;G
M)8GK!('OQ,P/#",U0) :09(:9F2/..FP>=[E"DZRK- *[)3K/FRH[MBNKP=A
MZ.M.P,TP" )F1>&3IYX[L<)]ZEPZQC??0R:,"?\W"N*(,P \IA-&L66EL6EP
M(PT\%HV Y] O_Q#P&'X:,L-BNN]&INYPE^NAD_BZX1F^888LLGGTY*D)<,=T
M]^GV/P9+D CK)@B3+44%6X")U!GG-D:@A\_%0LQQCL/4<P'&)&Z8 )B/>!I9
M+$9^-D*8@^9BI\]6($QJAH;GI;&>6'ZB.YYIZ8%OFKKO![X'. ;^/W9>#_P)
M"*\[4MH.U)SSX&\_<[S 9EC[G]F.$YB!$[# =[D=NBD#-6;$,(=^^X<8Q@%]
M-; \2S=L/]*=, AU%L9,-QS3=0T[#@//PA(]P<0+]NGV/RK#S/K.K:,IY@I.
M%@:.P1CGG@6<##!Z%(=Q#/+,<OPXB>/1%'/@G.S="HZ);)L%(0_04<5T)X'_
M1*%EZ%[" I-[H6.[Y+(RPG 2^JLM;4=KS$.Z_PEWG2@!Y24$(,-"*V2F:X8F
M#TT6.5$\NI\._OX/D0PVO;<Y\_0X"5/=B9Q8#VV.+:WCE*>^9X<I%AN< *:=
M>,X^W?\[LL>(:VSO.:BAYJJB \3-$,Q]IS0=.N>[ZQH[(^?;+\ZW&JQCV!:W
M+=O2/<,,L)Z"J[,8V)_ANI$5)Q%/[>#)4V\2!,[$\,*[=;P?<MKDR&_VL*[/
MR&_VC=^L("V/I\Q':!4Q"]MZAWJ41$P/#(_';NHG#B(M%U'6Q Q7,\T.C]]L
MD5VVMK?A???+N\^.GGLZK;%-Y%.,G>OEC-RL3:3WY.D]M8G<.1MOW0W9VZZ%
MKY9\IEE'V@F;PVYAO\4F"^YY5L5U5:EFK\=SEE]6&>7[M&T:L75CUC2$?<NK
M.A==7U^+%L/=*+M]:K-+(_Z:@?J6Q5M0Z<>BUJII4>=HOV8)90VV&9!)?Z=8
M9Z>*NNPTQHU[NU6VNU4TNZ4MBS,.PY?:1;:<TO-QTQYS;8M='$HT[LVIO>V<
M&FWBIP6-TSZ4S060H/Z"<YE_R?.*7U#S7&JV!M/^HV8E7)?\$LYS491+;+K[
M$A[43$/_ SOMPF\&2Q9O6L!SM!P:IA0/HQS!7KOPZ@M6)GI>%%]PTSHKH"[
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M^HTG+74SO,0YRAQU%9MGABA-"..J4:0'=Q;>+L3Y64%0JY&+B%L;#HF7<\/
M0(-3>#5<,@"5UQ(-W EQ:;)2+!]V9S&]K$C@HXBCN1;B>-!K<ZF!NK= DPVJ
M\' $B%EP\VAC^_1K.2V;N9J7M!/".="BA4C!0UM_K>G.H'R@2]>?!JFH"BTL
MB@+U>B";2EIJX/_-:S($E7A=RR\<MI=XJU@ARIO>0GXRCTPMDA<1"028!M;:
MZHE%00 2O.+.D/%#FE66@H4W[!(92%E<( '@TN;4.@!?3 M6QJ3V8[%12[B/
M9["!9!* 3:HX&46(G_9VL.2 34K1F$J8)@3U$ZR3#S34#HO0Y>SAB68< #3
M-Q<+XH3+"B"N1,4TUI'V:MZPN8G0(%A./X&]SEDLY-DFZB=037H$8?Y+937
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M?G6.?OKC7M[/'9G5JRYUO.TF33SO)DV\:KA]HW*]$^D3$]S6%R(:GHPO(AV
MDAE/2-#LY39=9S^Y[B*MS2(9V):_JE0-(89[$?%%&S33N=R##-B52H=M0+R(
M'6RMD](-V[7%B-HALN!6]_=MMK*X!%B-)FI+ ZW)=UUE-"C+Y<[(,'+EPAZ4
M]D.K,A78(#T'M/ZX!#S1%*?LQ3',*+8@H_B%IE0B*=58=!"M2_)367ZZEP>
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MJ^>Z&6J-1B8Q8(2&#5Z-5_)[\&(2KM%21 %,&K,C_2/A*2=).H'[!O>IK;L
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MA9V/-\I/'E3^CEB:.70^SRO<S6W]AHA0TH4Z@9&S;=8@D!/HQ4,U_V\0R 7
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M "JX/W(Q2J,B2Q)2F7\I!71DJ _Y[DS9,%\UEPWO"'$3D)4["3$#J/SW?$/
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MDVS9A_N:Y2;H65W?#-MS+"4P6ZQ+CLP66_*L=0$=GH.'UR/CO%T_B^DS!?^
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M!10@EK=A*X&0NM('?PNH(*W=!EG+RQT3TI94>_C-8R.C8Z7\^7)P],32H4!
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M*-PT9R@%H;S_X]0/M%U[!1"L[WPSF*JQRJ.X?J>J 0RKMSRFOA07F)*4$R5
M_;^M)"6Z4B)S45\(^D26PQO3+,TH@L^]2*5%) ^YWH5>T F<Y9QY00[@QUOJ
MHKWN (-DX@\VRT5J!6"D"S;G!#;GCQ=LSKN928.\S6;O?=*>,#Q,7^60I>3,
M 8YGG2'I'^,H<C>O**88E>] ?!'$.J$HSJ(>T8RJ6B.R*=GP3MN5\S/>OBQU
M%+B*2@Z$7$2B ;#+$(WBB3*,XU;>DOVDGH4<#_'O%S?EZ=R4KI2>684M\SF/
M(6FYQ<!TK;US"=,L'2*N ]1M"3#H'00KT*P;8A;H5H>$'<]]@7J-O9'02JD?
MRQ<1A^>7S?"T=![1,-;6BW=RL>?MP,$S? T0@$63Q@9/S!H32P]#?P/.W:X/
MZ=/0@F$1J;+@<]D/3[<?-!YA) "A/-!-+: I-=U\9AD%$J.6=LDD(H8)$WCZ
MW(I?5N^I3[,='#:Y87+FYJJH&D U[;"G)MQ&^$.5HV'V.J]$7EC;?B]K^XM=
MVW3% N?M2^6"/!<^137M<H:CKXLQ6(_7Y6@^]=',,29"$@@V35/YH)B>\@,*
MY]X&(O#U[E9J6$1&[[)F3[MF*;FS]H&,B8:4DE>9^_2@ZR1-A9P/+P6K6A#$
MMBV(<UJ1K<GN5-CZ-((.N.\-@-&9(>?^CCF1FO.+2[]\4'I$HG#75&X:?86\
MH93<N ?(GTVT+S#FHE CK7 T-3VW9T)*2'L$)D,M0/H=Z;JN&F0I#.!*P(+4
M!J"D$E]V_7;QA[]\NNBNJ1W00,B,=5]LPCA"!X;:EL9-6*6_%*G^](<A-/]B
M,1M@USIJW0#S;H\M/>P'P'C9Y=XY$=:^D%&B_+0-6'H+2G:LC,<]/FP ;S,1
MC1(1RQ3I6Z9[5=_#).M/I51^QVW:)Z@4Y@/S7*BWZ!(XO2[*)^\(#Q@4CU9:
M:;5VK$SK;K-A9FG9[!=(ZU/>4%-3,+$6<EBS PP,/:2BE[TVIA6G^5*;?5K
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MZ\O\TC0<_-[IN7Q"DFTTJ9K9,H$L1";('CM-E?V8\F$PDU(VS9]L<=HJOLJ
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MEK:TY$MIU'+KN)^WTEUTE )'+X,-/IC)GTQVHZ:E,"IJK]B*=#&\O4GU&,V
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M=\>[_X9WDX\<'9$,)PQM@HT; .%>-I$LM7'=K%8%BR9*@\IQ=$]^DT>M&+@
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MB.^&&JC#8L1'-1CW][FO;Q<**++=P&J"QAQ]%]:04@8U%K$6G(H$Y;3K5G&
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M?D4NBILQF2M=4E"FH-+TR_V663VGA"">/\$&:Q3A#3(Y;UKTN\&#%362XIZ
MTKR( R6JZ;(Q;.;FD.8?S-J5KNF,G>6ZA-AZRJ8WXSY=/92AQ9("'D)[)%^&
M"6MFSJKV-B,N()4:&\D'<P9"QXC.V4?-JO _SQ%,FM@!";S$N",&"DR!CW\
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M=,/SZ J+@.&H0VJ)!9:U8?KJ@971>DK0C^CSV H^5RWH]35==N:=RM>TXO6
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M1&%_9FHLV=[HK=!^)B(3Q+^ZQK093U"ORG ?[MQ/Y5?"T%>[[?GJ.V9X  C
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M*E'1D 0-0B#/NMU@/J@TLV%,B"%1V#Z*8FEB2QFM,',WJ<'78!0U5R*09?O
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M%XE4KU 3HL;K"FA$_[O6O^Q@)!$<<:J]+?M_KYZ=:F^_5G,](VKS("4-$;(
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M5<:+I6\839WZX+E5=-(%^3==JC9U]SPXC_D*D/78"74REW#\6G+7))HN!=.
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M_Q=,Y$ 45JOO)0QL".QUO7K^[.S_^4O;?@ [OAF1B@W/^NJO7Q%88!]N@?T
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M<:W9=7-57]3'L$96;KG5'EYPHE@Y">\+D#&OA7()(Y;A(A)Q-HT=GM=4E^W
M*! T:/75,.RD.8J63H@^N1E%C&=27^U6B;0//A2%E9U5SYJ&:)B%%#5R2NFD
M(4HHL?F%N*+%;U1D&N49!FI9CGR>%B"MB-+,/:""58B00V<P9U1 E#'&V)R\
MOMC<CNH81]O9EE!I9VY!1Z.HL4_J@A3QY24@/=NV:ZX8LL3B? N5J]>+!0GV
M,OB,W:'("$R3\4?11\PE5"'TG8 E?8K.RCOA &K'695YUF!1IL*#U#=E29Q
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MQZY*O OO?5 M8'9 I@Z^,""N(M)E>DWMWA.K#-[S< 2 2&'N%;.J3]%(WKF
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M,:30#UQ2'472!-)TZO:0EME?//M4;S(KI_R[M!U_Y=*,?RMO]96D*YE Y [
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M9%"=W<X?'3@RO<[NUS_8BCA#@.LXH,@*4TSDP:<$+(OW>921O? D7C,X5KK
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MJ"]53%7K]D$GE"HWUXH-5*BUS(5L&!EAV<]E0LBVK?F2.6.2Y4PTZP9!ILS
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M^,2?T;B1#]P["4/0N?45HT/F,WP^-AGI4CDGK@+X=B4:'2+7SEA7("M7291
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M?9VS343>F,"/SR$49@)W] 86+BW95N4@!*E :7HY=6&$#WOA\>/M57THX]5
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MZT6RD 2+->Z*$)WR9'%ST,+;HJ+HU=F]CFA(44]C9C1413-Z;,@Y,I3):Y5
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M9'X5[G;=%=H"V+L'0X_R:-2I807A\U#C>9IT%<#(*A81F083L-1[7HA1K'A
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MD4AK,S*==.T>6Q-IK:JG.":"CN27EJ15![<)7+[\ %<%--;,W0[O6XFU@Y3
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M[3TS:KT]]A'-W7KI_JRKG<0^:B&SAH?+,R#ARPT@(C#E!#+(S-7AD/OGN3;
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M2GF5#'G8W:X_1U@JW8XFV\FYVU89-ZA[6;HUN^N<8&1GK0+N"NV2(FEP,1E
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MJWXG^=X!F7-1# 6#(AVY+[(VC\\L@,]$Q6R<TFR];HOKOO&)*[T+N3:,,,Q
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M#TF:)S.?'O27CE(+_\#^Q[.:'_D9Q^$CSJ^3"5-\&?KCV0WH-R>/9%(5\C$
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M.+O>%(1";_"+@E;0JZ@1M<'OU0:_P YG;K $NR@XVMG(]P0NBN]>$SB]U<.
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M<&VY=VSK_Z@L(G^(]KJ!M/X>'0[FAPT2>TJ,K]&(MN"(/@7)7S*!L0QEF;N
M!N,:_"XW1#MVQ N*TC/TS_;^R;S;YF"0))50,<!18L-KD%GE<D(!80G/8JYX
MBK!7?-]VZU-;=1KA(BM=KRP,CY%S6QEZXS$P9[M#X1^#MT_E4(%VC]H>-YIN
MGUH[(7-['^I=Z-5>330F2*GD\X?/E8T-65^*7HNZ^-8&CV)%"4=9 NP=I)G%
MB@ .8[-733*M)4MMW*YG%5C'KKVF^$@E8IOHC&?W=IM1+'Z)RK5C 5N+[5T,
MU74DN,IYFDE;VB&V?C6: DH4!4FL>*RAP!#2V4)]L76"/[G3:N !H>V [,@Q
MPKATPS+NJ+AQ]3!?_<!$;H%M+I578MN=]K//JX]_XU5S?1KF/G5N/1$+5P37
MM>.Q*^1Z K*G?*YO"_V6EP/.-:O(UHPD29YE",A4"8"AQ(#'/ ="IS;I*E4"
M>FT,CW<WM9WB9MK,K;C1?"6O'T6=P-@B25E, ))< 1Q+FU*)9"#F2)LE'2G-
MM9]Y/QS*XUCZK9_77R+1BA?=E4M[* J*L1OUA\-M8+H_YB49+"+;#Y5 E'ZB
MLU%IW$WQI]3M^-:Y517/K/'85#J;68*!3'*@(9( 8VL!8(D"J;;9MI'("?6S
M:0<5;VK+P7:EP&#EM1M-?;TFPWX%CM;MBXWMT(;K"PSK&04B0Z(?O'QD$.$N
M5%PR)+"'2T\&[:5GP-!6Q<MW!J5NCT0YISEE$C 6<X"Y9( P 0'+I%D-.%*>
M+FC[NYD:J6^*Z4KO8KH'@'3CT_/A&9@7'Y>_W8[&[O8R6^5R X;='(4E5$C-
M_D[&#9<YJNA.*,SQIWL20;<YM<8QAK*<)!2!E'%D3J&ZJ6[' :,Q8B27.N;0
MQWB\U?;4K,--G/7Z,.]M<=Q&S7&J]\-BZ/GM (#_]-U5-=2<W6IYW(FZJ]+.
M[-SS2 A[W*'+X.8?+1W$LYPKE*6Y!ES'&F B"6!*)B#E2J5YBC1AL+^%[K0
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MO0^H;M/S?*B&-G+XHW2F5\A \0@'.KF@3\BIR(,33_>C@*<5P3<DD!,<$ZX
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M)QL=1HK>9XL7K/IZLRR_%5+)YP^?C4QO%J^+!5L(:R47=?&M3:G%$I'FB&+
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M4Z>)QHP(D,88F>-Z3 %AF3+']9AIE619KGB'YZN%HYT_!)JKS@;<7S8Q'\&
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M>D5T@D>6?H\5<>DY E!#J:4A7R02#; PPV"&!(&<I8JFG#"6>088!1V#<9Q
M+SX*;MP=%-F!>7P#:2/L5?1V@^E&X'"<[HQ-('X_W=^H7.^L_E/>=W_1;PVH
MS#GC@S6D-5$3DBL!E>1 Y_::728)X%Q"(+#@,!,\U]2)YQ^U.C4NM]X,1547
M@LVCWPV:]\O.:\0C .4Q;,=IH3<80]]9],/!><KOU?O8M#8O;$UI\[?-='[<
MUBA3=J_XJVFY_Q][)KJS,_IK.9=O;N^6Y;=F$%8E$C*1L3Q1.=!2VZ#R/ 8\
M3E.0Z(QB1:A&9MGWR79WN*^I3=.UJ%&Q):MGNKLCT+JMY8$ &W@J;[#:%G.
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M7-V):RO_Q![D<>.MV$Q.(JM"9'4(F,/5$;U065V^PP^;Y]41G)/,KZ[/N>5
MK/29)>U_LQI%7"AE/I2 TM36OJ80D(2E .H8<AAGF<1>O9TOC#,V3U4?\VSE
M=%GI>>'J<QYV$UK#G(=Y =7Q..PB#$&/PTY'>87CL(NJGC\.NWSYZW30^LU<
MN"[N%]6RLNQR.M54I[E"MFJ>*8 T9X RS(&63*1IFB0\]3I9[T'&L3FA6M+H
MT8IJ%B'=,TQ[L*?C2=GK6JGO [. [:<J3<LR_CH!MM1V/,VD6DPQD@Y1YR3\
M2[5]:H$X="^GMJ&ZYO#*LA$,F]N%Q_WB+7N>K=F\;DJ*<ZF2E!KW'[/$+(6Y
MB2A3J0'57.24)QIK+W;1UM'&YLAWPI:+,G"_B&IY?;-DVR!V\\C!@.O9MQYC
M-MMBUD>K5Q=0@N6.MHTU<!*H@]JGV9PN-W5O\O9A5MCV-:5?^F!^5TP9XGF2
MZ 2D&60 )9  GDCS'66$4@8A08EOE[>34<;F,[9-S"I)FU/*4E;_1F^GH+9[
MBV!0]>PE.J'4J=G;111NZO9V^M3!V[U=5.Q<O[?+%W<+&@Y/)#\9J3<KV\Y[
MJE&NN"($2,PD0#Q6)E2@",1F'4D3G& 8>\4+EP8:VVO_Y9:,E8MH<IH1DL4I
MB 4V(5B>Q("KS!9TJB3+L,SC!$]_J!5?#HGG_H!_-43=@JT0*/7L04_R9792
MAHNOKN$0*+2Z.,R@4=4U98\#JJO7=^5M*]8/^K?E4A9W"_E5K7[,A"J^+N?2
MMN/3C(L89"2SF_J* ()T#)(T)0@K#DGNU#;W^E!C<Z]64IN\_&AEC0HCH2^1
MU450W3Q"&*AZ]@D-2J6890)=(VCTM0VR#A16U] (1F!U<:"!Z:NN*7Q*7G7U
MCF[^X:A7=]4J]$&_F\TWYK>G-&V8)YPES*S"M%( X2P%G%(-B.T2$\<\317R
MBR$\)1A?:-$H %BE0;T[OZV+%LNGYTUY1K\MG]YF9T5L;;P^WZS+!I+KY0&9
MQ'=C7N,-)Y&LL.B^]>]KY83H6$"< YI#$RD*P@"-60Q$"G6:YIA3X34U]&CC
M(>:+$PN+2Z2?I<TK,QJ;JZWESEA^,&.Z34D]FJCG>:J1/*I%KQM&E]5)U9NX
M)_<DJC4*-WUU1"[0G.8[^J 374=HCF>_KH_I>(0AQ.9I,[=Y@^_4\TJ)67FJ
M8KZ?J_)X92'OGI:K]>R_R]]?Y'F;"D(2E6$$,I@D "$L -5FT9W1C.-8BI1(
MT8$V*91\3J_P\.1*-N7I;]&>DI'<T]+SJ"24*1U/58:TS$ ','MVV-=I$FVU
M*I<&^WI-HD:S2=ER8UV5WVS5"WAB$QCP4(<[H<0:]APH,)@G1T:AG]\QK6G;
MM7O;,_9MM=5RV)M[JE*:Y3E-01PGECDJ@X"E&@/-M$@1SF4"O?*V70<>6_3;
MR&T#JJWDD^CME>W!V\!W<[A]0-JS0VU'LRZ4[Z?1I2]:H1)Z7(<=-DO'$XR3
MU!O?^SM6FYA%X]MEV353+<1,%1]G"W6_5D_%5.6)3(72@/(T XBE"G">4Z!(
MRC.=)R*6?G4E%X<:FT>RDD8'HD9_6F&C4EK?WI:7$79S0F%PZ]GM=(7,ORSD
M*AJA"D N#S1LJ<=5A4^*.J[?T:$-YAYQ1M,NS>X:%U-*=<J%8"!'=LO6TF 2
MF26V@@-: DR:0B<&S-91QN8B&GZ:NDAVV]=26&$]^BQ>1+7=-P3#JN]H9)_&
M9[)KB/@V%$P>?2=#P#50@\ENL/FUD;P&1VN_R(LW#]<8\IK\!QT@KUY\<]>R
ML@1X*A-S'>(<Y)*D "6< H8@!R)+N$PPQLJOD.UX@+&YP?WN9)/H?\;_$L=P
MQQ@PB8PTD[CZKSFV8IOU]^5J]M]*1JRP'_+?#>S?__F?S%SQKRFTMR1IN9_S
M3HDRV_/@3\F_1@F>I#B9)#$J+S,_Q@A/<@R;$69%L;%/M[TA]\Y.NHPVL>0^
MS\H2@ZKY2^=V5-6'P_7LOKO)>S^QWV\[]>^5B>]+M'MI.'6@?_@F4]7C7ZNQ
MU(%R+<VD#J_KYJ?>*;Z^7Q3K53EY?3(F?K=\8K/%-#7P0 ESP&/, ")$ Y9F
M F0Y@S&E,,Z8%U?8I8'&YK>LG-%.T$ED18W^K(3U7.!=!-?M?0\!6<_O?4>T
MO%_]:U $<@$7AQG4%5Q3]M@E7+V^PYKN\)E_F,] N3]N6;'-6ZB*M0V2IHHQ
MF,@8@=RF]"*<:D!3XRFDU+E."4Y3%'N<,[J//.H3Q$90CU6,&]P.*[]PZ+V2
M ]D3>0MDN;H)CJ;' C$XJ@.M%@.@Z[=T] *J=1WI]J3A%I5>FAVL,/WN[++_
M=F,M[MT/-IO;HX,/RU59E_ME.9^;[^TETUCD6"0H!3FEU*Q;<V4[<&4@QUSP
ME(E<Q4Y[_;U+.K9 LBJZYX[%^;RU.'^K=Z27JZI4/_K3ZA[5RCL&IOU_7%PV
M)T?R(>A[@_/_2?O[[+J.Y',PU,YMOY^'4'N_ QBE??^X3P$&W(,> ,?#?>PA
M!AR8SJDAWF]BI^)A_5VMOGUGB[,L(D?)NN4?WYFEW[9SZ90S3J6M+M 4<H R
MI0&19N4J<IX*3A,*\V%(H$)K-K;@Y[<]RJA;B8%' W+?G%.O^:$8)!BZB:EJ
MV]AE"T]4XA.M#4!M/%8G51I5_&2AVNLV/0*BJ[[L_]KT6,'U^FN0:O5ESF!4
M7+T)>&MZ]-UB/2OKUV8_U%<E-JNR]>+[G[8=@)(?C(G>EE5NI:(/^CU;+6:+
MQZ*AV=[E\F8QA"A'&"AE-R\4)H!HJ$&L11PK6VR.>;=$ZE BCFWBWD\2_KQ<
MFT_%C,WG+U7MFM$UVBF[7]S6-1<[F*4=I^97M5_?<^R>Z?;5VS=9HV!D_5RT
MIZ*]J5%RUV=@H*3PT,8(GCX>3,!72C0/#?#EE/3@(X5H[%+5:=YMTXNF&J4,
M2<P R6D"$,DTX%(0(#G)8I)"+OT*;-J'&YN//VKD<B;]JG.%^!7<W;QT.#1[
M]K@G35OJJN^=L'TU:KD$2B\-6DX&>\7&+)<4;V_(<O&N5VC?.%4TH0IJ!1(A
M)4 YYH#F*@6I8BAF.DY)+*;/9<C]=<U6:S<7=)-,/N_4L63]O5YOU.-L8:<'
M&YR8I4E4#3U@%\4IRD6BJ+2MOC &*$O,E$%2!2CG.2(YH1HEM:W>+^0H+=7(
MU9^=WMMTVM>R$,R48EG*0*HS!%!,":"")4! B7*&L::03M?+-9N/S#H[F7I,
MRW5N36HWS#@S-PO+(J24:PU&&".ZQ06#F:;GL"%4Z]"1]/P,G89]DRQ_G0Z<
M%Q.\@SRT>]7*;%WN!9I1#BH%W\T*,5\6F_U-%ZGBG.2)!@HQ9&EF$D"1SH#0
M::QRF:=FZO2M:7$??FS+JCWIRS?W0'[_ A$/.SBZS][0[=M?M@$;[62/_NQE
MGZH;;@&+4CP&'[QDQ1^8<P4M'9[2D=2@[F!G'EYS)FP[HE$H,X%C"B@6W 22
M" )*1 :XIFDN39RO<J=BY>M#C<YQU0P@\YW$GD0&EU%U<TUAL.K9#>T)N<>:
MTD.[N>MHA"(RN#S0L$0&5Q4^(3*X?D<W!_%)K:N>=I8J89L3]6VY5W97DZ.^
M8<5,3',4$Y0E'+ ,Y0#!) 8L$0*PG"008IDFRJDW2,?QQ^9*/C5LHP[LLGX^
MQM<P;HZG1[A[]D86Z;KYY2]6^%_WDD(-WOL%N5LVWU*'<'ZJ(WB!G)?OZ(-Z
MM([0'+NYKH_I>FBV%$K)PI[2V=IMNQGTH#\N%X_?U.K)EK%,>:X)PA"#A,:V
ME:94@&%N5GQ0JU2GB";4\^#LVI!C\W"-Q-4)^MQ(&IEAGR)I9/4]*[L*M^MY
M64@0>S\SV\>O$=?N'UN!@94X>M>&98>3,U=X@IV>71UPX!,T5P!.3]&<[[R9
M)J4ZHZLX(Z8Q(7DB.0(T2^T!O9: 4AM695!J;((JQK..;"G[XXS-N>R3IC1D
M)9W/XB]AZ[Y;="-B VP+[3A'*B%[)1TYAT-X[I&#45Z+@N2<JBU,)&<O[QB$
MF(_'=U:H!SZ?/58TO1MUO_BD?JZ__4/-?ZC?EXOU]V*:9DG&4IV!6'/K(3 '
MG,C4++QRA7.E4IAQOW8@CB/[O '#M %I!(^66\DG=@W 5?3,9F4G$'LVN[";
MH^M2D^BI5,4S7G&TC&/0$A[MOB.7!N:'$YAM)]))]!^*K:*'1<!2 D^00L4O
MCJ,.&\3X07$2R7C>WC4QJ.Q%^_[GLUK(V7ICG6+53DV^V:P_+=?_H=;VLV*\
M%\Q5GFF0*9D!)(SC(JF@ .H\5HG$C"+H%=\X#CRV@&?GNG3T7-.NEV<\JN%<
M-]ZK3EDV;HP)L=S88Z!G]F)7PKXY"H[6<8R0>L"\[Y"I[F"]+W/4"!WQS3HR
M8D<O:EUZM)#Y!7Y0!4LE<!QVX*P!/S!.$P0\[^_FRZJ-IZ]KMBZ+B#Y:(UNW
M63&8Q7',(!(IB%&N 8HQ!91G"9!9+$TPEF-%O2IK6D<;F]>J]UVWTD:-N!UY
MXMJA=O-&P0#LV07=@)VWVW'"))"O:1]K4 ?CI/:Q5W&[J9LKV58(WA6%*H_Y
M]\[O?E?,GO#+A\476R]B"7C-!9^6BU7SH]W;WN/&9U#F20X18)28E5\B*>"(
M)D!PE7"H<B3]6@0&E6YLKFI7X#R)*OW*\&I/PZA1,3+OX%;)\JI]-<O#HUNZ
M'83]$+@YQ5<S;<].]%6LZNU^>T$_D+L.*]N@[KT76(^G@WX&\9L^I)I-[\QD
M).V$]&'.'J<PR["MV0:08>/ZL6" 9Q2!5,2YX@0EF*4NKO_DR6-SVUOA(BN=
MFZ,]A:O=2=X$0L\.SE%_9Y=T4=<S[J10XE\>ES_^M[FG\B3FFYT#.7W2("__
M106:%_?R!9T3H6QN^>?5\L=,FI7ERQ^%9:RT+:<*FZ%Y9YGO2V\PM:L_E&H"
MF#;+0"0Y 231"4B@TAQ)FN0Y\2G!<1_:Z[4=H-[&)N64U33/M>R6T^:7NAWW
MK^:_6H.(;57PSH)RM8I;A-0/UCU[!PMS60SS>1_F/QJ8M\)'=]=A[I+UY(E8
MN(0GUX&'SG7R!.1,FI/O$[HYM8=GM6+VB1]-!*,J%FB5"8%U"A#D&J \8X!F
M)L+0,8TI5$PP-W[;RT.,+;;82AC-K8AE8RH_+W0&1C=O<QLX/7N5'2ZE=)-
MO-C7=0_D'\X,,*@?N*S@\?O><F6(+B8?C'WOGNQ!T11K*J4MY9"Y^8(X%8!K
M&0.<Z0QIE"28L^Y=3'8#C>T=MY)%K!3MEI8E>TBZO> A\.GY-3_AQ"^QNFO'
MZL:&):= ]-*P9&^85VQ8<JIL>\.2,]=W(,'?RT;:I[)]__7SY]_+]EU3F.*8
M$BP!4D@!A 0$-!4$Q$)+F2N),N*44^@VW-@\PD%J(3O@C[9">_"'7T>ZW5>$
MQZ]GC[&?:'A$O6WEC?ZL)/;A8+^.H0>1>E L!V)#OX)I(#9S9V1:*<FO/V4X
M7G%GC0[(P=WOZIHK8%=J]F/SS3S@[N?,]@A'E$D4@USE J X2P"G26K"K]B6
MC6A&8J]3NM,AQN9A=Q)&5L3H3RND=R; "9!N@==M\/3L0#V1Z7#.?TGY8(?[
M)P,,?*)_2<'38_R+5W:NT'A>J>]J4<Q^J"I)X)-:/^AO[.<T3PAB*5< \Q2;
ML(IC0)! @*E<"TTSR9$?]]+EL<:VTWL@:EGRZEV<<1%6MS<^$%C]QTY[.!T4
MK$XBNX^[U)&1>!+='14,?V:VJCMH'<<UN,+5<EP<:>AZCFLJGZGIN'I+R.+2
MJG#DCX5YCAG-LDW_4'<+>9[2_+/Y9-E4Q_G&4DY7+;LKHO*I9#J':8Q AEEN
MUG99!KA*<R#3F&C,B8B55[U8K]*.+7 Y+,F<[95D[E?M1QNK=Z2>GN?+%Z6B
M9ZM?B(K74)\!-[<Y&LOV['@;/2<'-;9-E=S9/AN[C@&3:*M>W5DC>O]3K<2L
M"$MI.X I>JWI#27K",J! \/N5DD<>M!N4]/^DO@KFRN[/;GC+K\38O.TF=L6
MPK^M3-SRQV*EV-RR"/_&9HLW2B]7RD9M!+*,L)@ %=N#Q#1E@&*6@DS2+,5(
M9CGSZBT51*JQ334[,:-'(Z??]!'&3F[3Q.#H#W'JL5-@KX4@,,("JZ+YW4ZM
MJ-0KVK.7U6P2\5(W&[*'FP>"8AW(WX>1:5"_'A3&8_\=]N'^>:#OS=RP?JFY
MOKZH9]M"V4X";+TIIECP5,6)!(K%,4 Z30 5)OH7.J$*\U@JA5S30ML&&ILW
MK63=<M%MI8TJ<=W31EO1;7>8(3'KV0=VA<LKR]0%BTY)IZT/'BP'U46]_914
MI^L[)G/9;F55>OJG954 N5A/9:H(S D%.4T10!G.3!@6)P9+@;"D4F38BY#O
M["AC<P15(T162NF9RG461+<8Z69H>G[?*U0J 2?13L2 .5UM"(1*ZSH[QK"9
M76UJGB1WM5X\< ?AIKFQE#/[#9OO*(6++4>MAIQ*1%.0*-OD(T4:$()SD'(&
M"8I5JJ'7466OTH[-]9QT5_VB;,6HG58ME[,5></F4<GK9JFL+$F*+Y-5O^9W
M<W:C,6K/3C- I]Y=F_JMSGLL[44OG,F#F.>U&^DZR?K7:([K WNPAK=>@[[.
M3%5OL]N5]J=-F0A&$I["C,6 <\X PI0"CC4&$J>YSCC*D/0J4 @NX=AFI']7
MA9V/2A:AG:S=>13#FW28&><F0_V%9ID]/4V47VHZGGGEHA%&,I><RO>7FC\N
MPAMZSK@\T WS!+\N#S^6IV%,^[R:V1.TO<S.ST9"NWC'-.>Q5AI0S6.SG!$)
M8()CP&F:I"E':9YXY4+T)^K89HXRFUN:F, 6(]A>AJ)MMV!HNWK,&J]NK?%/
M'UOFP5)?FQMQR"?\^8KUN\TDO1HFY)32CZ##SRV] GYVDNEWQ Z54?<+L;)U
MEN]4]>_]XDZ(U4;M,[J\9ZOY2Y/B\Z";E*HD%CHG- <)510@'E- $AH#237,
MDT3&,7'JB76C'&.;)TJ:A^_6J#4IJ=5BOWU6E4FGK#+-&J1T,<M*'X]"H1N,
MUSY?#&B2GB>#1HGHET8-2P$1U9I$!VV[2F6VN6S1@VZ6$<.8Q*.H:QC3#%3M
MU:^)_&K";@>VM5CLAL</5T5V.P8'Y64!'O<ZNVT/FW6Q9@N;3UAOS62<4IX3
M 0@59O&44P@H9,H6">?F#YEFE-0-W[^NV6H]S)[;B9P^[_BQM#W.BZ5L=J(K
MZCQCKAYGB_(PJ&DN_FK;<*>VECI%F,48B#B! %&A 4NS%" I19[3E)IE=&WK
M]POYE[%T(^N0=E:EQ&,T\C![K3>9;?R+Y>U>ZYZ>X]MKO6B$D>RUGLKWE]IK
MO0AOZ+W6RP-U6/WN/:Q^O+$KM+4$-=$"TR+.)!. <<MDCQ@$!&D$),$0HS21
M@CAQBCJ--K:5[)Z\S>*TKO.R'8.L[)$5WF-U=!5OAV5I2!3[SC'; W#K);>X
M=:$&N0J@QR(R)) #+17; 0VT!G3%I76E=_4APZWG7/4Y6+4YWQ2"D^T/8W.;
M^_O?2KZK#U@^K]33;/-TMY#EI751F&6#*SZI]13&.H<:8Y#E5 !$+#&CY9?E
M2L \9<HF/DP7ZM$6';C%YC=*Y/2RT.IEV9>KOW?EHRJ*OT5[BI1=:'<G6#8%
M8EO.ZT_S>*L%W4+O(:SR2LQR^Y9IM(E^J?7YM31/=4]CHU*IDA>A+R:ZSOCV
M0ECG+\TK\MIUAJZ=_J[[8SONF8GO2F[FMOK6'C"]>7D[9T7QS68V3"4G62YL
M*\V8$8 @R@ I"16H(K'(.$26T,4C=>#R6&.+A!M1RRKYDN_ +(E+<:,_2X$]
MF9S:8';<DP@#7M^["]UQ\]\@N(Y(J*5^RTC#+MJOJWRR_':XI2/-V^>'>@U"
M&38>0C,@D%;&/:00F%])(*6.&=80QM3I8/CDR6-S"T8P3P:W+49N;WDGS?L^
M4?W\<'WEZL_2=JQI*'*V[7.'Y60[5N>$BNWD@JYESY:(:?6\7)5+[[)%VUL;
M)JQ>WBZEFF(*&21$VBP_:#>PI)FTDQC(V/P?M@D<W*GBT7&\L;VA=57O@<R3
MJK^@@3FJ)8^LZ+X%T>VXM[_?/:#9\UL? L@.I=).\-Q0,=W^_($+IYV4/:V?
M=KNMVZ1>MNIZT'=5:^79XO'S<CX3+]77;^KG^HU1X;^F>2(U23 T$!,*$)8:
M4"PQ(&G.I4020>&U-' ;=FS.IFJ79T)=LT0KFLW0<B%OEG$;.;.%)_<+(\GL
M*?HP6YAEVXS-S6_T<O547NL73#C:QBW2"(]XSPYI"_9.Y$E4B1O]6?]KY8Y*
MP0-&*GY(!0IC' <=-,;Q ^(X /*\NS.O9-DUWNY;K^\6\GW3.-[N0"*.:*8I
M!5EJUBI(QA108;N!J#A--(G36'B10;0--C97U<A:%<(U@DZB1<OFHC_".$TX
MI@39[M\:($@)(+'6($'<3!94YI*F/A3 P1 >@ -X&(3=G'LHW'IVZ8V8D_(T
MKSJA>+]#+NC&MPLDX=@A+P\U-+GC5:7/<#->OR=$P[4ZUZ.8ZE1GB8(,4!(+
MXS4( 5PJ DP,*2%*1"YXW+WI6C/,V#SR4>.U2?1<"WI+][4MIFY^XG:D>O80
M)UW8/E\#Z<9.;,<8]-*-;3O(*W9D.U:TO2O;R=7=',#[FBYZCZZUWAY5-,TD
M(1E(.+==8U.SH$PR#)1"!.$,(:J<\JZNCC0^-U#E6:V7T7-3A+A/M.WG#2X#
M[.80@L#6]QG3-;;JFJ,Z_)[U570">8O+XPSJ,*ZJ>^PSKM_0)67SP!$5=XO%
MALV_V-V6^2Z"X%C$@J: 8^,S$&$"\"2'@&5,*R2)CK%'UN;U <?F1"H9HU4I
MI&<@X0QRNP?I [IA@PM+457A6$E\/=;HAJ-/QF98/(=*VKP55\_T37>0VC,X
M'9XS8!*GNU:'>9P>]W5,&;+>W:8A*?ENL[(;>66AT;^S^6;?\Q?;'A%3GE$H
MM<J!$D("A$V$QS,N00XETSIE4.5>"SQO"<;FK^\O=54Q(:#]R]J&@]5OJCS\
M;=VXY^K0WU9N<6*O%N@[?BQQK82/*NFC2OQ)5"HPJ5.7FM"\AV8GG?$+E='D
M/?ZP>4Y=X3G)?NK\H(%+D.TNFSW9;?) BY(X]]MWMJ@E_+!<:65/%.\7E0[3
MQ!+5VK96,6:6V]I\83E-0(HRH4T,;%VN7TK\@-([^8-!T^??6H<\GQN?,'R]
M:@?K._KID5GT+U/C6NF_E[]?1!6!^-I L"M%VJ)@J5\J'$90 =O=>*]=&]M!
M\K]&U6QWDP2KI[U!A&Z3X<?EXM$R?=NRA6DL$YC1G *9Z0P@""4@+.. 4B'S
M.%$($J^CX?V'C^THN*0W_[ATK90]BY>;?^^*0L\.V(H%2A2L8.$\XCEU [FL
M@T</ZE/.*77\TI^]YH9&*9^6BV6S45 U=GW_T_H2-4U33;36'' L4X#R5 +&
M$@1BE,5"495K[=7^H'VXL2W,JSE^5C<F5I60OW9(XKB"LN/Q;##L^MY)+6';
MEW3;W+D6]G(DW:W-RE540O9;N3S8\(U7KBI^M@/+];LZ.I/5(UO,_KL,0=Z:
M$&(YG\GRASK;;S\Q]LVFF"U44;Q3A5C-RI#C;B&/\@%GJMAELB8Q3RG*8X M
M@3&"<0X(311(E(8(*B4E\O-%?4H[-E?V[;LJ%S]L\>+INGJUJ:/G&XNE^G:<
M>WI.H@--)]'9]'+SZUK?:$_A,G5NIW+4Z!S]V4M*]"#F">7!>Y5UV E@"-A/
MYH]!!KTAEK5.;J6^F]EL]D-5D]O'95$<]RC=ZT\J_W-3K.N4Q@=MVP +B"G+
M: *0B+'Y(A"@,=: 9$DL(28Z3NCTAUKQI5?<&T T'V>U+V!_/NNH:W/TR]RH
M]&MDG=!!%^'":%91D!1;_3H$T2',FRN<\LQVXV:YM;%. )6" YF*!,;01!?2
MJUSI-8P[<$-N:]11V]1C"36PI?J.&=[>3R*G#MZ_E:^G5=4L89E>V_Z76\W*
MD"%HY^[06(=<PH40:_C%7D PSRX+0SZ_XX$IVU)3E.T./JM5N7L]U5 )(>(4
M9+G* 4HU,3.R1"!-.$%$QDIZMN&\,-#87+"5L^32+5,0[%&D7,[G;%78#C35
ML:3OJ>0EB!V/$ , U_=Y']MCG)G4/5R,G-4!7\ #N2M0A#H]NS3,L$==5Y0]
M.9>Z=GTW!['7_:1\7'&W67]?KFR,,DV%T#S.*(@1R0!":0PXIMRX#)Y(#(WW
MP-+'1[2,-38W\78_:XQMQ>R>N]"&LYNC"(1>S[[BL*]3)6BTDS2<LW" (Y"_
M:!MI4)?AH/*QUW"YI:/CL#Q7#_KOS)Z,KQ]67VQGZKN?LV)*)4Q41AB(!4X!
MPFD&*&5FQ8^Y3%0>XT1[U8%?'&ET3J,D8C,392VJ)7(IA8W^M.)Z<MI=!MC1
M7X2 K6]OT14Q?W=Q#8U0SN+B.,.ZBFOJGCB*JS?<6)-<'X@54YB@E&J>@)A#
MXQY23 #!- 4J3F*8HX3G.?3)5#D9873I*G:,:'=T6Q][=RU$W@+IN$-S"SQ]
M;[5L,7E_#9/N=<?'>H<N.=X^_W6JC8_5NUAH?'*AWPM=K-;3W]G/V=/FJ2YY
M11JBF",%.$G,\H")&-!,(R!B)3 56<Z84U7@R9/'-J_7PKF]KZ<XM;^G-VG?
M\_M9RQ6PU/>BMFUOI;EI[XTT/^W>QM/G#?(67E2C>?LN7]!M&KT38O.TF=L\
M_;:=Q>WN/26V5B'! "9)#)" "2 (E^MW2;!*4,Z\8G#/\<?V!N^)'RW+9"JQ
MKT!Y&N,W'?L:Q&VR[A'FGEW%/L)5NMJ![-M\M?JTQ#9U-6%_T/.1CN %B@=\
M1Q\T6N@(S7$LT?4Q'6@).J?A5TVL'G2UW?&;7<T<%J=-F8H1B;4 '"66S4!(
MP+2*0<8D3SFD"%+'7B<]2^KT>@]:Q%4+^;]+^;MLA_9MVW8W.P9[#5FBQ=M+
MM-XT)5K\7(E6W7?R03>[N+7&AS6]XS"[!^?#.,P_$%7$ZW\,_+@F^C=.*T5%
MC\,/QVS1/X8'A!@##-?Q@((5W^\6TOYC2_-^L+DMRKM;OV6KU8L9I"Q2GY)4
MQ"(5.<AR'5MB- B(H!!@DC)&D"2Y]")&<QIU;,LC*VV9KR3L-VHGM^>)A1/B
M2*@LYRD&.L<F_$+0K$JI"<1RK#*8:B&H2OQR08-C/DRBYZ"H.YX9A4:R[_.C
M!L+RFSV1)Q%;1XW4%>U(P+,D'Y1"G2LYC3GL&9,/#"?G35XW=^R@M/AA'KI<
MO?Q]N?JO^\7GU5*HHIAF$".<Y@RP/%, V9[T-*8,\%S$L8:2(C\^W//#C,W'
M6^' ; &>*_$\^RR=1]+-J=R.3\]>9"O@)+(BEEP3E9 3$^VV;0WZMV5JQ2)4
MCZ;S@PS;L*E5T9/N3>U7=]PS+PJU+MYN5I:W<:HSIN)$0D I1P#AG .6*082
MQ@6.M50"2I]CYX.GC_/(653"1:P4U7-_^P \Q]WKKI#TO3==RC6):LD"[CB?
M4SC4?O+!LX?=+3ZGULE>\-F+NKVI7U2AS$W?RQZL/]1\61+B[ZTAWRX7ZQ43
MZV]+LS2T[7T^+%?E#G3QS8SX;OG$9HMIG&!,8)(!D3,-4,XEX&F:FQF>)]!.
M[AIZM4D,(M78PH!&J;H?\E:M0XKG1C/+DUCK%IDOU<F.>9.L?M&?E8:>:6UA
M;.WFD :W8,^.;$CC>3O#H& '<J)A9!K4^0:%\=AIAWUXUPZ;7Y_8?-[4,D]3
MJA,8$PV((F8Y)HS'-M]!0+#0<2YRJ+C3#MR%YX_- 5<B1J6,6ZX!WUZ9APBV
M.\, N/3LUOP@Z=#U\JSB-W2Y/'S>P%TMSRISVL7R_&5=3N+5:J:*-U^45.K)
M5BT:'_%#K=8S\^UG@Z$R$: L*PR:7B,II!E$)@1+( -(<P8HI!*8Q1?%1&<R
M39%SMP#?T<?VNE?R1V^BG0;1G@K15H>J9,;G.-77+BYGXSVBW?>)MQ_0UW,:
M R#N<RS=(_)#'38'^JA['AEW!*[](-CWH0,>[W;4]_#0MNM#.LP?5V/.O\_6
MWS\8259L_MO22+$H__[\O#(_R ^;A9PM'K]N.+.'QL5_F&?!*94\041J@!-,
M 8*( D;R!'"B<B02C'F:.4\Q/0@XMEFH$3;2E;03R\$XW]AOHZ*1?!+IV:I8
M1R]& P^OV(=]'::J5[;:"%;ZT3^,AE&M8K33<1)MS5VK&7W=V=AJ&L%7MJ_'
MQ/C*=AYH[GPU>_M-MCT:HW4^[F/<X:;L'E$[F-7['*?#Q&\YE'9TZ&_-& NV
M6/\^6]BJF*IQTB>U_F(D76S4%%.8**D18*)LMY$Q0'BB@#*+24D9I5GLQ"'F
M/_38)NM:3.,*RJY>"[6.5I6D'E[;#WR'^;8W2'N>24LFKYW@=GN\$GT2-4#7
M[=-L3<J7GH'VF/AZ WR@*2TL\'[S5"?L6F<@OR<.-[=TTO1@UNCVA!MZVWU?
MSLT=1=4OX]-RK=[-"C%?%IN5VO$8*RY8+@4&RF;C(IFF=CH0YL<DAEC)-.;*
MNZ>=R\ACFPWV"74Z-*=S MOM-+47"/O>%=R3^7\U78>LV-%.[IY(G+WA"ME[
MSFG<X7O.^<!QMM><UP-N9"PI.WR6/"@/^H]"E0DO=T_+U;IF:]ZV],@AS6-"
M0:KR#""="<!T%EN^(XHD4U)D7J[*5X"Q>:Q]$6V1[\IJ )8:; I5Y:)U9#YQ
M-8B;.^L3YIZ]VE$'X$G%F60A-O)'I0*3Z, ,M0X]T*MXHA>:?<5U^-<A9_$$
MYR)WB^]S!MNF?U^L9T^V\/CMLEA;.MMF]V":YS#C@FB0,RX!0MAXQ21)@$QS
MAG/!5*:<LO'Z$&YL'O-@]T_N[?ZQX]T_7>_^/>[M_M5[^F6.UW8SO_<-WLN6
M[VWS/H@]1[UQO]4PLBJ6%OTZ HOVOET?Q+)_B:WZ3A8>8I/^J@EZV*"_/.;8
M-^>OHA5@8_[Z&!TW86:/BYF>"69$:.L.AA)&->) 9Y;>+<D1H%F2@X02FA A
MN5;":P?&:=BQ3<U?-T]/;/52TI_O%#C7"\IS<\;-"(X[,\&A[7M;IAW*OG9D
MO& *M1WC-NBP>S%>0)QLQ/C=W=%)=:65J)LM/VS6Q9J5@?&7Y7QNW*?]XQ13
MP>,LRX#.=0Y0)C) N28@S6"B+"VM9_O5?L0<FQ.L.6"6#0>,IZOKQY2.KO'5
M#=2W*RVI>]ZT4_SPAN+GS3F*GUI5\\U.V>A/JVY4ZQO2"?=JD%!.NQ\AAW7R
MO0)],BGT.UJW2>0SF\G[Q;_-%N:K\9.J6$\)2KC(F0+"S 0 ,84!21D$ I,4
M0XYYKHC/!' ZQ-B<]^?[?XMFM6PV[7-3IF#SS3I:+-?1LY'?]J%;VV[R\R5;
M^/GV,PB[^>7;<.O9IUKA+%>&%2]JY OG B_K'LA]G1E@4-=S6<%CM]%R98<]
M[(>W][L6BV6GM6T_-;M^_KY<K;^9S[EEFZA^.X5(88$9 [F,33RH,@)XEG @
M1<9@C'4JD?LNM??P8W,5Q_TIV:Z;8;FY;#4 I:>8;77PV);T-X_#5G*OH/=]
MCF=;3>Z!;L7?;R%9[@[N0+\?!G2/W=Y>P1]H/S>\$?RV:SMCV+HAZ__4X;9<
M.VM\L*G:_2D=@\F5;>&R?OD\MQL?"VES4,I]W#U:"B()YS!6@$!FZY*4  Q*
M8D+,1& ,DQPA[15=7A]S;'/(Q^7B$7R<V6J$;^;W9>5?>5[=D2_$!7;'D#,L
MF#W/#3?@Z!^0NB,3*D)U&''8D-4=@I,8UN/6KD2&8F4S0-ZIZM_[1;WQ6GQ1
M0LU^V K.J8AQ3GA,0<*,VT$,6T8-A &3B&D49PQAUM#:?_-A-[P^MM-K<TA4
M_VV(1+1:T&BUE=27]M !=S?G$PS&H2@1*S&C7QJ!?[6TB%M$OUQ'M ,WHCM$
MP9@2'88<F#?1'813%D6/>_W)>^HVY2\PX=]F:_/)9X1#XW%2H+E-\>)Q G@2
M2Y"D6*$L18ER2_$Z]_"QA36E4/8$!":_\%^C1EQWXIX3]-K]QJV8].P??.'P
M(NVYI'<GQIZ3APU&UW-)C7VNGHO7=-C]^JR,<<UR^5$UI/H/>K__[W(N_UB8
M9WW[KFPS\>+N<:7*K?EI#E.:XR0SR$&S;$F995(0 F0F<L ::41BIVYAMXDQ
MME=^IXC]H%=M;NQW8K\W>&'4B396GZBPVD2L4<=CCZ:[Y1PVR :Q1]\;\@>F
M^+HUQ7YQ5/1U9XKU=Q65RD1W@YK#8^ML$+,,M(76IWG\-M-N1K5U4ZW[TX?;
M7+L9@8--MMN?UC7]YV3[KI@2QK#"$@.5)F::BG4&>,83$V^2A/!<:^ZWNW9N
MD+%-0E_/G;EX)^"< =-MV7HK1#W/"Q4ZWP[WY0/2];>I'RS5Y,P0 R>*7%;R
M-,VCY=INK_IA_?G'V4+=K]53,84L$R)-.>!,IP )'%OJ?@4T43Q)%$I2Y-69
MZ<(X8WOACV@3HC^MI%$IJN?.^25@W=[\ '#U_/)W0LK;!5S!(9 7N#3*H([@
MBJK'ON#:Y1W;MLU988*,,KS8?68S)B5'! &5,&[I(#2@7,9 (*T%R3-&N%?>
M[ME1QN8*2B'+B+IB+.WL"<YCZN8';D:J9R_0!23_CE]M((3J\'5VC&$[>K6I
M>=+!J_7B$-P+'V>,S^:S]<M49C0G*LL E<K$ DHB0+#Q!BGDF1(RR;F$/LU[
M+HSCY0 &:^.SW%;[S\LCF7DC[BTT"CMLW=Q  ,1Z=@0GI @?K^)T(^O!"0J]
MD!OL1GE%#H,35=NI"DXO[[@-H.;FKX^_J84MC;Q;R#OY-%O,3,QAQOJA:MJ#
MHJ;;3E0JN3T!)[&@QDN8%0/APK@*""%EF4X\&P!YC3ZVX*$6?A(]5N*7Y<KL
M0 '/700O6SAN+_2%<-_[#@VXO^V!>RA[0[E27&>:]]^6Z );J/T*K[&'W<CH
M LO)#D>GAPS,B\YL@4Q-V&IY6I.I2FB,)<<@%=P6-F*S0,(Y!*G4--8Y%3!A
M@S"BGX@V-L?8B%DF]F[YT"WI>;3^QW(@8NQ3 SJ<Y+V:67KVIB'(KVM[?FCL
M6=)>)Z]FS8$(SF^RZE^"+Z63=8<C-;]H@-[HS$]''#M7RA6D@E&87QZAV^*C
M6<3,5&'$.:6?O.-%V2MO2BQ#>0:QW9),S+I#I("(6($8YCQ5DB4HYS[K#M>!
MQS:S[LE=ONS[DO_S/Y$$YO]:4[#ZK3R<#>&VZ.@#WIYGR&-D:R+;/QM1 ZXM
M?-$)M*QP'G;0%84O&,>+">_[>R)+*:Y4W_]FKEP7]XO/:C5;RK\KRS2IY)WQ
MK^S1+'G42LP*]7DU,QZ:"2HH2A. M2( (6HK#'0.%$YXKN(LEL1IH?$*LH_-
M7]8*1(]6 R6C7V:+2"[G<Q/;/-M\0JOUKX&Y5@)^$ARW>,9IW[XWB!Q860I7
M6I8* 5M_46$PB1H4HAJ&J,$A*H$8D*TEO/6&HG )*/FX>%W"F\2;[*4'$;K-
MC'<_V&QNZUYL23";*YNS4.?<VSFYHE"N&!:-K+-B2C2%>99*\X'*;-\)I@!-
M*0$IBB5.>9PGPBO'T%> L<U1)4LIMY+Y343>P+O-)GW"V?.44*8K[62=1%M=
M@%ZN@-5F2]I>T\.&\^-=<0ODC+V'']2C=@7GV"UV?DXWW_:!S5;_SN:;B@[>
M+C#VEAN_*V:;8LB'Q1<KP6JV>#07?%HN5LV/I0C?RA)6K"G5<9:#.-$FIK<T
M[32G$"B5I(FF@D'F18H53+*Q>4.K6%1J-HFVTI<K\GWYHS]+X3V3M,*9T\V5
MOHJ1>O:Q@>SC[5Z#8QG([X:3:U"''!S.8T\=?H#78;DU$XU6L[61UNKP_N?S
M;%4^P6T!+RF%(L8*Q"@7 $&1&[<O*1 H2_*,*\EB+[?_JMJ,;:IH-G<$,Q_Y
M^7R@[9U>/R^!-GS&\BD8P1:0ZP[0'B;5_O\.E7%N"PUAXY%P_=ZFR[BVCH8P
M6VCFX#!"=9N_CQY=\:1O*V5WE,;;$TJ*2![G&@*L<0)0:K[P&!& S5<HM$BU
M<NIRW56 L<V2[]1B^31;6'?S-[^IT!MZM]FK3T![GG!.O/\Q;?\^O_LD>C>;
M;^S5?1PB=T4QD$OW'GY0+]P5G&/'V?DY'=-AEHM'6_EK=[5^9^MZ5^N+>JY<
M<O&@C4==B-DSFW]1EO1.6FD^S K!YC8=9TJS-.$Q%H 3E %$: IXEL5 0RXQ
MSP5F&?)*D[E1H+'Y0ILG%OVR*D6UNQ0+6\GVM%RLOQ>>RX2;3>682#.@ ?I.
ML+%LFR6/@%5F$M7JO-AMI%IRZT<KV<OTPX 9-X%@#)6)<ZLXPV;H! +O)',G
MU',[;@RQN:IK*]^:4'8F51745D1^=F_JFXF/"^/5;7XQ2K12*>: 2$O]J3,$
M6*9R$/,TSIG&4$BOJ-)K]+&YT0.):^I/5?6XV GMN>WB90W';9*^,.Y[6X-5
MQ'^EY)/H$.TO>VA_<T#;?^.A"VJA-@J\QAYV8=\%EI.%>*>'=&4T_F&\Z'+U
M\DFMIR)/4T81!EDF,$"4)X )X\,DEU2GRJ90*Q_WM?_PL7FGK6R^3,1[>.4Y
MCXE.B$W!E+9I20:(@N9' N,8PIQ(D?E4PW?&:X 2^!!XN3GDKBCT[&^W8DTB
M(UA(MN53=8.Q*N\]>F#VY%.E3EF2SUS3,;NLIE?^S%[L8>!;VUK+-A5**4NT
MC$W\A<S[B90&QLHY@#D6$ NM8>[%7'5^F+%YMBTW^',EIF>^V'DHW5[=VP'J
M^27>8E-+:.*F2L: &5ZM&(3*XSH_R+#96JV*GN1DM5\]6-UV2>5RT-%[*@G%
MJ>8$Q#3A $$"C9N@)O:)8X4QPBK-W'N/A9)J;%[EH'I4[E6/LN/J45U7CS[N
M58^6$4K$-_*Q9>KLT<3M[NO5#->SM[NMXK<B/=KJUIX(V^?KV7<)]VTV_$M4
M;WO9<HBJ[<N8]U"P?6:PL==J7\8G0)EVR\/]NY&\7ZQGZY</L[E:O36/>S0!
M_90SNU> <\ P5P#A! '*J !"0Y91F4FS-'9M2'+F^6.;&RL1HU+&J!'2O2/)
M.03;)ZP N/0\]?A!XM65I$7Q3HU)SCUOL-XD+<KLMR=INZQ#Z'QG (!5Y?/]
MPO+*SWXHVS6MY@R+508SF5) <88!BBU_&\D(T'F,*6'"$D$[!\3M8XWM5;;"
M-E7]6W$C*Z]'Z',%7H=@-!QH/;_GE_&Z3K?F#9Q')!@.P('BNPX?/+\XS0V1
MUNCKRB.&BZG<=#F(E!QOZ3?]T-8KB&FF8:)B+4"<$@00(S'@6BD ,<0TSM-<
M<CTU3^++T-F'Y?@^'_Y]*?K[[#?B U8GS-4]GC8V%7NVL(V>GC<EH^Q"K:N.
MZ-O$_8BMUZL9WZSMKE*T7AYTA:HY/B9EX:PH$_^K1WOF\?C9ETI%8IE*@&4"
M 4J3!)C@EX),<HY)@O,,.G7QZMVZ0TRH)[8]Z-JUW$E?6;LRH+&VJFUVQN(#
MF=%MR[LWX_0\<7LFJ9;B#Y^7>H#:P$FIU=BCS$@]@*5K.NKA0SJL(FQ:UL?E
M-CJ#C$L-50822%.;4F]6#2S- $]2F.%<$PG=F4\/GSTVIU8F*%KQ/&+;([0<
M%@'=,>C9=VS5[Q+C'^'@$=-WQV.@&/[ZQ\(O9#^O<&N(?G3+<"'Y>5D/0O +
MEW3-@B^*M\N%C0K50KS<";':L/G=^BU;K5[,+\NJXJGQ/X+%B@*A$ %(8P08
MIQHHKFB:4YZ8:-LOU=UAU+%YJUK*DKE5-,*OM^TK9LJ34L8->K?P*3B@/;L^
M*V^T)W!42QPR"]T#D6"IYBYC#IQ/[@'#:=*XS\T=<X[FI2V5/%\W6?/33S,J
M=<XI!M2>@B!M<RI1GH,4"9G$'&4<"Z\<)*=AQ^:"JO/'<LT'>%EA+?:$]LQ0
M<@/>S?^$A[-G!W2V2GUWWC=IVET$3&CR@BA4@I/;H,,F/'D!<9( Y7=WQZ9]
MRZ>G6=4-]&XA=R[0S/%3K*#*N>) B-AXHLQV[<6$ J4T2W":X%CYM>Z[/-;8
MW,^>J&7^Q(&PGBW\6A!V<SF!<.O9SW2#S+^AWW4P0K7U:QEIV.9^UU4^:?'G
M<(M_YD9-B??R_J?X;N>/3^;C,!4D0RB/$T"8M!1TB *.% 2<"HW3F&<QAZZI
M&^<&&)MK:&2,&B$C*Z5[\L99$-L=00AH^HXR_%#QRM]H4[U3 L?9!PZ6P=&F
MSGX*1^MUK\-:MK<9W,Y/%C,<PY0#K<SR!660 1)G")"<()50B! CT^>2X^7K
MFJW6;O'#0-+[O%7'.O3W@KU1C[-%R2[ V=PRD^VQDA6O1DOF^H& +.,)3#.0
MI0+:PAH%J)DX0(PA))G *6.L_D"\7\B_^,>AT:"_#\/[Z@#TK_A)< MY1VC;
M 9?IMY+.'1S$_F6HY3QM-A(2.5>I_U)T<9ZF"$T,YSM\QZV/J@WZW\MZI/7#
MZHL=Z=W24H),L<H9QS$!&<?$-N5$@#$S7Z4:$JHATK%;4TZ'L<:VOBE%M5D=
MM; &TZ@4-_JS$MB3';L-9L?]CS#@];W_T1TW_TV0ZXB$V@1I&6G839#K*I]L
M@CC<TB&+Y7<FOL\6:O5BDT/+\ID/F]6BY+&\6\@/LY\EHV6=K9#GB98098#K
M3 ($XPQ03&*0"\V9PB3/4_<<%Y^1Q^96MK)/(M5(/XET(W^Y9:AK#3R20[R,
MT>YN>H6X9^>SA^[[';I;T2<EO(WT79)PO'#V2-'I"^^!$GB\< ^4Y-,%LM84
M(*\'#I<@U$7/@_2A3@_H,"&4Q$MUZ&H>_$45:Q.>VH,[^X<_S(C-BZ%DS"!6
M&A!%J=T&R0'-- (Y(HE,!4VPV]F^W[!CFPJ^5IG<-<V^?4-66]GK-.^-E=[#
M/;F;P&$.Z 78OK</2MB:U@5&ZF@G=L7X%I6"=_'][N!Z./Y>0![(Z[N"'<CA
M>T/5ZNW=GS:<J_?6\,#/^]_=;</@LX%5K5;U<ZNDQ333L<PD!=)F1J"\9($I
MW3K'(DYHGF1>&P5GQAB;^]Z*6/GJ2?0_XW^)8Q@]LU7TH^K@!.-)')?_-959
M;+/^OER5_?&LPU\LFS_,BF)3_W*_MH>52^G?+57!/_\3S.)_3>$D*GF6*SH+
M41KTX$^)W[[$.6NZ[4?<:*.>9X*=>6JBS[JKUGT)=+@]B!84 NT]G!MAT#V'
M%A6/]QK:+NU2;R__<U-4^1O?EG=2SJQS8_//;";O%V_9\VS-YF_+4^'[Q7NV
MFK\T&Z---ZR7:4HP8U"E((]C#I#6&%"-,9!4T9RF"&EHO*]ZM!EFWUQ+\V\6
MR^E%H=6+<B)<CYMW5<[";!$I*W:DFC.2)N?=D9TCE/$<HM2!;#$0S=Y.&5O1
MN5,GLOI8N]0:3:+:5/>+J-1J=YSU\75,Y<,Q,*C)!@J&AS&=)W5!,*#;Z0UN
M'V9 "H1@F!S2)(1[;->H?/FL5NL7R\VPMGVDFLV>C[.%NE^KIV+*8BWC7&F@
MB*6G89P!EDAA?I0*,TP2B3*_(/W:D..+V2N))R5!R+IJ1==('?UIY8Y*P3T/
M]QS =XVI0T+:>XA],YH=PFU7@()%WU<''#@8=P7@-#9WOK.;"_JB?JC%1GTP
M,MM4:]NRR=+HO36.<?FD5N]_BOFF[.=4%,K\O_S&?DX%0QA32D&B$@$00@)0
MAB$0,E>"9E"))/;Q21UD&)N3JE7P\T!=L'=S23TCVK./JJ6/[(L4-?)7?)^-
M!K;TJ]8A:I2(C!;AG-8-$ ;R8ETD&-2MW0#1L9^[Y5&=.0&?GN?+%Z7*;8_/
MYL/[G17[#&QY#&6N*00:I3;TD@F@YC:0LTPS*!*$(?=D!FP?<6Q.K:)IJV6N
M#P<:J;O1!%Y!W&7K(#"./;NRJQ!V9PZ\@J4W?V X3 =E$>SR\>Q")N@&CP.E
MX)4'#4TLZ*;7&7I!QQN[U_8N%U5;J&HA7E$Z60[HU0\E/RQ7'S8V!\(>#=A"
M@JF.4Y(RCD&:I!E B1" :)6 C-,$XCA5E'@U^O268&S>^^T^]]RJEKKD1=&E
MW.7QU;8&HQ/'G+^5W,+77K'OV>/7L#>=ZBKQ&YJY+_MFJ%2(&AW"UAEW@B]@
M];'?^(/7)'>"YURE<K<'^=<OO[6$]MNVX@IAEF2$@"1)(4 9CX'Y-&J@,\22
M!!*:9<Z%RP=/'I\3,\*Y= N_ EB[W[D)AM[]B2,"7G7)9[7M5)!\^*3!*I'/
M*K!?@GS^@F[1B.W'>[\PCRK#VF^6?7>*%->0I,AR!YA74#$)S&N7@UAC))@B
M!'&GU6'+&&-[&;^*[TINJDZL9>_J==.[.MI)7D1_EL)[[L:?@]@M6+@1N)Y?
MWQ/,OG7"S#L&:$$ET"Q_;H1!Y_$6%8]GZK9+.Q[=J3+9Z^-L/7LLU[D-,:PM
MN%.8 I*IU,S,"@%*8P@R"A.<QTI#[;4,N3#.V%Q#+6:TD]/S,.X"G(XG<+>#
MU/>QVPD^US=^_,_9VF$(=;AV891A3]3:53TY1KMR>3<?\('-5F6ZW/WB>;,N
M/MJF5&G]P64"FB @%8!B+ #B. 6,"UM!)UD:2X8RYG5&UC+6V'S!+Z5P4>JY
MF="&IIL;"(11SZ[ 2KE-;"T%G40U8CWX! =, OF%MI$&]0T.*A_[!Y=;.BX=
M9H68+XO-2CWH?4:!+VK>]*,K3@@%BF_JY_J-T>F_IBDF6":*@HS+&""8"T!P
M&H,,)3$AF118.*WT \DS-E]3;K[4E"*[3D(')"1V3]J3]_!6HSDN7(8S1=^+
MG':>5K.Z,4)'I=0AESAA\ NU'+I1FF&73F&@.UEF!7IL-U=[O_BAJG3.;^8!
M=>O V7_O+R>D";TPS1'(89H#Q#0&1' !4ID("55&&//:M+D^Y-@<YD[BHB,I
MB@/,;OXO+'@]NS@OW+Q=F3L4@;R5PX"#.B1W (Y]CL>='1*%NO4<OGM^7BWM
M ="F7';^AWD$G-J(3>0( <R%!$A! AA&$D@E,Z1Q E/D3J<23JZQ.:A&QDAO
M:A8X/5L5Z^C%"-M[1_:SAFOW9J]HCIY=WI>;NK!O[?BAL:/5+X*O8T./;*C7
ML>5 .5,#V]0OT2H\\JWI6 &'&RYI*SQ&!ZE=/3S>;]8M5NOI5[..9ZO9\L-R
MI00KUG54F2C*B2 QB&6N 4(Y!81Q"7*N2492I!ASV@JY/,38YL)&.C>?V0)=
M^Q06!I"^MTUKP0+ND5[7NRW:-G?O1=KFIUV4W?+@03S%=<6:E][ARH[GH_7B
MOE[Z?UM^8S^M[[!=BHV+,&.=9UJ=LIQ21#,&I)0,H$1J$R9+FV:!*<E@KC%)
M/6K_;Y7'Z0T8ONC?2*^*<J+^KN85!<FS+5E>5>K9:F;;3+CJ(5RH]7I>3>U+
M75(8KE\B9DEK/?=%.QO5\1BW3QL-=,Y;J3"QM4C1GNR3\^37NWDUX"GPC2B&
M.B;N*L:PY\@W@G5RT'SK\SHV"-VUMS21V]>]=O#OR[=]*E,AC/]4 &*9V'[%
M''!BN9XTS/.,F8@JUM.U;5SGYDZO#>@526V'[=%?ECWY]KJ EBZSV)/[G_^)
M)##_U]H]>C8)O0:_F_\+"6K/?N[C$9+OVU'S;PSJ"$6HGJ#7AANV':BC\B>=
M0%WOZ]J%>/%H,SYM,IW=:[W[.2NFC#*89L:=Q#2' !$E -=V488S@15/98:]
M\MW.#3*V9=EA[JN9Z\T(T9]64L^CE+.(.OJ*&W'JVS\<I+JZ0=2A>_!E#((U
M"SXSQ,"]@2\K>=H*N.7:;B_]P^J1+>KCE+?+1;&<SV35$F,A/]NJLGK+\D%_
MF"W80LS8_*OY31G3%MOR"\R@0589+Z'MUDU.,\!S\YV&2L:(QR2/O1H#!Y%J
M;&YE7ZE)=*!6.<?N*V87<EO5HIUNWJ4R8>WLYKL&MU[/SFXHPWD[R*! !_*H
M860:U 4'A?'89X=]>(<C[H_*+$8_,%$2FM7[Q5F.8Y(F$G F%4!)9I:+"FD0
M9QQ!Q2%1;JQCEP88F^LM18P:&3V.*,^!YW!>?",D?0=O!VAT8:@X!XO'$>R-
M\ QTENKXH?$[ VU1O?4P\]Q]PYU*MDA]<+S8=EVX&HRD^<3I1$%M8LTLSC.
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M<^HVTSK*V-Q=/>'7(DZ:;R(K;/2P\*AQOPRL:V1T(US#A$;^2'6(CUJ0N"%
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M_XY>#O>"@ATJ42"(3,/F%H2$\20=(>C#.]*^E]WHMV^RPE0KI@F0$BJ 8IP
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MH<^IVBD)^N!!@^4^GQ-_/^7Y[-\[;L97+_'GU5*KHBC9<CZHW92"(44ZCU.
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M5=RBUL @#]IFM["'[+7842/WI$PV7E=T?N^OHMRUZZX'8&&[\+H,_!I=>3T
MN="EU^<)/33>JKM1IR3!6IOP%F>YI:I#&I $<9"GS/Q/B!1QKU;?#F..+<X]
MZ!\E=T('[+[EU?H[,(0].Z=KW;=ZZ 3N = 0K;9>HS>X!P1>K;9NZA:^W27<
MT@(?Y\V\8<5,E%';?&.C$ILZMLOORF/%4X@ET#"QC4$% YRDU#@D$^TR*A+,
M_&KSN\DQ-O^TS]IMMUTWZRVA;ZE'O48I-8FV>7K;G+*N-.M^MG,\<>C?(GT?
M2>P9XUS^WJE%*I;T?C+Y;L0S.#VZGQ2O1(;>":K+U.?='M>5Z+RP' 5LKHHZ
MI- :(YTR#3CD"J \QK;*C %)!&1Q+AE.O5C)3D88FS>T MJ7[W&YE$54+.>.
MU:N7(70\[[@%F+X/.&I,2NEZ"+@NZAZ,9/SX^0-3BU]0[Y10_-*%EU[G?1M\
M--_]G__1_,9\L4D _^=__/]02P,$%     @ AHBD5FN.?$[L:0  Z-4$ !4
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MP20C&RTR1%WJH /I0LJ*_JRU$_4P1>->! Z$IH9*Z !2=VR*8"DR*;HF4H=
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M!IE(T(#VW6Z/V%/"Y"AJ/1C.WW 9%^W256XR?5E7;9C1M"Q$)3T%'+;N4B^
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MKXF75_3E:I*9$YK)S16/J]&&@DB^(@C.??0A*X6#Q?$75'32G*YA_'68@#N
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M<PV&9&W\O@%CN!'=@*6#&._!' 470LVPX;5/1YT^9"A>-:@!Z6S+WFFML?W
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MEE^V&C\7*->:4,8X"(N%3HC(P&EG@"4K>9*QSL%I#.(=21NWO=!@ON80BNG
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M1NGJ7S_>0MY+3"-#>/'Y=SCJT<DD$C(Z#DF=*NM, *(C4N10LB@HN&T=J#U
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MYC>_^](X;K>D@7 WJ**ZO$2]LUSR8W41VE5UGGW<0+6==Q'[&!6>=(PIF:,
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M);HI1/2>;@K'MYJTN8.^/#S!H=I_6W_QMBQ8]\OW1>WG\B4ZFLQ=M6)*QQI
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M-+S.GK .E"%6!94+E.AM,DP5([>[AU[\U+@)J990:<O5SMS;^S>EK UY:U%
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MO'Q3IG]7>.>PST?2G5S^JRM'(F)-,69M?\2]?Q4BH,YA)$+95P,C^8>XK%0
M</HZ5BLY@7E<Z0FS,K6<CE5K-:]9]=9J7L/_7=9ML:[5OF6-5K7)JC=MR\++
M^=5D4<7# 6 K]H/+"J(JLZ[?DRB6_8FZ)#T'EGEY_#:(-[32[J=ZASUQN6P_
M'LJ(_?+F_.BH?&46_X.@IADO90Q8LW/K.%NXCNH@%$*Q_@\%:R4R"3.5JX,"
M<TB*><3\/OLH>F'"PPD@[J)R=70.OXZO"B3#!0;X)$:'T=*+?<9'/@A^T[IO
MM^ZJ-:O ZLU:L< XNQ8N'_-0,-L/ S_DJ'?8_E;2XH,?AOY8A-M!BG@H6$.
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M'T:J\';+?_=#&4^FA=ELS\?Z:G6V.S;P56_P92A<:B-;VB^K252>/L)[X"@
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M?E[";*V%]G_6NBL[BS/@C)%Q.^:,,4[LI(^E"<)\3(-\2G&-LKK,#P3U<E%
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M 44OB4UR4 T?#W$W,N4K8G\@R$&:GX)A[4^=WA&'$&D4&>Y+3IL2T#R;I66
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M9S$$+:F49LPB'[P0+U6#H\AG4BE!D40L%LR#*\"0<V^D4E)W"%\K7I7A7K6
MYLLG/(BK!IQ,-KP%F"_Z?6-%R'NP709\+DA7Z=5%V)>M6D'QWI5\@PNR[!&C
M2G@M$]HN8!8JW4LDB\%AS&+JF(V4'YP$[I & V!1]N"R5 4G@<^$,*\!>\<*
MF+,-8Y&J91<<F\4)F:7XI='20X,Q$+6:BLOGW(,A!68&;)ERI7@ 3H+FZ"7H
MV8SSZ6Q\%J7!(G]!/%9$*Q<!T,K@7<' !"M97)OUFSS^/ D"BZO2/( V8-AU
MKRH5:[OQ=Z.-//"DC%_424 QQ>JNH[?O)MH+VG^HH]_9X9+ZW/TFBE^^J+?.
MA/Y-?DM8/& !^0BJ-F QFG\ )!^@U_)=#_UGUF.N2\G_)<.@F+G&%,(6\,<3
M9BV77=9.GVD2-P?5.6U8S<:2'W1:M4Z?ND&.T[):B ;G%P:H4Y]<TH .LO$_
M'W+6)__@ 0U<#K=_4D$F.$DO7]1 6'Z'S^0Z9BK*A$Z8VUAZL>N->,"%-)R+
MOE+UX]KA7UOI0#AKO([2"*D5]7]206O7K9K2-%%H5K@[,?.I\E67UGRG#_9"
M*<-1I_KX".V)T$]D]B-:J8 M&<#K5:NK%<K>)RGLXO#._Q[&CWITP"J]F-&[
M"NU#*-"A_IA.Q&)G=[%Z7C @<&JV55T.:6=?S^'NZMAE-? UKU:K[4J3KUKH
MRO,0+O[_UP_O/MR2KE,PMMQN&K5JU9=MWJK5,+@QR^+M%*?ED+.M0TX(*O/\
M">K4';I7$BX>ACD$U)HUK]'<*P&\APL Q^U^[E);O5>O-YR]MM]UB, =@#S^
M*P$ -3-)<1&((A\7@TD>$Y:@!_7\&B-1$KM#*ABR2(1]9#BNX]!+7$D\B&(&
M@5X.YH&9@9RN2/0FC[-H.<2VG&:OU=HKL;E)"R6 -3^#^#P16)-#@ZQ><PU<
M">BLS1_"Q>?WP_5^2N@]&Q^PZ);0_W-DS\/G_3 .D)D@#X-GP ,J;;&&K"37
M)-.5@,*KGWZZRO-D2A &Y4XA2P*Z,X?;_Y<O:O7<]:X21&$^@Y+FSLZ4!<CY
MITM<P<B3BA)&1"=QKV&,,ERE7%>QC*FB9SU/P\@-LGDX@&F:[@ 7@[P,CC)X
MP&1=X6*P9A]):58!61IP(1 R'*D4@8,W"R5,G@ZQ)TQ56B1V',MBY&'X9T)]
M+N>20U\C,V8?65F'N-T?'8!8FGTL:FL,[E"H73OGX0AYE8L&R.[3VG3*$MC"
M9%4CZ^LTIQL7B:6,<NP9J,N;BP^OG_=<Y'3C+6Z@^QM#GA8/R&=DVZFV/.-B
M\!%Y*O0NUZLM03^9S>8'K _*P&#]1OLR-#.R*QE@LV*ZLPQY\@5Y$) G7[G>
M&(@\_39=FT!/UZ*"4.S4"3W[HT(;Y.6)?I_[G$IF9J-TIA:VK/Z8*L=FBNDL
MT '[#\BI'<@VHX3>8^OIPUB^/@!=Q'.W'C?:C5ZKOG\@D+GAAV%*F0'9C3Z4
MA0KD?2?8*]EYX4P9;*"7B K6OMAR%YQM*ET4KR2TBONZ,:=^5F^KQ79B;E/$
M:K^2H.E*]UF\$J\+5QJS];;Y!9A;]?GR1&5R\JFJ:J%*UJ#)LJ;@*D%;6=+M
MYVT@W'_OT:9%=.O;5*G8JV1IJCZS>RYX&&01]YX)-^;1RB(,WR)T/>K>#>(P
M";S*=)=YJ]JHTK/T+^:PIG>Z0_W6/M6]]:@KF;=I1:3I<T4@:"T6\3#Z?66]
ME/(Q:.;4UMD6FW7OF]62V@3$59OJFU6KM;PI?#,3N3NS5']:B S-2=&4F(*<
M:$9:TR"'5"[N?>PZR+"((=Z\AB; ]PG'F]O0)+A^7@9@"1AXN/W'%@NU;1U9
M"G#'/T%S^]+NLS^1 ="U/Y&E0/MYN#@@*\(\,=CO#+]N7A?;PT7@GL7(N@!O
M2D\W_\P%@& 6S$A]1)5K&[-!N";7MH31T)-*R+Z9S,VE+ L$]P#,T[/62\]<
M*P?$Q05@B)CQK@D8Y,\@E*"9Y^L4D5$BI#H%@+JJ/GU^&E,)PX,<0$R(2CBW
M2%>CH:O4_L#C QGGJ8URYE:0@<#F ^29E1!9:R=KTK;*X #$S"%CNI%S10P?
M/G/W+=\@E, %\(JD3UV9Q/AA%78DX88QME"F1U6-DH";RGYR&(?)8(BW6\L$
MW\A.-K:4:*_EXOR*1''H,B$*YO2LJR&_.J5G^=@&M,7*=L.L5:Y"O_Q%:$7,
MTF+P"DB BD;U="M(6D]H>%K[W-" I:=TZWC.LVX^?TUJ_]P(L>6CS4(L?6K&
M G4HT,J:Z];1;()N?8A8D\5T']%WU@1HFX0* <@@]\V>N?P2P/L'H\"F]OWS
MY&^H$.!MJ-?-(XNC.D$<:Y56$X"WC5LW/W=V^G.&(=W,OA\:"CF'*PO5'ZZO
MO'^]I(JLXKI)@>LGN!C@Q:^Z^0B<)7,ZWG/VEM&FEU(6T,>+XSK-J @<DQNT
M(L=F(@-7"JD0;-3S)\_9/O>3P%5;0JA/)!-H.^</ 0HUU1NS<1C?J;RF+??(
M-*M6.RIV")Z3-8.XYYV0ZDQ;U<L18J& %FZA@!9JHHYN?LCSRK?NN;B.(@"S
M]%]K.EV"F'B@B<!,Z-<$>(@5GC0 B#OS6R:/&?,DP)0'(M3\44T%7@*&;A[S
MQ##5?@3.&.J"MZ:BCVCUR^!T7!;/<[1+Z#WB[CW=/C9S@Y+K8195U&H&8@R"
M>YB#MCH<V?M#-C;8%A=S)^TA./]YKG\)O6<JY$<._D@$GM\'Q+/?%!7GE28N
M#';U CD*+)8X56MLDSG5:%OVLEM4P\F<:J=5'@YC.4A1LV7F5&[#C24@EA;%
MVJ@94VW4=0==DP\S8ZI]2!E3>BPX7MY0&SMO:'IF#.X!(>V"YX/L?S NT-PR
MW3Q:>4*C%P*T\H1M4Z1RS03(_F7AEU'O5Y)FD4U(HF=DE'S SQ4N-JB<D>"M
M5*,>ZJ5;O\X+%O??^8P-.0?KL>U?2-7\R2Y=QF81E]',8GIJ2PY5Z\4=0)[%
MZJ8,9Q)W@ BN,2<B8B[>M@!]$B':PHY1V'@;MXR//?EAL1 MEBX]@,H :I(Y
M2F)W2 7P8F^Z\?_P5!6N+1FK:#A_66#_[")P/1P_7U?M=>-.>K0/*A/H3 PC
M(41%  7G!.>V0&Y4(#U:KHX^5VN]U#4I79'<V:92^GXGIS5=-Q)OF483$'@4
M;P>XI@"Q6DU:K!XO/483@)<5HIM'7*;3[0_(J_,DCEG@8I\CK,GY<O-^S:D%
M&ZFZ#;1FRP1I!Z4W]2$(5\FHQ^+LP2G=MS*TK:U0O@)= %+2GL]FI(<QA+B*
M;)]&@G6F'\X\+B*?3CH\T WKA\Y2T]@+I0Q''87@/8LE=ZE?H3X?!!T]=N;R
MV9A[<MBIVU;35M2^D< 'TILV;*[:EKYT(KWE:_53RW'JF9>KEIUY+?>U;:O1
M:A9Z[8DFV9 -P(B(!C\?U8Z>8*?1K2IPB0A][I$75?USEEXWCL3RY71T.D[T
M0$"(B/JW9K5:4Q$PB*JW+Z$<1CL7"*<0RW6#(*&S#*LI@-MC8U9+OQV\=8@9
MECS*E@['%.M?7,4U7R)!?1Z*W'S%;[",Q0B(]G:@5+'VOP2/JW9&M6T@E*F*
MRN&L Q+;LNS#6G']=M1V)=!_-5@U5YYH*_GM;L[^(LT4[%U#0HH$TW5K7L/.
MJ,](%';LOKT;[?)THO_1L<O3KKMK?PUD&)V?<V@/#H,5SK1AVO2OOOXISL+M
M@I[^N@.%BLT7;27$;=LZQ?#-:TVKV=[*-Z\YX-47<Z(W>:U:IMN#RP^O;5=;
MNW^M;0%C[/ZU+<MIU[8/4)KKG?!4LK-,<GIY0Q_;V.%,0V75,ZW2/O6=W5@*
M6TI6=?:ZZFU[[_X_$QI(+B<KO.EYQFEORC@KG#T$SK*=^<S=LK%58=JS9:PH
M]_CK[[OOWQ2>[D@EFRBII??E;1LE;>I/-7<>>V8Y?#E!Z2):&LW:X]6T2P6Q
MK!(3A6PSF[79J!5IZ9O!V)?.G7-S'7/\\^)D6:5J.8W%][H0D+)X-VRWG/._
MR:3X=E,?.[9V"\-?S'4KR/N[TB1VJ9ID5]-8?QV_)5N&C JK6\TEN4J_/%RQ
M.D1.;MIJ#WIIG'Q:XGSL;D'[?DR2_<,D[<(D9<YA[V"K9"G3O9E)+J[:Z,$%
MZ>EDR20* _)X@E04A_=<46K."C+G_OE^.%9?1326NMIP$,)P"9F?'I'-E6:R
MK[5BM^B*!8$EJ/8'#N8<<-9TZUSB12G3Q!LZ(Z3H=#$&IL<DC(E(>H+]:<[R
M-:?I!N35 2*9!> A OMZ2>B+Z,!%S;F[53XT95K+3";]R*A'=%OY.G*:F5NW
M:JK)*!1<;[B)F4\EOV?I D6JGN8>G-K$QT=H#TQ;(K,?F;/^6MT67QDMFDM6
M+ .W.._,_Q[&CQPQ8)5>S.A=A?;!B>E0?TPGXHE+!(R6-NO8.G!X"LN:5G,.
MB%F1#'.@N@/7H*DTP289,W8G2#\.1Z!_7<;!!PO[L]T:1/MG10M3%-09ZQ?;
M#TB)U#.5R#]" (RN<[,6UP!L9V521?8)1GOO'\WL7Y?(,?/O&7EE.Z_)"-XT
M)#$XF\K5[*=]G^U9,8XI.!Q_)N 1L=B?9#/-H4/2RX3D'1"HNC\=>N6G"_Y
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M:6]N<W$Q+FAT;5!+ 0(4 Q0    ( (6(I%;YCS]6.08  &0<   >
M      "  8L0  !E>&AI8FET,S(Q8V5R=&EF:6-A=&EO;G-Q,2YH=&U02P$"
M% ,4    " "%B*16,V1,6MM_ @!U&!0 $0              @ $ %P  ;G!C
M92TR,#(S,#,S,2YH=&U02P$"% ,4    " "%B*16U7GYJ*L-  #DC0  $0
M            @ $*EP( ;G!C92TR,#(S,#,S,2YX<V102P$"% ,4    " "%
MB*16R_M]]= 8  "8Z0  %0              @ 'DI ( ;G!C92TR,#(S,#,S
M,5]C86PN>&UL4$L! A0#%     @ A8BD5IM*>=UR.   8F0" !4
M     ( !Y[T" &YP8V4M,C R,S S,S%?9&5F+GAM;%!+ 0(4 Q0    ( (6(
MI%94PRR<4KH  !KA!P 5              "  8SV @!N<&-E+3(P,C,P,S,Q
M7VQA8BYX;6Q02P$"% ,4    " "&B*16:XY\3NQI  #HU00 %0
M    @ $1L0, ;G!C92TR,#(S,#,S,5]P<F4N>&UL4$L! A0#%     @ AHBD
M5D1B:!X($P  9HD  !T              ( !,!L$ &YP8V4M97AH:6)I=#$P
M,7$Q,C R,S$P>'$N:'1M4$L! A0#%     @ AHBD5MGI<AX2%0  HOH  !T
M             ( !<RX$ &YP8V4M97AH:6)I=#$P,G$Q,C R,S$P>'$N:'1M
64$L%!@     +  L ! ,  ,!#!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
